temozolomide has been researched along with Glioma in 1356 studies
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was aimed at analyzing the efficacy and safety of an injectable form of chlorogenic acid (CGA) in patients with recurrent high-grade glioma after standard of care treatments, through a first-in-human, open-label, dose-escalation phase I trial." | 9.69 | Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up. ( Chen, F; Deng, J; Jiang, J; Kang, X; Kang, Z; Li, S; Li, W; Yang, H; Zhang, J, 2023) |
| "In an international randomised controlled phase II study of temozolomide (TMZ) versus TMZ in combination with bevacizumab (BEV) in locally diagnosed non-1p/19q co-deleted World Health Organization grade 2 or 3 gliomas with a first and contrast-enhancing recurrence after initial radiotherapy, and overall survival at 12 months was not significantly different (61% in the TMZ arm and 55% in the TMZ + BEV arm)." | 9.69 | Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatmen ( Bottomley, A; Clement, PM; Coens, C; de Vos, FYF; Ghislain, I; Golfinopoulos, V; Idbaih, A; Klein, M; Lewis, J; Machingura, A; Mulholland, PJ; Reijneveld, JC; Taal, W; Taphoorn, MJB; van den Bent, MJ; Wick, W, 2023) |
| " In our study, we aim to explore the efficacy and safety of temozolomide combined with radiotherapy in the treatment of malignant glioma (MG) and its influence on postoperative complications and survival rate of patients." | 9.51 | Efficacy and Safety of Temozolomide Combined with Radiotherapy in the Treatment of Malignant Glioma. ( Li, J; Wei, S, 2022) |
| "In this article, we have compared and analyzed the clinical effects of temozolomide single agent and combined doxorubicin in the treatment of glioma." | 9.51 | Comparison of Clinical Effects of Temozolomide Single Agent and Combined Doxorubicin in the Treatment of Glioma. ( Chen, L; Liu, Y, 2022) |
| "The KNOG-1101 study showed improved 2-year PFS with temozolomide during and after radiotherapy compared to radiotherapy alone for patients with anaplastic gliomas." | 9.51 | Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study). ( Ahn, GS; Chang, JH; Choe, G; Choi, BS; Hong, YK; Hwang, K; Joo, J; Jung, TY; Kang, SG; Kim, CY; Kim, EY; Kim, JH; Kim, SH; Kim, TM; Kim, YJ; Lee, DE; Nam, DH; Park, CK; Yoo, H, 2022) |
| "CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists." | 9.34 | Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. ( Affronti, ML; Desjardins, A; Friedman, HS; Healy, P; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Patel, MP; Peters, KB; Randazzo, DM; Woodring, S, 2020) |
| "We investigated the efficacy of temozolomide during and after radiotherapy in Korean adults with anaplastic gliomas without 1p/19q co-deletion." | 9.34 | Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study). ( Chang, JH; Choe, G; Choi, BS; Hong, YK; Hwang, K; Joo, J; Jung, TY; Kang, SG; Kim, CY; Kim, EY; Kim, JH; Kim, SH; Kim, TM; Kim, YJ; Lee, DE; Nam, DH; Park, CK; Yoo, H, 2020) |
| "A Pediatric Brain Tumor Consortium (PBTC) phase I/II trial of veliparib and radiation followed by veliparib and temozolomide (TMZ) was conducted in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG)." | 9.34 | A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study. ( Adesina, A; Ansell, P; Baxter, PA; Billups, CA; Blaney, SM; Broniscer, A; Dunkel, IJ; Fouladi, M; Giranda, V; Kilburn, L; Li, XN; Onar-Thomas, A; Paulino, A; Poussaint, TY; Quaddoumi, I; Smith, ER; Su, JM; Thompson, P, 2020) |
| "To report the long-term outcomes of the RTOG 0424 study of a high-risk, low-grade glioma population treated with concurrent and adjuvant temozolomide (TMZ) and radiation therapy (RT)." | 9.34 | Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424. ( Bahary, JP; Barani, IJ; Bovi, JA; Chakravatri, A; D'Souza, D; Doyle, T; Fisher, BJ; Fiveash, JB; Fox, S; Howard, SP; Kwok, Y; Laack, NN; Lesser, GJ; Macdonald, DR; Mehta, MP; Michael Yu, HH; Pugh, SL; Rogers, CL; Strasser, JF; Wahl, DR; Werner-Wasik, M; Won, M, 2020) |
| "The optimal management of high risk WHO grade II gliomas after surgery is debated including the role of initial temozolomide to delay radiotherapy and risk of cognitive defects." | 9.30 | Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016. ( Bello, L; Bertero, L; Carapella, CM; Caroli, M; Cassoni, P; Dealis, C; Faedi, M; Marchese, G; Migliore, E; Pace, A; Pellerino, A; Rudà, R; Soffietti, R, 2019) |
| " Gliomas, which are common in dogs and also represent the majority of fatal brain tumours in humans, can be amenable to chemotherapy with temozolomide." | 9.30 | Intratumoral temozolomide in spontaneous canine gliomas: feasibility of a novel therapy using implanted microcylinders. ( Hicks, J; Holmes, S; Howerth, E; Kaplan, E; Kaplan, J; Kent, M; Platt, S; Senneca, C; Stewart, G, 2019) |
| " We sought to study vorinostat (VOR), a histone deacetylase inhibitor, in combination with bevacizumab (BEV) and daily metronomic temozolomide (TMZ) in a Phase I/II trial in recurrent high-grade gliomas (HGGs)." | 9.27 | Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. ( Desjardins, A; Friedman, HS; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Peters, KB; Reardon, DA, 2018) |
| "1/CATNON intergroup trial was designed to evaluate the impact on concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic gliomas." | 9.27 | Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis. ( Abrunhosa-Branquinho, AN; Bar-Deroma, R; Baumert, BG; Clementel, E; Collette, S; Feuvret, L; Hurkmans, CW; Liu, Y; Van Beek, K; van den Bent, M; Weber, DC, 2018) |
| "Adult patients with intermediate- to high-grade glioma on adjuvant temozolomide (TMZ) with facilities for live video call were invited to participate in the study." | 9.27 | Shadow study: randomized comparison of clinic with video follow-up in glioma undergoing adjuvant temozolomide therapy. ( Chakraborty, S; Chandrasekharan, A; Dsouza, H; Goda, JS; Gupta, T; Jalali, R; Krishnatry, R; M, C; Pande, N; Patil, VM; Tonse, R; Vallathol, DH, 2018) |
| "In this study, MGMT promoter methylation was an independent prognostic biomarker of high-risk, low-grade glioma treated with temozolomide and radiotherapy." | 9.27 | Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. ( Aldape, KD; Ashby, LS; Bahary, JP; Becker, AP; Bell, EH; Chakraborty, AR; Chakravarti, A; Fabian, D; Fisher, BJ; Fleming, J; Gray, HJ; Kwok, Y; Laack, NN; Lesser, GJ; Liu, Z; Macdonald, DR; McElroy, JP; Mehta, MP; Robins, HI; Schultz, CJ; Walker, EM; Werner-Wasik, M; Yu, HM; Zhang, P, 2018) |
| "Mibefradil (MIB), previously approved for treatment of hypertension, is a selective T-type calcium channel blocker with preclinical activity in high-grade gliomas (HGGs)." | 9.24 | Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. ( Desai, AS; Desideri, S; Fisher, JD; Grossman, SA; Holdhoff, M; Leal, J; Lesser, GJ; Lieberman, FS; Lodge, MA; Nabors, LB; Read, WL; Schiff, D; Supko, JG; Wahl, RL; Walbert, T; Ye, X, 2017) |
| "While our study failed to meet the primary endpoint for objective radiographic response, patients with high-risk low-grade glioma receiving adjuvant temozolomide demonstrated a high rate of radiographic stability and favorable survival outcomes while meaningfully delaying radiotherapy." | 9.24 | Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. ( Berger, MS; Butowski, N; Chang, SM; Clarke, JL; Costello, JF; Dayal, M; Haas-Kogan, DA; Lin, Y; Molinaro, AM; Nelson, S; Perry, A; Phillips, JJ; Prados, M; Wahl, M, 2017) |
| "Following maximal surgical resection, newly diagnosed children with nonmetastatic high-grade glioma underwent involved field radiotherapy with concurrent temozolomide." | 9.22 | Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. ( Brat, DJ; Burger, PC; Buxton, A; Cohen, KJ; Eckel, SP; Hamilton, RL; Jakacki, RI; Krailo, MD; Lavey, RS; Pollack, IF; Rosenblum, MK; Zhou, T, 2016) |
| "In malignant glioma (MG) patients undergoing radiation therapy (RT) with concomitant temozolomide, chemoradiation-induced nausea and vomiting (cRINV) degrades quality of life (QoL) and reduces treatment adherence, which thereby potentially compromises cancer control." | 9.22 | Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ). ( Affronti, ML; Allen, K; Desjardins, A; Friedman, HS; Healy, PN; Herndon, JE; Kirkpatrick, J; McSherry, F; Peters, KB; Vredenburgh, JJ; Woodring, S, 2016) |
| "Overall, there was no significant difference in progression-free survival in patients with low-grade glioma when treated with either radiotherapy alone or temozolomide chemotherapy alone." | 9.22 | Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. ( Balana, C; Baumert, BG; Brandes, AA; Bravo-Marques, J; Bromberg, JE; Capper, D; Chinot, O; Clement, PM; Dhermain, F; Dif, N; Enting, R; Feuvret, L; Gijtenbeek, JMM; Gorlia, T; Hartmann, C; Hassel, MB; Hegi, ME; Hoang-Xuan, K; Kantor, G; Kros, JM; Kurscheid, S; Lacombe, D; Marosi, C; Mason, WP; Nordal, RA; Rees, J; Reijneveld, JC; Reni, M; Rossiter, JP; Ryan, G; Stupp, R; Taphoorn, MJB; Thiessen, B; Tzuk-Shina, T; van den Bent, MJ; von Deimling, A; Wick, W, 2016) |
| "This trial was designed to evaluate the safety and clinical responses to a combination of temozolomide (TMZ) chemotherapy and immunotherapy with fusions of DCs and glioma cells in patients with glioblastoma (GBM)." | 9.22 | Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma. ( Akasaki, Y; Arai, T; Hayashi, K; Homma, S; Joki, T; Kikuchi, T; Koido, S; Komita, H; Mori, R; Murayama, Y; Ohkusa, T; Suzuki, Y; Tanaka, T; Tasaki, T; Watanabe, N; Yamamoto, Y; Yanagisawa, T, 2016) |
| "Radiation Therapy Oncology Group (RTOG) 0424 was a phase 2 study of a high-risk low-grade glioma (LGG) population who were treated with temozolomide (TMZ) and radiation therapy (RT), and outcomes were compared to those of historical controls." | 9.20 | Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424. ( Bahary, JP; Brachman, DG; Chakravarti, A; Coons, SW; Fisher, BJ; Hu, C; Lesser, GJ; Liu, J; Macdonald, DR; Mehta, M; Ryu, S; Werner-Wasik, M, 2015) |
| "60 patients of postoperative malignant glioma were randomly assigned into two groups, 30 patients were treated with 3D-CRT plus tamoxifen (treatment group), and the other 30 patients with 3D-CRT plus temozolomide (control group)." | 9.20 | Clinical observation of three dimensional conformal radiotherapy with tamoxifen in treatment of postoperative malignant glioma. ( Ding, WX; Gu, L; Guo, XW; Huang, XE; Liu, YC; Yin, XX; Zhou, SB, 2015) |
| "Temozolomide (TMZ) and BCNU have demonstrated anti-glioma synergism in preclinical models." | 9.20 | BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase ( Ashby, L; Asher, AL; Blaker, BD; Boltes, P; Brick, W; Burri, SH; Heideman, BE; Judy, K; Kelly, R; Norton, HJ; Prabhu, RS; Sumrall, AL; Symanowski, JT; Wiggins, WF, 2015) |
| "This phase I study aimed to evaluate safety, maximum tolerated dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of voxtalisib (SAR245409, XL765), a pan-class I phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor, in combination with temozolomide (TMZ), with or without radiation therapy (RT), in patients with high-grade glioma." | 9.20 | Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. ( Ahluwalia, MS; Cloughesy, TF; Egile, C; Fathallah-Shaykh, HM; Jiang, J; Lager, JJ; Laird, AD; Mohile, N; Omuro, A; Tang, J; Wen, PY, 2015) |
| "Iniparib is a prodrug that converts to highly reactive cytotoxic metabolites intracellularly with activity in preclinical glioma models." | 9.20 | Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas. ( Blakeley, JO; Chi, AS; Desideri, S; Emmons, G; Garcia Ribas, I; Grossman, SA; Mikkelsen, T; Nabors, LB; Peereboom, D; Rosenfeld, MR; Supko, JG; Ye, X, 2015) |
| "To evaluate the efficacy of limited margins intensity-modulated radiotherapy (IMRT) with temozolomide chemotherapy in patients with malignant glioma, and explore the prognostic factors of malignant glioma." | 9.20 | [Randomized controlled study of limited margins IMRT and temozolomide chemotherapy in patients with malignant glioma]. ( Cao, Y; Sun, J; Yang, X; Zhang, W, 2015) |
| " The primary objective of this study was to determine the safety of the combination of PPX with temozolomide and concurrent radiation for high-grade gliomas." | 9.19 | Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study. ( Boxerman, J; Cielo, D; Constantinou, M; Dipetrillo, T; Donahue, J; Elinzano, H; Evans, D; Goldman, M; Isdale, D; Jeyapalan, S; Kinsella, T; Mantripragada, K; Oyelese, A; Puthawala, Y; Rosati, K; Safran, H; Santaniello, A; Stopa, E, 2014) |
| "A multicenter, two stage phase II study, investigated irinotecan plus temozolomide in children with newly diagnosed high grade glioma." | 9.17 | A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study. ( Ashley, D; Breazna, A; Cisar, L; Clausen, N; Cruz-Martinez, O; Dorman, A; Elliott, M; English, M; Frappaz, D; Fuster, JL; Geoerger, B; Gesner, L; Grill, J; Hargrave, D; Icher, C; Leblond, P; Perilongo, G; Pietsch, T; Rialland, X, 2013) |
| "The alkylating agent temozolomide (TMZ) is widely used for the treatment of gliomas." | 9.17 | Secondary hematological malignancies associated with temozolomide in patients with glioma. ( Miyakita, Y; Momota, H; Narita, Y; Shibui, S, 2013) |
| "To evaluate the efficacy and safety of temozolomide (TMZ) versus semustine (Me-CCNU) in the treatment of recurrent glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA)." | 9.17 | [Multicenter randomized controlled study of temozolomide versus semustine in the treatment of recurrent malignant glioma]. ( Sun, J; Yang, SY; Yang, XJ, 2013) |
| " Multiple glioma cell lines were analyzed for viability after treatment with radiation, temozolomide, or sorafenib or combinations of them." | 9.17 | A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. ( Andrews, DW; Camphausen, K; Den, RB; Dicker, AP; Dougherty, E; Friedman, DP; Glass, J; Green, MR; Hegarty, S; Hyslop, T; Kamrava, M; Lawrence, YR; Marinucchi, M; Sheng, Z; Werner-Wasik, M, 2013) |
| "In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedule in the treatment of recurrent malignant gliomas (MGs)." | 9.17 | Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. ( Abrey, LE; Chan, TA; Deangelis, LM; Gavrilovic, IT; Heguy, A; Hormigo, A; Hottinger, AF; Huse, JT; Kaley, TJ; Kaufman, A; Khasraw, M; Lassman, AB; Mellinghoff, I; Nolan, CP; Omuro, A; Panageas, KS; Reiner, AS; Salvant, C, 2013) |
| "We undertook this phase I study to investigate the feasibility of the combination of temozolomide (TMZ) and lapatinib (LP) and to define the maximum tolerated dose (MTD) of LP in patients with relapsed high-grade gliomas." | 9.17 | A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas. ( Bobos, M; Chrisafi, S; Fountzilas, G; Karavasilis, V; Kotoula, V; Lambaki, S; Pentheroudakis, G; Televantou, D, 2013) |
| "The new standard treatment of glioblastoma multiforme is concurrent radiotherapy (RT) and temozolomide." | 9.16 | Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma. ( Amin, P; Cheston, S; Dhople, A; DiBiase, S; Flannery, T; Meisenberg, B; Patel, A; Patel, S, 2012) |
| "To estimate the sustained (≥8 weeks) objective response rate in pediatric patients with recurrent or progressive high-grade gliomas (HGG, Stratum A) or brainstem gliomas (BSG, Stratum B) treated with the combination of O6-benzylguanine (O6BG) and temozolomide(®) (TMZ)." | 9.16 | A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. ( Balis, FM; Berg, SL; Boyett, JM; Geyer, JR; Goldman, S; Gururangan, S; Kun, LE; McLendon, RE; Minturn, JE; Packer, RJ; Pollack, IF; Poussaint, TY; Wallace, D; Warren, KE, 2012) |
| "Patients with high-grade glioma can be treated with carmustine wafers or following the Stupp protocol." | 9.16 | Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis. ( Aurrecoechea-Obieta, J; Bilbao-Barandica, G; Canales-Llantada, M; Carbayo-Lozano, G; Catalán-Uribarrena, G; Galbarriatu-Gutiérrez, L; Igartua-Azkune, A; Pomposo-Gaztelu, I; Ruiz de Gopegui-Ruiz, E; Undabeitia-Huertas, J, 2012) |
| "To evaluate the toxicity and maximum tolerated dose (MTD) of arsenic trioxide (ATO) in combination with temozolomide (TMZ) and radiation therapy (RT) in malignant gliomas." | 9.16 | Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas. ( Chandler, JP; Grimm, SA; Jovanovic, B; Levy, RM; Marymont, M; McCarthy, K; Muro, K; Newman, SB; Raizer, JJ, 2012) |
| "The assessment of the therapeutic response of high-grade gliomas treated with concomitant chemoradiotherapy (CCRT) using temozolomide is difficult because of the frequent occurrence of early imaging changes that are indistinguishable from tumor progression, termed pseudoprogression." | 9.16 | Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Lee, WJ; Park, CK; Park, SH; Sohn, CH; Yi, KS, 2012) |
| "A phase I, dose-finding study of vorinostat in combination with temozolomide (TMZ) was conducted to determine the maximum tolerated dose (MTD), safety, and pharmacokinetics in patients with high-grade glioma (HGG)." | 9.16 | Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. ( Ames, MM; Chang, SM; Cloughesy, TF; Desideri, S; Drappatz, J; Espinoza-Delgado, I; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lee, EQ; Lieberman, FS; McGovern, RM; Prados, MD; Puduvalli, VK; Reid, JM; Robins, HI; Wen, PY; Xu, J; Ye, X; Yung, WK, 2012) |
| "The objective of this prospective, monocentric phase-II pilot study was to evaluate toxicity and efficacy of neoadjuvant temozolomide (TMZ) and 13-cis retinoic acid (13-cRA) treatment in patients with newly diagnosed anaplastic gliomas after total or subtotal tumor resection." | 9.15 | Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05). ( Bogdahn, U; Brawanski, A; Grauer, O; Hartmann, C; Hau, P; Pascher, C; Pietsch, T; Proescholdt, M; Weller, M; Wick, W; Zeman, F, 2011) |
| "To study the safety and efficacy of three-dimensional conformal radiotherapy in combination with temozolomide in treatment of patients with diffuse brainstem glioma." | 9.15 | [Safety and efficacy of three-dimensional conformal radiotherapy combined with temozolomide in treatment of diffuse brainstem gliomas]. ( Cai, CL; Fang, HH; Kang, JB; Li, FM; Nie, Q, 2011) |
| "Patients with newly diagnosed oligodendroglioma or oligoastrocytoma with a MIB-1 index of >5% or recurrent low-grade gliomas received temozolomide (75 mg/m(2)/day in 11-week cycles of 7 weeks on/4 weeks off)." | 9.14 | Phase II study of protracted daily temozolomide for low-grade gliomas in adults. ( Black, PM; Bradshaw, J; Ciampa, A; Doherty, L; Drappatz, J; Kesari, S; LaFrankie, D; Levy, B; Ligon, KL; Macklin, EA; Muzikansky, A; Norden, AD; Radakovic, G; Ramakrishna, N; Santagata, S; Schiff, D; Wen, PY, 2009) |
| "This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administering O(6)-BG in combination with temozolomide." | 9.14 | Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5-day dosing regimens of temozolomide (TMZ) in combination with O(6)-benzylguanine (O(6)-BG)." | 9.14 | Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| " We investigated the time course of tumor metabolism in low-grade gliomas (LGG) during temozolomide chemotherapy, and compared metabolic responses as measured with positron emission tomography (PET) with volume responses as revealed by magnetic resonance imaging (MR)." | 9.14 | Early metabolic responses in temozolomide treated low-grade glioma patients. ( Bärtschi, E; Bruehlmeier, M; Buettner, UW; Hefti, M; Hofer, S; Roelcke, U; Uhlmann, C; Wyss, M, 2009) |
| "To present outcome data in a prospective study of radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in children with diffuse intrinsic pontine gliomas (DIPGs)." | 9.14 | Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. ( Arora, B; Dutta, D; Gupta, T; Jalali, R; Kurkure, P; Munshi, A; Raut, N; Sarin, R, 2010) |
| "This multicenter phase II study conducted by the Spanish Neuro-Oncology Group evaluated the activity of an extended, dose-dense temozolomide regimen in patients with temozolomide-refractory malignant glioma." | 9.14 | Extended-schedule dose-dense temozolomide in refractory gliomas. ( Balaña, C; Berrocal, A; Gallego, O; Garcia Lopez, J; Gil, M; Iglesias, L; Perez Segura, P; Reynes, G; Rodríguez, J; Yaya, R, 2010) |
| "Heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma received cisplatin at a dose of 75 mg/m(2) on day 1 and temozolomide at a dose of 150 mg/m(2) on days 1 to 5 every 21 days until progression or major toxicity." | 9.14 | A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma. ( Della Puppa, A; Lombardi, G; Pastorelli, D; Rotilio, A; Scienza, R; Zustovich, F, 2009) |
| "To investigate the efficacy and safety of temozolomide (TMZ) and lomustine (CCNU) in malignant brain gliomas." | 9.14 | [A multicenter randomized controlled study of temozolomide in 97 patients with malignant brain glioma]. ( Chang, Y; Fu, Z; Liu, XM; Liu, XY; Qian, ZZ; Wang, HQ; Yang, SY; Yu, H, 2009) |
| "PURPOSE Concomitant temozolomide (TMZ)/radiotherapy followed by adjuvant TMZ has increased survival in patients with glioblastoma multiforme (GBM)." | 9.14 | Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. ( Bélanger, K; Easaw, J; Eisenstat, DD; Forsyth, P; Fulton, D; Kavan, P; Kirby, S; Macdonald, DR; Mason, WP; Perry, JR; Pouliot, JF; Shields, C; Thiessen, B, 2010) |
| "Twenty-two patients with newly diagnosed malignant glioma who received standard radiation/temozolomide therapy were recruited for the study." | 9.14 | Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma. ( Chiba, Y; Hashimoto, N; Hosen, N; Kagawa, N; Kinoshita, M; Murao, A; Nishida, S; Oji, Y; Oka, Y; Sugiyama, H; Tsuboi, A; Yoshimine, T, 2010) |
| "Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG)." | 9.14 | Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. ( Beall, S; Brada, M; Collins, VP; Erridge, S; Gabe, R; Gattamaneni, R; Hopkins, K; Lee, SM; Levy, D; Rampling, R; Saran, F; Stenning, S; Thompson, LC, 2010) |
| "To assess survival, local control and toxicity using fractionated stereotactic conformal radiotherapy (FSCRT) boost and temozolomide in high-grade gliomas (HGGs)." | 9.14 | Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report. ( Albanese, A; Anile, C; Apicella, G; Azario, L; Balducci, M; Cellini, N; Chiesa, S; D'Agostino, GR; de Bonis, P; Dinapoli, N; Fiorentino, A; Frascino, V; Manfrida, S; Mangiola, A; Mantini, G; Valentini, V, 2010) |
| "We performed a new phase II trial enrolling patients with newly diagnosed high-grade glioma (HGG) to test the efficacy of a weekly alternating temozolomide (TMZ) schedule after surgery and concomitant chemoradiotherapy." | 9.13 | Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas. ( D'Amico, A; Dall'oglio, S; Gabbani, M; Maluta, S; Pasini, F; Passarin, MG; Pioli, F; Talacchi, A; Turazzi, S, 2008) |
| "A multicenter phase I clinical trial, namely, Integrated Japanese Multicenter Clinical Trial: A Phase I Study of Interferon-beta and Temozolomide for Glioma in Combination with Radiotherapy (INTEGRA Study), is being conducted for patients with high-grade glioma in order to evaluate the safety, feasibility and preliminary clinical effectiveness of the combination of interferon-beta and temozolomide." | 9.13 | A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study). ( Aoki, T; Hashimoto, N; Kayama, T; Kurisu, K; Natsume, A; Nishikawa, R; Ogura, M; Takahashi, H; Wakabayashi, T; Yoshida, J; Yoshimine, T, 2008) |
| "This is a phase-I study of gefitinib in combination with temozolomide in patients with gliomas." | 9.13 | Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. ( Chang, S; Cloughesy, T; Dancey, J; Fink, K; Junck, L; Kuhn, J; Prados, MD; Robins, HI; Wen, PY; Yung, WK, 2008) |
| "Twice-daily dosing may enhance the efficacy of temozolomide in the treatment of recurrent gliomas without increasing toxicity." | 9.13 | Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. ( Alavi, J; Balmaceda, C; Chen, J; Cheung, YK; Fine, RL; Fisher, PG; Pannullo, S; Peereboom, D; Sisti, M, 2008) |
| "We determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of imatinib mesylate, an inhibitor of the receptor tyrosine kinases platelet-derived growth factor receptor (PDGFR), the proto-oncogene product c-kit, and the fusion protein Bcr-Abl, when administered for 8 days in combination with temozolomide (TMZ) to malignant glioma (MG) patients." | 9.13 | Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. ( Desjardins, A; Egorin, MJ; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Lagattuta, TF; McLendon, R; Quinn, JA; Reardon, DA; Rich, JN; Salvado, AJ; Sathornsumetee, S; Vredenburgh, JJ, 2008) |
| "The aim of the present study was to determine in patients with progressive or recurrent low grade gliomas, the response rate and toxicity incurred by a continued schedule of temozolomide chemotherapy administered before radiation therapy, and to explore correlations between response and survival with 1p/19q deletions and MGMT promoter methylation status." | 9.13 | Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. ( Bertorelle, R; Blatt, V; Bonaldi, L; Brandes, AA; Ermani, M; Franceschi, E; Tosoni, A, 2008) |
| "To evaluate outcome after fractionated stereotactic radiotherapy (FSRT) and concomitant daily temozolomide (TMZ) in patients with recurrent gliomas." | 9.13 | Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. ( Bischof, M; Combs, SE; Debus, J; Hof, H; Oertel, S; Schulz-Ertner, D; Welzel, T, 2008) |
| "A phase I trial was conducted to determine the maximum tolerated dose (MTD) of temozolomide given in combination with lomustine in newly diagnosed pediatric patients with high-grade gliomas." | 9.13 | A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. ( Adamson, PC; Blaney, SM; Flom, L; Ingle, AM; Jakacki, RI; Pollack, IF; Prados, MD; Timmerman, R; Yates, A; Zhou, T, 2008) |
| "We performed a Cochrane Review to examine studies using different techniques to measure MGMT and predict survival in glioblastoma patients treated with temozolomide." | 9.12 | MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review. ( Brandner, S; Cheng, HY; Dawson, S; Faulkner, CL; Higgins, JPT; Jefferies, S; Kelly, C; Kurian, KM; McAleenan, A; Schmidt, L; Spiga, F; Wragg, C, 2021) |
| "Recent developments in pharmacogenomics have created opportunities for predicting temozolomide response in gliomas." | 9.12 | Comprehensive pharmacogenomics characterization of temozolomide response in gliomas. ( Long, J; Tong, S; Wang, B; Wang, Y; Wu, J; Zhong, P, 2021) |
| "We searched Medline and Embase (Jan 1994-Jan 2021) for studies evaluating the effect of temozolomide monotherapy on cell viability of at least one malignant glioma cell line." | 9.12 | Temozolomide sensitivity of malignant glioma cell lines - a systematic review assessing consistencies between in vitro studies. ( Brennan, PM; Bruce, M; Hannan, CJ; Poon, MTC; Simpson, JE, 2021) |
| "In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the treatment of IDH-mutant gliomas." | 9.12 | From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas. ( Sun, X; Turcan, S, 2021) |
| "Temozolomide (TMZ) is a first-choice alkylating agent inducted as a gold standard therapy for glioblastoma multiforme (GBM) and astrocytoma." | 9.12 | Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance. ( Kumar, A; Shrivastava, A; Srivastava, C; Tomar, MS, 2021) |
| "The objective of the study was to evaluate the efficacy and toxicity of Temozolomide (TMZ) administered for 5 consecutive days in three daily dosing in children with recurrent or refractory high-grade glioma." | 9.12 | Phase II trial of temozolomide in children with recurrent high-grade glioma. ( Abate, ME; Attinà, G; Caldarelli, M; Cefalo, G; Clerico, A; Colosimo, C; Di Rocco, C; Garré, ML; Lazzareschi, I; Madon, E; Massimino, M; Maurizi, P; Mazzarella, G; Riccardi, R; Ridola, V; Ruggiero, A; Sandri, A, 2006) |
| "Temozolomide (TMZ) a recent, oral, second generation alkylating agent is a chemotherapeutic with demonstrated efficacy for the treatment of high-grade gliomas." | 9.12 | Surgery, radiotherapy and temozolomide in treating high-grade gliomas. ( Barbarisi, M; Moraci, A; Moraci, M; Parlato, C, 2006) |
| "The purpose of this study was to define the maximum tolerated dose of erlotinib and characterize its pharmaco-kinetics and safety profile, alone and with temozolomide, with and without enzyme-inducing antiepileptic drugs (EIAEDs), in patients with malignant gliomas." | 9.12 | Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. ( Burton, E; Butowski, N; Chang, S; Fedoroff, A; Kapadia, A; Kelley, SK; Lamborn, KR; Malec, M; Page, MS; Prados, MD; Rabbitt, J; Xie, D, 2006) |
| "The purpose of this study was to monitor the metabolic effects of temozolomide (TMZ) chemotherapy in malignant gliomas by means of repeated positron emission tomography (PET) with [(11)C]methionine (MET)." | 9.12 | Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. ( Burghaus, L; Galldiks, N; Heiss, WD; Herholz, K; Jacobs, AH; Kracht, LW; Thomas, A, 2006) |
| "Since anaplastic gliomas (AG) depend on matrix metalloproteinases for tumor cell invasion and angiogenesis, we undertook this phase II study to evaluate the matrix metalloproteinase inhibitor marimastat (MT), combined with the alkylator temozolomide (TMZ) in patients with recurrent AG, looking for improved outcomes." | 9.12 | Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. ( Aldape, KD; Conrad, CA; Gilbert, MR; Groves, MD; Hess, KR; Jaeckle, K; Levin, VA; Liu, V; Puduvalli, VK; Yung, WK, 2006) |
| "Temozolomide (TMZ) has demonstrated activity and acceptable toxicity for the treatment of recurrent malignant gliomas in carious prospective phase II studies." | 9.12 | [Temozolomide in the treatment of recurrent malignant glioma]. ( Ishii, N; Iwasaki, Y; Kobayashi, H; Murata, J; Sawamura, Y, 2006) |
| "The methylation status of the O6-methylguanine-methyltransferase promoter (MGMTP) was evaluated in 68 low-grade gliomas treated by neoadjuvant temozolomide." | 9.12 | MGMT methylation: a marker of response to temozolomide in low-grade gliomas. ( Benouaich-Amiel, A; Crinière, E; Delattre, JY; Everhard, S; Hoang-Xuan, K; Kaloshi, G; Kujas, M; Lejeune, J; Marie, Y; Mokhtari, K; Sanson, M; Thillet, J, 2006) |
| "We conducted a phase II study to assess the efficacy of oral temozolomide (TMZ) in children with progressive low-grade glioma." | 9.12 | Temozolomide in children with progressive low-grade glioma. ( Allen, JC; Desjardins, A; Fisher, MJ; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Krauser, JM; Phillips, PC; Quinn, JA; Reardon, DA; Vredenburgh, JJ; Watral, MA, 2007) |
| "Evaluation of toxicity and efficacy of an alternating weekly regimen of temozolomide administered 1 week on and 1 week off in patients with recurrent glioma." | 9.12 | Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. ( Blaschke, B; Felsberg, J; Herrlinger, U; Meyermann, R; Platten, M; Reifenberger, G; Steinbach, JP; Weller, M; Wick, A; Wick, W, 2007) |
| "To determine the maximum tolerated dose of irinotecan when administrated with temozolomide every 28 days, in patients with recurrent malignant glioma who were also receiving CYP450 enzyme-inducing antiepileptic drugs (EIAED), and to characterize the pharmacokinetics of irinotecan and its metabolites." | 9.12 | Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. ( Aldape, KD; Chang, SM; Cloughesy, T; DeAngelis, LM; Fine, H; Fink, KL; Junck, L; Kuhn, J; Lamborn, K; Lieberman, F; Loghin, ME; Metha, M; Prados, MD; Robins, IH; Wen, P; Yung, WK, 2007) |
| "Patients with recurrent malignant glioma at any time during recurrence were treated with oral temozolomide at a dose of 150 mg/m2 per day on a 5-day schedule every 28 days." | 9.11 | Temozolomide in the treatment of recurrent malignant glioma. ( Chang, SM; Lamborn, K; Malec, M; Page, M; Prados, MD; Rabbitt, J; Theodosopoulos, P, 2004) |
| "We report a phase II trial of cisplatinum and temozolomide (TMZ) combination in recurrent malignant glioma patients." | 9.11 | Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. ( Boiardi, A; Broggi, G; Eoli, M; Lamperti, E; Maccagnano, E; Salmaggi, A; Silvani, A, 2004) |
| "Temozolomide (TMZ) and 1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU) are reported to be active agents in anaplastic glioma (AG)." | 9.11 | Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. ( Chang, SM; Fine, H; Fink, KL; Greenberg, H; Hess, K; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, M; Prados, MD; Robins, HI; Schold, C; Yung, WK, 2004) |
| "This report describes a single-centre study with temozolomide (TMZ) (200 mg m(-2) day(-1) x 5 per cycle of 28 days) in children with (recurrent) high-grade glioma." | 9.11 | Temozolomide in paediatric high-grade glioma: a key for combination therapy? ( Couanet, D; Grill, J; Kalifa, C; Lelouch-Tubiana, A; Vassal, G; Verschuur, AC, 2004) |
| "Thirty-two patients with relapsing glioma were treated with temozolomide in two university hospitals in Finland." | 9.11 | Temozolomide treatment in glioma--experiences in two university hospitals in Finland. ( Aaltonen, K; Mäenpää, HO; Mäntylä, R; Minn, H, 2004) |
| "The administration of temozolomide after RT did not alter the poor prognosis associated with newly diagnosed diffuse brainstem glioma in children." | 9.11 | Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98). ( Bowers, DC; Broniscer, A; Chintagumpala, M; Fouladi, M; Gajjar, A; Iacono, L; Krasin, MJ; Stewart, C; Wallace, D, 2005) |
| "The authors determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of irinotecan (CPT-11), a topoisomerase I inhibitor, when administered with temozolomide among patients with recurrent malignant glioma (MG)." | 9.11 | Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. ( Badruddoja, M; Burkart, JL; Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, R; Newton, HB; Provenzale, J; Quinn, JA; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, J, 2005) |
| "To determine the anti-tumour efficacy and safety profile of temozolomide in local Chinese patients with recurrent malignant glioma." | 9.11 | Temozolomide in the treatment of recurrent malignant glioma in Chinese patients. ( Chan, DT; Chan, YL; Ng, HK; Poon, WS, 2005) |
| "To determine the response rate of the malignant gliomas of childhood to an oral, daily schedule of temozolomide." | 9.10 | Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. ( Couanet, D; Doz, F; Dugan, M; Frappaz, D; Griffiths, PD; Hobson, R; Ironside, J; Jaspan, T; Jouvet, A; Lashford, LS; Pearson, AD; Robson, K; Thiesse, P; Vassal, G, 2002) |
| "Although temozolomide is active against recurrent malignant glioma, responses in many patients are modest and short-lived." | 9.10 | Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. ( Benita-Weiss, M; Bushunow, P; Coyle, TE; Evans, B; Friedman, H; Korones, DN; Mechtler, L; Quinn, JA; Reardon, DA, 2003) |
| "Temozolomide (TMZ) and 13-cis-retinoic acid (cRA) have shown activity in prior single-agent trials of recurrent malignant gliomas (MG)." | 9.10 | Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. ( Chang, S; Cloughesy, T; Fine, H; Fink, K; Greenberg, H; Hess, KR; Jaeckle, KA; Kuhn, J; Mehta, M; Nicholas, MK; Pollack, IF; Prados, M; Schiff, D; Yung, WK, 2003) |
| "Temozolomide (TMZ) is an oral alkylating agent with a good safety profile and proven efficacy in the treatment of malignant glioma." | 9.10 | Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. ( Foster, T; Newlands, ES; Zaknoen, S, 2003) |
| "The aim of this study was to assess the efficacy of temozolomide in patients with World Health Organisation (WHO) grade II gliomas treated with surgery alone using imaging and clinical criteria." | 9.10 | Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. ( Abson, C; Ashley, S; Brada, M; Britton, J; Gonsalves, A; Hines, F; Sardell, S; Traish, D; Viviers, L; Westbury, C; Wilkins, P, 2003) |
| "Forty-three patients affected with LGG (29 astrocytoma, four oligodendroglioma and 10 mixed oligo-astrocytoma) were treated with temozolomide (TMZ) at the time of documented clinical and radiological progression." | 9.10 | Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. ( Canalini, P; Carapella, CM; Carosi, M; Cianciulli, AM; Galiè, E; Giannarelli, D; Jandolo, B; Pace, A; Telera, S; Vidiri, A, 2003) |
| "Temozolomide is an effective agent in the treatment of recurrent malignant gliomas." | 9.10 | A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. ( Abrey, LE; Bazylewicz, KA; Khan, RB; Malkin, MG; Raizer, JJ, 2002) |
| "Forty-one patients with high-grade glioma, at second recurrence or progression, of which twenty-two (54%) had glioblastoma multiforme, ten (24%) anaplastic astrocytoma, and nine (22%) anaplastic oligodendroglioma were administered temozolomide, 150 mg/m2/daily for five days every four weeks." | 9.09 | Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. ( Amistà, P; Basso, U; Berti, F; Brandes, AA; Ermani, M; Gardiman, M; Monfardini, S; Pinna, G; Rotilio, A; Scienza, R, 2001) |
| "Temozolomide, a new oral cytotoxic agent, was given to 75 patients with malignant gliomas." | 9.08 | The Charing Cross Hospital experience with temozolomide in patients with gliomas. ( Bower, M; Brampton, MH; Brock, C; Colquhoun, I; Evans, H; Glaser, MG; Illingworth, RD; Lewis, P; Newlands, ES; O'Reilly, SM; Rice-Edwards, JM; Richards, PG, 1996) |
| "Patients with progressive or recurrent supratentorial high-grade gliomas were entered into a multicentre phase II trial to evaluate the efficacy and toxicity of temozolomide." | 9.08 | Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. ( Begent, RJ; Bleehen, NM; Bower, M; Brada, M; Brampton, MH; Calvert, H; Colquhoun, I; Lewis, P; Newlands, ES, 1997) |
| "The majority of patients with high-risk lower grade gliomas (LGG) are treated with single-agent temozolomide (TMZ) and radiotherapy despite three randomized trials showing a striking overall survival benefit with adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiotherapy." | 9.05 | Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. ( Atkins, KM; Dietrich, J; Loeffler, JS; McDuff, SGR; Oh, KS; Shih, HA, 2020) |
| "Resistance of malignant glioma, including glioblastoma (GBM), to the chemotherapeutic temozolomide (TMZ) remains a key obstacle in treatment strategies." | 8.98 | Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics. ( Ghatnekar, GG; Gourdie, RG; Grek, CL; Naus, CC; Sheng, Z; Sin, WC, 2018) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 8.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| "There is a growing body of evidence that carmustine wafer implantation during surgery is an effective therapeutic adjunct to the standard combined radio-chemotherapy regimen using temozolomide in newly diagnosed and recurrent high-grade glioma patient management with a statistically significant survival benefit demonstrated across several randomized clinical trials, as well as prospective and retrospective studies (grade A recommendation)." | 8.95 | Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery. ( Caire, F; Guyotat, J; Menei, P; Metellus, P; Pallud, J; Roux, A, 2017) |
| "This review article summarizes in vitro, in vivo, and clinical evidence pertaining to temozolomide (TMZ) and bevacizumab (BEV) efficacy and mechanism of action in gliomas." | 8.91 | Current evidence of temozolomide and bevacizumab in treatment of gliomas. ( Chattipakorn, N; Chattipakorn, SC; Nanegrungsunk, D; Onchan, W, 2015) |
| "The goal of this meta-analysis was to identify the temozolomide (TMZ) regimen with optimal efficacy and tolerance for treatment of recurrent high-grade glioma (HGG)." | 8.91 | The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis. ( Chen, X; Guo, Z; Ma, X; Wang, D; Wei, W, 2015) |
| "This analysis was conducted to evaluate the efficacy and safety of temozolomide based chemotherapy in treating patients with glioma." | 8.90 | Comprehensive analysis of temozolomide treatment for patients with glioma. ( Liang, H; Xing, BZ; Yang, WB, 2014) |
| "Temozolomide (TMZ) is an alkylating agent currently used as first-line therapy for gliomas treatment due to its DNA-damaging effect." | 8.89 | O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas. ( Cao, H; Chen, L; Fan, CH; Jiang, G; Liu, WL; Wen, C, 2013) |
| "High-grade glioma patients receiving concomitant chemoradiotherapy with temozolomide 75mg/m(2) during six to seven weeks or dose-dense temozolomide regimens especially in combination with chronic use of corticosteroids have a high risk for developing Pneumocystis jirovecii pneumonia." | 8.89 | Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas. ( Bleeker-Rovers, CP; De Vos, FY; Gijtenbeek, JM; van Herpen, CM, 2013) |
| "We searched three online databases to systematically identify publications testing temozolomide in animal models of glioma." | 8.89 | Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted? ( Egan, KJ; Hirst, TC; Macleod, MR; Sena, ES; Vesterinen, HM; Whittle, IR, 2013) |
| "The standard therapy for newly diagnosed malignant gliomas comprises surgery, radiotherapy, and commonly temozolomide chemotherapy." | 8.87 | An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting. ( Kyritsis, AP; Levin, VA, 2011) |
| "Temozolomide-based chemotherapy represents an incremental improvement in the treatment of patients with high-grade gliomas." | 8.86 | Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. ( Chamberlain, MC, 2010) |
| "One barrier to successful treatment of malignant glioma is resistance to alkylating agents such as temozolomide." | 8.85 | New (alternative) temozolomide regimens for the treatment of glioma. ( Platten, M; Weller, M; Wick, W, 2009) |
| "The temozolomide is a promising orally cytotoxic agent used in malignant glioma." | 8.83 | The safety of the temozolomide in patients with malignant glioma. ( Dario, A; Tomei, G, 2006) |
| "Temozolomide is a novel oral alkylating agent that has been approved for the treatment of patients with refractory malignant glioma." | 8.81 | New approaches for temozolomide therapy: use in newly diagnosed glioma. ( Newlands, E; Stupp, R, 2001) |
| "Complete resection of glioblastoma via a supraorbital transciliary approach with 5-Aminolevulinic Acid use was performed without any complications, as demonstrated on postoperative MRI." | 8.31 | Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note. ( Aboukaïs, R; Bourgeois, P; Devalckeneer, A; Lejeune, JP; Reyns, N, 2023) |
| " Even with aggressive treatment, tumor recurrence is almost universal and patient prognosis is poor because many GBM cell subpopulations, especially the mesenchymal and glioma stem cell populations, are resistant to temozolomide (TMZ), the most commonly used chemotherapeutic in GBM." | 8.31 | αCT1 peptide sensitizes glioma cells to temozolomide in a glioblastoma organoid platform. ( Che, J; DePalma, TJ; Mezache, LS; Sivakumar, H; Skardal, A; Swindle-Reilly, K; Tallman, MM; Veeraraghavan, R; Venere, M, 2023) |
| "Temozolomide (TMZ) is a conventional chemotherapeutic drug for glioma, however, its clinical application and efficacy is severely restricted by its drug resistance properties." | 8.31 | The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma. ( Li, L; Liu, H; Ma, H; Qian, F; Quan, A; Ren, Y; Wang, L; Xu, H; Yu, R; Zhang, Y, 2023) |
| " In this study, we investigated the role of KDM1A/LSD1 in DNA double-strand break (DSB) repair and a combination of KDM1A inhibitor and temozolomide (TMZ) in vitro and in vivo using patient-derived glioma stem cells (GSCs)." | 8.31 | Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma. ( Alejo, S; Brenner, AJ; Chen, Y; Clarke, K; Gilbert, AR; He, Y; Jayamohan, S; Johnson, JD; Lai, Z; Li, W; Lv, Y; Palacios, BE; Pratap, UP; Sareddy, GR; Suzuki, T; Tekmal, RR; Vadlamudi, RK; Venkata, PP; Viswanadhapalli, S; Weldon, K; Ye, Z; Zhao, W; Zheng, S; Zou, Y, 2023) |
| "The development of resistance to temozolomide (TMZ), a standard chemotherapeutic, limits the effective treatment of glioblastoma (GBM)." | 8.31 | The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model. ( Kucheryavykh, L; Kucheryavykh, Y; Nuñez, R; Ortiz-Rivera, J, 2023) |
| " We aimed to clarify the interplay between purinergic signaling and chemotherapeutic drug temozolomide (TMZ) in human glioma cell line." | 8.31 | Purinergic approach to effective glioma treatment with temozolomide reveals enhanced anti-cancer effects mediated by P2X7 receptor. ( Czach, S; Czarnecka, J; Nowak, W; Roszek, K; Szymczak, B, 2023) |
| "Temozolomide (TMZ) is the preferred chemotherapy strategy for glioma therapy." | 8.31 | Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma. ( Deng, Y; Du, H; Hou, X; Liu, J; Liu, W; Liu, Y; Qiao, J; Shu, X; Sun, B; Wang, H, 2023) |
| "The chemoresistance of temozolomide-based therapy is a serious limitation for lasting effective treatment of gliomas, while the underlying mechanisms remain unclear." | 8.31 | Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-κB/MGMT Axis. ( Chen, S; Li, J; Li, M; Li, X; Li, Z; Liao, X; Qian, W; Song, L; Tang, M; Xu, Y; Yu, R; Zhang, S; Zheng, H, 2023) |
| "Temozolomide (TMZ)-based chemotherapy plays a central part in glioma treatment." | 8.31 | SRSF4 Confers Temozolomide Resistance of Glioma via Accelerating Double Strand Break Repair. ( Liu, X; Sun, Y; Wang, X; Wu, Z; Yan, W; You, Y; Zhang, Y, 2023) |
| "This study investigated the effect of frequently used analgesics in cancer pain management (flurbiprofen (FLU), tramadol (TRA), and morphine (MOR)) and a novel α2-adrenergic agonist (dexmedetomidine, DEX) on temozolomide (TMZ) sensitivity in glioma cells." | 8.31 | Analgesics can affect the sensitivity of temozolomide to glioma chemotherapy through gap junction. ( Guo, S; Tao, L; Wang, Y; Yu, M; Zhang, S; Zhang, X, 2023) |
| "Resistance to temozolomide (TMZ) remains an important cause of treatment failure in patients with glioblastoma multiforme (GBM)." | 8.31 | TRIM25 promotes temozolomide resistance in glioma by regulating oxidative stress and ferroptotic cell death via the ubiquitination of keap1. ( Hu, Z; Liu, X; Ma, L; Sun, T; Wan, J; Wang, L; Wei, J; Zhang, C; Zhang, Y; Zhou, L, 2023) |
| "Temozolomide (TMZ) is the leading chemotherapeutic agent used for glioma therapy due to its good oral absorption and blood-brain barrier permeability." | 8.31 | Magnolol and Temozolomide exhibit a synergistic anti-glioma activity through MGMT inhibition. ( Das, S; Dhara, D; Kundu, M; Mandal, M; Nandi, S, 2023) |
| "To investigate if triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro." | 8.31 | Triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro. ( Fuchs, D; Morandi, L; Nytko, KJ; Rohrer Bley, C; Tonon, C; Weyland, MS, 2023) |
| "In our previous study, we found for the first time that temozolomide (TMZ), the first-line chemotherapeutic agent for glioblastoma (GBM), can generate a large amount of reactive oxygen species (ROS) under ultrasound irradiation." | 8.31 | Temozolomide-based sonodynamic therapy induces immunogenic cell death in glioma. ( Jiao, J; Tong, X; Wen, B; Wu, Q; Xu, L; Yan, H; Yang, R; Zhou, Y, 2023) |
| "To investigate the effect of Temozolomide combined with intensity modulated radiation therapy on serum factor, immune function and clinical efficacy in postoperative glioma patients." | 8.31 | Effect of Temozolomide Combined with Intensity Modulated Radiation Therapy on Serum Factor, Immune Function and Clinical Efficacy in Postoperative Glioma Patients. ( Fan, R; Liu, J; Liu, Z; Yuan, J, 2023) |
| "To explore the mechanism through which curcumol reverses primary drug resistance in glioma cells." | 8.31 | [Curcumol reverses temozolomide resistance in glioma cells by regulating the UTX/MGMT axis]. ( Qian, Y; Sun, J; Tan, R; Tian, N; Xing, J, 2023) |
| " With novel strategies focused on targeting hypoxia-inducible factor (HIF) regulatory pathways, recent evidence has shown that Acriflavine (ACF) can effectively target glioma invasiveness and recurrence." | 8.12 | Combined intracranial Acriflavine, temozolomide and radiation extends survival in a rat glioma model. ( Alomari, S; Brem, H; Cecia, A; Darjee, N; Domb, AJ; Gorelick, NL; Mangraviti, A; Rottenberg, Y; Serra, R; Shapira-Furman, T; Tyler, B, 2022) |
| "Nearly 10% of patients with adult diffuse glioma develop clinically significant myelotoxicity while on temozolomide (TMZ) leading to treatment interruptions." | 8.12 | Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study. ( Chatterjee, A; Dasgupta, A; Epari, S; Gupta, T; Kota, PK; Kowtal, P; Moitra, P; Patil, V; Sarin, R, 2022) |
| "Temozolomide (TMZ) is a first-line chemotherapeutic agent for the treatment of glioma." | 8.12 | The RNA-binding protein fragile-X mental retardation autosomal 1 (FXR1) modulates glioma cells sensitivity to temozolomide by regulating ferroptosis. ( Duan, S; Gong, F; Li, Q; Wei, Y, 2022) |
| "We retrospectively analyzed cytopenia during temozolomide-based concomitant radiochemotherapy in 492 patients with glioma." | 8.12 | Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma. ( Filipski, K; Filmann, N; Fokas, E; Forster, MT; Harter, PN; Herrlinger, U; Ronellenfitsch, MW; Steinbach, JP; Voss, M; Zeiner, PS, 2022) |
| " Temozolomide is widely used first-line chemotherapy drug to treat glioma patients, but development of temozolomide resistance is almost inevitable." | 8.12 | Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain. ( Bian, XW; Cai, XW; Cao, MF; Gai, QJ; He, J; He, MM; Leng, P; Lu, HM; Mao, M; Qin, Y; Wang, C; Wang, Y; Wang, YX; Wen, XM; Yang, FC; Yao, XH; Yao, XX; Zhu, J, 2022) |
| "The aim of this study was to clarify whether PET with 11C-methyl-l-methionine (11C-met PET) can predict consequential outcomes at the time of discontinuing temozolomide (TMZ)-adjuvant chemotherapy in patients with residual isocitrate dehydrogenase gene (IDH)-mutant lower-grade glioma." | 8.12 | PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma. ( Beppu, T; Fujiwara, S; Iwaya, T; Nomura, JI; Ogasawara, K; Sasaki, T; Sato, Y; Sugai, T; Terasaki, K; Yamada, N, 2022) |
| "We sought to evaluate the effects of concurrent temozolomide-based chemoradiation therapy on neurocognitive function in patients with low-grade glioma (LGG)." | 8.12 | Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas. ( Ahluwalia, MS; Angelov, L; Barnett, GH; Chao, ST; Chen, Y; Hogan, T; Kissel, C; Lapin, B; Mohammadi, A; Murphy, ES; Naugle, R; Park, DY; Parsons, MW; Peereboom, DM; Schuermeyer, I; Stevens, GHJ; Suh, JH; Tewari, S; Tom, MC; Yu, JS, 2022) |
| "Temozolomide (TMZ) is generally applied for glioma treatment, while drug resistance of TMZ limits its therapeutic efficacy." | 8.12 | Mannose inhibits proliferation and promotes apoptosis to enhance sensitivity of glioma cells to temozolomide through Wnt/β-catenin signaling pathway. ( Fei, YQ; Shi, RT; Song, Z; Wu, JZ; Zhou, YF, 2022) |
| "To study the relationship between temozolomide (TMZ) chemotherapy-resistant cells and stem cells in gliomas." | 8.12 | Preliminary Study on Relationship Between Temozolomide Chemotherapy-Resistant Cells and Stem Cells in Gliomas. ( Cunzu, W; Dingchao, X; Min, X; Xun, Z, 2022) |
| "Temozolomide (TMZ), an oral alkylating agent, is the widely used first-line chemotherapeutic reagent for glioma in clinical practice." | 8.12 | Hispidulin Enhances Temozolomide (TMZ)-Induced Cytotoxicity against Malignant Glioma Cells ( Chen, Z; Lei, J; Sheng, C; Song, S; Zhu, G; Zhu, J, 2022) |
| "Glioblastoma patients have a poor prognosis mainly due to temozolomide (TMZ) resistance." | 8.12 | High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1/MRP1 upregulation. ( Andrade-Tomaz, M; Contieri, B; de Souza, I; Gomes, LR; Guedes, CB; Latancia, MT; Lazarini, M; Mendes, D; Monteiro, LKS; Porchia, BFMM; Rocha, CRR; Silva, MM, 2022) |
| " Optical microscopy and flow cytometry were employed to assess the differences in glioblastoma cells morphology, proliferation, and cytotoxicity of anticancer drug temozolomide (TMZ) due to increased substrate viscosity." | 8.12 | Substrate viscosity impairs temozolomide-mediated inhibition of glioblastoma cells' growth. ( Bucki, R; Cieśluk, M; Kochanowicz, J; Kułakowska, A; Piktel, E; Pogoda, K; Skłodowski, K; Wnorowska, U, 2022) |
| " Temozolomide is the standard of care for gliomas, frequently results in resistance to drug and tumor recurrence." | 8.12 | Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration of Human U251 Glioma Cells. ( Alaverdian, DA; Buntovskaya, AS; Chernov, AN; Fedorov, EV; Filatenkova, TA; Galimova, ES; Glushakov, RI; Kim, AV; Matsko, MV; Shamova, OV; Skliar, SS; Tsapieva, AN, 2022) |
| "The complex of formononetin and calycosin (FMN/CAL) shows a synergistic effect on temozolomide in the treatment of malignant glioma, however the mechanism is unclear." | 8.12 | The mechanism of formononetin/calycosin compound optimizing the effects of temozolomide on C6 malignant glioma based on metabolomics and network pharmacology. ( Fan, H; Fan, Y; Huang, T; Li, J; Li, S; Qiu, R; Zhang, Q; Zhou, Y, 2022) |
| "Systemic chemotherapy including monotherapy with temozolomide (TMZ) or bevacizumab (BEV); two-drug combinations, such as irinotecan (IRI) and BEV, TMZ and BEV and a three-drug combination with TMZ, IRI and BEV (TIB) have been used in treating patients with progressive high-grade gliomas including glioblastoma (GBM)." | 8.12 | Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab. ( Ballester, LY; Bhattacharjee, MB; Brown, RE; Buja, LM; Chen, L; Glass, WF; Hergenroeder, GW; Hunter, RL; Linendoll, N; Lu, G; Pilichowska, M; Pillai, AK; Rao, M; Tian, X; Wu, JK; Zhang, R; Zhu, JJ; Zhu, P, 2022) |
| "Brain radiotherapy combined with concomitant and six cycles of adjuvant temozolomide (TMZ) is the standard treatment for newly diagnosed high-grade gliomas (HGGs)." | 8.12 | Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis. ( Ai, P; Chen, J; He, L; Huang, Y; Li, R; Liu, Z; Pei, Y; Peng, X; Wang, J; Wei, Z; Zhao, F, 2022) |
| "It has been noted that temozolomide resistance occurs in a number of malignancies, including glioma, although the underlying cause of this is unknown." | 8.12 | CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study. ( Bai, S; Chen, H; Fan, LL; Hu, Y; Luo, GQ; Yan, ZJ, 2022) |
| " The main cause is the presence of glioma stem cells (GSCs), exceptionally resistant to temozolomide (TMZ) treatment." | 8.12 | TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients. ( Amantini, C; Maggi, F; Morelli, MB; Nabissi, M; Pallini, R; Ricci-Vitiani, L; Santoni, G, 2022) |
| " However, the underlying mechanisms of lncRNA in temozolomide (TMZ)-resistant gliomas were not well understood, hindering the improvement of TMZ-based therapies." | 8.12 | Long Noncoding RNA KCNQ1OT1 Confers Gliomas Resistance to Temozolomide and Enhances Cell Growth by Retrieving PIM1 From miR-761. ( Feng, Y; Gao, W; Han, S; Li, K; Wang, W; Wu, D, 2022) |
| "Thirty rats with glioma were divided into control group, temozolomide (TMZ) group (TMZ 30 mg/kg once daily for 5 day), and TMZ plus Caffeine group (TMZ 30 mg/kg once daily for 5 day and caffeine 100 mg/kg once daily for 2 weeks)." | 8.12 | Caffeine Inhibits Growth of Temozolomide-Treated Glioma via Increasing Autophagy and Apoptosis but Not via Modulating Hypoxia, Angiogenesis, or Endoplasmic Reticulum Stress in Rats. ( Chen, JC; Hwang, JH, 2022) |
| " Therefore, we aimed to examine the Synergistic effects of Gefitinib (GFI) in combination with Temozolomide on VEGF and MMPs in glioma cell line (U87MG)." | 8.12 | Synergistic Effect of Gefitinib and Temozolomide on U87MG Glioblastoma Angiogenesis. ( Hossienpour, M; Karami, A; Kiani, A; Mohammadi Noori, E; Najafi, K; Rahpyma, M, 2022) |
| "Glioma is the most frequent primary malignancy in the brain; temozolomide (TMZ) is the first-line chemotherapeutic agent used to combat this tumor." | 8.02 | AEG-1 silencing attenuates M2-polarization of glioma-associated microglia/macrophages and sensitizes glioma cells to temozolomide. ( Li, J; Ma, Y; Sun, X; Sun, Y; Wang, Y; Zhang, X; Zhao, X, 2021) |
| "Drug resistance strikingly limits the therapeutic effect of temozolomide (TMZ) (a common drug for glioma)." | 8.02 | A positive feedback loop of lncRNA-RMRP/ZNRF3 axis and Wnt/β-catenin signaling regulates the progression and temozolomide resistance in glioma. ( Han, B; Hu, J; Jia, W; Liu, T; Tan, S; Xin, Y, 2021) |
| " CDC20 expression is increased in a variety of tumors and associated with temozolomide (TMZ) resistance in glioma cells." | 8.02 | Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. ( Ding, Y; He, L; Pan, Y; Song, X; Yu, S; Zhang, C; Zheng, C, 2021) |
| "Temozolomide (TMZ) is widely used for glioma therapy in the clinic." | 8.02 | LncRNA MIR155HG Promotes Temozolomide Resistance by Activating the Wnt/β-Catenin Pathway Via Binding to PTBP1 in Glioma. ( He, X; Liu, Q; Sheng, J; Wang, K; Yu, W; Zhu, S, 2021) |
| "Temozolomide (TMZ) is the major chemotherapy agent in glioma, and isocitrate dehydrogenase (IDH) is a well-known prognostic marker in glioma." | 8.02 | Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas. ( Chen, W; Jing, J; Li, R; Mao, P; Sun, Q; Wang, J; Wang, M; Yu, X, 2021) |
| "The purpose of this study is to clarify the clinical features of temozolomide (TMZ)-related hepatitis B virus (HBV) reactivation and to identify HBV reactivation predictive factors." | 8.02 | Hepatitis B virus reactivation during temozolomide administration for malignant glioma. ( Chonan, M; Inoue, J; Kanamori, M; Masamune, A; Osada, Y; Saito, R; Shimoda, Y; Shoji, T; Tominaga, T; Uenohara, H, 2021) |
| "EORTC study 22033-26033 showed no difference in progression-free survival between high-risk low-grade glioma receiving either radiotherapy (RT) or temozolomide (TMZ) chemotherapy alone as primary treatment." | 8.02 | Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033. ( Baumert, BG; Ben Hassel, M; Bromberg, JC; Drijver, AJ; Eekers, DBP; Freixa, SV; Golfinopoulos, V; Gorlia, T; Hoang-Xuan, K; Hottinger, AF; Klein, M; Lucas, A; Reijneveld, JC; Stupp, R; Taphoorn, MJB; Tzuk-Shina, T; van den Bent, MJ; Vauleon, E, 2021) |
| "Temozolomide (TMZ) is a first-line chemotherapy drug for the treatment of malignant glioma and resistance to it poses a major challenge." | 8.02 | Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway. ( Hu, YH; Jiao, BH; Wang, CY; Wu, JL, 2021) |
| " Temozolomide (TMZ) is widely used in the treatment of glioblastoma and is considered as the primary treatment modality." | 8.02 | Molecular biological investigation of temozolomide and KC7F2 combination in U87MG glioma cell line. ( Abbaszade, Z; Avci, CB; Bagca, BG, 2021) |
| "Temozolomide (TMZ), an alkylating agent with a broad-spectrum antitumor activity, ability to cross blood-brain barrier (BBB), shown to be effective against malignant glioma." | 8.02 | Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population. ( Baburaj, G; Jose, A; Kumar, JP; Munisamy, M; Munisamy, S; Subbiah, V; Thomas, L, 2021) |
| "Previous studies showed that the chemotherapeutic effect of temozolomide (TMZ) and vincristine (VCR) against glioma might be blunted by the co-culture with astrocytes, and connexin-43 (CX43) was thought to play a vital role in the communication between glioma cells and astrocytes." | 8.02 | AS602801 sensitizes glioma cells to temozolomide and vincristine by blocking gap junction communication between glioma cells and astrocytes. ( Fan, T; Fu, X; Gong, Y; Huang, Y; Li, Z; Wang, H; Xiang, P; Zhang, S, 2021) |
| " However, whether glioma stem cells (GSCs) can be sensitized to chemotherapy via combined treatment with temozolomide (TMZ) and nicardipine is unclear." | 8.02 | Nicardipine sensitizes temozolomide by inhibiting autophagy and promoting cell apoptosis in glioma stem cells. ( Dong, J; Dong, X; Jiang, Q; Li, H; Liu, L; Shi, J; Wang, H; Wang, L, 2021) |
| "Temozolomide (TMZ) is the internationally recognized and preferred drug for glioma chemotherapy treatment." | 8.02 | Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p. ( Chen, Z; Li, H; Li, Y; Liu, Q; Su, J; Wu, M; Zhang, C, 2021) |
| "Chemotherapy improves overall survival after surgery and radiotherapy for newly diagnosed high-risk IDH-mutant low-grade gliomas (LGGs), but a proportion of patients treated with temozolomide (TMZ) will develop recurrent tumors with TMZ-induced hypermutation." | 8.02 | Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. ( Berger, MS; Butowski, N; Chang, SM; Choi, S; Clarke, JL; Costello, JF; Grimmer, MR; Haas-Kogan, D; Hilz, S; Hong, C; Mazor, T; McDermott, M; Molinaro, AM; Oberheim Bush, NA; Phillips, JJ; Shai, A; Solomon, DA; Taylor, JW; Villanueva-Meyer, J; Wahl, M; Wainer, BH; Yu, Y, 2021) |
| " In this study we investigated the role of FOXO3a in regulating the sensitivity of glioma cells to temozolomide (TMZ) and its relationship with BNIP3-mediated mitophagy." | 8.02 | FOXO3a protects glioma cells against temozolomide-induced DNA double strand breaks via promotion of BNIP3-mediated mitophagy. ( Chi, GF; Ge, PF; He, C; Liang, SP; Lu, S; Luo, TF; Piao, MH; Wang, CC; Wang, L; Wang, XZ; Wang, ZC, 2021) |
| " However, the alterations in gut microbiota observed during glioma growth and temozolomide (TMZ) therapy remain poorly understood." | 8.02 | Temozolomide-Induced Changes in Gut Microbial Composition in a Mouse Model of Brain Glioma. ( Jiang, Y; Jin, XQ; Li, J; Li, XC; Li, YR; Li, ZQ; Ma, C; Wang, ZF; Wu, BS; Yao, J, 2021) |
| "Our data revealed (i) a clinical association of the EMT-like process with glioma malignancy and a poor survival and (ii) an anticancer and temozolomide sensitizing effect of rabeprazole by repressing EMT." | 8.02 | Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition. ( Babu, D; Mudiraj, A; Panigrahi, M; Prakash Babu, P; Y B V K, C; Yadav, N, 2021) |
| "Temozolomide (TMZ) resistance limits its application in glioma." | 8.02 | Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma. ( Bu, X; Chen, X; Ding, C; Gu, J; Kang, D; Lin, Y; Lin, Z; Sun, Y; Wu, X; Wu, Z; Yi, X; You, H; Zhang, G, 2021) |
| " This study investigated whether the improved oxygenation and perfusion that has been previously observed with RRx-001 both preclinically and clinically in the context of a brain metastasis trial was correlated with increased penetration and accumulation of the cytotoxic chemotherapies, irinotecan and temozolomide, in orthotopically implanted gliomas, priming tumours for improved response." | 8.02 | Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas. ( Cabrales, P; Oronsky, B; Reid, T, 2021) |
| "Temozolomide (TMZ) is currently one of the first‑line drugs used for the treatment of high‑grade gliomas." | 8.02 | lncRNA TUG1 inhibits the cancer stem cell‑like properties of temozolomide‑resistant glioma cells by interacting with EZH2. ( Cao, Y; Chai, W; Long, J; Shao, D; Song, H; Tang, D; Wang, Y, 2021) |
| "Temozolomide (TMZ) resistance is the main challenge in the management of glioma patients." | 8.02 | Heparanase confers temozolomide resistance by regulation of exosome secretion and circular RNA composition in glioma. ( Cao, L; Chen, Z; Jiang, Z; Li, W; Li, X; Si, J, 2021) |
| "To report clinical outcomes of temozolomide (TMZ)-based radio-chemotherapy and adjuvant chemotherapy in patients with aggressive/high-risk low-grade glioma (LGG)." | 8.02 | Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy. ( Anand, S; Chatterjee, A; Epari, S; Goda, JS; Gupta, T; Jalali, R; Krishnatry, R; Moiyadi, A; Panda, P; Patil, V, 2021) |
| "A maximal surgical resection followed by radiotherapy and chemotherapy with temozolomide (TMZ) as the representative agent is the standard therapy for gliomas." | 8.02 | The function and mechanism of the JARID2/CCND1 axis in modulating glioma cell growth and sensitivity to temozolomide (TMZ). ( Chen, Y; Jiang, W; Kuang, W; Liu, Z; Tian, Y, 2021) |
| "Apatinib and TMZ may represent an alternative treatment option for patients with recurrent high-gradeglioma, especially those with a low Karnofsky performance status." | 8.02 | Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas. ( Feng, M; Gan, W; Huang, Y; Li, X; Liu, J; Shao, Y; Wang, X; Yao, H; Zhang, C; Zhou, Y, 2021) |
| "Temozolomide (TMZ) is one of the most common drugs selected for glioma chemotherapy, but the therapeutic effect of glioma treatment is usually limited due to its resistance." | 7.96 | LINC00174 down-regulation decreases chemoresistance to temozolomide in human glioma cells by regulating miR-138-5p/SOX9 axis. ( Chen, M; Li, B; Song, J; Wang, F; Zhao, H, 2020) |
| " Here, we detail anti-PD-L1 antibody effects on the tumor microenvironment, including Mϕ infiltration, using a temozolomide (TMZ)-treated glioma model." | 7.96 | Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cell ( Akutsu, H; Ishikawa, E; Kohzuki, H; Matsuda, M; Matsumura, A; Miyazaki, T; Sakamoto, N; Sugii, N; Takano, S, 2020) |
| "Temozolomide (TMZ) is a drug of choice in glioblastoma treatment." | 7.96 | Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions. ( Barciszewska, AM; Barciszewski, J; Belter, A, 2020) |
| "A generally used chemotherapeutic drug for glioma, a frequently diagnosed brain tumour, is temozolomide (TMZ)." | 7.96 | miR-152-5p suppresses glioma progression and tumorigenesis and potentiates temozolomide sensitivity by targeting FBXL7. ( Cao, Y; Fang, Y; He, R; Kong, S; Wang, B; Zhao, Z, 2020) |
| "Glioma is a brain tumour that is often diagnosed, and temozolomide (TMZ) is a common chemotherapeutic drug used in glioma." | 7.96 | MiR-3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway. ( Cao, Y; Kong, S; Li, X; Li, Z; Meng, Y; Xin, Y, 2020) |
| "To some extent, Si wei xiao xiu yin combined with temozolomide can inhibit the growth of subcutaneous xenografts in glioma nude mice." | 7.96 | New advances on the inhibition of Siwei Xiaoliuyin combined with Temozolomide in glioma based on the regulatory mechanism of miRNA21/221. ( Chen, H; Chen, Y; Li, C; Sharma, A; Sharma, HS; Tan, Q; Xie, C; Yang, Y; Zhan, W; Zhang, Z, 2020) |
| "Temozolomide is the most effective chemotherapy for malignant glioma." | 7.96 | Temozolomide desensitization followed by metronomic dosing in patients with hypersensitivity. ( Divekar, RD; Johnson, DR; Maddox, DE; Neth, BJ; Ruff, MW; Uhm, JH, 2020) |
| "This study investigated the effects of temozolomide (TMZ) and/or checkpoint kinase inhibitor AZD7762 in human glioma cells." | 7.96 | Temozolomide and AZD7762 Induce Synergistic Cytotoxicity Effects on Human Glioma Cells. ( Chen, Y; Tsai, YH; Tseng, BJ; Tseng, SH, 2020) |
| " Concurrent temozolomide (TMZ) radiation-the cornerstone of glioma control-extends the overall median survival of GB patients by only a few months over radiotherapy alone." | 7.96 | Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas. ( Chen, TC; Cho, HY; Duc, TC; Hartman, H; Hofman, FM; Huang, M; Minea, RO; Schönthal, AH; Swenson, SD, 2020) |
| "Glioma, especially glioblastoma (GBM), is the most aggressive malignant brain tumor and its standard therapy is often ineffective because of temozolomide (TMZ) resistance." | 7.96 | Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma. ( Cai, HP; Chen, FR; Chen, ZP; Guo, CC; Ma, JX; Ni, XR; Wang, J; Wu, WC; Yu, YJ; Yu, ZH, 2020) |
| " However, the function of circ_0005198 in the temozolomide (TMZ) resistance of glioma has not been well elucidated." | 7.96 | Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis. ( Deng, Y; Liu, C; Meng, X; Xiao, L; Zhu, H, 2020) |
| "Our study elucidated the role of oncogenic LINC01198 in glioma proliferation and temozolomide resistance, and this role may serve as a promising target for glioma therapy." | 7.91 | LINC01198 promotes proliferation and temozolomide resistance in a NEDD4-1-dependent manner, repressing PTEN expression in glioma. ( Chen, HJ; Chen, WL; Ge, JW; Hou, GQ; Zhang, XH, 2019) |
| " However, the role of circular RNA CEP128 in the resistance of glioma cells to temozolomide has not yet been characterized." | 7.91 | Knockdown of circular RNA CEP128 suppresses proliferation and improves cytotoxic efficacy of temozolomide in glioma cells by regulating miR-145-5p. ( Feng, H; Hua, L; Huang, L; Shen, B; Zhang, X, 2019) |
| "Bortezomib was found to inhibit glioma growth and improved TMZ chemotherapy efficacy, probably via down-regulating the FOXM1-Survivin axis." | 7.91 | Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis. ( Chen, JX; Du, L; Huang, GH; Li, QR; Lv, SQ; Tang, JH; Xiang, Y; Xu, QF; Yang, L; Zhang, ZX; Zhou, Z; Zhu, LR, 2019) |
| " To evaluate antitumor activity in vivo, 5-aza was administered alone and in combination with temozolomide (TMZ) in a PDX glioma model harboring IDH1 R132H mutation." | 7.91 | Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. ( Borodovsky, A; Chan, T; da Costa Rosa, M; Festuccia, WT; Riggins, GJ; Yamashita, AS, 2019) |
| "Chemotherapy is the main postsurgical and adjuvant therapy for glioma, and intrinsic or acquired temozolomide (TMZ) resistance may result in poor prognosis." | 7.91 | MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2. ( Feng, B; Ren, H; Wang, J; Yu, J; Yuan, Z; Zhang, B; Zhang, X; Zhao, C; Zhuang, J, 2019) |
| "Mesoporous silica nanoparticles (MSNPs) of a small diameter were loaded with the anticancer drug temozolomide (TMZ), coated with polydopamine (PDA), and conjugated with Asn-Gly-Arg (NGR) for use in the treatment of glioma." | 7.91 | Combination of 3-methyladenine therapy and Asn-Gly-Arg (NGR)-modified mesoporous silica nanoparticles loaded with temozolomide for glioma therapy in vitro. ( Cheng, Y; Huang, N; Huang, Q; Tan, Y; Tang, M; Zhang, P; Zhang, X; Zhao, G, 2019) |
| "For our studies, we have particularly chosen C6 rat glioma cell line due to several reasons: i) We previously showed that MPA reduced growth and induced procarbazine-sensitization in C6 cells; ii) temozolomide has a triazene-type molecular structure like procarbazine; iii) other groups previously showed that C6 glioma cell line is more resistant to temozolomide than human glioma cells; hence it may provide a native model of chemoresistance." | 7.91 | Medroxyprogesterone effects on colony growth, autophagy and mitochondria of C6 glioma cells are augmented with tibolone and temozolomide: Cell kinetic and electron microscopical studies with a broad review of the literature. ( Altinoz, MA; Bilir, A; Elmaci, İ; Ozpinar, A, 2019) |
| "Glioma is a frequently diagnosed brain tumors and Temozolomide (TMZ) is a common chemotherapeutic drug for glioma." | 7.91 | MicroRNA-34a-5p suppresses tumorigenesis and progression of glioma and potentiates Temozolomide-induced cytotoxicity for glioma cells by targeting HMGA2. ( Fu, T; Gao, M; Ma, S; Zhao, S, 2019) |
| " In this preliminary study, the purpose was to evaluate the feasibility of APT imaging in monitoring the early therapeutic response to nitroxoline (NTX) in a temozolomide (TMZ)-resistant glioblastoma multiforme (GBM) mouse model, which was compared with diffusion-weighted imaging (DWI)." | 7.91 | Assessment of Early Therapeutic Response to Nitroxoline in Temozolomide-Resistant Glioblastoma by Amide Proton Transfer Imaging: A Preliminary Comparative Study with Diffusion-weighted Imaging. ( Cho, HR; Choi, SH; Kumari, N; Thakur, N, 2019) |
| "The aim of this current work was to study the therapeutic enhancement of temozolomide (TMZ) on gliomavia combining with calycosin and FMN." | 7.91 | In vitro and in vivo Study on Glioma Treatment Enhancement by Combining Temozolomide with Calycosin and Formononetin. ( Fan, H; Fan, Y; Li, Y; Ni, Q; Zhang, X, 2019) |
| "The present study investigated the effects of the combined treatment of two peptide nucleic acids (PNAs), directed against microRNAs involved in caspase‑3 mRNA regulation (miR‑155‑5p and miR‑221‑3p) in the temozolomide (TMZ)‑resistant T98G glioma cell line." | 7.91 | Targeting miR‑155‑5p and miR‑221‑3p by peptide nucleic acids induces caspase‑3 activation and apoptosis in temozolomide‑resistant T98G glioma cells. ( Borgatti, M; Brognara, E; Cabrini, G; Corradini, R; Cosenza, LC; Dechecchi, MC; Fabbri, E; Finotti, A; Gambari, R; Gasparello, J; Lampronti, I; Manicardi, A; Milani, R, 2019) |
| "We formulated an ultra-small, gadolinium-based nanoparticle (AGuIX) with theranostic properties to simultaneously enhance MRI tumor delineation and radiosensitization in a glioma model." | 7.91 | Ultrasmall theranostic gadolinium-based nanoparticles improve high-grade rat glioma survival. ( Appelboom, G; Barbier, EL; Bräuer-Krisch, E; Chang, SD; Dufort, S; Le Duc, G; Lux, F; Roux, S; Sancey, L; Tillement, O; Verry, C; Zhang, M, 2019) |
| "This study aimed to screen in vitro antitumour activity of the redox couple avarol/avarone against the human malignant glioma cell line U-251 MG for the first time." | 7.88 | The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells. ( Glumac, M; Jakimov, D; Kojic, V; Pejin, B; Tommonaro, G, 2018) |
| "We evaluated stereotactic volume modulated arc radiotherapy (VMAT) for canine gliomas, alone (radiotherapy [RT]) and in combination with temozolomide (RT + TMZ), compared with palliation." | 7.88 | Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas. ( Bianchi, C; Carrara, N; Dolera, M; Finesso, S; Malfassi, L; Marcarini, S; Mazza, G; Pavesi, S; Sala, M; Urso, G, 2018) |
| "Numerous studies suggested autophagy was involved in temozolomide (TMZ) resistance in glioma." | 7.88 | Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression. ( Du, J; Fang, X; Huang, X; Jiang, C; Li, X; Liu, Z; Shen, F; Su, J; Wang, X, 2018) |
| "Although upfront temozolomide (TMZ) has been widely-used to treat 1p/19q-codeleted diffuse low-grade gliomas (LGG), its long-term impact on the growth kinetics of these tumors has not been determined." | 7.88 | Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics. ( Alentorn, A; Barritault, M; Bruna, J; Delattre, JY; Ducray, F; Honnorat, J; Idbaih, A; Izquierdo, C; Kaloshi, G; Meyronet, D; Ricard, D; Simó, M, 2018) |
| "Resistance to temozolomide (TMZ) is a major clinical challenge in glioma treatment, but the mechanisms of TMZ resistance are poorly understood." | 7.88 | Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2. ( Ding, Y; Hu, R; Liu, X; Wang, Q; Yang, M; Zhang, X; Zhou, W, 2018) |
| " In this study we aimed to evaluate the relationship of FBW7 with glioma pathology and prognosis, and examine its effect in glioma malignancies and temozolomide (TMZ)-based therapy." | 7.88 | FBW7 is associated with prognosis, inhibits malignancies and enhances temozolomide sensitivity in glioblastoma cells. ( Cui, Y; Feng, H; He, H; Ji, A; Li, J; Li, S; Lin, J; Lu, Y; Qiu, G; Song, C; Zou, Y, 2018) |
| "To study the effects of combinational treatment of hyperbaric oxygen (HBO) and nanotemozolomide in glioma." | 7.88 | Hyperbaric oxygen as an adjuvant to temozolomide nanoparticle inhibits glioma growth by inducing G2/M phase arrest. ( Hu, J; Wu, X; Xie, Y; Yang, X; Zeng, X; Zhu, Y, 2018) |
| "A standard post-concomitant radiochemotherapy involving adjuvant temozolomide (TMZ) was stopped after 6 cycles for high-grade gliomas (HGG)." | 7.88 | Tumor Volume Changes During and After Temozolomide Treatment for Newly Diagnosed Higher-Grade Glioma (III and IV). ( Ho, JT; Ho, RW; Lin, WC; Lin, YJ; Lin, YT; Lu, CH; Tsai, NW; Wang, HC, 2018) |
| "Temozolomide (TMZ)-induced side effects and drug tolerance to human gliomas are still challenging issues now." | 7.88 | Improved effects of honokiol on temozolomide-induced autophagy and apoptosis of drug-sensitive and -tolerant glioma cells. ( Chang, CK; Chen, KY; Chen, RM; Chio, CC; Chuang, JY; Liu, CC; Liu, SH, 2018) |
| "Temozolomide (TMZ) is the most frequent adjuvant chemotherapy drug in gliomas." | 7.88 | Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model. ( Dai, B; Li, J; Qi, N; Zhang, G, 2018) |
| "To investigate the clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent glioma." | 7.88 | [Clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent brain glioma]. ( Jiang, C; Li, X; Liu, S; Tang, S; Zhao, H, 2018) |
| "Temozolomide, a key drug in the treatment of malignant glioma, can cause profound lymphopenia and various opportunistic infectious diseases." | 7.88 | Cytomegalovirus Hemorrhagic Cystitis in a Malignant Glioma Patient Treated with Temozolomide. ( Furukawa, R; Homma, H; Horiuchi, H; Inoue, T; Usui, K, 2018) |
| "Temozolomide (TMZ) is currently the first-line drug used for clinical postoperative or non-surgical chemotherapy for glioma, but acquired and intrinsic resistance to TMZ limits its application." | 7.88 | Synergistic Anticancer Effects of Formononetin and Temozolomide on Glioma C6 Cells. ( Fan, H; Li, Y; Ni, Q; Wang, Y; Zhang, X, 2018) |
| " Multidrug resistance, particularly resistance to temozolomide (TMZ), is a challenge in combating glioma, and more effective therapies are needed." | 7.88 | Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo. ( Bai, Y; Chen, Y; Dong, X; Hong, X; Li, S; Li, Y; Liu, X; Su, X; Zhao, G, 2018) |
| "Temozolomide (TMZ) is a first-line chemotherapeutic drug for malignant gliomas." | 7.88 | Honokiol enhances temozolomide-induced apoptotic insults to malignant glioma cells via an intrinsic mitochondrion-dependent pathway. ( Chen, RM; Chio, CC; Liu, SH; Mohanraj, M; Tai, YT; Yang, ST, 2018) |
| "Postoperative management of anaplastic glioma remains without a clear standard of care-in this study we report outcomes for patients treated with radiotherapy (RT) with and without temozolomide (TMZ)." | 7.88 | Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide. ( Chan, MD; Debinski, W; Farris, M; Helis, C; Laxton, AW; Lesser, GJ; Lo, HW; Lucas, JT; McTyre, E; Mott, R; Soike, M; Strowd, RE; Tatter, SB, 2018) |
| "To compare various pro-apoptotic effects of synthetic 4-thiazolidinone derivative (Les-3288), doxorubicin (Dox) and temozolomide (TMZ) in the treatment of human glioma U251 cells to improve treatment outcomes of glioblastoma and avoid anticancer drug resistance." | 7.85 | Differential pro-apoptotic effects of synthetic 4-thiazolidinone derivative Les-3288, doxorubicin and temozolomide in human glioma U251 cells. ( Finiuk, N; Grytsyna, II; Klyuchivska, OY; Lehka, L; Lesyk, RB; Panchuk, RR; Starykovych, MO; Stoika, RS; Zіmenkovsky, BS; Коbylinska, LI, 2017) |
| "Temozolomide (TMZ) is widely used in high-grade glioma (HGG)." | 7.85 | Haematological malignancies following temozolomide treatment for paediatric high-grade glioma. ( Beilken, A; Corbacioglu, S; Dilloo, D; Driever, PH; Dürken, M; Gielen, GH; Hoffmann, M; Karremann, M; Krämer, N; Kramm, CM; Kulozik, A; Scheurlen, W; von Bueren, AO; Wiese, M, 2017) |
| "Here we evaluated whether glioma sensitive or resistant to temozolomide (TMZ) modulate macrophage polarization and inflammatory pathways associated." | 7.85 | Glioma sensitive or chemoresistant to temozolomide differentially modulate macrophage protumor activities. ( Azambuja, JH; Beira, FT; Braganhol, E; da Silveira, EF; de Carvalho, TR; do Couto, CT; Oliveira, PS; Pacheco, S; Spanevello, RM; Stefanello, FM, 2017) |
| " Gliomas are devastating cancers and their positive treatment outcome using Temozolomide (TMZ) is limited due to its short plasma half-life, systemic toxicity and limited access through the blood-brain barrier (BBB)." | 7.85 | Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433). ( Ahsan, SM; Kondapi, AK; Kumar, JM; Kumari, S; Rao, NM, 2017) |
| "Temozolomide (TMZ) for malignant gliomas is traditionally dosed in 5 out of a 28-day cycle, however alternative regimens exist, including dose-dense." | 7.85 | Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma. ( Howard, TA; Villano, JL; Zhou, Z, 2017) |
| "In this study, we demonstrated that temozolomide (TMZ) and propyl gallate (PG) combination enhanced the inhibition of migration in human U87MG glioma cells." | 7.85 | Propyl Gallate Exerts an Antimigration Effect on Temozolomide-Treated Malignant Glioma Cells through Inhibition of ROS and the NF- ( Chen, CH; Chen, KT; Cheng, YC; Chung, CY; Lee, IN; Lee, MH; Lu, FJ; Yang, JT, 2017) |
| "To explore the efficacy and toxicity of an extended schedule of temozolomide (50 mg/mq 1 week on/1 week off) in a population of newly diagnosed low-grade gliomas (LGG)." | 7.85 | Temozolomide low-dose chemotherapy in newly diagnosed low-grade gliomas: activity, safety, and long-term follow-up. ( Carapella, CM; Carosi, M; Fabi, A; Giannarelli, D; Marucci, L; Maschio, M; Merola, R; Pace, A; Vidiri, A; Villani, V, 2017) |
| " In this study, we investigated the effect of silver nanoparticles (AgNPs) on human glioma U251 cells and its role in the combinational use with Temozolomide (TMZ), an imidazotetrazine derivative of the alkylating agent dacarbazine, against glioma cells." | 7.85 | Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells. ( Chen, H; Gong, Z; Gui, Q; Guo, X; Liang, P; Meng, J; Shi, H; Xu, Y; Zhu, W, 2017) |
| " When treated with temozolomide (TMZ), an oral alkylating chemotherapy drug, most low-grade gliomas (LGG) show an initial volume decrease but this effect is rarely long lasting." | 7.85 | Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model. ( Alentorn, A; Delattre, JY; Ducray, F; Grenier, E; Honnorat, J; Idbaih, A; Kaloshi, G; Mazzocco, P; Ollier, E; Psimaras, D; Ricard, D; Samson, A, 2017) |
| " Glioma cells may synthetize the antioxidant glutathione by importing cystine through a cystine/glutamate antiporter, which is inhibited by sulfasalazine (SAS)." | 7.85 | Characteristics of sulfasalazine-induced cytotoxicity in C6 rat glioma cells. ( Castilho, RF; de Melo, DR; Facchini, G; Ferreira, CV; Ignarro, RS; Pelizzaro-Rocha, KJ; Rogerio, F, 2017) |
| "The occurrence of an inherent or acquired resistance to temozolomide (TMZ) is a major burden for patients suffering from glioma." | 7.85 | Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2. ( Cai, L; Su, Z; Tu, M; Yu, Z; Zeng, B; Zheng, W; Zhu, D, 2017) |
| "The present study aimed to investigate whether overexpression of integrin-linked kinase (ILK) affects drug resistance to temozolomide (TMZ) in glioma cells." | 7.85 | Overexpression of ILK promotes temozolomide resistance in glioma cells. ( Bao, L; Liang, F; Wang, B; Zhang, SM; Zhang, SQ; Zhao, YS, 2017) |
| "Despite multimodal therapy with radiation and the DNA alkylating agent temozolomide (TMZ), malignant gliomas remain incurable." | 7.85 | PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas. ( Bahassi, EM; Chan, TA; Chu, Z; Koncar, RF; Qi, X; Romick-Rosendale, LE; Wells, SI, 2017) |
| "We investigated the effect of chemoradiotherapy with PP2 and temozolomide (TMZ) on malignant glioma cells using clonogenic assays and in vivo brain tumor model." | 7.83 | The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo. ( Chie, EK; Cho, BJ; Choi, EJ; Eom, KY; Kim, IA; Kim, IH; Kim, JH; Kim, JS; Paek, SH; Wu, HG, 2016) |
| "Arginine-glycine-aspartic acid peptide (RGD)-modified nanostructured lipid carriers (NLCs) were used for the delivery of temozolomide (TMZ) into the GBM to provide a new paradigm in gliomatosis cerebri treatment." | 7.83 | Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy. ( Du, J; Mao, G; Song, S; Zhu, X, 2016) |
| "Temozolomide is a standard chemotherapy agent for malignant gliomas, but the efficacy is still not satisfactory." | 7.83 | Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells. ( Kanamori, M; Saito, R; Shibahara, I; Sonoda, Y; Sugiyama, S; Tominaga, T; Zhang, R, 2016) |
| "We aimed to analyze the value of seizure reduction and radiological response as prognostic markers of survival in patients with low-grade glioma (LGG) treated with temozolomide (TMZ) chemotherapy." | 7.83 | Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide. ( Dirven, L; Heimans, JJ; Koekkoek, JA; Postma, TJ; Reijneveld, JC; Taphoorn, MJ; Vos, MJ, 2016) |
| "A gene drug delivery system for glioma therapy based on transferrin (Tf)-modified polyamidoamine dendrimer (PAMAM) was prepared." | 7.83 | Plasmid pORF-hTRAIL targeting to glioma using transferrin-modified polyamidoamine dendrimer. ( Gao, S; Hao, B; Hong, B; Jiang, C; Li, J, 2016) |
| " Human glioma U87MG or LNZ308 cells overexpressing either wild-type (wt) EGFR or EGFRvIII were treated with nimotuzumab, temozolomide, or both." | 7.83 | Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo. ( Nagane, M; Nitta, Y; Shimizu, S; Shiokawa, Y; Shishido-Hara, Y; Suzuki, K, 2016) |
| " Food and Drug Administration and EMA-approved xCT inhibitor, sulfasalazine (SAS) in gliomas." | 7.83 | Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema. ( Buchfelder, M; Dörfler, A; Engelhorn, T; Eyüpoglu, IY; Fan, Z; Ghoochani, A; Klucken, J; Minakaki, G; Rauh, M; Savaskan, N; Sehm, T, 2016) |
| "The effects of KLF8 on glioma cell proliferation, apoptosis and chemosensitivity to temozolomide (TMZ) were analyzed by Cell Counting Kit 8 assay and flow cytometry assay." | 7.83 | KLF8 Promotes Temozolomide Resistance in Glioma Cells via β-Catenin Activation. ( Wang, E; Wu, F; Yu, G, 2016) |
| "HIF-1α downregulation sensitizes U251 glioma cells to the temozolomide treatment via inhibiting MGMT expression and Notch1 pathway activation." | 7.83 | Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment. ( Huang, GH; Li, N; Lv, SQ; Ma, ZX; Sidlauskas, K; Tang, JH; Xiang, Y; Xu, QF; Zhang, EE, 2016) |
| "Temozolomide (TMZ), an oral alkylator of the imidazotetrazine family, is used to treat glioma." | 7.83 | Evidence for the Inhibition by Temozolomide, an Imidazotetrazine Family Alkylator, of Intermediate-Conductance Ca2+-Activated K+ Channels in Glioma Cells. ( Hsieh, YJ; Hsu, CW; Huang, CW; Huang, YM; Hung, TY; Sze, CI; Wu, SJ; Wu, SN; Yeh, PS, 2016) |
| "Although temozolomide (TMZ) is the most effective chemotherapy agent for glioma, chemotherapy resistance has limited its clinical use." | 7.83 | Fluoxetine synergizes with temozolomide to induce the CHOP-dependent endoplasmic reticulum stress-related apoptosis pathway in glioma cells. ( Chen, MH; Chen, W; Ma, J; Sun, LL; Wang, DC; Wang, FZ; Wang, H; Wang, XD; Yang, YR, 2016) |
| " In the case of glioma, temozolomide (TMZ) is the main option for treatment, but it has limited success due to drug resistance." | 7.83 | NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells. ( Fortunato, RS; Kajitani, GS; Menck, CF; Quinet, A; Rocha, CR, 2016) |
| "Temozolomide (TMZ) improves Glioblastoma Multiforme (GBM) patient survival." | 7.83 | Temozolomide induces the expression of the glioma Big Potassium (gBK) ion channel, while inhibiting fascin-1 expression: possible targets for glioma therapy. ( Ahluwalia, A; Chau, V; Ge, L; Hoa, NT; Jadus, MR; Kruse, CA; Martini, F, 2016) |
| "Temozolomide (TMZ) is the most commonly used alkylating agent in glioma chemotherapy." | 7.83 | miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectely. ( Liao, Y; Liu, J; Liu, Q; Lv, R; Qiu, X; Wu, M; Xiao, S; Yang, Z, 2016) |
| "Genotoxic chemotherapy with temozolomide (TMZ) is a mainstay of treatment for glioblastoma (GBM); however, at best, TMZ provides only modest survival benefit to a subset of patients." | 7.83 | Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide. ( Johnston, G; Lincoln, FA; Murphy, BM; Noonan, J; Rehm, M; Weyhenmeyer, BC; Würstle, ML, 2016) |
| " 1) VPA treatment clearly sensitized glioma cells to temozolomide: A protruding VPA-induced molecular feature in this context was the transcriptional upregulation/reexpression of numerous solute carrier (SLC) transporters that was also reflected by euchromatinization on the histone level and a reexpression of SLC transporters in human biopsy samples after VPA treatment." | 7.83 | Molecular dissection of the valproic acid effects on glioma cells. ( Hau, P; Herold-Mende, C; Hoja, S; Proescholdt, M; Rehli, M; Riemenschneider, MJ; Schulze, M, 2016) |
| " In the OP group with GBM and anaplastic glioma, patients treated with RT combined with temozolomide (TMZ) manifested significantly longer OS and PFS compared with patients assigned to RT alone (P < 0." | 7.83 | Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma. ( Cai, J; Jiang, T; Li, S; Li, W; Peng, X; Qiu, X; Wang, Y; Wu, C; Yang, P; Yao, K; You, G; Zhang, C; Zhang, W, 2016) |
| "Concomitant use of temozolomide (TMZ) and radiotherapy, which is the standard therapy for patients with high-grade glioma, involves a unique regimen with multiple-day, long-term administration." | 7.83 | Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study. ( Akutsu, H; Ishikawa, E; Matsuda, M; Matsumura, A; Takano, S; Yamamoto, T, 2016) |
| " Iron chelators have been shown to have anti-tumor activity; however, deferiprone (DFP), an orally administered iron chelator, has not been previously evaluated in gliomas." | 7.83 | Deferiprone Enhances Temozolomide Cytotoxicity in Glioma Cells. ( Alexiou, GA; Gerogianni, P; Kyritsis, AP; Vartholomatos, E, 2016) |
| " As poor differentiation and low apoptosis are closely associated with poor survival rates and a poor response to radio/chemotherapy in patients with cancer, the prognostic value of Dec1 expression was examined in the present study and its correlation with response to temozolomide (TMZ) chemotherapy was analyzed in patients with glioma." | 7.83 | Dec1 expression predicts prognosis and the response to temozolomide chemotherapy in patients with glioma. ( Bian, H; Huang, Y; Li, XM; Lin, W; Wang, J; Yao, L; Yin, AA; Zhang, J; Zhang, W; Zhang, X, 2016) |
| "Temozolomide (TMZ), an alkylating agent of the imidazotetrazine series, is a first-line chemotherapeutic drug used in the clinical therapy of glioblastoma multiforme, the most common and high-grade primary glioma in adults." | 7.83 | The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death. ( Chang, CK; Chen, KC; Chen, PH; Cheng, CH; Ho, KH; Lee, CC; Lin, CW; Liu, AJ; Shih, CM, 2016) |
| "The aim of this study was to investigate the effect of downregulating Hedgehog pathway by GANT61 on human glioma cells, examine the consequent changes of temozolomide (TMZ)-induced effects and explore the molecular mechanisms." | 7.83 | GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment. ( Cai, J; Chen, L; Jiang, C; Li, J; Li, R; Li, Y; Sun, Y; Yao, K; Zhai, X; Zhang, J; Zhao, S, 2016) |
| " With the aim to better understand the resistance/susceptibility processes associated to temozolomide (TMZ) treatment, the current study was performed in three human malignant glioma cell lines by focusing on several levels: (a) apoptotic index and senescence, (b) DNA damage, and (c) interaction of HSPB1 with players of the DNA damage response." | 7.81 | Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells. ( Castro, GN; Cayado-Gutiérrez, N; Ciocca, DR; Cuello-Carrión, FD; Fanelli, MA; Nadin, SB; Sottile, M; Zoppino, FC, 2015) |
| " Here, we examine the molecular mechanisms by which epigallocatechin gallate (EGCG), a bioactive polyphenol in green tea, inhibits the stem cell characteristics of glioma stem-like cells (GSLCs) and synergizes with temozolomide (TMZ), a DNA-methylating agent commonly used as first-line chemotherapy in gliomas." | 7.81 | EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition. ( Du, B; Li, HY; Ma, JW; Wang, SX; Xie, SM; Ye, JC; Zhang, Y; Zhong, XY, 2015) |
| "The purpose of this study was to assess the efficacy and toxicity of radiotherapy (RT) with concurrent temozolomide (TMZ) chemotherapy followed by adjuvant TMZ in children with diffuse intrinsic pontine glioma (DIPG)." | 7.81 | Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise? ( Attinà, G; Balducci, M; Caldarelli, M; Colosimo, C; Lazzareschi, I; Mastrangelo, S; Maurizi, P; Riccardi, R; Ridola, V; Rizzo, D; Ruggiero, A; Scalzone, M, 2015) |
| " The autophagy inhibitor chloroquine (CQ) potentiates temozolomide (TMZ) cytotoxicity in glioma cells, but it is not known whether CQ does this by inhibiting mitochondrial autophagy." | 7.81 | Chloroquine potentiates temozolomide cytotoxicity by inhibiting mitochondrial autophagy in glioma cells. ( Akiyama, Y; Hori, YS; Horio, Y; Hosoda, R; Kuno, A; Maruyama, M; Mikami, T; Mikuni, N; Sebori, R; Sugino, T; Suzuki, K; Tsukamoto, M; Wanibuchi, M, 2015) |
| " Temozolomide (TMZ) is currently used to intervene glioma multiforme (GBM), but an acquired chemotherapeutic resistance maybe occurred due to undesired autophagy." | 7.81 | Bcl2L12 with a BH3-like domain in regulating apoptosis and TMZ-induced autophagy: a prospective combination of ABT-737 and TMZ for treating glioma. ( Cheng, JT; Chou, AK; Chou, CH; Hong, YR; Howng, SL; Huang, WS; Li, YY; Lieu, AS; Loh, JK; Wang, YT; Yang, MC, 2015) |
| "Temozolomide (TMZ) increases the overall survival of patients with glioblastoma (GBM), but its role in the clinical management of diffuse low-grade gliomas (LGG) is still being defined." | 7.81 | Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. ( Aburatani, H; Aihara, K; Berger, MS; Chang, SM; Costello, JF; Fouse, SD; Hallbeck, M; Heimans, JJ; Hong, C; Johnson, BE; Kloezeman, JJ; Lamfers, ML; Malmström, A; Mazor, T; Molinaro, AM; Mukasa, A; Reijneveld, JC; Saito, N; Söderkvist, P; Stenmark-Askmalm, M; Taylor, BS; van Thuijl, HF; Wesseling, P; Ylstra, B, 2015) |
| "To investigate programmed cell death induced by temozolomide in rat glioma C6 cell line." | 7.81 | [Caspase-independent programmed cell death induced by temozolomide in rat glioma C6 cell line]. ( Liu, L; Zhang, M, 2015) |
| " In this project, we evaluated the effects of silibinin, a natural plant component of milk thistle seeds, to potentiate toxic effects of chemotherapy drugs such as temozolomide, etoposide and irinotecan on LN229, U87 and A172 (P53 and phosphatase and tensin homolog (PTEN) -tumor suppressor-mutated) glioma cell lines." | 7.81 | The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines. ( Elhag, R; Mazzio, EA; Soliman, KF, 2015) |
| "Temozolomide (TMZ) is the first line drug in the care of high grade gliomas." | 7.81 | Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: a very long term comparative study and literature review. ( Clemente, MA; Corsa, P; Cossa, S; Donno, E; Munafò, T; Parisi, F; Parisi, S; Perrone, A; Piombino, M; Raguso, A; Sanpaolo, G; Valle, G, 2015) |
| "This study was initiated to test the feasibility and toxicity of a regimen that alternates the administration of weekly carboplatin and vincristine with temozolomide in the management of children with progressive and/or symptomatic low-grade glioma." | 7.81 | A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: a Children's Oncology Group study†. ( Adesina, A; Chintagumpala, M; Eckel, SP; Gajjar, A; Krailo, M; Lau, C; Morris, M; Packer, R, 2015) |
| "Acute severe lymphopenia (ASL) frequently develops during radiation therapy (RT) and concurrent temozolomide (TMZ) for high-grade glioma (HGG) and is associated with decreased survival." | 7.81 | Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma. ( Badiyan, SN; Campian, JL; Chicoine, MR; DeWees, TA; Dunn, G; Fergus, S; Huang, J; Kim, AH; Linette, G; Mullen, DF; Robinson, CG; Simpson, JR; Speirs, CK; Tran, DD, 2015) |
| "The objective of the study was to determine whether astrocytes and brain endothelial cells protect glioma cells from temozolomide through an endothelin-dependent signaling mechanism and to examine the therapeutic efficacy of the dual endothelin receptor antagonist, macitentan, in orthotopic models of human glioblastoma." | 7.81 | Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice. ( Aldape, K; Choi, HJ; Conrad, CA; Fidler, IJ; He, J; Kim, MS; Kim, SJ; Langley, RR; Lee, HJ; Lehembre, F; Regenass, U; Weinberg, JS; Wu, Q; Yung, WK, 2015) |
| "We retrospectively investigated the prognostic impact of molecular phenotypes in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide (TMZ)." | 7.81 | Prognostic impact of molecular phenotype in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide. ( Choi, YR; Kim, HR; Kong, DS; Lee, JI; Nam, DH; Seol, HJ, 2015) |
| " We investigated whether the widely used chemotherapeutic agent temozolomide (TMZ) can sensitize glioma stem-like cells (GSCs) from human glioblastoma multiforme (GBM) to TRAIL-induced apoptosis." | 7.81 | Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein. ( Anhua, W; Jia, L; Long, L; Yunchao, B; Zhitao, J, 2015) |
| " The introduction of temozolomide (TMZ) has advanced chemotherapy for malignant gliomas." | 7.81 | NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. ( Chen, Y; Cheng, Y; Li, Y; Xie, G; Yao, G; Yu, Z; Zhang, G; Zhao, G; Zhou, G, 2015) |
| "Temozolomide plays a critical role in curing glioma at present." | 7.81 | Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation. ( Gao, J; Huang, G; Liu, H; Wang, L; Wang, Z, 2015) |
| "A total of nine patients with malignant glioma, postoperatively presenting with a Karnofsky performance score (KPS) below 70, were treated with standalone metronomic low-dose chemotherapy with temozolomide and celecoxib (cyclo-oxygenase-2 inhibitor)." | 7.81 | Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment. ( Brawanski, KR; Freyschlag, CF; Grams, AE; Kerschbaumer, J; Nowosielski, M; Petr, O; Pinggera, D; Schmidt, FA; Seiz, M; Thomé, C; Tuettenberg, J, 2015) |
| "Temozolomide (TMZ) as a concomitant and adjuvant chemotherapy to radiotherapy following maximal surgical resection is the established standard therapy for patients with newly diagnosed high-grade glioma." | 7.81 | Profile Analysis of Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study. ( Akutsu, H; Ishikawa, E; Matsuda, M; Matsumura, A; Nakai, K; Onuma, K; Yamamoto, T, 2015) |
| "Mesoporous silica nanoparticles (MSNPs), 100 nm in size, incorporating a Cy5 fluorophore within the silica framework, are synthesized and loaded with the anti-cancer drug temozolomide (TMZ), used in the treatment of gliomas." | 7.81 | Combined Delivery of Temozolomide and Anti-miR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells. ( Bertucci, A; Brognara, E; Corradini, R; De Cola, L; Gambari, R; Manicardi, A; Prasetyanto, EA; Septiadi, D, 2015) |
| "Glioblastoma (GBM) generally exhibits high IC50 values for its standard drug treatment, temozolomide (TMZ)." | 7.81 | Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells. ( Ananta, JS; Massoud, TF; Paulmurugan, R, 2015) |
| "Temozolomide (TMZ) with radiotherapy is the current standard of care for newly diagnosed glioma." | 7.81 | MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells. ( Chen, Q; Han, J, 2015) |
| "To assess effectiveness of 5-aminolevulinic acid (5-ALA, Gliolan(®)) in patients treated for malignant glioma under typical daily practice conditions in Spain, using complete resection rate (CR) and progression free survival at 6 months (PFS6)." | 7.80 | Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study). ( Arza, C; Díez Valle, R; Galván, J; Romariz, C; Slof, J; Vidal, C, 2014) |
| "The aim of this study is to investigate the inhibitory effects of 2T-P400, a derivative of temozolomide (TMZ), on glioma growth." | 7.80 | The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection. ( Dong, J; Li, R; Tang, D; Wang, L; Wu, J; Zhang, J, 2014) |
| " This study employed intracranial human glioma models to evaluate the effect of BEV alone and in combination with temozolomide (TMZ) and/or radiation therapy (XRT) on overall survival." | 7.80 | Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models. ( Blakeley, JO; Brastianos, H; Brem, H; Goodwin, RC; Grossman, R; Hwang, L; Lal, B; Mangraviti, A; Tyler, B; Wicks, RT; Zadnik, P, 2014) |
| "To investigate the mechanisms of action of the tumoricidal effects of temozolomide against the human glioma cell line U251 in vitro, and to provide preclinical proof-of-concept studies of the effects of temozolomide-containing regimens." | 7.80 | Mechanism of temozolomide-induced antitumour effects on glioma cells. ( Hu, JA; Shen, W; Zheng, JS, 2014) |
| "Present work mainly evaluated the inhibitory effects of lidamycin (LDM), an enediyne antibiotic, on angiogenesis or glioma-induced angiogenesis in vitro and in vivo, especially its synergistic anti-angiogenesis with temozolomide (TMZ)." | 7.80 | Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin. ( Li, XQ; Li, Y; Liu, H; Ouyang, ZG; Shang, Y; Zhang, SH; Zhen, YS, 2014) |
| " In the present study aimed to: (i) evaluate the concordance between MGMT promoter methylation status in tumor tissue and plasma; (ii) monitor MGMT promoter methylation status in plasma taken before and during temozolomide treatment; (iii) explore the value of MGMT promoter methylation status in plasma as a prognostic/predictive biomarker in glioma patients." | 7.80 | MGMT promoter methylation in plasma of glioma patients receiving temozolomide. ( Cassoni, P; Castiglione, A; De Marco, L; Fiano, V; Gillio-Tos, A; Grasso, C; Magistrello, M; Merletti, F; Rudà, R; Sacerdote, C; Senetta, R; Soffietti, R; Tondat, F; Trevisan, E; Trevisan, M, 2014) |
| "Temozolomide (TMZ), used to treat glioblastoma and malignant glioma, induces autophagy, apoptosis and senescence in cancer cells." | 7.80 | Antitumor effect of fibrin glue containing temozolomide against malignant glioma. ( Anai, S; Hide, T; Kuratsu, J; Kuroda, J; Makino, K; Nakamura, H; Shinojima, N; Takezaki, T; Yano, S, 2014) |
| "We present a case of inadvertent high-dose therapy with temozolomide in a child with recurrent diffuse intrinsic pontine glioma followed by a rapid clinical response." | 7.80 | Inadvertent high-dose therapy with temozolomide in a child with recurrent pontine glioma followed by a rapid clinical response but deteriorated after substitution with low-dose therapy. ( Altonok, D; Konski, A; Poulik, J; Sood, S; Wang, ZJ, 2014) |
| "Autophagy is a cytoprotective process, which occurs following temozolomide (TMZ) treatment, and contributes to glioma chemoresistance and TMZ treatment failure." | 7.80 | Temozolomide induces autophagy via ATM‑AMPK‑ULK1 pathways in glioma. ( Li, B; Wang, Q; Wang, W; Xie, B; Zou, Y, 2014) |
| "B10 is a glycosylated derivative of betulinic acid with promising activity against glioma cells." | 7.80 | Hypoxia enhances the antiglioma cytotoxicity of B10, a glycosylated derivative of betulinic acid. ( Bähr, O; Fischer, S; Fulda, S; Harter, PN; Kögel, D; Mittelbronn, M; Paschke, R; Reichert, S; Ronellenfitsch, MW; Steinbach, JP; Thiepold, AL; Weller, M, 2014) |
| "The present work evaluated the synergistic efficacy of an enediyne antibiotic lidamycin (LDM) plus temozolomide (TMZ) against glioma in vitro and in vivo." | 7.80 | Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction. ( Li, XQ; Li, Y; Liu, H; Ouyang, ZG; Shang, Y; Zhang, SH; Zhen, YS, 2014) |
| "To study the therapeutic effect of intranasal administration of temozolomide (TMZ) for brain-targeting delivery in a rat model bearing orthotopic C6 glioma xenografts." | 7.80 | [Intranasal administration of temozolomide for brain-targeting delivery: therapeutic effect on glioma in rats]. ( Gao, Y; Li, Y; Liu, G; Ma, L; Wang, Y; Zhou, X, 2014) |
| "This study explored the effects of telomerase reverse transcriptase (TERT) promoter mutations on transcriptional activity of the TERT gene under hypoxic and temozolomide (TMZ) treatment conditions, and investigated the status and prognostic value of these mutations in gliomas." | 7.80 | TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas. ( Chen, C; Han, S; Li, Z; Meng, L; Wu, A; Zhang, X, 2014) |
| "This study evaluated the toxicity profiles of temozolomide in the treatment of malignant glioma as either concurrent or adjuvant chemotherapy." | 7.80 | Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. ( Bae, SH; Cho, SY; Kim, CY; Kim, TM; Kim, YH; Kim, YJ; Lee, MM; Lee, SH; Park, CK; Park, MJ, 2014) |
| "The combined application of aplysin and TMZ significantly sensitizes glioma cells to TMZ action, compared with TMZ alone." | 7.80 | Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level. ( Ge, N; Gong, A; Liang, H; Lu, L; Yao, W, 2014) |
| "Temozolomide (TMZ), a DNA methylating agent, is widely used in the adjuvant treatment of malignant gliomas." | 7.80 | Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase. ( Fukai, J; Koizumi, F; Nakao, N, 2014) |
| "These results suggest that concomitant treatment with NPe6-PDT and temozolomide is a potentially useful therapy for glioma." | 7.80 | Concomitant treatment with temozolomide enhances apoptotic cell death in glioma cells induced by photodynamic therapy with talaporfin sodium. ( Akimoto, J; Beppu, M; Fujiwara, Y; Hiranuma, M; Hironaka, C; Miki, Y; Moritake, K; Omata, H, 2014) |
| "We report the safety and feasibility of a 3 days on/11 days off temozolomide regimen for the treatment of recurrent malignant gliomas." | 7.80 | Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas. ( Brown, BD; Brown, T; Juarez, T; Kesari, S; Piccioni, DE; Saria, MG; van Vugt, VA, 2014) |
| "For glioma, temozolomide (TMZ) is a commonly used chemotherapy drug and photodynamic therapy (PDT) is an important adjuvant therapy." | 7.80 | Combination of photodynamic therapy and temozolomide on glioma in a rat C6 glioma model. ( Guo, M; Hu, S; Shen, L; Zhang, X, 2014) |
| " The purpose of this study was to assess the preclinical therapeutic efficacy of FUS-BBB opening for enhanced temozolomide (TMZ) delivery in glioma treatment." | 7.80 | Pharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment. ( Chen, JY; Chen, PY; Huang, CY; Liu, HL; Wang, HY; Wei, KC, 2014) |
| "Nine post-temozolomide recurrent or progressive high-grade glioma patients (seven with glioblastoma and two with anaplastic astrocytoma) were treated with BV monotherapy." | 7.80 | Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report. ( Kobayashi, K; Nagane, M; Shimizu, S; Shiokawa, Y; Shishido-Hara, Y; Tanaka, M; Tsuchiya, K, 2014) |
| "Glioma cells rich in miR-181b were more sensitive to temozolomide." | 7.79 | miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1. ( Chen, FR; Chen, ZP; Sai, K; Wang, J, 2013) |
| "In the U87 intracerebral glioma model, within the first day of administration of cediranib, the intratumoral concentrations of TMZ in tumor ECF were slightly, but not statistically significantly, increased when compared to the treatment of TMZ alone with radiographic evidence of a normalized BBB." | 7.79 | Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model. ( Blakeley, JO; Brem, H; Grossman, R; Khan, U; Kim, E; Pathak, AP; Rudek, MA; Tyler, B; Zadnik, P, 2013) |
| "To compare retrospectively outcome after photon radiotherapy alone, radiochemotherapy with temozolomide (TMZ), and carbon ion radiotherapy in patients with high-grade gliomas and to generate a hypothetical outcome curve for C12 and TMZ." | 7.79 | Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis. ( Bruckner, T; Combs, SE; Debus, J; Kamada, T; Kieser, M; Mizoe, JE; Tsujii, H, 2013) |
| "The recent progress in chemotherapy for malignant gliomas is attributable to the introduction of the DNA-methylating agent temozolomide (TMZ); however, drug resistance remains a major issue." | 7.79 | The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells. ( Adachi, K; Hayashi, T; Hirose, Y; Ohba, S, 2013) |
| "Bortezomib induced caspase-3 activation and apoptotic cell death in stable glioma cell lines and in glioma stem-like cells (GSCs) derived from malignant tumor specimens Furthermore, TMZ-resistant glioma cell lines retained susceptibility to the proteasome inhibition." | 7.79 | Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. ( Alexandru, D; Bigner, D; Bota, DA; Friedman, HS; Keir, ST; Vredenburgh, J, 2013) |
| "Study the feasibility and effectiveness of a treatment associated surgery, intraoperative chemotherapy (carmustine wafers), and concomitant radiochemotherapy (temozolomide) for the management of newly diagnosed, high-grade gliomas." | 7.79 | Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases. ( Colin, P; Debreuve, A; Duntze, J; Eap, C; Emery, E; Guillamo, JS; Jovenin, N; Lechapt-Zalcman, E; Litré, CF; Menei, P; Metellus, P; Peruzzi, P; Rousseaux, P; Théret, E, 2013) |
| " In previous studies the alkylating agent temozolomide (TMZ) incorporated into a polymer, pCPP:SA, also for local delivery, and OncoGel were individually shown to increase efficacy in a rat glioma model." | 7.79 | Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model. ( Brem, H; Eberhart, CG; Fowers, KD; Hwang, L; Li, KW; Okonma, S; Recinos, VR; Tyler, BM; Vellimana, AK; Zhang, Y, 2013) |
| "Combined temozolomide (TMZ) and radiation therapy (RT) is often used as initial treatment for anaplastic glioma." | 7.79 | Combined temozolomide and radiation as an initial treatment for anaplastic glioma. ( Chong, DQ; Chua, ET; Lim, KH; Ng, WH; See, SJ; Tan, SH; Tham, CK; Thomas, J, 2013) |
| " Here we studied these responses in glioma cells treated with the methylating agent temozolomide (TMZ), which is a first-line chemotherapeutic for this malignancy." | 7.79 | Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage. ( Christmann, M; Kaina, B; Knizhnik, AV; Nikolova, T; Quiros, S; Roos, WP; Tomaszowski, KH, 2013) |
| "The coumarins 5-methoxy-6,7-methylenedioxycoumarin 1 5-(3-methyl-2-butenyloxy)-6,7-methylenedioxycoumarin 2 and 5-(2,3-dihydroxy-3-methylbutyloxy)-6,7-methylenedioxycoumarin 3 isolated from Pterocaulon species showed significant cytotoxicity against two glioma cells lines." | 7.78 | Selective cytotoxicity and apoptosis induction in glioma cell lines by 5-oxygenated-6,7-methylenedioxycoumarins from Pterocaulon species. ( Battastini, AM; Bernardi, A; Eifler-Lima, VL; Figueiró, F; Hamerski, L; Pinto, AC; Pires, EN; Salbego, CG; Teixeira, HF; Vianna, DR; Visentin, LC; von Poser, GL, 2012) |
| "Temozolomide (TMZ) is a novel cytotoxic alkylating agent for chemotherapy of malignant gliomas." | 7.78 | Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen. ( Dong, XT; Li, JM; Li, Y; Pan, Q; Wang, HM; Wang, W; Yang, XJ, 2012) |
| "Temozolomide (TMZ) is given in addition to radiotherapy in glioma patients, but its interaction with the commonly prescribed antiepileptic drug valproic acid (VPA) is largely unknown." | 7.78 | Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation. ( Lafleur, MV; Slotman, BJ; Sminia, P; Stalpers, LJ; Van den Berg, J; Van Nifterik, KA, 2012) |
| "The introduction of temozolomide (TMZ) has advanced chemotherapy for malignant gliomas." | 7.78 | LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway. ( Chen, L; Han, L; Jiang, C; Jiang, T; Kang, C; Liu, Y; Pu, P; Shi, Z; Zhang, K; Zheng, Y, 2012) |
| "The alkylating agent temozolomide (TMZ) is the major chemotherapeutic drug used clinically in the treatment of malignant gliomas." | 7.78 | Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. ( Lee, CC; Lin, CJ; Lin, TY; Lin, YF; Shih, CM; Shih, YL; Wang, SH, 2012) |
| "In this study, we investigated the effects of temozolomide (TMZ)/Poly (lactide-co-glycolide)(PLGA)/nano-hydroxyapatite microspheres on the behavior of U87 glioma cells." | 7.78 | The effect of temozolomide/poly(lactide-co-glycolide) (PLGA)/nano-hydroxyapatite microspheres on glioma U87 cells behavior. ( Qiu, B; Tian, A; Wang, M; Wu, A; Xue, X; Zhang, D, 2012) |
| "Polysorbate 80 coated temozolomide-loaded PLGA-based superparamagnetic nanoparticles (P80-TMZ/SPIO-NPs) were successfully synthesized and characterized as drug carriers and diagnosis agent for malignant brain glioma." | 7.78 | Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma. ( Ling, Y; Wei, K; Zhong, S; Zou, F, 2012) |
| " All three were found to have been treated with temozolomide after surgery for malignant glioma." | 7.78 | Fatal pneumonia associated with temozolomide therapy in patients with malignant glioma. ( Abe, S; Azuma, A; Fujita, K; Gemma, A; Hayashi, H; Kobayashi, K; Kokuho, N; Morimoto, T; Saito, Y; Tanaka, T, 2012) |
| "We analyzed the usefulness of initial or recurrent treatment of temozolomide (TMZ) in pediatric high-grade gliomas (HGGs)." | 7.78 | Prognosis of pediatric high-grade gliomas with temozolomide treatment: a retrospective, multicenter study. ( Baek, HJ; Choi, HS; Jung, TY; Kim, CY; Kim, DS; Kim, IA; Kim, SH; Ra, YS, 2012) |
| "The combination of hyperbaric oxygen with temozolomide produced an important reduction in glioma growth and effective approach to the treatment of glioblastoma." | 7.78 | Combination hyperbaric oxygen and temozolomide therapy in C6 rat glioma model. ( Bilir, A; Bozkurt, ER; Dagıstan, Y; Karaca, I; Ozar, E; Toklu, A; Yagmurlu, K, 2012) |
| "Temozolomide (TMZ) has become a key therapeutic agent in patients with malignant gliomas; however, its survival benefit remains unsatisfactory." | 7.78 | Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells. ( Hou, Y; Jeong, CH; Jeun, SS; Kim, SM; Lim, JY; Park, KY; Ryu, CH; Woo, JS; Yoon, WS, 2012) |
| " We previously demonstrated that temozolomide (TMZ), an alkylating agent for brain tumor chemotherapy, induced reactive oxygen species (ROS)/extracellular signal-regulated kinase (ERK)-mediated autophagy to protect glioma cells from apoptosis." | 7.78 | Inhibition of mitochondria- and endoplasmic reticulum stress-mediated autophagy augments temozolomide-induced apoptosis in glioma cells. ( Chen, TH; Lee, CC; Lin, CH; Lin, CJ; Shih, CM; Shih, YL; Wang, SH, 2012) |
| "Currently, treatment of malignant gliomas with temozolomide in addition to surgical resection and radiotherapy remains the foundation of glioma therapy." | 7.78 | Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth. ( Chen, Y; Cui, B; Dai, X; Dong, J; Huang, Q; Lan, Q; Tang, D; Zhang, J; Zhou, G, 2012) |
| " In this study, we explored the most effective schedule of the miR-21 inhibitor (miR-21i) and Temozolomide (TMZ) combined treatment in human glioma cells." | 7.78 | Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR-21 inhibitor gene therapy. ( Kang, C; Long, L; Pu, P; Qian, X; Ren, Y; Sheng, J; Shi, Z; Yuan, X, 2012) |
| "Temozolomide (TMZ) is an oral alkylating agent widely used in the treatment of refractory glioma." | 7.78 | The synergistic therapeutic effect of temozolomide and hyperbaric oxygen on glioma U251 cell lines is accompanied by alterations in vascular endothelial growth factor and multidrug resistance-associated protein-1 levels. ( Cao, K; Li, QY; Lu, PS; Lu, XY; Yuan, ZC, 2012) |
| " Recently, in a phase II trial in Brazil for the treatment of temozolomide (TMZ)-resistant malignant gliomas, POH was well tolerated when administered intranasally." | 7.78 | Perillyl alcohol for the treatment of temozolomide-resistant gliomas. ( Chen, TC; Cho, HY; Goldkorn, A; Hofman, FM; Jhaveri, N; Lee, DJ; Leong, MN; Louie, SG; Petasis, NA; Schönthal, AH; Torres, S; Tseng, J; Wang, W; Xu, T, 2012) |
| "Implantable and poly (d,l-lactide-co-glycolide) (PLGA) microparticles were developed to deliver temozolomide (TM) continuously in interstitial chemotherapy for glioma." | 7.77 | Temozolomide/PLGA microparticles: a new protocol for treatment of glioma in rats. ( Liu, JM; Yue, ZJ; Zhang, H; Zhang, YH, 2011) |
| "We investigated pseudoprogression (psPD) in patients with malignant gliomas treated with radiotherapy (RT) and maintenance temozolomide (TMZ) in terms of incidence, outcomes, and predictive and prognostic factors." | 7.77 | Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53. ( Choe, GY; Han, JH; Kang, HC; Kim, CY; Kim, IA; Kim, JH, 2011) |
| "This prospective study was performed to determine the efficacy, safety, and tolerability of concurrent chemoradiotherapy (CCRT) followed by adjuvant chemotherapy with temozolomide (TMZ) in the treatment of patients with WHO grade III gliomas." | 7.77 | Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study. ( Bae, SH; Cha, SH; Cho, WH; Choe, G; Jung, HW; Kim, CY; Kim, DG; Kim, IA; Kim, IH; Kim, YH; Lee, MM; Moon, S; Park, CK; Park, SH, 2011) |
| "To investigate the possible cytotoxic interactions between the chemotherapeutic drug temozolomide (TMZ) and the cyclooxygenase-2 inhibitor meloxicam (MLC) or of both drugs combined with X-rays in three human glioma cell lines (D384, Hs 683 and U251)." | 7.77 | Anti-tumour effects by a trimodal combination of temozolomide, meloxicam and X-rays in cultures of human glioma cells. ( Slotman, BJ; Van Den Berg, J; van Nifterik, KA; Van Rijn, J, 2011) |
| " Induction of autophagy by temozolomide (TMZ) has been noted in glioma cell lines." | 7.77 | Induction of autophagy in temozolomide treated malignant gliomas. ( Aoki, H; Fujii, Y; Kakita, A; Miyahara, H; Natsumeda, M; Takahashi, H; Toyoshima, Y; Uzuka, T; Yajima, N, 2011) |
| "Temozolomide (TMZ) is an oral alkylating agent that has been widely used in the treatment of refractory glioma, although inherent and acquired resistance to this drug is common." | 7.77 | Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation. ( Chang, YJ; Chen, CH; Chung, KT; Ku, MS; Yang, JT, 2011) |
| "Temozolomide (TMZ) is the preferred chemotherapeutic agent in the treatment of glioma following surgical resection and/or radiation." | 7.77 | N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide. ( Banze, LA; Brown, AR; Goellner, EM; Hamilton, RL; Moore, B; Sobol, RW; Svilar, D; Tang, JB; Trivedi, RN; Wang, XH, 2011) |
| " Corticorelin acetate (Xerecept) or human corticotrophin-releasing factor (hCRF) is a comparatively new drug and has been evaluated in two orthotopic glioma models (U87 and C6), by a direct comparison with dexamethasone and temozolomide." | 7.77 | Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas. ( Blasberg, RG; de Stanchina, E; Gamez, I; Huang, R; Kochetkov, T; Moroz, MA; Ryan, RP; Shi, W; Thaler, H, 2011) |
| "To study the impact of two human glioma tissue resistance genes MGMT and ERCC(2) on the temozolomide-based treatment of malignant gliomas and detect the relationship of their expressions." | 7.77 | [Comparison of MGMT and ERCC₂ expression in temozolomide for the treatment of malignant glioma drug resistance and their genetic relationship]. ( Hou, X; Sun, JH; Wang, JJ; Wu, ZC; Zhao, Y; Zheng, YR, 2011) |
| "This study was designed to evaluate proton magnetic resonance spectroscopy ((1)H-MRS) for monitoring the WHO grade II glioma (low-grade glioma (LGG)) treated with temozolomide (TMZ)." | 7.77 | Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy. ( Abud, L; Capelle, L; Chiras, J; Costalat, R; De Marco, G; Guillevin, R; Habas, C; Hoang-Xuan, K; Menuel, C; Taillibert, S; Vallée, JN, 2011) |
| " In vitro Southern Blot analysis and cytopathic effect assays demonstrate high anti-glioma potency, which was significantly increased in combination with temozolomide (TMZ), daunorubicin and cisplatin." | 7.77 | YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma. ( Anton, M; Gänsbacher, B; Haczek, C; Holm, PS; Holzmüller, R; Kasajima, A; Lage, H; Mantwill, K; Rognoni, E; Schlegel, J; Schuster, T; Treue, D; Weichert, W, 2011) |
| "Patients with high-grade gliomas (HGG) routinely receive radiation, temozolomide, and glucocorticoids." | 7.77 | Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. ( Carraway, H; Desideri, S; Grossman, SA; Lesser, G; Piantadosi, S; Sloan, A; Ye, X, 2011) |
| "Temozolomide (TMZ) is an alkylating agent that has yielded significant benefits and is a current standard agent in the treatment of malignant gliomas." | 7.77 | Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas. ( Fukushima, T; Katayama, Y; Ogino, A; Ohta, T; Okamoto, Y; Sano, E; Tashiro, S; Tsumoto, K; Watanabe, T; Yachi, K; Yoshino, A, 2011) |
| "Prolonged administration of temozolomide is widely used in patients with glioblastoma; whereas the treatment of anaplastic glioma differs between neurooncological centres." | 7.77 | Prolonged administration of temozolomide in adult patients with anaplastic glioma. ( Freyschlag, CF; Janzen, E; Lohr, F; Schmieder, K; Seiz, M; Smolczyk, DR; Thomé, C; Tuettenberg, J; Weiss, C; Wenz, F, 2011) |
| "To study the efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide (TMZ) for gliomas." | 7.77 | [Efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide for glioma]. ( Tu, Q; Wang, L; Zhou, R; Zhou, W, 2011) |
| "In this study, we investigated the potential of combined treatment with temozolomide (TMZ) chemotherapy and tumor antigen-pulsed dendritic cells (DCs) and the underlying immunological factors of TMZ chemoimmunotherapy with an intracranial GL26 glioma animal model." | 7.76 | Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. ( Chung, DS; Hong, YK; Kim, CH; Kim, CK; Kim, TG; Park, JS; Park, SD, 2010) |
| "We hypothesized that the observed clinical synergy of orally administered TMZ and carmustine (BCNU) wafers would translate into even greater effectiveness with the local delivery of BCNU and TMZ and the addition of radiotherapy in animal models of malignant glioma." | 7.76 | Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. ( Bekelis, K; Brem, H; Li, KW; Recinos, VR; Sunshine, SB; Tyler, BM; Vellimana, A, 2010) |
| "Treatment for glioblastoma multiforme includes the alkylating agent temozolomide combined with ionizing radiation." | 7.76 | Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. ( Bradshaw, TD; Laughton, CA; Madhusudan, S; Stevens, MF; Zhang, J, 2010) |
| "Temozolomide (TMZ) has been accepted as a standard antitumor drug for glioma worldwide." | 7.76 | Flow cytometric analysis for the mechanism of the new antineoplastic agent temozolomide in glioma cells. ( Kawamoto, K; Li, Y; Numa, Y; Oishi, T; Oshige, H; Yamahara, T; Zhen, Y, 2010) |
| " We present the case of a 26-year-old male suffering a fatal ICH in the context of treatment of a high grade glioma with temozolomide." | 7.76 | Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide. ( Anderson, WS; Dunn, I; Norden, A; Sure, D, 2010) |
| "There is a growing evidence of using Temozolomide as upfront therapy for progressive low grade gliomas." | 7.76 | Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide. ( Dehais, C; Delattre, JY; Ducray, F; Hoang-Xuan, K; Houillier, C; Idbaih, A; Kaloshi, G; Laigle-Donadey, F; Omuro, A; Psimaras, D; Sanson, M; Sierra del Rio, M; Taillibert, S, 2010) |
| "Temozolomide is the major drug in the treatment of malignant gliomas." | 7.76 | Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide. ( Akmansu, M; Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Oner, Y; Ozturk, B; Uncu, D; Yaman, E; Yildiz, R, 2010) |
| "Malignant glioma patients treated with the golden standard therapy, focal radiotherapy plus concomitant daily temozolomide (radiotherapy/TMZ), often suffer severe lymphopenia." | 7.76 | Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment. ( Akutsu, H; Ishikawa, E; Matsumura, A; Nakai, K; Sakamoto, N; Takano, S; Tsuboi, K; Yamamoto, T, 2010) |
| "Temozolomide (TM) has anti-tumor activity in patients with malignant glioma." | 7.76 | Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model. ( Liu, JM; Tang, GS; Wang, Y; Yue, ZJ; Zhang, H; Zhang, YH, 2010) |
| "Temozolomide (TMZ) is an oral alkylating agent used for the treatment of high-grade gliomas." | 7.76 | Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain. ( Bailey, SM; Darley-Usmar, VM; Diers, A; Gillespie, GY; Griguer, CE; Landar, A; Markert, JM; McClugage, SG; Nozell, SE; Oliva, CR; Sarkaria, JN, 2010) |
| " Sensitivity of glioma cells to TMZ is dependent on the level of cellular O(6)-methylguanine-DNA methyltransferase (MGMT) repair activity." | 7.75 | The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity. ( Ancheta, K; Chtchetinin, J; Cloughesy, T; Lai, A; Nghiemphu, PL; Remington, M, 2009) |
| " In this study, we used pharmacokinetic and pharmacodynamic approaches to investigate how sunitinib at different dose levels affects brain distribution of temozolomide (TMZ), and to ascertain the relationship between intratumoral TMZ concentrations and tumor vascularity in an orthotopic human glioma model." | 7.75 | Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. ( Gallo, JM; Zhou, Q, 2009) |
| "Temozolomide (TMZ) and carmustine (BCNU), cancer-drugs usually used in the treatment of gliomas, are DNA-methylating agents producing O6-methylguanine." | 7.75 | Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells. ( Cattaneo, E; Magrassi, L; Papait, R; Rigamonti, D, 2009) |
| "High grade gliomas are one of the most difficult cancers to treat and despite surgery, radiotherapy and temozolomide-based chemotherapy, the prognosis of glioma patients is poor." | 7.75 | Drugs targeting the mitochondrial pore act as cytotoxic and cytostatic agents in temozolomide-resistant glioma cells. ( Amoroso, R; Bartoli, B; Benvenuti, L; Gagliardi, R; Gremigni, V; Lena, A; Rechichi, M; Rossi, L; Salvetti, A; Scarcelli, V; Vecchio, D, 2009) |
| "Temozolomide (TMZ) is the standard of care for patients with newly diagnosed glioblastoma (GBM) as well as those with recurrent anaplastic glioma (AG) and GBM." | 7.75 | Rechallenge with temozolomide in patients with recurrent gliomas. ( Bogdahn, U; Hau, P; Jauch, T; Pascher, C; Weller, M; Wick, A; Wick, W, 2009) |
| "Temozolomide (TMZ) is an alkylating agent used in the management of gliomas." | 7.75 | Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? ( Bell, D; Khasraw, M; Wheeler, H, 2009) |
| "We have completed in vivo safety and efficacy studies of the use of a novel drug delivery system, a gel matrix-temozolomide formulation that is injected intracranially into the post-resection cavity, as a candidate for glioma therapy." | 7.75 | Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection. ( Akbar, U; Duntsch, C; Jones, T; Michael, M; Shukla, A; Sun, Y; Winestone, J, 2009) |
| "Temozolomide is considered the standard of care and drug of choice for the treatment of initially diagnosed malignant gliomas." | 7.75 | Glioma-associated endothelial cells are chemoresistant to temozolomide. ( Chen, TC; Golden, EB; Hofman, FM; Pen, L; Schönthal, AH; Sivakumar, W; Virrey, JJ; Wang, W, 2009) |
| " On the other hand, temozolomide (TMZ), an oral bioavailable alkylating agent with excellent tolerability, has demonstrated efficacy and has become a key therapeutic agent in patients with malignant gliomas; however, its survival benefit remains unsatisfactory." | 7.75 | Effect of IFN-beta on human glioma cell lines with temozolomide resistance. ( Fukushima, T; Katayama, Y; Naruse, N; Ogino, A; Ohta, T; Okamoto, Y; Sano, E; Watanabe, T; Yachi, K; Yoshino, A, 2009) |
| "Previous studies have revealed that p38, a member of the family of stress-activated protein kinases (SAPKs), cooperates with the Chk1-pathway to bring about temozolomide (TMZ)-induced G2 arrest, and that the inhibition of either pathway alone is sufficient to sensitize U87MG glioma cells to TMZ-induced cytotoxicity." | 7.75 | Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells. ( Hirose, Y; Kawase, T; Ohba, S; Sano, H, 2009) |
| "Human malignant glioma cells U251-MG were cultured and assigned to four groups with different treatments for 3 days: temozolomide group (100 micromol/L), thalidomide group (100 microg/L), temozolomide (100 micromol/L) plus thalidomide group (100 microg/L) and control group." | 7.75 | Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro. ( Gao, S; Ji, YW; Pan, Q; Yang, XJ; Zhang, WG, 2009) |
| "Our data suggest that temozolomide is an active regimen for malignant gliomas." | 7.74 | Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment. ( Akmansu, M; Benekli, M; Buyukberber, S; Coskun, U; Gunel, N; Kaya, AO; Ozkan, S; Ozturk, B; Uner, A; Yamac, D; Yaman, E; Yildiz, R, 2008) |
| "Although high AGT levels may mediate resistance in a portion of these samples, MMR deficiency does not seem to be responsible for mediating temozolomide resistance in adult malignant glioma." | 7.74 | Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. ( Ali-Osman, F; Bigner, DD; Friedman, AH; Friedman, HS; Horne, KS; Johnson, SP; Lister, DW; Maxwell, JA; McLendon, RE; Modrich, PL; Quinn, JA; Rasheed, A, 2008) |
| "Use of antiangiogenic therapy with radiation and temozolomide in the primary management of high-grade glioma is feasible." | 7.74 | Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. ( Eagan, P; Fischer, I; Golfinos, JG; Gruber, ML; Kelly, P; Knopp, EA; Medabalmi, P; Narayana, A; Parker, E; Raza, S; Zagzag, D, 2008) |
| " In this study, the authors investigate the nature of the SP phenotype in 2 glioma cell lines, U87MG and T98G, and their response to temozolomide." | 7.74 | Characterization of a side population of astrocytoma cells in response to temozolomide. ( Ang, BT; Chong, KH; Chua, C; See, SJ; Tang, C; Wong, MC; Zaiden, N, 2008) |
| " In this study, we explored whether novel delivery methods will represent new and effective ways to treat gliomas and if adjuvant therapy with the chemotherapeutic agent temozolomide would enhance the cytotoxic properties of TRAIL in glioma lines resistant to TRAIL monotherapy." | 7.74 | Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide. ( Classon, M; Hingtgen, S; Ren, X; Shah, K; Terwilliger, E; Weissleder, R, 2008) |
| "Human GBM-derived cell lines U87, G44, G112, and the gliosarcoma-derived line G28 were treated with EPO, with and without combinations of irradiation or temozolomide (TMZ)." | 7.74 | Erythropoietin augments survival of glioma cells after radiation and temozolomide. ( Ehrenreich, H; Giese, A; Hasselblatt, M; Hassouna, I; Jelkmann, W; Kim, E; Rave-Fränk, M; Schulz-Schaeffer, W; Sperling, S, 2008) |
| "In the 4-year retrospective study, 31 patients with histologically confirmed malignant gliomas, in which 10 patients received radiotherapy followed by temozolomide (group A) and 21 patients received radiotherapy alone (group B)." | 7.74 | Radiotherapy followed by adjuvant temozolomide treatment of malignant glioma. ( Chang, HW; Chang, WN; Ho, JT; Lin, WC; Lin, YJ; Lu, CH; Wang, HC; Yang, TM, 2008) |
| "Methylating drugs such as temozolomide (TMZ) are widely used in the treatment of brain tumours (malignant gliomas)." | 7.74 | Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. ( Batista, LF; Kaina, B; Menck, CF; Naumann, SC; Roos, WP; Weller, M; Wick, W, 2007) |
| "The purpose of the present study was to develop implantable poly(D,L-lactide-co-glycolide) (PLGA) microparticles for continuous delivery of intact 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide (temozolomide, TM) for about a 1-month period and to evaluate its cytotoxicity against Glioma C6 cancer cells." | 7.74 | Temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro. ( Gao, S; Zhang, H, 2007) |
| "Dose-limiting adverse effects of thrombocytopenia and leukopenia prevent augmentation of current temozolomide (TMZ) dosing protocols; therefore, we hypothesized that the direct intracranial delivery of TMZ would lead to improved efficacy in an animal model of malignant glioma in an animal model." | 7.74 | Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. ( Brem, H; Brem, S; Caplan, J; Legnani, F; Li, K; Pradilla, G; Tyler, B, 2007) |
| "Case report of a 77-year-old woman with a radiation-induced, high-grade cerebellar glioma that responded durably to temozolomide." | 7.74 | Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide. ( Doherty, LM; Drappatz, J; Kesari, S; Monje, ML; Ramakrishna, NR; Wen, PY; Young, G, 2007) |
| "The aim of this study was to investigate the effect of temozolomide (TZM) in combination with X-rays on proliferation and migration in human glioma spheroids." | 7.74 | The inhibition of proliferation and migration of glioma spheroids exposed to temozolomide is less than additive if combined with irradiation. ( Fehlauer, F; Muench, M; Rades, D; Richter, E, 2007) |
| "To evaluate the natural progression and the impact of temozolomide in low-grade gliomas and to correlate these changes with the profile of genetic alterations." | 7.74 | Dynamic history of low-grade gliomas before and after temozolomide treatment. ( Amiel-Benouaich, A; Capelle, L; Carpentier, AF; Cornu, P; Delattre, JY; Duffau, H; Guillevin, R; Hoang-Xuan, K; Kaloshi, G; Kujas, M; Laigle-Donadey, F; Lejeune, J; Mandonnet, E; Marie, Y; Mokhtari, K; Omuro, A; Ricard, D; Sanson, M; Taillibert, S, 2007) |
| "To evaluate the predictive impact of chromosome 1p/19q deletions on the response and outcome of progressive low-grade gliomas (LGG) treated with up-front temozolomide (TMZ) chemotherapy." | 7.74 | Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. ( Benouaich-Amiel, A; Capelle, L; Carpentier, A; Cornu, P; Delattre, JY; Diakite, F; Duffau, H; Hoang-Xuan, K; Idbaih, A; Iraqi, W; Kaloshi, G; Laigle-Donadey, F; Lejeune, J; Mokhtari, K; Omuro, A; Paris, S; Polivka, M; Renard, MA; Sanson, M; Simon, JM; Taillibert, S, 2007) |
| "Methylation of the O(6)-methyguanine-DNA methyltransferase (MGMT) gene promoter in gliomas has been reported to be a useful predictor of the responsiveness to temozolomide (TMZ)." | 7.74 | A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation. ( Fujii, M; Ishii, D; Ito, M; Maruta, H; Natsume, A; Shimato, S; Wakabayashi, T; Yoshida, J, 2008) |
| " In this study, as we determined p53 gene mutation occurring in multinucleated giant cell glioblastoma, we investigated the role of Aurora-B in formation of multinucleated cells in human neoplasm cells with various p53 statuses as well as cytotoxity of glioma cells to temozolomide (TMZ), a common oral alkylating agent used in the treatment of gliomas." | 7.74 | Inhibition of Aurora-B function increases formation of multinucleated cells in p53 gene deficient cells and enhances anti-tumor effect of temozolomide in human glioma cells. ( Fujita, M; Inagaki, M; Katsumata, S; Mizuno, M; Nakahara, N; Natsume, A; Osawa, H; Satoh, Y; Tsuno, T; Wakabayashi, T; Yoshida, J, 2007) |
| "Treatment of malignant glioma involves concomitant temozolomide and ionizing radiation (IR)." | 7.74 | Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy. ( Bickenbach, K; Galanopoulos, N; Pytel, P; Rawlani, V; Veerapong, J; Weichselbaum, RR; Yamini, B; Yu, X, 2007) |
| "Diffusion tensor imaging and multiple voxel magnetic resonance spectroscopy were performed in the MRI follow-up of a patient with a glioma treated with temozolomide chemotherapy." | 7.74 | Diffusion tensor imaging and chemical shift imaging assessment of heterogeneity in low grade glioma under temozolomide chemotherapy. ( Enting, RH; Heesters, MA; Irwan, R; Meiners, LC; Oudkerk, M; Potze, JH; Sijens, PE; van der Graaf, WT, 2007) |
| "To evaluate the feasibility, safety and efficacy of daily temozolomide concurrent with postoperative radiotherapy in malignant glioma." | 7.73 | Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma. ( Eich, HT; Kocher, M; Kunze, S; Müller, RP; Semrau, R, 2005) |
| " This was of interest because E6 silencing of p53 sensitizes U87MG astrocytic glioma cells to BCNU and temozolomide (TMZ), cytotoxic drugs that are modestly helpful in the treatment of aggressive astrocytic gliomas." | 7.73 | Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide. ( Cairncross, JG; Mymryk, JS; Xu, GW, 2005) |
| "To describe the results of the treatment of recurrent glioma with temozolomide." | 7.73 | [Favourable result for temozolomide in recurrent high-grade glioma]. ( Enting, RH; Kros, JM; Sillevis Smitt, PA; Taal, W; van den Bent, MJ; van der Rijt, CD; van Heuvel, I, 2005) |
| "Children and young adults with recurrent or treatment-induced malignant gliomas have limited responses to temozolomide or oral VP-16 when either is administered as a single agent." | 7.73 | Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas. ( Bouffet, E; Foreman, N; Korones, DN; Smith, A, 2006) |
| "Alkylating agents, such as temozolomide, are among the most effective cytotoxic agents used for malignant gliomas, but responses remain very poor." | 7.73 | IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. ( Hatano, H; Ishii, D; Mizuno, M; Natsume, A; Tsuno, T; Wakabayashi, T; Yoshida, J, 2005) |
| "The chemotherapeutic agent temozolomide (TMZ) and the anti-angiogenic agent thalidomide (THD) have both demonstrated anti-tumor activity in patients with recurrent malignant glioma." | 7.73 | Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model. ( Jeon, HJ; Kim, H; Kim, JH; Kim, JS; Kim, JT; Kim, MH; Kim, YJ; Lee, DS; Nam, DH; Park, SY; Shin, T; Son, MJ; Song, HS, 2006) |
| "The purpose of this study was to determine whether a combination treatment of temozolomide with celecoxib is effective in the rat orthotopic glioma model." | 7.73 | Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. ( Groves, MD; Kang, SG; Kim, JS; Nam, DH; Park, K, 2006) |
| "The authors investigated the safety of 75 mg/m2 temozolomide for 21 days every 28 days in glioma patients." | 7.73 | Is protracted low-dose temozolomide feasible in glioma patients? ( Blatt, V; Brandes, AA; Cavallo, G; Ermani, M; Franceschi, E; Gardiman, M; Ghimenton, C; Pasetto, L; Scopece, L; Tosoni, A, 2006) |
| "To re-evaluate the cost effectiveness and median overall survival (OS) achieved in patients with recurrent malignant gliomas treated with temozolomide in British Columbia, as compared to previous lomustine use in the same patient population based on updated outcomes data." | 7.73 | Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia. ( Mabasa, VH; Taylor, SC, 2006) |
| "Temozolomide (TMZ) is a DNA methylating agent that has shown promising antitumor activity against high grade glioma." | 7.73 | Potentiation of antiglioma effect with combined temozolomide and interferon-beta. ( Hong, YK; Joe, YA; Kim, TG; Park, JA, 2006) |
| "To assess the activity and tolerability of temozolomide in children with progressive low-grade gliomas (LGGs)." | 7.72 | Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas. ( Finlay, JL; Knopp, EA; Kuo, DJ; Miller, DC; Weiner, HL; Wisoff, J, 2003) |
| "Temozolomide (TMZ, 3,4-dihydro-3-methyl-4-oxoimidazo [5,1-d]-as-tetrazine-8-carboxamide) is a new alkylating agent with promising antitumour efficacy for malignant gliomas." | 7.72 | Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. ( Germano, IM; Ito, H; Kanzawa, T; Kondo, S; Kondo, Y; Kyo, S, 2003) |
| "To assess whether the survival of patients with recurrent malignant glioma receiving temozolomide in everyday practice is comparable to that reported in previous studies." | 7.72 | Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study. ( Maltoni, S; Messori, A; Pelagotti, F; Trippoli, S; Vacca, F; Vaiani, M, 2003) |
| "Temozolomide (TMZ) is currently being evaluated for the treatment of high-grade gliomas in children." | 7.72 | A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas. ( Fouladi, M; Gajjar, AJ; Kirstein, MN; Nair, G; Panetta, JC; Stewart, CF, 2003) |
| " In this study, we present that temozolomide (TMZ), a new alkylating agent, inhibited the viability of malignant glioma cells in a dose-dependent manner and induced G2/M arrest." | 7.72 | Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. ( Germano, IM; Ito, H; Kanzawa, T; Komata, T; Kondo, S; Kondo, Y, 2004) |
| "Using a methylation-specific PCR approach, we assessed the methylation status of the CpG island of MGMT in 92 glioma patients who received temozolomide as first-line chemotherapy or as treatment for relapses." | 7.72 | CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. ( Aguirre-Cruz, L; Arribas, L; Balaña, C; Esteller, M; García-Lopez, JL; García-Villanueva, M; Paz, MF; Piquer, J; Pollan, M; Reynes, G; Rojas-Marcos, I; Safont, MJ; Sanchez-Cespedes, M; Yaya-Tur, R, 2004) |
| "Temozolomide, an imidazotetrazine prodrug has shown activity in phase II studies in patients with high-grade glioma at first recurrence." | 7.71 | Temozolomide as second-line chemotherapy for relapsed gliomas. ( Ashley, S; Brada, M; Dowe, A; Hines, F; Kong, A; Short, SC; Traish, D; Trent, S, 2002) |
| "Temozolomide (TZM) is a novel methylating agent currently under investigation for treatment of recurrent high-grade gliomas." | 7.71 | Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. ( Graziani, G; Navarra, P; Portarena, I; Scerrati, M; Tentori, L; Torino, F, 2002) |
| "Temozolomide has an evolving role in the treatment of high grade gliomas." | 7.71 | An Australian experience with temozolomide for the treatment of recurrent high grade gliomas. ( Ashley, DL; Cher, L; Harris, MT; Rosenthal, MA, 2001) |
| " To determine whether forced cell-cycle progression selectively sensitizes tumor cells to alkylating agents, we examined the effects of overexpressing the E2F-1 protein (a positive regulator of cell-cycle progression) on the sensitivity of two malignant human glioma cell lines, U-251 MG and D-54 MG, to BCNU and temozolomide." | 7.71 | Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. ( Fueyo, J; Gomez-Manzano, C; Groves, MD; He, J; Hu, M; Lemoine, MG; Liu, TJ; Mitlianga, P; Yung, AW, 2001) |
| "Gene therapy for malignant glioma with the herpes simplex virus thymidine kinase/ganciclovir (HSV-tk/GCV) system is already in the stage of clinical trials, but still needs major improvement to achieve greater clinical efficacy." | 7.71 | Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma. ( Chou, TC; Droege, JW; Fels, C; Kramm, CM; Rainov, NG; Schäfer, C, 2001) |
| "Temozolomide (TMZ) is a newly approved alkylating agent for the treatment of malignant gliomas." | 7.71 | Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. ( Berman, E; Gallo, JM; Ma, J; Murphy, M; O'Dwyer, PJ; Reed, K, 2002) |
| "Forty patients with recurrent malignant gliomas had been treated with temozolomide (Temodal)." | 7.71 | [Treatment of recidive malignant gliomas with temozolomide]. ( Afra, D; Sipos, L; Vitanovics, D, 2002) |
| "To investigate the effect of temozolomide, a 3-methyl derivative of mitozolomide in combination with X-rays in human glioma-derived cell lines." | 7.70 | Survival of human glioma cells treated with various combination of temozolomide and X-rays. ( Heimans, JJ; Slotman, BJ; van den Berg, J; van der Valk, P; van Rijn, J, 2000) |
| " Temozolomide is a novel methylating agent with proven efficacy against malignant gliomas (MGs) after systemic administration but with dose-limiting myelotoxicity." | 7.70 | Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. ( Archer, GE; Bigner, DD; Friedman, AH; Friedman, HS; Heimberger, AB; Hulette, C; McLendon, RE; Sampson, JH, 2000) |
| "Glioma is a common type of brain tumor with high incidence and mortality rates." | 7.01 | TFR2 regulates ferroptosis and enhances temozolomide chemo-sensitization in gliomas. ( Cai, J; Chen, Q; Hong, Y; Sun, Q; Tian, D; Tong, S; Xu, Y; Ye, L; Ye, Z, 2023) |
| " Methods This is an open-label, 2-arm Phase 1b/2a study (N = 56) of galunisertib (intermittent dosing: 14 days on/14 days off per cycle of 28 days) in combination with TMZ/RTX (n = 40), versus a control arm (TMZ/RTX, n = 16)." | 6.94 | Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. ( Burkholder, T; Capper, D; Cleverly, AL; Desjardins, A; Estrem, ST; Forsyth, P; Guba, SC; Gueorguieva, I; Lahn, MM; Rodon, J; Suarez, C; Wang, S; Wick, A, 2020) |
| " In clinical practice, Chinese doctors often use radiotherapy combined with temozolomide (TMZ) to treat these patients, although large-scale prospective studies are lacking." | 6.90 | Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial. ( Guan, H; He, L; He, Y; Mu, X; Peng, X; Wang, J; Wang, Y, 2019) |
| "Temozolomide (TMZ) is an auxiliary alkylating agent that is extensively used in conjunction with surgical resection and forms the mainstay of clinical treatment strategies for gliomas." | 6.82 | Regulation of temozolomide resistance via lncRNAs: Clinical and biological properties of lncRNAs in gliomas (Review). ( Du, J; Li, S; Peng, C; Peng, F; Xie, X, 2022) |
| " Metronomic dosing of cytotoxic chemotherapy has emerged as a promising option to achieve this objective." | 6.82 | Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas. ( Alsop, DC; Callahan, A; Giarusso, B; O'Loughlin, L; Timmons, J; Wong, ET, 2016) |
| "Patients with newly diagnosed anaplastic astrocytoma (AA) or anaplastic oligo-astrocytoma (AOA) were treated with concurrent radiotherapy (60 Gy over 6 weeks) and temozolomide (75 mg/m(2)), and six adjuvant 28-day cycles of either dose-dense (150 mg/m(2), days 1-7, 15-21) or metronomic (50 mg/m(2), days 1-28) temozolomide." | 6.80 | Radiotherapy and temozolomide for anaplastic astrocytic gliomas. ( Abrey, LE; Braunthal, SG; DeAngelis, LM; Huse, JT; Lassman, AB; Nayak, L; Panageas, KS; Pentsova, E; Reiner, AS, 2015) |
| "Temozolomide was administered at a dose of 150 mg/m(2) daily for five days for the first 28-day cycle and escalated to 200 mg/m(2), during subsequent cycles." | 6.76 | A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. ( Coan, AD; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Peters, KB; Reardon, DA; Threatt, S; Vredenburgh, JJ, 2011) |
| " Metronomic dosing of temozolomide (TMZ) combined with standard radiotherapy may improve survival by increasing the therapeutic index and anti-angiogenic effect of TMZ." | 6.75 | A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma. ( Bartels, U; Baruchel, S; Bouffet, E; Eisenstat, D; Gammon, J; Huang, A; Hukin, J; Johnston, DL; Samson, Y; Sharp, JR; Stempak, D; Stephens, D; Tabori, U, 2010) |
| " CB related adverse events occurring in more than one patient were fatigue, gait disturbance, nystagmus, and confusion." | 6.73 | Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. ( Asher, AL; Chang, SM; Croteau, D; Grahn, AY; Husain, SR; Kunwar, S; Lang, FF; Parker, K; Puri, RK; Sampson, JH; Shaffrey, M; Sherman, JW; Vogelbaum, MA, 2007) |
| "Perillyl alcohol has shown to have both chemopreventive and chemotherapeutic activities in preclinical studies." | 6.73 | Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. ( da Fonseca, CO; Fischer, J; Futuro, D; Gattass, CR; Nagel, J; Quirico-Santos, T; Schwartsmann, G, 2008) |
| "Temozolomide is a well-tolerated agent that results in objective responses and stabilisation of disease." | 6.72 | Phase II study of two-weekly temozolomide in patients with high-grade gliomas. ( Ashley, D; Cher, L; Dowling, A; Jennens, R; Rosenthal, MA; Wong, S; Woods, AM, 2006) |
| "We conducted a study to determine the dose-limiting toxicity of an extended dosing schedule of temozolomide (TMZ) when used with a fixed dose of BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine), taking advantage of TMZ's ability to deplete O6-alkylguanine-DNA-alkyltransferase and the synergistic activity of these two agents." | 6.71 | Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. ( Abrey, LE; Kleber, M; Malkin, MG; Raizer, JJ, 2004) |
| "Temozolomide is a novel second-generation oral alkylating agent with demonstrated efficacy and safety in patients with recurrent glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA)." | 6.70 | A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. ( Friedman, HS; Gilbert, MR; Kuttesch, JF; Olson, JJ; Prados, MD; Reaman, GH; Zaknoen, SL, 2002) |
| " The absolute bioavailability of TMZ was 0." | 6.69 | Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. ( Bauer, J; Biollaz, J; Buclin, T; Decosterd, LA; Gander, M; Lejeune, F; Leyvraz, S; Marzolini, C; Shen, F, 1998) |
| "Temozolomide may cause thrombocytopenia or neutropenia in 3-4% of glioblastoma patients, respectively." | 6.55 | MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case. ( Altinoz, MA; Bolukbasi, FH; Ekmekci, CG; Elmaci, I; Sari, R; Sav, A; Yenmis, G, 2017) |
| "Temozolomide (TMZ) is an oral alkylating agent with established effects on the central nervous system of glioblastoma (GBM) patients." | 6.52 | Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens?: a meta-analysis. ( Du, S; Liao, G; Ren, C; Sun, H; Xie, X; Yuan, YW, 2015) |
| "Temozolomide (TMZ) is a DNA-alkylating agent used for the treatment of glioma, astrocytoma, and melanoma." | 6.47 | A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy. ( Jiang, G; Liu, YQ; Pei, DS; Wei, ZP; Xin, Y; Zheng, JN, 2011) |
| "Temozolomide (TMZ) is an oral alkylating agent with activity in high and LGG." | 6.47 | Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity. ( Athanasiou, T; Lashkari, HP; Moreno, L; Saso, S; Zacharoulis, S, 2011) |
| "Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug." | 6.45 | Temozolomide in malignant gliomas: current use and future targets. ( Bressler, LR; Seery, TE; Villano, JL, 2009) |
| "Temozolomide has proven benefit in grade II/III gliomas progressive following standard therapy and when added to radiation for glioblastoma." | 6.44 | Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation. ( Schiff, D, 2007) |
| "Temozolomide (TMZ) is an alkylating agent that was approved for anaplastic astrocytoma and glioblastoma." | 6.43 | Optimal role of temozolomide in the treatment of malignant gliomas. ( Hegi, ME; Stupp, R; van den Bent, MJ, 2005) |
| "Irinotecan is a water-soluble derivative of camptothecin, an alkylator originally extracted from the Chinese tree Camptotheca acuminata." | 6.42 | The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. ( Friedman, HS; Houghton, PJ; Keir, ST, 2003) |
| " The drug is well tolerated with dose limiting myelosuppression and thrombocytopenia occurring in less than 10% of patients at current dosage schedules." | 6.41 | The use of temozolomide in recurrent malignant gliomas. ( Gaya, A; Greenstein, A; Rees, J; Stebbing, J, 2002) |
| "Temozolomide is a novel, oral, second-generation alkylating agent." | 6.41 | Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. ( Friedman, HS, 2000) |
| "Temozolomide, a new drug, has shown promise in treating malignant gliomas and other difficult-to-treat tumors." | 6.41 | Temozolomide and treatment of malignant glioma. ( Calvert, H; Friedman, HS; Kerby, T, 2000) |
| " For patients with recurrent malignant glioma, temozolomide provides a therapeutic option with a predictable safety profile, clinical efficacy, and convenient dosing that can provide important quality-of-life benefits." | 6.41 | Temozolomide for recurrent high-grade glioma. ( Macdonald, DR, 2001) |
| "Gliomas are one of the most common primary malignant tumors of the central nervous system, and have an unfavorable prognosis." | 5.91 | Role of COL6A2 in malignant progression and temozolomide resistance of glioma. ( Hong, X; Ouyang, J; Peng, X; Wang, P; Xiao, B; Zhang, J; Zou, J, 2023) |
| "Glioma is an extremely aggressive primary brain tumor, which is highly resistant to chemotherapy, presenting a therapeutic challenge." | 5.91 | Induction of apoptosis in glioma cells by lycorine via reactive oxygen species generation and regulation of NF-κB pathways. ( Ding, L; Huo, M; Su, J; Yao, Q; Yin, W, 2023) |
| "Givinostat is a pan-histone deacetylase (HDAC) inhibitor that has demonstrated excellent tolerability as well as efficacy in patients with polycythemia vera." | 5.91 | Givinostat Inhibition of Sp1-dependent MGMT Expression Sensitizes Glioma Stem Cells to Temozolomide. ( Kitanaka, C; Mitobe, Y; Nakagawa-Saito, Y; Okada, M; Sugai, A; Suzuki, S; Togashi, K, 2023) |
| "Gliomas are the most prevalent primary tumor in the central nervous system, with an abysmal 5-year survival rate and alarming mortality." | 5.91 | Drug metabolism-related gene ABCA1 augments temozolomide chemoresistance and immune infiltration abundance of M2 macrophages in glioma. ( Liang, Q; Liu, Y; Xu, Z; Yan, Y, 2023) |
| "Temozolomide (TMZ) is a widely used chemotherapeutic drug for glioma." | 5.72 | FOXM1-mediated NUF2 expression confers temozolomide resistance to human glioma cells by regulating autophagy via the PI3K/AKT/mTOR signaling pathway. ( Guo, L; Wu, Z, 2022) |
| "Gliomas are the most common type of primary brain tumors, with high recurrence rate and mortality." | 5.72 | ZNF300 enhances temozolomide resistance in gliomas by regulating lncRNA SNHG12. ( Fu, J; Peng, J; Tu, G, 2022) |
| "Glioma is a common type of malignant and aggressive tumor in the brain." | 5.72 | Elevated GIGYF2 expression suppresses tumor migration and enhances sensitivity to temozolomide in malignant glioma. ( Chen, M; Feng, W; Li, J; Li, M; Li, T; Liu, Y; Xia, X; Yang, W; Yuan, Q; Zhang, S; Zhou, X; Zuo, M, 2022) |
| " Investigation of adjuvant trotabresib + temozolomide and concomitant trotabresib + temozolomide + radiotherapy in patients with newly diagnosed glioblastoma is ongoing (NCT04324840)." | 5.69 | Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study. ( Amoroso, B; Aronchik, I; Chang, H; Filvaroff, E; González León, P; Hanna, B; Manuel Sepúlveda, J; Mendez, C; Moreno, V; Nikolova, Z; Pérez-Núñez, Á; Reardon, DA; Sanchez-Perez, T; Stephens, D; Vogelbaum, MA; Zuraek, M, 2023) |
| "This study was aimed at analyzing the efficacy and safety of an injectable form of chlorogenic acid (CGA) in patients with recurrent high-grade glioma after standard of care treatments, through a first-in-human, open-label, dose-escalation phase I trial." | 5.69 | Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up. ( Chen, F; Deng, J; Jiang, J; Kang, X; Kang, Z; Li, S; Li, W; Yang, H; Zhang, J, 2023) |
| "In an international randomised controlled phase II study of temozolomide (TMZ) versus TMZ in combination with bevacizumab (BEV) in locally diagnosed non-1p/19q co-deleted World Health Organization grade 2 or 3 gliomas with a first and contrast-enhancing recurrence after initial radiotherapy, and overall survival at 12 months was not significantly different (61% in the TMZ arm and 55% in the TMZ + BEV arm)." | 5.69 | Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatmen ( Bottomley, A; Clement, PM; Coens, C; de Vos, FYF; Ghislain, I; Golfinopoulos, V; Idbaih, A; Klein, M; Lewis, J; Machingura, A; Mulholland, PJ; Reijneveld, JC; Taal, W; Taphoorn, MJB; van den Bent, MJ; Wick, W, 2023) |
| "Glioma is the most common primary intracranial tumor." | 5.62 | FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide. ( Huang, L; Jiang, T; Li, G; Liu, Y; Zhao, Z; Zhou, K, 2021) |
| "Temozolomide (TMZ) is a DNA alkylating agent and is currently a first line chemotherapeutic treatment for GBM." | 5.62 | Inhibition of Nrf2 might enhance the anti-tumor effect of temozolomide in glioma cells via inhibition of Ras/Raf/MEK signaling pathway. ( Lu, Z; Sun, W; Yu, J; Zhang, W, 2021) |
| "Temozolomide (TMZ) has been widely used as a first-line treatment for GBM." | 5.62 | Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting. ( Li, N; Li, Y; Lv, Y; Sha, C; Sun, K; Tang, S; Wang, A; Wang, L; Yan, X; Yu, Y, 2021) |
| "Temozolomide (TMZ) is an effective chemotherapy drug for glioblastoma, but the resistance to TMZ has come to represent a major clinical problem, and its underlying mechanism has yet to be elucidated." | 5.62 | Exosomal connexin 43 regulates the resistance of glioma cells to temozolomide. ( Bi, QC; Gan, LJ; Han, XJ; Hong, T; Jiang, LP; Lan, XM; Liu, LH; Tan, RJ; Wei, MJ; Yang, ZJ; Zhang, LL, 2021) |
| "Temozolomide (TMZ) is an alkylating agent widely used for glioma treatment." | 5.62 | miR-23b-5p promotes the chemosensitivity of temozolomide via negatively regulating TLR4 in glioma. ( Cui, B; Gao, K; Qiao, Y; Wang, T, 2021) |
| "Perampanel (PER) is a noncompetitive α-amino-3-hydroxy-5-methyl-4-isoaxazolepropionate acid receptor antagonist that has recently been approved for treating focal epilepsy as a secondary drug of choice." | 5.56 | Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy. ( Chonan, M; Kanamori, M; Nakasato, N; Osawa, SI; Saito, R; Suzuki, H; Tominaga, T; Watanabe, M, 2020) |
| " Because the free drug cannot pass the blood-brain barrier (BBB), we investigated the use of nanocarriers for transport of the drug through the BBB and its efficacy when combined with radiotherapy and temozolomide (TMZ) in glioma spheroids." | 5.56 | Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma. ( Becerril Aragon, G; Bikhezar, F; de Kruijff, RM; de Vries, HE; Denkova, AG; Gasol Garcia, A; Narayan, RS; Slotman, BJ; Sminia, P; Torrelo Villa, G; van der Meer, AJGM; van der Pol, SMA, 2020) |
| " These results form part of the basis for the translation of the therapy to patients with GBM but the dosing and timing of delivery will have to be explored in depth both experimentally and clinically." | 5.56 | Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas. ( Darabi, A; Enríquez Pérez, J; Kopecky, J; Siesjö, P; Visse, E, 2020) |
| "The prognosis of glioma is generally poor and is the cause of primary malignancy in the brain." | 5.56 | MicroRNA-155-3p promotes glioma progression and temozolomide resistance by targeting Six1. ( Chen, G; Chen, Z; Zhao, H, 2020) |
| "Glioma is a common cancer that affects people worldwide with high morbidity and mortality." | 5.56 | miR-149 rs2292832 C allele enhances the cytotoxic effect of temozolomide against glioma cells. ( Guo, J; Ling, G; Liu, Q; Luo, J; Luo, X; Ning, X; Xu, B, 2020) |
| "In adults, glioma is the most commonly occurring and invasive brain tumour." | 5.56 | CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells. ( Cao, Y; Kong, S; Li, X; Qi, Y; Shang, S, 2020) |
| "Osthole was the most effective." | 5.56 | Coumarins modulate the anti-glioma properties of temozolomide. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Maciejczyk, A; Rzeski, W; Skalicka-Woźniak, K; Sumorek-Wiadro, J; Wertel, I; Zając, A, 2020) |
| " Side effects associated with chemotherapy delays or modifications included thrombocytopenia (28%) and nausea/vomiting (19%), with temozolomide dosing most frequently modified." | 5.56 | Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience. ( Browd, SR; Cole, BL; Crotty, EE; Ellenbogen, RG; Ermoian, RP; Geyer, JR; Hauptman, JS; Leary, SES; Lee, A; Lockwood, CM; Millard, NE; Ojemann, JG; Olson, JM; Paulson, VA; Sato, AA; Vitanza, NA, 2020) |
| "Glioma is the most aggressive primary malignant brain tumor." | 5.56 | Injectable postoperative enzyme-responsive hydrogels for reversing temozolomide resistance and reducing local recurrence after glioma operation. ( Han, Y; Jia, J; Liu, H; Lu, Y; Shen, J; Wang, L; Xu, H; Yu, R; Zhang, L; Zhao, Z, 2020) |
| "Temozolomide (TMZ) is an alkylating chemotherapy agent used in the clinical treatment of glioblastoma multiforme (GBM) patients." | 5.56 | Piperine synergistically enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines. ( Jeong, S; Jung, S; Oh, JW; Park, GS; Shin, J, 2020) |
| "Glioma is one of the most aggressive forms of brain tumor and is hallmarked by high rate of mortality, metastasis and drug resistance." | 5.56 | Downregulation of hsa_circ_0000936 sensitizes resistant glioma cells to temozolomide by sponging miR-1294. ( Feng, H; Hua, L; Huang, L; Zhang, X, 2020) |
| "Glioma is the most malignant tumour of the human brain still lacking effective treatment modalities." | 5.56 | Synthetic Betulin Derivatives Inhibit Growth of Glioma Cells ( Bębenek, E; Boryczka, S; Dmoszyńska-Graniczka, M; Król, SK; Stepulak, A; Sławińska-Brych, A, 2020) |
| " In our study, we aim to explore the efficacy and safety of temozolomide combined with radiotherapy in the treatment of malignant glioma (MG) and its influence on postoperative complications and survival rate of patients." | 5.51 | Efficacy and Safety of Temozolomide Combined with Radiotherapy in the Treatment of Malignant Glioma. ( Li, J; Wei, S, 2022) |
| "In this article, we have compared and analyzed the clinical effects of temozolomide single agent and combined doxorubicin in the treatment of glioma." | 5.51 | Comparison of Clinical Effects of Temozolomide Single Agent and Combined Doxorubicin in the Treatment of Glioma. ( Chen, L; Liu, Y, 2022) |
| "Glioma is one of the most lethal malignancies and molecular regulators driving gliomagenesis are incompletely understood." | 5.51 | DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide. ( Dai, X; He, Q; Shao, Y; Tan, B; Wang, J; Weng, Q; Yang, B; Zhao, M, 2019) |
| "Glioma is the most common neoplasm of the central nervous system, with the highest mortality rate." | 5.51 | Iguratimod encapsulated PLGA-NPs improves therapeutic outcome in glioma, glioma stem-like cells and temozolomide resistant glioma cells. ( Faming, W; Hang, S; Hongyan, Z; Liudi, Y; Mengmeng, T; Younis, M, 2019) |
| "Temozolomide (TMZ) is a first-line alkylating agent for glioblastoma multiforme (GBM)." | 5.51 | IGF-1-enhanced miR-513a-5p signaling desensitizes glioma cells to temozolomide by targeting the NEDD4L-inhibited Wnt/β-catenin pathway. ( Chen, KC; Chen, PH; Cheng, CH; Chou, CM; Ho, KH; Lee, CC; Shih, CM, 2019) |
| "The KNOG-1101 study showed improved 2-year PFS with temozolomide during and after radiotherapy compared to radiotherapy alone for patients with anaplastic gliomas." | 5.51 | Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study). ( Ahn, GS; Chang, JH; Choe, G; Choi, BS; Hong, YK; Hwang, K; Joo, J; Jung, TY; Kang, SG; Kim, CY; Kim, EY; Kim, JH; Kim, SH; Kim, TM; Kim, YJ; Lee, DE; Nam, DH; Park, CK; Yoo, H, 2022) |
| "Malignant gliomas are aggressive primary neoplasms that originate in the glial cells of the brain or the spine with notable resistance to standard treatment options." | 5.51 | Resveratrol restores sensitivity of glioma cells to temozolamide through inhibiting the activation of Wnt signaling pathway. ( Bu, XY; Gao, YS; Han, SY; Hu, S; Qu, MQ; Wang, BQ; Wang, JY; Yan, ZY; Yang, B; Yang, HC, 2019) |
| "Malignant glioma is a lethal brain tumor with a low survival rate and poor prognosis." | 5.51 | Carnosic acid potentiates the anticancer effect of temozolomide by inducing apoptosis and autophagy in glioma. ( Lan, Q; Mao, J; Shao, N; Wang, R; Xue, L; Zhi, F, 2019) |
| "Glioma is the most common brain malignancy." | 5.51 | Local delivery of temozolomide via a biologically inert carrier (Temodex) prolongs survival in glioma patients, irrespectively of the methylation status of MGMT. ( Fedulov, A; Karlsson, I; Lokot, I; Pejler, G; Veevnik, D; Yurkshtovich, N; Yurkshtovich, T, 2019) |
| "Glioma is a primary intracranial malignant tumor with poor prognosis." | 5.51 | Development of transferrin-modified poly(lactic-co-glycolic acid) nanoparticles for glioma therapy. ( Liu, G; Mao, J; Meng, X; Yang, Y; Zhao, C, 2019) |
| " The purpose of our study was to explore if PDT combined with TMZ can effectively inhibit glioma cells by influencing NHE1 in vitro." | 5.51 | Photodynamic therapy combined with temozolomide inhibits C6 glioma migration and invasion and promotes mitochondrial-associated apoptosis by inhibiting sodium-hydrogen exchanger isoform 1. ( Chen, L; Chi, D; Cong, D; Gao, S; Hu, S; Ji, H; Jia, Y; Jin, J; Liang, B; Zhou, P, 2019) |
| "The therapeutic treatment of glioblastoma multiforme (GBM) remains a major challenge." | 5.51 | Angiopep-2 Modified Cationic Lipid-Poly-Lactic-Co-Glycolic Acid Delivery Temozolomide and DNA Repair Inhibitor Dbait to Achieve Synergetic Chemo-Radiotherapy Against Glioma. ( Hua, L; Li, S; Liang, J; Liu, H; Xu, Q; Ye, C; Yu, R; Zhao, L, 2019) |
| "Radiochemotherapy involving cisplatinum-based polychemotherapy is more toxic than radiotherapy in combination with temozolomide." | 5.48 | Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients. ( Bison, B; Bojko, S; Gielen, GH; Hoffmann, M; Kortmann, RD; Kramm, CM; Pietsch, T; Seidel, C; von Bueren, AO; Warmuth-Metz, M, 2018) |
| "Temozolomide (TMZ) has been considered to be one of the most effective chemotherapeutic agents to prolong the survival of patients with glioblastoma." | 5.48 | Differential Characterization of Temozolomide-Resistant Human Glioma Cells. ( Chen, CC; Huang, BR; Lai, SW; Lin, C; Lin, HY; Liu, YS; Lu, DY; Tsai, CF, 2018) |
| "Glioma is the most common intracranial malignant tumors, accounting for about 40% of intracranial tumors." | 5.48 | MiR-634 sensitizes glioma cells to temozolomide by targeting CYR61 through Raf-ERK signaling pathway. ( Jiang, Y; Tan, Z; Zhao, J, 2018) |
| " Our results demonstrate benefit of ddTMZ after previous treatment with standard TMZ dosing with no apparent increase in treatment-related toxicities." | 5.48 | Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study. ( Garcia, CR; Gruber, L; Kumar, SS; Lightner, DD; Morgan, RM; Slone, SA; Villano, JL, 2018) |
| "Highly malignant gliomas are characterized by pronounced intra‑ and intertumoral heterogeneity." | 5.48 | APOBEC3B is expressed in human glioma, and influences cell proliferation and temozolomide resistance. ( Hattermann, K; Held-Feindt, J; Lucius, R; Schmitt, C; Synowitz, M, 2018) |
| "Human glioma is the most common type of primary brain tumor." | 5.48 | Downregulation of miR-196b Promotes Glioma Cell Sensitivity to Temozolomide Chemotherapy and Radiotherapy. ( Liu, J; Lv, H; Ma, R; Shao, C; Zhang, G; Zheng, G, 2018) |
| " ATOR showed similar cytotoxic effect as TMZ to glioma cells, and it may be a safer drug, regarding side effect induction, than chemotherapic agents." | 5.48 | Atorvastatin Promotes Cytotoxicity and Reduces Migration and Proliferation of Human A172 Glioma Cells. ( Dal-Cim, T; Lopes, FG; Ludka, FK; Nedel, CB; Oliveira, KA; Tasca, CI, 2018) |
| "Glioma is the most common primary brain tumor and has an undesirable prognosis due to the blood-brain barrier (BBB) and drug resistance." | 5.46 | β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1. ( Fang, Y; Luo, L; Ning, B; Wang, N; Zhang, Q, 2017) |
| "Gliomas are the most common and primary tumors of the central nervous system in adults." | 5.46 | Temozolomide increases MHC-I expression via NF-κB signaling in glioma stem cells. ( Guan, Y; Qiu, B; Wang, Y; Wu, A; Zhang, D; Zhang, L, 2017) |
| "Chlorpromazine is a United States Food and Drug Administration-approved phenothiazine widely used as a psychotropic in clinical practice." | 5.46 | Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit. ( Griguer, CE; Langford, C; Oliva, CR; Suto, MJ; Zhang, W, 2017) |
| "Guanosine (GUO) is an endogenous nucleoside involved in extracellular signaling that presents neuroprotective effects and also shows the effect of inducing differentiation in cancer cells." | 5.46 | Guanosine promotes cytotoxicity via adenosine receptors and induces apoptosis in temozolomide-treated A172 glioma cells. ( Dal-Cim, TA; Lopes, FG; Nedel, CB; Oliveira, KA; Tasca, CI, 2017) |
| "Temozolomide (TMZ) is an effective drug for malignant glioma, however, the intracellular and molecular mechanisms behind this anti-cancer effect have yet to be fully understood." | 5.46 | Down-Regulation of AQP4 Expression via p38 MAPK Signaling in Temozolomide-Induced Glioma Cells Growth Inhibition and Invasion Impairment. ( Chen, Y; Gao, F; Hou, J; Jiang, R; Kang, L; Li, Y; Liu, H; Liu, X; Yang, M; Yi, Y, 2017) |
| "Temozolomide (TMZ) was used for clinical postoperative or non-surgical chemotherapy patients." | 5.46 | Combination of sonodynamic with temozolomide inhibits C6 glioma migration and promotes mitochondrial pathway apoptosis via suppressing NHE-1 expression. ( Chen, L; Cong, D; Hu, S; Li, Q; Li, Y; Wang, D, 2017) |
| "Glioma is a common malignant brain tumor originating in the central nervous system." | 5.43 | Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery. ( Fan, Y; Lv, S; Wu, M; Xiao, B; Ye, M; Zhu, X, 2016) |
| "Malignant gliomas are among the most frequent and aggressive cerebral tumors, characterized by high proliferative and invasive indexes." | 5.43 | KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment. ( Catalano, M; Chece, G; D'Alessandro, G; Di Angelantonio, S; Esposito, V; Grimaldi, A; Limatola, C; Mainiero, F; Porzia, A; Ragozzino, D; Salvati, M; Santoro, A; Wulff, H, 2016) |
| "Gliomas are the most common primary intracranial malignant tumors in adults." | 5.43 | Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients. ( Cai, J; Han, B; Jiang, C; Lin, L; Meng, X; Ming, J; Sun, B; Wang, G, 2016) |
| "Temozolomide (TMZ) is an alkylating agent used for the treatment of aggressive forms of brain tumor based on its antitumor actions." | 5.43 | Temozolomide inhibits cellular growth and motility via targeting ERK signaling in glioma C6 cells. ( Gao, S; Liang, J; Wang, W; Wang, Y, 2016) |
| "Seizures are a common symptom in patients with low-grade glioma (LGG), negatively influencing quality of life, if uncontrolled." | 5.42 | Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide. ( Dirven, L; Heimans, JJ; Koekkoek, JA; Postma, TJ; Reijneveld, JC; Taphoorn, MJ; Vos, MJ, 2015) |
| "Malignant glioma is a common and lethal primary brain tumor in adults." | 5.42 | VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells. ( Chen, H; Chen, J; Chen, Y; Fan, J; Hu, L; Huai, C; Lu, D; Meng, D; Qin, R; Song, X; Sun, R; Wang, D; Wang, H; Wang, J; Wang, S; Xu, T; Yang, J; Yang, S; Yun, D; Zhang, X; Zhao, Y, 2015) |
| "These results suggest that Liq treatment enhances glioma cell susceptibility to TMZ by inhibiting the PI3K/AKT/mTOR pathway." | 5.42 | Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway. ( Chen, J; Jing, L; Li, L; Li, S; Ling, Q; Liu, X; Wang, H; Wang, L; Xia, M; Yang, S, 2015) |
| "Glioma is resistant to the apoptotic effects of chemotherapy and the mechanism underlying its chemoresistance is not currently understood." | 5.42 | Downregulation of osteopontin enhances the sensitivity of glioma U251 cells to temozolomide and cisplatin by targeting the NF-κB/Bcl‑2 pathway. ( Li, P; Liu, H; Qian, C; Shi, L; Wang, Y; Yan, W; You, Y; Zhang, J, 2015) |
| "Glioma is the most common malignant and fatal primary tumor in the central nervous system in adults." | 5.42 | MiR-203 sensitizes glioma cells to temozolomide and inhibits glioma cell invasion by targeting E2F3. ( Huo, L; Tang, G; Wu, J; Xiao, G, 2015) |
| "Temozolomide (TMZ) is an oral alkylating chemotherapeutic agent that prolongs the survival of patients with glioblastoma (GBM)." | 5.42 | A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells. ( Barciszewska, AM; Gurda, D; Głodowicz, P; Naskręt-Barciszewska, MZ; Nowak, S, 2015) |
| "Glioma is one of the most common primary tumors of the central nervous system in adults." | 5.42 | Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells. ( Chen, FR; Chen, YS; Chen, ZP; Guo, CC; Panasci, L; Qiu, ZK; Sai, K; Shen, D; Wang, J; Yang, QY, 2015) |
| "Gliomas are the most common primary brain tumors." | 5.42 | Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study. ( Berger, FR; Boccard, SG; Geraci, S; Marand, SV; Pelletier, LA; Pycroft, L, 2015) |
| " Temozolomide (TMZ) has anti-proliferative and cytotoxic effects and is indicated for glioblastoma multiforme and recurrent mesenchymal astrocytoma." | 5.41 | Progress in research and development of temozolomide brain-targeted preparations: a review. ( Chen, J; Fan, W; Fu, Z; Wu, X; Xu, Y; Yang, J, 2023) |
| " This preclinical study sought to test the efficacy of the food additive Triacetin (glyceryl triacetate, GTA) as a novel therapy to increase acetate bioavailability in glioma cells." | 5.40 | Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma. ( Davies, MT; Driscoll, HE; Jaworski, DM; Lawler, SE; Long, PM; Penar, PL; Pendlebury, WW; Spees, JL; Teasdale, BA; Tsen, AR; Viapiano, MS, 2014) |
| " We report five patients who received long-term treatment with TMZ chemotherapy at normal dosing levels." | 5.40 | Long-term treatment with temozolomide in malignant glioma. ( Defrates, SR; Lightner, DD; Mannas, JP; Pittman, T; Villano, JL, 2014) |
| "Temozolomide (TMZ) is a first-line chemotherapeutic agent but the efficacy is limited by intrinsic and acquired resistance in GBM." | 5.40 | Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-κB signaling in glioma initiating cells. ( Chen, YS; Chen, ZP; Guan, S; Guo, CC; Li, WP; Li, WY; Mou, YG; Sai, K; Wang, J; Yang, QY, 2014) |
| "Temozolomide (TMZ) is an alkylating agent used for the treatment of glioblastoma multiforme (GBM), the main form of human brain tumours in adults." | 5.40 | Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma. ( Gratas, C; Oliver, L; Rabé, M; Séry, Q; Vallette, FM, 2014) |
| "Diffuse brainstem glioma is a rare disease in adults." | 5.40 | Temozolomide after radiotherapy in recurrent "low grade" diffuse brainstem glioma in adults. ( Delattre, JY; Laigle-Donadey, F; Martin-Duverneuil, N; Mokhtari, K; Reyes-Botero, G, 2014) |
| "Malignant glioma is a severe type of brain tumor with a poor prognosis and few options for therapy." | 5.40 | Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo. ( Belizário, JE; de Andrade-Lima, LC; Garcia, CC; Menck, CF; Munford, V; Quinet, A; Rocha, CR; Vieira, DB, 2014) |
| "Quinolinic acid is a product of tryptophan degradation and may serve as a precursor for NAD(+), an important enzymatic cofactor for enzymes such as the DNA repair protein PARP." | 5.39 | The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress. ( Adams, S; Ahrendt, T; Bode, HB; Guillemin, GJ; Oezen, I; Opitz, CA; Platten, M; Radlwimmer, B; Sahm, F; von Deimling, A; Wick, W, 2013) |
| "C6 rat gliomas were incubated with low-dose TMZ to induce chemoresistance." | 5.39 | Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas. ( Baden, A; Doi, Y; Kanagawa, M; Mizoi, K; Oka, S; Ono, T; Sasajima, T; Shimada, N, 2013) |
| "Previously, it has been shown that treatment of glioma cells with temozolomide (TMZ) and radiation (XRT) induces the expression of metalloproteinase 14 (MMP14)." | 5.39 | Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas. ( Auffinger, B; Baryshnikov, AY; Borovjagin, A; Dey, M; Guo, D; Han, Y; Kim, CK; Lesniak, MS; Pytel, P; Sarvaiya, P; Thaci, B; Ulasov, I; Yi, R; Zhang, L, 2013) |
| "Aspirin microsphere treatment induced slight apoptosis and modestly inhibited proliferation of LN229 and U87 cells in vitro and in vivo through inhibition of β-catenin transactivation." | 5.39 | Aspirin-/TMZ-coloaded microspheres exert synergistic antiglioma efficacy via inhibition of β-catenin transactivation. ( Chen, LY; Han, L; Kang, CS; Liu, CY; Pu, PY; Qian, XM; Shi, ZD; Yuan, XB; Zhang, JX; Zhang, KL, 2013) |
| " These data reassuringly suggest that BEV does not significantly change the ECF tumor concentrations of TMZ in either tumor-bearing or normal brain when dosed 36 h prior to TMZ." | 5.38 | The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas. ( Blakeley, JO; Brastianos, H; Brem, H; Grossman, R; Rudek, MA; Tyler, B; Zadnik, P, 2012) |
| "Temozolomide was administered to three patients at initial diagnosis and five patients at recurrence after failing prior radiotherapy." | 5.38 | Temozolomide or bevacizumab for spinal cord high-grade gliomas. ( Gavrilovic, IT; Kaley, TJ; Mondesire-Crump, I, 2012) |
| " Dose-response and cellular growth assays indicate that erlotinib reduces cell proliferation in all tested cell lines without inducing cytotoxic effects." | 5.38 | EGFR inhibition in glioma cells modulates Rho signaling to inhibit cell motility and invasion and cooperates with temozolomide to reduce cell growth. ( Fernández de Mattos, S; Ramis, G; Rodríguez, J; Thomàs-Moyà, E; Villalonga, P, 2012) |
| "All patients had seizure disorders that were treated with anticonvulsants." | 5.37 | Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. ( Moldovan, K; Pouratian, N; Schiff, D; Shaffrey, ME; Sherman, JH; Starke, RM; Yeoh, HK, 2011) |
| "Malignant gliomas are highly lethal tumors resistant to current therapies." | 5.37 | Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. ( Barnes, JW; Chaponis, D; Dellagatta, JL; Fast, E; Greene, ER; Kesari, S; Kieran, MW; Kung, AL; Panagrahy, D; Ramakrishna, N; Sauvageot, C; Stiles, C; Wen, PY, 2011) |
| "The long-term TMZ-treated astroglioma cells, but not the Hs683 oligodendroglioma cells, developed in vivo a certain level of resistance to TMZ, which correlated with the up- regulation of CXCL2, CXCL3 and CXCL8 expression in the U373 and T98G astroglioma cells." | 5.37 | Temozolomide-induced modification of the CXC chemokine network in experimental gliomas. ( Berger, W; Bruyère, C; Kast, RE; Kiss, R; Lefranc, F; Lonez, C; Mijatovic, T; Ruysschaert, JM; Spiegl-Kreinecker, S, 2011) |
| "Cediranib is a highly potent receptor tyrosine kinase inhibitor that inhibits all three VEGF receptors." | 5.37 | Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic. ( Andersen, B; Dicker, AP; Lawrence, RY; Liu, Y; Wachsberger, PR; Xia, X, 2011) |
| "Temozolomide (TMZ), is a new alkylating agent with promising antitumour efficacy for malignant gliomas, and the effect of TMZ on GSCs invasion has not been known." | 5.37 | Temozolomide decreases invasion of glioma stem cells by down-regulating TGF-β2. ( Jing, Z; Qiu, B; Wang, Y; Wu, A; Zhang, D, 2011) |
| "Malignant glioma is an invasive disease of the central nervous system." | 5.37 | Down-regulation of EGFR prolonged cell growth of glioma but did not increase the sensitivity to temozolomide. ( Fujioka, K; Ikeda, K; Inaba, N; Inoue, Y; Ishizawa, S; Kimura, M; Manome, Y; Saito, H, 2011) |
| " The growing body of evidence demonstrating the clinical importance of O6-methylguanine methyltransferase (MGMT) has generated a considerable interest in the exploration of strategies to overcome MGMT-mediated resistance to alkylating agents; for example protracted administration of Temozolomide (TMZ) may result in more extensive and sustained depletion of MGMT; for this reason a variety of dosing schedules that increase the duration of exposure and the cumulative dose of TMZ are being investigated for the treatment of patient with recurrent malignant glioma after standard treatment." | 5.37 | Rechallenge with temozolomide in recurrent glioma. ( Botturi, A; Fariselli, L; Ferrari, D; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A; Simonetti, G, 2011) |
| "Temozolomide (TMZ) is a recently introduced alkylating agent that has yielded significant benefits and become a key agent in the treatment of high-grade gliomas." | 5.36 | Gene expression profiling predicts response to temozolomide in malignant gliomas. ( Fukushima, T; Katayama, Y; Naruse, N; Ogino, A; Ohta, T; Okamoto, Y; Sano, E; Tsumoto, K; Watanabe, T; Yachi, K; Yoshino, A, 2010) |
| "High-grade gliomas are among the most lethal of all cancers." | 5.36 | Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas. ( Binello, E; Emdad, L; Germano, IM; Qadeer, ZA; Uzzaman, M, 2010) |
| " The system analysis technique, embodied in the convolution integral, generated an impulse response function that, when convolved with temozolomide plasma concentration input functions, yielded predicted normal brain and brain tumor temozolomide concentration profiles for different temozolomide dosing regimens (75-200 mg/m(2)/d)." | 5.35 | A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. ( Aboagye, EO; Brock, CS; Gallo, JM; Price, PM; Rosso, L; Saleem, A; Turkheimer, FE, 2009) |
| " Dasatinib in combination with temozolomide more effectively increased the therapeutic efficacy of temozolomide than when dasatinib was combined with carboplatin or irinotecan." | 5.35 | Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. ( de Groot, J; LaFortune, T; Milano, V; Piao, Y, 2009) |
| "Treatment of malignant gliomas has changed substantially over the last few years." | 5.35 | Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma. ( Benekli, M; Buyukberber, N; Buyukberber, S; Coskun, O; Coskun, U; Kaya, AO; Ozturk, B; Yaman, E; Yildiz, R, 2009) |
| "Cilengitide is a cyclic peptide antagonist of integrins alphavbeta3 and alphavbeta5 that is currently being evaluated as a novel therapeutic agent for recurrent and newly diagnosed glioblastoma." | 5.35 | Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. ( Adams, B; Maurer, GD; Stupp, R; Tabatabai, G; Tritschler, I; Weller, M; Wick, W, 2009) |
| " Thus, our results show that polymeric nanocapsules are able to increase the intratumoral bioavailability of indomethacin and reduce the growth of implanted gliomas." | 5.35 | Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. ( Battastini, AM; Bernardi, A; Braganhol, E; Edelweiss, MI; Figueiró, F; Guterres, SS; Jäger, E; Pohlmann, AR, 2009) |
| " The effect of ZD6474, a potent inhibitor of VEGF-receptor-2, was evaluated in combination with either radiotherapy or temozolomide." | 5.35 | Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model. ( Bergenheim, AT; Bergström, P; Henriksson, R; Johansson, M; Sandström, M, 2008) |
| "Gliomas are the most common primary brain tumor in adults, but the efficacy of chemotherapy is limited." | 5.35 | Dihydroartemisinin potentiates the cytotoxic effect of temozolomide in rat C6 glioma cells. ( Fang, SH; Huang, XJ; Li, CT; Lu, YB; Wei, EQ; Zhang, WP, 2008) |
| "CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists." | 5.34 | Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. ( Affronti, ML; Desjardins, A; Friedman, HS; Healy, P; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Patel, MP; Peters, KB; Randazzo, DM; Woodring, S, 2020) |
| "We investigated the efficacy of temozolomide during and after radiotherapy in Korean adults with anaplastic gliomas without 1p/19q co-deletion." | 5.34 | Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study). ( Chang, JH; Choe, G; Choi, BS; Hong, YK; Hwang, K; Joo, J; Jung, TY; Kang, SG; Kim, CY; Kim, EY; Kim, JH; Kim, SH; Kim, TM; Kim, YJ; Lee, DE; Nam, DH; Park, CK; Yoo, H, 2020) |
| "A Pediatric Brain Tumor Consortium (PBTC) phase I/II trial of veliparib and radiation followed by veliparib and temozolomide (TMZ) was conducted in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG)." | 5.34 | A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study. ( Adesina, A; Ansell, P; Baxter, PA; Billups, CA; Blaney, SM; Broniscer, A; Dunkel, IJ; Fouladi, M; Giranda, V; Kilburn, L; Li, XN; Onar-Thomas, A; Paulino, A; Poussaint, TY; Quaddoumi, I; Smith, ER; Su, JM; Thompson, P, 2020) |
| "To report the long-term outcomes of the RTOG 0424 study of a high-risk, low-grade glioma population treated with concurrent and adjuvant temozolomide (TMZ) and radiation therapy (RT)." | 5.34 | Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424. ( Bahary, JP; Barani, IJ; Bovi, JA; Chakravatri, A; D'Souza, D; Doyle, T; Fisher, BJ; Fiveash, JB; Fox, S; Howard, SP; Kwok, Y; Laack, NN; Lesser, GJ; Macdonald, DR; Mehta, MP; Michael Yu, HH; Pugh, SL; Rogers, CL; Strasser, JF; Wahl, DR; Werner-Wasik, M; Won, M, 2020) |
| " Three patients (12%) were changed to standard temozolomide dosing due to side effects, including intractable nausea (n = 2) and multiple cytopenias (n = 1)." | 5.34 | Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. ( Gasco, J; Pouratian, N; Schiff, D; Shaffrey, ME; Sherman, JH, 2007) |
| "Temozolomide treatment of high-grade tv-a gliomas provided a 14-day growth delay compared with vehicle controls." | 5.34 | Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. ( Hambardzumyan, D; Holland, EC; Kreger, AR; Leopold, WR; McConville, P; Moody, JB; Rehemtulla, A; Ross, BD; Woolliscroft, MJ, 2007) |
| "The time-to-maximum plasma concentration (tmax) of TMZ was about 1 h and the elimination half-life of terminal excretion phase (t 1/2lambda z) was about 2 h." | 5.34 | Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians. ( Adachi, J; Aoki, T; Matsutani, M; Mishima, K; Mizutani, T; Nishikawa, R; Nojima, K, 2007) |
| "Chemo-therapeutic treatment of glioma patients has minor success." | 5.33 | Expression of ABC-1 transporter is elevated in human glioma cells under irradiation and temozolomide treatment. ( Golubnitschaja, O; Haertel, N; Moenkemann, H; Schüller, H; Trog, D, 2005) |
| "Perifosine is an oral Akt inhibitor which exerts a marked cytotoxic effect on human tumor cell lines, and is currently being tested in several phase II trials for treatment of major human cancers." | 5.33 | Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. ( Holland, EC; Momota, H; Nerio, E, 2005) |
| "Surgical cure of glioblastomas is virtually impossible and their clinical course is mainly determined by the biologic behavior of the tumor cells and their response to radiation and chemotherapy." | 5.33 | Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. ( Beerenwinkel, N; Feiden, W; Hartmann, C; Ketter, R; Lengauer, T; Meese, E; Rahnenführer, J; Steudel, WI; Stockhammer, F; Strowitzki, M; Urbschat, S; von Deimling, A; Wemmert, S; Zang, KD, 2005) |
| "Temozolomide (TMZ) is a methylating agent which prolongs survival when administered during and after radiotherapy in the first-line treatment of glioblastoma and which also has significant activity in recurrent disease." | 5.33 | O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. ( Hermisson, M; Kaina, B; Klumpp, A; Nagel, G; Roos, W; Weller, M; Wick, W; Wischhusen, J, 2006) |
| "Gliomas are primary brain tumors associated with a poor prognosis partly due to resistance to conventional therapies." | 5.33 | Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model. ( Itasaka, S; Kim, JT; Lee, JI; Nam, DH, 2006) |
| "Temozolomide is a recently introduced alkylating agent that has yielded a significant benefit in the treatment of high-grade gliomas." | 5.33 | Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line. ( Auger, N; Dutrillaux, B; Idbaih, A; Legrier, ME; Poupon, MF; Sanson, M; Thillet, J; Wanherdrick, K, 2006) |
| "Temozolomide is an alkylating cytostatic drug that finds increasing application in the treatment of melanoma, anaplastic astrocytoma and glioblastoma multiforme." | 5.32 | Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids. ( Arnold, H; Damasceno, R; Günther, W; Pawlak, E; Terzis, AJ, 2003) |
| " It is proposed that the net balance of antiangiogenic drug-mediated pharmacodynamic actions will determine how drug disposition in tumors may be affected." | 5.32 | Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models. ( Gallo, JM; Guo, P; Li, S; Ma, J; Reed, K, 2003) |
| "Temozolomide (TMZ) is a DNA alkylating agent currently used as adjuvant treatment for anaplastic astrocytomas." | 5.32 | Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. ( Bedwell, J; Germano, IM; Kanzawa, T; Kondo, S; Kondo, Y, 2003) |
| " The population pharmacokinetic analysis was performed with nonlinear mixed-effect modeling software." | 5.32 | Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. ( Buclin, T; Csajka, C; Decosterd, LA; Lejeune, F; Leyvraz, S; Ostermann, S; Stupp, R, 2004) |
| " In this work we investigated the effect of association of temozolomide (TMZ), an orally bioavailable alkylating agent, with three chemotherapeutic drugs, liposomal doxorubicin (DOXO), cis-platinum (CDDP)." | 5.32 | Effect of association of temozolomide with other chemotherapic agents on cell growth inhibition in glioma cell lines. ( Balzarotti, M; Boiardi, A; Calatozzolo, C; Ciusani, E; Croci, D; Salmaggi, A, 2004) |
| "The optimal management of high risk WHO grade II gliomas after surgery is debated including the role of initial temozolomide to delay radiotherapy and risk of cognitive defects." | 5.30 | Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016. ( Bello, L; Bertero, L; Carapella, CM; Caroli, M; Cassoni, P; Dealis, C; Faedi, M; Marchese, G; Migliore, E; Pace, A; Pellerino, A; Rudà, R; Soffietti, R, 2019) |
| " Gliomas, which are common in dogs and also represent the majority of fatal brain tumours in humans, can be amenable to chemotherapy with temozolomide." | 5.30 | Intratumoral temozolomide in spontaneous canine gliomas: feasibility of a novel therapy using implanted microcylinders. ( Hicks, J; Holmes, S; Howerth, E; Kaplan, E; Kaplan, J; Kent, M; Platt, S; Senneca, C; Stewart, G, 2019) |
| "Combined PET-MRI with the tracer O-(2-18F-fluoroethyl)-l-tyrosine (18F-FET) prior to re-RT was performed in recurrent glioma patients in a phase I trial." | 5.30 | Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation. ( Albert, NL; Bartenstein, P; Belka, C; Corradini, S; Fleischmann, DF; Förster, S; la Fougère, C; Niyazi, M; Rottler, M; Schwaiger, M; Siepmann, T; Unterrainer, M, 2019) |
| " We sought to study vorinostat (VOR), a histone deacetylase inhibitor, in combination with bevacizumab (BEV) and daily metronomic temozolomide (TMZ) in a Phase I/II trial in recurrent high-grade gliomas (HGGs)." | 5.27 | Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. ( Desjardins, A; Friedman, HS; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Peters, KB; Reardon, DA, 2018) |
| "The European Organisation for Research and Treatment of Cancer (EORTC) 22033-26033 clinical trial (NCT00182819) investigated whether initial temozolomide (TMZ) chemotherapy confers survival advantage compared with radiotherapy (RT) in low-grade glioma (LGG) patients." | 5.27 | Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial. ( Balana, C; Baumert, BG; Ben Hassel, M; Brandes, AA; Chinot, O; Dhermain, F; Enting, R; Erdem-Eraslan, L; French, PJ; Gao, Y; Gijtenbeek, JMM; Gorlia, T; Hegi, ME; Hoang-Xuan, K; Kros, JM; Mason, WP; Ryan, GF; Sillevis Smitt, P; Stupp, R; van den Bent, MJ; van Linde, ME; von Deimling, A; Vos, M; Weenink, B, 2018) |
| "1/CATNON intergroup trial was designed to evaluate the impact on concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic gliomas." | 5.27 | Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis. ( Abrunhosa-Branquinho, AN; Bar-Deroma, R; Baumert, BG; Clementel, E; Collette, S; Feuvret, L; Hurkmans, CW; Liu, Y; Van Beek, K; van den Bent, M; Weber, DC, 2018) |
| "Adult patients with intermediate- to high-grade glioma on adjuvant temozolomide (TMZ) with facilities for live video call were invited to participate in the study." | 5.27 | Shadow study: randomized comparison of clinic with video follow-up in glioma undergoing adjuvant temozolomide therapy. ( Chakraborty, S; Chandrasekharan, A; Dsouza, H; Goda, JS; Gupta, T; Jalali, R; Krishnatry, R; M, C; Pande, N; Patil, VM; Tonse, R; Vallathol, DH, 2018) |
| "In this study, MGMT promoter methylation was an independent prognostic biomarker of high-risk, low-grade glioma treated with temozolomide and radiotherapy." | 5.27 | Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. ( Aldape, KD; Ashby, LS; Bahary, JP; Becker, AP; Bell, EH; Chakraborty, AR; Chakravarti, A; Fabian, D; Fisher, BJ; Fleming, J; Gray, HJ; Kwok, Y; Laack, NN; Lesser, GJ; Liu, Z; Macdonald, DR; McElroy, JP; Mehta, MP; Robins, HI; Schultz, CJ; Walker, EM; Werner-Wasik, M; Yu, HM; Zhang, P, 2018) |
| "Mibefradil (MIB), previously approved for treatment of hypertension, is a selective T-type calcium channel blocker with preclinical activity in high-grade gliomas (HGGs)." | 5.24 | Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. ( Desai, AS; Desideri, S; Fisher, JD; Grossman, SA; Holdhoff, M; Leal, J; Lesser, GJ; Lieberman, FS; Lodge, MA; Nabors, LB; Read, WL; Schiff, D; Supko, JG; Wahl, RL; Walbert, T; Ye, X, 2017) |
| "While our study failed to meet the primary endpoint for objective radiographic response, patients with high-risk low-grade glioma receiving adjuvant temozolomide demonstrated a high rate of radiographic stability and favorable survival outcomes while meaningfully delaying radiotherapy." | 5.24 | Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. ( Berger, MS; Butowski, N; Chang, SM; Clarke, JL; Costello, JF; Dayal, M; Haas-Kogan, DA; Lin, Y; Molinaro, AM; Nelson, S; Perry, A; Phillips, JJ; Prados, M; Wahl, M, 2017) |
| "Following maximal surgical resection, newly diagnosed children with nonmetastatic high-grade glioma underwent involved field radiotherapy with concurrent temozolomide." | 5.22 | Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. ( Brat, DJ; Burger, PC; Buxton, A; Cohen, KJ; Eckel, SP; Hamilton, RL; Jakacki, RI; Krailo, MD; Lavey, RS; Pollack, IF; Rosenblum, MK; Zhou, T, 2016) |
| "In malignant glioma (MG) patients undergoing radiation therapy (RT) with concomitant temozolomide, chemoradiation-induced nausea and vomiting (cRINV) degrades quality of life (QoL) and reduces treatment adherence, which thereby potentially compromises cancer control." | 5.22 | Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ). ( Affronti, ML; Allen, K; Desjardins, A; Friedman, HS; Healy, PN; Herndon, JE; Kirkpatrick, J; McSherry, F; Peters, KB; Vredenburgh, JJ; Woodring, S, 2016) |
| "Temozolomide chemotherapy versus radiotherapy in patients with a high-risk low-grade glioma has been shown to have no significant effect on progression-free survival." | 5.22 | Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. ( Back, M; Baumert, BG; Borchers, C; Bottomley, A; Brandes, AA; Bromberg, JEC; Chinot, O; Coens, C; Enting, RH; Golfinopoulos, V; Gorlia, T; Hassel, MB; Hau, P; Hoang-Xuan, K; Kantor, G; Klein, M; Mason, WP; Reijneveld, JC; Reni, M; Ryan, G; Smits, A; Stupp, R; Taphoorn, MJB; Thiessen, B; Verger, E; Wick, A, 2016) |
| "Overall, there was no significant difference in progression-free survival in patients with low-grade glioma when treated with either radiotherapy alone or temozolomide chemotherapy alone." | 5.22 | Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. ( Balana, C; Baumert, BG; Brandes, AA; Bravo-Marques, J; Bromberg, JE; Capper, D; Chinot, O; Clement, PM; Dhermain, F; Dif, N; Enting, R; Feuvret, L; Gijtenbeek, JMM; Gorlia, T; Hartmann, C; Hassel, MB; Hegi, ME; Hoang-Xuan, K; Kantor, G; Kros, JM; Kurscheid, S; Lacombe, D; Marosi, C; Mason, WP; Nordal, RA; Rees, J; Reijneveld, JC; Reni, M; Rossiter, JP; Ryan, G; Stupp, R; Taphoorn, MJB; Thiessen, B; Tzuk-Shina, T; van den Bent, MJ; von Deimling, A; Wick, W, 2016) |
| "This trial was designed to evaluate the safety and clinical responses to a combination of temozolomide (TMZ) chemotherapy and immunotherapy with fusions of DCs and glioma cells in patients with glioblastoma (GBM)." | 5.22 | Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma. ( Akasaki, Y; Arai, T; Hayashi, K; Homma, S; Joki, T; Kikuchi, T; Koido, S; Komita, H; Mori, R; Murayama, Y; Ohkusa, T; Suzuki, Y; Tanaka, T; Tasaki, T; Watanabe, N; Yamamoto, Y; Yanagisawa, T, 2016) |
| "Radiation Therapy Oncology Group (RTOG) 0424 was a phase 2 study of a high-risk low-grade glioma (LGG) population who were treated with temozolomide (TMZ) and radiation therapy (RT), and outcomes were compared to those of historical controls." | 5.20 | Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424. ( Bahary, JP; Brachman, DG; Chakravarti, A; Coons, SW; Fisher, BJ; Hu, C; Lesser, GJ; Liu, J; Macdonald, DR; Mehta, M; Ryu, S; Werner-Wasik, M, 2015) |
| "60 patients of postoperative malignant glioma were randomly assigned into two groups, 30 patients were treated with 3D-CRT plus tamoxifen (treatment group), and the other 30 patients with 3D-CRT plus temozolomide (control group)." | 5.20 | Clinical observation of three dimensional conformal radiotherapy with tamoxifen in treatment of postoperative malignant glioma. ( Ding, WX; Gu, L; Guo, XW; Huang, XE; Liu, YC; Yin, XX; Zhou, SB, 2015) |
| "Temozolomide (TMZ) and BCNU have demonstrated anti-glioma synergism in preclinical models." | 5.20 | BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase ( Ashby, L; Asher, AL; Blaker, BD; Boltes, P; Brick, W; Burri, SH; Heideman, BE; Judy, K; Kelly, R; Norton, HJ; Prabhu, RS; Sumrall, AL; Symanowski, JT; Wiggins, WF, 2015) |
| "This phase I study aimed to evaluate safety, maximum tolerated dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of voxtalisib (SAR245409, XL765), a pan-class I phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor, in combination with temozolomide (TMZ), with or without radiation therapy (RT), in patients with high-grade glioma." | 5.20 | Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. ( Ahluwalia, MS; Cloughesy, TF; Egile, C; Fathallah-Shaykh, HM; Jiang, J; Lager, JJ; Laird, AD; Mohile, N; Omuro, A; Tang, J; Wen, PY, 2015) |
| "In a phase II study for patients with relapsed small cell lung cancer (SCLC), the administration of Temozolomide, an alkylating agent used in gliomas and anaplastic astrocytoma, showed a effective activity when O(6) -methylguanine-DNA methyltransferase (MGMT) gene promoter was methylated." | 5.20 | Frequency of O⁶-methylguanine-DNA methyltransferase promoter methylation in cytological samples from small cell lung cancer. ( Boldorini, R; Buosi, R; Gaudino, E; Mancuso, G; Mercalli, F; Mezzapelle, R; Miglio, U; Paganotti, A; Rena, O; Veggiani, C, 2015) |
| "Iniparib is a prodrug that converts to highly reactive cytotoxic metabolites intracellularly with activity in preclinical glioma models." | 5.20 | Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas. ( Blakeley, JO; Chi, AS; Desideri, S; Emmons, G; Garcia Ribas, I; Grossman, SA; Mikkelsen, T; Nabors, LB; Peereboom, D; Rosenfeld, MR; Supko, JG; Ye, X, 2015) |
| "To evaluate the efficacy of limited margins intensity-modulated radiotherapy (IMRT) with temozolomide chemotherapy in patients with malignant glioma, and explore the prognostic factors of malignant glioma." | 5.20 | [Randomized controlled study of limited margins IMRT and temozolomide chemotherapy in patients with malignant glioma]. ( Cao, Y; Sun, J; Yang, X; Zhang, W, 2015) |
| "A phase II trial was performed to evaluate the efficacy of a dose-dense, 7 days on/7 days off schedule of temozolomide for patients with recurrent high-grade gliomas (HGG)." | 5.19 | Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. ( Berger, MS; Butowski, NA; Chang, SM; Clarke, JL; DeSilva, A; Han, SJ; Molinaro, AM; Prados, MD; Rolston, JD, 2014) |
| "We evaluated the prognostic and predictive value of a range of molecular changes in the setting of a randomised trial comparing standard PCV (procarbazine, CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea) and vincristine) chemotherapy with the standard temozolomide (TMZ) 5-day (200 mg/m2/day) schedule and a 21-day (100 mg/m2/day) schedule in chemo-naïve, high-grade glioma (non-oligodendroglial tumours; WHO (World Health Organisation) grades III and IV) patients at first progression following radiotherapy." | 5.19 | Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial. ( Brada, M; Chan, R; Collins, VP; Di, Y; Gabe, R; Ichimura, K; Pearson, D; Stenning, SP; Thompson, LC, 2014) |
| " The primary objective of this study was to determine the safety of the combination of PPX with temozolomide and concurrent radiation for high-grade gliomas." | 5.19 | Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study. ( Boxerman, J; Cielo, D; Constantinou, M; Dipetrillo, T; Donahue, J; Elinzano, H; Evans, D; Goldman, M; Isdale, D; Jeyapalan, S; Kinsella, T; Mantripragada, K; Oyelese, A; Puthawala, Y; Rosati, K; Safran, H; Santaniello, A; Stopa, E, 2014) |
| "A multicenter, two stage phase II study, investigated irinotecan plus temozolomide in children with newly diagnosed high grade glioma." | 5.17 | A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study. ( Ashley, D; Breazna, A; Cisar, L; Clausen, N; Cruz-Martinez, O; Dorman, A; Elliott, M; English, M; Frappaz, D; Fuster, JL; Geoerger, B; Gesner, L; Grill, J; Hargrave, D; Icher, C; Leblond, P; Perilongo, G; Pietsch, T; Rialland, X, 2013) |
| "The alkylating agent temozolomide (TMZ) is widely used for the treatment of gliomas." | 5.17 | Secondary hematological malignancies associated with temozolomide in patients with glioma. ( Miyakita, Y; Momota, H; Narita, Y; Shibui, S, 2013) |
| "To evaluate the efficacy and safety of temozolomide (TMZ) versus semustine (Me-CCNU) in the treatment of recurrent glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA)." | 5.17 | [Multicenter randomized controlled study of temozolomide versus semustine in the treatment of recurrent malignant glioma]. ( Sun, J; Yang, SY; Yang, XJ, 2013) |
| " Multiple glioma cell lines were analyzed for viability after treatment with radiation, temozolomide, or sorafenib or combinations of them." | 5.17 | A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. ( Andrews, DW; Camphausen, K; Den, RB; Dicker, AP; Dougherty, E; Friedman, DP; Glass, J; Green, MR; Hegarty, S; Hyslop, T; Kamrava, M; Lawrence, YR; Marinucchi, M; Sheng, Z; Werner-Wasik, M, 2013) |
| "In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedule in the treatment of recurrent malignant gliomas (MGs)." | 5.17 | Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. ( Abrey, LE; Chan, TA; Deangelis, LM; Gavrilovic, IT; Heguy, A; Hormigo, A; Hottinger, AF; Huse, JT; Kaley, TJ; Kaufman, A; Khasraw, M; Lassman, AB; Mellinghoff, I; Nolan, CP; Omuro, A; Panageas, KS; Reiner, AS; Salvant, C, 2013) |
| "We undertook this phase I study to investigate the feasibility of the combination of temozolomide (TMZ) and lapatinib (LP) and to define the maximum tolerated dose (MTD) of LP in patients with relapsed high-grade gliomas." | 5.17 | A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas. ( Bobos, M; Chrisafi, S; Fountzilas, G; Karavasilis, V; Kotoula, V; Lambaki, S; Pentheroudakis, G; Televantou, D, 2013) |
| "To evaluate in a single center retrospectively the efficacy and tolerability of a weekly regimen, which alternates temozolomide (TMZ) in patients with recurrent or progressive high-grade glioma (HGG)." | 5.17 | "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center. ( Berhorn, T; Blau, T; Dunkl, V; Fink, GR; Galldiks, N; Schroeter, M, 2013) |
| "The new standard treatment of glioblastoma multiforme is concurrent radiotherapy (RT) and temozolomide." | 5.16 | Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma. ( Amin, P; Cheston, S; Dhople, A; DiBiase, S; Flannery, T; Meisenberg, B; Patel, A; Patel, S, 2012) |
| "This paper aims to study the value of MRI and Thallium 201 ((201)Tl) single-photon emission computed tomography (SPECT) in the prediction of overall survival (OS) in glioma patients treated with temozolomide (TMZ) and to evaluate timing of radiological follow-up." | 5.16 | MRI and thallium-201 SPECT in the prediction of survival in glioma. ( Berkhof, J; Bosma, I; Buter, J; Heimans, JJ; Hoekstra, OS; Lagerwaard, FJ; Noske, DP; Postma, TJ; Reijneveld, JC; Sanchez, E; Sizoo, EM; Vos, MJ, 2012) |
| "To estimate the sustained (≥8 weeks) objective response rate in pediatric patients with recurrent or progressive high-grade gliomas (HGG, Stratum A) or brainstem gliomas (BSG, Stratum B) treated with the combination of O6-benzylguanine (O6BG) and temozolomide(®) (TMZ)." | 5.16 | A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. ( Balis, FM; Berg, SL; Boyett, JM; Geyer, JR; Goldman, S; Gururangan, S; Kun, LE; McLendon, RE; Minturn, JE; Packer, RJ; Pollack, IF; Poussaint, TY; Wallace, D; Warren, KE, 2012) |
| "Patients with high-grade glioma can be treated with carmustine wafers or following the Stupp protocol." | 5.16 | Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis. ( Aurrecoechea-Obieta, J; Bilbao-Barandica, G; Canales-Llantada, M; Carbayo-Lozano, G; Catalán-Uribarrena, G; Galbarriatu-Gutiérrez, L; Igartua-Azkune, A; Pomposo-Gaztelu, I; Ruiz de Gopegui-Ruiz, E; Undabeitia-Huertas, J, 2012) |
| "To compare the therapeutic efficacy of two regimens of postoperative radiotherapy with concurrent chemotherapy using temozolomide (TMZ) and teniposide (VM-26) plus semustine (Me-CCNU) in adult patients with grade III-IV cerebral gliomas." | 5.16 | [Comparison of two regimens of postoperative concurrent chemoradiotherapy in adult patients with grade III-IV cerebral gliomas]. ( Gu, K; Wang, J; Zhai, X; Zhang, J, 2012) |
| "4 Gy radiotherapy with up-front temozolomide in previously untreated low-grade glioma." | 5.16 | Quality assurance in the EORTC 22033-26033/CE5 phase III randomized trial for low grade glioma: the digital individual case review. ( Bar-Deroma, R; Baumert, BG; Fairchild, A; Fenton, PA; Gulyban, A; Stupp, R; Weber, DC, 2012) |
| "To evaluate the toxicity and maximum tolerated dose (MTD) of arsenic trioxide (ATO) in combination with temozolomide (TMZ) and radiation therapy (RT) in malignant gliomas." | 5.16 | Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas. ( Chandler, JP; Grimm, SA; Jovanovic, B; Levy, RM; Marymont, M; McCarthy, K; Muro, K; Newman, SB; Raizer, JJ, 2012) |
| "The assessment of the therapeutic response of high-grade gliomas treated with concomitant chemoradiotherapy (CCRT) using temozolomide is difficult because of the frequent occurrence of early imaging changes that are indistinguishable from tumor progression, termed pseudoprogression." | 5.16 | Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Lee, WJ; Park, CK; Park, SH; Sohn, CH; Yi, KS, 2012) |
| "A phase I, dose-finding study of vorinostat in combination with temozolomide (TMZ) was conducted to determine the maximum tolerated dose (MTD), safety, and pharmacokinetics in patients with high-grade glioma (HGG)." | 5.16 | Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. ( Ames, MM; Chang, SM; Cloughesy, TF; Desideri, S; Drappatz, J; Espinoza-Delgado, I; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lee, EQ; Lieberman, FS; McGovern, RM; Prados, MD; Puduvalli, VK; Reid, JM; Robins, HI; Wen, PY; Xu, J; Ye, X; Yung, WK, 2012) |
| "The objective of this prospective, monocentric phase-II pilot study was to evaluate toxicity and efficacy of neoadjuvant temozolomide (TMZ) and 13-cis retinoic acid (13-cRA) treatment in patients with newly diagnosed anaplastic gliomas after total or subtotal tumor resection." | 5.15 | Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05). ( Bogdahn, U; Brawanski, A; Grauer, O; Hartmann, C; Hau, P; Pascher, C; Pietsch, T; Proescholdt, M; Weller, M; Wick, W; Zeman, F, 2011) |
| "Forty-two patients with glioblastoma and 16 patients with anaplastic glioma who had received concurrent radiation and temozolomide and adjuvant temozolomide were enrolled at first relapse." | 5.15 | Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. ( Aldape, K; Chang, SM; Chen, A; Cloughesy, TF; de Groot, JF; Deangelis, LM; Gilbert, MR; Jackson, EF; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, MP; Prados, MD; Robins, HI; Wen, PY; Yao, J; Yung, WK, 2011) |
| "Patients with newly diagnosed malignant glioma received AdV-tk at 3 × 10(10), 1 × 10(11), or 3 × 10(11) vector particles (vp) via tumor bed injection at time of surgery followed by 14 days of valacyclovir." | 5.15 | Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. ( Aguilar, LK; Aguilar-Cordova, E; Baskin, DS; Bell, SD; Cavaliere, R; Chakravarti, A; Chiocca, EA; Grecula, J; Grossman, RG; Hardcastle, J; Harris, KS; Kaur, B; Lo, S; Manzanera, AG; McGregor, J; Monterroso, C; New, PZ; Newton, H; Ray-Chaudhuri, A; Trask, TW, 2011) |
| "To study the safety and efficacy of three-dimensional conformal radiotherapy in combination with temozolomide in treatment of patients with diffuse brainstem glioma." | 5.15 | [Safety and efficacy of three-dimensional conformal radiotherapy combined with temozolomide in treatment of diffuse brainstem gliomas]. ( Cai, CL; Fang, HH; Kang, JB; Li, FM; Nie, Q, 2011) |
| "Patients with newly diagnosed oligodendroglioma or oligoastrocytoma with a MIB-1 index of >5% or recurrent low-grade gliomas received temozolomide (75 mg/m(2)/day in 11-week cycles of 7 weeks on/4 weeks off)." | 5.14 | Phase II study of protracted daily temozolomide for low-grade gliomas in adults. ( Black, PM; Bradshaw, J; Ciampa, A; Doherty, L; Drappatz, J; Kesari, S; LaFrankie, D; Levy, B; Ligon, KL; Macklin, EA; Muzikansky, A; Norden, AD; Radakovic, G; Ramakrishna, N; Santagata, S; Schiff, D; Wen, PY, 2009) |
| "This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administering O(6)-BG in combination with temozolomide." | 5.14 | Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| "This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5-day dosing regimens of temozolomide (TMZ) in combination with O(6)-benzylguanine (O(6)-BG)." | 5.14 | Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Vredenburgh, JJ; Walker, A, 2009) |
| " We investigated the time course of tumor metabolism in low-grade gliomas (LGG) during temozolomide chemotherapy, and compared metabolic responses as measured with positron emission tomography (PET) with volume responses as revealed by magnetic resonance imaging (MR)." | 5.14 | Early metabolic responses in temozolomide treated low-grade glioma patients. ( Bärtschi, E; Bruehlmeier, M; Buettner, UW; Hefti, M; Hofer, S; Roelcke, U; Uhlmann, C; Wyss, M, 2009) |
| "To present outcome data in a prospective study of radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in children with diffuse intrinsic pontine gliomas (DIPGs)." | 5.14 | Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. ( Arora, B; Dutta, D; Gupta, T; Jalali, R; Kurkure, P; Munshi, A; Raut, N; Sarin, R, 2010) |
| "This multicenter phase II study conducted by the Spanish Neuro-Oncology Group evaluated the activity of an extended, dose-dense temozolomide regimen in patients with temozolomide-refractory malignant glioma." | 5.14 | Extended-schedule dose-dense temozolomide in refractory gliomas. ( Balaña, C; Berrocal, A; Gallego, O; Garcia Lopez, J; Gil, M; Iglesias, L; Perez Segura, P; Reynes, G; Rodríguez, J; Yaya, R, 2010) |
| "Heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma received cisplatin at a dose of 75 mg/m(2) on day 1 and temozolomide at a dose of 150 mg/m(2) on days 1 to 5 every 21 days until progression or major toxicity." | 5.14 | A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma. ( Della Puppa, A; Lombardi, G; Pastorelli, D; Rotilio, A; Scienza, R; Zustovich, F, 2009) |
| "To investigate the efficacy and safety of temozolomide (TMZ) and lomustine (CCNU) in malignant brain gliomas." | 5.14 | [A multicenter randomized controlled study of temozolomide in 97 patients with malignant brain glioma]. ( Chang, Y; Fu, Z; Liu, XM; Liu, XY; Qian, ZZ; Wang, HQ; Yang, SY; Yu, H, 2009) |
| "PURPOSE Concomitant temozolomide (TMZ)/radiotherapy followed by adjuvant TMZ has increased survival in patients with glioblastoma multiforme (GBM)." | 5.14 | Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. ( Bélanger, K; Easaw, J; Eisenstat, DD; Forsyth, P; Fulton, D; Kavan, P; Kirby, S; Macdonald, DR; Mason, WP; Perry, JR; Pouliot, JF; Shields, C; Thiessen, B, 2010) |
| "Twenty-two patients with newly diagnosed malignant glioma who received standard radiation/temozolomide therapy were recruited for the study." | 5.14 | Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma. ( Chiba, Y; Hashimoto, N; Hosen, N; Kagawa, N; Kinoshita, M; Murao, A; Nishida, S; Oji, Y; Oka, Y; Sugiyama, H; Tsuboi, A; Yoshimine, T, 2010) |
| "Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG)." | 5.14 | Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. ( Beall, S; Brada, M; Collins, VP; Erridge, S; Gabe, R; Gattamaneni, R; Hopkins, K; Lee, SM; Levy, D; Rampling, R; Saran, F; Stenning, S; Thompson, LC, 2010) |
| "To assess survival, local control and toxicity using fractionated stereotactic conformal radiotherapy (FSCRT) boost and temozolomide in high-grade gliomas (HGGs)." | 5.14 | Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report. ( Albanese, A; Anile, C; Apicella, G; Azario, L; Balducci, M; Cellini, N; Chiesa, S; D'Agostino, GR; de Bonis, P; Dinapoli, N; Fiorentino, A; Frascino, V; Manfrida, S; Mangiola, A; Mantini, G; Valentini, V, 2010) |
| "We performed a new phase II trial enrolling patients with newly diagnosed high-grade glioma (HGG) to test the efficacy of a weekly alternating temozolomide (TMZ) schedule after surgery and concomitant chemoradiotherapy." | 5.13 | Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas. ( D'Amico, A; Dall'oglio, S; Gabbani, M; Maluta, S; Pasini, F; Passarin, MG; Pioli, F; Talacchi, A; Turazzi, S, 2008) |
| "A multicenter phase I clinical trial, namely, Integrated Japanese Multicenter Clinical Trial: A Phase I Study of Interferon-beta and Temozolomide for Glioma in Combination with Radiotherapy (INTEGRA Study), is being conducted for patients with high-grade glioma in order to evaluate the safety, feasibility and preliminary clinical effectiveness of the combination of interferon-beta and temozolomide." | 5.13 | A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study). ( Aoki, T; Hashimoto, N; Kayama, T; Kurisu, K; Natsume, A; Nishikawa, R; Ogura, M; Takahashi, H; Wakabayashi, T; Yoshida, J; Yoshimine, T, 2008) |
| "This is a phase-I study of gefitinib in combination with temozolomide in patients with gliomas." | 5.13 | Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. ( Chang, S; Cloughesy, T; Dancey, J; Fink, K; Junck, L; Kuhn, J; Prados, MD; Robins, HI; Wen, PY; Yung, WK, 2008) |
| "Twice-daily dosing may enhance the efficacy of temozolomide in the treatment of recurrent gliomas without increasing toxicity." | 5.13 | Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. ( Alavi, J; Balmaceda, C; Chen, J; Cheung, YK; Fine, RL; Fisher, PG; Pannullo, S; Peereboom, D; Sisti, M, 2008) |
| "We determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of imatinib mesylate, an inhibitor of the receptor tyrosine kinases platelet-derived growth factor receptor (PDGFR), the proto-oncogene product c-kit, and the fusion protein Bcr-Abl, when administered for 8 days in combination with temozolomide (TMZ) to malignant glioma (MG) patients." | 5.13 | Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. ( Desjardins, A; Egorin, MJ; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Lagattuta, TF; McLendon, R; Quinn, JA; Reardon, DA; Rich, JN; Salvado, AJ; Sathornsumetee, S; Vredenburgh, JJ, 2008) |
| "The aim of the present study was to determine in patients with progressive or recurrent low grade gliomas, the response rate and toxicity incurred by a continued schedule of temozolomide chemotherapy administered before radiation therapy, and to explore correlations between response and survival with 1p/19q deletions and MGMT promoter methylation status." | 5.13 | Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. ( Bertorelle, R; Blatt, V; Bonaldi, L; Brandes, AA; Ermani, M; Franceschi, E; Tosoni, A, 2008) |
| "To evaluate outcome after fractionated stereotactic radiotherapy (FSRT) and concomitant daily temozolomide (TMZ) in patients with recurrent gliomas." | 5.13 | Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. ( Bischof, M; Combs, SE; Debus, J; Hof, H; Oertel, S; Schulz-Ertner, D; Welzel, T, 2008) |
| "A phase I trial was conducted to determine the maximum tolerated dose (MTD) of temozolomide given in combination with lomustine in newly diagnosed pediatric patients with high-grade gliomas." | 5.13 | A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. ( Adamson, PC; Blaney, SM; Flom, L; Ingle, AM; Jakacki, RI; Pollack, IF; Prados, MD; Timmerman, R; Yates, A; Zhou, T, 2008) |
| "We performed a Cochrane Review to examine studies using different techniques to measure MGMT and predict survival in glioblastoma patients treated with temozolomide." | 5.12 | MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review. ( Brandner, S; Cheng, HY; Dawson, S; Faulkner, CL; Higgins, JPT; Jefferies, S; Kelly, C; Kurian, KM; McAleenan, A; Schmidt, L; Spiga, F; Wragg, C, 2021) |
| "Recent developments in pharmacogenomics have created opportunities for predicting temozolomide response in gliomas." | 5.12 | Comprehensive pharmacogenomics characterization of temozolomide response in gliomas. ( Long, J; Tong, S; Wang, B; Wang, Y; Wu, J; Zhong, P, 2021) |
| "We searched Medline and Embase (Jan 1994-Jan 2021) for studies evaluating the effect of temozolomide monotherapy on cell viability of at least one malignant glioma cell line." | 5.12 | Temozolomide sensitivity of malignant glioma cell lines - a systematic review assessing consistencies between in vitro studies. ( Brennan, PM; Bruce, M; Hannan, CJ; Poon, MTC; Simpson, JE, 2021) |
| "In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the treatment of IDH-mutant gliomas." | 5.12 | From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas. ( Sun, X; Turcan, S, 2021) |
| "Temozolomide (TMZ) is a first-choice alkylating agent inducted as a gold standard therapy for glioblastoma multiforme (GBM) and astrocytoma." | 5.12 | Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance. ( Kumar, A; Shrivastava, A; Srivastava, C; Tomar, MS, 2021) |
| "The objective of the study was to evaluate the efficacy and toxicity of Temozolomide (TMZ) administered for 5 consecutive days in three daily dosing in children with recurrent or refractory high-grade glioma." | 5.12 | Phase II trial of temozolomide in children with recurrent high-grade glioma. ( Abate, ME; Attinà, G; Caldarelli, M; Cefalo, G; Clerico, A; Colosimo, C; Di Rocco, C; Garré, ML; Lazzareschi, I; Madon, E; Massimino, M; Maurizi, P; Mazzarella, G; Riccardi, R; Ridola, V; Ruggiero, A; Sandri, A, 2006) |
| "Temozolomide (TMZ) a recent, oral, second generation alkylating agent is a chemotherapeutic with demonstrated efficacy for the treatment of high-grade gliomas." | 5.12 | Surgery, radiotherapy and temozolomide in treating high-grade gliomas. ( Barbarisi, M; Moraci, A; Moraci, M; Parlato, C, 2006) |
| "The purpose of this study was to define the maximum tolerated dose of erlotinib and characterize its pharmaco-kinetics and safety profile, alone and with temozolomide, with and without enzyme-inducing antiepileptic drugs (EIAEDs), in patients with malignant gliomas." | 5.12 | Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. ( Burton, E; Butowski, N; Chang, S; Fedoroff, A; Kapadia, A; Kelley, SK; Lamborn, KR; Malec, M; Page, MS; Prados, MD; Rabbitt, J; Xie, D, 2006) |
| "The purpose of this study was to monitor the metabolic effects of temozolomide (TMZ) chemotherapy in malignant gliomas by means of repeated positron emission tomography (PET) with [(11)C]methionine (MET)." | 5.12 | Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. ( Burghaus, L; Galldiks, N; Heiss, WD; Herholz, K; Jacobs, AH; Kracht, LW; Thomas, A, 2006) |
| "Since anaplastic gliomas (AG) depend on matrix metalloproteinases for tumor cell invasion and angiogenesis, we undertook this phase II study to evaluate the matrix metalloproteinase inhibitor marimastat (MT), combined with the alkylator temozolomide (TMZ) in patients with recurrent AG, looking for improved outcomes." | 5.12 | Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. ( Aldape, KD; Conrad, CA; Gilbert, MR; Groves, MD; Hess, KR; Jaeckle, K; Levin, VA; Liu, V; Puduvalli, VK; Yung, WK, 2006) |
| "Temozolomide (TMZ) has demonstrated activity and acceptable toxicity for the treatment of recurrent malignant gliomas in carious prospective phase II studies." | 5.12 | [Temozolomide in the treatment of recurrent malignant glioma]. ( Ishii, N; Iwasaki, Y; Kobayashi, H; Murata, J; Sawamura, Y, 2006) |
| "The methylation status of the O6-methylguanine-methyltransferase promoter (MGMTP) was evaluated in 68 low-grade gliomas treated by neoadjuvant temozolomide." | 5.12 | MGMT methylation: a marker of response to temozolomide in low-grade gliomas. ( Benouaich-Amiel, A; Crinière, E; Delattre, JY; Everhard, S; Hoang-Xuan, K; Kaloshi, G; Kujas, M; Lejeune, J; Marie, Y; Mokhtari, K; Sanson, M; Thillet, J, 2006) |
| "We conducted a phase II study to assess the efficacy of oral temozolomide (TMZ) in children with progressive low-grade glioma." | 5.12 | Temozolomide in children with progressive low-grade glioma. ( Allen, JC; Desjardins, A; Fisher, MJ; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Krauser, JM; Phillips, PC; Quinn, JA; Reardon, DA; Vredenburgh, JJ; Watral, MA, 2007) |
| "Evaluation of toxicity and efficacy of an alternating weekly regimen of temozolomide administered 1 week on and 1 week off in patients with recurrent glioma." | 5.12 | Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. ( Blaschke, B; Felsberg, J; Herrlinger, U; Meyermann, R; Platten, M; Reifenberger, G; Steinbach, JP; Weller, M; Wick, A; Wick, W, 2007) |
| "To determine the maximum tolerated dose of irinotecan when administrated with temozolomide every 28 days, in patients with recurrent malignant glioma who were also receiving CYP450 enzyme-inducing antiepileptic drugs (EIAED), and to characterize the pharmacokinetics of irinotecan and its metabolites." | 5.12 | Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. ( Aldape, KD; Chang, SM; Cloughesy, T; DeAngelis, LM; Fine, H; Fink, KL; Junck, L; Kuhn, J; Lamborn, K; Lieberman, F; Loghin, ME; Metha, M; Prados, MD; Robins, IH; Wen, P; Yung, WK, 2007) |
| "A phase II trial was initiated to analyze the activity of continuously administered pioglitazone and rofecoxib combined with low-dose chemotherapy (capecitabine or temozolomide) in patients with high-grade gliomas (glioblastoma or anaplastic glioma)." | 5.12 | Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. ( Baumgart, U; Bogdahn, U; Hau, P; Hirschmann, B; Kunz-Schughart, L; Muhleisen, H; Reichle, A; Ruemmele, P; Steinbrecher, A; Weimann, E, 2007) |
| "Patients with recurrent malignant glioma at any time during recurrence were treated with oral temozolomide at a dose of 150 mg/m2 per day on a 5-day schedule every 28 days." | 5.11 | Temozolomide in the treatment of recurrent malignant glioma. ( Chang, SM; Lamborn, K; Malec, M; Page, M; Prados, MD; Rabbitt, J; Theodosopoulos, P, 2004) |
| "We report a phase II trial of cisplatinum and temozolomide (TMZ) combination in recurrent malignant glioma patients." | 5.11 | Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. ( Boiardi, A; Broggi, G; Eoli, M; Lamperti, E; Maccagnano, E; Salmaggi, A; Silvani, A, 2004) |
| "Temozolomide (TMZ) and 1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU) are reported to be active agents in anaplastic glioma (AG)." | 5.11 | Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. ( Chang, SM; Fine, H; Fink, KL; Greenberg, H; Hess, K; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, M; Prados, MD; Robins, HI; Schold, C; Yung, WK, 2004) |
| "This report describes a single-centre study with temozolomide (TMZ) (200 mg m(-2) day(-1) x 5 per cycle of 28 days) in children with (recurrent) high-grade glioma." | 5.11 | Temozolomide in paediatric high-grade glioma: a key for combination therapy? ( Couanet, D; Grill, J; Kalifa, C; Lelouch-Tubiana, A; Vassal, G; Verschuur, AC, 2004) |
| "Thirty-two patients with relapsing glioma were treated with temozolomide in two university hospitals in Finland." | 5.11 | Temozolomide treatment in glioma--experiences in two university hospitals in Finland. ( Aaltonen, K; Mäenpää, HO; Mäntylä, R; Minn, H, 2004) |
| "The administration of temozolomide after RT did not alter the poor prognosis associated with newly diagnosed diffuse brainstem glioma in children." | 5.11 | Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98). ( Bowers, DC; Broniscer, A; Chintagumpala, M; Fouladi, M; Gajjar, A; Iacono, L; Krasin, MJ; Stewart, C; Wallace, D, 2005) |
| "The authors determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of irinotecan (CPT-11), a topoisomerase I inhibitor, when administered with temozolomide among patients with recurrent malignant glioma (MG)." | 5.11 | Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. ( Badruddoja, M; Burkart, JL; Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, R; Newton, HB; Provenzale, J; Quinn, JA; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, J, 2005) |
| "To determine the anti-tumour efficacy and safety profile of temozolomide in local Chinese patients with recurrent malignant glioma." | 5.11 | Temozolomide in the treatment of recurrent malignant glioma in Chinese patients. ( Chan, DT; Chan, YL; Ng, HK; Poon, WS, 2005) |
| "To determine the response rate of the malignant gliomas of childhood to an oral, daily schedule of temozolomide." | 5.10 | Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. ( Couanet, D; Doz, F; Dugan, M; Frappaz, D; Griffiths, PD; Hobson, R; Ironside, J; Jaspan, T; Jouvet, A; Lashford, LS; Pearson, AD; Robson, K; Thiesse, P; Vassal, G, 2002) |
| "Although temozolomide is active against recurrent malignant glioma, responses in many patients are modest and short-lived." | 5.10 | Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. ( Benita-Weiss, M; Bushunow, P; Coyle, TE; Evans, B; Friedman, H; Korones, DN; Mechtler, L; Quinn, JA; Reardon, DA, 2003) |
| "Temozolomide (TMZ) and 13-cis-retinoic acid (cRA) have shown activity in prior single-agent trials of recurrent malignant gliomas (MG)." | 5.10 | Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. ( Chang, S; Cloughesy, T; Fine, H; Fink, K; Greenberg, H; Hess, KR; Jaeckle, KA; Kuhn, J; Mehta, M; Nicholas, MK; Pollack, IF; Prados, M; Schiff, D; Yung, WK, 2003) |
| "Temozolomide (TMZ) is an oral alkylating agent with a good safety profile and proven efficacy in the treatment of malignant glioma." | 5.10 | Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. ( Foster, T; Newlands, ES; Zaknoen, S, 2003) |
| "The aim of this study was to assess the efficacy of temozolomide in patients with World Health Organisation (WHO) grade II gliomas treated with surgery alone using imaging and clinical criteria." | 5.10 | Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. ( Abson, C; Ashley, S; Brada, M; Britton, J; Gonsalves, A; Hines, F; Sardell, S; Traish, D; Viviers, L; Westbury, C; Wilkins, P, 2003) |
| "Forty-three patients affected with LGG (29 astrocytoma, four oligodendroglioma and 10 mixed oligo-astrocytoma) were treated with temozolomide (TMZ) at the time of documented clinical and radiological progression." | 5.10 | Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. ( Canalini, P; Carapella, CM; Carosi, M; Cianciulli, AM; Galiè, E; Giannarelli, D; Jandolo, B; Pace, A; Telera, S; Vidiri, A, 2003) |
| "Temozolomide is an effective agent in the treatment of recurrent malignant gliomas." | 5.10 | A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. ( Abrey, LE; Bazylewicz, KA; Khan, RB; Malkin, MG; Raizer, JJ, 2002) |
| "Forty-one patients with high-grade glioma, at second recurrence or progression, of which twenty-two (54%) had glioblastoma multiforme, ten (24%) anaplastic astrocytoma, and nine (22%) anaplastic oligodendroglioma were administered temozolomide, 150 mg/m2/daily for five days every four weeks." | 5.09 | Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. ( Amistà, P; Basso, U; Berti, F; Brandes, AA; Ermani, M; Gardiman, M; Monfardini, S; Pinna, G; Rotilio, A; Scienza, R, 2001) |
| "Temozolomide, a new oral cytotoxic agent, was given to 75 patients with malignant gliomas." | 5.08 | The Charing Cross Hospital experience with temozolomide in patients with gliomas. ( Bower, M; Brampton, MH; Brock, C; Colquhoun, I; Evans, H; Glaser, MG; Illingworth, RD; Lewis, P; Newlands, ES; O'Reilly, SM; Rice-Edwards, JM; Richards, PG, 1996) |
| "Patients with progressive or recurrent supratentorial high-grade gliomas were entered into a multicentre phase II trial to evaluate the efficacy and toxicity of temozolomide." | 5.08 | Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. ( Begent, RJ; Bleehen, NM; Bower, M; Brada, M; Brampton, MH; Calvert, H; Colquhoun, I; Lewis, P; Newlands, ES, 1997) |
| "Temozolomide, a methylating imidazotetrazinone, has antitumor activity against gliomas, malignant melanoma, and mycosis fungoides and is presently administered as a 5-day oral schedule every 4 weeks." | 5.08 | Phase I trial of temozolomide using an extended continuous oral schedule. ( Bower, M; Brampton, MH; Brock, CS; Colquhoun, I; Evans, H; Glaser, M; Newlands, ES; Roddie, M; Rustin, GJ; Wedge, SR, 1998) |
| "The majority of patients with high-risk lower grade gliomas (LGG) are treated with single-agent temozolomide (TMZ) and radiotherapy despite three randomized trials showing a striking overall survival benefit with adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiotherapy." | 5.05 | Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. ( Atkins, KM; Dietrich, J; Loeffler, JS; McDuff, SGR; Oh, KS; Shih, HA, 2020) |
| " For glioblastoma, the irradiation dose of 60 Gy in 30 fractions with concomitant and adjuvant temozolomide is currently considered as a standard of treatment, and further dose escalation has failed to be of benefit in clinical trials." | 4.98 | Fractionated Radiotherapy of Intracranial Gliomas. ( Ghia, AJ, 2018) |
| " Temozolomide, a monofunctional alkylator, was the first chemotherapeutic agent to definitively improve survival in adults with newly diagnosed glioblastoma used in combination with radiation therapy with the most pronounced effect being in a subgroup of tumors with MGMT promoter methylation." | 4.98 | Chemotherapy of High-Grade Astrocytomas in Adults. ( Hoang, N; Puduvalli, VK, 2018) |
| "Resistance of malignant glioma, including glioblastoma (GBM), to the chemotherapeutic temozolomide (TMZ) remains a key obstacle in treatment strategies." | 4.98 | Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics. ( Ghatnekar, GG; Gourdie, RG; Grek, CL; Naus, CC; Sheng, Z; Sin, WC, 2018) |
| " In low- and high-grade gliomas, the most frequent brain tumors, germinal MMR defects are rare; however, hypermutations associated with mutations or decreased expression of MMR genes are rather frequent, occurring in 20-60% of the tumors at recurrence after alkylating chemotherapy with temozolomide." | 4.95 | Hypermutations in gliomas: a potential immunotherapy target. ( Corbetta, C; Finocchiaro, G; Langella, T; Pellegatta, S, 2017) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 4.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| "There is a growing body of evidence that carmustine wafer implantation during surgery is an effective therapeutic adjunct to the standard combined radio-chemotherapy regimen using temozolomide in newly diagnosed and recurrent high-grade glioma patient management with a statistically significant survival benefit demonstrated across several randomized clinical trials, as well as prospective and retrospective studies (grade A recommendation)." | 4.95 | Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery. ( Caire, F; Guyotat, J; Menei, P; Metellus, P; Pallud, J; Roux, A, 2017) |
| "Malignant gliomas are highly invasive tumors, associated with a dismal survival rate despite standard of care, which includes surgical resection, radiotherapy and chemotherapy with temozolomide (TMZ)." | 4.95 | Single vs. combination immunotherapeutic strategies for glioma. ( Asad, AS; Candolfi, M; Castro, MG; Chandran, M; Koschmann, C; Lowenstein, PR; Mineharu, Y; Shah, D; Yadav, VN, 2017) |
| "This review article summarizes in vitro, in vivo, and clinical evidence pertaining to temozolomide (TMZ) and bevacizumab (BEV) efficacy and mechanism of action in gliomas." | 4.91 | Current evidence of temozolomide and bevacizumab in treatment of gliomas. ( Chattipakorn, N; Chattipakorn, SC; Nanegrungsunk, D; Onchan, W, 2015) |
| "The goal of this meta-analysis was to identify the temozolomide (TMZ) regimen with optimal efficacy and tolerance for treatment of recurrent high-grade glioma (HGG)." | 4.91 | The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis. ( Chen, X; Guo, Z; Ma, X; Wang, D; Wei, W, 2015) |
| "This analysis was conducted to evaluate the efficacy and safety of temozolomide based chemotherapy in treating patients with glioma." | 4.90 | Comprehensive analysis of temozolomide treatment for patients with glioma. ( Liang, H; Xing, BZ; Yang, WB, 2014) |
| "Temozolomide (TMZ) is an alkylating agent currently used as first-line therapy for gliomas treatment due to its DNA-damaging effect." | 4.89 | O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas. ( Cao, H; Chen, L; Fan, CH; Jiang, G; Liu, WL; Wen, C, 2013) |
| "High-grade glioma patients receiving concomitant chemoradiotherapy with temozolomide 75mg/m(2) during six to seven weeks or dose-dense temozolomide regimens especially in combination with chronic use of corticosteroids have a high risk for developing Pneumocystis jirovecii pneumonia." | 4.89 | Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas. ( Bleeker-Rovers, CP; De Vos, FY; Gijtenbeek, JM; van Herpen, CM, 2013) |
| "We searched three online databases to systematically identify publications testing temozolomide in animal models of glioma." | 4.89 | Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted? ( Egan, KJ; Hirst, TC; Macleod, MR; Sena, ES; Vesterinen, HM; Whittle, IR, 2013) |
| "The standard therapy for newly diagnosed malignant gliomas comprises surgery, radiotherapy, and commonly temozolomide chemotherapy." | 4.87 | An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting. ( Kyritsis, AP; Levin, VA, 2011) |
| "Progress in treating diffuse gliomas remains limited and is principally concerned with the confirmation that cystostatics as nitrosureum derivatives and temozolomide play a role in the treatment of these tumours." | 4.87 | [Issues around diffuse glioma]. ( van den Bent, MJ, 2011) |
| "Temozolomide is an oral alkylating agent with established antitumor activity in patients with primary brain tumors and melanoma." | 4.86 | Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. ( Hwu, WJ; Neyns, B; Reardon, DA; Tosoni, A, 2010) |
| "Temozolomide-based chemotherapy represents an incremental improvement in the treatment of patients with high-grade gliomas." | 4.86 | Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. ( Chamberlain, MC, 2010) |
| "One barrier to successful treatment of malignant glioma is resistance to alkylating agents such as temozolomide." | 4.85 | New (alternative) temozolomide regimens for the treatment of glioma. ( Platten, M; Weller, M; Wick, W, 2009) |
| " The standard care for glioblastoma is surgery and concomitant radio- and chemotherapy with temozolomide (TMZ), followed by adjuvant treatment with TMZ." | 4.85 | Insights into pharmacotherapy of malignant glioma in adults. ( D'Elia, A; Formichella, AI; Frati, A; Salvati, M, 2009) |
| " Temozolomide is a novel second-generation alkylating agent that has shown efficacy for the treatment of high-grade gliomas." | 4.84 | [Glioma therapy up-date]. ( Dalmau, J; de la Fuente, BP; Rosenfeld, M, 2007) |
| "The temozolomide is a promising orally cytotoxic agent used in malignant glioma." | 4.83 | The safety of the temozolomide in patients with malignant glioma. ( Dario, A; Tomei, G, 2006) |
| "Surgery and radiation have been the mainstays of therapy for most glioma patients, but temozolomide chemotherapy has recently been proven to prolong overall survival in patients with glioblastoma." | 4.83 | Glioma therapy in adults. ( Norden, AD; Wen, PY, 2006) |
| "The current standard of care for malignant gliomas is surgical resection and radiotherapy followed by extended adjuvant treatment with the alkylating agent temozolomide." | 4.83 | Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas. ( Alonso, MM; Fueyo, J; Gomez-Manzano, C; Jiang, H; Piao, Y, 2006) |
| " The place of chemotherapy is growing not only for anaplastic oligodendrogliomas, more chemosensitive (particularly when they harbor 1p19q codeletions), but also for glioblastomas patients, which have been shown to benefit from radiotherapy plus concomitant and adjuvant temozolomide." | 4.83 | [Pattern of care of high-grade gliomas]. ( Laigle-Donadey, F; Sanson, M, 2006) |
| "Temozolomide is a novel oral alkylating agent that has been approved for the treatment of patients with refractory malignant glioma." | 4.81 | New approaches for temozolomide therapy: use in newly diagnosed glioma. ( Newlands, E; Stupp, R, 2001) |
| " Preclinical and phase I trials have shown the additive or synergistic activity of temozolomide combined with carmustine against solid tumors, including malignant glioma, and the sequence-dependent effects of the combination." | 4.81 | Temozolomide in combination with other cytotoxic agents. ( Prados, M, 2001) |
| " Temozolomide, an alkylating agent that can be administered orally, has been approved for the treatment of recurrent malignant glioma on a daily schedule for 5-day cycles." | 4.81 | Current and future developments in the use of temozolomide for the treatment of brain tumours. ( Gander, M; Leyvraz, S; Newlands, E; Stupp, R, 2001) |
| "Complete resection of glioblastoma via a supraorbital transciliary approach with 5-Aminolevulinic Acid use was performed without any complications, as demonstrated on postoperative MRI." | 4.31 | Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note. ( Aboukaïs, R; Bourgeois, P; Devalckeneer, A; Lejeune, JP; Reyns, N, 2023) |
| " Based on CRISPR-Cas9 library screening, we found that mucin1 (MUC1) is essential for EGFRvIII glioma cell survival and temozolomide (TMZ) resistance." | 4.31 | MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII. ( Cui, XT; Fang, ZY; Fu, JQ; Kang, CS; Liu, SZ; Liu, X; Qiu, ZJ; Su, DY; Tong, F; Wang, GX; Wang, JC; Wang, QX; Zhao, JX; Zhou, JH, 2023) |
| " Even with aggressive treatment, tumor recurrence is almost universal and patient prognosis is poor because many GBM cell subpopulations, especially the mesenchymal and glioma stem cell populations, are resistant to temozolomide (TMZ), the most commonly used chemotherapeutic in GBM." | 4.31 | αCT1 peptide sensitizes glioma cells to temozolomide in a glioblastoma organoid platform. ( Che, J; DePalma, TJ; Mezache, LS; Sivakumar, H; Skardal, A; Swindle-Reilly, K; Tallman, MM; Veeraraghavan, R; Venere, M, 2023) |
| "Temozolomide (TMZ) is a conventional chemotherapeutic drug for glioma, however, its clinical application and efficacy is severely restricted by its drug resistance properties." | 4.31 | The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma. ( Li, L; Liu, H; Ma, H; Qian, F; Quan, A; Ren, Y; Wang, L; Xu, H; Yu, R; Zhang, Y, 2023) |
| "Temozolomide (TMZ) delivery was investigated in CT2A and PDGFB-driven RCAS/tv-a orthotopic glioma models." | 4.31 | Wnt signaling regulates MFSD2A-dependent drug delivery through endothelial transcytosis in glioma. ( Cao, H; Chao, M; Dimberg, A; He, L; Huang, H; Li, Y; Shi, X; Tang, J; Uhrbom, L; Wang, J; Wang, L; Xiao, B; Xie, Y; Xin, L; Yang, F; Zhang, L; Zhang, X; Zhang, Y, 2023) |
| " In this study, we investigated the role of KDM1A/LSD1 in DNA double-strand break (DSB) repair and a combination of KDM1A inhibitor and temozolomide (TMZ) in vitro and in vivo using patient-derived glioma stem cells (GSCs)." | 4.31 | Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma. ( Alejo, S; Brenner, AJ; Chen, Y; Clarke, K; Gilbert, AR; He, Y; Jayamohan, S; Johnson, JD; Lai, Z; Li, W; Lv, Y; Palacios, BE; Pratap, UP; Sareddy, GR; Suzuki, T; Tekmal, RR; Vadlamudi, RK; Venkata, PP; Viswanadhapalli, S; Weldon, K; Ye, Z; Zhao, W; Zheng, S; Zou, Y, 2023) |
| "The development of resistance to temozolomide (TMZ), a standard chemotherapeutic, limits the effective treatment of glioblastoma (GBM)." | 4.31 | The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model. ( Kucheryavykh, L; Kucheryavykh, Y; Nuñez, R; Ortiz-Rivera, J, 2023) |
| " We aimed to clarify the interplay between purinergic signaling and chemotherapeutic drug temozolomide (TMZ) in human glioma cell line." | 4.31 | Purinergic approach to effective glioma treatment with temozolomide reveals enhanced anti-cancer effects mediated by P2X7 receptor. ( Czach, S; Czarnecka, J; Nowak, W; Roszek, K; Szymczak, B, 2023) |
| "Temozolomide (TMZ), the primary drug for glioma treatment, has limited treatment efficacy." | 4.31 | CEBPB upregulates P4HA2 to promote the malignant biological behavior in IDH1 wildtype glioma. ( Li, M; Li, S; Wang, S; Wu, J; Zhao, W, 2023) |
| "Although temozolomide (TMZ) has been used as a standard adjuvant chemotherapeutic agent for primary glioblastoma (GBM), treating isocitrate dehydrogenase wild-type (IDH-wt) cases remains challenging due to intrinsic and acquired drug resistance." | 4.31 | Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma. ( Cho, HJ; Choi, SW; Kim, D; Kim, Y; Kong, DS; Koo, H; Kwon, YJ; Lee, HW; Lee, JI; Lee, K; Mu, Q; Nam, Y; Oh, JW; Park, CK; Park, WY; Sa, JK; Seo, YJ; Seol, HJ; Shin, S; Wang, J; Yang, Y; Yoon, Y; Zhu, Z, 2023) |
| "Temozolomide (TMZ) is the preferred chemotherapy strategy for glioma therapy." | 4.31 | Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma. ( Deng, Y; Du, H; Hou, X; Liu, J; Liu, W; Liu, Y; Qiao, J; Shu, X; Sun, B; Wang, H, 2023) |
| "The chemoresistance of temozolomide-based therapy is a serious limitation for lasting effective treatment of gliomas, while the underlying mechanisms remain unclear." | 4.31 | Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-κB/MGMT Axis. ( Chen, S; Li, J; Li, M; Li, X; Li, Z; Liao, X; Qian, W; Song, L; Tang, M; Xu, Y; Yu, R; Zhang, S; Zheng, H, 2023) |
| "Temozolomide plays a role in treating melanoma refractory to immunomodulatory and mitogen-activated protein kinase-targeted approaches, but its efficacy is limited." | 4.31 | Preclinical Activity of 4-Demethyl-4-cholesteryloxycarbonylpenclomedine in Melanoma. ( Benes, EN; Friedlander, P; Jursic, B; Morgan, LR; Rodgers, AH, 2023) |
| "Temozolomide (TMZ)-based chemotherapy plays a central part in glioma treatment." | 4.31 | SRSF4 Confers Temozolomide Resistance of Glioma via Accelerating Double Strand Break Repair. ( Liu, X; Sun, Y; Wang, X; Wu, Z; Yan, W; You, Y; Zhang, Y, 2023) |
| "This study investigated the effect of frequently used analgesics in cancer pain management (flurbiprofen (FLU), tramadol (TRA), and morphine (MOR)) and a novel α2-adrenergic agonist (dexmedetomidine, DEX) on temozolomide (TMZ) sensitivity in glioma cells." | 4.31 | Analgesics can affect the sensitivity of temozolomide to glioma chemotherapy through gap junction. ( Guo, S; Tao, L; Wang, Y; Yu, M; Zhang, S; Zhang, X, 2023) |
| "Resistance to temozolomide (TMZ) remains an important cause of treatment failure in patients with glioblastoma multiforme (GBM)." | 4.31 | TRIM25 promotes temozolomide resistance in glioma by regulating oxidative stress and ferroptotic cell death via the ubiquitination of keap1. ( Hu, Z; Liu, X; Ma, L; Sun, T; Wan, J; Wang, L; Wei, J; Zhang, C; Zhang, Y; Zhou, L, 2023) |
| "Temozolomide (TMZ) is the leading chemotherapeutic agent used for glioma therapy due to its good oral absorption and blood-brain barrier permeability." | 4.31 | Magnolol and Temozolomide exhibit a synergistic anti-glioma activity through MGMT inhibition. ( Das, S; Dhara, D; Kundu, M; Mandal, M; Nandi, S, 2023) |
| "To investigate if triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro." | 4.31 | Triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro. ( Fuchs, D; Morandi, L; Nytko, KJ; Rohrer Bley, C; Tonon, C; Weyland, MS, 2023) |
| "The present study suggests that IFI30 is a regulator of the EMT-like phenotype and acts not only as a prognostic marker but also as a potential therapeutic target for temozolomide-resistant glioma." | 4.31 | Interferon-γ inducible protein 30 promotes the epithelial-mesenchymal transition-like phenotype and chemoresistance by activating EGFR/AKT/GSK3β/β-catenin pathway in glioma. ( Chen, Y; Ji, F; Lan, Q; Li, S; Wang, Q; Wu, C; Xu, H; Yu, P, 2023) |
| "The potential targets and mechanisms of quercetin in glioma treatment were predicted based on network pharmacology and molecular docking." | 4.31 | Quercetin induces MGMT ( Chen, J; Li, B; Mu, J; Wang, Q; Wang, W; Wu, X; Xu, L; Yin, Z; Yuan, X; Zeng, Z; Zhu, X; Zou, Y, 2023) |
| "In our previous study, we found for the first time that temozolomide (TMZ), the first-line chemotherapeutic agent for glioblastoma (GBM), can generate a large amount of reactive oxygen species (ROS) under ultrasound irradiation." | 4.31 | Temozolomide-based sonodynamic therapy induces immunogenic cell death in glioma. ( Jiao, J; Tong, X; Wen, B; Wu, Q; Xu, L; Yan, H; Yang, R; Zhou, Y, 2023) |
| "To investigate the effect of Temozolomide combined with intensity modulated radiation therapy on serum factor, immune function and clinical efficacy in postoperative glioma patients." | 4.31 | Effect of Temozolomide Combined with Intensity Modulated Radiation Therapy on Serum Factor, Immune Function and Clinical Efficacy in Postoperative Glioma Patients. ( Fan, R; Liu, J; Liu, Z; Yuan, J, 2023) |
| "To explore the mechanism through which curcumol reverses primary drug resistance in glioma cells." | 4.31 | [Curcumol reverses temozolomide resistance in glioma cells by regulating the UTX/MGMT axis]. ( Qian, Y; Sun, J; Tan, R; Tian, N; Xing, J, 2023) |
| "Low-grade gliomas are primary brain tumors that arise from glial cells and are usually treated with temozolomide (TMZ) as a chemotherapeutic option." | 4.31 | Overcoming chemotherapy resistance in low-grade gliomas: A computational approach. ( Ayala-Hernández, LE; Bosque, JJ; Chulián, S; Delobel, T; García-Ferrer, M; Murek, M; Pérez-Beteta, J; Pérez-García, VM; Piñero, P; Schucht, P, 2023) |
| "In this study, to screen for candidate markers of temozolomide (TMZ) resistance in glioblastoma, we artificially established TMZ drug-resistant glioblastoma (GBM) cell lines, U251-TMZ and U87-TMZ." | 4.31 | Identification of potential glioma drug resistance target proteins based on ultra-performance liquid chromatography-mass spectrometry differential proteomics. ( Bian, L; Li, D; Li, K; Lin, B; Liu, X; Xi, Z; Yan, J; Yang, Q, 2023) |
| " With novel strategies focused on targeting hypoxia-inducible factor (HIF) regulatory pathways, recent evidence has shown that Acriflavine (ACF) can effectively target glioma invasiveness and recurrence." | 4.12 | Combined intracranial Acriflavine, temozolomide and radiation extends survival in a rat glioma model. ( Alomari, S; Brem, H; Cecia, A; Darjee, N; Domb, AJ; Gorelick, NL; Mangraviti, A; Rottenberg, Y; Serra, R; Shapira-Furman, T; Tyler, B, 2022) |
| "Patients with glioblastoma (GBM) are treated with radiotherapy (RT) and temozolomide (TMZ)." | 4.12 | Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models. ( Campian, JL; Chheda, MG; Ferrando-Martinez, S; Ghosh, S; Hallahan, D; Hu, T; Jash, A; Kapoor, V; Lee, BH; Mahadevan, A; Page, L; Rifai, K; Thotala, D; Thotala, S; Wolfarth, AA; Yan, R; Yang, SH, 2022) |
| "Nearly 10% of patients with adult diffuse glioma develop clinically significant myelotoxicity while on temozolomide (TMZ) leading to treatment interruptions." | 4.12 | Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study. ( Chatterjee, A; Dasgupta, A; Epari, S; Gupta, T; Kota, PK; Kowtal, P; Moitra, P; Patil, V; Sarin, R, 2022) |
| " The present study was designed to investigate the role of hsa_circ_0072309 in autophagy and temozolomide (TMZ) sensitivity in glioblastoma (GBM)." | 4.12 | Hsa_circ_0072309 enhances autophagy and TMZ sensitivity in glioblastoma. ( Chen, Q; Deng, G; Liu, B; Sun, Q; Xu, Y; Xu, Z; Ye, L; Yuan, F; Zhang, S, 2022) |
| "A broad panel of primary and temozolomide (TMZ)-resistant human glioma cell lines were screened by cell viability assays, flow cytometry, and crystal violet assays to investigate the therapeutic efficacy of Gamitrinib." | 4.12 | Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas. ( Abdullah, K; Ashley, DM; Bowie, M; Chen, Y; Deek, RA; Du, K; Flaherty, KT; Hariharan, S; Herlyn, M; Keir, ST; Khasraw, M; Ku, Y; Labrie, M; Li, S; Lin, X; Liu, H; Liu, L; Lu, Y; Mills, GB; Savani, MR; Sugarman, ET; Tian, M; Waitkus, M; Wei, S; Wei, Z; Wu, D; Wu, K; Yin, D; Yu, S; Zhang, G, 2022) |
| "Temozolomide (TMZ) is a first-line chemotherapeutic agent for the treatment of glioma." | 4.12 | The RNA-binding protein fragile-X mental retardation autosomal 1 (FXR1) modulates glioma cells sensitivity to temozolomide by regulating ferroptosis. ( Duan, S; Gong, F; Li, Q; Wei, Y, 2022) |
| "We retrospectively analyzed cytopenia during temozolomide-based concomitant radiochemotherapy in 492 patients with glioma." | 4.12 | Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma. ( Filipski, K; Filmann, N; Fokas, E; Forster, MT; Harter, PN; Herrlinger, U; Ronellenfitsch, MW; Steinbach, JP; Voss, M; Zeiner, PS, 2022) |
| " Temozolomide is widely used first-line chemotherapy drug to treat glioma patients, but development of temozolomide resistance is almost inevitable." | 4.12 | Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain. ( Bian, XW; Cai, XW; Cao, MF; Gai, QJ; He, J; He, MM; Leng, P; Lu, HM; Mao, M; Qin, Y; Wang, C; Wang, Y; Wang, YX; Wen, XM; Yang, FC; Yao, XH; Yao, XX; Zhu, J, 2022) |
| "The aim of this study was to clarify whether PET with 11C-methyl-l-methionine (11C-met PET) can predict consequential outcomes at the time of discontinuing temozolomide (TMZ)-adjuvant chemotherapy in patients with residual isocitrate dehydrogenase gene (IDH)-mutant lower-grade glioma." | 4.12 | PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma. ( Beppu, T; Fujiwara, S; Iwaya, T; Nomura, JI; Ogasawara, K; Sasaki, T; Sato, Y; Sugai, T; Terasaki, K; Yamada, N, 2022) |
| "We sought to evaluate the effects of concurrent temozolomide-based chemoradiation therapy on neurocognitive function in patients with low-grade glioma (LGG)." | 4.12 | Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas. ( Ahluwalia, MS; Angelov, L; Barnett, GH; Chao, ST; Chen, Y; Hogan, T; Kissel, C; Lapin, B; Mohammadi, A; Murphy, ES; Naugle, R; Park, DY; Parsons, MW; Peereboom, DM; Schuermeyer, I; Stevens, GHJ; Suh, JH; Tewari, S; Tom, MC; Yu, JS, 2022) |
| "Temozolomide (TMZ) is generally applied for glioma treatment, while drug resistance of TMZ limits its therapeutic efficacy." | 4.12 | Mannose inhibits proliferation and promotes apoptosis to enhance sensitivity of glioma cells to temozolomide through Wnt/β-catenin signaling pathway. ( Fei, YQ; Shi, RT; Song, Z; Wu, JZ; Zhou, YF, 2022) |
| "To study the relationship between temozolomide (TMZ) chemotherapy-resistant cells and stem cells in gliomas." | 4.12 | Preliminary Study on Relationship Between Temozolomide Chemotherapy-Resistant Cells and Stem Cells in Gliomas. ( Cunzu, W; Dingchao, X; Min, X; Xun, Z, 2022) |
| " However, the role of lncRNAs in temozolomide (TMZ) resistance in glioblastoma multiforme (GBM) remains largely undefined." | 4.12 | lncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PIK3R2-mediated PI3K/AKT pathway in glioma. ( Guo, H; He, Z; Lenahan, C; Liu, B; Tang, W; Wang, C; Xu, N; Zeng, H; Zhou, J, 2022) |
| "Temozolomide (TMZ), an oral alkylating agent, is the widely used first-line chemotherapeutic reagent for glioma in clinical practice." | 4.12 | Hispidulin Enhances Temozolomide (TMZ)-Induced Cytotoxicity against Malignant Glioma Cells ( Chen, Z; Lei, J; Sheng, C; Song, S; Zhu, G; Zhu, J, 2022) |
| "Glioblastoma patients have a poor prognosis mainly due to temozolomide (TMZ) resistance." | 4.12 | High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1/MRP1 upregulation. ( Andrade-Tomaz, M; Contieri, B; de Souza, I; Gomes, LR; Guedes, CB; Latancia, MT; Lazarini, M; Mendes, D; Monteiro, LKS; Porchia, BFMM; Rocha, CRR; Silva, MM, 2022) |
| " Optical microscopy and flow cytometry were employed to assess the differences in glioblastoma cells morphology, proliferation, and cytotoxicity of anticancer drug temozolomide (TMZ) due to increased substrate viscosity." | 4.12 | Substrate viscosity impairs temozolomide-mediated inhibition of glioblastoma cells' growth. ( Bucki, R; Cieśluk, M; Kochanowicz, J; Kułakowska, A; Piktel, E; Pogoda, K; Skłodowski, K; Wnorowska, U, 2022) |
| " Temozolomide is the standard of care for gliomas, frequently results in resistance to drug and tumor recurrence." | 4.12 | Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration of Human U251 Glioma Cells. ( Alaverdian, DA; Buntovskaya, AS; Chernov, AN; Fedorov, EV; Filatenkova, TA; Galimova, ES; Glushakov, RI; Kim, AV; Matsko, MV; Shamova, OV; Skliar, SS; Tsapieva, AN, 2022) |
| "Our previous researches showed that essential oil (EO) of chuanxiong could promote temozolomide (TMZ) entry into glioma cells in vitro and enhance TMZ-induced anticancer efficiency in vivo, and therefore, the aim of this study was to investigate whether EO could increase the concentration accumulation of TMZ in brain or tumor of C6 glioma rats and the related mechanisms." | 4.12 | Essential oil of Ligusticum chuanxiong Hort. Regulated P-gp protein and tight junction protein to change pharmacokinetic parameters of temozolomide in blood, brain and tumor. ( Hu, PY; Liu, SS; Liu, XJ; Shuai, SY; Yang, M; Yue, PF; Zhang, GS; Zheng, Q, 2022) |
| "This study aims to investigate the role of hypoxia-induced long non-coding small nucleolar RNA host gene 14 (lncRNA SNHG14) in glioma temozolomide (TMZ) resistance and underlying mechanisms." | 4.12 | Mechanisms for hypoxia ( Gong, M; Liao, X; Liao, Y; Liu, Y; Meng, L; Mo, X; Zhao, H, 2022) |
| "The complex of formononetin and calycosin (FMN/CAL) shows a synergistic effect on temozolomide in the treatment of malignant glioma, however the mechanism is unclear." | 4.12 | The mechanism of formononetin/calycosin compound optimizing the effects of temozolomide on C6 malignant glioma based on metabolomics and network pharmacology. ( Fan, H; Fan, Y; Huang, T; Li, J; Li, S; Qiu, R; Zhang, Q; Zhou, Y, 2022) |
| "Systemic chemotherapy including monotherapy with temozolomide (TMZ) or bevacizumab (BEV); two-drug combinations, such as irinotecan (IRI) and BEV, TMZ and BEV and a three-drug combination with TMZ, IRI and BEV (TIB) have been used in treating patients with progressive high-grade gliomas including glioblastoma (GBM)." | 4.12 | Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab. ( Ballester, LY; Bhattacharjee, MB; Brown, RE; Buja, LM; Chen, L; Glass, WF; Hergenroeder, GW; Hunter, RL; Linendoll, N; Lu, G; Pilichowska, M; Pillai, AK; Rao, M; Tian, X; Wu, JK; Zhang, R; Zhu, JJ; Zhu, P, 2022) |
| " The present study investigated four common antiepileptic drugs, perampanel, carbamazepine (CBZ), sodium valproate (VPA) and levetiracetam (LEV), which are expected to have antitumor effects, and determined the most beneficial drug for the treatment of malignant glioma by comparing antitumor effects such as inhibition of cell proliferation and suppression of migration and invasion (using Transwell assays)." | 4.12 | Anti‑tumor effects of anti‑epileptic drugs in malignant glioma cells. ( Hanashima, Y; Hara, H; Katayama, Y; Ozawa, Y; Sano, E; Sumi, K; Tatsuoka, J; Yagi, C; Yamamuro, S; Yoshimura, S; Yoshino, A, 2022) |
| "Brain radiotherapy combined with concomitant and six cycles of adjuvant temozolomide (TMZ) is the standard treatment for newly diagnosed high-grade gliomas (HGGs)." | 4.12 | Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis. ( Ai, P; Chen, J; He, L; Huang, Y; Li, R; Liu, Z; Pei, Y; Peng, X; Wang, J; Wei, Z; Zhao, F, 2022) |
| "It has been noted that temozolomide resistance occurs in a number of malignancies, including glioma, although the underlying cause of this is unknown." | 4.12 | CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study. ( Bai, S; Chen, H; Fan, LL; Hu, Y; Luo, GQ; Yan, ZJ, 2022) |
| " The main cause is the presence of glioma stem cells (GSCs), exceptionally resistant to temozolomide (TMZ) treatment." | 4.12 | TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients. ( Amantini, C; Maggi, F; Morelli, MB; Nabissi, M; Pallini, R; Ricci-Vitiani, L; Santoni, G, 2022) |
| " However, the underlying mechanisms of lncRNA in temozolomide (TMZ)-resistant gliomas were not well understood, hindering the improvement of TMZ-based therapies." | 4.12 | Long Noncoding RNA KCNQ1OT1 Confers Gliomas Resistance to Temozolomide and Enhances Cell Growth by Retrieving PIM1 From miR-761. ( Feng, Y; Gao, W; Han, S; Li, K; Wang, W; Wu, D, 2022) |
| "Thirty rats with glioma were divided into control group, temozolomide (TMZ) group (TMZ 30 mg/kg once daily for 5 day), and TMZ plus Caffeine group (TMZ 30 mg/kg once daily for 5 day and caffeine 100 mg/kg once daily for 2 weeks)." | 4.12 | Caffeine Inhibits Growth of Temozolomide-Treated Glioma via Increasing Autophagy and Apoptosis but Not via Modulating Hypoxia, Angiogenesis, or Endoplasmic Reticulum Stress in Rats. ( Chen, JC; Hwang, JH, 2022) |
| " Therefore, we aimed to examine the Synergistic effects of Gefitinib (GFI) in combination with Temozolomide on VEGF and MMPs in glioma cell line (U87MG)." | 4.12 | Synergistic Effect of Gefitinib and Temozolomide on U87MG Glioblastoma Angiogenesis. ( Hossienpour, M; Karami, A; Kiani, A; Mohammadi Noori, E; Najafi, K; Rahpyma, M, 2022) |
| "Glioma is the most frequent primary malignancy in the brain; temozolomide (TMZ) is the first-line chemotherapeutic agent used to combat this tumor." | 4.02 | AEG-1 silencing attenuates M2-polarization of glioma-associated microglia/macrophages and sensitizes glioma cells to temozolomide. ( Li, J; Ma, Y; Sun, X; Sun, Y; Wang, Y; Zhang, X; Zhao, X, 2021) |
| "Drug resistance strikingly limits the therapeutic effect of temozolomide (TMZ) (a common drug for glioma)." | 4.02 | A positive feedback loop of lncRNA-RMRP/ZNRF3 axis and Wnt/β-catenin signaling regulates the progression and temozolomide resistance in glioma. ( Han, B; Hu, J; Jia, W; Liu, T; Tan, S; Xin, Y, 2021) |
| " CDC20 expression is increased in a variety of tumors and associated with temozolomide (TMZ) resistance in glioma cells." | 4.02 | Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. ( Ding, Y; He, L; Pan, Y; Song, X; Yu, S; Zhang, C; Zheng, C, 2021) |
| "Temozolomide (TMZ) is widely used for glioma therapy in the clinic." | 4.02 | LncRNA MIR155HG Promotes Temozolomide Resistance by Activating the Wnt/β-Catenin Pathway Via Binding to PTBP1 in Glioma. ( He, X; Liu, Q; Sheng, J; Wang, K; Yu, W; Zhu, S, 2021) |
| "Temozolomide (TMZ) is the major chemotherapy agent in glioma, and isocitrate dehydrogenase (IDH) is a well-known prognostic marker in glioma." | 4.02 | Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas. ( Chen, W; Jing, J; Li, R; Mao, P; Sun, Q; Wang, J; Wang, M; Yu, X, 2021) |
| "The goal of this study was to develop a new method based on Oncothermia with concomitant use of the temozolomide (TMZ)-loaded magnetic nanoparticles conjugated with folic acid (TMZ/MNPs-FA) and alternative magnetic field (AMF) and evaluate its efficacy in the treatment of C6 glioma in rats." | 4.02 | Thermosensitive magnetic nanoparticles exposed to alternating magnetic field and heat-mediated chemotherapy for an effective dual therapy in rat glioma model. ( Afzalipour, R; Karimi, MY; Khoee, S; Khoei, S; Motevalian, M; Raoufi, NJ; Shirvalilou, S, 2021) |
| "The purpose of this study is to clarify the clinical features of temozolomide (TMZ)-related hepatitis B virus (HBV) reactivation and to identify HBV reactivation predictive factors." | 4.02 | Hepatitis B virus reactivation during temozolomide administration for malignant glioma. ( Chonan, M; Inoue, J; Kanamori, M; Masamune, A; Osada, Y; Saito, R; Shimoda, Y; Shoji, T; Tominaga, T; Uenohara, H, 2021) |
| "EORTC study 22033-26033 showed no difference in progression-free survival between high-risk low-grade glioma receiving either radiotherapy (RT) or temozolomide (TMZ) chemotherapy alone as primary treatment." | 4.02 | Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033. ( Baumert, BG; Ben Hassel, M; Bromberg, JC; Drijver, AJ; Eekers, DBP; Freixa, SV; Golfinopoulos, V; Gorlia, T; Hoang-Xuan, K; Hottinger, AF; Klein, M; Lucas, A; Reijneveld, JC; Stupp, R; Taphoorn, MJB; Tzuk-Shina, T; van den Bent, MJ; Vauleon, E, 2021) |
| "Temozolomide (TMZ) is a first-line chemotherapy drug for the treatment of malignant glioma and resistance to it poses a major challenge." | 4.02 | Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway. ( Hu, YH; Jiao, BH; Wang, CY; Wu, JL, 2021) |
| " Temozolomide (TMZ) is widely used in the treatment of glioblastoma and is considered as the primary treatment modality." | 4.02 | Molecular biological investigation of temozolomide and KC7F2 combination in U87MG glioma cell line. ( Abbaszade, Z; Avci, CB; Bagca, BG, 2021) |
| "Temozolomide (TMZ), an alkylating agent with a broad-spectrum antitumor activity, ability to cross blood-brain barrier (BBB), shown to be effective against malignant glioma." | 4.02 | Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population. ( Baburaj, G; Jose, A; Kumar, JP; Munisamy, M; Munisamy, S; Subbiah, V; Thomas, L, 2021) |
| "Previous studies showed that the chemotherapeutic effect of temozolomide (TMZ) and vincristine (VCR) against glioma might be blunted by the co-culture with astrocytes, and connexin-43 (CX43) was thought to play a vital role in the communication between glioma cells and astrocytes." | 4.02 | AS602801 sensitizes glioma cells to temozolomide and vincristine by blocking gap junction communication between glioma cells and astrocytes. ( Fan, T; Fu, X; Gong, Y; Huang, Y; Li, Z; Wang, H; Xiang, P; Zhang, S, 2021) |
| " However, whether glioma stem cells (GSCs) can be sensitized to chemotherapy via combined treatment with temozolomide (TMZ) and nicardipine is unclear." | 4.02 | Nicardipine sensitizes temozolomide by inhibiting autophagy and promoting cell apoptosis in glioma stem cells. ( Dong, J; Dong, X; Jiang, Q; Li, H; Liu, L; Shi, J; Wang, H; Wang, L, 2021) |
| "Temozolomide (TMZ) is the internationally recognized and preferred drug for glioma chemotherapy treatment." | 4.02 | Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p. ( Chen, Z; Li, H; Li, Y; Liu, Q; Su, J; Wu, M; Zhang, C, 2021) |
| " The present study evaluates the effects of AT101, alone or in combination with temozolomide (TMZ), in a microenvironmental glioma stem cell niche model of two GBM cell lines (U251MG and U87MG)." | 4.02 | Effects of the Anti-Tumorigenic Agent AT101 on Human Glioblastoma Cells in the Microenvironmental Glioma Stem Cell Niche. ( Caylioglu, D; Held-Feindt, J; Hellmold, D; Kubelt, C; Meyer, RJ; Synowitz, M, 2021) |
| "Chemotherapy improves overall survival after surgery and radiotherapy for newly diagnosed high-risk IDH-mutant low-grade gliomas (LGGs), but a proportion of patients treated with temozolomide (TMZ) will develop recurrent tumors with TMZ-induced hypermutation." | 4.02 | Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. ( Berger, MS; Butowski, N; Chang, SM; Choi, S; Clarke, JL; Costello, JF; Grimmer, MR; Haas-Kogan, D; Hilz, S; Hong, C; Mazor, T; McDermott, M; Molinaro, AM; Oberheim Bush, NA; Phillips, JJ; Shai, A; Solomon, DA; Taylor, JW; Villanueva-Meyer, J; Wahl, M; Wainer, BH; Yu, Y, 2021) |
| " In this study we investigated the role of FOXO3a in regulating the sensitivity of glioma cells to temozolomide (TMZ) and its relationship with BNIP3-mediated mitophagy." | 4.02 | FOXO3a protects glioma cells against temozolomide-induced DNA double strand breaks via promotion of BNIP3-mediated mitophagy. ( Chi, GF; Ge, PF; He, C; Liang, SP; Lu, S; Luo, TF; Piao, MH; Wang, CC; Wang, L; Wang, XZ; Wang, ZC, 2021) |
| " However, the alterations in gut microbiota observed during glioma growth and temozolomide (TMZ) therapy remain poorly understood." | 4.02 | Temozolomide-Induced Changes in Gut Microbial Composition in a Mouse Model of Brain Glioma. ( Jiang, Y; Jin, XQ; Li, J; Li, XC; Li, YR; Li, ZQ; Ma, C; Wang, ZF; Wu, BS; Yao, J, 2021) |
| "Our data revealed (i) a clinical association of the EMT-like process with glioma malignancy and a poor survival and (ii) an anticancer and temozolomide sensitizing effect of rabeprazole by repressing EMT." | 4.02 | Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition. ( Babu, D; Mudiraj, A; Panigrahi, M; Prakash Babu, P; Y B V K, C; Yadav, N, 2021) |
| "Temozolomide (TMZ) resistance limits its application in glioma." | 4.02 | Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma. ( Bu, X; Chen, X; Ding, C; Gu, J; Kang, D; Lin, Y; Lin, Z; Sun, Y; Wu, X; Wu, Z; Yi, X; You, H; Zhang, G, 2021) |
| " This study investigated whether the improved oxygenation and perfusion that has been previously observed with RRx-001 both preclinically and clinically in the context of a brain metastasis trial was correlated with increased penetration and accumulation of the cytotoxic chemotherapies, irinotecan and temozolomide, in orthotopically implanted gliomas, priming tumours for improved response." | 4.02 | Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas. ( Cabrales, P; Oronsky, B; Reid, T, 2021) |
| "Temozolomide (TMZ) is currently one of the first‑line drugs used for the treatment of high‑grade gliomas." | 4.02 | lncRNA TUG1 inhibits the cancer stem cell‑like properties of temozolomide‑resistant glioma cells by interacting with EZH2. ( Cao, Y; Chai, W; Long, J; Shao, D; Song, H; Tang, D; Wang, Y, 2021) |
| "Temozolomide (TMZ) resistance is the main challenge in the management of glioma patients." | 4.02 | Heparanase confers temozolomide resistance by regulation of exosome secretion and circular RNA composition in glioma. ( Cao, L; Chen, Z; Jiang, Z; Li, W; Li, X; Si, J, 2021) |
| "Glioma stem cells (GSCs) are tumour initiating cells which contribute to treatment resistance, temozolomide (TMZ) chemotherapy and radiotherapy, in glioblastoma (GBM), the most aggressive adult brain tumour." | 4.02 | Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM. ( Düssmann, H; Juric, V; Lamfers, MLM; Murphy, BM; Prehn, JHM; Rehm, M, 2021) |
| "To report clinical outcomes of temozolomide (TMZ)-based radio-chemotherapy and adjuvant chemotherapy in patients with aggressive/high-risk low-grade glioma (LGG)." | 4.02 | Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy. ( Anand, S; Chatterjee, A; Epari, S; Goda, JS; Gupta, T; Jalali, R; Krishnatry, R; Moiyadi, A; Panda, P; Patil, V, 2021) |
| "A maximal surgical resection followed by radiotherapy and chemotherapy with temozolomide (TMZ) as the representative agent is the standard therapy for gliomas." | 4.02 | The function and mechanism of the JARID2/CCND1 axis in modulating glioma cell growth and sensitivity to temozolomide (TMZ). ( Chen, Y; Jiang, W; Kuang, W; Liu, Z; Tian, Y, 2021) |
| "Apatinib and TMZ may represent an alternative treatment option for patients with recurrent high-gradeglioma, especially those with a low Karnofsky performance status." | 4.02 | Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas. ( Feng, M; Gan, W; Huang, Y; Li, X; Liu, J; Shao, Y; Wang, X; Yao, H; Zhang, C; Zhou, Y, 2021) |
| "Temozolomide (TMZ) is one of the most common drugs selected for glioma chemotherapy, but the therapeutic effect of glioma treatment is usually limited due to its resistance." | 3.96 | LINC00174 down-regulation decreases chemoresistance to temozolomide in human glioma cells by regulating miR-138-5p/SOX9 axis. ( Chen, M; Li, B; Song, J; Wang, F; Zhao, H, 2020) |
| "Temozolomide (TMZ) is a frequently used chemotherapy for glioma; however, chemoresistance is a major problem limiting its effectiveness." | 3.96 | A ( An, W; Attenello, F; Bi, J; Chen, B; Chen, J; Guo, D; He, A; Lu, W; Qian, Y; Shi, J; Shi, T; Wang, W; Zhang, L; Zhao, Z, 2020) |
| " Here, we detail anti-PD-L1 antibody effects on the tumor microenvironment, including Mϕ infiltration, using a temozolomide (TMZ)-treated glioma model." | 3.96 | Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cell ( Akutsu, H; Ishikawa, E; Kohzuki, H; Matsuda, M; Matsumura, A; Miyazaki, T; Sakamoto, N; Sugii, N; Takano, S, 2020) |
| "Temozolomide (TMZ) is a drug of choice in glioblastoma treatment." | 3.96 | Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions. ( Barciszewska, AM; Barciszewski, J; Belter, A, 2020) |
| "A generally used chemotherapeutic drug for glioma, a frequently diagnosed brain tumour, is temozolomide (TMZ)." | 3.96 | miR-152-5p suppresses glioma progression and tumorigenesis and potentiates temozolomide sensitivity by targeting FBXL7. ( Cao, Y; Fang, Y; He, R; Kong, S; Wang, B; Zhao, Z, 2020) |
| "Emerging data suggest that a subset of patients with diffuse isocitrate dehydrogenase (IDH)-mutant low-grade glioma (LGG) who receive adjuvant temozolomide (TMZ) recur with hypermutation in association with malignant progression to higher-grade tumors." | 3.96 | MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. ( Berger, MS; Bollam, S; Chang, SM; Clarke, J; Costello, JF; Grimmer, MR; Hong, C; Mathur, R; Molinaro, AM; Oberheim-Bush, NA; Petrecca, K; Phillips, JJ; Zhang, M; Zhang, Y, 2020) |
| "Glioma is a brain tumour that is often diagnosed, and temozolomide (TMZ) is a common chemotherapeutic drug used in glioma." | 3.96 | MiR-3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway. ( Cao, Y; Kong, S; Li, X; Li, Z; Meng, Y; Xin, Y, 2020) |
| " However, the standard chemotherapy drug for glioma, temozolomide (TMZ), cannot induce ICD as it cannot activate IFN-I signaling." | 3.96 | Intranasal Delivery of Immunotherapeutic Nanoformulations for Treatment of Glioma Through in situ Activation of Immune Response. ( Cai, X; Cao, G; Du, B; Hu, J; Ke, C; Li, H; Li, L; Liu, X; Xin, X; Yin, P, 2020) |
| "To some extent, Si wei xiao xiu yin combined with temozolomide can inhibit the growth of subcutaneous xenografts in glioma nude mice." | 3.96 | New advances on the inhibition of Siwei Xiaoliuyin combined with Temozolomide in glioma based on the regulatory mechanism of miRNA21/221. ( Chen, H; Chen, Y; Li, C; Sharma, A; Sharma, HS; Tan, Q; Xie, C; Yang, Y; Zhan, W; Zhang, Z, 2020) |
| " Here, diffusion MRI data were acquired in a GL261 glioma mouse model before and during treatment with Temozolomide." | 3.96 | Noninvasive diffusion magnetic resonance imaging of brain tumour cell size for the early detection of therapeutic response. ( Agliardi, G; Alexander, DC; Atkinson, D; Brandner, S; Breen-Norris, JO; d'Esposito, A; Hipwell, B; Hyare, H; Ianus, A; Lythgoe, MF; Panagiotaki, E; Punwani, S; Ramasawmy, R; Rees, J; Roberts, TA; Siow, B; Taylor, V; Walker-Samuel, S, 2020) |
| "Temozolomide (TMZ) is an oral alkylating agent used for the treatment of glioblastoma and is now becoming a chemotherapeutic option in patients diagnosed with high-risk low-grade gliomas." | 3.96 | MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas. ( Bao, Z; Galán-Ganga, M; Jiang, T; Kim, H; Kroon, P; Liu, H; Mu, Q; Nam, DH; Oldrini, B; Rabadan, R; Rodriguez-Perales, S; Sa, JK; Squatrito, M; Vaquero-Siguero, N; Verhaak, RGW; Wang, J; Wang, Z; Zhang, Y; Zhao, J, 2020) |
| "Temozolomide is the most effective chemotherapy for malignant glioma." | 3.96 | Temozolomide desensitization followed by metronomic dosing in patients with hypersensitivity. ( Divekar, RD; Johnson, DR; Maddox, DE; Neth, BJ; Ruff, MW; Uhm, JH, 2020) |
| "This study investigated the effects of temozolomide (TMZ) and/or checkpoint kinase inhibitor AZD7762 in human glioma cells." | 3.96 | Temozolomide and AZD7762 Induce Synergistic Cytotoxicity Effects on Human Glioma Cells. ( Chen, Y; Tsai, YH; Tseng, BJ; Tseng, SH, 2020) |
| " Concurrent temozolomide (TMZ) radiation-the cornerstone of glioma control-extends the overall median survival of GB patients by only a few months over radiotherapy alone." | 3.96 | Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas. ( Chen, TC; Cho, HY; Duc, TC; Hartman, H; Hofman, FM; Huang, M; Minea, RO; Schönthal, AH; Swenson, SD, 2020) |
| "Glioma is the most common primary malignant tumour in the brain; temozolomide (TMZ) is the most prevalent chemotherapeutic drug currently used to combat this cancer." | 3.96 | LINC00470 promotes tumour proliferation and invasion, and attenuates chemosensitivity through the LINC00470/miR-134/Myc/ABCC1 axis in glioma. ( Li, Y; Liu, Q; Long, W; Pan, Y; Qin, C; Su, J; Wang, J; Wang, X; Wu, C; Xiao, K; Xiao, Q, 2020) |
| "Glioma, especially glioblastoma (GBM), is the most aggressive malignant brain tumor and its standard therapy is often ineffective because of temozolomide (TMZ) resistance." | 3.96 | Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma. ( Cai, HP; Chen, FR; Chen, ZP; Guo, CC; Ma, JX; Ni, XR; Wang, J; Wu, WC; Yu, YJ; Yu, ZH, 2020) |
| " However, the function of circ_0005198 in the temozolomide (TMZ) resistance of glioma has not been well elucidated." | 3.96 | Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis. ( Deng, Y; Liu, C; Meng, X; Xiao, L; Zhu, H, 2020) |
| " The potential importance of the detected metabolic heterogeneity was tested in three glioma cell lines (grade III-IV) using protein expression analyses (Western blot and WES Simple) and therapeutic drug (temozolomide), metabolic inhibitor treatments (including glutaminase inhibitor) to compare the effects of rapamycin (RAPA) and glutaminase inhibitor combinations in vitro (Alamar Blue and SRB tests)." | 3.96 | Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells. ( Dankó, T; Hujber, Z; Jeney, A; Krencz, I; Pápay, J; Petővári, G; Raffay, R; Rajnai, H; Sebestyén, A; Vetlényi, E, 2020) |
| " We identified hybrid compounds 1d and 1e to be remarkably more potent against glioma and more efficient in decreasing invasive cell properties than temozolomide and endowed with chemical and plasma stability." | 3.91 | Targeting gliomas with triazene-based hybrids: Structure-activity relationship, mechanistic study and stability. ( Braga, C; Brites, D; Matilde Marques, M; Moreira, R; Oliveira, MC; Perry, MJ; Vaz, AR, 2019) |
| "Our study elucidated the role of oncogenic LINC01198 in glioma proliferation and temozolomide resistance, and this role may serve as a promising target for glioma therapy." | 3.91 | LINC01198 promotes proliferation and temozolomide resistance in a NEDD4-1-dependent manner, repressing PTEN expression in glioma. ( Chen, HJ; Chen, WL; Ge, JW; Hou, GQ; Zhang, XH, 2019) |
| " However, the role of circular RNA CEP128 in the resistance of glioma cells to temozolomide has not yet been characterized." | 3.91 | Knockdown of circular RNA CEP128 suppresses proliferation and improves cytotoxic efficacy of temozolomide in glioma cells by regulating miR-145-5p. ( Feng, H; Hua, L; Huang, L; Shen, B; Zhang, X, 2019) |
| "Bortezomib was found to inhibit glioma growth and improved TMZ chemotherapy efficacy, probably via down-regulating the FOXM1-Survivin axis." | 3.91 | Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis. ( Chen, JX; Du, L; Huang, GH; Li, QR; Lv, SQ; Tang, JH; Xiang, Y; Xu, QF; Yang, L; Zhang, ZX; Zhou, Z; Zhu, LR, 2019) |
| " To evaluate antitumor activity in vivo, 5-aza was administered alone and in combination with temozolomide (TMZ) in a PDX glioma model harboring IDH1 R132H mutation." | 3.91 | Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. ( Borodovsky, A; Chan, T; da Costa Rosa, M; Festuccia, WT; Riggins, GJ; Yamashita, AS, 2019) |
| "The aromatase inhibitor, letrozole, is being investigated in experimental animal models as a novel treatment for high-grade gliomas (HGGs)." | 3.91 | Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats. ( Adams, CH; Arora, P; DasGupta, B; Desai, PB; Gudelsky, G, 2019) |
| "Chemotherapy is the main postsurgical and adjuvant therapy for glioma, and intrinsic or acquired temozolomide (TMZ) resistance may result in poor prognosis." | 3.91 | MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2. ( Feng, B; Ren, H; Wang, J; Yu, J; Yuan, Z; Zhang, B; Zhang, X; Zhao, C; Zhuang, J, 2019) |
| "Mesoporous silica nanoparticles (MSNPs) of a small diameter were loaded with the anticancer drug temozolomide (TMZ), coated with polydopamine (PDA), and conjugated with Asn-Gly-Arg (NGR) for use in the treatment of glioma." | 3.91 | Combination of 3-methyladenine therapy and Asn-Gly-Arg (NGR)-modified mesoporous silica nanoparticles loaded with temozolomide for glioma therapy in vitro. ( Cheng, Y; Huang, N; Huang, Q; Tan, Y; Tang, M; Zhang, P; Zhang, X; Zhao, G, 2019) |
| "For our studies, we have particularly chosen C6 rat glioma cell line due to several reasons: i) We previously showed that MPA reduced growth and induced procarbazine-sensitization in C6 cells; ii) temozolomide has a triazene-type molecular structure like procarbazine; iii) other groups previously showed that C6 glioma cell line is more resistant to temozolomide than human glioma cells; hence it may provide a native model of chemoresistance." | 3.91 | Medroxyprogesterone effects on colony growth, autophagy and mitochondria of C6 glioma cells are augmented with tibolone and temozolomide: Cell kinetic and electron microscopical studies with a broad review of the literature. ( Altinoz, MA; Bilir, A; Elmaci, İ; Ozpinar, A, 2019) |
| "Glioma is a frequently diagnosed brain tumors and Temozolomide (TMZ) is a common chemotherapeutic drug for glioma." | 3.91 | MicroRNA-34a-5p suppresses tumorigenesis and progression of glioma and potentiates Temozolomide-induced cytotoxicity for glioma cells by targeting HMGA2. ( Fu, T; Gao, M; Ma, S; Zhao, S, 2019) |
| "Both of the temozolomide (TMZ)-resistant and CtIP deficient glioma cell lines were successfully generated." | 3.91 | CtIP contributes to non-homologous end joining formation through interacting with ligase IV and promotion of TMZ resistance in glioma cells. ( Han, N; Jiang, H; Sun, J; Xu, HY; Yang, B, 2019) |
| " In this preliminary study, the purpose was to evaluate the feasibility of APT imaging in monitoring the early therapeutic response to nitroxoline (NTX) in a temozolomide (TMZ)-resistant glioblastoma multiforme (GBM) mouse model, which was compared with diffusion-weighted imaging (DWI)." | 3.91 | Assessment of Early Therapeutic Response to Nitroxoline in Temozolomide-Resistant Glioblastoma by Amide Proton Transfer Imaging: A Preliminary Comparative Study with Diffusion-weighted Imaging. ( Cho, HR; Choi, SH; Kumari, N; Thakur, N, 2019) |
| "The aim of this current work was to study the therapeutic enhancement of temozolomide (TMZ) on gliomavia combining with calycosin and FMN." | 3.91 | In vitro and in vivo Study on Glioma Treatment Enhancement by Combining Temozolomide with Calycosin and Formononetin. ( Fan, H; Fan, Y; Li, Y; Ni, Q; Zhang, X, 2019) |
| "The present study investigated the effects of the combined treatment of two peptide nucleic acids (PNAs), directed against microRNAs involved in caspase‑3 mRNA regulation (miR‑155‑5p and miR‑221‑3p) in the temozolomide (TMZ)‑resistant T98G glioma cell line." | 3.91 | Targeting miR‑155‑5p and miR‑221‑3p by peptide nucleic acids induces caspase‑3 activation and apoptosis in temozolomide‑resistant T98G glioma cells. ( Borgatti, M; Brognara, E; Cabrini, G; Corradini, R; Cosenza, LC; Dechecchi, MC; Fabbri, E; Finotti, A; Gambari, R; Gasparello, J; Lampronti, I; Manicardi, A; Milani, R, 2019) |
| "We formulated an ultra-small, gadolinium-based nanoparticle (AGuIX) with theranostic properties to simultaneously enhance MRI tumor delineation and radiosensitization in a glioma model." | 3.91 | Ultrasmall theranostic gadolinium-based nanoparticles improve high-grade rat glioma survival. ( Appelboom, G; Barbier, EL; Bräuer-Krisch, E; Chang, SD; Dufort, S; Le Duc, G; Lux, F; Roux, S; Sancey, L; Tillement, O; Verry, C; Zhang, M, 2019) |
| "This study aimed to screen in vitro antitumour activity of the redox couple avarol/avarone against the human malignant glioma cell line U-251 MG for the first time." | 3.88 | The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells. ( Glumac, M; Jakimov, D; Kojic, V; Pejin, B; Tommonaro, G, 2018) |
| "We evaluated stereotactic volume modulated arc radiotherapy (VMAT) for canine gliomas, alone (radiotherapy [RT]) and in combination with temozolomide (RT + TMZ), compared with palliation." | 3.88 | Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas. ( Bianchi, C; Carrara, N; Dolera, M; Finesso, S; Malfassi, L; Marcarini, S; Mazza, G; Pavesi, S; Sala, M; Urso, G, 2018) |
| "Numerous studies suggested autophagy was involved in temozolomide (TMZ) resistance in glioma." | 3.88 | Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression. ( Du, J; Fang, X; Huang, X; Jiang, C; Li, X; Liu, Z; Shen, F; Su, J; Wang, X, 2018) |
| "Although upfront temozolomide (TMZ) has been widely-used to treat 1p/19q-codeleted diffuse low-grade gliomas (LGG), its long-term impact on the growth kinetics of these tumors has not been determined." | 3.88 | Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics. ( Alentorn, A; Barritault, M; Bruna, J; Delattre, JY; Ducray, F; Honnorat, J; Idbaih, A; Izquierdo, C; Kaloshi, G; Meyronet, D; Ricard, D; Simó, M, 2018) |
| "The present study aims to investigate the efficacy of PAMAM-chitosan conjugate based TMZ nanoformulation (PCT) against gliomas in vitro as well as in vivo." | 3.88 | Chitosan Engineered PAMAM Dendrimers as Nanoconstructs for the Enhanced Anti-Cancer Potential and Improved In vivo Brain Pharmacokinetics of Temozolomide. ( Gupta, L; Gupta, U; Nakhate, KT; Qayum, A; Sahu, H; Sharma, AK; Singh, SK, 2018) |
| " Localized FRT to total dose of 60 Gy with concurrent and adjuvant temozolomide (TMZ) resulted in a statistically significant survival improvement of patients with newly diagnosed glioblastoma compared to those treated with FRT alone, and has emerged as the cornerstone of therapy." | 3.88 | Role of Radiosensitizers in Radiation Treatment of Gliomas. ( Cohen, RJ; Mehta, MP, 2018) |
| " However, a randomized controlled study (RTOG 9802) showed that adding of procarbazine, CCNU, and vincristine (PCV) chemotherapy to fractionated radiotherapy (FRT) in patients with "high-risk" WHO grade II gliomas, including DA, has significant positive impact on both progression-free survival and overall survival." | 3.88 | Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults. ( Narita, Y, 2018) |
| "Resistance to temozolomide (TMZ) is a major clinical challenge in glioma treatment, but the mechanisms of TMZ resistance are poorly understood." | 3.88 | Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2. ( Ding, Y; Hu, R; Liu, X; Wang, Q; Yang, M; Zhang, X; Zhou, W, 2018) |
| " In this study we aimed to evaluate the relationship of FBW7 with glioma pathology and prognosis, and examine its effect in glioma malignancies and temozolomide (TMZ)-based therapy." | 3.88 | FBW7 is associated with prognosis, inhibits malignancies and enhances temozolomide sensitivity in glioblastoma cells. ( Cui, Y; Feng, H; He, H; Ji, A; Li, J; Li, S; Lin, J; Lu, Y; Qiu, G; Song, C; Zou, Y, 2018) |
| "To study the effects of combinational treatment of hyperbaric oxygen (HBO) and nanotemozolomide in glioma." | 3.88 | Hyperbaric oxygen as an adjuvant to temozolomide nanoparticle inhibits glioma growth by inducing G2/M phase arrest. ( Hu, J; Wu, X; Xie, Y; Yang, X; Zeng, X; Zhu, Y, 2018) |
| "The incidence, risk factors, and outcomes of low-grade glioma patients who undergo malignant transformation (MT) in the era of temozolomide are not well known." | 3.88 | Risk Factors for Malignant Transformation of Low-Grade Glioma. ( Ahluwalia, MS; Barnett, GH; Chao, ST; Jia, X; Kotecha, R; Leyrer, CM; Murphy, ES; Parsons, M; Peereboom, DM; Prayson, RA; Stevens, GHJ; Suh, JH; Vogelbaum, MA; Yu, JS, 2018) |
| "A standard post-concomitant radiochemotherapy involving adjuvant temozolomide (TMZ) was stopped after 6 cycles for high-grade gliomas (HGG)." | 3.88 | Tumor Volume Changes During and After Temozolomide Treatment for Newly Diagnosed Higher-Grade Glioma (III and IV). ( Ho, JT; Ho, RW; Lin, WC; Lin, YJ; Lin, YT; Lu, CH; Tsai, NW; Wang, HC, 2018) |
| "Previous studies showed Demethoxycurcumin (DMC) has stronger anti-glioma and anti-GSCs effects both in vitro and in vivo." | 3.88 | DMC is not better than TMZ on intracranial anti-glioma effects. ( Shi, L; Sun, G, 2018) |
| "Temozolomide (TMZ)-induced side effects and drug tolerance to human gliomas are still challenging issues now." | 3.88 | Improved effects of honokiol on temozolomide-induced autophagy and apoptosis of drug-sensitive and -tolerant glioma cells. ( Chang, CK; Chen, KY; Chen, RM; Chio, CC; Chuang, JY; Liu, CC; Liu, SH, 2018) |
| "Temozolomide (TMZ) is the most frequent adjuvant chemotherapy drug in gliomas." | 3.88 | Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model. ( Dai, B; Li, J; Qi, N; Zhang, G, 2018) |
| "To investigate the clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent glioma." | 3.88 | [Clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent brain glioma]. ( Jiang, C; Li, X; Liu, S; Tang, S; Zhao, H, 2018) |
| "Temozolomide, a key drug in the treatment of malignant glioma, can cause profound lymphopenia and various opportunistic infectious diseases." | 3.88 | Cytomegalovirus Hemorrhagic Cystitis in a Malignant Glioma Patient Treated with Temozolomide. ( Furukawa, R; Homma, H; Horiuchi, H; Inoue, T; Usui, K, 2018) |
| "Temozolomide (TMZ) is currently the first-line drug used for clinical postoperative or non-surgical chemotherapy for glioma, but acquired and intrinsic resistance to TMZ limits its application." | 3.88 | Synergistic Anticancer Effects of Formononetin and Temozolomide on Glioma C6 Cells. ( Fan, H; Li, Y; Ni, Q; Wang, Y; Zhang, X, 2018) |
| " Multidrug resistance, particularly resistance to temozolomide (TMZ), is a challenge in combating glioma, and more effective therapies are needed." | 3.88 | Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo. ( Bai, Y; Chen, Y; Dong, X; Hong, X; Li, S; Li, Y; Liu, X; Su, X; Zhao, G, 2018) |
| "Temozolomide (TMZ) is a first-line chemotherapeutic drug for malignant gliomas." | 3.88 | Honokiol enhances temozolomide-induced apoptotic insults to malignant glioma cells via an intrinsic mitochondrion-dependent pathway. ( Chen, RM; Chio, CC; Liu, SH; Mohanraj, M; Tai, YT; Yang, ST, 2018) |
| "The survival rate in high-grade glioma (HGG) patients receiving a combined regimen of radiotherapy (RT) and temozolomide after tumor resection was increased." | 3.88 | A prospective longitudinal evaluation of cognition and depression in postoperative patients with high-grade glioma following radiotherapy and chemotherapy. ( Chang, J; Di, J; Lu, X; Qi, F; Song, X; Wang, Q; Yu, Y; Zhang, L; Zhou, Y, 2018) |
| "Postoperative management of anaplastic glioma remains without a clear standard of care-in this study we report outcomes for patients treated with radiotherapy (RT) with and without temozolomide (TMZ)." | 3.88 | Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide. ( Chan, MD; Debinski, W; Farris, M; Helis, C; Laxton, AW; Lesser, GJ; Lo, HW; Lucas, JT; McTyre, E; Mott, R; Soike, M; Strowd, RE; Tatter, SB, 2018) |
| "To compare various pro-apoptotic effects of synthetic 4-thiazolidinone derivative (Les-3288), doxorubicin (Dox) and temozolomide (TMZ) in the treatment of human glioma U251 cells to improve treatment outcomes of glioblastoma and avoid anticancer drug resistance." | 3.85 | Differential pro-apoptotic effects of synthetic 4-thiazolidinone derivative Les-3288, doxorubicin and temozolomide in human glioma U251 cells. ( Finiuk, N; Grytsyna, II; Klyuchivska, OY; Lehka, L; Lesyk, RB; Panchuk, RR; Starykovych, MO; Stoika, RS; Zіmenkovsky, BS; Коbylinska, LI, 2017) |
| "Numerous studies have reported that glioma patients with isocitrate dehydrogenase 1(IDH1) R132H mutation are sensitive to temozolomide treatment." | 3.85 | IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway. ( Cai, W; He, M; Li, K; Liu, A; Luo, M; Ouyang, L; Pi, R; Tu, Y, 2017) |
| "Temozolomide (TMZ) is widely used in high-grade glioma (HGG)." | 3.85 | Haematological malignancies following temozolomide treatment for paediatric high-grade glioma. ( Beilken, A; Corbacioglu, S; Dilloo, D; Driever, PH; Dürken, M; Gielen, GH; Hoffmann, M; Karremann, M; Krämer, N; Kramm, CM; Kulozik, A; Scheurlen, W; von Bueren, AO; Wiese, M, 2017) |
| "Here we evaluated whether glioma sensitive or resistant to temozolomide (TMZ) modulate macrophage polarization and inflammatory pathways associated." | 3.85 | Glioma sensitive or chemoresistant to temozolomide differentially modulate macrophage protumor activities. ( Azambuja, JH; Beira, FT; Braganhol, E; da Silveira, EF; de Carvalho, TR; do Couto, CT; Oliveira, PS; Pacheco, S; Spanevello, RM; Stefanello, FM, 2017) |
| " Gliomas are devastating cancers and their positive treatment outcome using Temozolomide (TMZ) is limited due to its short plasma half-life, systemic toxicity and limited access through the blood-brain barrier (BBB)." | 3.85 | Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433). ( Ahsan, SM; Kondapi, AK; Kumar, JM; Kumari, S; Rao, NM, 2017) |
| "Temozolomide (TMZ) for malignant gliomas is traditionally dosed in 5 out of a 28-day cycle, however alternative regimens exist, including dose-dense." | 3.85 | Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma. ( Howard, TA; Villano, JL; Zhou, Z, 2017) |
| "In this study, we demonstrated that temozolomide (TMZ) and propyl gallate (PG) combination enhanced the inhibition of migration in human U87MG glioma cells." | 3.85 | Propyl Gallate Exerts an Antimigration Effect on Temozolomide-Treated Malignant Glioma Cells through Inhibition of ROS and the NF- ( Chen, CH; Chen, KT; Cheng, YC; Chung, CY; Lee, IN; Lee, MH; Lu, FJ; Yang, JT, 2017) |
| " The triazene Temozolomide (TMZ), an alkylating drug, is the classical chemotherapeutic agent for gliomas, but has been disappointing against the highly invasive and resistant nature of GBM." | 3.85 | Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference? ( Braga, C; Brites, D; Bronze, MR; Falcão, AS; Moreira, R; Perry, MJ; Pinheiro, R; Santos, G, 2017) |
| "To explore the efficacy and toxicity of an extended schedule of temozolomide (50 mg/mq 1 week on/1 week off) in a population of newly diagnosed low-grade gliomas (LGG)." | 3.85 | Temozolomide low-dose chemotherapy in newly diagnosed low-grade gliomas: activity, safety, and long-term follow-up. ( Carapella, CM; Carosi, M; Fabi, A; Giannarelli, D; Marucci, L; Maschio, M; Merola, R; Pace, A; Vidiri, A; Villani, V, 2017) |
| " In this study, we investigated the effect of silver nanoparticles (AgNPs) on human glioma U251 cells and its role in the combinational use with Temozolomide (TMZ), an imidazotetrazine derivative of the alkylating agent dacarbazine, against glioma cells." | 3.85 | Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells. ( Chen, H; Gong, Z; Gui, Q; Guo, X; Liang, P; Meng, J; Shi, H; Xu, Y; Zhu, W, 2017) |
| " When treated with temozolomide (TMZ), an oral alkylating chemotherapy drug, most low-grade gliomas (LGG) show an initial volume decrease but this effect is rarely long lasting." | 3.85 | Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model. ( Alentorn, A; Delattre, JY; Ducray, F; Grenier, E; Honnorat, J; Idbaih, A; Kaloshi, G; Mazzocco, P; Ollier, E; Psimaras, D; Ricard, D; Samson, A, 2017) |
| " Glioma cells may synthetize the antioxidant glutathione by importing cystine through a cystine/glutamate antiporter, which is inhibited by sulfasalazine (SAS)." | 3.85 | Characteristics of sulfasalazine-induced cytotoxicity in C6 rat glioma cells. ( Castilho, RF; de Melo, DR; Facchini, G; Ferreira, CV; Ignarro, RS; Pelizzaro-Rocha, KJ; Rogerio, F, 2017) |
| "The occurrence of an inherent or acquired resistance to temozolomide (TMZ) is a major burden for patients suffering from glioma." | 3.85 | Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2. ( Cai, L; Su, Z; Tu, M; Yu, Z; Zeng, B; Zheng, W; Zhu, D, 2017) |
| "Temozolomide (TMZ)-based chemotherapy is a standard strategy for glioma, while chemoresistance remains a major therapeutic challenge." | 3.85 | LncRNA CASC2 Interacts With miR-181a to Modulate Glioma Growth and Resistance to TMZ Through PTEN Pathway. ( Cheng, L; Fu, J; Guo, Y; Liao, Y; Liu, Q; Peng, R; Shen, L; Zhao, H, 2017) |
| "The present study aimed to investigate whether overexpression of integrin-linked kinase (ILK) affects drug resistance to temozolomide (TMZ) in glioma cells." | 3.85 | Overexpression of ILK promotes temozolomide resistance in glioma cells. ( Bao, L; Liang, F; Wang, B; Zhang, SM; Zhang, SQ; Zhao, YS, 2017) |
| "Despite multimodal therapy with radiation and the DNA alkylating agent temozolomide (TMZ), malignant gliomas remain incurable." | 3.85 | PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas. ( Bahassi, EM; Chan, TA; Chu, Z; Koncar, RF; Qi, X; Romick-Rosendale, LE; Wells, SI, 2017) |
| "Although methylguanine-DNA-methyltransferase (MGMT) plays an important role in resistance to temozolomide (TMZ) in glioma, 40% of gliomas with MGMT inactivation are still resistant to TMZ." | 3.85 | FoxM1-mediated RFC5 expression promotes temozolomide resistance. ( Du, FY; Ge, L; Gong, AH; Han, X; Jin, J; Peng, WX; Zhang, CL, 2017) |
| "We investigated the effect of chemoradiotherapy with PP2 and temozolomide (TMZ) on malignant glioma cells using clonogenic assays and in vivo brain tumor model." | 3.83 | The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo. ( Chie, EK; Cho, BJ; Choi, EJ; Eom, KY; Kim, IA; Kim, IH; Kim, JH; Kim, JS; Paek, SH; Wu, HG, 2016) |
| "Arginine-glycine-aspartic acid peptide (RGD)-modified nanostructured lipid carriers (NLCs) were used for the delivery of temozolomide (TMZ) into the GBM to provide a new paradigm in gliomatosis cerebri treatment." | 3.83 | Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy. ( Du, J; Mao, G; Song, S; Zhu, X, 2016) |
| "Temozolomide is a standard chemotherapy agent for malignant gliomas, but the efficacy is still not satisfactory." | 3.83 | Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells. ( Kanamori, M; Saito, R; Shibahara, I; Sonoda, Y; Sugiyama, S; Tominaga, T; Zhang, R, 2016) |
| "We aimed to analyze the value of seizure reduction and radiological response as prognostic markers of survival in patients with low-grade glioma (LGG) treated with temozolomide (TMZ) chemotherapy." | 3.83 | Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide. ( Dirven, L; Heimans, JJ; Koekkoek, JA; Postma, TJ; Reijneveld, JC; Taphoorn, MJ; Vos, MJ, 2016) |
| "A gene drug delivery system for glioma therapy based on transferrin (Tf)-modified polyamidoamine dendrimer (PAMAM) was prepared." | 3.83 | Plasmid pORF-hTRAIL targeting to glioma using transferrin-modified polyamidoamine dendrimer. ( Gao, S; Hao, B; Hong, B; Jiang, C; Li, J, 2016) |
| " Human glioma U87MG or LNZ308 cells overexpressing either wild-type (wt) EGFR or EGFRvIII were treated with nimotuzumab, temozolomide, or both." | 3.83 | Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo. ( Nagane, M; Nitta, Y; Shimizu, S; Shiokawa, Y; Shishido-Hara, Y; Suzuki, K, 2016) |
| "We identified a single significant correlation resulting in increased overall survival from temozolomide in lower-grade glioma with IDH1 R132H mutations." | 3.83 | Systematic analysis of overall survival and interactions between tumor mutations and drug treatment. ( Gatto, F; Nielsen, J, 2016) |
| " Food and Drug Administration and EMA-approved xCT inhibitor, sulfasalazine (SAS) in gliomas." | 3.83 | Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema. ( Buchfelder, M; Dörfler, A; Engelhorn, T; Eyüpoglu, IY; Fan, Z; Ghoochani, A; Klucken, J; Minakaki, G; Rauh, M; Savaskan, N; Sehm, T, 2016) |
| "The effects of KLF8 on glioma cell proliferation, apoptosis and chemosensitivity to temozolomide (TMZ) were analyzed by Cell Counting Kit 8 assay and flow cytometry assay." | 3.83 | KLF8 Promotes Temozolomide Resistance in Glioma Cells via β-Catenin Activation. ( Wang, E; Wu, F; Yu, G, 2016) |
| "HIF-1α downregulation sensitizes U251 glioma cells to the temozolomide treatment via inhibiting MGMT expression and Notch1 pathway activation." | 3.83 | Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment. ( Huang, GH; Li, N; Lv, SQ; Ma, ZX; Sidlauskas, K; Tang, JH; Xiang, Y; Xu, QF; Zhang, EE, 2016) |
| "Temozolomide (TMZ), an oral alkylator of the imidazotetrazine family, is used to treat glioma." | 3.83 | Evidence for the Inhibition by Temozolomide, an Imidazotetrazine Family Alkylator, of Intermediate-Conductance Ca2+-Activated K+ Channels in Glioma Cells. ( Hsieh, YJ; Hsu, CW; Huang, CW; Huang, YM; Hung, TY; Sze, CI; Wu, SJ; Wu, SN; Yeh, PS, 2016) |
| "Although temozolomide (TMZ) is the most effective chemotherapy agent for glioma, chemotherapy resistance has limited its clinical use." | 3.83 | Fluoxetine synergizes with temozolomide to induce the CHOP-dependent endoplasmic reticulum stress-related apoptosis pathway in glioma cells. ( Chen, MH; Chen, W; Ma, J; Sun, LL; Wang, DC; Wang, FZ; Wang, H; Wang, XD; Yang, YR, 2016) |
| " Here, we report increased MAP kinase-interacting kinase (MNK)-regulated phosphorylation of translation initiation factor 4E (eIF4E) in glioma cells upon temozolomide (TMZ) treatment and in medullary thyroid carcinoma (MTC) cells in response to targeted radionuclide therapy." | 3.83 | Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy. ( Behe, M; Frank, S; Grzmil, M; Hemmings, BA; Hess, D; Moncayo, G; Schibli, R; Seebacher, J, 2016) |
| "Twenty patients with high grade glioma relapse received a stereotactic radiation; among them two patients received temozolomide and eight patients received bevacizumab; among the latter, four received also irinotecan." | 3.83 | Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse. ( Ahle, G; Antoni, D; Atlani, D; Chaussemy, D; Clavier, JB; Couchot, J; Gaultier, C; Haoming, QC; Jastaniah, Z; Noël, G; Schott, R; Srour, R, 2016) |
| " In the case of glioma, temozolomide (TMZ) is the main option for treatment, but it has limited success due to drug resistance." | 3.83 | NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells. ( Fortunato, RS; Kajitani, GS; Menck, CF; Quinet, A; Rocha, CR, 2016) |
| "Temozolomide (TMZ) improves Glioblastoma Multiforme (GBM) patient survival." | 3.83 | Temozolomide induces the expression of the glioma Big Potassium (gBK) ion channel, while inhibiting fascin-1 expression: possible targets for glioma therapy. ( Ahluwalia, A; Chau, V; Ge, L; Hoa, NT; Jadus, MR; Kruse, CA; Martini, F, 2016) |
| "Temozolomide (TMZ) is the most commonly used alkylating agent in glioma chemotherapy." | 3.83 | miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectely. ( Liao, Y; Liu, J; Liu, Q; Lv, R; Qiu, X; Wu, M; Xiao, S; Yang, Z, 2016) |
| "Genotoxic chemotherapy with temozolomide (TMZ) is a mainstay of treatment for glioblastoma (GBM); however, at best, TMZ provides only modest survival benefit to a subset of patients." | 3.83 | Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide. ( Johnston, G; Lincoln, FA; Murphy, BM; Noonan, J; Rehm, M; Weyhenmeyer, BC; Würstle, ML, 2016) |
| " 1) VPA treatment clearly sensitized glioma cells to temozolomide: A protruding VPA-induced molecular feature in this context was the transcriptional upregulation/reexpression of numerous solute carrier (SLC) transporters that was also reflected by euchromatinization on the histone level and a reexpression of SLC transporters in human biopsy samples after VPA treatment." | 3.83 | Molecular dissection of the valproic acid effects on glioma cells. ( Hau, P; Herold-Mende, C; Hoja, S; Proescholdt, M; Rehli, M; Riemenschneider, MJ; Schulze, M, 2016) |
| " In the OP group with GBM and anaplastic glioma, patients treated with RT combined with temozolomide (TMZ) manifested significantly longer OS and PFS compared with patients assigned to RT alone (P < 0." | 3.83 | Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma. ( Cai, J; Jiang, T; Li, S; Li, W; Peng, X; Qiu, X; Wang, Y; Wu, C; Yang, P; Yao, K; You, G; Zhang, C; Zhang, W, 2016) |
| "Concomitant use of temozolomide (TMZ) and radiotherapy, which is the standard therapy for patients with high-grade glioma, involves a unique regimen with multiple-day, long-term administration." | 3.83 | Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study. ( Akutsu, H; Ishikawa, E; Matsuda, M; Matsumura, A; Takano, S; Yamamoto, T, 2016) |
| " Iron chelators have been shown to have anti-tumor activity; however, deferiprone (DFP), an orally administered iron chelator, has not been previously evaluated in gliomas." | 3.83 | Deferiprone Enhances Temozolomide Cytotoxicity in Glioma Cells. ( Alexiou, GA; Gerogianni, P; Kyritsis, AP; Vartholomatos, E, 2016) |
| " As poor differentiation and low apoptosis are closely associated with poor survival rates and a poor response to radio/chemotherapy in patients with cancer, the prognostic value of Dec1 expression was examined in the present study and its correlation with response to temozolomide (TMZ) chemotherapy was analyzed in patients with glioma." | 3.83 | Dec1 expression predicts prognosis and the response to temozolomide chemotherapy in patients with glioma. ( Bian, H; Huang, Y; Li, XM; Lin, W; Wang, J; Yao, L; Yin, AA; Zhang, J; Zhang, W; Zhang, X, 2016) |
| "Temozolomide (TMZ), an alkylating agent of the imidazotetrazine series, is a first-line chemotherapeutic drug used in the clinical therapy of glioblastoma multiforme, the most common and high-grade primary glioma in adults." | 3.83 | The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death. ( Chang, CK; Chen, KC; Chen, PH; Cheng, CH; Ho, KH; Lee, CC; Lin, CW; Liu, AJ; Shih, CM, 2016) |
| "The aim of this study was to investigate the effect of downregulating Hedgehog pathway by GANT61 on human glioma cells, examine the consequent changes of temozolomide (TMZ)-induced effects and explore the molecular mechanisms." | 3.83 | GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment. ( Cai, J; Chen, L; Jiang, C; Li, J; Li, R; Li, Y; Sun, Y; Yao, K; Zhai, X; Zhang, J; Zhao, S, 2016) |
| "Twenty-two newly diagnosed patients with primary malignant gliomas underwent 6 weeks of combined modality treatment (CMD) with radiation and temozolomide followed by six monthly cycles of temozolomide." | 3.81 | Analysis of salivary fluid and chemosensory functions in patients treated for primary malignant brain tumors. ( Case, D; Dietrich, AM; Duncan, SE; Harmon, M; Lesser, G; Mirlohi, S, 2015) |
| " With the aim to better understand the resistance/susceptibility processes associated to temozolomide (TMZ) treatment, the current study was performed in three human malignant glioma cell lines by focusing on several levels: (a) apoptotic index and senescence, (b) DNA damage, and (c) interaction of HSPB1 with players of the DNA damage response." | 3.81 | Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells. ( Castro, GN; Cayado-Gutiérrez, N; Ciocca, DR; Cuello-Carrión, FD; Fanelli, MA; Nadin, SB; Sottile, M; Zoppino, FC, 2015) |
| " Here, we examine the molecular mechanisms by which epigallocatechin gallate (EGCG), a bioactive polyphenol in green tea, inhibits the stem cell characteristics of glioma stem-like cells (GSLCs) and synergizes with temozolomide (TMZ), a DNA-methylating agent commonly used as first-line chemotherapy in gliomas." | 3.81 | EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition. ( Du, B; Li, HY; Ma, JW; Wang, SX; Xie, SM; Ye, JC; Zhang, Y; Zhong, XY, 2015) |
| "The purpose of this study was to assess the efficacy and toxicity of radiotherapy (RT) with concurrent temozolomide (TMZ) chemotherapy followed by adjuvant TMZ in children with diffuse intrinsic pontine glioma (DIPG)." | 3.81 | Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise? ( Attinà, G; Balducci, M; Caldarelli, M; Colosimo, C; Lazzareschi, I; Mastrangelo, S; Maurizi, P; Riccardi, R; Ridola, V; Rizzo, D; Ruggiero, A; Scalzone, M, 2015) |
| " The autophagy inhibitor chloroquine (CQ) potentiates temozolomide (TMZ) cytotoxicity in glioma cells, but it is not known whether CQ does this by inhibiting mitochondrial autophagy." | 3.81 | Chloroquine potentiates temozolomide cytotoxicity by inhibiting mitochondrial autophagy in glioma cells. ( Akiyama, Y; Hori, YS; Horio, Y; Hosoda, R; Kuno, A; Maruyama, M; Mikami, T; Mikuni, N; Sebori, R; Sugino, T; Suzuki, K; Tsukamoto, M; Wanibuchi, M, 2015) |
| " Temozolomide (TMZ) is currently used to intervene glioma multiforme (GBM), but an acquired chemotherapeutic resistance maybe occurred due to undesired autophagy." | 3.81 | Bcl2L12 with a BH3-like domain in regulating apoptosis and TMZ-induced autophagy: a prospective combination of ABT-737 and TMZ for treating glioma. ( Cheng, JT; Chou, AK; Chou, CH; Hong, YR; Howng, SL; Huang, WS; Li, YY; Lieu, AS; Loh, JK; Wang, YT; Yang, MC, 2015) |
| "We retrospectively identified 68 consecutive patients with high-grade gliomas treated by surgical resection followed by radiation therapy and temozolomide, who then developed increasing enhancing mass lesions indeterminate for treatment-related changes versus recurrent tumor." | 3.81 | Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence. ( Beal, K; Martinez, N; Omuro, A; Prager, AJ; Young, RJ; Zhang, Z, 2015) |
| "Temozolomide (TMZ) is an effective agent for clinical glioma treatment, but the innate and acquired resistance of glioma always limits its application." | 3.81 | p38 MAPK-dependent Nrf2 induction enhances the resistance of glioma cells against TMZ. ( Gu, Y; Liu, J; Ma, L; Qi, J; Yu, W; Zhang, X, 2015) |
| " Using a therapeutically relevant model of DNA damage-induced senescence in human glioma cells, we demonstrated that acute treatment with temozolomide induces DNA damage, a transitory activation of PRKAA/AMPK-ULK1 and MAPK14/p38 and the sustained inhibition of AKT-MTOR." | 3.81 | Single-cell analysis challenges the connection between autophagy and senescence induced by DNA damage. ( Bueno e Silva, MM; Filippi-Chiela, EC; Lenz, G; Thomé, MP, 2015) |
| "Temozolomide (TMZ) increases the overall survival of patients with glioblastoma (GBM), but its role in the clinical management of diffuse low-grade gliomas (LGG) is still being defined." | 3.81 | Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. ( Aburatani, H; Aihara, K; Berger, MS; Chang, SM; Costello, JF; Fouse, SD; Hallbeck, M; Heimans, JJ; Hong, C; Johnson, BE; Kloezeman, JJ; Lamfers, ML; Malmström, A; Mazor, T; Molinaro, AM; Mukasa, A; Reijneveld, JC; Saito, N; Söderkvist, P; Stenmark-Askmalm, M; Taylor, BS; van Thuijl, HF; Wesseling, P; Ylstra, B, 2015) |
| "To investigate programmed cell death induced by temozolomide in rat glioma C6 cell line." | 3.81 | [Caspase-independent programmed cell death induced by temozolomide in rat glioma C6 cell line]. ( Liu, L; Zhang, M, 2015) |
| " In this project, we evaluated the effects of silibinin, a natural plant component of milk thistle seeds, to potentiate toxic effects of chemotherapy drugs such as temozolomide, etoposide and irinotecan on LN229, U87 and A172 (P53 and phosphatase and tensin homolog (PTEN) -tumor suppressor-mutated) glioma cell lines." | 3.81 | The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines. ( Elhag, R; Mazzio, EA; Soliman, KF, 2015) |
| "Temozolomide is used widely to treat malignant glioma, but the overall response to this agent is generally poor." | 3.81 | Decoy Receptor DcR1 Is Induced in a p50/Bcl3-Dependent Manner and Attenuates the Efficacy of Temozolomide. ( Balyasnikova, IV; Bernal, GM; Cahill, KE; Crawley, CD; Larsen, GF; Mansour, NM; Nunez, L; Spretz, R; Voce, DJ; Weichselbaum, RR; Wu, L; Yamini, B; Zhang, W, 2015) |
| "Temozolomide (TMZ) is the first line drug in the care of high grade gliomas." | 3.81 | Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: a very long term comparative study and literature review. ( Clemente, MA; Corsa, P; Cossa, S; Donno, E; Munafò, T; Parisi, F; Parisi, S; Perrone, A; Piombino, M; Raguso, A; Sanpaolo, G; Valle, G, 2015) |
| "This study was initiated to test the feasibility and toxicity of a regimen that alternates the administration of weekly carboplatin and vincristine with temozolomide in the management of children with progressive and/or symptomatic low-grade glioma." | 3.81 | A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: a Children's Oncology Group study†. ( Adesina, A; Chintagumpala, M; Eckel, SP; Gajjar, A; Krailo, M; Lau, C; Morris, M; Packer, R, 2015) |
| " Second, we demonstrate that a combination of temozolomide and an experimental therapy in a glioma PDX model yields an effect, similar to an additive version of the DTE curves for the mono-therapies, except that there is a 30 day delay in peak inhibition." | 3.81 | Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapies. ( Ashcraft, KA; Boss, MK; Choudhury, KR; Dewhirst, MW; Keir, ST, 2015) |
| "Acute severe lymphopenia (ASL) frequently develops during radiation therapy (RT) and concurrent temozolomide (TMZ) for high-grade glioma (HGG) and is associated with decreased survival." | 3.81 | Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma. ( Badiyan, SN; Campian, JL; Chicoine, MR; DeWees, TA; Dunn, G; Fergus, S; Huang, J; Kim, AH; Linette, G; Mullen, DF; Robinson, CG; Simpson, JR; Speirs, CK; Tran, DD, 2015) |
| "The objective of the study was to determine whether astrocytes and brain endothelial cells protect glioma cells from temozolomide through an endothelin-dependent signaling mechanism and to examine the therapeutic efficacy of the dual endothelin receptor antagonist, macitentan, in orthotopic models of human glioblastoma." | 3.81 | Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice. ( Aldape, K; Choi, HJ; Conrad, CA; Fidler, IJ; He, J; Kim, MS; Kim, SJ; Langley, RR; Lee, HJ; Lehembre, F; Regenass, U; Weinberg, JS; Wu, Q; Yung, WK, 2015) |
| "We retrospectively investigated the prognostic impact of molecular phenotypes in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide (TMZ)." | 3.81 | Prognostic impact of molecular phenotype in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide. ( Choi, YR; Kim, HR; Kong, DS; Lee, JI; Nam, DH; Seol, HJ, 2015) |
| " We investigated whether the widely used chemotherapeutic agent temozolomide (TMZ) can sensitize glioma stem-like cells (GSCs) from human glioblastoma multiforme (GBM) to TRAIL-induced apoptosis." | 3.81 | Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein. ( Anhua, W; Jia, L; Long, L; Yunchao, B; Zhitao, J, 2015) |
| " The introduction of temozolomide (TMZ) has advanced chemotherapy for malignant gliomas." | 3.81 | NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. ( Chen, Y; Cheng, Y; Li, Y; Xie, G; Yao, G; Yu, Z; Zhang, G; Zhao, G; Zhou, G, 2015) |
| "Temozolomide plays a critical role in curing glioma at present." | 3.81 | Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation. ( Gao, J; Huang, G; Liu, H; Wang, L; Wang, Z, 2015) |
| "A total of nine patients with malignant glioma, postoperatively presenting with a Karnofsky performance score (KPS) below 70, were treated with standalone metronomic low-dose chemotherapy with temozolomide and celecoxib (cyclo-oxygenase-2 inhibitor)." | 3.81 | Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment. ( Brawanski, KR; Freyschlag, CF; Grams, AE; Kerschbaumer, J; Nowosielski, M; Petr, O; Pinggera, D; Schmidt, FA; Seiz, M; Thomé, C; Tuettenberg, J, 2015) |
| "Temozolomide (TMZ) as a concomitant and adjuvant chemotherapy to radiotherapy following maximal surgical resection is the established standard therapy for patients with newly diagnosed high-grade glioma." | 3.81 | Profile Analysis of Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study. ( Akutsu, H; Ishikawa, E; Matsuda, M; Matsumura, A; Nakai, K; Onuma, K; Yamamoto, T, 2015) |
| " In addition, in contrast to IDH1-mutated gliomas, IDH1-wild-type primary GBMs rarely developed hypermutation following temozolomide (TMZ) treatment, indicating low risk for TMZ-induced hypermutation for these tumors under the standard regimen." | 3.81 | Spatiotemporal Evolution of the Primary Glioblastoma Genome. ( Cho, HJ; Johnson, MD; Joo, KM; Jung, YS; Kim, BS; Kim, J; Kim, Y; Kong, DS; Lee, IH; Lee, J; Lee, JI; Nam, DH; Nam, SH; Park, CK; Park, PJ; Park, WY; Seol, HJ; Yoon, Y, 2015) |
| "Mesoporous silica nanoparticles (MSNPs), 100 nm in size, incorporating a Cy5 fluorophore within the silica framework, are synthesized and loaded with the anti-cancer drug temozolomide (TMZ), used in the treatment of gliomas." | 3.81 | Combined Delivery of Temozolomide and Anti-miR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells. ( Bertucci, A; Brognara, E; Corradini, R; De Cola, L; Gambari, R; Manicardi, A; Prasetyanto, EA; Septiadi, D, 2015) |
| "Glioblastoma (GBM) generally exhibits high IC50 values for its standard drug treatment, temozolomide (TMZ)." | 3.81 | Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells. ( Ananta, JS; Massoud, TF; Paulmurugan, R, 2015) |
| " Here, we built protein interaction networks associated with chemoresistance to temozolomide, an alkylating agent used in glioma therapy, and analyzed their modular structure and robustness against intentional attack." | 3.81 | Topological robustness analysis of protein interaction networks reveals key targets for overcoming chemotherapy resistance in glioma. ( Azevedo, H; Moreira-Filho, CA, 2015) |
| "The EpiBrainRad study is a prospective cohort study including newly diagnosed high grade gliomas patients treated by radiotherapy and concomitant-adjuvant temozolomide chemotherapy." | 3.81 | EpiBrainRad: an epidemiologic study of the neurotoxicity induced by radiotherapy in high grade glioma patients. ( Benderitter, M; Bernier, MO; Brochet, B; Delattre, JY; Douzane, H; Durand, T; Feuvret, L; Hoang-Xuan, K; Jacob, S; Lebouil, L; Leclercq, D; Lestaevel, P; Milliat, F; Noël, G; Psimaras, D; Rahimian, A; Ricard, D; Tamarat, R; Vayatis, N, 2015) |
| "Temozolomide (TMZ) with radiotherapy is the current standard of care for newly diagnosed glioma." | 3.81 | MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells. ( Chen, Q; Han, J, 2015) |
| "To assess effectiveness of 5-aminolevulinic acid (5-ALA, Gliolan(®)) in patients treated for malignant glioma under typical daily practice conditions in Spain, using complete resection rate (CR) and progression free survival at 6 months (PFS6)." | 3.80 | Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study). ( Arza, C; Díez Valle, R; Galván, J; Romariz, C; Slof, J; Vidal, C, 2014) |
| "The aim of this study is to investigate the inhibitory effects of 2T-P400, a derivative of temozolomide (TMZ), on glioma growth." | 3.80 | The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection. ( Dong, J; Li, R; Tang, D; Wang, L; Wu, J; Zhang, J, 2014) |
| " This study employed intracranial human glioma models to evaluate the effect of BEV alone and in combination with temozolomide (TMZ) and/or radiation therapy (XRT) on overall survival." | 3.80 | Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models. ( Blakeley, JO; Brastianos, H; Brem, H; Goodwin, RC; Grossman, R; Hwang, L; Lal, B; Mangraviti, A; Tyler, B; Wicks, RT; Zadnik, P, 2014) |
| "Following tumor resection, the majority of high-grade glioma (HGG) patients are treated with a combined modality regimen of radiotherapy and temozolomide." | 3.80 | Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal study. ( Bosma, I; Buter, J; de Groot, M; Douw, L; Froklage, FE; Heimans, JJ; Klein, M; Lagerwaard, FJ; Oosterbaan, LJ; Postma, TJ; Reijneveld, JC; Sanchez, E; Sizoo, EM; Uitdehaag, BM, 2014) |
| "To investigate the mechanisms of action of the tumoricidal effects of temozolomide against the human glioma cell line U251 in vitro, and to provide preclinical proof-of-concept studies of the effects of temozolomide-containing regimens." | 3.80 | Mechanism of temozolomide-induced antitumour effects on glioma cells. ( Hu, JA; Shen, W; Zheng, JS, 2014) |
| "Present work mainly evaluated the inhibitory effects of lidamycin (LDM), an enediyne antibiotic, on angiogenesis or glioma-induced angiogenesis in vitro and in vivo, especially its synergistic anti-angiogenesis with temozolomide (TMZ)." | 3.80 | Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin. ( Li, XQ; Li, Y; Liu, H; Ouyang, ZG; Shang, Y; Zhang, SH; Zhen, YS, 2014) |
| " In the present study aimed to: (i) evaluate the concordance between MGMT promoter methylation status in tumor tissue and plasma; (ii) monitor MGMT promoter methylation status in plasma taken before and during temozolomide treatment; (iii) explore the value of MGMT promoter methylation status in plasma as a prognostic/predictive biomarker in glioma patients." | 3.80 | MGMT promoter methylation in plasma of glioma patients receiving temozolomide. ( Cassoni, P; Castiglione, A; De Marco, L; Fiano, V; Gillio-Tos, A; Grasso, C; Magistrello, M; Merletti, F; Rudà, R; Sacerdote, C; Senetta, R; Soffietti, R; Tondat, F; Trevisan, E; Trevisan, M, 2014) |
| "Temozolomide (TMZ), used to treat glioblastoma and malignant glioma, induces autophagy, apoptosis and senescence in cancer cells." | 3.80 | Antitumor effect of fibrin glue containing temozolomide against malignant glioma. ( Anai, S; Hide, T; Kuratsu, J; Kuroda, J; Makino, K; Nakamura, H; Shinojima, N; Takezaki, T; Yano, S, 2014) |
| "We present a case of inadvertent high-dose therapy with temozolomide in a child with recurrent diffuse intrinsic pontine glioma followed by a rapid clinical response." | 3.80 | Inadvertent high-dose therapy with temozolomide in a child with recurrent pontine glioma followed by a rapid clinical response but deteriorated after substitution with low-dose therapy. ( Altonok, D; Konski, A; Poulik, J; Sood, S; Wang, ZJ, 2014) |
| "Autophagy is a cytoprotective process, which occurs following temozolomide (TMZ) treatment, and contributes to glioma chemoresistance and TMZ treatment failure." | 3.80 | Temozolomide induces autophagy via ATM‑AMPK‑ULK1 pathways in glioma. ( Li, B; Wang, Q; Wang, W; Xie, B; Zou, Y, 2014) |
| "B10 is a glycosylated derivative of betulinic acid with promising activity against glioma cells." | 3.80 | Hypoxia enhances the antiglioma cytotoxicity of B10, a glycosylated derivative of betulinic acid. ( Bähr, O; Fischer, S; Fulda, S; Harter, PN; Kögel, D; Mittelbronn, M; Paschke, R; Reichert, S; Ronellenfitsch, MW; Steinbach, JP; Thiepold, AL; Weller, M, 2014) |
| "The present work evaluated the synergistic efficacy of an enediyne antibiotic lidamycin (LDM) plus temozolomide (TMZ) against glioma in vitro and in vivo." | 3.80 | Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction. ( Li, XQ; Li, Y; Liu, H; Ouyang, ZG; Shang, Y; Zhang, SH; Zhen, YS, 2014) |
| "To study the therapeutic effect of intranasal administration of temozolomide (TMZ) for brain-targeting delivery in a rat model bearing orthotopic C6 glioma xenografts." | 3.80 | [Intranasal administration of temozolomide for brain-targeting delivery: therapeutic effect on glioma in rats]. ( Gao, Y; Li, Y; Liu, G; Ma, L; Wang, Y; Zhou, X, 2014) |
| "This study explored the effects of telomerase reverse transcriptase (TERT) promoter mutations on transcriptional activity of the TERT gene under hypoxic and temozolomide (TMZ) treatment conditions, and investigated the status and prognostic value of these mutations in gliomas." | 3.80 | TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas. ( Chen, C; Han, S; Li, Z; Meng, L; Wu, A; Zhang, X, 2014) |
| "Isocitrate dehydrogenase 1 (IDH1) mutations occur in most lower grade glioma and not only drive gliomagenesis but are also associated with longer patient survival and improved response to temozolomide." | 3.80 | Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance. ( Mukherjee, J; Ohba, S; Pieper, RO; See, WL, 2014) |
| "This study evaluated the toxicity profiles of temozolomide in the treatment of malignant glioma as either concurrent or adjuvant chemotherapy." | 3.80 | Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. ( Bae, SH; Cho, SY; Kim, CY; Kim, TM; Kim, YH; Kim, YJ; Lee, MM; Lee, SH; Park, CK; Park, MJ, 2014) |
| "The combined application of aplysin and TMZ significantly sensitizes glioma cells to TMZ action, compared with TMZ alone." | 3.80 | Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level. ( Ge, N; Gong, A; Liang, H; Lu, L; Yao, W, 2014) |
| "Temozolomide (TMZ), a DNA methylating agent, is widely used in the adjuvant treatment of malignant gliomas." | 3.80 | Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase. ( Fukai, J; Koizumi, F; Nakao, N, 2014) |
| "These results suggest that concomitant treatment with NPe6-PDT and temozolomide is a potentially useful therapy for glioma." | 3.80 | Concomitant treatment with temozolomide enhances apoptotic cell death in glioma cells induced by photodynamic therapy with talaporfin sodium. ( Akimoto, J; Beppu, M; Fujiwara, Y; Hiranuma, M; Hironaka, C; Miki, Y; Moritake, K; Omata, H, 2014) |
| "Twenty-three consecutive high-grade glioma patients were treated with radiotherapy (2 Gy/60 Gy) with concomitant and adjuvant temozolomide." | 3.80 | ADC texture--an imaging biomarker for high-grade glioma? ( Asklund, T; Birgander, R; Brynolfsson, P; Garpebring, A; Hauksson, J; Henriksson, R; Karlsson, M; Nilsson, D; Nyholm, T; Trygg, J, 2014) |
| "We report the safety and feasibility of a 3 days on/11 days off temozolomide regimen for the treatment of recurrent malignant gliomas." | 3.80 | Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas. ( Brown, BD; Brown, T; Juarez, T; Kesari, S; Piccioni, DE; Saria, MG; van Vugt, VA, 2014) |
| "For glioma, temozolomide (TMZ) is a commonly used chemotherapy drug and photodynamic therapy (PDT) is an important adjuvant therapy." | 3.80 | Combination of photodynamic therapy and temozolomide on glioma in a rat C6 glioma model. ( Guo, M; Hu, S; Shen, L; Zhang, X, 2014) |
| " The purpose of this study was to assess the preclinical therapeutic efficacy of FUS-BBB opening for enhanced temozolomide (TMZ) delivery in glioma treatment." | 3.80 | Pharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment. ( Chen, JY; Chen, PY; Huang, CY; Liu, HL; Wang, HY; Wei, KC, 2014) |
| "Nine post-temozolomide recurrent or progressive high-grade glioma patients (seven with glioblastoma and two with anaplastic astrocytoma) were treated with BV monotherapy." | 3.80 | Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report. ( Kobayashi, K; Nagane, M; Shimizu, S; Shiokawa, Y; Shishido-Hara, Y; Tanaka, M; Tsuchiya, K, 2014) |
| "Glioma cells rich in miR-181b were more sensitive to temozolomide." | 3.79 | miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1. ( Chen, FR; Chen, ZP; Sai, K; Wang, J, 2013) |
| "In the U87 intracerebral glioma model, within the first day of administration of cediranib, the intratumoral concentrations of TMZ in tumor ECF were slightly, but not statistically significantly, increased when compared to the treatment of TMZ alone with radiographic evidence of a normalized BBB." | 3.79 | Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model. ( Blakeley, JO; Brem, H; Grossman, R; Khan, U; Kim, E; Pathak, AP; Rudek, MA; Tyler, B; Zadnik, P, 2013) |
| "Temozolomide is an oral alkylating agent with proven efficacy in recurrent high-grade glioma." | 3.79 | Effect of temozolomide on male gametes: an epigenetic risk to the offspring? ( Bashamboo, A; Berthaut, I; Deluen, F; Dessolle, L; McElreavey, K; Montjean, D; Morcel, K; Poirot, C; Ravel, C, 2013) |
| " The alkylating agent temozolomide (TMZ) has been shown to improve the overall survival in patients with malignant gliomas, especially in tumors with methylated promoter of the O6-methylguanine-DNA-methyltransferase (MGMT) gene." | 3.79 | Restoration of sensitivity in chemo-resistant glioma cells by cold atmospheric plasma. ( Boxhammer, V; Klämpfl, TG; Köritzer, J; Li, YF; Morfill, GE; Schäfer, A; Schlegel, J; Schwenk-Zieger, S; Shimizu, T; Welz, C; Zimmermann, JL, 2013) |
| "To compare retrospectively outcome after photon radiotherapy alone, radiochemotherapy with temozolomide (TMZ), and carbon ion radiotherapy in patients with high-grade gliomas and to generate a hypothetical outcome curve for C12 and TMZ." | 3.79 | Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis. ( Bruckner, T; Combs, SE; Debus, J; Kamada, T; Kieser, M; Mizoe, JE; Tsujii, H, 2013) |
| "The recent progress in chemotherapy for malignant gliomas is attributable to the introduction of the DNA-methylating agent temozolomide (TMZ); however, drug resistance remains a major issue." | 3.79 | The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells. ( Adachi, K; Hayashi, T; Hirose, Y; Ohba, S, 2013) |
| "Bortezomib induced caspase-3 activation and apoptotic cell death in stable glioma cell lines and in glioma stem-like cells (GSCs) derived from malignant tumor specimens Furthermore, TMZ-resistant glioma cell lines retained susceptibility to the proteasome inhibition." | 3.79 | Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. ( Alexandru, D; Bigner, D; Bota, DA; Friedman, HS; Keir, ST; Vredenburgh, J, 2013) |
| "Study the feasibility and effectiveness of a treatment associated surgery, intraoperative chemotherapy (carmustine wafers), and concomitant radiochemotherapy (temozolomide) for the management of newly diagnosed, high-grade gliomas." | 3.79 | Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases. ( Colin, P; Debreuve, A; Duntze, J; Eap, C; Emery, E; Guillamo, JS; Jovenin, N; Lechapt-Zalcman, E; Litré, CF; Menei, P; Metellus, P; Peruzzi, P; Rousseaux, P; Théret, E, 2013) |
| " In previous studies the alkylating agent temozolomide (TMZ) incorporated into a polymer, pCPP:SA, also for local delivery, and OncoGel were individually shown to increase efficacy in a rat glioma model." | 3.79 | Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model. ( Brem, H; Eberhart, CG; Fowers, KD; Hwang, L; Li, KW; Okonma, S; Recinos, VR; Tyler, BM; Vellimana, AK; Zhang, Y, 2013) |
| "Combined temozolomide (TMZ) and radiation therapy (RT) is often used as initial treatment for anaplastic glioma." | 3.79 | Combined temozolomide and radiation as an initial treatment for anaplastic glioma. ( Chong, DQ; Chua, ET; Lim, KH; Ng, WH; See, SJ; Tan, SH; Tham, CK; Thomas, J, 2013) |
| " Temozolomide is an alkylating agent approved for treating malignant gliomas." | 3.79 | Impact of temozolomide on gonadal function in patients with primary malignant brain tumors. ( Blackwood, R; Brown, M; Harmon, M; Lesser, G; Lovato, J; Strowd, RE; Yalcinkaya, T, 2013) |
| " Here we studied these responses in glioma cells treated with the methylating agent temozolomide (TMZ), which is a first-line chemotherapeutic for this malignancy." | 3.79 | Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage. ( Christmann, M; Kaina, B; Knizhnik, AV; Nikolova, T; Quiros, S; Roos, WP; Tomaszowski, KH, 2013) |
| "The coumarins 5-methoxy-6,7-methylenedioxycoumarin 1 5-(3-methyl-2-butenyloxy)-6,7-methylenedioxycoumarin 2 and 5-(2,3-dihydroxy-3-methylbutyloxy)-6,7-methylenedioxycoumarin 3 isolated from Pterocaulon species showed significant cytotoxicity against two glioma cells lines." | 3.78 | Selective cytotoxicity and apoptosis induction in glioma cell lines by 5-oxygenated-6,7-methylenedioxycoumarins from Pterocaulon species. ( Battastini, AM; Bernardi, A; Eifler-Lima, VL; Figueiró, F; Hamerski, L; Pinto, AC; Pires, EN; Salbego, CG; Teixeira, HF; Vianna, DR; Visentin, LC; von Poser, GL, 2012) |
| "After previous treatment with standard radiotherapy (with or without temozolomide) patients with recurrent malignant glioma received bevacizumab (10 mg/kg intravenous) on Day 1 and Day 15 during radiotherapy." | 3.78 | Irradiation and bevacizumab in high-grade glioma retreatment settings. ( Belka, C; Ertl, L; Ganswindt, U; Geisler, J; Kreth, FW; la Fougère, C; Linn, J; Niyazi, M; Schwarz, SB; Siefert, A; Tonn, JC, 2012) |
| "Temozolomide (TMZ) is a novel cytotoxic alkylating agent for chemotherapy of malignant gliomas." | 3.78 | Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen. ( Dong, XT; Li, JM; Li, Y; Pan, Q; Wang, HM; Wang, W; Yang, XJ, 2012) |
| "Temozolomide (TMZ) is given in addition to radiotherapy in glioma patients, but its interaction with the commonly prescribed antiepileptic drug valproic acid (VPA) is largely unknown." | 3.78 | Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation. ( Lafleur, MV; Slotman, BJ; Sminia, P; Stalpers, LJ; Van den Berg, J; Van Nifterik, KA, 2012) |
| "The introduction of temozolomide (TMZ) has advanced chemotherapy for malignant gliomas." | 3.78 | LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway. ( Chen, L; Han, L; Jiang, C; Jiang, T; Kang, C; Liu, Y; Pu, P; Shi, Z; Zhang, K; Zheng, Y, 2012) |
| "The alkylating agent temozolomide (TMZ) is the major chemotherapeutic drug used clinically in the treatment of malignant gliomas." | 3.78 | Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. ( Lee, CC; Lin, CJ; Lin, TY; Lin, YF; Shih, CM; Shih, YL; Wang, SH, 2012) |
| "In this study, we investigated the effects of temozolomide (TMZ)/Poly (lactide-co-glycolide)(PLGA)/nano-hydroxyapatite microspheres on the behavior of U87 glioma cells." | 3.78 | The effect of temozolomide/poly(lactide-co-glycolide) (PLGA)/nano-hydroxyapatite microspheres on glioma U87 cells behavior. ( Qiu, B; Tian, A; Wang, M; Wu, A; Xue, X; Zhang, D, 2012) |
| "Temozolomide (TMZ) is approved for the treatment of high-grade gliomas such as glioblastoma (GBM) multiforme and refractory anaplastic astrocytoma, but it is also used in indications not mentioned in the summary of product characteristics (SPC)." | 3.78 | A multicenter prospective observational study of the conformity of temozolomide prescriptions in France. ( Bertholle, V; Billard, M; Borget, I; Brignone, M; Cartalat, S; Charlety, D; Chinot, O; Exinger, D; Gensollen, S; Hassani, Y; Labrande, C; Lahille, B; Pedeboscq, S; Pinguet, F; Prebay, D; Taillibert, S; Tilleul, P, 2012) |
| "The current treatment regimen for glioma patients is surgery, followed by radiation therapy plus temozolomide (TMZ), followed by 6 months of adjuvant TMZ." | 3.78 | Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival. ( Brodie, C; Brown, SL; Golembieski, WA; King, DA; Rempel, SA; Schultz, CR, 2012) |
| "Polysorbate 80 coated temozolomide-loaded PLGA-based superparamagnetic nanoparticles (P80-TMZ/SPIO-NPs) were successfully synthesized and characterized as drug carriers and diagnosis agent for malignant brain glioma." | 3.78 | Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma. ( Ling, Y; Wei, K; Zhong, S; Zou, F, 2012) |
| "The DNA alkylating agent temozolomide (TMZ) is widely used in the treatment of human malignancies such as glioma and melanoma." | 3.78 | Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death. ( Amin, S; Cheng, Y; Huber-Keener, KJ; Liao, J; Ren, X; Sharma, AK; Sk, UH; Sun, YW; Yang, JM; Zhang, L; Zhang, Y, 2012) |
| " All three were found to have been treated with temozolomide after surgery for malignant glioma." | 3.78 | Fatal pneumonia associated with temozolomide therapy in patients with malignant glioma. ( Abe, S; Azuma, A; Fujita, K; Gemma, A; Hayashi, H; Kobayashi, K; Kokuho, N; Morimoto, T; Saito, Y; Tanaka, T, 2012) |
| "We analyzed the usefulness of initial or recurrent treatment of temozolomide (TMZ) in pediatric high-grade gliomas (HGGs)." | 3.78 | Prognosis of pediatric high-grade gliomas with temozolomide treatment: a retrospective, multicenter study. ( Baek, HJ; Choi, HS; Jung, TY; Kim, CY; Kim, DS; Kim, IA; Kim, SH; Ra, YS, 2012) |
| "The combination of hyperbaric oxygen with temozolomide produced an important reduction in glioma growth and effective approach to the treatment of glioblastoma." | 3.78 | Combination hyperbaric oxygen and temozolomide therapy in C6 rat glioma model. ( Bilir, A; Bozkurt, ER; Dagıstan, Y; Karaca, I; Ozar, E; Toklu, A; Yagmurlu, K, 2012) |
| "Temozolomide (TMZ) has become a key therapeutic agent in patients with malignant gliomas; however, its survival benefit remains unsatisfactory." | 3.78 | Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells. ( Hou, Y; Jeong, CH; Jeun, SS; Kim, SM; Lim, JY; Park, KY; Ryu, CH; Woo, JS; Yoon, WS, 2012) |
| " We previously demonstrated that temozolomide (TMZ), an alkylating agent for brain tumor chemotherapy, induced reactive oxygen species (ROS)/extracellular signal-regulated kinase (ERK)-mediated autophagy to protect glioma cells from apoptosis." | 3.78 | Inhibition of mitochondria- and endoplasmic reticulum stress-mediated autophagy augments temozolomide-induced apoptosis in glioma cells. ( Chen, TH; Lee, CC; Lin, CH; Lin, CJ; Shih, CM; Shih, YL; Wang, SH, 2012) |
| "Currently, treatment of malignant gliomas with temozolomide in addition to surgical resection and radiotherapy remains the foundation of glioma therapy." | 3.78 | Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth. ( Chen, Y; Cui, B; Dai, X; Dong, J; Huang, Q; Lan, Q; Tang, D; Zhang, J; Zhou, G, 2012) |
| " In this study, we explored the most effective schedule of the miR-21 inhibitor (miR-21i) and Temozolomide (TMZ) combined treatment in human glioma cells." | 3.78 | Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR-21 inhibitor gene therapy. ( Kang, C; Long, L; Pu, P; Qian, X; Ren, Y; Sheng, J; Shi, Z; Yuan, X, 2012) |
| "Temozolomide (TMZ) is an oral alkylating agent widely used in the treatment of refractory glioma." | 3.78 | The synergistic therapeutic effect of temozolomide and hyperbaric oxygen on glioma U251 cell lines is accompanied by alterations in vascular endothelial growth factor and multidrug resistance-associated protein-1 levels. ( Cao, K; Li, QY; Lu, PS; Lu, XY; Yuan, ZC, 2012) |
| " Recently, in a phase II trial in Brazil for the treatment of temozolomide (TMZ)-resistant malignant gliomas, POH was well tolerated when administered intranasally." | 3.78 | Perillyl alcohol for the treatment of temozolomide-resistant gliomas. ( Chen, TC; Cho, HY; Goldkorn, A; Hofman, FM; Jhaveri, N; Lee, DJ; Leong, MN; Louie, SG; Petasis, NA; Schönthal, AH; Torres, S; Tseng, J; Wang, W; Xu, T, 2012) |
| "To test the effect of starvation on glioma cells in vitro, we treated primary mouse glia, murine GL26, rat C6 and human U251, LN229 and A172 glioma cells with Temozolomide in ad lib and STS mimicking conditions." | 3.78 | Fasting enhances the response of glioma to chemo- and radiotherapy. ( Brandhorst, S; Chen, TC; Conti, PS; Hwang, S; Lee, C; Longo, VD; Safdie, F; Wang, W; Wei, M, 2012) |
| "Human glioma cell lines, T98-G, and SF295, were treated with temozolomide (TMZ) or irradiation (IR), with or without VPA (1." | 3.78 | Histone deacetylase inhibitor, 2-propylpentanoic acid, increases the chemosensitivity and radiosensitivity of human glioma cell lines in vitro. ( Chen, FR; Chen, ZP; Li, C; Shao, CJ; Wu, MW; Xia, YF, 2012) |
| "Implantable and poly (d,l-lactide-co-glycolide) (PLGA) microparticles were developed to deliver temozolomide (TM) continuously in interstitial chemotherapy for glioma." | 3.77 | Temozolomide/PLGA microparticles: a new protocol for treatment of glioma in rats. ( Liu, JM; Yue, ZJ; Zhang, H; Zhang, YH, 2011) |
| "We investigated pseudoprogression (psPD) in patients with malignant gliomas treated with radiotherapy (RT) and maintenance temozolomide (TMZ) in terms of incidence, outcomes, and predictive and prognostic factors." | 3.77 | Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53. ( Choe, GY; Han, JH; Kang, HC; Kim, CY; Kim, IA; Kim, JH, 2011) |
| "Temozolomide (TMZ) is an oral alkylating agent with proven antitumoral activity in preclinical and clinical studies in adults with high-grade glioma (HGG)." | 3.77 | Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors. ( Barone, G; Lazzareschi, I; Riccardi, R; Ridola, V; Rizzo, D; Ruggiero, A, 2011) |
| " Whether MGMT promoter methylation correlates with tumor response to temozolomide in low-grade gliomas is less clear." | 3.77 | Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas. ( Mariani, L; Ochsenbein, AF; Schubert, AD; Vassella, E, 2011) |
| "This prospective study was performed to determine the efficacy, safety, and tolerability of concurrent chemoradiotherapy (CCRT) followed by adjuvant chemotherapy with temozolomide (TMZ) in the treatment of patients with WHO grade III gliomas." | 3.77 | Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study. ( Bae, SH; Cha, SH; Cho, WH; Choe, G; Jung, HW; Kim, CY; Kim, DG; Kim, IA; Kim, IH; Kim, YH; Lee, MM; Moon, S; Park, CK; Park, SH, 2011) |
| "Genotyping of putative determinants of temozolomide (TMZ)-induced life-threatening bone marrow suppression was performed in two patients with glioma treated with adjuvant TMZ and radiation therapy." | 3.77 | Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patients. ( Berg, A; Kolesar, J; Mehta, M; Petrich, RJ; Steen, P; Sylvester, RK; Tate, JM, 2011) |
| "To investigate the possible cytotoxic interactions between the chemotherapeutic drug temozolomide (TMZ) and the cyclooxygenase-2 inhibitor meloxicam (MLC) or of both drugs combined with X-rays in three human glioma cell lines (D384, Hs 683 and U251)." | 3.77 | Anti-tumour effects by a trimodal combination of temozolomide, meloxicam and X-rays in cultures of human glioma cells. ( Slotman, BJ; Van Den Berg, J; van Nifterik, KA; Van Rijn, J, 2011) |
| "Temozolomide (TMZ) is commonly used for the therapy of malignant glioma and induces thrombocytopenia in a fraction of patients." | 3.77 | Immature and absolute platelet count changes and thrombocytopenia in malignant glioma. ( Elandt, K; Heinzl, H; Marosi, C; Preusser, M; Schwarzinger, I, 2011) |
| " Induction of autophagy by temozolomide (TMZ) has been noted in glioma cell lines." | 3.77 | Induction of autophagy in temozolomide treated malignant gliomas. ( Aoki, H; Fujii, Y; Kakita, A; Miyahara, H; Natsumeda, M; Takahashi, H; Toyoshima, Y; Uzuka, T; Yajima, N, 2011) |
| "Temozolomide (TMZ) is an oral alkylating agent that has been widely used in the treatment of refractory glioma, although inherent and acquired resistance to this drug is common." | 3.77 | Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation. ( Chang, YJ; Chen, CH; Chung, KT; Ku, MS; Yang, JT, 2011) |
| "We analyzed prospectively whether MGMT (O(6)-methylguanine-DNA methyltransferase) mRNA expression gains prognostic/predictive impact independent of MGMT promoter methylation in malignant glioma patients undergoing radiotherapy with concomitant and adjuvant temozolomide or temozolomide alone." | 3.77 | O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. ( Egensperger, R; Eigenbrod, S; Hinske, LC; Kreth, FW; Kreth, S; Kretzschmar, HA; Ledderose, C; Lutz, J; Thon, N; Tonn, JC, 2011) |
| "Temozolomide (TMZ) is the preferred chemotherapeutic agent in the treatment of glioma following surgical resection and/or radiation." | 3.77 | N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide. ( Banze, LA; Brown, AR; Goellner, EM; Hamilton, RL; Moore, B; Sobol, RW; Svilar, D; Tang, JB; Trivedi, RN; Wang, XH, 2011) |
| " Corticorelin acetate (Xerecept) or human corticotrophin-releasing factor (hCRF) is a comparatively new drug and has been evaluated in two orthotopic glioma models (U87 and C6), by a direct comparison with dexamethasone and temozolomide." | 3.77 | Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas. ( Blasberg, RG; de Stanchina, E; Gamez, I; Huang, R; Kochetkov, T; Moroz, MA; Ryan, RP; Shi, W; Thaler, H, 2011) |
| "To study the impact of two human glioma tissue resistance genes MGMT and ERCC(2) on the temozolomide-based treatment of malignant gliomas and detect the relationship of their expressions." | 3.77 | [Comparison of MGMT and ERCC₂ expression in temozolomide for the treatment of malignant glioma drug resistance and their genetic relationship]. ( Hou, X; Sun, JH; Wang, JJ; Wu, ZC; Zhao, Y; Zheng, YR, 2011) |
| "This study was designed to evaluate proton magnetic resonance spectroscopy ((1)H-MRS) for monitoring the WHO grade II glioma (low-grade glioma (LGG)) treated with temozolomide (TMZ)." | 3.77 | Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy. ( Abud, L; Capelle, L; Chiras, J; Costalat, R; De Marco, G; Guillevin, R; Habas, C; Hoang-Xuan, K; Menuel, C; Taillibert, S; Vallée, JN, 2011) |
| " In vitro Southern Blot analysis and cytopathic effect assays demonstrate high anti-glioma potency, which was significantly increased in combination with temozolomide (TMZ), daunorubicin and cisplatin." | 3.77 | YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma. ( Anton, M; Gänsbacher, B; Haczek, C; Holm, PS; Holzmüller, R; Kasajima, A; Lage, H; Mantwill, K; Rognoni, E; Schlegel, J; Schuster, T; Treue, D; Weichert, W, 2011) |
| "We tested the use of the small-molecule Inhibitor of Apoptosis Protein (IAP) inhibitor LBW242 in combination with the standard-of-care therapies of irradiation and temozolomide for malignant gliomas." | 3.77 | A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo. ( Barnes, J; Fast, EM; Keating, J; Kesari, S; Kieran, MW; Kung, AL; Ramakrishna, N; Veldhuijzen van Zanten, SE; Zawel, L; Ziegler, DS, 2011) |
| "Patients with high-grade gliomas (HGG) routinely receive radiation, temozolomide, and glucocorticoids." | 3.77 | Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. ( Carraway, H; Desideri, S; Grossman, SA; Lesser, G; Piantadosi, S; Sloan, A; Ye, X, 2011) |
| "Temozolomide (TMZ) is an alkylating agent that has yielded significant benefits and is a current standard agent in the treatment of malignant gliomas." | 3.77 | Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas. ( Fukushima, T; Katayama, Y; Ogino, A; Ohta, T; Okamoto, Y; Sano, E; Tashiro, S; Tsumoto, K; Watanabe, T; Yachi, K; Yoshino, A, 2011) |
| "Temozolomide (TMZ) is an alkylating agent used for treating gliomas." | 3.77 | Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production. ( Gillespie, GY; Griguer, CE; Moellering, DR; Oliva, CR, 2011) |
| "Our results highlight involvement of miRNAs in the induction of apoptosis in glioma cells by fatty acids and temozolomide." | 3.77 | MicroRNA profile of polyunsaturated fatty acid treated glioma cells reveal apoptosis-specific expression changes. ( Das, UN; Faragó, N; Fehér, LZ; Kitajka, K; Puskás, LG, 2011) |
| "Prolonged administration of temozolomide is widely used in patients with glioblastoma; whereas the treatment of anaplastic glioma differs between neurooncological centres." | 3.77 | Prolonged administration of temozolomide in adult patients with anaplastic glioma. ( Freyschlag, CF; Janzen, E; Lohr, F; Schmieder, K; Seiz, M; Smolczyk, DR; Thomé, C; Tuettenberg, J; Weiss, C; Wenz, F, 2011) |
| "To study the efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide (TMZ) for gliomas." | 3.77 | [Efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide for glioma]. ( Tu, Q; Wang, L; Zhou, R; Zhou, W, 2011) |
| "The introduction of temozolomide (TMZ) has advanced chemotherapy for malignant gliomas." | 3.76 | Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells. ( Hirose, Y; Kawase, T; Ohba, S; Yazaki, T; Yoshida, K, 2010) |
| "In this study, we investigated the potential of combined treatment with temozolomide (TMZ) chemotherapy and tumor antigen-pulsed dendritic cells (DCs) and the underlying immunological factors of TMZ chemoimmunotherapy with an intracranial GL26 glioma animal model." | 3.76 | Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. ( Chung, DS; Hong, YK; Kim, CH; Kim, CK; Kim, TG; Park, JS; Park, SD, 2010) |
| "We hypothesized that the observed clinical synergy of orally administered TMZ and carmustine (BCNU) wafers would translate into even greater effectiveness with the local delivery of BCNU and TMZ and the addition of radiotherapy in animal models of malignant glioma." | 3.76 | Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. ( Bekelis, K; Brem, H; Li, KW; Recinos, VR; Sunshine, SB; Tyler, BM; Vellimana, A, 2010) |
| "Treatment for glioblastoma multiforme includes the alkylating agent temozolomide combined with ionizing radiation." | 3.76 | Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. ( Bradshaw, TD; Laughton, CA; Madhusudan, S; Stevens, MF; Zhang, J, 2010) |
| "Early assessment of radiotherapy (RT) quality in the ongoing EORTC trial comparing primary temozolomide versus RT in low-grade gliomas." | 3.76 | Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: First evaluation of quality of radiotherapy planning. ( Aird, E; Bar-Deroma, R; Baumert, BG; Bernard Davis, J; Collette, L; Fenton, P; Gulyban, A; Musat, E; Roelofs, E; Stupp, R; Weber, DC, 2010) |
| "Temozolomide (TMZ) has been accepted as a standard antitumor drug for glioma worldwide." | 3.76 | Flow cytometric analysis for the mechanism of the new antineoplastic agent temozolomide in glioma cells. ( Kawamoto, K; Li, Y; Numa, Y; Oishi, T; Oshige, H; Yamahara, T; Zhen, Y, 2010) |
| " We present the case of a 26-year-old male suffering a fatal ICH in the context of treatment of a high grade glioma with temozolomide." | 3.76 | Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide. ( Anderson, WS; Dunn, I; Norden, A; Sure, D, 2010) |
| "A retrospective multicenter study was conducted in 26 French Departments of Neurosurgery to analyze practices of French neurosurgeons using Gliadel, compare the adverse effects and survival with those of previous phase III trials, and assess survival in patients with newly diagnosed malignant gliomas (MG) receiving Gliadel plus radiochemotherapy with temozolomide (TMZ)." | 3.76 | Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. ( Capelle, L; Guyotat, J; Jacquet, G; Loiseau, H; Menei, P; Metellus, P; Parot-Schinkel, E, 2010) |
| "There is a growing evidence of using Temozolomide as upfront therapy for progressive low grade gliomas." | 3.76 | Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide. ( Dehais, C; Delattre, JY; Ducray, F; Hoang-Xuan, K; Houillier, C; Idbaih, A; Kaloshi, G; Laigle-Donadey, F; Omuro, A; Psimaras, D; Sanson, M; Sierra del Rio, M; Taillibert, S, 2010) |
| "Temozolomide is the major drug in the treatment of malignant gliomas." | 3.76 | Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide. ( Akmansu, M; Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Oner, Y; Ozturk, B; Uncu, D; Yaman, E; Yildiz, R, 2010) |
| "Malignant glioma patients treated with the golden standard therapy, focal radiotherapy plus concomitant daily temozolomide (radiotherapy/TMZ), often suffer severe lymphopenia." | 3.76 | Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment. ( Akutsu, H; Ishikawa, E; Matsumura, A; Nakai, K; Sakamoto, N; Takano, S; Tsuboi, K; Yamamoto, T, 2010) |
| "Temozolomide (TM) has anti-tumor activity in patients with malignant glioma." | 3.76 | Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model. ( Liu, JM; Tang, GS; Wang, Y; Yue, ZJ; Zhang, H; Zhang, YH, 2010) |
| "Temozolomide (TMZ) is an oral alkylating agent used for the treatment of high-grade gliomas." | 3.76 | Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain. ( Bailey, SM; Darley-Usmar, VM; Diers, A; Gillespie, GY; Griguer, CE; Landar, A; Markert, JM; McClugage, SG; Nozell, SE; Oliva, CR; Sarkaria, JN, 2010) |
| "From 2005 to 2009, 24 patients treated with Temozolomide for a low-grade glioma were included in the study (12 women who underwent a fertility preservation consultation and 12 women who did not)." | 3.76 | [Unknown gonadotoxicity chemotherapy and preservation of fertility: example of Temozolomide]. ( Lefebvre, G; Poirot, C; Prades, M; Sanson, M; Schubert, B; Sitbon Sitruk, L, 2010) |
| " We assessed the ability of 17-AAG to inhibit the growth of glioma cell lines and glioma stem cells both in vitro and in vivo and assessed its ability to synergize with radiation and/or temozolomide, the standard therapies for GBM." | 3.75 | Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. ( Barnes, J; Dellagatta, J; Kesari, S; Kieran, MW; Kung, AL; Ramakrishna, NR; Sauvageot, CM; Stiles, CD; Weatherbee, JL; Wen, PY; Winters, SE, 2009) |
| " Sensitivity of glioma cells to TMZ is dependent on the level of cellular O(6)-methylguanine-DNA methyltransferase (MGMT) repair activity." | 3.75 | The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity. ( Ancheta, K; Chtchetinin, J; Cloughesy, T; Lai, A; Nghiemphu, PL; Remington, M, 2009) |
| "Radiotherapy (RT) and concomitant/adjuvant therapy with temozolomide (Temodar) is a common treatment regimen for children and adults with glioma." | 3.75 | Bone marrow transplantation for severe aplastic anemia secondary to temozolomide. ( Broniscer, A; Ellison, D; Kasow, K; Morris, EB; Reiss, U, 2009) |
| " In this study, we used pharmacokinetic and pharmacodynamic approaches to investigate how sunitinib at different dose levels affects brain distribution of temozolomide (TMZ), and to ascertain the relationship between intratumoral TMZ concentrations and tumor vascularity in an orthotopic human glioma model." | 3.75 | Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. ( Gallo, JM; Zhou, Q, 2009) |
| "Seven patients (4 men; 3 women) ages 34-69 years (median 44), with gliomas (3 Grade 2; 4 Grade 3) were treated with surgery, all but one with involved-field radiotherapy and all with alkylator-based chemotherapy (temozolomide; 6 patients, nitrosoureas; 5 patients, both agents; 5 patients)." | 3.75 | Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia. ( Chamberlain, MC; Raizer, J, 2009) |
| "Temozolomide (TMZ) and carmustine (BCNU), cancer-drugs usually used in the treatment of gliomas, are DNA-methylating agents producing O6-methylguanine." | 3.75 | Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells. ( Cattaneo, E; Magrassi, L; Papait, R; Rigamonti, D, 2009) |
| "High grade gliomas are one of the most difficult cancers to treat and despite surgery, radiotherapy and temozolomide-based chemotherapy, the prognosis of glioma patients is poor." | 3.75 | Drugs targeting the mitochondrial pore act as cytotoxic and cytostatic agents in temozolomide-resistant glioma cells. ( Amoroso, R; Bartoli, B; Benvenuti, L; Gagliardi, R; Gremigni, V; Lena, A; Rechichi, M; Rossi, L; Salvetti, A; Scarcelli, V; Vecchio, D, 2009) |
| "Temozolomide (TMZ) is the standard of care for patients with newly diagnosed glioblastoma (GBM) as well as those with recurrent anaplastic glioma (AG) and GBM." | 3.75 | Rechallenge with temozolomide in patients with recurrent gliomas. ( Bogdahn, U; Hau, P; Jauch, T; Pascher, C; Weller, M; Wick, A; Wick, W, 2009) |
| "Temozolomide (TMZ) is an alkylating agent used in the management of gliomas." | 3.75 | Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? ( Bell, D; Khasraw, M; Wheeler, H, 2009) |
| "We have completed in vivo safety and efficacy studies of the use of a novel drug delivery system, a gel matrix-temozolomide formulation that is injected intracranially into the post-resection cavity, as a candidate for glioma therapy." | 3.75 | Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection. ( Akbar, U; Duntsch, C; Jones, T; Michael, M; Shukla, A; Sun, Y; Winestone, J, 2009) |
| "Temozolomide is considered the standard of care and drug of choice for the treatment of initially diagnosed malignant gliomas." | 3.75 | Glioma-associated endothelial cells are chemoresistant to temozolomide. ( Chen, TC; Golden, EB; Hofman, FM; Pen, L; Schönthal, AH; Sivakumar, W; Virrey, JJ; Wang, W, 2009) |
| "The effects of folate supplementations were analyzed on the global DNA methylation status, the methylation status of DNA repeat element, the sensitivity of temozolomide-induced apoptosis, and the proliferation index of glioma cells." | 3.75 | Folate supplementation limits the aggressiveness of glioma via the remethylation of DNA repeats element and genes governing apoptosis and proliferation. ( Campion, L; Cartron, PF; Charbord, J; Debien, E; Hervouet, E; Menanteau, J; Vallette, FM, 2009) |
| " On the other hand, temozolomide (TMZ), an oral bioavailable alkylating agent with excellent tolerability, has demonstrated efficacy and has become a key therapeutic agent in patients with malignant gliomas; however, its survival benefit remains unsatisfactory." | 3.75 | Effect of IFN-beta on human glioma cell lines with temozolomide resistance. ( Fukushima, T; Katayama, Y; Naruse, N; Ogino, A; Ohta, T; Okamoto, Y; Sano, E; Watanabe, T; Yachi, K; Yoshino, A, 2009) |
| "Previous studies have revealed that p38, a member of the family of stress-activated protein kinases (SAPKs), cooperates with the Chk1-pathway to bring about temozolomide (TMZ)-induced G2 arrest, and that the inhibition of either pathway alone is sufficient to sensitize U87MG glioma cells to TMZ-induced cytotoxicity." | 3.75 | Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells. ( Hirose, Y; Kawase, T; Ohba, S; Sano, H, 2009) |
| "Human malignant glioma cells U251-MG were cultured and assigned to four groups with different treatments for 3 days: temozolomide group (100 micromol/L), thalidomide group (100 microg/L), temozolomide (100 micromol/L) plus thalidomide group (100 microg/L) and control group." | 3.75 | Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro. ( Gao, S; Ji, YW; Pan, Q; Yang, XJ; Zhang, WG, 2009) |
| "Methionine depletion causes a demonstrable increase in glutathione levels for medulloblastoma (Daoy) and glioma (D54) cells, with a decrease in MGMT activity for Daoy cells." | 3.75 | Methionine restriction reduces the chemosensitivity of central nervous system tumour cell lines. ( Estlin, EJ; McGown, A; Najim, N; Podmore, ID, 2009) |
| " For example, Temozolomide (TMZ) exhibits some antitumor activity against brain tumors, so does Trastuzumab (Herceptin, Her-2 inhibitor), which might be effective against Her2 neu overexpressing gliomas." | 3.75 | Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model. ( Khaitan, D; Meister, EA; Ningaraj, NS; Sankpal, UT; Vats, TS, 2009) |
| "Our data suggest that temozolomide is an active regimen for malignant gliomas." | 3.74 | Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment. ( Akmansu, M; Benekli, M; Buyukberber, S; Coskun, U; Gunel, N; Kaya, AO; Ozkan, S; Ozturk, B; Uner, A; Yamac, D; Yaman, E; Yildiz, R, 2008) |
| "Although high AGT levels may mediate resistance in a portion of these samples, MMR deficiency does not seem to be responsible for mediating temozolomide resistance in adult malignant glioma." | 3.74 | Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. ( Ali-Osman, F; Bigner, DD; Friedman, AH; Friedman, HS; Horne, KS; Johnson, SP; Lister, DW; Maxwell, JA; McLendon, RE; Modrich, PL; Quinn, JA; Rasheed, A, 2008) |
| "Use of antiangiogenic therapy with radiation and temozolomide in the primary management of high-grade glioma is feasible." | 3.74 | Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. ( Eagan, P; Fischer, I; Golfinos, JG; Gruber, ML; Kelly, P; Knopp, EA; Medabalmi, P; Narayana, A; Parker, E; Raza, S; Zagzag, D, 2008) |
| " The siRNA-treated glioma cell lines GOS-3 and U87-MG were subjected to two chemotherapeutic agents; taxol and Temozolomide (TMZ)." | 3.74 | Silencing DNA methyltransferase (DNMT) enhances glioma chemosensitivity. ( Patel, R; Shervington, A, 2008) |
| " In this study, the authors investigate the nature of the SP phenotype in 2 glioma cell lines, U87MG and T98G, and their response to temozolomide." | 3.74 | Characterization of a side population of astrocytoma cells in response to temozolomide. ( Ang, BT; Chong, KH; Chua, C; See, SJ; Tang, C; Wong, MC; Zaiden, N, 2008) |
| " In this study, we explored whether novel delivery methods will represent new and effective ways to treat gliomas and if adjuvant therapy with the chemotherapeutic agent temozolomide would enhance the cytotoxic properties of TRAIL in glioma lines resistant to TRAIL monotherapy." | 3.74 | Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide. ( Classon, M; Hingtgen, S; Ren, X; Shah, K; Terwilliger, E; Weissleder, R, 2008) |
| "Human GBM-derived cell lines U87, G44, G112, and the gliosarcoma-derived line G28 were treated with EPO, with and without combinations of irradiation or temozolomide (TMZ)." | 3.74 | Erythropoietin augments survival of glioma cells after radiation and temozolomide. ( Ehrenreich, H; Giese, A; Hasselblatt, M; Hassouna, I; Jelkmann, W; Kim, E; Rave-Fränk, M; Schulz-Schaeffer, W; Sperling, S, 2008) |
| "In the 4-year retrospective study, 31 patients with histologically confirmed malignant gliomas, in which 10 patients received radiotherapy followed by temozolomide (group A) and 21 patients received radiotherapy alone (group B)." | 3.74 | Radiotherapy followed by adjuvant temozolomide treatment of malignant glioma. ( Chang, HW; Chang, WN; Ho, JT; Lin, WC; Lin, YJ; Lu, CH; Wang, HC; Yang, TM, 2008) |
| "Methylating drugs such as temozolomide (TMZ) are widely used in the treatment of brain tumours (malignant gliomas)." | 3.74 | Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. ( Batista, LF; Kaina, B; Menck, CF; Naumann, SC; Roos, WP; Weller, M; Wick, W, 2007) |
| "The purpose of the present study was to develop implantable poly(D,L-lactide-co-glycolide) (PLGA) microparticles for continuous delivery of intact 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide (temozolomide, TM) for about a 1-month period and to evaluate its cytotoxicity against Glioma C6 cancer cells." | 3.74 | Temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro. ( Gao, S; Zhang, H, 2007) |
| " Glioma cells underwent either irradiation or temozolomide treatment alone, or combined radio/chemo treatment." | 3.74 | Non-sufficient cell cycle control as possible clue for the resistance of human malignant glioma cells to clinically relevant treatment conditions. ( Breipohl, W; Golubnitschaja, O; Moenkemann, H; Schild, H; Schueller, H; Trog, D, 2007) |
| "DNA alkylating agents including temozolomide (TMZ) and 1,3-bis[2-chloroethyl]-1-nitroso-urea (BCNU) are the most common form of chemotherapy in the treatment of gliomas." | 3.74 | The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. ( Chen, CC; D'Andrea, A; Taniguchi, T, 2007) |
| "Dose-limiting adverse effects of thrombocytopenia and leukopenia prevent augmentation of current temozolomide (TMZ) dosing protocols; therefore, we hypothesized that the direct intracranial delivery of TMZ would lead to improved efficacy in an animal model of malignant glioma in an animal model." | 3.74 | Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. ( Brem, H; Brem, S; Caplan, J; Legnani, F; Li, K; Pradilla, G; Tyler, B, 2007) |
| "Case report of a 77-year-old woman with a radiation-induced, high-grade cerebellar glioma that responded durably to temozolomide." | 3.74 | Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide. ( Doherty, LM; Drappatz, J; Kesari, S; Monje, ML; Ramakrishna, NR; Wen, PY; Young, G, 2007) |
| "The aim of this study was to investigate the effect of temozolomide (TZM) in combination with X-rays on proliferation and migration in human glioma spheroids." | 3.74 | The inhibition of proliferation and migration of glioma spheroids exposed to temozolomide is less than additive if combined with irradiation. ( Fehlauer, F; Muench, M; Rades, D; Richter, E, 2007) |
| "To evaluate the natural progression and the impact of temozolomide in low-grade gliomas and to correlate these changes with the profile of genetic alterations." | 3.74 | Dynamic history of low-grade gliomas before and after temozolomide treatment. ( Amiel-Benouaich, A; Capelle, L; Carpentier, AF; Cornu, P; Delattre, JY; Duffau, H; Guillevin, R; Hoang-Xuan, K; Kaloshi, G; Kujas, M; Laigle-Donadey, F; Lejeune, J; Mandonnet, E; Marie, Y; Mokhtari, K; Omuro, A; Ricard, D; Sanson, M; Taillibert, S, 2007) |
| "To evaluate the predictive impact of chromosome 1p/19q deletions on the response and outcome of progressive low-grade gliomas (LGG) treated with up-front temozolomide (TMZ) chemotherapy." | 3.74 | Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. ( Benouaich-Amiel, A; Capelle, L; Carpentier, A; Cornu, P; Delattre, JY; Diakite, F; Duffau, H; Hoang-Xuan, K; Idbaih, A; Iraqi, W; Kaloshi, G; Laigle-Donadey, F; Lejeune, J; Mokhtari, K; Omuro, A; Paris, S; Polivka, M; Renard, MA; Sanson, M; Simon, JM; Taillibert, S, 2007) |
| "A novel alkylating agent, temozolomide, has proven efficacious in the treatment of malignant gliomas." | 3.74 | O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies. ( Akagi, T; Aoyanagi, E; Kaneko, S; Sasai, K; Tabu, K; Tanaka, S, 2007) |
| "Methylation of the O(6)-methyguanine-DNA methyltransferase (MGMT) gene promoter in gliomas has been reported to be a useful predictor of the responsiveness to temozolomide (TMZ)." | 3.74 | A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation. ( Fujii, M; Ishii, D; Ito, M; Maruta, H; Natsume, A; Shimato, S; Wakabayashi, T; Yoshida, J, 2008) |
| " In this study, as we determined p53 gene mutation occurring in multinucleated giant cell glioblastoma, we investigated the role of Aurora-B in formation of multinucleated cells in human neoplasm cells with various p53 statuses as well as cytotoxity of glioma cells to temozolomide (TMZ), a common oral alkylating agent used in the treatment of gliomas." | 3.74 | Inhibition of Aurora-B function increases formation of multinucleated cells in p53 gene deficient cells and enhances anti-tumor effect of temozolomide in human glioma cells. ( Fujita, M; Inagaki, M; Katsumata, S; Mizuno, M; Nakahara, N; Natsume, A; Osawa, H; Satoh, Y; Tsuno, T; Wakabayashi, T; Yoshida, J, 2007) |
| " The potential therapeutic value of MGMT hypermethylation evaluation using MS-MLPA was shown in a group of 20 glioblastoma patients receiving temozolomide chemotherapy." | 3.74 | MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. ( Boots-Sprenger, SH; Cornelissen, SJ; Dekkers, MM; Errami, A; Jeuken, JW; Sijben, A; Vriezen, M; Wesseling, P, 2007) |
| "Treatment of malignant glioma involves concomitant temozolomide and ionizing radiation (IR)." | 3.74 | Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy. ( Bickenbach, K; Galanopoulos, N; Pytel, P; Rawlani, V; Veerapong, J; Weichselbaum, RR; Yamini, B; Yu, X, 2007) |
| "Diffusion tensor imaging and multiple voxel magnetic resonance spectroscopy were performed in the MRI follow-up of a patient with a glioma treated with temozolomide chemotherapy." | 3.74 | Diffusion tensor imaging and chemical shift imaging assessment of heterogeneity in low grade glioma under temozolomide chemotherapy. ( Enting, RH; Heesters, MA; Irwan, R; Meiners, LC; Oudkerk, M; Potze, JH; Sijens, PE; van der Graaf, WT, 2007) |
| "Currently, the most efficacious treatment for malignant gliomas is temozolomide; however, gliomas expressing the DNA repair enzyme O(6)-methylguanine-DNA methyltransferase (MGMT) are resistant to this drug." | 3.74 | Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. ( Alonso, MM; Bekele, BN; Fueyo, J; Gomez-Manzano, C; Yung, WK, 2007) |
| "In mice bearing SF188V+ human glioma xenografts, measurements of temozolomide pharmacokinetic properties and sunitinib pharmacodynamic activities were evaluated, the latter including determinants for vascular normalization, including CD31, collagen IV, and alpha-SMA." | 3.74 | Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. ( Gallo, JM; Guo, P; Zhou, Q, 2008) |
| "The in vitro cytotoxicity of TRA-8 and temozolomide (Tmz) or RT was examined using adenosine triphosphate-dependent viability and clonogenic survival assays with five glioma cell lines." | 3.74 | Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5. ( Belenky, ML; Buchsbaum, DJ; Fiveash, JB; Gillespie, GY; Oliver, PG; Zhou, T, 2008) |
| "To evaluate the feasibility, safety and efficacy of daily temozolomide concurrent with postoperative radiotherapy in malignant glioma." | 3.73 | Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma. ( Eich, HT; Kocher, M; Kunze, S; Müller, RP; Semrau, R, 2005) |
| " This was of interest because E6 silencing of p53 sensitizes U87MG astrocytic glioma cells to BCNU and temozolomide (TMZ), cytotoxic drugs that are modestly helpful in the treatment of aggressive astrocytic gliomas." | 3.73 | Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide. ( Cairncross, JG; Mymryk, JS; Xu, GW, 2005) |
| "To describe the results of the treatment of recurrent glioma with temozolomide." | 3.73 | [Favourable result for temozolomide in recurrent high-grade glioma]. ( Enting, RH; Kros, JM; Sillevis Smitt, PA; Taal, W; van den Bent, MJ; van der Rijt, CD; van Heuvel, I, 2005) |
| "Children and young adults with recurrent or treatment-induced malignant gliomas have limited responses to temozolomide or oral VP-16 when either is administered as a single agent." | 3.73 | Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas. ( Bouffet, E; Foreman, N; Korones, DN; Smith, A, 2006) |
| "Alkylating agents, such as temozolomide, are among the most effective cytotoxic agents used for malignant gliomas, but responses remain very poor." | 3.73 | IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. ( Hatano, H; Ishii, D; Mizuno, M; Natsume, A; Tsuno, T; Wakabayashi, T; Yoshida, J, 2005) |
| "To develop a valid treatment strategy for recurrent high-grade gliomas using stereotactic hypofractionated reirradiation based on biologic imaging and temozolomide." | 3.73 | Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. ( Franz, M; Grosu, AL; Gumprecht, H; Molls, M; Nieder, C; Piert, M; Schwaiger, M; Stärk, S; Thamm, R; Weber, WA, 2005) |
| "The chemotherapeutic agent temozolomide (TMZ) and the anti-angiogenic agent thalidomide (THD) have both demonstrated anti-tumor activity in patients with recurrent malignant glioma." | 3.73 | Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model. ( Jeon, HJ; Kim, H; Kim, JH; Kim, JS; Kim, JT; Kim, MH; Kim, YJ; Lee, DS; Nam, DH; Park, SY; Shin, T; Son, MJ; Song, HS, 2006) |
| "The purpose of this study was to determine whether a combination treatment of temozolomide with celecoxib is effective in the rat orthotopic glioma model." | 3.73 | Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. ( Groves, MD; Kang, SG; Kim, JS; Nam, DH; Park, K, 2006) |
| "The authors investigated the safety of 75 mg/m2 temozolomide for 21 days every 28 days in glioma patients." | 3.73 | Is protracted low-dose temozolomide feasible in glioma patients? ( Blatt, V; Brandes, AA; Cavallo, G; Ermani, M; Franceschi, E; Gardiman, M; Ghimenton, C; Pasetto, L; Scopece, L; Tosoni, A, 2006) |
| "Previously we defined a pathway of transforming growth factor beta (TGF-beta) and stromal cell-derived factor-1/CXC chemokine ligand 12 (SDF-1alpha/CXCL12) dependent migration of adult haematopoietic stem and progenitor cells (HPC) towards glioma cells in vitro and their homing to experimental gliomas in vivo." | 3.73 | Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12. ( Frank, B; Möhle, R; Tabatabai, G; Weller, M; Wick, W, 2006) |
| "To re-evaluate the cost effectiveness and median overall survival (OS) achieved in patients with recurrent malignant gliomas treated with temozolomide in British Columbia, as compared to previous lomustine use in the same patient population based on updated outcomes data." | 3.73 | Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia. ( Mabasa, VH; Taylor, SC, 2006) |
| "Temozolomide (TMZ) is a DNA methylating agent that has shown promising antitumor activity against high grade glioma." | 3.73 | Potentiation of antiglioma effect with combined temozolomide and interferon-beta. ( Hong, YK; Joe, YA; Kim, TG; Park, JA, 2006) |
| "Temozolomide (TMZ)-induced O6-methylguanine (MG) DNA lesions, if not removed by MG-DNA methyltransferase (MGMT), mispair with thymine, trigger rounds of futile mismatch repair (MMR), and in glioma cells lead to prolonged G2-M arrest and ultimately cell death." | 3.72 | Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. ( Berger, MS; Erickson, LC; Hirose, Y; Kreklau, EL; Pieper, RO, 2003) |
| "To assess the activity and tolerability of temozolomide in children with progressive low-grade gliomas (LGGs)." | 3.72 | Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas. ( Finlay, JL; Knopp, EA; Kuo, DJ; Miller, DC; Weiner, HL; Wisoff, J, 2003) |
| "Temozolomide (TMZ, 3,4-dihydro-3-methyl-4-oxoimidazo [5,1-d]-as-tetrazine-8-carboxamide) is a new alkylating agent with promising antitumour efficacy for malignant gliomas." | 3.72 | Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. ( Germano, IM; Ito, H; Kanzawa, T; Kondo, S; Kondo, Y; Kyo, S, 2003) |
| "To assess whether the survival of patients with recurrent malignant glioma receiving temozolomide in everyday practice is comparable to that reported in previous studies." | 3.72 | Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study. ( Maltoni, S; Messori, A; Pelagotti, F; Trippoli, S; Vacca, F; Vaiani, M, 2003) |
| "Temozolomide (TMZ) is currently being evaluated for the treatment of high-grade gliomas in children." | 3.72 | A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas. ( Fouladi, M; Gajjar, AJ; Kirstein, MN; Nair, G; Panetta, JC; Stewart, CF, 2003) |
| " In this study, we present that temozolomide (TMZ), a new alkylating agent, inhibited the viability of malignant glioma cells in a dose-dependent manner and induced G2/M arrest." | 3.72 | Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. ( Germano, IM; Ito, H; Kanzawa, T; Komata, T; Kondo, S; Kondo, Y, 2004) |
| "The Chk1 and p38 mitogen-activated protein kinase (MAPK) pathways play key roles in the G2 arrest caused by exposing glioma cells to temozolomide (TMZ)." | 3.72 | Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide. ( Berger, MS; Hirose, Y; Katayama, M; Pieper, RO, 2004) |
| "Using a methylation-specific PCR approach, we assessed the methylation status of the CpG island of MGMT in 92 glioma patients who received temozolomide as first-line chemotherapy or as treatment for relapses." | 3.72 | CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. ( Aguirre-Cruz, L; Arribas, L; Balaña, C; Esteller, M; García-Lopez, JL; García-Villanueva, M; Paz, MF; Piquer, J; Pollan, M; Reynes, G; Rojas-Marcos, I; Safont, MJ; Sanchez-Cespedes, M; Yaya-Tur, R, 2004) |
| "Temozolomide, an imidazotetrazine prodrug has shown activity in phase II studies in patients with high-grade glioma at first recurrence." | 3.71 | Temozolomide as second-line chemotherapy for relapsed gliomas. ( Ashley, S; Brada, M; Dowe, A; Hines, F; Kong, A; Short, SC; Traish, D; Trent, S, 2002) |
| " BCNU, fotemustin, and temozolomide dramatically increased the time of survival of the Hs683 oligodendroglioma-bearing mice, whereas temozolomide only induced a weak but nevertheless statistically significant increase in the U373 glioma-bearing mice." | 3.71 | Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. ( Branle, F; Camby, I; Geurts-Moespot, A; Jeuken, J; Kiss, R; Lefranc, F; Salmon, I; Sprenger, S; Sweep, F, 2002) |
| "Temozolomide (TZM) is a novel methylating agent currently under investigation for treatment of recurrent high-grade gliomas." | 3.71 | Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. ( Graziani, G; Navarra, P; Portarena, I; Scerrati, M; Tentori, L; Torino, F, 2002) |
| "Temozolomide has an evolving role in the treatment of high grade gliomas." | 3.71 | An Australian experience with temozolomide for the treatment of recurrent high grade gliomas. ( Ashley, DL; Cher, L; Harris, MT; Rosenthal, MA, 2001) |
| " To determine whether forced cell-cycle progression selectively sensitizes tumor cells to alkylating agents, we examined the effects of overexpressing the E2F-1 protein (a positive regulator of cell-cycle progression) on the sensitivity of two malignant human glioma cell lines, U-251 MG and D-54 MG, to BCNU and temozolomide." | 3.71 | Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. ( Fueyo, J; Gomez-Manzano, C; Groves, MD; He, J; Hu, M; Lemoine, MG; Liu, TJ; Mitlianga, P; Yung, AW, 2001) |
| "Gene therapy for malignant glioma with the herpes simplex virus thymidine kinase/ganciclovir (HSV-tk/GCV) system is already in the stage of clinical trials, but still needs major improvement to achieve greater clinical efficacy." | 3.71 | Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma. ( Chou, TC; Droege, JW; Fels, C; Kramm, CM; Rainov, NG; Schäfer, C, 2001) |
| "Temozolomide (TMZ) is a newly approved alkylating agent for the treatment of malignant gliomas." | 3.71 | Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. ( Berman, E; Gallo, JM; Ma, J; Murphy, M; O'Dwyer, PJ; Reed, K, 2002) |
| "Forty patients with recurrent malignant gliomas had been treated with temozolomide (Temodal)." | 3.71 | [Treatment of recidive malignant gliomas with temozolomide]. ( Afra, D; Sipos, L; Vitanovics, D, 2002) |
| "Spectral analysis could distinguish tumour kinetics from normal tissue kinetics in an individual [11C]-temozolomide study and demonstrated a markedly greater volume of distribution (VD) in glioma than in normal brain, although there was no appreciable difference in mean residence time." | 3.70 | Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study. ( Brock, CS; Cunningham, VJ; Harte, RJ; Jones, T; Matthews, JC; Meikle, SR; Price, P; Wells, P, 1998) |
| "To investigate the effect of temozolomide, a 3-methyl derivative of mitozolomide in combination with X-rays in human glioma-derived cell lines." | 3.70 | Survival of human glioma cells treated with various combination of temozolomide and X-rays. ( Heimans, JJ; Slotman, BJ; van den Berg, J; van der Valk, P; van Rijn, J, 2000) |
| " Temozolomide is a novel methylating agent with proven efficacy against malignant gliomas (MGs) after systemic administration but with dose-limiting myelotoxicity." | 3.70 | Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. ( Archer, GE; Bigner, DD; Friedman, AH; Friedman, HS; Heimberger, AB; Hulette, C; McLendon, RE; Sampson, JH, 2000) |
| " Common nonocular treatment-emergent adverse events (TEAEs) with both second-line and first-line Depatux-M included lymphopenia (42%, 33%, respectively), thrombocytopenia (39%, 47%), alanine aminotransferase increase (29%, 47%), and aspartate aminotransferase increase (24%, 60%); incidence of grade ≥3 TEAEs was 66% and 53%, respectively." | 3.01 | Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial. ( Asai, K; Beppu, T; Date, I; Kagawa, N; Kanamori, M; Kasai, S; Kobayashi, H; Kumabe, T; Kuroda, J; Matsuda, M; Mishima, K; Muragaki, Y; Nagane, M; Narita, Y; Nishimura, Y; Ocampo, C; Ueki, K; Xiong, H; Yamada, M, 2021) |
| "Gliomas are the most common primary central nervous system tumors; despite recent advances in diagnosis and treatment, glioma patients generally have a poor prognosis." | 3.01 | Current and promising treatment strategies in glioma. ( Bebyn, M; Furtak, J; Koper, A; Koper, K; Śledzińska, P, 2023) |
| "Glioma is a deadly form of brain cancer, and the difficulty of treating glioma is exacerbated by the chemotherapeutic resistance developed in the tumor cells over the time of treatment." | 3.01 | Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells. ( Chung, S; Huang, J; Sugimoto, Y; Zhang, M, 2023) |
| "Glioma is a common type of brain tumor with high incidence and mortality rates." | 3.01 | TFR2 regulates ferroptosis and enhances temozolomide chemo-sensitization in gliomas. ( Cai, J; Chen, Q; Hong, Y; Sun, Q; Tian, D; Tong, S; Xu, Y; Ye, L; Ye, Z, 2023) |
| "Malignant primary brain tumors cause more than 15 000 deaths per year in the United States." | 3.01 | Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. ( Mellinghoff, IK; Schaff, LR, 2023) |
| "Temozolomide (TMZ) is a DNA alkylating agent that can cross the blood-brain barrier." | 3.01 | Expert opinion on translational research for advanced glioblastoma treatment. ( Cui, X; Kang, C; Wang, Q; Wang, Y; Zhou, J, 2023) |
| " Methods This is an open-label, 2-arm Phase 1b/2a study (N = 56) of galunisertib (intermittent dosing: 14 days on/14 days off per cycle of 28 days) in combination with TMZ/RTX (n = 40), versus a control arm (TMZ/RTX, n = 16)." | 2.94 | Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. ( Burkholder, T; Capper, D; Cleverly, AL; Desjardins, A; Estrem, ST; Forsyth, P; Guba, SC; Gueorguieva, I; Lahn, MM; Rodon, J; Suarez, C; Wang, S; Wick, A, 2020) |
| " In clinical practice, Chinese doctors often use radiotherapy combined with temozolomide (TMZ) to treat these patients, although large-scale prospective studies are lacking." | 2.90 | Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial. ( Guan, H; He, L; He, Y; Mu, X; Peng, X; Wang, J; Wang, Y, 2019) |
| " TMZ is an orally bioavailable prodrug, which is well absorbed from the gastrointestinal tract and is converted to its active alkylating metabolite 5-(3-methyl triazen-1-yl)imidazole-4-carbozamide (MTIC) spontaneously in physiological condition that does not require hepatic involvement." | 2.82 | Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems. ( Alyautdin, R; Chubarev, V; Grigorevskikh, E; Ismail, N; Merkulov, V; Petrenko, D; Smolyarchuk, E; Sologova, S; Syzrantsev, N, 2022) |
| "Temozolomide (TMZ) is an auxiliary alkylating agent that is extensively used in conjunction with surgical resection and forms the mainstay of clinical treatment strategies for gliomas." | 2.82 | Regulation of temozolomide resistance via lncRNAs: Clinical and biological properties of lncRNAs in gliomas (Review). ( Du, J; Li, S; Peng, C; Peng, F; Xie, X, 2022) |
| "Gliomas are the deadliest of all primary brain tumors, and they constitute a serious global health problem." | 2.82 | MicroRNA delivery systems in glioma therapy and perspectives: A systematic review. ( Abrahantes-Pérez, MDC; Barajas-Olmos, F; García-Ortiz, H; Hernández-Cuenca, YE; Jiménez-Morales, JM; Orozco, L; Quiñones-Hinojosa, A; Reyes-Abrahantes, A; Reyes-González, J; Ruiz-García, H, 2022) |
| "Gliomas are tumors of the primary central nervous system associated with poor prognosis and high mortality." | 2.82 | MicroRNAs, Key Regulators in Glioma Progression as Potential Therapeutic Targets for Chinese Medicine. ( Du, J; Fan, H; Kuang, X; Peng, F; Xie, X, 2022) |
| " Metronomic dosing of cytotoxic chemotherapy has emerged as a promising option to achieve this objective." | 2.82 | Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas. ( Alsop, DC; Callahan, A; Giarusso, B; O'Loughlin, L; Timmons, J; Wong, ET, 2016) |
| "Patients with newly diagnosed anaplastic astrocytoma (AA) or anaplastic oligo-astrocytoma (AOA) were treated with concurrent radiotherapy (60 Gy over 6 weeks) and temozolomide (75 mg/m(2)), and six adjuvant 28-day cycles of either dose-dense (150 mg/m(2), days 1-7, 15-21) or metronomic (50 mg/m(2), days 1-28) temozolomide." | 2.80 | Radiotherapy and temozolomide for anaplastic astrocytic gliomas. ( Abrey, LE; Braunthal, SG; DeAngelis, LM; Huse, JT; Lassman, AB; Nayak, L; Panageas, KS; Pentsova, E; Reiner, AS, 2015) |
| "The primary objective of this augmental, prospective, uncontrolled phase II multicentre trial was to assess adverse events (AE) associated with malignant glioma resection using 5-aminolevulinic (5-ALA)." | 2.76 | Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA. ( Kern, BC; Krex, D; Mehdorn, HM; Nestler, U; Pichlmeier, U; Stockhammer, F; Stummer, W; Vince, GH, 2011) |
| "Temozolomide was administered at a dose of 150 mg/m(2) daily for five days for the first 28-day cycle and escalated to 200 mg/m(2), during subsequent cycles." | 2.76 | A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. ( Coan, AD; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Peters, KB; Reardon, DA; Threatt, S; Vredenburgh, JJ, 2011) |
| " Metronomic dosing of temozolomide (TMZ) combined with standard radiotherapy may improve survival by increasing the therapeutic index and anti-angiogenic effect of TMZ." | 2.75 | A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma. ( Bartels, U; Baruchel, S; Bouffet, E; Eisenstat, D; Gammon, J; Huang, A; Hukin, J; Johnston, DL; Samson, Y; Sharp, JR; Stempak, D; Stephens, D; Tabori, U, 2010) |
| " CB related adverse events occurring in more than one patient were fatigue, gait disturbance, nystagmus, and confusion." | 2.73 | Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. ( Asher, AL; Chang, SM; Croteau, D; Grahn, AY; Husain, SR; Kunwar, S; Lang, FF; Parker, K; Puri, RK; Sampson, JH; Shaffrey, M; Sherman, JW; Vogelbaum, MA, 2007) |
| "Perillyl alcohol has shown to have both chemopreventive and chemotherapeutic activities in preclinical studies." | 2.73 | Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. ( da Fonseca, CO; Fischer, J; Futuro, D; Gattass, CR; Nagel, J; Quirico-Santos, T; Schwartsmann, G, 2008) |
| "Gliomas are the most common central nervous system tumors." | 2.72 | Prognostic and Predictive Biomarkers in Gliomas. ( Bebyn, MG; Furtak, J; Kowalewski, J; Lewandowska, MA; Śledzińska, P, 2021) |
| "Temozolomide is a well-tolerated agent that results in objective responses and stabilisation of disease." | 2.72 | Phase II study of two-weekly temozolomide in patients with high-grade gliomas. ( Ashley, D; Cher, L; Dowling, A; Jennens, R; Rosenthal, MA; Wong, S; Woods, AM, 2006) |
| "We conducted a study to determine the dose-limiting toxicity of an extended dosing schedule of temozolomide (TMZ) when used with a fixed dose of BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine), taking advantage of TMZ's ability to deplete O6-alkylguanine-DNA-alkyltransferase and the synergistic activity of these two agents." | 2.71 | Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. ( Abrey, LE; Kleber, M; Malkin, MG; Raizer, JJ, 2004) |
| "Temozolomide is a novel second-generation oral alkylating agent with demonstrated efficacy and safety in patients with recurrent glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA)." | 2.70 | A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. ( Friedman, HS; Gilbert, MR; Kuttesch, JF; Olson, JJ; Prados, MD; Reaman, GH; Zaknoen, SL, 2002) |
| " The absolute bioavailability of TMZ was 0." | 2.69 | Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. ( Bauer, J; Biollaz, J; Buclin, T; Decosterd, LA; Gander, M; Lejeune, F; Leyvraz, S; Marzolini, C; Shen, F, 1998) |
| "Fotemustine 100 mg/m2 was given intravenously on day 2, 4 hours after TMZ." | 2.69 | Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. ( Belanich, M; Biollaz, J; Bonfanti, M; Colella, G; D'Incalci, M; Decosterd, L; Gander, M; Lejeune, F; Leyvraz, S; Liénard, D; Marzolini, C; Perey, L; Shen, F; Yarosh, D, 1999) |
| " Temozolomide demonstrated linear and reproducible pharmacokinetics and was rapidly absorbed (mean Tmax approximately 1 h) and eliminated (mean t1/2 = 1." | 2.69 | Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. ( Batra, V; Beale, P; Brada, M; Cutler, D; Dugan, M; Judson, I; Moore, S; Reidenberg, P; Statkevich, P, 1999) |
| "Temozolomide was initially studied intravenously at doses between 50-200 mg m-2 and subsequently was given orally up to 1,200 mg m-2." | 2.67 | Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). ( Blackledge, GR; Brampton, MH; Hoffman, R; Newlands, ES; Quarterman, CP; Rustin, GJ; Slack, JA; Smith, DB; Stevens, MF; Stuart, NS, 1992) |
| "Temozolomide (TMZ) is an antiangiogenic agent." | 2.58 | Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas. ( Guillevin, R; Lecarpentier, Y; Vallée, A; Vallée, JN, 2018) |
| "Glioma is the most common primary cancer of the central nervous system, and around 50% of patients present with the most aggressive form of the disease, glioblastoma." | 2.58 | Current state of immunotherapy for glioblastoma. ( Bettegowda, C; Lim, M; Weller, M; Xia, Y, 2018) |
| "Temozolomide may cause thrombocytopenia or neutropenia in 3-4% of glioblastoma patients, respectively." | 2.55 | MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case. ( Altinoz, MA; Bolukbasi, FH; Ekmekci, CG; Elmaci, I; Sari, R; Sav, A; Yenmis, G, 2017) |
| "889 with respect to OS, while BEV in combination with TMZ - with a probability of 0." | 2.53 | A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT). ( Ding, L; Gao, L; Lv, P; Qi, L; Wang, S; Wang, W; Xu, Y; Zhao, D; Zhong, Y, 2016) |
| "Temozolomide (TMZ) is an oral alkylating agent with established effects on the central nervous system of glioblastoma (GBM) patients." | 2.52 | Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens?: a meta-analysis. ( Du, S; Liao, G; Ren, C; Sun, H; Xie, X; Yuan, YW, 2015) |
| "Gliomas are the most frequent primary brain tumors." | 2.50 | [Management of gliomas]. ( Chapet, S; Lévy, S; Mazeron, JJ, 2014) |
| "Gliomas are the most frequent primary brain tumors in adults." | 2.49 | High-grade glioma in elderly patients: can the oncogeriatrician help? ( Chinot, O; Crétel, E; Retornaz, F; Rousseau, F; Tabouret, E; Tassy, L, 2013) |
| "Angiocentric gliomas have recently been reclassified as a separate central nervous system tumor." | 2.48 | Imaging characteristics of an unusual, high-grade angiocentric glioma: a case report and review of the literature. ( Aguilar, HN; Hung, RW; Kotylak, T; Mehta, V, 2012) |
| "Temozolomide (TMZ) is a DNA-alkylating agent used for the treatment of glioma, astrocytoma, and melanoma." | 2.47 | A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy. ( Jiang, G; Liu, YQ; Pei, DS; Wei, ZP; Xin, Y; Zheng, JN, 2011) |
| "Temozolomide (TMZ) is an oral alkylating agent with activity in high and LGG." | 2.47 | Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity. ( Athanasiou, T; Lashkari, HP; Moreno, L; Saso, S; Zacharoulis, S, 2011) |
| "Temozolomide is a second-generation alkylating chemotherapeutic agent, introduced to therapy of primary brain tumors in the 1990s." | 2.46 | Temozolomide: Expanding its role in brain cancer. ( Adair, J; Kiem, HP; Mrugala, MM, 2010) |
| "Temozolomide is an oral alkylating cytotoxic agent of second generation, used in the treatment of high-grade gliomas." | 2.45 | [Prescription guidebook for temozolomide usage in brain tumors]. ( Borget, I; Brignone, M; Cartalat-Carel, S; Chinot, O; Hassani, Y; Taillandier, L; Taillibert, S; Tilleul, P, 2009) |
| "Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug." | 2.45 | Temozolomide in malignant gliomas: current use and future targets. ( Bressler, LR; Seery, TE; Villano, JL, 2009) |
| "Glioma is a highly invasive, rapidly spreading form of brain cancer that is resistant to surgical and medical treatment." | 2.44 | Potential biochemical therapy of glioma cancer. ( Fan, XJ; Fu, YJ; Liang, AH; Liu, ZL; Xu, CG; Xu, QL; Yang, J; Yin, LT, 2007) |
| "Temozolomide has proven benefit in grade II/III gliomas progressive following standard therapy and when added to radiation for glioblastoma." | 2.44 | Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation. ( Schiff, D, 2007) |
| "High-grade glioma is a devastating disease that leaves the majority of its victims dead within 2 years." | 2.44 | Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. ( Kleinberg, LR; Lin, SH, 2008) |
| "Additionally, there is evidence that treatment-related necrosis occurs more frequently and earlier after temozolomide chemotherapy than after radiotherapy alone." | 2.44 | Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. ( Brandsma, D; Sminia, P; Stalpers, L; Taal, W; van den Bent, MJ, 2008) |
| "Temozolomide (TMZ) is a promising new drug that seems to be effective in patients with recurrent disease." | 2.43 | Adjuvant chemotherapy in the treatment of high grade gliomas. ( Brandes, AA; Lonardi, S; Tosoni, A, 2005) |
| "Temozolomide (TMZ) is an alkylating agent that was approved for anaplastic astrocytoma and glioblastoma." | 2.43 | Optimal role of temozolomide in the treatment of malignant gliomas. ( Hegi, ME; Stupp, R; van den Bent, MJ, 2005) |
| "Irinotecan is a water-soluble derivative of camptothecin, an alkylator originally extracted from the Chinese tree Camptotheca acuminata." | 2.42 | The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. ( Friedman, HS; Houghton, PJ; Keir, ST, 2003) |
| "Temozolomide has activity and a favorable safety profile in all dosing schedules tested." | 2.42 | Temozolomide: realizing the promise and potential. ( Dolan, ME; Nagasubramanian, R, 2003) |
| "Temozolomide is an imidazotetrazine with a mechanism of action and efficacy similar to dacarbazine (DTIC)." | 2.41 | Temozolomide: a novel oral alkylating agent. ( Danson, SJ; Middleton, MR, 2001) |
| " The drug is well tolerated with dose limiting myelosuppression and thrombocytopenia occurring in less than 10% of patients at current dosage schedules." | 2.41 | The use of temozolomide in recurrent malignant gliomas. ( Gaya, A; Greenstein, A; Rees, J; Stebbing, J, 2002) |
| "Temozolomide is a novel, oral, second-generation alkylating agent." | 2.41 | Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. ( Friedman, HS, 2000) |
| "Temozolomide, a new drug, has shown promise in treating malignant gliomas and other difficult-to-treat tumors." | 2.41 | Temozolomide and treatment of malignant glioma. ( Calvert, H; Friedman, HS; Kerby, T, 2000) |
| " For patients with recurrent malignant glioma, temozolomide provides a therapeutic option with a predictable safety profile, clinical efficacy, and convenient dosing that can provide important quality-of-life benefits." | 2.41 | Temozolomide for recurrent high-grade glioma. ( Macdonald, DR, 2001) |
| "Moreover, the efficacy of the treatment of glioma cells with temozolomide (TMZ) and Gli1 inhibitor GANT61 was higher than that of TMZ alone." | 1.91 | Differential role of Pax6 and its interaction with Shh-Gli1-IDH2 axis in regulation of glioma growth and chemoresistance. ( Ahmed, SP; Ali, A; Arif, SH; Chosdol, K; Farheen, S; Hoda, MF; Kausar, T; Mariyath P M, M; Nayeem, SM; Shahi, MH, 2023) |
| "Gliomas are one of the most common primary malignant tumors of the central nervous system, and have an unfavorable prognosis." | 1.91 | Role of COL6A2 in malignant progression and temozolomide resistance of glioma. ( Hong, X; Ouyang, J; Peng, X; Wang, P; Xiao, B; Zhang, J; Zou, J, 2023) |
| "Glioma is an extremely aggressive primary brain tumor, which is highly resistant to chemotherapy, presenting a therapeutic challenge." | 1.91 | Induction of apoptosis in glioma cells by lycorine via reactive oxygen species generation and regulation of NF-κB pathways. ( Ding, L; Huo, M; Su, J; Yao, Q; Yin, W, 2023) |
| "High-grade gliomas (HGG) are aggressive brain tumors associated with short median patient survival and limited response to therapies, driving the need to develop tools to improve patient outcomes." | 1.91 | The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors. ( Brochu-Gaudreau, K; Charbonneau, M; Dubois, CM; Fortin, D; Harper, K; Lucien, F; Perreault, A; Roy, LO; Tian, S, 2023) |
| "Givinostat is a pan-histone deacetylase (HDAC) inhibitor that has demonstrated excellent tolerability as well as efficacy in patients with polycythemia vera." | 1.91 | Givinostat Inhibition of Sp1-dependent MGMT Expression Sensitizes Glioma Stem Cells to Temozolomide. ( Kitanaka, C; Mitobe, Y; Nakagawa-Saito, Y; Okada, M; Sugai, A; Suzuki, S; Togashi, K, 2023) |
| "Temozolomide (TMZ) has been used as an initial therapy for gliomas." | 1.91 | LncRNA GSCAR promotes glioma stem cell maintenance via stabilizing SOX2 expression. ( Chen, M; Chen, Y; Jiang, X; Jin, Z; Li, Y; Liu, B; Pu, J; Shi, Y; Yan, D; Yang, C; Yuan, Y; Zhai, H; Zhang, C; Zhang, Y, 2023) |
| "Temozolomide has been mainly used for the treatment of malignant gliomas over a decade." | 1.91 | [Medical Treatments for Malignant Brain Tumor]. ( Kitamura, Y; Toda, M, 2023) |
| "Temozolomide (TMZ) is a standard chemotherapeutic for GBM, but TMZ treatment benefits are compromised by chemoresistance." | 1.91 | Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance. ( Cui, X; Kang, C; Liu, X; Tong, F; Wang, G; Wang, Q; Wang, Y; Zhao, J; Zhou, J, 2023) |
| "Diffuse gliomas are a heterogeneous category of primary central nervous system tumors." | 1.91 | Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences. ( Baird, L; Beadling, C; Corless, C; Harrington, CA; Moore, S; Neff, T; Wood, MD, 2023) |
| "Gliomas are the most prevalent primary tumor in the central nervous system, with an abysmal 5-year survival rate and alarming mortality." | 1.91 | Drug metabolism-related gene ABCA1 augments temozolomide chemoresistance and immune infiltration abundance of M2 macrophages in glioma. ( Liang, Q; Liu, Y; Xu, Z; Yan, Y, 2023) |
| "The incidence of gliomas is increasing." | 1.72 | CCL2 activates AKT signaling to promote glycolysis and chemoresistance in glioma cells. ( Ding, P; Lu, B; Nie, X; Qian, Y; Xu, J, 2022) |
| "Since high grade gliomas are aggressive brain tumors, intensive search for new treatment options is ongoing." | 1.72 | Tumor treating fields therapy is feasible and safe in a 3-year-old patient with diffuse midline glioma H3K27M - a case report. ( Dohmen, H; Gött, H; Kiez, S; Kolodziej, M; Stein, M, 2022) |
| "Glioma is the most common and malignant brain tumor with poor prognosis." | 1.72 | LINC01564 Promotes the TMZ Resistance of Glioma Cells by Upregulating NFE2L2 Expression to Inhibit Ferroptosis. ( Li, X; Luo, C; Nie, C; Qian, K; Wang, X; Zeng, Y, 2022) |
| "Glioma is one of the main causes of cancer-related mortality worldwide and is associated with high heterogeneity." | 1.72 | Tryptophan hydroxylase 1 drives glioma progression by modulating the serotonin/L1CAM/NF-κB signaling pathway. ( Gao, X; Guo, Z; Xie, Q; Yang, Q; Zhang, J; Zhong, C, 2022) |
| "Temozolomide (TMZ) is a widely used chemotherapeutic drug for glioma." | 1.72 | FOXM1-mediated NUF2 expression confers temozolomide resistance to human glioma cells by regulating autophagy via the PI3K/AKT/mTOR signaling pathway. ( Guo, L; Wu, Z, 2022) |
| "Gliomas are the most common primary intracranial tumors and closely related to circadian clock." | 1.72 | Circadian Clock Genes Act as Diagnostic and Prognostic Biomarkers of Glioma: Clinic Implications for Chronotherapy. ( Chai, R; Huang, W; Li, N; Liang, Y; Liao, M; Ou, L; Tang, Q; Wang, S; Wang, X; Zheng, K, 2022) |
| "Gliomas are the most common type of primary brain tumors, with high recurrence rate and mortality." | 1.72 | ZNF300 enhances temozolomide resistance in gliomas by regulating lncRNA SNHG12. ( Fu, J; Peng, J; Tu, G, 2022) |
| "Glioblastoma is the most common brain tumor." | 1.72 | ( Balkanov, AS; Belyaev, AY; Glazkov, AA; Kobyakov, GL; Rozanov, ID; Shmakov, PN; Strunina, YV; Telysheva, EN; Usachev, DY, 2022) |
| "Glioma is a fatal tumor originating from the brain, which accounts for most intracranial malignancies." | 1.72 | SLC11A1 as a stratification indicator for immunotherapy or chemotherapy in patients with glioma. ( Fang, C; Liu, Y; Lou, M; Shao, A; Wang, W; Wang, X; Xu, H; Xu, Y; Yuan, L; Zhang, A; Zhang, Z; Zhu, Q, 2022) |
| "Glioma is a common type of malignant and aggressive tumor in the brain." | 1.72 | Elevated GIGYF2 expression suppresses tumor migration and enhances sensitivity to temozolomide in malignant glioma. ( Chen, M; Feng, W; Li, J; Li, M; Li, T; Liu, Y; Xia, X; Yang, W; Yuan, Q; Zhang, S; Zhou, X; Zuo, M, 2022) |
| "Glioma is the most common and malignant primary brain tumour in adults and has a dismal prognosis." | 1.62 | Accurately Controlled Delivery of Temozolomide by Biocompatible UiO-66-NH ( Chen, H; Gu, J; Jiang, J; Li, C; Li, Y; Luo, C; Qian, J; Wan, Z; Wang, J; Zhu, J, 2021) |
| "Glioma is the most common primary intracranial tumor." | 1.62 | FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide. ( Huang, L; Jiang, T; Li, G; Liu, Y; Zhao, Z; Zhou, K, 2021) |
| "Temozolomide (TMZ) is a DNA alkylating agent and is currently a first line chemotherapeutic treatment for GBM." | 1.62 | Inhibition of Nrf2 might enhance the anti-tumor effect of temozolomide in glioma cells via inhibition of Ras/Raf/MEK signaling pathway. ( Lu, Z; Sun, W; Yu, J; Zhang, W, 2021) |
| "Temozolomide (TMZ) has been used to treat glioma." | 1.62 | Circ-VPS18 Knockdown Enhances TMZ Sensitivity and Inhibits Glioma Progression by MiR-370/RUNX1 Axis. ( Jia, X; Li, W; Liu, Q; Ma, Q; Wang, X; Yan, P, 2021) |
| "Lower grade mIDH1 gliomas are classified into 2 molecular subgroups: 1p/19q codeletion/TERT-promoter mutations or inactivating mutations in α-thalassemia/mental retardation syndrome X-linked (ATRX) and TP53." | 1.62 | Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice. ( Alghamri, MS; Appelman, H; Carney, SV; Castro, MG; Edwards, MB; Garcia-Fabiani, MB; Gauss, JC; Haase, S; Kadiyala, P; Kleer, CG; Li, D; Liu, Y; Lowenstein, PR; Moon, JJ; Núñez, FJ; Nunez, FM; Schwendeman, A; Sun, Y; Taher, A; Yu, M; Zhao, L, 2021) |
| "Temozolomide (TMZ) has been widely used as a first-line treatment for GBM." | 1.62 | Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting. ( Li, N; Li, Y; Lv, Y; Sha, C; Sun, K; Tang, S; Wang, A; Wang, L; Yan, X; Yu, Y, 2021) |
| "Canine glioma is a common brain tumor with poor prognosis despite surgery and/or radiation therapy." | 1.62 | The NRG3/ERBB4 signaling cascade as a novel therapeutic target for canine glioma. ( Akiyoshi, H; Ichikawa, T; Inoue, M; Kamishina, H; Kurozumi, K; Matsumoto, Y; Nakamoto, Y; Noguchi, S, 2021) |
| "Temozolomide (TMZ) is an effective chemotherapy drug for glioblastoma, but the resistance to TMZ has come to represent a major clinical problem, and its underlying mechanism has yet to be elucidated." | 1.62 | Exosomal connexin 43 regulates the resistance of glioma cells to temozolomide. ( Bi, QC; Gan, LJ; Han, XJ; Hong, T; Jiang, LP; Lan, XM; Liu, LH; Tan, RJ; Wei, MJ; Yang, ZJ; Zhang, LL, 2021) |
| "Differentiating treatment necrosis from tumor recurrence poses a diagnostic conundrum for many clinicians in neuro-oncology." | 1.62 | Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas. ( Cui, Y; Gao, F; Jiang, H; Li, M; Lin, S; Ren, X; Zhao, W, 2021) |
| "Temozolomide (TMZ) is an alkylating agent widely used for glioma treatment." | 1.62 | miR-23b-5p promotes the chemosensitivity of temozolomide via negatively regulating TLR4 in glioma. ( Cui, B; Gao, K; Qiao, Y; Wang, T, 2021) |
| "Glioma is the most common malignant tumor of the brain in adult patients." | 1.62 | Molecular Characterization of AEBP1 at Transcriptional Level in Glioma. ( Huang, R; Sun, S; Tong, X; Wang, K; Wang, Z; Wu, C, 2021) |
| "Perampanel (PER) is a noncompetitive α-amino-3-hydroxy-5-methyl-4-isoaxazolepropionate acid receptor antagonist that has recently been approved for treating focal epilepsy as a secondary drug of choice." | 1.56 | Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy. ( Chonan, M; Kanamori, M; Nakasato, N; Osawa, SI; Saito, R; Suzuki, H; Tominaga, T; Watanabe, M, 2020) |
| " Because the free drug cannot pass the blood-brain barrier (BBB), we investigated the use of nanocarriers for transport of the drug through the BBB and its efficacy when combined with radiotherapy and temozolomide (TMZ) in glioma spheroids." | 1.56 | Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma. ( Becerril Aragon, G; Bikhezar, F; de Kruijff, RM; de Vries, HE; Denkova, AG; Gasol Garcia, A; Narayan, RS; Slotman, BJ; Sminia, P; Torrelo Villa, G; van der Meer, AJGM; van der Pol, SMA, 2020) |
| " These results form part of the basis for the translation of the therapy to patients with GBM but the dosing and timing of delivery will have to be explored in depth both experimentally and clinically." | 1.56 | Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas. ( Darabi, A; Enríquez Pérez, J; Kopecky, J; Siesjö, P; Visse, E, 2020) |
| "We identified the preoperative seizure frequency threshold by plotting a receiver operating characteristic curve." | 1.56 | Short-term outcomes and predictors of post-surgical seizures in patients with supratentorial low-grade gliomas. ( Chen, Q; Deng, G; Gao, L; Jiang, H; Liu, B; Tan, Y; Wang, J; Yang, K; Yuan, F, 2020) |
| "The prognosis of glioma is generally poor and is the cause of primary malignancy in the brain." | 1.56 | MicroRNA-155-3p promotes glioma progression and temozolomide resistance by targeting Six1. ( Chen, G; Chen, Z; Zhao, H, 2020) |
| "Glioma is a common cancer that affects people worldwide with high morbidity and mortality." | 1.56 | miR-149 rs2292832 C allele enhances the cytotoxic effect of temozolomide against glioma cells. ( Guo, J; Ling, G; Liu, Q; Luo, J; Luo, X; Ning, X; Xu, B, 2020) |
| "In adults, glioma is the most commonly occurring and invasive brain tumour." | 1.56 | CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells. ( Cao, Y; Kong, S; Li, X; Qi, Y; Shang, S, 2020) |
| "Temozolomide is a conventional chemotherapy drug for adjuvant treatment of patients with high-risk gliomas, including grade II to grade IV." | 1.56 | Blockade of Cell Volume Regulatory Protein NKCC1 Increases TMZ-Induced Glioma Apoptosis and Reduces Astrogliosis. ( Amankulor, NM; Begum, G; Castro, MG; Ding, D; Dodelson, J; Fiesler, VM; Gayden, J; Guan, X; Hasan, MN; Hu, B; Jia, W; Kohanbash, G; Luo, L; Sun, B; Sun, D, 2020) |
| "The standard-of-care treatments for gliomas include surgical resection, radiation, and temozolomide administration; however, they have been ineffective in providing significant increases in median survival." | 1.56 | Synthetic High-density Lipoprotein Nanodiscs for Personalized Immunotherapy Against Gliomas. ( Aikins, M; Castro, MG; Hassani Najafabadi, A; Kadiyala, P; Lowenstein, PR; Moon, JJ; Scheetz, L; Schwendeman, A; Son, S; Sun, X, 2020) |
| "Osthole was the most effective." | 1.56 | Coumarins modulate the anti-glioma properties of temozolomide. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Maciejczyk, A; Rzeski, W; Skalicka-Woźniak, K; Sumorek-Wiadro, J; Wertel, I; Zając, A, 2020) |
| " Side effects associated with chemotherapy delays or modifications included thrombocytopenia (28%) and nausea/vomiting (19%), with temozolomide dosing most frequently modified." | 1.56 | Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience. ( Browd, SR; Cole, BL; Crotty, EE; Ellenbogen, RG; Ermoian, RP; Geyer, JR; Hauptman, JS; Leary, SES; Lee, A; Lockwood, CM; Millard, NE; Ojemann, JG; Olson, JM; Paulson, VA; Sato, AA; Vitanza, NA, 2020) |
| "Gliomas are intrinsic brain tumours, which are classified by the World Health Organization (WHO) into different grades of malignancy, with glioblastoma being the most frequent and most malignant subtype (WHO grade IV)." | 1.56 | A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults. ( Hofer, S; Hottinger, AF; Hundsberger, T; Läubli, H; Mamot, C; Pesce, G; Reinert, M; Roelcke, U; Roth, P; Schucht, P; Weller, M, 2020) |
| "Glioma is the most aggressive primary malignant brain tumor." | 1.56 | Injectable postoperative enzyme-responsive hydrogels for reversing temozolomide resistance and reducing local recurrence after glioma operation. ( Han, Y; Jia, J; Liu, H; Lu, Y; Shen, J; Wang, L; Xu, H; Yu, R; Zhang, L; Zhao, Z, 2020) |
| "Temozolomide (TMZ) is an alkylating chemotherapy agent used in the clinical treatment of glioblastoma multiforme (GBM) patients." | 1.56 | Piperine synergistically enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines. ( Jeong, S; Jung, S; Oh, JW; Park, GS; Shin, J, 2020) |
| "Temozolomide chemotherapy was an independent index to prolong overall survival in high ABCC8 mRNA expression glioma patients, whereas in patients with low expression, there was no significant difference." | 1.56 | ABCC8 mRNA expression is an independent prognostic factor for glioma and can predict chemosensitivity. ( Chai, R; Huang, L; Jiang, T; Li, G; Liu, Y; Wang, Y; Zhao, Z; Zhou, K, 2020) |
| "Glioma is one of the most aggressive forms of brain tumor and is hallmarked by high rate of mortality, metastasis and drug resistance." | 1.56 | Downregulation of hsa_circ_0000936 sensitizes resistant glioma cells to temozolomide by sponging miR-1294. ( Feng, H; Hua, L; Huang, L; Zhang, X, 2020) |
| "Glioma is the most malignant tumour of the human brain still lacking effective treatment modalities." | 1.56 | Synthetic Betulin Derivatives Inhibit Growth of Glioma Cells ( Bębenek, E; Boryczka, S; Dmoszyńska-Graniczka, M; Król, SK; Stepulak, A; Sławińska-Brych, A, 2020) |
| "Cell invasion and metastasis were measured by cell invasion assays." | 1.56 | Relationship between CYP17A1-Mediated DNA Demethylation and Proliferation, Invasion and Metastasis of Glioma Cells. ( Lv, W; Meng, L; Zhou, Y, 2020) |
| "Glioma is one of the most lethal malignancies and molecular regulators driving gliomagenesis are incompletely understood." | 1.51 | DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide. ( Dai, X; He, Q; Shao, Y; Tan, B; Wang, J; Weng, Q; Yang, B; Zhao, M, 2019) |
| "Glioma is the most common malignant tumor of the central nervous system (CNS)." | 1.51 | Blood-Brain Barrier- and Blood-Brain Tumor Barrier-Penetrating Peptide-Derived Targeted Therapeutics for Glioma and Malignant Tumor Brain Metastases. ( Chen, L; Chen, PR; Gao, Y; Li, C; Lin, J; Xu, N; Zeng, D; Zhang, W; Zhu, X, 2019) |
| "Glioma is the most common neoplasm of the central nervous system, with the highest mortality rate." | 1.51 | Iguratimod encapsulated PLGA-NPs improves therapeutic outcome in glioma, glioma stem-like cells and temozolomide resistant glioma cells. ( Faming, W; Hang, S; Hongyan, Z; Liudi, Y; Mengmeng, T; Younis, M, 2019) |
| "Temozolomide (TMZ) is a first-line alkylating agent for glioblastoma multiforme (GBM)." | 1.51 | IGF-1-enhanced miR-513a-5p signaling desensitizes glioma cells to temozolomide by targeting the NEDD4L-inhibited Wnt/β-catenin pathway. ( Chen, KC; Chen, PH; Cheng, CH; Chou, CM; Ho, KH; Lee, CC; Shih, CM, 2019) |
| "Diffuse low-grade gliomas (DLGG) are brain tumors of young adults." | 1.51 | Data-Driven Predictive Models of Diffuse Low-Grade Gliomas Under Chemotherapy. ( Abdallah, MB; Blonski, M; Darlix, A; de Champfleur, NM; Duffau, H; Gaudeau, Y; Moureaux, JM; Taillandier, L; Wantz-Mezieres, S, 2019) |
| "Malignant gliomas are aggressive primary neoplasms that originate in the glial cells of the brain or the spine with notable resistance to standard treatment options." | 1.51 | Resveratrol restores sensitivity of glioma cells to temozolamide through inhibiting the activation of Wnt signaling pathway. ( Bu, XY; Gao, YS; Han, SY; Hu, S; Qu, MQ; Wang, BQ; Wang, JY; Yan, ZY; Yang, B; Yang, HC, 2019) |
| "Malignant glioma is a lethal brain tumor with a low survival rate and poor prognosis." | 1.51 | Carnosic acid potentiates the anticancer effect of temozolomide by inducing apoptosis and autophagy in glioma. ( Lan, Q; Mao, J; Shao, N; Wang, R; Xue, L; Zhi, F, 2019) |
| "our data underline re-RT as a safe and feasible treatment with limited rate of toxicity, and a combined ones as a better option for selected patients." | 1.51 | Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO). ( Alongi, F; Amelio, D; Borzillo, V; Ciammella, P; Clerici, E; di Monale, MB; Draghini, L; Fariselli, L; Ferrarese, F; Fiorentino, A; Galaverni, M; Krengli, M; Livi, L; Magrini, S; Maranzano, E; Masini, L; Minniti, G; Muto, P; Navarria, P; Pasqualetti, F; Pinzi, V; Scartoni, D; Scoccianti, S; Scorsetti, M; Tomatis, S, 2019) |
| "Glioma is the most common brain malignancy." | 1.51 | Local delivery of temozolomide via a biologically inert carrier (Temodex) prolongs survival in glioma patients, irrespectively of the methylation status of MGMT. ( Fedulov, A; Karlsson, I; Lokot, I; Pejler, G; Veevnik, D; Yurkshtovich, N; Yurkshtovich, T, 2019) |
| " The procedure was well-tolerated, with no adverse clinical or radiologic events related to the procedure." | 1.51 | Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study. ( Alkins, R; Bethune, A; Heyn, C; Huang, Y; Hynynen, K; Ironside, S; Lipsman, N; Mainprize, T; Meng, Y; Perry, J; Sahgal, A; Trudeau, M, 2019) |
| "Glioma is a primary intracranial malignant tumor with poor prognosis." | 1.51 | Development of transferrin-modified poly(lactic-co-glycolic acid) nanoparticles for glioma therapy. ( Liu, G; Mao, J; Meng, X; Yang, Y; Zhao, C, 2019) |
| "Gliomas are incurable solid tumors with extremely high relapse rate and definite mortality." | 1.51 | Roscovitine effectively enhances antitumor activity of temozolomide in vitro and in vivo mediated by increased autophagy and Caspase-3 dependent apoptosis. ( Babu, PP; Narne, P; Pandey, V; Ranjan, N, 2019) |
| "Glioma is a common brain tumor with a high mortality rate." | 1.51 | Mild thermotherapy and hyperbaric oxygen enhance sensitivity of TMZ/PSi nanoparticles via decreasing the stemness in glioma. ( Bai, X; Hu, M; Jia, L; Li, Y; Tan, X; Wang, Q; Yang, X; Zeng, X; Zhang, Z; Zhu, Y, 2019) |
| " The purpose of our study was to explore if PDT combined with TMZ can effectively inhibit glioma cells by influencing NHE1 in vitro." | 1.51 | Photodynamic therapy combined with temozolomide inhibits C6 glioma migration and invasion and promotes mitochondrial-associated apoptosis by inhibiting sodium-hydrogen exchanger isoform 1. ( Chen, L; Chi, D; Cong, D; Gao, S; Hu, S; Ji, H; Jia, Y; Jin, J; Liang, B; Zhou, P, 2019) |
| "The therapeutic treatment of glioblastoma multiforme (GBM) remains a major challenge." | 1.51 | Angiopep-2 Modified Cationic Lipid-Poly-Lactic-Co-Glycolic Acid Delivery Temozolomide and DNA Repair Inhibitor Dbait to Achieve Synergetic Chemo-Radiotherapy Against Glioma. ( Hua, L; Li, S; Liang, J; Liu, H; Xu, Q; Ye, C; Yu, R; Zhao, L, 2019) |
| "Glioma is the most common type of primary brain tumor and has an undesirable prognosis." | 1.48 | β-asarone inhibited cell growth and promoted autophagy via P53/Bcl-2/Bclin-1 and P53/AMPK/mTOR pathways in Human Glioma U251 cells. ( Fang, Y; Luo, L; Ning, B; Wang, N; Zhang, Q, 2018) |
| "Radiochemotherapy involving cisplatinum-based polychemotherapy is more toxic than radiotherapy in combination with temozolomide." | 1.48 | Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients. ( Bison, B; Bojko, S; Gielen, GH; Hoffmann, M; Kortmann, RD; Kramm, CM; Pietsch, T; Seidel, C; von Bueren, AO; Warmuth-Metz, M, 2018) |
| "Temozolomide (TMZ) has been considered to be one of the most effective chemotherapeutic agents to prolong the survival of patients with glioblastoma." | 1.48 | Differential Characterization of Temozolomide-Resistant Human Glioma Cells. ( Chen, CC; Huang, BR; Lai, SW; Lin, C; Lin, HY; Liu, YS; Lu, DY; Tsai, CF, 2018) |
| "Oligodendrogliomas are therapy-responsive tumors, which have better prognosis compared to their astrocytic counterparts." | 1.48 | Chemotherapy of Oligodendrogliomas. ( Drappatz, J; Lieberman, F, 2018) |
| "Glioma is the most common intracranial malignant tumors, accounting for about 40% of intracranial tumors." | 1.48 | MiR-634 sensitizes glioma cells to temozolomide by targeting CYR61 through Raf-ERK signaling pathway. ( Jiang, Y; Tan, Z; Zhao, J, 2018) |
| "Temozolomide (TMZ) is a standard chemotherapeutic drug used in the treatment of glioblastoma multiforme (GBM); however, resistance to this drug is common." | 1.48 | Association between SOX9 and CA9 in glioma, and its effects on chemosensitivity to TMZ. ( Cheng, Y; Jin, W; Liu, H; Liu, N; Tu, Y; Wang, X; Wang, Z; Xu, X; Yang, H; Zhang, P; Zhang, Y, 2018) |
| "Gliomas are a lethal class of brain cancer, with a median survival below 15 months in spite of therapeutic advances." | 1.48 | TRIM14 promotes chemoresistance in gliomas by activating Wnt/β-catenin signaling via stabilizing Dvl2. ( Cao, L; Li, J; Song, J; Song, L; Tan, Z; Wu, G; Wu, W; Zhang, W; Zhou, Y; Zhu, J, 2018) |
| " Our results demonstrate benefit of ddTMZ after previous treatment with standard TMZ dosing with no apparent increase in treatment-related toxicities." | 1.48 | Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study. ( Garcia, CR; Gruber, L; Kumar, SS; Lightner, DD; Morgan, RM; Slone, SA; Villano, JL, 2018) |
| "Glioma is the most common and lethal primary brain tumor." | 1.48 | Cell Subpopulations Overexpressing p75NTR Have Tumor-initiating Properties in the C6 Glioma Cell Line. ( Chen, MF; Cheng, CY; Wang, TC; Yang, WH, 2018) |
| "Highly malignant gliomas are characterized by pronounced intra‑ and intertumoral heterogeneity." | 1.48 | APOBEC3B is expressed in human glioma, and influences cell proliferation and temozolomide resistance. ( Hattermann, K; Held-Feindt, J; Lucius, R; Schmitt, C; Synowitz, M, 2018) |
| "Human glioma is the most common type of primary brain tumor." | 1.48 | Downregulation of miR-196b Promotes Glioma Cell Sensitivity to Temozolomide Chemotherapy and Radiotherapy. ( Liu, J; Lv, H; Ma, R; Shao, C; Zhang, G; Zheng, G, 2018) |
| " ATOR showed similar cytotoxic effect as TMZ to glioma cells, and it may be a safer drug, regarding side effect induction, than chemotherapic agents." | 1.48 | Atorvastatin Promotes Cytotoxicity and Reduces Migration and Proliferation of Human A172 Glioma Cells. ( Dal-Cim, T; Lopes, FG; Ludka, FK; Nedel, CB; Oliveira, KA; Tasca, CI, 2018) |
| "Glioma is the most common primary brain tumor and has an undesirable prognosis due to the blood-brain barrier (BBB) and drug resistance." | 1.46 | β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1. ( Fang, Y; Luo, L; Ning, B; Wang, N; Zhang, Q, 2017) |
| "Gliomas are the most common and primary tumors of the central nervous system in adults." | 1.46 | Temozolomide increases MHC-I expression via NF-κB signaling in glioma stem cells. ( Guan, Y; Qiu, B; Wang, Y; Wu, A; Zhang, D; Zhang, L, 2017) |
| "Chlorpromazine is a United States Food and Drug Administration-approved phenothiazine widely used as a psychotropic in clinical practice." | 1.46 | Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit. ( Griguer, CE; Langford, C; Oliva, CR; Suto, MJ; Zhang, W, 2017) |
| "Guanosine (GUO) is an endogenous nucleoside involved in extracellular signaling that presents neuroprotective effects and also shows the effect of inducing differentiation in cancer cells." | 1.46 | Guanosine promotes cytotoxicity via adenosine receptors and induces apoptosis in temozolomide-treated A172 glioma cells. ( Dal-Cim, TA; Lopes, FG; Nedel, CB; Oliveira, KA; Tasca, CI, 2017) |
| "Temozolomide (TMZ) is an effective drug for malignant glioma, however, the intracellular and molecular mechanisms behind this anti-cancer effect have yet to be fully understood." | 1.46 | Down-Regulation of AQP4 Expression via p38 MAPK Signaling in Temozolomide-Induced Glioma Cells Growth Inhibition and Invasion Impairment. ( Chen, Y; Gao, F; Hou, J; Jiang, R; Kang, L; Li, Y; Liu, H; Liu, X; Yang, M; Yi, Y, 2017) |
| "Although the treatments of malignant glioma include surgery, radiotherapy and chemotherapy by oral drug administration, the prognosis of patients with glioma remains very poor." | 1.46 | Thermoresponsive nanocomposite gel for local drug delivery to suppress the growth of glioma by inducing autophagy. ( Chen, J; Ding, L; Duan, Y; Huang, C; Li, R; Shen, M; Sun, Y; Wang, Q; Zhang, X, 2017) |
| "Temozolomide (TMZ) was used for clinical postoperative or non-surgical chemotherapy patients." | 1.46 | Combination of sonodynamic with temozolomide inhibits C6 glioma migration and promotes mitochondrial pathway apoptosis via suppressing NHE-1 expression. ( Chen, L; Cong, D; Hu, S; Li, Q; Li, Y; Wang, D, 2017) |
| "The current treatment of glioblastoma multiforme (GBM) is limited by the restricted arsenal of agents which effectively cross the blood brain barrier (BBB)." | 1.46 | The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts. ( Adhikari, B; Akers, J; Brandel, MG; Carter, BS; Chen, CC; Deming, T; Futalan, D; Li, J, 2017) |
| "Malignant gliomas are a group of aggressive neoplasms among human cancers." | 1.46 | Hyperthermia with different temperatures inhibits proliferation and promotes apoptosis through the EGFR/STAT3 pathway in C6 rat glioma cells. ( An, TT; Chen, YD; Dong, TX; Liu, PF; Xu, YT; Yang, XH; Zhang, W; Zhang, Y, 2017) |
| "Among 350 glioma and ganglioglioma cases, the MGMT promoter tested positive for methylation in 53." | 1.46 | Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas. ( Chen, L; Hu, Z; Li, Z; Liu, C; Liu, L; Lu, D; Teng, L; Wang, L; Zhao, L, 2017) |
| "6 μg/day) with negligible leakage into the peripheral blood (<100 ng) rendering ~1000 fold differential drug dosage in tumor versus peripheral blood." | 1.46 | Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma. ( Ashokan, A; Gowd, GS; Junnuthula, VR; Koyakutty, M; Nair, SV; Panikar, D; Peethambaran, R; Ramachandran, R; Thomas, A; Thomas, J; Unni, AK, 2017) |
| "Glioma is the most frequent primary central nervous system tumor." | 1.46 | β-Elemene Selectively Inhibits the Proliferation of Glioma Stem-Like Cells Through the Downregulation of Notch1. ( Chen, FR; Chen, ZP; Feng, HB; Guo, CC; Jiang, HR; Mei, X; Qu, Y; Sai, K; Wang, J; Yang, QY; Zhang, ZP; Zhao, YY, 2017) |
| " In conclusion, this work reports at least four compounds (5b, 5e, 5g and 6e) with potential anti-tumor effect against glioblastoma multiform cell presenting activity at low concentrations and safe profile of cytotoxicity." | 1.43 | Thiazolidin-4-ones from 4-(methylthio)benzaldehyde and 4-(methylsulfonyl)benzaldehyde: Synthesis, antiglioma activity and cytotoxicity. ( Azambuja, JH; Braganhol, E; Cunico, W; da Silva, CEH; da Silva, DS; de Carvalho, TR; Frizzo, CP; Soares, MSP; Spanevello, RM; Zimmer, GC, 2016) |
| "Orthotopic xenograft model of human brain cancer cells is a good preclinical model for evaluation of antitumor compounds." | 1.43 | [Establishment of a glioma orthotopic xenograft model based on imaging technology]. ( Chen, XG; Ji, M; Lai, FF; Lü, YH; Wang, LY, 2016) |
| "Glioma is a common malignant brain tumor originating in the central nervous system." | 1.43 | Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery. ( Fan, Y; Lv, S; Wu, M; Xiao, B; Ye, M; Zhu, X, 2016) |
| "Primary brain tumors are hallmarked for their destructive activity on the microenvironment and vasculature." | 1.43 | A versatile ex vivo technique for assaying tumor angiogenesis and microglia in the brain. ( Buchfelder, M; Eyüpoglu, IY; Fan, Z; Ghoochani, A; Hock, S; Savaskan, NE; Sehm, T; Yakubov, E, 2016) |
| "Malignant gliomas are among the most frequent and aggressive cerebral tumors, characterized by high proliferative and invasive indexes." | 1.43 | KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment. ( Catalano, M; Chece, G; D'Alessandro, G; Di Angelantonio, S; Esposito, V; Grimaldi, A; Limatola, C; Mainiero, F; Porzia, A; Ragozzino, D; Salvati, M; Santoro, A; Wulff, H, 2016) |
| "Dysembryoplastic neuroepithelial tumors (DNETs) are low-grade neuroglial tumors that are traditionally considered to be benign hamartoma-like mass lesions." | 1.43 | Radiologic response to radiation therapy concurrent with temozolomide for progressive simple dysembryoplastic neuroepithelial tumor. ( Fenstermaker, RA; Mechtler, LL; Morr, S; Prasad, D; Qiu, J, 2016) |
| "Gliomas are the most common primary intracranial malignant tumors in adults." | 1.43 | Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients. ( Cai, J; Han, B; Jiang, C; Lin, L; Meng, X; Ming, J; Sun, B; Wang, G, 2016) |
| "Glioma is still difficult to treat because of its high malignancy, high recurrence rate, and high resistance to anticancer drugs." | 1.43 | 3D bioprinted glioma stem cells for brain tumor model and applications of drug susceptibility. ( Dai, X; Lan, Q; Ma, C; Xu, T, 2016) |
| "Gliomas are the most common primary brain tumors in adults and invariably carry a poor prognosis." | 1.43 | Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement. ( Blondin, N; Chaudhry, A; Connelly, J; Hormigo, A; Hu, J; Mohilie, N, 2016) |
| "Temozolomide (TMZ) is an alkylating agent used for the treatment of aggressive forms of brain tumor based on its antitumor actions." | 1.43 | Temozolomide inhibits cellular growth and motility via targeting ERK signaling in glioma C6 cells. ( Gao, S; Liang, J; Wang, W; Wang, Y, 2016) |
| "Diffuse low-grade gliomas are rare primitive cerebral tumours of adults." | 1.43 | Predictive models for diffuse low-grade glioma patients under chemotherapy. ( Ben Abdallah, M; Blonski, M; Gaudeau, Y; Moureaux, JM; Taillandier, L; Wantz-Mezieres, S, 2016) |
| "Seizures are a common symptom in patients with low-grade glioma (LGG), negatively influencing quality of life, if uncontrolled." | 1.42 | Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide. ( Dirven, L; Heimans, JJ; Koekkoek, JA; Postma, TJ; Reijneveld, JC; Taphoorn, MJ; Vos, MJ, 2015) |
| "Malignant glioma is a common and lethal primary brain tumor in adults." | 1.42 | VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells. ( Chen, H; Chen, J; Chen, Y; Fan, J; Hu, L; Huai, C; Lu, D; Meng, D; Qin, R; Song, X; Sun, R; Wang, D; Wang, H; Wang, J; Wang, S; Xu, T; Yang, J; Yang, S; Yun, D; Zhang, X; Zhao, Y, 2015) |
| "Gliomas are the most malignant and aggressive primary brain tumor in adults." | 1.42 | Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation. ( Chen, J; Cui, D; Ni, L; Shi, J; Shi, W; Sun, B; Zuo, H, 2015) |
| "These results suggest that Liq treatment enhances glioma cell susceptibility to TMZ by inhibiting the PI3K/AKT/mTOR pathway." | 1.42 | Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway. ( Chen, J; Jing, L; Li, L; Li, S; Ling, Q; Liu, X; Wang, H; Wang, L; Xia, M; Yang, S, 2015) |
| "Glioma is resistant to the apoptotic effects of chemotherapy and the mechanism underlying its chemoresistance is not currently understood." | 1.42 | Downregulation of osteopontin enhances the sensitivity of glioma U251 cells to temozolomide and cisplatin by targeting the NF-κB/Bcl‑2 pathway. ( Li, P; Liu, H; Qian, C; Shi, L; Wang, Y; Yan, W; You, Y; Zhang, J, 2015) |
| "Glioma is the most common malignant and fatal primary tumor in the central nervous system in adults." | 1.42 | MiR-203 sensitizes glioma cells to temozolomide and inhibits glioma cell invasion by targeting E2F3. ( Huo, L; Tang, G; Wu, J; Xiao, G, 2015) |
| "Temozolomide (TMZ) is an oral alkylating chemotherapeutic agent that prolongs the survival of patients with glioblastoma (GBM)." | 1.42 | A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells. ( Barciszewska, AM; Gurda, D; Głodowicz, P; Naskręt-Barciszewska, MZ; Nowak, S, 2015) |
| "Glioma is one of the most common primary tumors of the central nervous system in adults." | 1.42 | Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells. ( Chen, FR; Chen, YS; Chen, ZP; Guo, CC; Panasci, L; Qiu, ZK; Sai, K; Shen, D; Wang, J; Yang, QY, 2015) |
| "Gliomas are the most common primary brain tumors." | 1.42 | Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study. ( Berger, FR; Boccard, SG; Geraci, S; Marand, SV; Pelletier, LA; Pycroft, L, 2015) |
| " This preclinical study sought to test the efficacy of the food additive Triacetin (glyceryl triacetate, GTA) as a novel therapy to increase acetate bioavailability in glioma cells." | 1.40 | Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma. ( Davies, MT; Driscoll, HE; Jaworski, DM; Lawler, SE; Long, PM; Penar, PL; Pendlebury, WW; Spees, JL; Teasdale, BA; Tsen, AR; Viapiano, MS, 2014) |
| " We report five patients who received long-term treatment with TMZ chemotherapy at normal dosing levels." | 1.40 | Long-term treatment with temozolomide in malignant glioma. ( Defrates, SR; Lightner, DD; Mannas, JP; Pittman, T; Villano, JL, 2014) |
| "Temozolomide (TMZ) is a first-line chemotherapeutic agent but the efficacy is limited by intrinsic and acquired resistance in GBM." | 1.40 | Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-κB signaling in glioma initiating cells. ( Chen, YS; Chen, ZP; Guan, S; Guo, CC; Li, WP; Li, WY; Mou, YG; Sai, K; Wang, J; Yang, QY, 2014) |
| "Diffuse gliomas were mainly located in the pons and frequently showed MRI contrast enhancement." | 1.40 | Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients. ( Brügge, D; Hottinger, A; Hundsberger, T; Putora, PM; Roelcke, U; Stupp, R; Tonder, M; Weller, M, 2014) |
| "Temozolomide (TMZ) is an alkylating agent used for the treatment of glioblastoma multiforme (GBM), the main form of human brain tumours in adults." | 1.40 | Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma. ( Gratas, C; Oliver, L; Rabé, M; Séry, Q; Vallette, FM, 2014) |
| "Glioma is one of the most aggressive and lethal human brain tumors." | 1.40 | MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras. ( Chen, Q; Jiang, BH; Jiang, C; Jiang, T; Kang, C; Li, C; Li, H; Liu, LZ; Liu, N; Liu, X; Qian, X; Shi, Z; Wang, L; Wang, X; You, Y, 2014) |
| "Diffuse brainstem glioma is a rare disease in adults." | 1.40 | Temozolomide after radiotherapy in recurrent "low grade" diffuse brainstem glioma in adults. ( Delattre, JY; Laigle-Donadey, F; Martin-Duverneuil, N; Mokhtari, K; Reyes-Botero, G, 2014) |
| "Malignant glioma is a severe type of brain tumor with a poor prognosis and few options for therapy." | 1.40 | Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo. ( Belizário, JE; de Andrade-Lima, LC; Garcia, CC; Menck, CF; Munford, V; Quinet, A; Rocha, CR; Vieira, DB, 2014) |
| "Glioblastoma are highly aggressive brain tumors with poor prognosis." | 1.40 | Suppressor of fused (Sufu) represses Gli1 transcription and nuclear accumulation, inhibits glioma cell proliferation, invasion and vasculogenic mimicry, improving glioma chemo-sensitivity and prognosis. ( Cai, J; Chang, L; Chen, L; Cui, Y; Dou, Z; Du, W; Jiang, C; Liu, X; Liu, Y; Wang, G; Wang, H; Wang, X; Yi, L; Zhang, P, 2014) |
| "Quinolinic acid is a product of tryptophan degradation and may serve as a precursor for NAD(+), an important enzymatic cofactor for enzymes such as the DNA repair protein PARP." | 1.39 | The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress. ( Adams, S; Ahrendt, T; Bode, HB; Guillemin, GJ; Oezen, I; Opitz, CA; Platten, M; Radlwimmer, B; Sahm, F; von Deimling, A; Wick, W, 2013) |
| "C6 rat gliomas were incubated with low-dose TMZ to induce chemoresistance." | 1.39 | Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas. ( Baden, A; Doi, Y; Kanagawa, M; Mizoi, K; Oka, S; Ono, T; Sasajima, T; Shimada, N, 2013) |
| "Previously, it has been shown that treatment of glioma cells with temozolomide (TMZ) and radiation (XRT) induces the expression of metalloproteinase 14 (MMP14)." | 1.39 | Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas. ( Auffinger, B; Baryshnikov, AY; Borovjagin, A; Dey, M; Guo, D; Han, Y; Kim, CK; Lesniak, MS; Pytel, P; Sarvaiya, P; Thaci, B; Ulasov, I; Yi, R; Zhang, L, 2013) |
| "Aspirin microsphere treatment induced slight apoptosis and modestly inhibited proliferation of LN229 and U87 cells in vitro and in vivo through inhibition of β-catenin transactivation." | 1.39 | Aspirin-/TMZ-coloaded microspheres exert synergistic antiglioma efficacy via inhibition of β-catenin transactivation. ( Chen, LY; Han, L; Kang, CS; Liu, CY; Pu, PY; Qian, XM; Shi, ZD; Yuan, XB; Zhang, JX; Zhang, KL, 2013) |
| "Angiocentric glioma is a recently recognized benign brain tumor with unknown histogenesis." | 1.39 | Malignant glioma with angiocentric features. ( Lu, JQ; Mehta, V; Patel, S; Pugh, J; Wilson, BA, 2013) |
| "More effective drugs for brain cancer and brain metastasis can be screened and can be identified with this technology." | 1.39 | Subcellular real-time imaging of the efficacy of temozolomide on cancer cells in the brain of live mice. ( Bouvet, M; Chishima, T; Endo, I; Hoffman, RM; Momiyama, M; Suetsugu, A, 2013) |
| " These data reassuringly suggest that BEV does not significantly change the ECF tumor concentrations of TMZ in either tumor-bearing or normal brain when dosed 36 h prior to TMZ." | 1.38 | The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas. ( Blakeley, JO; Brastianos, H; Brem, H; Grossman, R; Rudek, MA; Tyler, B; Zadnik, P, 2012) |
| "Temozolomide was administered to three patients at initial diagnosis and five patients at recurrence after failing prior radiotherapy." | 1.38 | Temozolomide or bevacizumab for spinal cord high-grade gliomas. ( Gavrilovic, IT; Kaley, TJ; Mondesire-Crump, I, 2012) |
| " Dose-response and cellular growth assays indicate that erlotinib reduces cell proliferation in all tested cell lines without inducing cytotoxic effects." | 1.38 | EGFR inhibition in glioma cells modulates Rho signaling to inhibit cell motility and invasion and cooperates with temozolomide to reduce cell growth. ( Fernández de Mattos, S; Ramis, G; Rodríguez, J; Thomàs-Moyà, E; Villalonga, P, 2012) |
| "All patients had seizure disorders that were treated with anticonvulsants." | 1.37 | Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. ( Moldovan, K; Pouratian, N; Schiff, D; Shaffrey, ME; Sherman, JH; Starke, RM; Yeoh, HK, 2011) |
| "Malignant gliomas are highly lethal tumors resistant to current therapies." | 1.37 | Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. ( Barnes, JW; Chaponis, D; Dellagatta, JL; Fast, E; Greene, ER; Kesari, S; Kieran, MW; Kung, AL; Panagrahy, D; Ramakrishna, N; Sauvageot, C; Stiles, C; Wen, PY, 2011) |
| "The long-term TMZ-treated astroglioma cells, but not the Hs683 oligodendroglioma cells, developed in vivo a certain level of resistance to TMZ, which correlated with the up- regulation of CXCL2, CXCL3 and CXCL8 expression in the U373 and T98G astroglioma cells." | 1.37 | Temozolomide-induced modification of the CXC chemokine network in experimental gliomas. ( Berger, W; Bruyère, C; Kast, RE; Kiss, R; Lefranc, F; Lonez, C; Mijatovic, T; Ruysschaert, JM; Spiegl-Kreinecker, S, 2011) |
| "Cediranib is a highly potent receptor tyrosine kinase inhibitor that inhibits all three VEGF receptors." | 1.37 | Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic. ( Andersen, B; Dicker, AP; Lawrence, RY; Liu, Y; Wachsberger, PR; Xia, X, 2011) |
| " The aim of the present study was to evaluate the efficacy and side effects of nimotuzumab in combination with chemotherapy for patients with malignant gliomas." | 1.37 | [Nimotuzumab in combination with chemotherapy for patients with malignant gliomas]. ( Chen, ZP; Jiang, XB; Mu, YG; Sai, K; Shen, D; Yang, QY; Zhang, XH, 2011) |
| "Temozolomide (TMZ), is a new alkylating agent with promising antitumour efficacy for malignant gliomas, and the effect of TMZ on GSCs invasion has not been known." | 1.37 | Temozolomide decreases invasion of glioma stem cells by down-regulating TGF-β2. ( Jing, Z; Qiu, B; Wang, Y; Wu, A; Zhang, D, 2011) |
| "Malignant glioma is an invasive disease of the central nervous system." | 1.37 | Down-regulation of EGFR prolonged cell growth of glioma but did not increase the sensitivity to temozolomide. ( Fujioka, K; Ikeda, K; Inaba, N; Inoue, Y; Ishizawa, S; Kimura, M; Manome, Y; Saito, H, 2011) |
| " The growing body of evidence demonstrating the clinical importance of O6-methylguanine methyltransferase (MGMT) has generated a considerable interest in the exploration of strategies to overcome MGMT-mediated resistance to alkylating agents; for example protracted administration of Temozolomide (TMZ) may result in more extensive and sustained depletion of MGMT; for this reason a variety of dosing schedules that increase the duration of exposure and the cumulative dose of TMZ are being investigated for the treatment of patient with recurrent malignant glioma after standard treatment." | 1.37 | Rechallenge with temozolomide in recurrent glioma. ( Botturi, A; Fariselli, L; Ferrari, D; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A; Simonetti, G, 2011) |
| "Concurrent treatment of the glioma cell line U87-MG with siRNA 1 and temozolomide (TMZ) resulted in a 13-fold reduction in the dose of TMZ required to achieve a similar effect if TMZ was used alone." | 1.36 | Can hsp90alpha-targeted siRNA combined with TMZ be a future therapy for glioma? ( Cruickshanks, N; Munje, C; Patel, R; Shervington, A; Shervington, L; Thakkar, D, 2010) |
| "Temozolomide (TMZ) is a recently introduced alkylating agent that has yielded significant benefits and become a key agent in the treatment of high-grade gliomas." | 1.36 | Gene expression profiling predicts response to temozolomide in malignant gliomas. ( Fukushima, T; Katayama, Y; Naruse, N; Ogino, A; Ohta, T; Okamoto, Y; Sano, E; Tsumoto, K; Watanabe, T; Yachi, K; Yoshino, A, 2010) |
| "High-grade gliomas are among the most lethal of all cancers." | 1.36 | Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas. ( Binello, E; Emdad, L; Germano, IM; Qadeer, ZA; Uzzaman, M, 2010) |
| "Glioma was strongly associated with high sCD14 [highest versus lowest quartile odds ratio (OR), 3." | 1.36 | Circulating levels of the innate and humoral immune regulators CD14 and CD23 are associated with adult glioma. ( Bracci, PM; McCoy, LS; Patoka, JS; Rice, T; Sison, JD; Wiemels, JL; Wiencke, JK; Wrensch, MR; Zhou, M, 2010) |
| " The system analysis technique, embodied in the convolution integral, generated an impulse response function that, when convolved with temozolomide plasma concentration input functions, yielded predicted normal brain and brain tumor temozolomide concentration profiles for different temozolomide dosing regimens (75-200 mg/m(2)/d)." | 1.35 | A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. ( Aboagye, EO; Brock, CS; Gallo, JM; Price, PM; Rosso, L; Saleem, A; Turkheimer, FE, 2009) |
| " Dasatinib in combination with temozolomide more effectively increased the therapeutic efficacy of temozolomide than when dasatinib was combined with carboplatin or irinotecan." | 1.35 | Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. ( de Groot, J; LaFortune, T; Milano, V; Piao, Y, 2009) |
| "Treatment of malignant gliomas has changed substantially over the last few years." | 1.35 | Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma. ( Benekli, M; Buyukberber, N; Buyukberber, S; Coskun, O; Coskun, U; Kaya, AO; Ozturk, B; Yaman, E; Yildiz, R, 2009) |
| "Cilengitide is a cyclic peptide antagonist of integrins alphavbeta3 and alphavbeta5 that is currently being evaluated as a novel therapeutic agent for recurrent and newly diagnosed glioblastoma." | 1.35 | Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. ( Adams, B; Maurer, GD; Stupp, R; Tabatabai, G; Tritschler, I; Weller, M; Wick, W, 2009) |
| "Temozolomide, the standard treatment of gliomas, although not an ABCG2 substrate, increases the SP in glioma cells, especially in cells missing PTEN." | 1.35 | PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. ( Bleau, AM; Brennan, CW; Fomchenko, EI; Hambardzumyan, D; Holland, EC; Huse, JT; Ozawa, T, 2009) |
| " Thus, our results show that polymeric nanocapsules are able to increase the intratumoral bioavailability of indomethacin and reduce the growth of implanted gliomas." | 1.35 | Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. ( Battastini, AM; Bernardi, A; Braganhol, E; Edelweiss, MI; Figueiró, F; Guterres, SS; Jäger, E; Pohlmann, AR, 2009) |
| " The effect of ZD6474, a potent inhibitor of VEGF-receptor-2, was evaluated in combination with either radiotherapy or temozolomide." | 1.35 | Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model. ( Bergenheim, AT; Bergström, P; Henriksson, R; Johansson, M; Sandström, M, 2008) |
| "Temozolomide has become the standard of care in newly diagnosed glioblastoma." | 1.35 | [Chemotherapy for brain tumors in adult patients]. ( Weller, M, 2008) |
| "Gliomas are the most common primary brain tumor in adults, but the efficacy of chemotherapy is limited." | 1.35 | Dihydroartemisinin potentiates the cytotoxic effect of temozolomide in rat C6 glioma cells. ( Fang, SH; Huang, XJ; Li, CT; Lu, YB; Wei, EQ; Zhang, WP, 2008) |
| "We studied 53 MG-PNETs in patients from 12 to 80 years of age (median = 54 years)." | 1.35 | Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. ( Burger, PC; Cochran, EJ; Gujrati, M; Holland, EC; Huse, JT; Jost, SC; Miller, CR; Perry, A; Qian, J; Raghavan, R; Rosenblum, MK; Scheithauer, BW; Zambrano, SC, 2009) |
| " Three patients (12%) were changed to standard temozolomide dosing due to side effects, including intractable nausea (n = 2) and multiple cytopenias (n = 1)." | 1.34 | Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. ( Gasco, J; Pouratian, N; Schiff, D; Shaffrey, ME; Sherman, JH, 2007) |
| " Although this approach is promising, there has not been any attempt to define optimal metronomic dosing regimens by integrating pharmacokinetic (PK) with pharmacodynamic (PD) measurements." | 1.34 | Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. ( Gallo, JM; Guo, P; Nuthalapati, S; Wang, X; Zhou, Q, 2007) |
| "Temozolomide treatment of high-grade tv-a gliomas provided a 14-day growth delay compared with vehicle controls." | 1.34 | Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. ( Hambardzumyan, D; Holland, EC; Kreger, AR; Leopold, WR; McConville, P; Moody, JB; Rehemtulla, A; Ross, BD; Woolliscroft, MJ, 2007) |
| "The time-to-maximum plasma concentration (tmax) of TMZ was about 1 h and the elimination half-life of terminal excretion phase (t 1/2lambda z) was about 2 h." | 1.34 | Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians. ( Adachi, J; Aoki, T; Matsutani, M; Mishima, K; Mizutani, T; Nishikawa, R; Nojima, K, 2007) |
| "Chemo-therapeutic treatment of glioma patients has minor success." | 1.33 | Expression of ABC-1 transporter is elevated in human glioma cells under irradiation and temozolomide treatment. ( Golubnitschaja, O; Haertel, N; Moenkemann, H; Schüller, H; Trog, D, 2005) |
| "Perifosine is an oral Akt inhibitor which exerts a marked cytotoxic effect on human tumor cell lines, and is currently being tested in several phase II trials for treatment of major human cancers." | 1.33 | Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. ( Holland, EC; Momota, H; Nerio, E, 2005) |
| "Surgical cure of glioblastomas is virtually impossible and their clinical course is mainly determined by the biologic behavior of the tumor cells and their response to radiation and chemotherapy." | 1.33 | Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. ( Beerenwinkel, N; Feiden, W; Hartmann, C; Ketter, R; Lengauer, T; Meese, E; Rahnenführer, J; Steudel, WI; Stockhammer, F; Strowitzki, M; Urbschat, S; von Deimling, A; Wemmert, S; Zang, KD, 2005) |
| "Temozolomide (TMZ) is a methylating agent which prolongs survival when administered during and after radiotherapy in the first-line treatment of glioblastoma and which also has significant activity in recurrent disease." | 1.33 | O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. ( Hermisson, M; Kaina, B; Klumpp, A; Nagel, G; Roos, W; Weller, M; Wick, W; Wischhusen, J, 2006) |
| "Gliomas are primary brain tumors associated with a poor prognosis partly due to resistance to conventional therapies." | 1.33 | Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model. ( Itasaka, S; Kim, JT; Lee, JI; Nam, DH, 2006) |
| "Malignant gliomas have a very poor prognosis." | 1.33 | A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. ( Avis, T; Barthorpe, S; Batchelor, TT; Bignell, G; Brackenbury, L; Buck, G; Butler, A; Cahill, DP; Clements, J; Cole, J; Davies, H; Dicks, E; Easton, DF; Edkins, S; Forbes, S; Futreal, PA; Gorton, M; Gray, K; Greenman, C; Halliday, K; Harrison, R; Hills, K; Hinton, J; Hunter, C; Jenkinson, A; Jones, D; Kosmidou, V; Laman, R; Levine, KK; Louis, DN; Lugg, R; Menzies, A; Mueller, W; O'Meara, S; Parker, A; Perry, J; Petty, R; Raine, K; Richardson, D; Riggins, G; Roy, JE; Shepherd, R; Small, A; Smith, R; Solomon, H; Stephens, P; Stevens, C; Stratton, MR; Teague, J; Tofts, C; Varian, J; West, S; Widaa, S; Wooster, R; Yates, A, 2006) |
| "Temozolomide is a recently introduced alkylating agent that has yielded a significant benefit in the treatment of high-grade gliomas." | 1.33 | Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line. ( Auger, N; Dutrillaux, B; Idbaih, A; Legrier, ME; Poupon, MF; Sanson, M; Thillet, J; Wanherdrick, K, 2006) |
| "Temozolomide is an alkylating cytostatic drug that finds increasing application in the treatment of melanoma, anaplastic astrocytoma and glioblastoma multiforme." | 1.32 | Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids. ( Arnold, H; Damasceno, R; Günther, W; Pawlak, E; Terzis, AJ, 2003) |
| " It is proposed that the net balance of antiangiogenic drug-mediated pharmacodynamic actions will determine how drug disposition in tumors may be affected." | 1.32 | Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models. ( Gallo, JM; Guo, P; Li, S; Ma, J; Reed, K, 2003) |
| "Temozolomide (TMZ) is a DNA alkylating agent currently used as adjuvant treatment for anaplastic astrocytomas." | 1.32 | Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. ( Bedwell, J; Germano, IM; Kanzawa, T; Kondo, S; Kondo, Y, 2003) |
| " The population pharmacokinetic analysis was performed with nonlinear mixed-effect modeling software." | 1.32 | Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. ( Buclin, T; Csajka, C; Decosterd, LA; Lejeune, F; Leyvraz, S; Ostermann, S; Stupp, R, 2004) |
| " In this work we investigated the effect of association of temozolomide (TMZ), an orally bioavailable alkylating agent, with three chemotherapeutic drugs, liposomal doxorubicin (DOXO), cis-platinum (CDDP)." | 1.32 | Effect of association of temozolomide with other chemotherapic agents on cell growth inhibition in glioma cell lines. ( Balzarotti, M; Boiardi, A; Calatozzolo, C; Ciusani, E; Croci, D; Salmaggi, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (0.88) | 18.2507 |
| 2000's | 296 (21.83) | 29.6817 |
| 2010's | 706 (52.06) | 24.3611 |
| 2020's | 342 (25.22) | 2.80 |
| Authors | Studies |
|---|---|
| Vianna, DR | 1 |
| Hamerski, L | 1 |
| Figueiró, F | 2 |
| Bernardi, A | 2 |
| Visentin, LC | 1 |
| Pires, EN | 1 |
| Teixeira, HF | 1 |
| Salbego, CG | 1 |
| Eifler-Lima, VL | 1 |
| Battastini, AM | 3 |
| von Poser, GL | 1 |
| Pinto, AC | 1 |
| Liu, Z | 12 |
| Yao, Y | 6 |
| Kogiso, M | 1 |
| Zheng, B | 2 |
| Deng, L | 2 |
| Qiu, JJ | 1 |
| Dong, S | 2 |
| Lv, H | 2 |
| Gallo, JM | 9 |
| Li, XN | 2 |
| Song, Y | 6 |
| Ye, X | 6 |
| Yu, S | 4 |
| Liang, Y | 2 |
| Huang, H | 4 |
| Lian, XY | 1 |
| Zhang, Z | 10 |
| da Silva, DS | 1 |
| da Silva, CEH | 1 |
| Soares, MSP | 1 |
| Azambuja, JH | 2 |
| de Carvalho, TR | 2 |
| Zimmer, GC | 1 |
| Frizzo, CP | 1 |
| Braganhol, E | 4 |
| Spanevello, RM | 2 |
| Cunico, W | 1 |
| Braga, C | 2 |
| Vaz, AR | 1 |
| Oliveira, MC | 1 |
| Matilde Marques, M | 1 |
| Moreira, R | 2 |
| Brites, D | 2 |
| Perry, MJ | 2 |
| Neves, BJ | 1 |
| Agnes, JP | 1 |
| Gomes, MDN | 1 |
| Henriques Donza, MR | 1 |
| Gonçalves, RM | 1 |
| Delgobo, M | 1 |
| Ribeiro de Souza Neto, L | 1 |
| Senger, MR | 1 |
| Silva-Junior, FP | 1 |
| Ferreira, SB | 1 |
| Zanotto-Filho, A | 1 |
| Andrade, CH | 1 |
| Xiang, W | 4 |
| Quadery, TM | 1 |
| Hamel, E | 1 |
| Luckett-Chastain, LR | 1 |
| Ihnat, MA | 1 |
| Mooberry, SL | 1 |
| Gangjee, A | 2 |
| Li, J | 30 |
| Sun, Y | 11 |
| Sun, X | 7 |
| Zhao, X | 3 |
| Ma, Y | 3 |
| Wang, Y | 35 |
| Zhang, X | 29 |
| Brandner, S | 2 |
| McAleenan, A | 1 |
| Kelly, C | 1 |
| Spiga, F | 1 |
| Cheng, HY | 1 |
| Dawson, S | 1 |
| Schmidt, L | 1 |
| Faulkner, CL | 1 |
| Wragg, C | 1 |
| Jefferies, S | 1 |
| Higgins, JPT | 1 |
| Kurian, KM | 1 |
| Wang, X | 32 |
| Wu, D | 7 |
| Qi, J | 4 |
| Zhang, Y | 30 |
| Wang, K | 5 |
| Zhou, D | 3 |
| Meng, QM | 1 |
| Nie, E | 2 |
| Wang, Q | 20 |
| Yu, RT | 1 |
| Zhou, XP | 1 |
| Tresch, NS | 1 |
| Fuchs, D | 2 |
| Morandi, L | 2 |
| Tonon, C | 2 |
| Rohrer Bley, C | 2 |
| Nytko, KJ | 2 |
| Narita, Y | 4 |
| Muragaki, Y | 1 |
| Kagawa, N | 2 |
| Asai, K | 1 |
| Nagane, M | 5 |
| Matsuda, M | 4 |
| Ueki, K | 1 |
| Kuroda, J | 2 |
| Date, I | 2 |
| Kobayashi, H | 2 |
| Kumabe, T | 1 |
| Beppu, T | 2 |
| Kanamori, M | 4 |
| Kasai, S | 1 |
| Nishimura, Y | 1 |
| Xiong, H | 1 |
| Ocampo, C | 1 |
| Yamada, M | 2 |
| Mishima, K | 2 |
| Śledzińska, P | 2 |
| Bebyn, MG | 1 |
| Furtak, J | 2 |
| Kowalewski, J | 1 |
| Lewandowska, MA | 1 |
| Liu, T | 1 |
| Hu, J | 11 |
| Han, B | 5 |
| Tan, S | 1 |
| Jia, W | 3 |
| Xin, Y | 3 |
| Wan, Z | 1 |
| Li, C | 13 |
| Gu, J | 5 |
| Qian, J | 4 |
| Zhu, J | 8 |
| Wang, J | 44 |
| Li, Y | 34 |
| Jiang, J | 4 |
| Chen, H | 13 |
| Luo, C | 5 |
| Tong, S | 3 |
| Wu, J | 11 |
| Long, J | 2 |
| Zhong, P | 1 |
| Wang, B | 5 |
| Helal, DO | 1 |
| Rouatbi, N | 1 |
| Han, S | 7 |
| Tzu-Wen Wang, J | 1 |
| Walters, AA | 1 |
| Abdel-Mottaleb, MMA | 1 |
| Kamel, AO | 1 |
| Geneidi, AS | 1 |
| Awad, GAS | 1 |
| Al-Jamal, KT | 1 |
| Lamb, LS | 1 |
| Pereboeva, L | 1 |
| Youngblood, S | 1 |
| Gillespie, GY | 5 |
| Nabors, LB | 3 |
| Markert, JM | 3 |
| Dasgupta, A | 2 |
| Langford, C | 2 |
| Spencer, HT | 1 |
| Lv, X | 2 |
| Sun, J | 9 |
| Hu, L | 4 |
| Qian, Y | 5 |
| Fan, C | 1 |
| Tian, N | 2 |
| Li, X | 27 |
| Zou, Z | 1 |
| Ma, E | 1 |
| Feng, S | 2 |
| Ding, Y | 4 |
| Zhang, C | 11 |
| He, L | 5 |
| Song, X | 4 |
| Zheng, C | 1 |
| Pan, Y | 2 |
| Zhou, K | 2 |
| Jiang, T | 16 |
| Liu, Y | 35 |
| Zhao, Z | 14 |
| Huang, L | 4 |
| Li, G | 5 |
| Lan, Q | 5 |
| Poon, MTC | 1 |
| Bruce, M | 1 |
| Simpson, JE | 1 |
| Hannan, CJ | 1 |
| Brennan, PM | 1 |
| Xie, HM | 1 |
| Richard, SA | 1 |
| Lan, Z | 1 |
| Qiu, X | 5 |
| Chen, Y | 25 |
| Bao, Z | 4 |
| Chen, L | 26 |
| Serra, R | 1 |
| Mangraviti, A | 2 |
| Gorelick, NL | 1 |
| Shapira-Furman, T | 1 |
| Alomari, S | 1 |
| Cecia, A | 1 |
| Darjee, N | 1 |
| Brem, H | 8 |
| Rottenberg, Y | 1 |
| Domb, AJ | 1 |
| Tyler, B | 5 |
| Peters, KB | 6 |
| Affronti, ML | 5 |
| Woodring, S | 3 |
| Lipp, E | 1 |
| Healy, P | 2 |
| Herndon, JE | 14 |
| Miller, ES | 1 |
| Freeman, MW | 1 |
| Randazzo, DM | 2 |
| Desjardins, A | 15 |
| Friedman, HS | 22 |
| Campian, JL | 2 |
| Ghosh, S | 1 |
| Kapoor, V | 1 |
| Yan, R | 1 |
| Thotala, S | 1 |
| Jash, A | 1 |
| Hu, T | 2 |
| Mahadevan, A | 1 |
| Rifai, K | 1 |
| Page, L | 1 |
| Lee, BH | 1 |
| Ferrando-Martinez, S | 1 |
| Wolfarth, AA | 1 |
| Yang, SH | 3 |
| Hallahan, D | 1 |
| Chheda, MG | 1 |
| Thotala, D | 1 |
| Moitra, P | 1 |
| Chatterjee, A | 2 |
| Kota, PK | 1 |
| Epari, S | 2 |
| Patil, V | 4 |
| Kowtal, P | 1 |
| Sarin, R | 2 |
| Gupta, T | 5 |
| Puca, AA | 1 |
| Lopardo, V | 1 |
| Montella, F | 1 |
| Di Pietro, P | 1 |
| Cesselli, D | 1 |
| Rolle, IG | 1 |
| Bulfoni, M | 1 |
| Di Sarno, V | 1 |
| Iaconetta, G | 1 |
| Campiglia, P | 1 |
| Vecchione, C | 1 |
| Beltrami, AP | 1 |
| Ciaglia, E | 1 |
| Park, DY | 2 |
| Tom, MC | 3 |
| Wei, W | 2 |
| Tewari, S | 2 |
| Ahluwalia, MS | 5 |
| Yu, JS | 5 |
| Chao, ST | 4 |
| Suh, JH | 3 |
| Peereboom, D | 3 |
| Stevens, GHJ | 3 |
| Barnett, GH | 3 |
| Angelov, L | 2 |
| Mohammadi, AM | 1 |
| Hogan, T | 2 |
| Kissel, C | 2 |
| Lapin, B | 2 |
| Schuermeyer, I | 2 |
| Parsons, MW | 2 |
| Naugle, R | 2 |
| Murphy, ES | 3 |
| Guo, A | 1 |
| Fang, G | 1 |
| Lin, Z | 3 |
| Zheng, S | 3 |
| Zhuang, Z | 1 |
| Lin, R | 1 |
| Lin, Y | 4 |
| Xu, J | 6 |
| Wu, PJ | 1 |
| Lai, TH | 1 |
| Sharma, P | 1 |
| Canella, A | 2 |
| Welker, AM | 2 |
| Beattie, CE | 2 |
| Elder, JB | 1 |
| Easley, M | 1 |
| Lonser, R | 1 |
| Jacob, NK | 1 |
| Pietrzak, M | 1 |
| Timmers, CM | 1 |
| Lang, F | 2 |
| Sampath, D | 2 |
| Puduvalli, VK | 6 |
| Li, T | 5 |
| Yang, M | 5 |
| Du, Q | 1 |
| Wang, R | 6 |
| Fu, B | 1 |
| Tan, Y | 4 |
| Cao, M | 1 |
| Hu, R | 2 |
| Mehraein-Ghomi, F | 1 |
| Forbes, ME | 1 |
| Namjoshi, SV | 1 |
| Ballard, EA | 1 |
| Song, Q | 1 |
| Chou, PC | 1 |
| Parker Kerrigan, BC | 1 |
| Lang, FF | 3 |
| Lesser, G | 4 |
| Debinski, W | 2 |
| Yang, X | 10 |
| Zhang, W | 19 |
| Ding, P | 2 |
| Nie, X | 1 |
| Lu, B | 2 |
| Gött, H | 1 |
| Kiez, S | 1 |
| Dohmen, H | 1 |
| Kolodziej, M | 1 |
| Stein, M | 1 |
| Wei, S | 2 |
| Yuan, F | 5 |
| Zhang, S | 14 |
| Sun, Q | 3 |
| Ye, L | 5 |
| Xu, Y | 13 |
| Xu, Z | 3 |
| Deng, G | 2 |
| Liu, B | 4 |
| Chen, Q | 8 |
| Bao, G | 1 |
| Zhang, M | 17 |
| Xiang, J | 2 |
| Zhou, H | 3 |
| Wahafu, A | 1 |
| Wu, W | 4 |
| Ma, X | 2 |
| Huo, L | 2 |
| Bai, X | 2 |
| Xie, W | 1 |
| Liu, P | 4 |
| Wang, M | 9 |
| Cheng, M | 2 |
| Zhao, D | 2 |
| Tang, J | 5 |
| He, Z | 5 |
| Yin, D | 1 |
| Lin, X | 2 |
| Savani, MR | 1 |
| Du, K | 1 |
| Ku, Y | 1 |
| Li, S | 19 |
| Liu, H | 16 |
| Tian, M | 1 |
| Bowie, M | 1 |
| Hariharan, S | 1 |
| Waitkus, M | 1 |
| Keir, ST | 4 |
| Sugarman, ET | 1 |
| Deek, RA | 1 |
| Labrie, M | 1 |
| Khasraw, M | 5 |
| Lu, Y | 10 |
| Mills, GB | 1 |
| Herlyn, M | 1 |
| Wu, K | 2 |
| Liu, L | 8 |
| Wei, Z | 4 |
| Flaherty, KT | 1 |
| Abdullah, K | 1 |
| Zhang, G | 7 |
| Ashley, DM | 2 |
| Wei, Y | 4 |
| Duan, S | 1 |
| Gong, F | 2 |
| Li, Q | 8 |
| Márquez, M | 1 |
| Olausson, KH | 1 |
| Alaiya, A | 1 |
| Nilsson, S | 1 |
| Meurling, L | 1 |
| Holmberg, AR | 1 |
| Zeiner, PS | 2 |
| Filipski, K | 2 |
| Filmann, N | 1 |
| Forster, MT | 2 |
| Voss, M | 1 |
| Fokas, E | 2 |
| Herrlinger, U | 5 |
| Harter, PN | 3 |
| Steinbach, JP | 8 |
| Ronellenfitsch, MW | 4 |
| Yang, FC | 1 |
| Wang, C | 10 |
| Gai, QJ | 1 |
| Mao, M | 1 |
| He, J | 3 |
| Qin, Y | 1 |
| Yao, XX | 1 |
| Wang, YX | 1 |
| Lu, HM | 1 |
| Cao, MF | 1 |
| He, MM | 1 |
| Wen, XM | 1 |
| Leng, P | 1 |
| Cai, XW | 1 |
| Yao, XH | 1 |
| Bian, XW | 3 |
| Hanisch, D | 1 |
| Krumm, A | 1 |
| Diehl, T | 1 |
| Stork, CM | 1 |
| Dejung, M | 1 |
| Butter, F | 1 |
| Kim, E | 4 |
| Brenner, W | 1 |
| Fritz, G | 1 |
| Hofmann, TG | 1 |
| Roos, WP | 3 |
| Milano, MT | 1 |
| Soltys, SG | 1 |
| Knisely, JPS | 1 |
| Sahgal, A | 2 |
| Nagpal, S | 1 |
| Lo, SS | 2 |
| Jabbari, S | 1 |
| Wang, TJC | 1 |
| Simonson, M | 1 |
| Palmer, JD | 1 |
| Gephart, MH | 1 |
| Halasz, LM | 1 |
| Garg, AK | 1 |
| Chiang, VLS | 1 |
| Chang, EL | 1 |
| Zhou, L | 7 |
| Huang, X | 2 |
| Li, H | 14 |
| Nie, C | 1 |
| Zeng, Y | 1 |
| Qian, K | 2 |
| Rosen, J | 2 |
| Ceccon, G | 2 |
| Bauer, EK | 1 |
| Werner, JM | 2 |
| Tscherpel, C | 2 |
| Dunkl, V | 3 |
| Rapp, M | 3 |
| Sabel, M | 3 |
| Heinzel, A | 1 |
| Schäfer, N | 3 |
| Ruge, M | 1 |
| Goldbrunner, R | 1 |
| Stoffels, G | 2 |
| Kabbasch, C | 1 |
| Fink, GR | 3 |
| Langen, KJ | 2 |
| Galldiks, N | 6 |
| Iwaya, T | 1 |
| Sato, Y | 1 |
| Nomura, JI | 1 |
| Terasaki, K | 1 |
| Sasaki, T | 1 |
| Yamada, N | 1 |
| Fujiwara, S | 1 |
| Sugai, T | 1 |
| Ogasawara, K | 1 |
| Luo, J | 2 |
| Bai, R | 1 |
| Bi, H | 1 |
| Shi, X | 3 |
| Qu, C | 1 |
| Zhang, J | 26 |
| Guo, Z | 3 |
| Xie, Q | 3 |
| Zhong, C | 1 |
| Gao, X | 1 |
| Yang, Q | 4 |
| Peereboom, DM | 2 |
| Mohammadi, A | 1 |
| Liang, Q | 3 |
| Di, Z | 1 |
| Di, L | 1 |
| Fei, YQ | 1 |
| Shi, RT | 1 |
| Zhou, YF | 1 |
| Wu, JZ | 1 |
| Song, Z | 1 |
| Ye, T | 1 |
| Chen, R | 2 |
| Zhou, Y | 10 |
| Wei, H | 2 |
| Zeng, Z | 3 |
| Geng, X | 2 |
| Wen, X | 1 |
| Yan, Q | 2 |
| Wang, T | 4 |
| Ling, C | 1 |
| Duan, J | 1 |
| Zheng, K | 2 |
| Sun, Z | 2 |
| Daisy Precilla, S | 1 |
| Kuduvalli, SS | 1 |
| Angeline Praveena, E | 1 |
| Thangavel, S | 1 |
| Anitha, TS | 1 |
| Ding, D | 3 |
| Li, Z | 18 |
| Cheng, L | 2 |
| You, Q | 1 |
| Tu, Z | 2 |
| Long, X | 2 |
| Wu, L | 4 |
| Zhu, X | 8 |
| Huang, K | 2 |
| McAleavey, PG | 1 |
| Walls, GM | 1 |
| Chalmers, AJ | 2 |
| Min, X | 1 |
| Dingchao, X | 1 |
| Xun, Z | 1 |
| Cunzu, W | 1 |
| Yeo, AT | 1 |
| Rawal, S | 1 |
| Delcuze, B | 1 |
| Christofides, A | 1 |
| Atayde, A | 1 |
| Strauss, L | 1 |
| Balaj, L | 1 |
| Rogers, VA | 1 |
| Uhlmann, EJ | 1 |
| Varma, H | 1 |
| Carter, BS | 3 |
| Boussiotis, VA | 1 |
| Charest, A | 1 |
| Zhou, J | 6 |
| Xu, N | 2 |
| Lenahan, C | 1 |
| Tang, W | 1 |
| Zeng, H | 2 |
| Guo, H | 1 |
| Petrenko, D | 1 |
| Chubarev, V | 1 |
| Syzrantsev, N | 1 |
| Ismail, N | 1 |
| Merkulov, V | 1 |
| Sologova, S | 1 |
| Grigorevskikh, E | 1 |
| Smolyarchuk, E | 1 |
| Alyautdin, R | 1 |
| Guo, L | 3 |
| Wu, Z | 6 |
| Wu, Y | 7 |
| Hu, Y | 5 |
| Tang, L | 2 |
| Yin, S | 1 |
| Lv, L | 2 |
| Zhou, P | 5 |
| Xie, X | 4 |
| Peng, F | 2 |
| Du, J | 7 |
| Peng, C | 1 |
| Chen, Z | 9 |
| Zhu, G | 1 |
| Sheng, C | 1 |
| Lei, J | 1 |
| Song, S | 2 |
| de Souza, I | 1 |
| Monteiro, LKS | 1 |
| Guedes, CB | 1 |
| Silva, MM | 1 |
| Andrade-Tomaz, M | 1 |
| Contieri, B | 1 |
| Latancia, MT | 1 |
| Mendes, D | 1 |
| Porchia, BFMM | 1 |
| Lazarini, M | 1 |
| Gomes, LR | 1 |
| Rocha, CRR | 1 |
| Hao, L | 1 |
| Wang, H | 17 |
| Chai, R | 3 |
| Liao, M | 1 |
| Ou, L | 1 |
| Tang, Q | 1 |
| Li, N | 5 |
| Huang, W | 2 |
| Wang, S | 9 |
| Chen, S | 6 |
| Qiu, Q | 1 |
| Wang, D | 7 |
| She, D | 1 |
| Yin, B | 1 |
| Gu, G | 1 |
| Chai, M | 1 |
| Heo, DN | 1 |
| He, H | 4 |
| Jiménez-Morales, JM | 1 |
| Hernández-Cuenca, YE | 1 |
| Reyes-Abrahantes, A | 1 |
| Ruiz-García, H | 1 |
| Barajas-Olmos, F | 1 |
| García-Ortiz, H | 1 |
| Orozco, L | 1 |
| Quiñones-Hinojosa, A | 1 |
| Reyes-González, J | 1 |
| Abrahantes-Pérez, MDC | 1 |
| Jo, J | 2 |
| Schiff, D | 9 |
| Cieśluk, M | 1 |
| Piktel, E | 1 |
| Wnorowska, U | 1 |
| Skłodowski, K | 1 |
| Kochanowicz, J | 1 |
| Kułakowska, A | 1 |
| Bucki, R | 1 |
| Pogoda, K | 1 |
| Fu, J | 3 |
| Peng, J | 2 |
| Tu, G | 1 |
| Chernov, AN | 1 |
| Filatenkova, TA | 1 |
| Glushakov, RI | 1 |
| Buntovskaya, AS | 1 |
| Alaverdian, DA | 1 |
| Tsapieva, AN | 1 |
| Kim, AV | 1 |
| Fedorov, EV | 1 |
| Skliar, SS | 1 |
| Matsko, MV | 2 |
| Galimova, ES | 1 |
| Shamova, OV | 1 |
| Liu, C | 7 |
| Liu, J | 16 |
| Shao, J | 1 |
| Huang, C | 3 |
| Dai, X | 5 |
| Shen, Y | 3 |
| Hou, W | 1 |
| Yu, Y | 7 |
| Garzio, K | 1 |
| McElroy, K | 1 |
| Grossman, S | 2 |
| Holdhoff, M | 2 |
| Ozer, B | 1 |
| Yankulina, O | 1 |
| Sandbhor, P | 1 |
| Goda, JS | 3 |
| Mohanty, B | 1 |
| Chaudhari, P | 1 |
| Dutt, S | 1 |
| Banerjee, R | 1 |
| Luo, K | 1 |
| Liu, A | 2 |
| Wu, H | 3 |
| Liu, Q | 14 |
| Dai, J | 1 |
| Wang, Z | 15 |
| Shuai, SY | 1 |
| Liu, SS | 1 |
| Liu, XJ | 1 |
| Zhang, GS | 1 |
| Zheng, Q | 1 |
| Yue, PF | 1 |
| Hu, PY | 1 |
| Zhao, H | 10 |
| Meng, L | 3 |
| Liao, X | 2 |
| Mo, X | 1 |
| Gong, M | 1 |
| Liao, Y | 5 |
| Yang, J | 9 |
| Fu, Z | 2 |
| Chen, J | 12 |
| Fan, W | 2 |
| Wu, X | 7 |
| Bebyn, M | 1 |
| Koper, A | 1 |
| Koper, K | 1 |
| Fan, Y | 4 |
| Huang, T | 3 |
| Fan, H | 4 |
| Zhang, Q | 8 |
| Qiu, R | 1 |
| Ji, Q | 1 |
| Han, Q | 1 |
| Kuang, X | 1 |
| Yan, X | 3 |
| Ma, C | 4 |
| Tian, F | 1 |
| Qu, J | 1 |
| Chen, X | 10 |
| Fu, G | 1 |
| Li, L | 6 |
| Zhao, Q | 2 |
| Ke, Z | 1 |
| Zhang, R | 3 |
| Cao, D | 1 |
| Wang, XL | 1 |
| Jiao, BH | 3 |
| Wu, JL | 2 |
| Yang, JK | 2 |
| Hu, YH | 2 |
| Cui, K | 1 |
| Lu, G | 1 |
| Zhu, P | 2 |
| Rao, M | 1 |
| Linendoll, N | 1 |
| Buja, LM | 1 |
| Bhattacharjee, MB | 1 |
| Brown, RE | 1 |
| Ballester, LY | 2 |
| Tian, X | 1 |
| Pilichowska, M | 1 |
| Wu, JK | 1 |
| Hergenroeder, GW | 1 |
| Glass, WF | 1 |
| Pillai, AK | 1 |
| Hunter, RL | 1 |
| Zhu, JJ | 2 |
| Farheen, S | 1 |
| Ahmed, SP | 1 |
| Mariyath P M, M | 1 |
| Kausar, T | 1 |
| Hoda, MF | 1 |
| Arif, SH | 1 |
| Nayeem, SM | 1 |
| Ali, A | 1 |
| Chosdol, K | 2 |
| Shahi, MH | 1 |
| Wu, P | 4 |
| Guo, J | 5 |
| Yang, H | 5 |
| Yuan, D | 2 |
| Balkanov, AS | 1 |
| Rozanov, ID | 1 |
| Glazkov, AA | 1 |
| Belyaev, AY | 1 |
| Kobyakov, GL | 1 |
| Shmakov, PN | 1 |
| Telysheva, EN | 1 |
| Strunina, YV | 1 |
| Usachev, DY | 1 |
| Yagi, C | 1 |
| Tatsuoka, J | 1 |
| Sano, E | 4 |
| Hanashima, Y | 1 |
| Ozawa, Y | 1 |
| Yoshimura, S | 1 |
| Yamamuro, S | 1 |
| Sumi, K | 1 |
| Hara, H | 1 |
| Katayama, Y | 5 |
| Yoshino, A | 5 |
| Cao, Y | 9 |
| Jin, L | 2 |
| Lv, Z | 1 |
| Yin, N | 1 |
| Zhang, H | 9 |
| Zhang, T | 4 |
| Liu, X | 19 |
| Zhao, G | 6 |
| Ehret, F | 1 |
| Hansch, A | 1 |
| Meinhardt, J | 1 |
| Hain, EG | 1 |
| Misch, M | 1 |
| Onken, J | 1 |
| Roohani, S | 1 |
| Koch, A | 2 |
| Schweizer, L | 1 |
| Radke, J | 1 |
| Kaul, D | 1 |
| Wu, M | 7 |
| Xu, C | 4 |
| Shi, Y | 4 |
| Huang, Y | 7 |
| Zhao, F | 1 |
| Pei, Y | 1 |
| Li, R | 7 |
| Ai, P | 2 |
| Peng, X | 7 |
| Jovanović, N | 1 |
| Lazarević, M | 1 |
| Cvetković, VJ | 1 |
| Nikolov, V | 1 |
| Kostić Perić, J | 1 |
| Ugrin, M | 1 |
| Pavlović, S | 1 |
| Mitrović, T | 1 |
| Chung, S | 3 |
| Sugimoto, Y | 3 |
| Huang, J | 7 |
| Liu, YF | 3 |
| Ji, YS | 3 |
| Etcheverry, A | 4 |
| Chen, K | 5 |
| Song, BQ | 3 |
| Lin, W | 5 |
| Yin, A | 3 |
| He, YL | 3 |
| Frosina, G | 3 |
| Moreno, V | 3 |
| Manuel Sepúlveda, J | 3 |
| Reardon, DA | 17 |
| Pérez-Núñez, Á | 3 |
| González León, P | 3 |
| Hanna, B | 3 |
| Filvaroff, E | 3 |
| Aronchik, I | 3 |
| Chang, H | 3 |
| Amoroso, B | 3 |
| Zuraek, M | 3 |
| Sanchez-Perez, T | 3 |
| Mendez, C | 3 |
| Stephens, D | 4 |
| Nikolova, Z | 3 |
| Vogelbaum, MA | 6 |
| Luo, GQ | 2 |
| Bai, S | 2 |
| Yan, ZJ | 2 |
| Fan, LL | 2 |
| Morelli, MB | 2 |
| Nabissi, M | 2 |
| Amantini, C | 2 |
| Maggi, F | 2 |
| Ricci-Vitiani, L | 2 |
| Pallini, R | 2 |
| Santoni, G | 2 |
| Devalckeneer, A | 2 |
| Aboukaïs, R | 2 |
| Bourgeois, P | 2 |
| Reyns, N | 2 |
| Lejeune, JP | 2 |
| Tong, F | 4 |
| Zhao, JX | 2 |
| Fang, ZY | 2 |
| Cui, XT | 2 |
| Su, DY | 2 |
| Zhou, JH | 2 |
| Wang, GX | 2 |
| Qiu, ZJ | 2 |
| Liu, SZ | 2 |
| Fu, JQ | 2 |
| Kang, CS | 4 |
| Wang, JC | 2 |
| Wang, QX | 2 |
| Hong, X | 4 |
| Zou, J | 2 |
| Ouyang, J | 2 |
| Xiao, B | 5 |
| Wang, P | 3 |
| Xu, H | 9 |
| Zhang, A | 3 |
| Fang, C | 1 |
| Zhu, Q | 1 |
| Wang, W | 19 |
| Yuan, L | 1 |
| Shao, A | 1 |
| Lou, M | 2 |
| Che, J | 1 |
| DePalma, TJ | 1 |
| Sivakumar, H | 1 |
| Mezache, LS | 1 |
| Tallman, MM | 1 |
| Venere, M | 1 |
| Swindle-Reilly, K | 1 |
| Veeraraghavan, R | 1 |
| Skardal, A | 1 |
| Nie, XH | 1 |
| Yin, R | 1 |
| Su, ZZ | 1 |
| Qiu, S | 1 |
| Qian, YF | 1 |
| Ren, Y | 3 |
| Qian, F | 1 |
| Wang, L | 23 |
| Ma, H | 2 |
| Quan, A | 1 |
| Yu, R | 7 |
| Xie, Y | 3 |
| Yang, F | 3 |
| Chao, M | 2 |
| Cao, H | 3 |
| Zhang, L | 20 |
| Xin, L | 1 |
| Uhrbom, L | 1 |
| Dimberg, A | 1 |
| Chou, FJ | 1 |
| Song, H | 5 |
| Davis, DL | 1 |
| Briceno, NJ | 1 |
| Cimino, PJ | 2 |
| Zaghloul, KA | 1 |
| Gilbert, MR | 8 |
| Armstrong, TS | 2 |
| Yang, C | 4 |
| Alejo, S | 1 |
| Palacios, BE | 1 |
| Venkata, PP | 1 |
| He, Y | 6 |
| Li, W | 7 |
| Johnson, JD | 1 |
| Jayamohan, S | 1 |
| Pratap, UP | 1 |
| Clarke, K | 1 |
| Zou, Y | 7 |
| Lv, Y | 3 |
| Weldon, K | 1 |
| Viswanadhapalli, S | 1 |
| Lai, Z | 1 |
| Ye, Z | 2 |
| Gilbert, AR | 1 |
| Suzuki, T | 1 |
| Tekmal, RR | 1 |
| Zhao, W | 4 |
| Vadlamudi, RK | 1 |
| Brenner, AJ | 1 |
| Sareddy, GR | 1 |
| Marsland, M | 1 |
| Dowdell, A | 1 |
| Faulkner, S | 1 |
| Jobling, P | 1 |
| Rush, RA | 1 |
| Gedye, C | 1 |
| Lynam, J | 1 |
| Griffin, CP | 1 |
| Baker, M | 1 |
| Marsland, J | 1 |
| Jiang, CC | 1 |
| Hondermarck, H | 1 |
| Jiang, Y | 7 |
| Lu, H | 3 |
| Hong, Y | 1 |
| Cai, J | 9 |
| Tian, D | 1 |
| Guo, C | 1 |
| Xu, P | 2 |
| Deng, M | 1 |
| Cai, L | 2 |
| Sai, K | 7 |
| Xi, S | 1 |
| Ouyang, H | 1 |
| Liu, M | 2 |
| Ni, X | 1 |
| Cao, X | 2 |
| Wu, S | 3 |
| Du, X | 3 |
| Su, J | 6 |
| Xue, X | 2 |
| Qin, Z | 1 |
| Zhou, T | 6 |
| Hu, X | 2 |
| Jiang, X | 3 |
| Lin, F | 1 |
| Ke, C | 2 |
| Hu, W | 3 |
| Zeng, J | 1 |
| Zhong, S | 3 |
| Li, D | 7 |
| Mou, Y | 1 |
| Yin, W | 1 |
| Huo, M | 1 |
| Yao, Q | 1 |
| Ding, L | 3 |
| Perwein, T | 1 |
| Giese, B | 1 |
| Nussbaumer, G | 1 |
| von Bueren, AO | 5 |
| van Buiren, M | 1 |
| Benesch, M | 2 |
| Kramm, CM | 5 |
| Ma, J | 5 |
| Dai, L | 2 |
| Yu, J | 4 |
| Bao, Y | 1 |
| Sofia, A | 1 |
| Wu, F | 4 |
| Xie, Z | 1 |
| Qian, W | 2 |
| Zhan, R | 1 |
| Liang, Z | 1 |
| Liu, F | 3 |
| Ortiz-Rivera, J | 1 |
| Nuñez, R | 1 |
| Kucheryavykh, Y | 1 |
| Kucheryavykh, L | 1 |
| Schaff, LR | 1 |
| Mellinghoff, IK | 1 |
| Charbonneau, M | 1 |
| Harper, K | 1 |
| Brochu-Gaudreau, K | 1 |
| Perreault, A | 1 |
| Roy, LO | 1 |
| Lucien, F | 1 |
| Tian, S | 1 |
| Fortin, D | 1 |
| Dubois, CM | 1 |
| Jia, JL | 1 |
| Alshamsan, B | 1 |
| Ng, TL | 1 |
| Nakagawa-Saito, Y | 1 |
| Mitobe, Y | 1 |
| Togashi, K | 1 |
| Suzuki, S | 1 |
| Sugai, A | 1 |
| Kitanaka, C | 1 |
| Okada, M | 2 |
| Szymczak, B | 1 |
| Czarnecka, J | 1 |
| Czach, S | 1 |
| Nowak, W | 1 |
| Roszek, K | 1 |
| Tang, S | 4 |
| Zhang, K | 2 |
| Tan, Z | 4 |
| Shen, L | 4 |
| Yang, L | 3 |
| Li, M | 7 |
| Nam, Y | 1 |
| Koo, H | 1 |
| Yang, Y | 8 |
| Shin, S | 1 |
| Zhu, Z | 2 |
| Kim, D | 1 |
| Cho, HJ | 3 |
| Mu, Q | 3 |
| Choi, SW | 1 |
| Sa, JK | 3 |
| Seo, YJ | 1 |
| Kim, Y | 6 |
| Lee, K | 1 |
| Oh, JW | 2 |
| Kwon, YJ | 2 |
| Park, WY | 2 |
| Kong, DS | 4 |
| Seol, HJ | 3 |
| Lee, JI | 4 |
| Park, CK | 8 |
| Lee, HW | 1 |
| Yoon, Y | 2 |
| Hou, X | 2 |
| Du, H | 2 |
| Deng, Y | 5 |
| Qiao, J | 2 |
| Liu, W | 5 |
| Shu, X | 1 |
| Sun, B | 8 |
| Zheng, H | 1 |
| Tang, M | 2 |
| Song, L | 2 |
| You, F | 1 |
| Hu, Z | 4 |
| Meng, Q | 1 |
| Gao, S | 6 |
| Friedlander, P | 1 |
| Morgan, LR | 1 |
| Benes, EN | 1 |
| Rodgers, AH | 1 |
| Jursic, B | 1 |
| Yan, W | 4 |
| You, Y | 4 |
| Mousavi, SM | 1 |
| Hosseindoost, S | 1 |
| Mahdian, SMA | 1 |
| Vousooghi, N | 1 |
| Rajabi, A | 1 |
| Jafari, A | 1 |
| Ostadian, A | 1 |
| Hamblin, MR | 1 |
| Hadjighassem, M | 1 |
| Mirzaei, H | 1 |
| Yuan, Y | 1 |
| Jin, Z | 2 |
| Zhai, H | 1 |
| Chen, M | 6 |
| Yan, D | 1 |
| Pu, J | 1 |
| Cui, L | 2 |
| Miao, W | 1 |
| Ju, Y | 1 |
| Chen, T | 1 |
| Gu, N | 1 |
| Cui, X | 2 |
| Kang, C | 8 |
| Graen, P | 1 |
| Christiansen, H | 2 |
| Polemikos, M | 1 |
| Heetfeld, C | 1 |
| Feuerhake, F | 1 |
| Wiese, B | 1 |
| Merten, R | 1 |
| Guo, S | 2 |
| Yu, M | 3 |
| Tao, L | 1 |
| Cui, H | 1 |
| Schilling, M | 1 |
| Herold-Mende, C | 3 |
| Reischl, M | 1 |
| Levkin, PA | 1 |
| Popova, AA | 1 |
| Turcan, Ş | 2 |
| Wei, J | 2 |
| Sun, T | 1 |
| Wan, J | 1 |
| Ma, L | 3 |
| Kitamura, Y | 2 |
| Toda, M | 2 |
| Ma, F | 1 |
| Guo, Y | 3 |
| Shen, H | 1 |
| Ma, W | 3 |
| Patrick, S | 1 |
| Lathoria, K | 1 |
| Suri, V | 2 |
| Sen, E | 1 |
| Merenzon, MA | 1 |
| Hincapie Arias, E | 1 |
| Bhatia, S | 1 |
| Shah, AH | 1 |
| Higgins, DMO | 1 |
| Villaverde, M | 1 |
| Belgorosky, D | 1 |
| Eijan, AM | 1 |
| Zhao, J | 4 |
| Wang, G | 5 |
| Kundu, M | 1 |
| Das, S | 3 |
| Nandi, S | 2 |
| Dhara, D | 1 |
| Mandal, M | 1 |
| Lv, W | 2 |
| He, W | 2 |
| Min, Z | 1 |
| Gong, L | 1 |
| Teng, C | 1 |
| Sun, S | 5 |
| Xin, H | 1 |
| Feng, SW | 1 |
| Wu, ZS | 1 |
| Chiu, YL | 1 |
| Huang, SM | 1 |
| Paradossi, G | 1 |
| Grossman, R | 4 |
| Riccitelli, F | 1 |
| Todaro, F | 1 |
| Ram, Z | 1 |
| Schioppa, S | 1 |
| Domenici, F | 1 |
| Fu, X | 3 |
| Shang, W | 1 |
| Makino, K | 3 |
| Otani, Y | 2 |
| Fujii, K | 1 |
| Ishida, J | 1 |
| Hirano, S | 1 |
| Suruga, Y | 1 |
| Washio, K | 1 |
| Nishida, K | 1 |
| Yanai, H | 1 |
| Tomida, S | 1 |
| Ennishi, D | 1 |
| Weyland, MS | 1 |
| Kang, Z | 1 |
| Kang, X | 1 |
| Deng, J | 1 |
| Chen, F | 2 |
| Yu, P | 1 |
| Ji, F | 1 |
| Wu, C | 4 |
| Yuan, X | 2 |
| Mu, J | 2 |
| Xu, L | 3 |
| Li, B | 6 |
| Yin, Z | 1 |
| Reijneveld, JC | 13 |
| Machingura, A | 1 |
| Coens, C | 3 |
| Taphoorn, MJB | 6 |
| Taal, W | 5 |
| Clement, PM | 2 |
| Idbaih, A | 10 |
| de Vos, FYF | 2 |
| Klein, M | 7 |
| Wick, W | 22 |
| Mulholland, PJ | 2 |
| Lewis, J | 2 |
| Golfinopoulos, V | 4 |
| Ghislain, I | 1 |
| Bottomley, A | 2 |
| van den Bent, MJ | 20 |
| Krajcer, A | 1 |
| Grzywna, E | 1 |
| Lewandowska-Łańcucka, J | 1 |
| Czarnywojtek, A | 1 |
| Borowska, M | 1 |
| Dyrka, K | 1 |
| Van Gool, S | 1 |
| Sawicka-Gutaj, N | 1 |
| Moskal, J | 1 |
| Kościński, J | 1 |
| Graczyk, P | 1 |
| Hałas, T | 1 |
| Lewandowska, AM | 1 |
| Czepczyński, R | 1 |
| Ruchała, M | 1 |
| Ou, M | 1 |
| Cho, HY | 3 |
| Thein, TZ | 1 |
| Swenson, SD | 2 |
| Minea, RO | 2 |
| Stathopoulos, A | 1 |
| Schönthal, AH | 5 |
| Hofman, FM | 6 |
| Chen, TC | 8 |
| Ni, H | 1 |
| Zhou, B | 2 |
| Nizar, R | 1 |
| Cazacu, S | 1 |
| Xiang, C | 1 |
| Krasner, M | 1 |
| Barbiro-Michaely, E | 1 |
| Gerber, D | 1 |
| Schwartz, J | 1 |
| Fried, I | 1 |
| Yuval, S | 1 |
| Brodie, A | 1 |
| Kazimirsky, G | 1 |
| Amos, N | 1 |
| Unger, R | 1 |
| Brown, S | 1 |
| Rogers, L | 1 |
| Penning, DH | 1 |
| Brodie, C | 2 |
| Ntafoulis, I | 1 |
| Kleijn, A | 2 |
| Ju, J | 1 |
| Jimenez-Cowell, K | 1 |
| Fabro, F | 1 |
| Chi Yen, RT | 1 |
| Balvers, RK | 2 |
| Stubbs, AP | 1 |
| Kers, TV | 1 |
| Kros, JM | 6 |
| Lawler, SE | 2 |
| Beerepoot, LV | 1 |
| Kremer, A | 1 |
| Verreault, M | 2 |
| Byrne, AT | 1 |
| O'Farrell, AC | 1 |
| Connor, K | 1 |
| Biswas, A | 1 |
| Salvucci, M | 1 |
| Prehn, JHM | 2 |
| Lambrechts, D | 1 |
| Dilcan, G | 1 |
| Lodi, F | 1 |
| Arijs, I | 1 |
| Dirven, CMF | 1 |
| Leenstra, S | 2 |
| Lamfers, MLM | 2 |
| Wood, MD | 2 |
| Beadling, C | 1 |
| Neff, T | 2 |
| Moore, S | 2 |
| Harrington, CA | 1 |
| Baird, L | 1 |
| Corless, C | 1 |
| Peruzzi, P | 4 |
| Dominas, C | 1 |
| Fell, G | 1 |
| Bernstock, JD | 1 |
| Blitz, S | 1 |
| Mazzetti, D | 1 |
| Zdioruk, M | 1 |
| Dawood, HY | 1 |
| Triggs, DV | 1 |
| Ahn, SW | 1 |
| Bhagavatula, SK | 1 |
| Davidson, SM | 1 |
| Tatarova, Z | 1 |
| Pannell, M | 1 |
| Truman, K | 1 |
| Ball, A | 1 |
| Gold, MP | 1 |
| Pister, V | 1 |
| Fraenkel, E | 1 |
| Chiocca, EA | 3 |
| Ligon, KL | 3 |
| Wen, PY | 15 |
| Jonas, O | 1 |
| Jiao, J | 1 |
| Yang, R | 3 |
| Wen, B | 1 |
| Wu, Q | 5 |
| Tong, X | 2 |
| Yan, H | 2 |
| Yan, Y | 1 |
| Pang, B | 1 |
| Song, D | 1 |
| Yan, M | 1 |
| Jiang, B | 1 |
| Mo, Z | 1 |
| Chang, Y | 4 |
| Chan, KHY | 1 |
| Loi, DSC | 1 |
| Tam, SST | 1 |
| Chan, AKY | 1 |
| Wu, AR | 1 |
| Poon, WS | 2 |
| Ng, HK | 2 |
| Chan, DTM | 1 |
| Iavarone, A | 1 |
| Nam, DH | 10 |
| Yuan, J | 2 |
| Fan, R | 1 |
| Bassi, R | 1 |
| Dei Cas, M | 1 |
| Tringali, C | 1 |
| Compostella, F | 1 |
| Paroni, R | 1 |
| Giussani, P | 1 |
| Krassnig, S | 1 |
| Leber, SL | 1 |
| Orthmann, A | 1 |
| Golob-Schwarzl, N | 1 |
| Huber, HJ | 1 |
| Wohlrab, C | 1 |
| Skofler, C | 1 |
| Pennauer, M | 1 |
| Raicht, A | 1 |
| Birkl-Toeglhofer, AM | 1 |
| Naumann, M | 1 |
| Mahdy-Ali, K | 1 |
| von Campe, G | 1 |
| Leoni, M | 1 |
| Alcaniz, J | 1 |
| Hoffmann, J | 1 |
| Wälchli, T | 1 |
| Weis, S | 1 |
| Haybaeck, J | 1 |
| Tan, IL | 1 |
| Perez, AR | 1 |
| Lew, RJ | 1 |
| Baldwin, A | 1 |
| Zhu, YK | 1 |
| Shah, MM | 1 |
| Berger, MS | 11 |
| Doudna, JA | 1 |
| Fellmann, C | 1 |
| Rautajoki, KJ | 1 |
| Jaatinen, S | 1 |
| Hartewig, A | 1 |
| Tiihonen, AM | 1 |
| Annala, M | 1 |
| Salonen, I | 1 |
| Valkonen, M | 1 |
| Simola, V | 1 |
| Vuorinen, EM | 1 |
| Kivinen, A | 1 |
| Rauhala, MJ | 1 |
| Nurminen, R | 1 |
| Maass, KK | 1 |
| Lahtela, SL | 1 |
| Jukkola, A | 1 |
| Yli-Harja, O | 2 |
| Helén, P | 1 |
| Pajtler, KW | 1 |
| Ruusuvuori, P | 1 |
| Haapasalo, J | 1 |
| Haapasalo, H | 1 |
| Nykter, M | 2 |
| Xing, J | 1 |
| Tan, R | 2 |
| Delobel, T | 1 |
| Ayala-Hernández, LE | 1 |
| Bosque, JJ | 1 |
| Pérez-Beteta, J | 1 |
| Chulián, S | 1 |
| García-Ferrer, M | 1 |
| Piñero, P | 1 |
| Schucht, P | 3 |
| Murek, M | 2 |
| Pérez-García, VM | 2 |
| Yan, J | 2 |
| Li, K | 7 |
| Bian, L | 1 |
| Lin, B | 1 |
| Xi, Z | 1 |
| Yun, Y | 2 |
| Zhu, R | 2 |
| Aguado, T | 1 |
| Romero-Revilla, JA | 1 |
| Granados, R | 1 |
| Campuzano, S | 1 |
| Torrente-Rodríguez, RM | 1 |
| Cuesta, ÁM | 1 |
| Albiñana, V | 1 |
| Botella, LM | 1 |
| Santamaría, S | 1 |
| Garcia-Sanz, JA | 1 |
| Pingarrón, JM | 1 |
| Sánchez-Sancho, F | 1 |
| Sánchez-Puelles, JM | 1 |
| Varlet, P | 2 |
| Le Teuff, G | 1 |
| Le Deley, MC | 1 |
| Giangaspero, F | 2 |
| Haberler, C | 2 |
| Jacques, TS | 2 |
| Figarella-Branger, D | 3 |
| Pietsch, T | 7 |
| Andreiuolo, F | 1 |
| Deroulers, C | 1 |
| Jaspan, T | 3 |
| Jones, C | 4 |
| Grill, J | 4 |
| Zhu, ZQ | 2 |
| Li, YX | 1 |
| Zhuang, QF | 1 |
| Lai, Y | 1 |
| Li, SF | 1 |
| Xu, XB | 1 |
| Liu, JM | 3 |
| Patel, MP | 2 |
| McSherry, F | 3 |
| Lipp, ES | 2 |
| Miller, E | 2 |
| Chen, WL | 1 |
| Chen, HJ | 1 |
| Hou, GQ | 1 |
| Zhang, XH | 3 |
| Ge, JW | 1 |
| Zhang, D | 6 |
| Qiao, Q | 1 |
| Zhao, M | 1 |
| Tan, B | 1 |
| Shao, Y | 2 |
| He, Q | 1 |
| Yang, B | 5 |
| Weng, Q | 1 |
| Rudà, R | 4 |
| Pellerino, A | 1 |
| Pace, A | 3 |
| Carapella, CM | 3 |
| Dealis, C | 1 |
| Caroli, M | 1 |
| Faedi, M | 1 |
| Bello, L | 1 |
| Migliore, E | 1 |
| Marchese, G | 1 |
| Bertero, L | 1 |
| Cassoni, P | 2 |
| Soffietti, R | 4 |
| Mei, S | 1 |
| Yang, P | 3 |
| Yang, S | 6 |
| Zheng, Y | 5 |
| Yao, L | 2 |
| Zhai, Z | 1 |
| Dai, Z | 1 |
| Hua, L | 4 |
| Feng, H | 5 |
| Shen, B | 1 |
| Sachdeva, R | 1 |
| Johnson, K | 1 |
| Kim, H | 4 |
| Celebre, A | 1 |
| Shahzad, U | 1 |
| Graham, MS | 1 |
| Kessler, JA | 1 |
| Chuang, JH | 1 |
| Karamchandani, J | 1 |
| Bredel, M | 1 |
| Verhaak, R | 1 |
| Zeng, D | 1 |
| Gao, Y | 7 |
| Chen, PR | 1 |
| Lin, J | 2 |
| Guerra-García, P | 1 |
| Marshall, LV | 2 |
| Cockle, JV | 1 |
| Ramachandran, PV | 1 |
| Saran, FH | 1 |
| Carceller, F | 2 |
| Younis, M | 1 |
| Faming, W | 1 |
| Hongyan, Z | 1 |
| Mengmeng, T | 1 |
| Hang, S | 1 |
| Liudi, Y | 1 |
| Hwang, K | 2 |
| Kim, TM | 4 |
| Chang, JH | 3 |
| Jung, TY | 3 |
| Kim, JH | 11 |
| Kim, SH | 3 |
| Yoo, H | 2 |
| Hong, YK | 6 |
| Kim, EY | 2 |
| Lee, DE | 2 |
| Joo, J | 2 |
| Kim, YJ | 5 |
| Choe, G | 4 |
| Choi, BS | 2 |
| Kang, SG | 3 |
| Kim, CY | 7 |
| Ren, T | 1 |
| Lin, M | 1 |
| McDuff, SGR | 1 |
| Dietrich, J | 2 |
| Atkins, KM | 1 |
| Oh, KS | 2 |
| Loeffler, JS | 2 |
| Shih, HA | 2 |
| Song, J | 5 |
| Wang, F | 5 |
| Chonan, M | 2 |
| Saito, R | 3 |
| Osawa, SI | 1 |
| Watanabe, M | 1 |
| Suzuki, H | 2 |
| Nakasato, N | 1 |
| Tominaga, T | 3 |
| Guan, H | 3 |
| Mu, X | 2 |
| Tomar, VS | 1 |
| Somasundaram, K | 2 |
| Tang, JH | 2 |
| Chen, JX | 1 |
| Li, QR | 1 |
| Zhu, LR | 1 |
| Xu, QF | 2 |
| Huang, GH | 2 |
| Zhang, ZX | 1 |
| Xiang, Y | 3 |
| Du, L | 2 |
| Zhou, Z | 3 |
| Lv, SQ | 2 |
| Chen, KC | 3 |
| Chen, PH | 3 |
| Ho, KH | 3 |
| Shih, CM | 5 |
| Chou, CM | 1 |
| Cheng, CH | 3 |
| Lee, CC | 5 |
| Pang, D | 2 |
| Feng, B | 2 |
| Geng, Y | 1 |
| Luo, Q | 1 |
| Yi, GZ | 2 |
| Guo, M | 2 |
| Qi, S | 4 |
| Huang, G | 4 |
| Bunevicius, A | 1 |
| McDannold, NJ | 1 |
| Golby, AJ | 1 |
| Bikhezar, F | 1 |
| de Kruijff, RM | 1 |
| van der Meer, AJGM | 1 |
| Torrelo Villa, G | 1 |
| van der Pol, SMA | 1 |
| Becerril Aragon, G | 1 |
| Gasol Garcia, A | 1 |
| Narayan, RS | 1 |
| de Vries, HE | 1 |
| Slotman, BJ | 4 |
| Denkova, AG | 1 |
| Sminia, P | 3 |
| Enríquez Pérez, J | 1 |
| Kopecky, J | 1 |
| Visse, E | 2 |
| Darabi, A | 3 |
| Siesjö, P | 3 |
| Jiang, H | 6 |
| Yang, K | 3 |
| Gao, L | 4 |
| He, A | 1 |
| Chen, B | 3 |
| Bi, J | 1 |
| Guo, D | 2 |
| Shi, T | 1 |
| Shi, J | 4 |
| An, W | 1 |
| Attenello, F | 1 |
| Lu, W | 2 |
| Miyazaki, T | 1 |
| Ishikawa, E | 4 |
| Sugii, N | 1 |
| Kohzuki, H | 1 |
| Akutsu, H | 4 |
| Sakamoto, N | 2 |
| Takano, S | 3 |
| Matsumura, A | 4 |
| Li, F | 4 |
| Wang, N | 4 |
| Song, C | 4 |
| Diao, X | 1 |
| Meng, X | 8 |
| Zhao, Y | 8 |
| Zha, C | 1 |
| Qi, T | 1 |
| Jiang, C | 13 |
| Lin, L | 5 |
| Baxter, PA | 1 |
| Su, JM | 1 |
| Onar-Thomas, A | 1 |
| Billups, CA | 1 |
| Poussaint, TY | 2 |
| Smith, ER | 1 |
| Thompson, P | 1 |
| Adesina, A | 2 |
| Ansell, P | 1 |
| Giranda, V | 1 |
| Paulino, A | 1 |
| Kilburn, L | 1 |
| Quaddoumi, I | 1 |
| Broniscer, A | 4 |
| Blaney, SM | 2 |
| Dunkel, IJ | 1 |
| Fouladi, M | 5 |
| Belter, A | 1 |
| Barciszewski, J | 1 |
| Barciszewska, AM | 2 |
| Wick, A | 7 |
| Suarez, C | 1 |
| Forsyth, P | 2 |
| Gueorguieva, I | 1 |
| Burkholder, T | 1 |
| Cleverly, AL | 1 |
| Estrem, ST | 1 |
| Lahn, MM | 1 |
| Guba, SC | 1 |
| Capper, D | 3 |
| Rodon, J | 1 |
| Xu, JX | 1 |
| Luan, XP | 1 |
| Kong, S | 3 |
| Fang, Y | 3 |
| He, R | 1 |
| Mathur, R | 1 |
| Grimmer, MR | 3 |
| Hong, C | 4 |
| Bollam, S | 1 |
| Petrecca, K | 2 |
| Clarke, J | 1 |
| Phillips, JJ | 3 |
| Oberheim-Bush, NA | 1 |
| Molinaro, AM | 5 |
| Chang, SM | 14 |
| Costello, JF | 6 |
| Kong, L | 1 |
| Gao, J | 3 |
| Mao, Y | 2 |
| Lu, JJ | 1 |
| Meng, Y | 4 |
| Yin, P | 1 |
| Cao, G | 1 |
| Xin, X | 1 |
| Cai, X | 2 |
| Du, B | 3 |
| Ding, C | 2 |
| Yi, X | 2 |
| Bu, X | 3 |
| Kang, D | 2 |
| von Roemeling, CA | 1 |
| Qie, Y | 1 |
| Yuan, H | 1 |
| Yang, Z | 3 |
| Deng, W | 1 |
| Bruno, KA | 1 |
| Chan, CK | 1 |
| Lee, AS | 1 |
| Rosenfeld, SS | 1 |
| Yun, K | 1 |
| Johnson, AJ | 1 |
| Mitchell, DA | 1 |
| Jiang, W | 2 |
| Kim, BYS | 1 |
| Chen, G | 3 |
| Ran, D | 1 |
| Chai, Z | 1 |
| Xie, C | 3 |
| Mao, J | 3 |
| Lu, L | 2 |
| Zhan, C | 1 |
| Xu, B | 3 |
| Luo, X | 2 |
| Ning, X | 1 |
| Ling, G | 1 |
| Fisher, BJ | 4 |
| Pugh, SL | 1 |
| Macdonald, DR | 5 |
| Chakravatri, A | 1 |
| Lesser, GJ | 6 |
| Fox, S | 1 |
| Rogers, CL | 1 |
| Werner-Wasik, M | 4 |
| Doyle, T | 1 |
| Bahary, JP | 3 |
| Fiveash, JB | 2 |
| Bovi, JA | 1 |
| Howard, SP | 1 |
| Michael Yu, HH | 1 |
| D'Souza, D | 1 |
| Laack, NN | 3 |
| Barani, IJ | 1 |
| Kwok, Y | 2 |
| Wahl, DR | 1 |
| Strasser, JF | 1 |
| Won, M | 1 |
| Mehta, MP | 5 |
| Shang, S | 1 |
| Qi, Y | 2 |
| Touat, M | 1 |
| Li, YY | 2 |
| Boynton, AN | 1 |
| Spurr, LF | 1 |
| Iorgulescu, JB | 1 |
| Bohrson, CL | 1 |
| Cortes-Ciriano, I | 1 |
| Birzu, C | 1 |
| Geduldig, JE | 1 |
| Pelton, K | 1 |
| Lim-Fat, MJ | 1 |
| Pal, S | 1 |
| Ferrer-Luna, R | 1 |
| Ramkissoon, SH | 1 |
| Dubois, F | 1 |
| Bellamy, C | 1 |
| Currimjee, N | 1 |
| Bonardi, J | 1 |
| Ho, P | 1 |
| Malinowski, S | 1 |
| Taquet, L | 1 |
| Jones, RE | 1 |
| Shetty, A | 1 |
| Chow, KH | 1 |
| Sharaf, R | 1 |
| Pavlick, D | 1 |
| Albacker, LA | 1 |
| Younan, N | 1 |
| Baldini, C | 1 |
| Giry, M | 1 |
| Guillerm, E | 1 |
| Ammari, S | 1 |
| Beuvon, F | 2 |
| Mokhtari, K | 6 |
| Alentorn, A | 3 |
| Dehais, C | 2 |
| Houillier, C | 3 |
| Laigle-Donadey, F | 7 |
| Psimaras, D | 4 |
| Lee, EQ | 2 |
| Nayak, L | 3 |
| McFaline-Figueroa, JR | 1 |
| Carpentier, A | 2 |
| Cornu, P | 3 |
| Capelle, L | 7 |
| Mathon, B | 1 |
| Barnholtz-Sloan, JS | 1 |
| Chakravarti, A | 6 |
| Bi, WL | 1 |
| Fehnel, KP | 1 |
| Alexandrescu, S | 1 |
| Chi, SN | 1 |
| Haas-Kogan, D | 2 |
| Batchelor, TT | 5 |
| Frampton, GM | 1 |
| Alexander, BM | 1 |
| Huang, RY | 1 |
| Ligon, AH | 1 |
| Coulet, F | 1 |
| Delattre, JY | 12 |
| Hoang-Xuan, K | 13 |
| Meredith, DM | 1 |
| Santagata, S | 2 |
| Duval, A | 1 |
| Sanson, M | 11 |
| Cherniack, AD | 1 |
| Marabelle, A | 1 |
| Park, PJ | 2 |
| Beroukhim, R | 1 |
| Bandopadhayay, P | 1 |
| Bielle, F | 1 |
| Sun, W | 3 |
| Lu, Z | 1 |
| Luo, L | 4 |
| Guan, X | 2 |
| Begum, G | 2 |
| Gayden, J | 1 |
| Hasan, MN | 2 |
| Fiesler, VM | 1 |
| Dodelson, J | 1 |
| Kohanbash, G | 2 |
| Hu, B | 2 |
| Amankulor, NM | 2 |
| Castro, MG | 6 |
| Sun, D | 3 |
| Scheetz, L | 1 |
| Kadiyala, P | 2 |
| Son, S | 1 |
| Hassani Najafabadi, A | 1 |
| Aikins, M | 1 |
| Lowenstein, PR | 4 |
| Schwendeman, A | 2 |
| Moon, JJ | 2 |
| Sumorek-Wiadro, J | 1 |
| Zając, A | 1 |
| Bądziul, D | 1 |
| Langner, E | 1 |
| Skalicka-Woźniak, K | 1 |
| Maciejczyk, A | 1 |
| Wertel, I | 1 |
| Rzeski, W | 1 |
| Jakubowicz-Gil, J | 1 |
| Zhan, W | 1 |
| Tan, Q | 1 |
| Sharma, HS | 1 |
| Sharma, A | 1 |
| Wu, B | 2 |
| Lyu, J | 1 |
| Tang, C | 3 |
| Hua, W | 2 |
| Hu, S | 5 |
| Morio, K | 1 |
| Watanabe, J | 1 |
| Tsujimoto, Y | 1 |
| Shi, H | 3 |
| Han, Z | 1 |
| Jia, J | 2 |
| Lu, J | 5 |
| Roberts, TA | 1 |
| Hyare, H | 1 |
| Agliardi, G | 1 |
| Hipwell, B | 1 |
| d'Esposito, A | 1 |
| Ianus, A | 1 |
| Breen-Norris, JO | 1 |
| Ramasawmy, R | 1 |
| Taylor, V | 1 |
| Atkinson, D | 1 |
| Punwani, S | 1 |
| Lythgoe, MF | 1 |
| Siow, B | 1 |
| Rees, J | 4 |
| Panagiotaki, E | 1 |
| Alexander, DC | 1 |
| Walker-Samuel, S | 1 |
| Yan, L | 1 |
| He, X | 3 |
| Sheng, J | 2 |
| Yu, W | 2 |
| Zhu, S | 1 |
| Crotty, EE | 1 |
| Leary, SES | 1 |
| Geyer, JR | 2 |
| Olson, JM | 1 |
| Millard, NE | 1 |
| Sato, AA | 1 |
| Ermoian, RP | 1 |
| Cole, BL | 1 |
| Lockwood, CM | 1 |
| Paulson, VA | 1 |
| Browd, SR | 1 |
| Ellenbogen, RG | 1 |
| Hauptman, JS | 1 |
| Lee, A | 1 |
| Ojemann, JG | 1 |
| Vitanza, NA | 1 |
| Roth, P | 5 |
| Hottinger, AF | 6 |
| Hundsberger, T | 3 |
| Läubli, H | 1 |
| Reinert, M | 1 |
| Mamot, C | 1 |
| Roelcke, U | 4 |
| Pesce, G | 2 |
| Hofer, S | 3 |
| Weller, M | 22 |
| Shen, J | 4 |
| Han, Y | 4 |
| Uram, Ł | 1 |
| Markowicz, J | 1 |
| Misiorek, M | 1 |
| Filipowicz-Rachwał, A | 1 |
| Wołowiec, S | 1 |
| Wałajtys-Rode, E | 1 |
| Wang, LH | 1 |
| Sui, L | 1 |
| Zhao, PH | 1 |
| Ma, HD | 1 |
| Liu, JY | 1 |
| Zhan, ZJ | 1 |
| Wang, YL | 1 |
| Kuo, YJ | 1 |
| Yang, YH | 1 |
| Lee, IY | 1 |
| Chen, PC | 1 |
| Yang, JT | 3 |
| Wang, TC | 2 |
| Lin, MH | 1 |
| Yang, WH | 2 |
| Cheng, CY | 2 |
| Chen, KT | 3 |
| Huang, WC | 1 |
| Lee, MH | 2 |
| Zhan, N | 1 |
| Cai, Q | 2 |
| Geng, R | 1 |
| Xiao, L | 3 |
| Mu, Z | 1 |
| Jiang, S | 1 |
| Jeong, S | 1 |
| Jung, S | 1 |
| Park, GS | 1 |
| Shin, J | 2 |
| Oldrini, B | 1 |
| Vaquero-Siguero, N | 1 |
| Kroon, P | 1 |
| Galán-Ganga, M | 1 |
| Rodriguez-Perales, S | 1 |
| Verhaak, RGW | 1 |
| Rabadan, R | 1 |
| Squatrito, M | 1 |
| Neth, BJ | 1 |
| Ruff, MW | 1 |
| Uhm, JH | 1 |
| Johnson, DR | 1 |
| Divekar, RD | 1 |
| Maddox, DE | 1 |
| Pinto, F | 1 |
| Costa, ÂM | 1 |
| Andrade, RP | 1 |
| Reis, RM | 1 |
| Folcuti, C | 1 |
| Horescu, C | 1 |
| Barcan, E | 1 |
| Alexandru, O | 2 |
| Tuta, C | 1 |
| Vatu, BI | 1 |
| Artene, SA | 1 |
| Dricu, A | 1 |
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Yu, D | 1 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 1 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 1 |
| Maeda, K | 1 |
| Punn, R | 1 |
| Noguchi, S | 2 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Bascuñán, J | 2 |
| Chu, Y | 1 |
| Tomita, M | 1 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Qiu, J | 2 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 1 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Zhao, S | 6 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Liu, ZM | 1 |
| Xue, XD | 1 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Cui, Y | 4 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 1 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 2 |
| Lin, D | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Xu, X | 3 |
| Dong, X | 4 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Dong, JH | 1 |
| Wu, G | 2 |
| Dong, XR | 1 |
| Tang, X | 1 |
| Tao, F | 1 |
| Tao, H | 1 |
| Lei, Y | 1 |
| Gan, H | 1 |
| Shan, A | 1 |
| Ma, Q | 3 |
| Zhang, E | 1 |
| Xue, F | 1 |
| Yan, Z | 2 |
| Meng, J | 2 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 1 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Li, P | 2 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, YS | 1 |
| Zhou, X | 7 |
| Hou, J | 2 |
| Lv, B | 1 |
| Gao, C | 1 |
| Lu, K | 1 |
| Ahmad, NH | 1 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Qu, Y | 3 |
| Yao, H | 2 |
| Lee, DF | 1 |
| Wen, L | 1 |
| Du, F | 1 |
| Ji, H | 2 |
| Wan, L | 1 |
| Wen, Q | 1 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Xiao, Z | 1 |
| Liao, J | 3 |
| Su, X | 2 |
| Bi, Z | 1 |
| Su, Q | 1 |
| Na, KJ | 1 |
| Choi, H | 1 |
| Oh, HR | 1 |
| Kim, YH | 3 |
| Lee, SB | 1 |
| Jung, YJ | 1 |
| Koh, J | 1 |
| Park, S | 1 |
| Lee, HJ | 2 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Cheon, GJ | 1 |
| Kang, KW | 1 |
| Lee, DS | 3 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 1 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 1 |
| Richter, C | 1 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 1 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Cheng, J | 1 |
| Kong, X | 1 |
| Yang, T | 2 |
| Dong, Y | 3 |
| Yuan, Z | 2 |
| Cao, J | 2 |
| Luo, Z | 1 |
| Mei, Z | 1 |
| Liang, C | 1 |
| Yu, K | 2 |
| Zhu, C | 1 |
| Huang, Z | 2 |
| Ge, J | 1 |
| Mi, Y | 1 |
| Kong, H | 1 |
| Xi, D | 1 |
| Ning, Q | 1 |
| Chang, X | 2 |
| Rathore, MG | 1 |
| Reddy, K | 1 |
| Shin, SH | 1 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Dong, Z | 1 |
| Mu, W | 1 |
| Gao, F | 5 |
| Ji, RY | 1 |
| Hou, Y | 5 |
| Tian, J | 2 |
| Ying, S | 1 |
| Tan, M | 1 |
| Feng, G | 1 |
| Kuang, Y | 1 |
| Chen, D | 1 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Kang, J | 2 |
| Cong, Z | 2 |
| Fu, D | 1 |
| Celestrin, CP | 1 |
| Rocha, GZ | 1 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 1 |
| Sahebkar, A | 1 |
| Mannarino, MR | 1 |
| Pirro, M | 1 |
| Patsourakos, NG | 1 |
| Kouvari, M | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 1 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Xi, J | 1 |
| Chen, W | 7 |
| Zhang, F | 1 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Yamada, H | 1 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 2 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Lyu, Y | 1 |
| Yu, N | 1 |
| Wen, Z | 1 |
| Hou, H | 1 |
| Zhao, T | 1 |
| Gupta, A | 1 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Saini, A | 1 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Brown, D | 2 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 1 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Weber, P | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Singh, M | 2 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 1 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Inoue, T | 2 |
| Soshi, S | 1 |
| Kubota, M | 1 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| Johnson, ML | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 1 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 1 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 2 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 2 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Singh, A | 1 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fang, J | 2 |
| Luo, T | 2 |
| Su, H | 1 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Zhao, K | 2 |
| Sacan, O | 1 |
| Turkyilmaz, IB | 1 |
| Bayrak, BB | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Yanardag, R | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Zheng, J | 1 |
| Tan, H | 1 |
| Maji, TK | 1 |
| J R, A | 1 |
| Mukherjee, S | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Dasgupta, K | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Ray, SK | 1 |
| Karmakar, D | 1 |
| Gao, W | 3 |
| Ma, S | 2 |
| Wu, T | 2 |
| Ye, C | 3 |
| Jiang, F | 1 |
| Hong, M | 1 |
| Hussain, M | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jamil, MI | 1 |
| Zhan, X | 1 |
| Cheng, D | 1 |
| Wu, CT | 1 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 1 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 1 |
| Lang, CC | 1 |
| Wang, XW | 1 |
| Yuan, LJ | 1 |
| Chen, WF | 1 |
| Luo, R | 1 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 1 |
| Pellegrini, M | 1 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 1 |
| Begum, R | 1 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 1 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Cui, M | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Gu, L | 2 |
| Mukhtar, A | 1 |
| Zhang, YY | 1 |
| Zhu, Y | 4 |
| Lu, DZ | 1 |
| Dong, W | 2 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Sun, H | 2 |
| Qi, MC | 1 |
| Chang, CC | 1 |
| Dinh, TK | 1 |
| Lee, YA | 1 |
| Wang, FN | 1 |
| Sung, YC | 1 |
| Yu, PL | 1 |
| Chiu, SC | 1 |
| Shih, YC | 1 |
| Wu, CY | 1 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| Moore, J | 1 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Duong, F | 1 |
| Kong, W | 1 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Fei, P | 1 |
| Kang, H | 1 |
| Xing, M | 1 |
| Shao, Z | 1 |
| Yuan, C | 1 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 1 |
| Singh, D | 1 |
| Ward, J | 1 |
| Cooper, A | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Lin, YL | 1 |
| Kuo, YF | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Xiao, M | 1 |
| Feng, X | 1 |
| Gao, R | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 1 |
| Marzo, I | 1 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 1 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Fu, Q | 1 |
| Yang, D | 1 |
| Sarapulova, A | 1 |
| Pang, Q | 2 |
| Wei, L | 1 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Jeong, SH | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Ning, J | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Gao, Z | 1 |
| Cao, T | 1 |
| Fu, Y | 1 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Chu, CH | 1 |
| Roberts, W | 1 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Gong, Q | 1 |
| Song, W | 1 |
| Cao, P | 1 |
| Gu, S | 1 |
| Zhou, G | 3 |
| Toma, C | 1 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Cho, J | 2 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Xie, S | 1 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Hao, Y | 1 |
| Chapovetsky, A | 1 |
| Liu, JJ | 1 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Eekers, DBP | 2 |
| Hoeben, A | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Wesseling, P | 3 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 2 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 1 |
| Hou, G | 1 |
| Cui, J | 1 |
| Xie, H | 1 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Kim, MJ | 1 |
| Han, C | 2 |
| White, K | 1 |
| Park, HJ | 1 |
| Boyd, K | 1 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Feng, J | 3 |
| Cheng, Q | 1 |
| Ren, X | 4 |
| Wei, Q | 1 |
| Pan, W | 1 |
| Situ, B | 1 |
| An, T | 1 |
| Zheng, L | 1 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 1 |
| Teixeira, JP | 1 |
| Costa, C | 1 |
| Syed, A | 1 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Ye, J | 1 |
| Liao, W | 1 |
| Zhang, P | 6 |
| Nabi, M | 1 |
| Cai, Y | 3 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Volpin, F | 1 |
| Woo, YC | 1 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Kamada, M | 1 |
| Ikeda, K | 3 |
| Manome, Y | 3 |
| Tseng, BJ | 1 |
| Tsai, YH | 1 |
| Tseng, SH | 1 |
| Duc, TC | 1 |
| Huang, M | 1 |
| Hartman, H | 1 |
| Feng, Y | 2 |
| Long, W | 1 |
| Qin, C | 1 |
| Xiao, K | 1 |
| Xiao, Q | 1 |
| Qin, H | 1 |
| Xu, Q | 3 |
| Zhao, L | 5 |
| Golebiewska, A | 1 |
| Hau, AC | 1 |
| Oudin, A | 1 |
| Stieber, D | 1 |
| Yabo, YA | 1 |
| Baus, V | 1 |
| Barthelemy, V | 1 |
| Klein, E | 1 |
| Bougnaud, S | 1 |
| Keunen, O | 1 |
| Wantz, M | 1 |
| Michelucci, A | 1 |
| Neirinckx, V | 1 |
| Muller, A | 1 |
| Kaoma, T | 1 |
| Nazarov, PV | 1 |
| Azuaje, F | 1 |
| De Falco, A | 1 |
| Flies, B | 1 |
| Richart, L | 1 |
| Poovathingal, S | 1 |
| Arns, T | 1 |
| Grzyb, K | 1 |
| Mock, A | 1 |
| Steino, A | 1 |
| May, P | 1 |
| Miletic, H | 1 |
| Malta, TM | 1 |
| Noushmehr, H | 1 |
| Jahn, W | 1 |
| Klink, B | 1 |
| Tanner, G | 1 |
| Stead, LF | 1 |
| Mittelbronn, M | 3 |
| Skupin, A | 1 |
| Hertel, F | 1 |
| Bjerkvig, R | 1 |
| Niclou, SP | 1 |
| Mao, P | 1 |
| Jing, J | 1 |
| Yu, X | 3 |
| Saeed, H | 1 |
| Tseng, YD | 1 |
| Afzalipour, R | 1 |
| Khoei, S | 1 |
| Khoee, S | 1 |
| Shirvalilou, S | 1 |
| Raoufi, NJ | 1 |
| Motevalian, M | 1 |
| Karimi, MY | 1 |
| Saini, G | 1 |
| Jalali, R | 5 |
| Ni, XR | 1 |
| Guo, CC | 5 |
| Yu, YJ | 1 |
| Yu, ZH | 1 |
| Cai, HP | 1 |
| Wu, WC | 1 |
| Ma, JX | 1 |
| Chen, FR | 5 |
| Chen, ZP | 9 |
| Mo, L | 2 |
| Tang, F | 1 |
| Yao, X | 1 |
| Shu, C | 1 |
| Xiong, J | 1 |
| Król, SK | 1 |
| Bębenek, E | 1 |
| Sławińska-Brych, A | 1 |
| Dmoszyńska-Graniczka, M | 1 |
| Boryczka, S | 1 |
| Stepulak, A | 1 |
| Shoji, T | 1 |
| Inoue, J | 1 |
| Osada, Y | 1 |
| Shimoda, Y | 1 |
| Uenohara, H | 1 |
| Masamune, A | 1 |
| Cloughesy, TF | 5 |
| Walbert, T | 2 |
| Butowski, N | 4 |
| Salacz, M | 1 |
| Perry, J | 3 |
| Damek, D | 2 |
| Bota, D | 1 |
| Bettegowda, C | 2 |
| Iwamoto, F | 1 |
| Placantonakis, D | 1 |
| Kim, L | 2 |
| Elder, B | 1 |
| Kaptain, G | 1 |
| Cachia, D | 1 |
| Moshel, Y | 1 |
| Brem, S | 2 |
| Piccioni, D | 1 |
| Landolfi, J | 1 |
| Chen, CC | 7 |
| Gruber, H | 1 |
| Rao, AR | 1 |
| Hogan, D | 1 |
| Accomando, W | 1 |
| Ostertag, D | 1 |
| Montellano, TT | 1 |
| Kheoh, T | 1 |
| Kabbinavar, F | 1 |
| Drijver, AJ | 1 |
| Bromberg, JC | 1 |
| Ben Hassel, M | 2 |
| Vauleon, E | 3 |
| Tzuk-Shina, T | 2 |
| Lucas, A | 1 |
| Freixa, SV | 1 |
| Gorlia, T | 7 |
| Stupp, R | 22 |
| Baumert, BG | 11 |
| Cheng, H | 1 |
| Lohmann, P | 1 |
| Shah, NJ | 1 |
| Yan, P | 1 |
| Jia, X | 2 |
| Patrizz, A | 1 |
| Dono, A | 1 |
| Zorofchian, S | 1 |
| Hines, G | 1 |
| Takayasu, T | 1 |
| Husein, N | 1 |
| Arevalo, O | 1 |
| Choi, HA | 1 |
| Savarraj, J | 1 |
| Tandon, N | 1 |
| Ganesh, BP | 1 |
| Kaur, B | 3 |
| McCullough, LD | 1 |
| Esquenazi, Y | 1 |
| Riva, M | 1 |
| Wouters, R | 1 |
| Sterpin, E | 1 |
| Giovannoni, R | 1 |
| Boon, L | 1 |
| Himmelreich, U | 1 |
| Gsell, W | 1 |
| Van Ranst, M | 1 |
| Coosemans, A | 1 |
| Nickerson, JP | 1 |
| Sayama, C | 1 |
| Raslan, AM | 1 |
| Ambady, P | 1 |
| Corless, CL | 1 |
| Nazemi, KJ | 1 |
| Zhu, H | 1 |
| Carney, SV | 1 |
| Gauss, JC | 1 |
| Garcia-Fabiani, MB | 1 |
| Haase, S | 1 |
| Alghamri, MS | 1 |
| Núñez, FJ | 1 |
| Taher, A | 1 |
| Nunez, FM | 1 |
| Edwards, MB | 1 |
| Kleer, CG | 1 |
| Appelman, H | 1 |
| Serrano-Heras, G | 2 |
| Castro-Robles, B | 1 |
| Romero-Sánchez, CM | 1 |
| Carrión, B | 1 |
| Barbella-Aponte, R | 1 |
| Sandoval, H | 1 |
| Segura, T | 2 |
| Wang, A | 2 |
| Sha, C | 2 |
| Sun, K | 2 |
| Chonco, L | 1 |
| Landete-Castillejos, T | 1 |
| Serrano, MP | 1 |
| Pérez-Barbería, FJ | 1 |
| González-Armesto, C | 1 |
| García, A | 1 |
| de Cabo, C | 1 |
| Lorenzo, JM | 1 |
| Oprita, A | 1 |
| Baloi, SC | 1 |
| Staicu, GA | 1 |
| Tache, DE | 1 |
| Danoiu, S | 1 |
| Micu, ES | 1 |
| Sevastre, AS | 1 |
| Wang, CY | 2 |
| Shi, S | 1 |
| Lu, S | 2 |
| Jing, X | 1 |
| Abbaszade, Z | 1 |
| Bagca, BG | 1 |
| Avci, CB | 1 |
| Okamura, R | 1 |
| Piccioni, DE | 2 |
| Boichard, A | 1 |
| Lee, S | 2 |
| Jimenez, RE | 1 |
| Sicklick, JK | 1 |
| Kato, S | 1 |
| Kurzrock, R | 1 |
| Inoue, M | 1 |
| Ichikawa, T | 1 |
| Kurozumi, K | 1 |
| Matsumoto, Y | 1 |
| Nakamoto, Y | 1 |
| Akiyoshi, H | 1 |
| Kamishina, H | 1 |
| Yuan, Q | 2 |
| Yang, W | 3 |
| Zuo, M | 2 |
| Xia, X | 3 |
| Shi, L | 4 |
| Zhou, Q | 4 |
| Steidl, E | 1 |
| Wagner, M | 1 |
| Divé, I | 1 |
| Bähr, O | 2 |
| Munisamy, M | 1 |
| Munisamy, S | 1 |
| Kumar, JP | 1 |
| Jose, A | 1 |
| Thomas, L | 1 |
| Baburaj, G | 1 |
| Subbiah, V | 1 |
| Gong, Y | 1 |
| Xiang, P | 1 |
| Fan, T | 1 |
| Jiang, Q | 2 |
| Dong, J | 4 |
| Yang, ZJ | 1 |
| Zhang, LL | 1 |
| Bi, QC | 1 |
| Gan, LJ | 1 |
| Wei, MJ | 1 |
| Hong, T | 1 |
| Tan, RJ | 1 |
| Lan, XM | 1 |
| Liu, LH | 1 |
| Han, XJ | 1 |
| Jiang, LP | 1 |
| Wielgat, P | 1 |
| Wawrusiewicz-Kurylonek, N | 1 |
| Czarnomysy, R | 1 |
| Rogowski, K | 1 |
| Bielawski, K | 1 |
| Car, H | 1 |
| Lo Dico, A | 2 |
| Martelli, C | 2 |
| Diceglie, C | 2 |
| Ottobrini, L | 2 |
| Gu, WT | 1 |
| Cheng, K | 1 |
| Jia, PF | 1 |
| Zhang, WF | 1 |
| Qiu, JT | 1 |
| Wu, ZB | 1 |
| Zhao, WG | 1 |
| Trifiletti, DM | 1 |
| Brown, PD | 1 |
| Zhang, B | 2 |
| Gao, Q | 1 |
| Ye, F | 1 |
| Qin, X | 1 |
| Jia, S | 1 |
| Pan, D | 1 |
| Jin, F | 1 |
| Li, ZY | 2 |
| Yuan, SW | 1 |
| Song, YY | 1 |
| Hameed, NUF | 1 |
| Zhuang, DX | 1 |
| Lu, JF | 1 |
| Gong, FY | 1 |
| Aibaidula, A | 1 |
| Shi, ZF | 1 |
| Guo, QH | 1 |
| Wu, JS | 1 |
| Caylioglu, D | 1 |
| Meyer, RJ | 1 |
| Hellmold, D | 1 |
| Kubelt, C | 1 |
| Synowitz, M | 4 |
| Held-Feindt, J | 6 |
| Villanueva-Meyer, J | 1 |
| Hilz, S | 1 |
| Solomon, DA | 1 |
| Choi, S | 2 |
| Wahl, M | 3 |
| Mazor, T | 3 |
| Shai, A | 1 |
| Wainer, BH | 1 |
| McDermott, M | 1 |
| Taylor, JW | 1 |
| Clarke, JL | 3 |
| Oberheim Bush, NA | 1 |
| Cheng, HS | 1 |
| Marvalim, C | 1 |
| Law, CLD | 1 |
| Low, ZYJ | 1 |
| Chong, YK | 1 |
| Ang, BT | 2 |
| Tan, NS | 1 |
| He, C | 1 |
| Wang, XZ | 1 |
| Wang, CC | 1 |
| Liang, SP | 1 |
| Luo, TF | 1 |
| Wang, ZC | 1 |
| Piao, MH | 1 |
| Chi, GF | 1 |
| Ge, PF | 1 |
| Li, XC | 1 |
| Wu, BS | 1 |
| Wang, ZF | 2 |
| Li, YR | 1 |
| Yao, J | 2 |
| Jin, XQ | 1 |
| Li, ZQ | 1 |
| Babu, D | 1 |
| Mudiraj, A | 1 |
| Yadav, N | 1 |
| Y B V K, C | 1 |
| Panigrahi, M | 1 |
| Prakash Babu, P | 1 |
| Lin, S | 2 |
| Wei, X | 2 |
| Zang, L | 1 |
| Che, F | 1 |
| You, H | 1 |
| Sasaki, H | 3 |
| Oronsky, B | 1 |
| Reid, T | 1 |
| Cabrales, P | 1 |
| Romero, D | 1 |
| Chai, W | 1 |
| Tang, D | 3 |
| Shao, D | 1 |
| Si, J | 1 |
| Cao, L | 2 |
| Jiang, Z | 1 |
| Wei, D | 1 |
| Singh, P | 1 |
| Lee, T | 1 |
| Mandl, HK | 1 |
| Piotrowski-Daspit, AS | 1 |
| Cheng, Y | 6 |
| Josowitz, A | 1 |
| Huttner, A | 1 |
| Bindra, RS | 1 |
| Xiao, H | 3 |
| Mark Saltzman, W | 1 |
| Feng, W | 1 |
| Chen, JC | 1 |
| Hwang, JH | 1 |
| Juric, V | 1 |
| Düssmann, H | 1 |
| Rehm, M | 2 |
| Murphy, BM | 2 |
| Tsai, HC | 1 |
| Wei, KC | 4 |
| Chen, PY | 3 |
| Huang, CY | 3 |
| Lin, YJ | 4 |
| Cheng, HW | 1 |
| Huang, CH | 1 |
| Wang, HT | 1 |
| Gao, K | 2 |
| Qiao, Y | 1 |
| Cui, B | 2 |
| Han, J | 2 |
| Chu, L | 1 |
| Xi, X | 1 |
| Kan, R | 1 |
| Ahn, GS | 1 |
| Anand, S | 1 |
| Panda, P | 1 |
| Moiyadi, A | 2 |
| Krishnatry, R | 2 |
| Kuang, W | 1 |
| Tian, Y | 3 |
| Xue, BZ | 1 |
| Wang, HF | 1 |
| Zhou, YJ | 1 |
| Tian, H | 1 |
| Abdelmaksou, A | 1 |
| Xue, J | 1 |
| Sun, MX | 1 |
| Yi, DY | 1 |
| Xiong, NX | 1 |
| Jiang, XB | 2 |
| Zhao, HY | 1 |
| Fu, P | 1 |
| Miao, YB | 1 |
| Chen, KH | 1 |
| Chen, CT | 1 |
| Mi, FL | 1 |
| Chiang, CS | 1 |
| Wang, JT | 1 |
| Lin, KJ | 1 |
| Sung, HW | 1 |
| Feng, M | 1 |
| Gan, W | 1 |
| Karami, A | 1 |
| Hossienpour, M | 1 |
| Mohammadi Noori, E | 1 |
| Rahpyma, M | 1 |
| Najafi, K | 1 |
| Kiani, A | 1 |
| Heravi Shargh, V | 1 |
| Luckett, J | 1 |
| Bouzinab, K | 1 |
| Paisey, S | 1 |
| Turyanska, L | 1 |
| Singleton, WGB | 1 |
| Lowis, S | 1 |
| Gershkovich, P | 1 |
| Bradshaw, TD | 3 |
| Stevens, MFG | 1 |
| Bienemann, A | 1 |
| Coyle, B | 1 |
| Zhao, B | 2 |
| Tesileanu, M | 1 |
| Verma, V | 2 |
| Mohania, D | 1 |
| Gupta, S | 1 |
| Babbar, AK | 1 |
| Rathi, B | 1 |
| Dhanda, RS | 1 |
| Yadav, M | 1 |
| Huang, R | 2 |
| Tomar, MS | 1 |
| Kumar, A | 1 |
| Srivastava, C | 1 |
| Shrivastava, A | 1 |
| Han, W | 1 |
| Cheng, S | 1 |
| Qian, Z | 1 |
| Salama, S | 1 |
| Sharaf, M | 1 |
| Salem, SM | 1 |
| Rasheed, MA | 1 |
| Salama, E | 1 |
| Elnahas, T | 1 |
| Lotfy, R | 1 |
| Zhong, X | 1 |
| Madhusudhan, T | 1 |
| Qu, X | 2 |
| Guo, K | 1 |
| Huang, Q | 3 |
| Dou, W | 1 |
| Feng, L | 1 |
| Han, L | 4 |
| Martins, ICA | 1 |
| Contieri, LS | 1 |
| Amaral, CL | 1 |
| Costa, SO | 1 |
| Souza, ACP | 1 |
| Ignacio-Souza, LM | 1 |
| Milanski, M | 1 |
| Torsoni, AS | 1 |
| Torsoni, MA | 1 |
| Braverman, V | 1 |
| Drineas, P | 1 |
| Musco, C | 2 |
| Upadhyay, J | 1 |
| Woodruff, DP | 1 |
| Zhou, S | 1 |
| Thurnherr, E | 1 |
| Meaney, CJ | 1 |
| Fusco, NM | 1 |
| Schultz, K | 1 |
| Enterline, L | 1 |
| Igboechi, O | 1 |
| Brahmbhatt, P | 1 |
| Hinkley, J | 1 |
| Clement, C | 1 |
| Harris, SN | 1 |
| Ortolan, SC | 1 |
| Edmonds, CR | 1 |
| Fields, KG | 1 |
| Liguori, GA | 1 |
| Galal, S | 1 |
| Principe, P | 1 |
| Mehta, R | 1 |
| Khabyeh-Hasbani, N | 1 |
| Hamilton, A | 1 |
| Fragomen, A | 1 |
| Rozbruch, SR | 1 |
| Ashouri-Sanjani, M | 1 |
| Mohammadi-Moghadam, S | 1 |
| Azimi, P | 1 |
| Arjmand, N | 1 |
| Lamplot, JD | 1 |
| Premkumar, A | 1 |
| James, EW | 1 |
| Lawton, CD | 1 |
| Pearle, AD | 1 |
| Azzalin, A | 1 |
| Nato, G | 1 |
| Parmigiani, E | 1 |
| Garello, F | 1 |
| Buffo, A | 1 |
| Magrassi, L | 2 |
| Carroll, KT | 1 |
| Hirshman, B | 1 |
| Ali, MA | 1 |
| Alattar, AA | 1 |
| Brandel, MG | 2 |
| Lochte, B | 1 |
| Lanman, T | 1 |
| Carter, B | 2 |
| Finocchiaro, G | 1 |
| Langella, T | 1 |
| Corbetta, C | 1 |
| Pellegatta, S | 1 |
| Supko, JG | 2 |
| Desai, AS | 1 |
| Read, WL | 1 |
| Lieberman, FS | 2 |
| Lodge, MA | 1 |
| Leal, J | 1 |
| Fisher, JD | 1 |
| Desideri, S | 4 |
| Grossman, SA | 4 |
| Wahl, RL | 1 |
| Sun, P | 1 |
| Lv, M | 1 |
| Tong, G | 1 |
| Jin, X | 1 |
| Ning, B | 2 |
| Qiu, B | 4 |
| Guan, Y | 1 |
| Wu, A | 5 |
| Коbylinska, LI | 1 |
| Klyuchivska, OY | 1 |
| Grytsyna, II | 1 |
| Finiuk, N | 1 |
| Panchuk, RR | 1 |
| Starykovych, MO | 1 |
| Lehka, L | 1 |
| Lesyk, RB | 1 |
| Zіmenkovsky, BS | 1 |
| Stoika, RS | 1 |
| Wang, HW | 2 |
| Xu, ZK | 1 |
| Liu, YG | 1 |
| Huang, N | 2 |
| Liu, S | 3 |
| Wu, N | 1 |
| Shen, HY | 1 |
| Weil, S | 1 |
| Osswald, M | 2 |
| Solecki, G | 1 |
| Grosch, J | 1 |
| Jung, E | 1 |
| Lemke, D | 2 |
| Ratliff, M | 1 |
| Hänggi, D | 1 |
| Winkler, F | 4 |
| Sullivan, KE | 1 |
| Rojas, K | 1 |
| Cerione, RA | 1 |
| Nakano, I | 2 |
| Wilson, KF | 1 |
| Silginer, M | 1 |
| Ouyang, L | 1 |
| He, M | 1 |
| Luo, M | 1 |
| Cai, W | 1 |
| Tu, Y | 2 |
| Pi, R | 1 |
| Altinoz, MA | 2 |
| Elmaci, I | 2 |
| Bolukbasi, FH | 1 |
| Ekmekci, CG | 1 |
| Yenmis, G | 1 |
| Sari, R | 1 |
| Sav, A | 1 |
| Ming, J | 2 |
| Oliva, CR | 3 |
| Suto, MJ | 1 |
| Griguer, CE | 3 |
| Ko, CY | 1 |
| Lin, CH | 2 |
| Chuang, JY | 2 |
| Chang, WC | 1 |
| Hsu, TI | 1 |
| Bielecka-Wajdman, AM | 1 |
| Lesiak, M | 1 |
| Ludyga, T | 1 |
| Sieroń, A | 1 |
| Obuchowicz, E | 1 |
| Pejin, B | 1 |
| Tommonaro, G | 1 |
| Glumac, M | 1 |
| Jakimov, D | 1 |
| Kojic, V | 1 |
| Kumthekar, P | 1 |
| Grimm, S | 1 |
| Chandler, J | 1 |
| Mehta, M | 6 |
| Marymont, M | 2 |
| Levy, R | 1 |
| Muro, K | 2 |
| Helenowski, I | 1 |
| McCarthy, K | 2 |
| Fountas, L | 1 |
| Raizer, J | 3 |
| Oliveira, KA | 2 |
| Dal-Cim, TA | 1 |
| Lopes, FG | 2 |
| Nedel, CB | 2 |
| Tasca, CI | 2 |
| Jiang, R | 2 |
| Yi, Y | 1 |
| Kang, L | 1 |
| Chen, CY | 1 |
| Feng, LY | 1 |
| Huang, WT | 1 |
| Chen, CH | 3 |
| Hsu, PW | 1 |
| Hood, LE | 1 |
| Chen, LY | 2 |
| Karremann, M | 1 |
| Krämer, N | 1 |
| Hoffmann, M | 2 |
| Wiese, M | 1 |
| Beilken, A | 1 |
| Corbacioglu, S | 1 |
| Dilloo, D | 1 |
| Driever, PH | 1 |
| Scheurlen, W | 1 |
| Kulozik, A | 1 |
| Gielen, GH | 2 |
| Dürken, M | 1 |
| Shen, M | 1 |
| Duan, Y | 1 |
| Lue, S | 1 |
| Tateishi, K | 1 |
| Higuchi, F | 1 |
| Miller, JJ | 1 |
| Koerner, MVA | 1 |
| Lelic, N | 1 |
| Shankar, GM | 1 |
| Tanaka, S | 4 |
| Fisher, DE | 1 |
| Iafrate, AJ | 1 |
| Wakimoto, H | 1 |
| Chi, AS | 2 |
| Cahill, DP | 3 |
| Dolera, M | 1 |
| Malfassi, L | 1 |
| Bianchi, C | 1 |
| Carrara, N | 1 |
| Finesso, S | 1 |
| Marcarini, S | 1 |
| Mazza, G | 1 |
| Pavesi, S | 1 |
| Sala, M | 1 |
| Urso, G | 1 |
| Kanemura, Y | 1 |
| Sumida, M | 1 |
| Okita, Y | 2 |
| Yoshioka, E | 1 |
| Yamamoto, A | 1 |
| Kanematsu, D | 1 |
| Handa, Y | 1 |
| Fukusumi, H | 1 |
| Inazawa, Y | 1 |
| Takada, AI | 1 |
| Nonaka, M | 1 |
| Nakajima, S | 1 |
| Mori, K | 1 |
| Goto, S | 1 |
| Kamigaki, T | 1 |
| Shofuda, T | 1 |
| Moriuchi, S | 1 |
| Yamasaki, M | 1 |
| Yoo, JY | 1 |
| Abas, FS | 1 |
| Kesanakurti, D | 1 |
| Nagarajan, P | 1 |
| Sulman, EP | 3 |
| Gumin, J | 1 |
| Gurcan, MN | 1 |
| da Silveira, EF | 1 |
| Oliveira, PS | 1 |
| Pacheco, S | 1 |
| do Couto, CT | 1 |
| Beira, FT | 1 |
| Stefanello, FM | 1 |
| Cong, D | 2 |
| Nathan, JK | 1 |
| Brezzell, AL | 1 |
| Kim, MM | 1 |
| Leung, D | 1 |
| Wilkinson, DA | 1 |
| Hervey-Jumper, SL | 1 |
| Parasramka, S | 1 |
| Talari, G | 1 |
| Rosenfeld, M | 2 |
| Villano, JL | 5 |
| Kumari, S | 1 |
| Ahsan, SM | 1 |
| Kumar, JM | 1 |
| Kondapi, AK | 1 |
| Rao, NM | 1 |
| Howard, TA | 1 |
| Zhang, ZH | 1 |
| Fan, XY | 1 |
| Zhao, ZT | 1 |
| Song, YM | 1 |
| Yu, CJ | 1 |
| Herting, CJ | 1 |
| Pitter, KL | 1 |
| Szulzewsky, F | 1 |
| Kaffes, I | 1 |
| Kaluzova, M | 1 |
| Park, JC | 1 |
| Brennan, C | 1 |
| Hambardzumyan, D | 3 |
| Kipper, FC | 1 |
| Silva, AO | 1 |
| Marc, AL | 1 |
| Confortin, G | 1 |
| Junqueira, AV | 1 |
| Neto, EP | 1 |
| Lenz, G | 2 |
| Adhikari, B | 1 |
| Futalan, D | 2 |
| Akers, J | 3 |
| Deming, T | 1 |
| Kim, WJ | 1 |
| Newman, WC | 1 |
| Shiraki, Y | 1 |
| Mii, S | 1 |
| Enomoto, A | 1 |
| Momota, H | 3 |
| Han, YP | 1 |
| Kato, T | 1 |
| Ushida, K | 1 |
| Kato, A | 1 |
| Asai, N | 1 |
| Murakumo, Y | 1 |
| Aoki, K | 1 |
| Ohka, F | 2 |
| Wakabayashi, T | 12 |
| Todo, T | 3 |
| Ogawa, S | 1 |
| Natsume, A | 11 |
| Takahashi, M | 1 |
| Yin, X | 1 |
| Zheng, N | 1 |
| Xia, J | 1 |
| Lin, CY | 1 |
| Li, RJ | 1 |
| Seidel, C | 2 |
| Bojko, S | 1 |
| Warmuth-Metz, M | 3 |
| Bison, B | 1 |
| Kortmann, RD | 4 |
| Mathivet, T | 1 |
| Bouleti, C | 1 |
| Van Woensel, M | 1 |
| Stanchi, F | 1 |
| Verschuere, T | 2 |
| Phng, LK | 1 |
| Dejaegher, J | 1 |
| Balcer, M | 1 |
| Matsumoto, K | 1 |
| Georgieva, PB | 1 |
| Belmans, J | 1 |
| Sciot, R | 1 |
| Stockmann, C | 1 |
| Mazzone, M | 1 |
| De Vleeschouwer, S | 1 |
| Gerhardt, H | 1 |
| Chen, YD | 2 |
| Dong, TX | 1 |
| Xu, YT | 1 |
| An, TT | 1 |
| Liu, PF | 1 |
| Yang, XH | 1 |
| Adeberg, S | 1 |
| Bernhardt, D | 1 |
| Harrabi, SB | 1 |
| Uhl, M | 1 |
| Paul, A | 1 |
| Bougatf, N | 1 |
| Unterberg, A | 1 |
| Haberer, T | 2 |
| Combs, SE | 4 |
| Herfarth, K | 1 |
| Debus, J | 5 |
| Rieken, S | 2 |
| Lee, IN | 1 |
| Lu, FJ | 1 |
| Chung, CY | 1 |
| Cheng, YC | 1 |
| Lu, D | 2 |
| Teng, L | 1 |
| Zhou, F | 2 |
| Yu, L | 2 |
| Roux, A | 1 |
| Caire, F | 1 |
| Guyotat, J | 3 |
| Menei, P | 3 |
| Metellus, P | 3 |
| Pallud, J | 3 |
| Shen, F | 3 |
| Fang, X | 2 |
| Izquierdo, C | 1 |
| Simó, M | 1 |
| Kaloshi, G | 7 |
| Ricard, D | 4 |
| Barritault, M | 1 |
| Meyronet, D | 1 |
| Bruna, J | 1 |
| Honnorat, J | 2 |
| Ducray, F | 5 |
| Zheng, M | 1 |
| Xie, L | 1 |
| Le Rhun, E | 1 |
| Carideo, L | 1 |
| Minniti, G | 3 |
| Mamede, M | 1 |
| Scaringi, C | 2 |
| Russo, I | 1 |
| Scopinaro, F | 1 |
| Cicone, F | 1 |
| Sharma, AK | 2 |
| Gupta, L | 1 |
| Sahu, H | 1 |
| Qayum, A | 1 |
| Singh, SK | 1 |
| Nakhate, KT | 1 |
| Gupta, U | 1 |
| Lai, SW | 1 |
| Huang, BR | 1 |
| Liu, YS | 1 |
| Lin, HY | 1 |
| Tsai, CF | 2 |
| Lu, DY | 1 |
| Lin, C | 1 |
| Flüh, C | 2 |
| Chitadze, G | 1 |
| Adamski, V | 1 |
| Hattermann, K | 5 |
| Kabelitz, D | 1 |
| Bady, P | 1 |
| Kurscheid, S | 2 |
| Delorenzi, M | 1 |
| Gijtenbeek, A | 1 |
| Enting, R | 3 |
| Thiessen, B | 4 |
| Chinot, O | 8 |
| Dhermain, F | 4 |
| Brandes, AA | 11 |
| Marosi, C | 5 |
| von Deimling, A | 8 |
| French, P | 1 |
| Hegi, ME | 6 |
| Duan, C | 2 |
| Dinislam, M | 1 |
| Ghia, AJ | 1 |
| Cohen, RJ | 1 |
| Hoang, N | 1 |
| Drappatz, J | 5 |
| Lieberman, F | 4 |
| Zhou, W | 4 |
| Ji, A | 1 |
| Qiu, G | 1 |
| Zeng, X | 3 |
| Leyrer, CM | 1 |
| Parsons, M | 1 |
| Kotecha, R | 1 |
| Prayson, RA | 1 |
| Wang, HC | 2 |
| Lin, YT | 1 |
| Lin, WC | 2 |
| Ho, RW | 1 |
| Tsai, NW | 1 |
| Ho, JT | 2 |
| Lu, CH | 2 |
| Weenink, B | 1 |
| Erdem-Eraslan, L | 1 |
| Sillevis Smitt, P | 1 |
| Vos, M | 1 |
| Ryan, GF | 1 |
| van Linde, ME | 2 |
| Mason, WP | 4 |
| Gijtenbeek, JMM | 2 |
| Balana, C | 5 |
| French, PJ | 2 |
| Sun, G | 1 |
| Vallée, A | 1 |
| Lecarpentier, Y | 1 |
| Guillevin, R | 4 |
| Vallée, JN | 2 |
| Abrunhosa-Branquinho, AN | 1 |
| Bar-Deroma, R | 3 |
| Collette, S | 1 |
| Clementel, E | 1 |
| Hurkmans, CW | 1 |
| Feuvret, L | 3 |
| Van Beek, K | 1 |
| van den Bent, M | 1 |
| Weber, DC | 3 |
| Chio, CC | 2 |
| Chen, KY | 1 |
| Chang, CK | 2 |
| Liu, CC | 1 |
| Liu, SH | 2 |
| Chen, RM | 2 |
| Ahmed, AK | 1 |
| Lv, S | 2 |
| Lim, M | 1 |
| Xia, Y | 1 |
| Zhao, P | 2 |
| Ge, M | 1 |
| Lan, C | 1 |
| Xu, S | 2 |
| Patil, VM | 1 |
| Pande, N | 1 |
| Chandrasekharan, A | 1 |
| M, C | 1 |
| Tonse, R | 1 |
| Dsouza, H | 1 |
| Vallathol, DH | 1 |
| Chakraborty, S | 1 |
| Pandith, AA | 1 |
| Qasim, I | 1 |
| Zahoor, W | 1 |
| Shah, P | 1 |
| Bhat, AR | 1 |
| Sanadhya, D | 1 |
| Shah, ZA | 1 |
| Naikoo, NA | 1 |
| Tan, D | 1 |
| Pang, FM | 1 |
| Liu, ZQ | 2 |
| Franco, DG | 1 |
| Moretti, IF | 1 |
| Marie, SKN | 1 |
| Liu, N | 5 |
| Jin, W | 1 |
| Chu, CW | 1 |
| Yang, MC | 2 |
| Chou, CH | 2 |
| Huang, WS | 2 |
| Hsiao, BX | 1 |
| Wang, YT | 2 |
| Chiou, SJ | 1 |
| Loh, JK | 2 |
| Hong, YR | 2 |
| Dai, B | 1 |
| Qi, N | 1 |
| Mackay, A | 2 |
| Burford, A | 2 |
| Molinari, V | 1 |
| Jones, DTW | 1 |
| Izquierdo, E | 1 |
| Brouwer-Visser, J | 1 |
| Rodriguez, D | 1 |
| Morgan, PS | 1 |
| Raman, P | 1 |
| Waanders, AJ | 1 |
| Resnick, AC | 1 |
| Massimino, M | 2 |
| Garrè, ML | 2 |
| Smith, H | 1 |
| Pfister, SM | 2 |
| Würdinger, T | 1 |
| Tam, R | 1 |
| Garcia, J | 1 |
| Thakur, MD | 1 |
| Vassal, G | 3 |
| Lam, FC | 1 |
| Morton, SW | 1 |
| Wyckoff, J | 1 |
| Vu Han, TL | 1 |
| Hwang, MK | 1 |
| Maffa, A | 1 |
| Balkanska-Sinclair, E | 1 |
| Yaffe, MB | 1 |
| Floyd, SR | 1 |
| Hammond, PT | 1 |
| Furukawa, R | 1 |
| Homma, H | 1 |
| Horiuchi, H | 1 |
| Usui, K | 1 |
| Loaiza, S | 1 |
| Carvajal, S | 1 |
| Giraldo, D | 1 |
| Galvis, A | 1 |
| Ortiz, L | 1 |
| Grek, CL | 1 |
| Sheng, Z | 2 |
| Naus, CC | 2 |
| Sin, WC | 2 |
| Gourdie, RG | 1 |
| Ghatnekar, GG | 1 |
| Guryanova, OA | 1 |
| Chen, C | 3 |
| Gimple, RC | 1 |
| Kung, HF | 1 |
| Rich, JN | 6 |
| Ping, YF | 1 |
| Bao, S | 2 |
| Ni, Q | 2 |
| Ji, M | 1 |
| Wang, LY | 1 |
| Lü, YH | 1 |
| Lai, FF | 1 |
| Chen, XG | 1 |
| Vu, HT | 1 |
| Hegazy, AM | 1 |
| Tadokoro, Y | 1 |
| Ueno, M | 1 |
| Kasahara, A | 1 |
| Takase, Y | 1 |
| Nomura, N | 1 |
| Peng, H | 1 |
| Ito, C | 1 |
| Ino, Y | 1 |
| Nakada, M | 2 |
| Hirao, A | 1 |
| Mardaleishvili, K | 1 |
| Orkodashvili, G | 1 |
| Sutera, P | 1 |
| Kalash, R | 1 |
| Flickinger, J | 1 |
| Engh, J | 1 |
| Heron, DE | 1 |
| Peng, Y | 2 |
| Shuai, X | 1 |
| Bell, EH | 1 |
| McElroy, JP | 1 |
| Fleming, J | 1 |
| Chakraborty, AR | 1 |
| Becker, AP | 1 |
| Fabian, D | 1 |
| Aldape, KD | 4 |
| Ashby, LS | 1 |
| Walker, EM | 1 |
| Yu, HM | 1 |
| Schultz, CJ | 1 |
| Gray, HJ | 1 |
| Robins, HI | 6 |
| Young, JS | 1 |
| Bernal, G | 1 |
| Polster, SP | 1 |
| Nunez, L | 3 |
| Larsen, GF | 3 |
| Mansour, N | 2 |
| Podell, M | 1 |
| Yamini, B | 5 |
| Calastri, MCJ | 1 |
| Rodrigues, NLTO | 1 |
| Hatori, G | 1 |
| Gregório, ML | 1 |
| Brancati, CIFO | 1 |
| Zanovelo, EM | 1 |
| Ferraz Filho, JRL | 1 |
| Neiva, CM | 1 |
| Rodrigues Junior, ACP | 1 |
| Godoy, MF | 1 |
| Lancelloti, CLP | 1 |
| Tognola, WA | 1 |
| Souza, DRS | 1 |
| Bernal, GM | 3 |
| Cahill, KE | 3 |
| Pytel, P | 4 |
| Fitzpatrick, CA | 1 |
| Mashek, H | 1 |
| Weichselbaum, RR | 4 |
| Wong, ET | 3 |
| Lok, E | 1 |
| Swanson, KD | 1 |
| Abdallah, MB | 1 |
| Blonski, M | 4 |
| Wantz-Mezieres, S | 2 |
| Gaudeau, Y | 2 |
| Taillandier, L | 7 |
| Moureaux, JM | 2 |
| Darlix, A | 2 |
| de Champfleur, NM | 1 |
| Duffau, H | 7 |
| Yu, T | 1 |
| Zhi, T | 1 |
| Koike, H | 1 |
| Bai, Y | 2 |
| Bai, YH | 1 |
| Zhan, YB | 1 |
| Yu, B | 1 |
| Wang, WW | 1 |
| Zhou, JQ | 1 |
| Chen, RK | 1 |
| Zhang, FJ | 1 |
| Zhao, XW | 1 |
| Duan, WC | 1 |
| Wang, YM | 1 |
| Bao, JJ | 1 |
| Zhang, ZY | 1 |
| Liu, XZ | 1 |
| Bi, Y | 1 |
| Yi, D | 1 |
| Gempt, J | 1 |
| Meyer, B | 1 |
| Smits, M | 1 |
| Clement, P | 1 |
| Chinot, OL | 2 |
| de Heer, I | 1 |
| Chai, RC | 1 |
| Zhang, KN | 1 |
| Liu, YQ | 2 |
| Wang, KY | 2 |
| Wang, YZ | 2 |
| López-Valero, I | 1 |
| Torres, S | 2 |
| Salazar-Roa, M | 1 |
| García-Taboada, E | 1 |
| Hernández-Tiedra, S | 1 |
| Guzmán, M | 1 |
| Sepúlveda, JM | 1 |
| Velasco, G | 1 |
| Lorente, M | 1 |
| Roberts, NB | 1 |
| Alqazzaz, A | 1 |
| Hwang, JR | 1 |
| Qi, X | 3 |
| Keegan, AD | 1 |
| Kim, AJ | 1 |
| Winkles, JA | 1 |
| Woodworth, GF | 1 |
| Hu, G | 4 |
| Zou, L | 1 |
| Yuan, AL | 1 |
| Ricks, CB | 1 |
| Bohm, AK | 1 |
| Lun, X | 1 |
| Maxwell, L | 1 |
| Safdar, S | 1 |
| Bukhari, S | 1 |
| Gerber, A | 1 |
| Sayeed, W | 1 |
| Bering, EA | 1 |
| Pedersen, H | 1 |
| Chan, JA | 1 |
| Marra, M | 1 |
| Kaplan, DR | 1 |
| Mason, W | 1 |
| Goodman, LD | 1 |
| Ezhilarasan, R | 1 |
| Kaufmann, AB | 1 |
| Cabral, M | 1 |
| Robbins, SM | 1 |
| Senger, DL | 1 |
| Cairncross, JG | 4 |
| Blough, MD | 2 |
| Garcia, CR | 1 |
| Slone, SA | 1 |
| Morgan, RM | 1 |
| Gruber, L | 1 |
| Kumar, SS | 1 |
| Lightner, DD | 2 |
| Yamashita, AS | 1 |
| da Costa Rosa, M | 1 |
| Borodovsky, A | 1 |
| Festuccia, WT | 1 |
| Chan, T | 1 |
| Riggins, GJ | 1 |
| Chen, MF | 1 |
| Tai, YT | 1 |
| Mohanraj, M | 1 |
| Yang, ST | 1 |
| Schmitt, C | 1 |
| Lucius, R | 2 |
| Hao, J | 1 |
| Haas, B | 1 |
| Schütte, L | 1 |
| Wos-Maganga, M | 1 |
| Weickhardt, S | 1 |
| Timmer, M | 1 |
| Eckstein, N | 1 |
| Carney, KE | 1 |
| Pigott, VM | 1 |
| Persson, AI | 2 |
| Giakoumettis, D | 1 |
| Pourzitaki, C | 1 |
| Vavilis, T | 1 |
| Tsingotjidou, A | 1 |
| Kyriakoudi, A | 1 |
| Tsimidou, M | 1 |
| Boziki, M | 1 |
| Sioga, A | 1 |
| Foroglou, N | 1 |
| Kritis, A | 1 |
| Debus, C | 1 |
| Afshar-Oromieh, A | 1 |
| Floca, R | 1 |
| Ingrisch, M | 1 |
| Knoll, M | 1 |
| Haberkorn, U | 1 |
| Abdollahi, A | 1 |
| Yang, HC | 1 |
| Wang, JY | 1 |
| Bu, XY | 1 |
| Wang, BQ | 1 |
| Yan, ZY | 1 |
| Gao, YS | 1 |
| Han, SY | 1 |
| Qu, MQ | 1 |
| Arora, P | 1 |
| Adams, CH | 1 |
| Gudelsky, G | 1 |
| DasGupta, B | 1 |
| Desai, PB | 1 |
| Hicks, J | 1 |
| Platt, S | 1 |
| Stewart, G | 1 |
| Senneca, C | 1 |
| Holmes, S | 1 |
| Kent, M | 1 |
| Howerth, E | 1 |
| Kaplan, J | 1 |
| Kaplan, E | 1 |
| Kebudi, R | 1 |
| Cakir, FB | 1 |
| Bay, SB | 1 |
| Gorgun, O | 1 |
| Altınok, P | 1 |
| Iribas, A | 1 |
| Agaoglu, FY | 1 |
| Darendeliler, E | 1 |
| Chen, XB | 1 |
| Ding, BQ | 1 |
| Liu, HL | 2 |
| He, T | 1 |
| Shao, N | 1 |
| Xue, L | 1 |
| Zhi, F | 1 |
| Donovan, LE | 1 |
| Lassman, AB | 5 |
| Dworkin, M | 1 |
| Mehan, W | 1 |
| Niemierko, A | 1 |
| Kamran, SC | 1 |
| Lamba, N | 1 |
| Martinez-Lage, M | 1 |
| Navarria, P | 2 |
| Clerici, E | 1 |
| Tomatis, S | 1 |
| Pinzi, V | 1 |
| Ciammella, P | 1 |
| Galaverni, M | 1 |
| Amelio, D | 1 |
| Scartoni, D | 1 |
| Scoccianti, S | 2 |
| Krengli, M | 1 |
| Masini, L | 1 |
| Draghini, L | 1 |
| Maranzano, E | 1 |
| Borzillo, V | 1 |
| Muto, P | 2 |
| Ferrarese, F | 1 |
| Fariselli, L | 2 |
| Livi, L | 1 |
| Pasqualetti, F | 1 |
| Fiorentino, A | 2 |
| Alongi, F | 1 |
| di Monale, MB | 1 |
| Magrini, S | 1 |
| Scorsetti, M | 2 |
| Qi, F | 1 |
| Di, J | 1 |
| Lu, X | 2 |
| Chang, J | 1 |
| Zhao, C | 2 |
| Ren, H | 2 |
| Zhuang, J | 1 |
| Karlsson, I | 1 |
| Veevnik, D | 1 |
| Fedulov, A | 1 |
| Yurkshtovich, N | 1 |
| Yurkshtovich, T | 1 |
| Pejler, G | 1 |
| Lokot, I | 1 |
| Ma, R | 2 |
| Zheng, G | 1 |
| Shao, C | 1 |
| Ozpinar, A | 1 |
| Bilir, A | 2 |
| Wan, X | 1 |
| Alvarez, AA | 1 |
| James, CD | 2 |
| Sastry, N | 1 |
| Cheng, SY | 1 |
| Mainprize, T | 1 |
| Lipsman, N | 1 |
| Bethune, A | 1 |
| Ironside, S | 1 |
| Heyn, C | 1 |
| Alkins, R | 1 |
| Trudeau, M | 1 |
| Hynynen, K | 1 |
| Back, M | 2 |
| Jayamanne, DT | 1 |
| Brazier, D | 1 |
| Newey, A | 1 |
| Bailey, D | 1 |
| Schembri, GP | 1 |
| Hsiao, E | 1 |
| Wong, M | 1 |
| Kastelan, M | 1 |
| Clarke, S | 1 |
| Wheeler, H | 2 |
| Tong, H | 1 |
| Xiao, J | 1 |
| Autran, D | 1 |
| Barrie, M | 1 |
| Matta, M | 1 |
| Monserrat, C | 1 |
| Campello, C | 2 |
| Petrirena, G | 1 |
| Boucard, C | 1 |
| Padovani, L | 1 |
| Loundou, A | 1 |
| Appay, R | 1 |
| Graillon, T | 1 |
| Dufour, H | 1 |
| Tabouret, E | 2 |
| Zong, Z | 1 |
| Pan, B | 1 |
| Mei, LH | 1 |
| Rutong, Y | 1 |
| Wei, M | 2 |
| Huang, S | 2 |
| Guo, Q | 2 |
| Maurer, GD | 2 |
| Heller, S | 1 |
| Wanka, C | 1 |
| Rieger, J | 2 |
| Fu, T | 1 |
| Gao, M | 1 |
| Deweyert, A | 1 |
| Iredale, E | 1 |
| Wong, E | 1 |
| Schmid, S | 1 |
| Hebb, MO | 1 |
| Liu, G | 3 |
| Yi, K | 1 |
| Cheng, W | 1 |
| Samo, AA | 1 |
| Salomoni, P | 1 |
| Fan, X | 4 |
| Pandey, V | 1 |
| Ranjan, N | 1 |
| Narne, P | 1 |
| Babu, PP | 1 |
| Han, N | 1 |
| Xu, HY | 1 |
| Tan, X | 1 |
| Jia, L | 2 |
| Hu, M | 2 |
| Miao, Z | 1 |
| Kumari, N | 1 |
| Thakur, N | 1 |
| Cho, HR | 1 |
| Choi, SH | 2 |
| Jia, Y | 1 |
| Chi, D | 1 |
| Jin, J | 2 |
| Liang, B | 1 |
| Mihajluk, K | 1 |
| Simms, C | 1 |
| Reay, M | 1 |
| Madureira, PA | 1 |
| Howarth, A | 1 |
| Murray, P | 1 |
| Nasser, S | 1 |
| Duckworth, CA | 1 |
| Pritchard, DM | 1 |
| Pilkington, GJ | 1 |
| Hill, R | 1 |
| Milani, R | 2 |
| Brognara, E | 3 |
| Fabbri, E | 2 |
| Manicardi, A | 3 |
| Corradini, R | 3 |
| Finotti, A | 2 |
| Gasparello, J | 2 |
| Borgatti, M | 2 |
| Cosenza, LC | 1 |
| Lampronti, I | 2 |
| Dechecchi, MC | 2 |
| Cabrini, G | 2 |
| Gambari, R | 3 |
| Petővári, G | 1 |
| Dankó, T | 1 |
| Krencz, I | 1 |
| Hujber, Z | 1 |
| Rajnai, H | 1 |
| Vetlényi, E | 1 |
| Raffay, R | 1 |
| Pápay, J | 1 |
| Jeney, A | 1 |
| Sebestyén, A | 1 |
| Liang, J | 2 |
| Dufort, S | 1 |
| Appelboom, G | 1 |
| Verry, C | 1 |
| Barbier, EL | 1 |
| Lux, F | 1 |
| Bräuer-Krisch, E | 1 |
| Sancey, L | 1 |
| Chang, SD | 1 |
| Roux, S | 1 |
| Tillement, O | 1 |
| Le Duc, G | 1 |
| Fleischmann, DF | 1 |
| Unterrainer, M | 1 |
| Corradini, S | 1 |
| Rottler, M | 1 |
| Förster, S | 1 |
| la Fougère, C | 2 |
| Siepmann, T | 1 |
| Schwaiger, M | 2 |
| Bartenstein, P | 1 |
| Belka, C | 2 |
| Albert, NL | 1 |
| Niyazi, M | 2 |
| Gui, S | 1 |
| Pan, J | 1 |
| Fan, J | 2 |
| Lee, D | 2 |
| Ho, AS | 1 |
| Pu, JK | 1 |
| Zhang, XQ | 1 |
| Lee, NP | 1 |
| Day, PJ | 1 |
| Lui, WM | 1 |
| Fung, CF | 1 |
| Leung, GK | 1 |
| Hargrave, D | 2 |
| Geoerger, B | 1 |
| Frappaz, D | 2 |
| Gesner, L | 1 |
| Cisar, L | 1 |
| Breazna, A | 1 |
| Dorman, A | 1 |
| Cruz-Martinez, O | 1 |
| Fuster, JL | 1 |
| Rialland, X | 1 |
| Icher, C | 1 |
| Leblond, P | 1 |
| Ashley, D | 2 |
| Perilongo, G | 2 |
| Elliott, M | 1 |
| English, M | 1 |
| Clausen, N | 1 |
| Gozé, C | 2 |
| Mandonnet, E | 3 |
| Rigau, V | 2 |
| Bauchet, L | 3 |
| Fabbro, M | 2 |
| Beauchesne, P | 2 |
| Baron, MH | 2 |
| Fontaine, D | 2 |
| Czabanka, M | 1 |
| Bruenner, J | 1 |
| Parmaksiz, G | 1 |
| Broggini, T | 1 |
| Topalovic, M | 1 |
| Bayerl, SH | 1 |
| Auf, G | 1 |
| Kremenetskaia, I | 1 |
| Nieminen, M | 1 |
| Jabouille, A | 1 |
| Mueller, S | 1 |
| Harms, U | 1 |
| Harms, C | 1 |
| Heppner, FL | 1 |
| Vajkoczy, P | 2 |
| Kohsaka, S | 1 |
| Kanno, H | 1 |
| Miyakita, Y | 2 |
| Shibui, S | 2 |
| Gutenberg, A | 1 |
| Lumenta, CB | 1 |
| Braunsdorf, WE | 1 |
| Mehdorn, HM | 3 |
| Westphal, M | 2 |
| Giese, A | 2 |
| Kruser, TJ | 1 |
| Sahm, F | 3 |
| Oezen, I | 1 |
| Opitz, CA | 1 |
| Radlwimmer, B | 1 |
| Ahrendt, T | 1 |
| Adams, S | 1 |
| Bode, HB | 1 |
| Guillemin, GJ | 1 |
| Platten, M | 6 |
| Li, RY | 1 |
| Chen, LC | 1 |
| Zhang, HY | 1 |
| Du, WZ | 1 |
| Wang, HB | 1 |
| Wen, JQ | 1 |
| Li, XF | 1 |
| Yang, DB | 1 |
| Li, YL | 1 |
| Jiang, CL | 1 |
| Yang, XJ | 3 |
| Yang, SY | 2 |
| Kumar, DM | 1 |
| Ramachandran, B | 1 |
| Nila, MV | 1 |
| Dharmalingam, K | 1 |
| Rudek, MA | 2 |
| Zadnik, P | 3 |
| Khan, U | 1 |
| Blakeley, JO | 4 |
| Pathak, AP | 1 |
| Berthaut, I | 1 |
| Montjean, D | 1 |
| Dessolle, L | 1 |
| Morcel, K | 1 |
| Deluen, F | 1 |
| Poirot, C | 2 |
| Bashamboo, A | 1 |
| McElreavey, K | 1 |
| Ravel, C | 1 |
| Ruggiero, A | 4 |
| Rizzo, D | 3 |
| Attinà, G | 3 |
| Lazzareschi, I | 4 |
| Maurizi, P | 3 |
| Ridola, V | 4 |
| Mastrangelo, S | 2 |
| Migliorati, R | 1 |
| Bertolini, P | 1 |
| Colosimo, C | 3 |
| Riccardi, R | 4 |
| Gramatzki, D | 1 |
| Herrmann, C | 1 |
| Happold, C | 2 |
| Becker, KA | 1 |
| Gulbins, E | 1 |
| Tabatabai, G | 3 |
| Gielen, PR | 1 |
| Aftab, Q | 1 |
| Ma, N | 1 |
| Chen, VC | 1 |
| Lozinsky, S | 1 |
| Agarwal, S | 1 |
| Al-Keilani, MS | 1 |
| Alqudah, MA | 1 |
| Sibenaller, ZA | 1 |
| Ryken, TC | 1 |
| Assem, M | 1 |
| Sasajima, T | 1 |
| Ono, T | 1 |
| Shimada, N | 1 |
| Doi, Y | 1 |
| Oka, S | 1 |
| Kanagawa, M | 1 |
| Baden, A | 1 |
| Mizoi, K | 1 |
| Niibori-Nambu, A | 1 |
| Midorikawa, U | 1 |
| Mizuguchi, S | 1 |
| Hide, T | 2 |
| Nagai, M | 1 |
| Komohara, Y | 1 |
| Nagayama, M | 1 |
| Hirayama, M | 1 |
| Kobayashi, D | 1 |
| Tsubota, N | 1 |
| Takezaki, T | 2 |
| Nakamura, H | 2 |
| Takeya, M | 1 |
| Kuratsu, J | 2 |
| Araki, N | 1 |
| Köritzer, J | 1 |
| Boxhammer, V | 1 |
| Schäfer, A | 1 |
| Shimizu, T | 1 |
| Klämpfl, TG | 1 |
| Li, YF | 1 |
| Welz, C | 1 |
| Schwenk-Zieger, S | 1 |
| Morfill, GE | 1 |
| Zimmermann, JL | 1 |
| Schlegel, J | 3 |
| Müller, K | 2 |
| Schlamann, A | 2 |
| Vordermark, D | 1 |
| Mohanty, S | 1 |
| Fritzell, S | 1 |
| Sandén, E | 2 |
| Eberstål, S | 1 |
| Díez Valle, R | 1 |
| Slof, J | 1 |
| Galván, J | 1 |
| Arza, C | 1 |
| Romariz, C | 1 |
| Vidal, C | 1 |
| LaRiviere, MJ | 1 |
| Voce, DJ | 2 |
| Kang, S | 1 |
| Spretz, R | 2 |
| Welp, U | 1 |
| Noriega, SE | 1 |
| Lukas, RV | 1 |
| Nicholas, MK | 2 |
| Bruckner, T | 1 |
| Mizoe, JE | 1 |
| Kamada, T | 1 |
| Tsujii, H | 1 |
| Kieser, M | 1 |
| Hayashi, T | 1 |
| Adachi, K | 1 |
| Ohba, S | 4 |
| Hirose, Y | 8 |
| Qiu, ZK | 2 |
| Shen, D | 3 |
| Chen, YS | 3 |
| Yang, QY | 5 |
| Feng, BH | 1 |
| Tsen, AR | 1 |
| Long, PM | 1 |
| Driscoll, HE | 1 |
| Davies, MT | 1 |
| Teasdale, BA | 1 |
| Penar, PL | 1 |
| Pendlebury, WW | 1 |
| Spees, JL | 1 |
| Viapiano, MS | 1 |
| Jaworski, DM | 1 |
| Bailey, S | 1 |
| Howman, A | 1 |
| Wheatley, K | 1 |
| Wherton, D | 1 |
| Boota, N | 1 |
| Pizer, B | 1 |
| Fisher, D | 1 |
| Kearns, P | 1 |
| Picton, S | 1 |
| Saran, F | 4 |
| Gibson, M | 1 |
| Glaser, A | 1 |
| Connolly, DJ | 1 |
| Ni, S | 2 |
| Qi, H | 2 |
| Epple, LM | 1 |
| Dodd, RD | 1 |
| Merz, AL | 1 |
| Dechkovskaia, AM | 1 |
| Herring, M | 1 |
| Winston, BA | 1 |
| Lencioni, AM | 1 |
| Russell, RL | 1 |
| Madsen, H | 1 |
| Nega, M | 1 |
| Dusto, NL | 1 |
| White, J | 1 |
| Bigner, DD | 7 |
| Nicchitta, CV | 1 |
| Serkova, NJ | 1 |
| Graner, MW | 1 |
| Mantwill, K | 3 |
| Naumann, U | 1 |
| Seznec, J | 1 |
| Girbinger, V | 1 |
| Lage, H | 2 |
| Surowiak, P | 1 |
| Beier, D | 2 |
| Holm, PS | 3 |
| Yu, H | 2 |
| Zaky, W | 1 |
| Wellner, M | 1 |
| Brown, RJ | 1 |
| Blüml, S | 1 |
| Finlay, JL | 3 |
| Dhall, G | 1 |
| Mannas, JP | 1 |
| Defrates, SR | 1 |
| Pittman, T | 1 |
| Stedt, H | 1 |
| Samaranayake, H | 1 |
| Pikkarainen, J | 1 |
| Määttä, AM | 1 |
| Alasaarela, L | 1 |
| Airenne, K | 1 |
| Ylä-Herttuala, S | 1 |
| Bota, DA | 3 |
| Alexandru, D | 1 |
| Bigner, D | 1 |
| Vredenburgh, J | 3 |
| Quintavalle, C | 1 |
| Mangani, D | 1 |
| Roscigno, G | 1 |
| Romano, G | 1 |
| Diaz-Lagares, A | 1 |
| Iaboni, M | 1 |
| Donnarumma, E | 1 |
| Fiore, D | 1 |
| De Marinis, P | 1 |
| Soini, Y | 1 |
| Esteller, M | 2 |
| Condorelli, G | 1 |
| Ulasov, I | 1 |
| Thaci, B | 1 |
| Sarvaiya, P | 1 |
| Yi, R | 1 |
| Auffinger, B | 1 |
| Kim, CK | 3 |
| Borovjagin, A | 1 |
| Dey, M | 2 |
| Baryshnikov, AY | 1 |
| Lesniak, MS | 4 |
| Fan, CH | 1 |
| Liu, WL | 1 |
| Wen, C | 1 |
| Jiang, G | 2 |
| Brastianos, H | 2 |
| Lal, B | 1 |
| Hwang, L | 2 |
| Wicks, RT | 1 |
| Goodwin, RC | 1 |
| Froklage, FE | 1 |
| Oosterbaan, LJ | 1 |
| Sizoo, EM | 3 |
| de Groot, M | 2 |
| Bosma, I | 2 |
| Sanchez, E | 2 |
| Douw, L | 1 |
| Heimans, JJ | 8 |
| Lagerwaard, FJ | 2 |
| Buter, J | 3 |
| Uitdehaag, BM | 2 |
| Postma, TJ | 6 |
| Liu, XY | 2 |
| Ren, YJ | 1 |
| Yang, WQ | 1 |
| Ming, ZJ | 1 |
| Yang, JM | 2 |
| Shen, W | 1 |
| Hu, JA | 1 |
| Zheng, JS | 1 |
| Johnson, BE | 2 |
| Barnes, M | 1 |
| Aihara, K | 2 |
| McLean, CY | 1 |
| Fouse, SD | 2 |
| Yamamoto, S | 2 |
| Ueda, H | 1 |
| Tatsuno, K | 1 |
| Asthana, S | 1 |
| Jalbert, LE | 1 |
| Nelson, SJ | 1 |
| Bollen, AW | 1 |
| Gustafson, WC | 1 |
| Charron, E | 1 |
| Weiss, WA | 2 |
| Smirnov, IV | 1 |
| Song, JS | 1 |
| Olshen, AB | 1 |
| Cha, S | 1 |
| Moore, RA | 1 |
| Mungall, AJ | 1 |
| Jones, SJM | 1 |
| Hirst, M | 1 |
| Marra, MA | 1 |
| Saito, N | 2 |
| Aburatani, H | 2 |
| Mukasa, A | 2 |
| Taylor, BS | 2 |
| Magaña-Maldonado, R | 1 |
| Manoutcharian, K | 1 |
| Hernández-Pedro, NY | 1 |
| Rangel-López, E | 1 |
| Pérez-De la Cruz, V | 1 |
| Rodríguez-Balderas, C | 1 |
| Sotelo, J | 1 |
| Pineda, B | 1 |
| Tassy, L | 1 |
| Crétel, E | 1 |
| Retornaz, F | 1 |
| Rousseau, F | 1 |
| Kapoor, S | 1 |
| Rallabandi, VP | 1 |
| Sakode, C | 1 |
| Padhi, R | 1 |
| Roy, PK | 1 |
| Low, SY | 1 |
| Ho, YK | 1 |
| Too, HP | 1 |
| Yap, CT | 1 |
| Ng, WH | 2 |
| Choi, EJ | 2 |
| Cho, BJ | 2 |
| Lee, DJ | 2 |
| Hwang, YH | 1 |
| Chun, SH | 1 |
| Kim, HH | 1 |
| Kim, IA | 6 |
| Vallero, SG | 1 |
| Bertin, D | 1 |
| Basso, ME | 1 |
| Pittana, LS | 1 |
| Mussano, A | 1 |
| Fagioli, F | 1 |
| Li, XQ | 2 |
| Ouyang, ZG | 2 |
| Zhang, SH | 2 |
| Shang, Y | 2 |
| Zhen, YS | 2 |
| Kim, SM | 2 |
| Woo, JS | 2 |
| Jeong, CH | 2 |
| Ryu, CH | 2 |
| Jang, JD | 1 |
| Jeun, SS | 3 |
| Fiano, V | 1 |
| Trevisan, M | 1 |
| Trevisan, E | 1 |
| Senetta, R | 1 |
| Castiglione, A | 1 |
| Sacerdote, C | 1 |
| Gillio-Tos, A | 1 |
| De Marco, L | 1 |
| Grasso, C | 1 |
| Magistrello, M | 1 |
| Tondat, F | 1 |
| Merletti, F | 1 |
| Wang, JB | 1 |
| Dong, DF | 1 |
| Wang, MD | 1 |
| Ito, M | 4 |
| Ranjit, M | 1 |
| Senga, T | 1 |
| Motomura, A | 1 |
| Motomura, K | 2 |
| Saito, K | 1 |
| Kato, K | 1 |
| Kato, Y | 1 |
| Soga, T | 1 |
| Mirlohi, S | 1 |
| Duncan, SE | 1 |
| Harmon, M | 2 |
| Case, D | 1 |
| Dietrich, AM | 1 |
| Guckenberger, M | 1 |
| Glück, A | 1 |
| Pietschmann, S | 1 |
| Wawer, A | 1 |
| Kramm, C | 1 |
| Han, SJ | 1 |
| Rolston, JD | 1 |
| Prados, MD | 12 |
| DeSilva, A | 1 |
| Butowski, NA | 1 |
| Anai, S | 1 |
| Shinojima, N | 1 |
| Yano, S | 1 |
| Wainwright, DA | 1 |
| Chang, AL | 1 |
| Balyasnikova, IV | 2 |
| Tobias, A | 1 |
| Kim, JW | 1 |
| Li, WY | 1 |
| Guan, S | 1 |
| Mou, YG | 1 |
| Li, WP | 2 |
| Wang, ZJ | 1 |
| Altonok, D | 1 |
| Sood, S | 1 |
| Konski, A | 1 |
| Poulik, J | 1 |
| Tonder, M | 1 |
| Hottinger, A | 1 |
| Brügge, D | 1 |
| Putora, PM | 1 |
| Xie, B | 1 |
| Fischer, S | 1 |
| Thiepold, AL | 1 |
| Reichert, S | 1 |
| Kögel, D | 2 |
| Paschke, R | 1 |
| Fulda, S | 1 |
| Lebrun-Frenay, C | 1 |
| Gratas, C | 1 |
| Séry, Q | 1 |
| Rabé, M | 1 |
| Oliver, L | 1 |
| Vallette, FM | 3 |
| Shi, Z | 3 |
| Qian, X | 3 |
| Liu, LZ | 2 |
| Jiang, BH | 2 |
| Li, HL | 1 |
| Cui, XL | 1 |
| Zhang, JN | 1 |
| Collins, VP | 2 |
| Ichimura, K | 1 |
| Di, Y | 1 |
| Pearson, D | 1 |
| Chan, R | 1 |
| Thompson, LC | 2 |
| Gabe, R | 2 |
| Brada, M | 9 |
| Stenning, SP | 1 |
| Shi, ZM | 1 |
| Jiang, CF | 1 |
| Chen, QD | 1 |
| Li, DM | 1 |
| Ge, X | 1 |
| Wang, XF | 1 |
| You, YP | 2 |
| Long, H | 1 |
| Que, T | 1 |
| Yi, L | 2 |
| Fang, W | 1 |
| Jain, D | 1 |
| Bajaj, A | 1 |
| Athawale, R | 1 |
| Shrikhande, S | 1 |
| Goel, PN | 1 |
| Nikam, Y | 1 |
| Gude, R | 1 |
| Prashant Raut, P | 1 |
| Nanegrungsunk, D | 1 |
| Onchan, W | 1 |
| Chattipakorn, N | 1 |
| Chattipakorn, SC | 1 |
| Mukherjee, J | 1 |
| See, WL | 1 |
| Pieper, RO | 4 |
| Williams, B | 1 |
| Smolkin, M | 1 |
| Wintermark, M | 1 |
| Shaffrey, ME | 3 |
| Lopes, MB | 1 |
| Bae, SH | 2 |
| Park, MJ | 1 |
| Lee, MM | 3 |
| Lee, SH | 2 |
| Cho, SY | 1 |
| Gong, A | 1 |
| Ge, N | 1 |
| Yao, W | 1 |
| Liang, H | 2 |
| Koekkoek, JA | 2 |
| Dirven, L | 2 |
| Vos, MJ | 5 |
| Taphoorn, MJ | 3 |
| Patil, AA | 1 |
| Sayal, P | 1 |
| Depondt, ML | 1 |
| Beveridge, RD | 1 |
| Roylance, A | 1 |
| Kriplani, DH | 1 |
| Myers, KN | 1 |
| Cox, A | 1 |
| Jellinek, D | 1 |
| Fernando, M | 1 |
| Carroll, TA | 1 |
| Collis, SJ | 1 |
| Lan, J | 1 |
| Xue, Y | 1 |
| Master, LM | 1 |
| Master, ZW | 1 |
| Fukai, J | 1 |
| Koizumi, F | 1 |
| Nakao, N | 1 |
| Cheray, M | 1 |
| Nadaradjane, A | 1 |
| Bonnet, P | 1 |
| Routier, S | 1 |
| Cartron, PF | 2 |
| Bao, ZS | 1 |
| Chen, HM | 2 |
| Yang, MY | 1 |
| Zhang, CB | 2 |
| Ye, WL | 1 |
| Hu, BQ | 1 |
| Ramakrishnan, V | 1 |
| Liu, YW | 3 |
| Hu, HM | 1 |
| Li, MY | 2 |
| Yao, K | 4 |
| Qiu, XG | 2 |
| Fan, XL | 1 |
| Song, WS | 1 |
| Li, RQ | 1 |
| Su, XD | 1 |
| Reyes-Botero, G | 1 |
| Martin-Duverneuil, N | 1 |
| Nagaishi, M | 1 |
| Sugiura, Y | 1 |
| Takano, I | 1 |
| Tanaka, Y | 1 |
| Suzuki, K | 3 |
| Yokoo, H | 1 |
| Hyodo, A | 1 |
| Castro, GN | 1 |
| Cayado-Gutiérrez, N | 1 |
| Zoppino, FC | 1 |
| Fanelli, MA | 1 |
| Cuello-Carrión, FD | 1 |
| Sottile, M | 1 |
| Nadin, SB | 1 |
| Ciocca, DR | 1 |
| Wang, SX | 1 |
| Ma, JW | 1 |
| Li, HY | 1 |
| Ye, JC | 1 |
| Xie, SM | 1 |
| Zhong, XY | 1 |
| Lévy, S | 1 |
| Chapet, S | 1 |
| Mazeron, JJ | 1 |
| Meng, D | 1 |
| Sun, R | 1 |
| Huai, C | 1 |
| Qin, R | 1 |
| Xu, T | 3 |
| Yun, D | 1 |
| Ferguson, M | 1 |
| Rodrigues, G | 1 |
| Bauman, G | 1 |
| Miki, Y | 1 |
| Akimoto, J | 2 |
| Omata, H | 1 |
| Moritake, K | 1 |
| Hiranuma, M | 1 |
| Hironaka, C | 1 |
| Fujiwara, Y | 1 |
| Beppu, M | 1 |
| Cai, T | 1 |
| Liao, F | 1 |
| Brynolfsson, P | 1 |
| Nilsson, D | 1 |
| Henriksson, R | 2 |
| Hauksson, J | 1 |
| Karlsson, M | 1 |
| Garpebring, A | 1 |
| Birgander, R | 1 |
| Trygg, J | 1 |
| Nyholm, T | 1 |
| Asklund, T | 1 |
| Shi, W | 2 |
| Zuo, H | 1 |
| Cui, D | 1 |
| Ni, L | 1 |
| van Vugt, VA | 1 |
| Brown, BD | 1 |
| Brown, T | 1 |
| Saria, MG | 1 |
| Juarez, T | 1 |
| Kesari, S | 6 |
| Chai, KM | 1 |
| Liaw, HJ | 1 |
| Fang, KM | 1 |
| Yang, CS | 1 |
| Tzeng, SF | 1 |
| Yang, WB | 1 |
| Xing, BZ | 1 |
| Ling, Q | 1 |
| Xia, M | 1 |
| Jing, L | 1 |
| Gong, H | 1 |
| Tang, Y | 1 |
| Rocha, CR | 2 |
| Garcia, CC | 1 |
| Vieira, DB | 1 |
| Quinet, A | 2 |
| de Andrade-Lima, LC | 1 |
| Munford, V | 1 |
| Belizário, JE | 1 |
| Menck, CF | 3 |
| Du, W | 1 |
| Dou, Z | 1 |
| Chang, L | 1 |
| Qian, C | 1 |
| Zhang, RR | 1 |
| Pointer, KB | 1 |
| Kuo, JS | 1 |
| Dempsey, RJ | 1 |
| Raizer, JJ | 4 |
| Fitzner, KA | 1 |
| Jacobs, DI | 1 |
| Bennett, CL | 1 |
| Liebling, DB | 1 |
| Luu, TH | 1 |
| Trifilio, SM | 1 |
| Grimm, SA | 2 |
| Fisher, MJ | 2 |
| Haleem, MS | 1 |
| Ray, PS | 1 |
| McKoy, JM | 2 |
| DeBoer, R | 1 |
| Tulas, KM | 1 |
| Deeb, M | 1 |
| Scalzone, M | 1 |
| Caldarelli, M | 2 |
| Balducci, M | 2 |
| Chen, JY | 1 |
| Wang, HY | 1 |
| Kostova, Y | 1 |
| Anton, M | 2 |
| Tang, G | 1 |
| Xiao, G | 1 |
| Hori, YS | 1 |
| Hosoda, R | 1 |
| Akiyama, Y | 1 |
| Sebori, R | 1 |
| Wanibuchi, M | 1 |
| Mikami, T | 1 |
| Sugino, T | 1 |
| Maruyama, M | 1 |
| Tsukamoto, M | 1 |
| Mikuni, N | 1 |
| Horio, Y | 1 |
| Kuno, A | 1 |
| Liu, R | 1 |
| Pérès, EA | 1 |
| Gérault, AN | 1 |
| Valable, S | 1 |
| Roussel, S | 1 |
| Toutain, J | 1 |
| Divoux, D | 1 |
| Guillamo, JS | 2 |
| Bernaudin, M | 1 |
| Petit, E | 1 |
| Cheng, JT | 1 |
| Lieu, AS | 1 |
| Howng, SL | 1 |
| Chou, AK | 1 |
| Prager, AJ | 1 |
| Martinez, N | 1 |
| Beal, K | 1 |
| Omuro, A | 7 |
| Young, RJ | 1 |
| Shao, Q | 1 |
| Huang, B | 1 |
| Chen, A | 3 |
| Speirs, CK | 2 |
| Simpson, JR | 2 |
| Robinson, CG | 2 |
| DeWees, TA | 2 |
| Tran, DD | 2 |
| Linette, G | 2 |
| Chicoine, MR | 2 |
| Dacey, RG | 1 |
| Rich, KM | 1 |
| Dowling, JL | 1 |
| Leuthardt, EC | 1 |
| Zipfel, GJ | 1 |
| Kim, AH | 2 |
| Xu, DS | 1 |
| Rosenfeld, A | 1 |
| Ponce, FA | 1 |
| Nakaji, P | 1 |
| Bhardwaj, RD | 1 |
| Pan, SJ | 2 |
| Wu, YB | 1 |
| Cai, S | 1 |
| Pan, YX | 2 |
| Bian, LG | 2 |
| Sun, QF | 2 |
| Hu, C | 1 |
| Coons, SW | 1 |
| Brachman, DG | 1 |
| Ryu, S | 1 |
| Kessler, T | 1 |
| Blaes, J | 2 |
| Rübmann, P | 1 |
| Milford, D | 1 |
| Urban, S | 1 |
| Jestaedt, L | 1 |
| Heiland, S | 1 |
| Bendszus, M | 1 |
| Hertenstein, A | 3 |
| Pfenning, PN | 1 |
| Ruiz de Almodóvar, C | 1 |
| Weiler, M | 2 |
| Gu, Y | 1 |
| Filippi-Chiela, EC | 1 |
| Bueno e Silva, MM | 1 |
| Thomé, MP | 1 |
| van Thuijl, HF | 1 |
| Malmström, A | 1 |
| Hallbeck, M | 1 |
| Kloezeman, JJ | 2 |
| Stenmark-Askmalm, M | 1 |
| Lamfers, ML | 2 |
| Söderkvist, P | 1 |
| Ylstra, B | 1 |
| Turner, KM | 1 |
| Ji, P | 1 |
| Granberg, KJ | 1 |
| Bernard, B | 1 |
| Cogdell, DE | 1 |
| Shmulevich, I | 1 |
| Yung, WK | 12 |
| Fuller, GN | 1 |
| Elhag, R | 1 |
| Mazzio, EA | 1 |
| Soliman, KF | 1 |
| Ampie, L | 1 |
| Kusne, Y | 1 |
| Sanai, N | 1 |
| Tao, B | 2 |
| Zhou, SB | 1 |
| Liu, YC | 1 |
| Yin, XX | 1 |
| Ding, WX | 1 |
| Guo, XW | 1 |
| Huang, XE | 1 |
| Mansour, NM | 1 |
| Crawley, CD | 1 |
| Valtorta, S | 1 |
| Raccagni, I | 1 |
| Belloli, S | 1 |
| Gianelli, U | 1 |
| Vaira, V | 1 |
| Politi, LS | 1 |
| Bosari, S | 1 |
| Lucignani, G | 1 |
| Moresco, RM | 1 |
| Parisi, S | 2 |
| Corsa, P | 1 |
| Raguso, A | 1 |
| Perrone, A | 1 |
| Cossa, S | 1 |
| Munafò, T | 1 |
| Sanpaolo, G | 1 |
| Donno, E | 1 |
| Clemente, MA | 1 |
| Piombino, M | 1 |
| Parisi, F | 1 |
| Valle, G | 1 |
| Qin, T | 1 |
| Chai, H | 1 |
| Tang, T | 1 |
| Yue, J | 1 |
| Kazda, T | 1 |
| Pospisil, P | 1 |
| Vrzal, M | 1 |
| Sevela, O | 1 |
| Prochazka, T | 1 |
| Jancalek, R | 1 |
| Slampa, P | 1 |
| Chintagumpala, M | 3 |
| Eckel, SP | 2 |
| Krailo, M | 1 |
| Morris, M | 1 |
| Packer, R | 1 |
| Lau, C | 1 |
| Gajjar, A | 3 |
| Gu, X | 1 |
| Ma, G | 1 |
| Liang, W | 1 |
| Berghauser Pont, LM | 1 |
| Dirven, CM | 1 |
| Sørensen, MD | 1 |
| Fosmark, S | 1 |
| Hellwege, S | 1 |
| Kristensen, BW | 1 |
| Beier, CP | 1 |
| Panageas, KS | 2 |
| Reiner, AS | 2 |
| Huse, JT | 4 |
| Pentsova, E | 1 |
| Braunthal, SG | 1 |
| Abrey, LE | 4 |
| DeAngelis, LM | 7 |
| Burri, SH | 1 |
| Prabhu, RS | 1 |
| Sumrall, AL | 1 |
| Brick, W | 1 |
| Blaker, BD | 1 |
| Heideman, BE | 1 |
| Boltes, P | 1 |
| Kelly, R | 1 |
| Symanowski, JT | 1 |
| Wiggins, WF | 1 |
| Ashby, L | 1 |
| Norton, HJ | 1 |
| Judy, K | 1 |
| Asher, AL | 2 |
| Levin, VA | 3 |
| Rinne, ML | 1 |
| Choudhury, KR | 1 |
| Ashcraft, KA | 1 |
| Boss, MK | 1 |
| Dewhirst, MW | 1 |
| Du, S | 1 |
| Liao, G | 1 |
| Ren, C | 1 |
| Yuan, YW | 1 |
| Yazaki, T | 2 |
| Katayama, M | 3 |
| Kimura, T | 1 |
| Fujiwara, H | 1 |
| Ohira, T | 1 |
| Yoshida, K | 3 |
| Fathallah-Shaykh, HM | 2 |
| Mohile, N | 1 |
| Lager, JJ | 1 |
| Laird, AD | 1 |
| Egile, C | 1 |
| Badiyan, SN | 1 |
| Mullen, DF | 1 |
| Fergus, S | 1 |
| Dunn, G | 1 |
| Stojković, S | 1 |
| Podolski-Renić, A | 1 |
| Dinić, J | 1 |
| Stanković, T | 1 |
| Banković, J | 1 |
| Hadžić, S | 1 |
| Paunović, V | 1 |
| Isaković, A | 1 |
| Tanić, N | 1 |
| Pešić, M | 1 |
| Bhuvanalakshmi, G | 1 |
| Arfuso, F | 1 |
| Millward, M | 1 |
| Dharmarajan, A | 1 |
| Warrier, S | 1 |
| Stegen, B | 1 |
| Butz, L | 1 |
| Klumpp, L | 1 |
| Zips, D | 1 |
| Dittmann, K | 1 |
| Ruth, P | 1 |
| Huber, SM | 1 |
| Eom, KY | 1 |
| Chie, EK | 1 |
| Wu, HG | 1 |
| Kim, IH | 3 |
| Paek, SH | 1 |
| Kim, JS | 5 |
| Gederaas, OA | 1 |
| Hauge, A | 1 |
| Ellingsen, PG | 1 |
| Berg, K | 1 |
| Altin, D | 1 |
| Bardal, T | 1 |
| Høgset, A | 1 |
| Lindgren, M | 1 |
| Kim, SJ | 1 |
| Kim, MS | 1 |
| Choi, HJ | 1 |
| Aldape, K | 2 |
| Weinberg, JS | 1 |
| Conrad, CA | 2 |
| Langley, RR | 1 |
| Lehembre, F | 1 |
| Regenass, U | 1 |
| Fidler, IJ | 1 |
| Kim, HR | 1 |
| Choi, YR | 1 |
| Zhitao, J | 1 |
| Long, L | 2 |
| Yunchao, B | 1 |
| Anhua, W | 1 |
| Miglio, U | 1 |
| Mezzapelle, R | 1 |
| Paganotti, A | 1 |
| Veggiani, C | 1 |
| Mercalli, F | 1 |
| Mancuso, G | 1 |
| Gaudino, E | 1 |
| Rena, O | 1 |
| Buosi, R | 1 |
| Boldorini, R | 1 |
| Hu, CW | 1 |
| Yin, GF | 1 |
| Wang, XR | 1 |
| Ren, BW | 1 |
| Zhang, WG | 2 |
| Bai, QL | 1 |
| Lv, YM | 1 |
| Li, WL | 1 |
| Zhao, WQ | 1 |
| Towner, RA | 1 |
| Ihnat, M | 1 |
| Saunders, D | 1 |
| Bastian, A | 1 |
| Smith, N | 1 |
| Pavana, RK | 1 |
| Yu, Z | 2 |
| Xie, G | 1 |
| Yao, G | 1 |
| Yao, M | 1 |
| Zong, H | 1 |
| Mao, G | 1 |
| Ye, M | 1 |
| Kerschbaumer, J | 1 |
| Schmidt, FA | 1 |
| Grams, AE | 1 |
| Nowosielski, M | 2 |
| Pinggera, D | 1 |
| Brawanski, KR | 1 |
| Petr, O | 1 |
| Thomé, C | 2 |
| Tuettenberg, J | 2 |
| Seiz, M | 2 |
| Freyschlag, CF | 2 |
| Sugimori, M | 1 |
| Hayakawa, Y | 1 |
| Boman, BM | 1 |
| Fields, JZ | 1 |
| Awaji, M | 1 |
| Kozano, H | 1 |
| Tamura, R | 1 |
| Ogata, T | 1 |
| Endo, S | 1 |
| Kurimoto, M | 1 |
| Kuroda, S | 1 |
| Mikkelsen, T | 1 |
| Rosenfeld, MR | 1 |
| Emmons, G | 1 |
| Garcia Ribas, I | 1 |
| Gurda, D | 1 |
| Głodowicz, P | 1 |
| Nowak, S | 1 |
| Naskręt-Barciszewska, MZ | 1 |
| Panasci, L | 1 |
| Boccard, SG | 1 |
| Marand, SV | 1 |
| Geraci, S | 1 |
| Pycroft, L | 1 |
| Berger, FR | 1 |
| Pelletier, LA | 1 |
| Wan, Y | 1 |
| Xie, D | 2 |
| Lu, P | 1 |
| Xie, J | 1 |
| Yamamoto, T | 3 |
| Nakai, K | 2 |
| Onuma, K | 1 |
| Kim, J | 1 |
| Lee, IH | 1 |
| Jung, YS | 1 |
| Nam, SH | 1 |
| Kim, BS | 1 |
| Johnson, MD | 1 |
| Joo, KM | 1 |
| Lee, J | 1 |
| Bertucci, A | 1 |
| Prasetyanto, EA | 2 |
| Septiadi, D | 1 |
| De Cola, L | 2 |
| Duerinck, J | 1 |
| Du Four, S | 1 |
| Sander, W | 1 |
| Van Binst, AM | 1 |
| Everaert, H | 2 |
| Michotte, A | 3 |
| Hau, P | 8 |
| Neyns, B | 6 |
| Guan, DG | 1 |
| Liao, SF | 1 |
| Zhao, TZ | 1 |
| Kouri, FM | 2 |
| Ritner, C | 1 |
| Stegh, AH | 2 |
| Shibahara, I | 1 |
| Sugiyama, S | 1 |
| Sonoda, Y | 1 |
| Ananta, JS | 1 |
| Paulmurugan, R | 1 |
| Massoud, TF | 1 |
| Wyss, MT | 1 |
| Crippa, F | 1 |
| Azevedo, H | 1 |
| Moreira-Filho, CA | 1 |
| Field, KM | 1 |
| Rosenthal, MA | 5 |
| Sawkins, K | 1 |
| Nowak, AK | 1 |
| Wickström, M | 1 |
| Dyberg, C | 1 |
| Milosevic, J | 1 |
| Einvik, C | 1 |
| Calero, R | 1 |
| Sveinbjörnsson, B | 1 |
| Kool, M | 1 |
| Kogner, P | 1 |
| Baryawno, N | 1 |
| Johnsen, JI | 1 |
| Hummel, TR | 1 |
| Salloum, R | 1 |
| Drissi, R | 1 |
| Kumar, S | 1 |
| Sobo, M | 1 |
| Goldman, S | 2 |
| Pai, A | 1 |
| Leach, J | 1 |
| Lane, A | 1 |
| Pruitt, D | 1 |
| Sutton, M | 1 |
| Chow, LM | 1 |
| Grimme, L | 1 |
| Doughman, R | 1 |
| Backus, L | 1 |
| Miles, L | 1 |
| Stevenson, C | 1 |
| DeWire, M | 1 |
| Wen, S | 1 |
| Liu, K | 1 |
| Luo, Y | 1 |
| Ji, X | 1 |
| Hanihara, M | 1 |
| Kawataki, T | 1 |
| Oh-Oka, K | 1 |
| Mitsuka, K | 1 |
| Nakao, A | 1 |
| Kinouchi, H | 1 |
| Zhao, XC | 1 |
| An, P | 1 |
| Wu, XY | 1 |
| Zhang, LM | 1 |
| Long, B | 1 |
| Chi, XY | 1 |
| Tong, DY | 1 |
| Ghoochani, A | 2 |
| Yakubov, E | 1 |
| Sehm, T | 3 |
| Fan, Z | 2 |
| Hock, S | 1 |
| Buchfelder, M | 3 |
| Eyüpoglu, IY | 4 |
| Savaskan, NE | 3 |
| Jhaveri, N | 3 |
| Agasse, F | 1 |
| Armstrong, D | 1 |
| Peng, L | 1 |
| Commins, D | 1 |
| Rosenstein-Sisson, R | 1 |
| Vaikari, VP | 2 |
| Santiago, SV | 1 |
| Santos, T | 1 |
| Durand, T | 1 |
| Jacob, S | 1 |
| Lebouil, L | 1 |
| Douzane, H | 1 |
| Lestaevel, P | 1 |
| Rahimian, A | 1 |
| Leclercq, D | 1 |
| Brochet, B | 1 |
| Tamarat, R | 1 |
| Milliat, F | 1 |
| Benderitter, M | 1 |
| Vayatis, N | 1 |
| Noël, G | 2 |
| Bernier, MO | 1 |
| Montagner, G | 1 |
| Bianchi, N | 1 |
| Breveglieri, G | 1 |
| Park, M | 1 |
| Choi, KH | 1 |
| Hong, B | 1 |
| Hao, B | 1 |
| Bartolotti, M | 1 |
| Tosoni, A | 5 |
| Franceschi, E | 4 |
| Toler, J | 1 |
| Deputy, S | 1 |
| Zakris, E | 1 |
| Bégué, RE | 1 |
| Nitta, Y | 1 |
| Shimizu, S | 2 |
| Shishido-Hara, Y | 2 |
| Shiokawa, Y | 2 |
| Yao, Z | 1 |
| Dang, X | 1 |
| Álvarez de Eulate-Beramendi, S | 1 |
| Álvarez-Vega, MA | 1 |
| Balbin, M | 1 |
| Sanchez-Pitiot, A | 1 |
| Vallina-Alvarez, A | 1 |
| Martino-González, J | 1 |
| Ouyang, M | 1 |
| White, EE | 1 |
| Zhang, I | 1 |
| Gao, H | 1 |
| Yanyan, S | 1 |
| Weng, Y | 1 |
| Da Fonseca, A | 1 |
| Shah, S | 1 |
| Manuel, ER | 1 |
| Vonderfecht, SL | 1 |
| Alizadeh, D | 1 |
| Berlin, JM | 1 |
| Badie, B | 1 |
| Kushal, S | 1 |
| Kota, R | 1 |
| Yeh, TS | 1 |
| Groshen, SL | 1 |
| Olenyuk, BZ | 1 |
| Shih, JC | 1 |
| Garros-Regulez, L | 1 |
| Aldaz, P | 1 |
| Arrizabalaga, O | 1 |
| Moncho-Amor, V | 1 |
| Carrasco-Garcia, E | 1 |
| Manterola, L | 1 |
| Moreno-Cugnon, L | 1 |
| Barrena, C | 1 |
| Villanua, J | 1 |
| Ruiz, I | 1 |
| Pollard, S | 1 |
| Lovell-Badge, R | 1 |
| Sampron, N | 1 |
| Garcia, I | 1 |
| Matheu, A | 1 |
| Wang, YY | 1 |
| Li, WB | 1 |
| Peng, XX | 1 |
| Conway, GE | 1 |
| Casey, A | 1 |
| Milosavljevic, V | 1 |
| Howe, O | 1 |
| Cullen, PJ | 1 |
| Curtin, JF | 1 |
| Liang, ML | 1 |
| Hsieh, TH | 1 |
| Ng, KH | 1 |
| Tsai, YN | 1 |
| Chao, ME | 1 |
| Liu, DJ | 1 |
| Chu, SS | 1 |
| Liu, YR | 1 |
| Liu, RS | 1 |
| Lin, SC | 1 |
| Ho, DM | 1 |
| Wong, TT | 2 |
| Yang, MH | 1 |
| Gatto, F | 1 |
| Nielsen, J | 1 |
| Maggini, L | 1 |
| Cabrera, I | 1 |
| Ruiz-Carretero, A | 1 |
| Robinet, E | 1 |
| Jakacki, RI | 3 |
| Cohen, KJ | 2 |
| Buxton, A | 1 |
| Krailo, MD | 1 |
| Burger, PC | 3 |
| Rosenblum, MK | 3 |
| Brat, DJ | 2 |
| Hamilton, RL | 3 |
| Lavey, RS | 1 |
| Pollack, IF | 5 |
| Rauh, M | 2 |
| Engelhorn, T | 1 |
| Minakaki, G | 1 |
| Dörfler, A | 1 |
| Klucken, J | 1 |
| Savaskan, N | 1 |
| Yu, G | 1 |
| Wang, E | 1 |
| Ma, ZX | 1 |
| Sidlauskas, K | 1 |
| Zhang, EE | 1 |
| D'Alessandro, G | 1 |
| Grimaldi, A | 1 |
| Chece, G | 1 |
| Porzia, A | 1 |
| Esposito, V | 2 |
| Santoro, A | 2 |
| Salvati, M | 2 |
| Mainiero, F | 1 |
| Ragozzino, D | 1 |
| Di Angelantonio, S | 1 |
| Wulff, H | 1 |
| Catalano, M | 1 |
| Limatola, C | 1 |
| Yeh, PS | 1 |
| Wu, SJ | 1 |
| Hung, TY | 1 |
| Huang, YM | 1 |
| Hsu, CW | 1 |
| Sze, CI | 1 |
| Hsieh, YJ | 1 |
| Huang, CW | 1 |
| Wu, SN | 1 |
| Fowkes, LA | 1 |
| Khabra, K | 1 |
| Moreno, L | 2 |
| Jones, DT | 1 |
| Hovestadt, V | 1 |
| Vaidya, S | 1 |
| Mandeville, H | 1 |
| Jerome, N | 1 |
| Bridges, LR | 1 |
| Laxton, R | 1 |
| Al-Sarraj, S | 1 |
| Leach, MO | 2 |
| Pearson, AD | 2 |
| Koh, DM | 1 |
| Zacharoulis, S | 2 |
| Morr, S | 1 |
| Prasad, D | 1 |
| Mechtler, LL | 1 |
| Fenstermaker, RA | 1 |
| Rotta, JM | 1 |
| de Oliveira, MF | 1 |
| Reis, RC | 1 |
| Botelho, RV | 1 |
| Allen, K | 1 |
| Kirkpatrick, J | 1 |
| Healy, PN | 1 |
| Vredenburgh, JJ | 9 |
| Yang, YR | 1 |
| Chen, MH | 1 |
| Wang, XD | 2 |
| Sun, LL | 1 |
| Wang, FZ | 1 |
| Wang, DC | 1 |
| Grzmil, M | 1 |
| Seebacher, J | 1 |
| Hess, D | 1 |
| Behe, M | 1 |
| Schibli, R | 1 |
| Moncayo, G | 1 |
| Frank, S | 1 |
| Hemmings, BA | 1 |
| Antoni, D | 1 |
| Jastaniah, Z | 1 |
| Haoming, QC | 1 |
| Gaultier, C | 1 |
| Ahle, G | 1 |
| Couchot, J | 1 |
| Atlani, D | 1 |
| Schott, R | 1 |
| Clavier, JB | 1 |
| Srour, R | 1 |
| Chaussemy, D | 1 |
| Kajitani, GS | 1 |
| Fortunato, RS | 1 |
| Hoa, NT | 1 |
| Ge, L | 2 |
| Martini, F | 1 |
| Chau, V | 1 |
| Ahluwalia, A | 1 |
| Kruse, CA | 1 |
| Jadus, MR | 1 |
| Xiao, S | 1 |
| Lv, R | 1 |
| Nolen, SC | 1 |
| Lee, B | 1 |
| Shantharam, S | 1 |
| Yu, HJ | 1 |
| Su, L | 1 |
| Billimek, J | 1 |
| Holla, FK | 1 |
| Blankenstein, MA | 1 |
| van Mierlo, TJM | 1 |
| Uitdehaag, BMJ | 1 |
| Chen, ZY | 1 |
| Xie, SD | 1 |
| Qi, ST | 1 |
| Qi, L | 1 |
| Zhong, Y | 1 |
| Lv, P | 1 |
| Cai, Z | 1 |
| Lan, T | 1 |
| Yu, C | 1 |
| Zhan, Q | 1 |
| Weyhenmeyer, BC | 1 |
| Noonan, J | 1 |
| Würstle, ML | 1 |
| Lincoln, FA | 1 |
| Johnston, G | 1 |
| Zhan, SK | 1 |
| Hoja, S | 1 |
| Schulze, M | 1 |
| Rehli, M | 1 |
| Proescholdt, M | 2 |
| Riemenschneider, MJ | 1 |
| Wilson, TJ | 1 |
| Zamler, DB | 1 |
| Doherty, R | 1 |
| Perry, A | 2 |
| Haas-Kogan, DA | 2 |
| Dayal, M | 1 |
| Prados, M | 6 |
| Nelson, S | 1 |
| You, G | 1 |
| Engel, D | 1 |
| Mentlein, R | 3 |
| Wiendieck, K | 1 |
| Berte, N | 1 |
| Lokan, S | 1 |
| Eich, M | 1 |
| Kaina, B | 5 |
| Ye, JA | 1 |
| Hou, CX | 1 |
| Zhan, SQ | 1 |
| Pinheiro, R | 1 |
| Santos, G | 1 |
| Bronze, MR | 1 |
| Falcão, AS | 1 |
| Dong, L | 1 |
| Bromberg, JEC | 1 |
| Ryan, G | 2 |
| Hassel, MB | 2 |
| Enting, RH | 3 |
| Reni, M | 3 |
| Kantor, G | 2 |
| Verger, E | 1 |
| Borchers, C | 1 |
| Smits, A | 1 |
| Hartmann, C | 5 |
| Bromberg, JE | 3 |
| Rossiter, JP | 1 |
| Dif, N | 1 |
| Bravo-Marques, J | 1 |
| Nordal, RA | 1 |
| Lacombe, D | 1 |
| Akasaki, Y | 2 |
| Kikuchi, T | 1 |
| Homma, S | 1 |
| Koido, S | 1 |
| Ohkusa, T | 1 |
| Tasaki, T | 1 |
| Hayashi, K | 1 |
| Komita, H | 1 |
| Watanabe, N | 1 |
| Suzuki, Y | 1 |
| Yamamoto, Y | 1 |
| Mori, R | 1 |
| Arai, T | 1 |
| Tanaka, T | 2 |
| Joki, T | 1 |
| Yanagisawa, T | 1 |
| Murayama, Y | 1 |
| Villani, V | 1 |
| Merola, R | 1 |
| Vidiri, A | 2 |
| Fabi, A | 1 |
| Carosi, M | 2 |
| Giannarelli, D | 2 |
| Marucci, L | 1 |
| Maschio, M | 1 |
| Cisneros Castillo, LR | 1 |
| Oancea, AD | 1 |
| Stüllein, C | 1 |
| Régnier-Vigouroux, A | 1 |
| Alexiou, GA | 1 |
| Gerogianni, P | 1 |
| Vartholomatos, E | 1 |
| Kyritsis, AP | 3 |
| Gao, YF | 1 |
| Zhu, T | 2 |
| Mao, CX | 1 |
| Liu, ZX | 1 |
| Wang, ZB | 1 |
| Mao, XY | 1 |
| Yin, JY | 1 |
| Zhou, HH | 1 |
| Connelly, J | 1 |
| Hormigo, A | 2 |
| Mohilie, N | 1 |
| Chaudhry, A | 1 |
| Blondin, N | 1 |
| Yang, JP | 1 |
| Tong, J | 1 |
| Jing, SY | 1 |
| Fan, B | 1 |
| Sun, GZ | 1 |
| Li, XM | 1 |
| Yin, AA | 1 |
| Bian, H | 1 |
| Timmons, J | 1 |
| Callahan, A | 1 |
| O'Loughlin, L | 1 |
| Giarusso, B | 1 |
| Alsop, DC | 1 |
| Schliesser, MG | 1 |
| Claus, R | 1 |
| Hielscher, T | 1 |
| Grimm, C | 1 |
| Weichenhan, D | 1 |
| Wiestler, B | 1 |
| Schramm, J | 1 |
| Weiß, EK | 1 |
| Baer, C | 1 |
| Schmidt-Graf, F | 1 |
| Schackert, G | 1 |
| Felsberg, J | 4 |
| Reifenberger, G | 4 |
| Sabel, MC | 3 |
| Meisner, C | 2 |
| Plass, C | 1 |
| Watanabe, S | 1 |
| Kuwabara, Y | 1 |
| Suehiro, S | 1 |
| Yamashita, D | 1 |
| Tanaka, M | 3 |
| Tanaka, A | 1 |
| Ohue, S | 1 |
| Araki, H | 1 |
| Liang, P | 1 |
| Zhu, W | 1 |
| Gui, Q | 1 |
| Guo, X | 1 |
| Gong, Z | 1 |
| Lin, CW | 2 |
| Liu, AJ | 2 |
| Zhai, X | 2 |
| Di, H | 1 |
| Ollier, E | 1 |
| Mazzocco, P | 1 |
| Grenier, E | 1 |
| Samson, A | 1 |
| Park, JS | 3 |
| Kim, IK | 1 |
| Park, I | 1 |
| Kim, C | 1 |
| Bae, J | 1 |
| Oh, SJ | 1 |
| Woo, DC | 1 |
| Augustin, HG | 1 |
| Kim, I | 1 |
| Koh, GY | 1 |
| Shen, WL | 1 |
| Ignarro, RS | 1 |
| Facchini, G | 1 |
| de Melo, DR | 1 |
| Pelizzaro-Rocha, KJ | 1 |
| Ferreira, CV | 1 |
| Castilho, RF | 1 |
| Rogerio, F | 1 |
| Zhu, D | 1 |
| Tu, M | 1 |
| Zeng, B | 1 |
| Zheng, W | 1 |
| Su, Z | 1 |
| de Groot, J | 2 |
| Wefel, JS | 1 |
| Yung, AW | 2 |
| Fisher, J | 1 |
| Peng, R | 1 |
| Liang, F | 1 |
| Bao, L | 1 |
| Zhao, YS | 1 |
| Zhang, SM | 1 |
| Zhang, SQ | 1 |
| Marsoner, T | 1 |
| Schmidt, OP | 1 |
| Triemer, T | 1 |
| Luedtke, NW | 1 |
| Koncar, RF | 1 |
| Chu, Z | 1 |
| Romick-Rosendale, LE | 1 |
| Wells, SI | 1 |
| Chan, TA | 2 |
| Bahassi, EM | 1 |
| Dal-Cim, T | 1 |
| Ludka, FK | 1 |
| Peng, WX | 1 |
| Han, X | 1 |
| Zhang, CL | 1 |
| Du, FY | 1 |
| Gong, AH | 1 |
| Kwintkiewicz, J | 1 |
| Tech, K | 1 |
| Frady, LN | 1 |
| Su, YT | 1 |
| Bautista, W | 1 |
| Moon, SI | 1 |
| MacDonald, J | 1 |
| Ewend, MG | 1 |
| Chamberlain, MC | 4 |
| Colman, H | 1 |
| Kim, BT | 1 |
| Bogdańska, MU | 1 |
| Bodnar, M | 1 |
| Belmonte-Beitia, J | 1 |
| Beck, J | 1 |
| Chen, BD | 1 |
| Li, QZ | 1 |
| Zhang, XJ | 1 |
| Ramachandran, R | 1 |
| Junnuthula, VR | 1 |
| Gowd, GS | 1 |
| Ashokan, A | 1 |
| Thomas, J | 2 |
| Peethambaran, R | 1 |
| Thomas, A | 2 |
| Unni, AK | 1 |
| Panikar, D | 1 |
| Nair, SV | 1 |
| Koyakutty, M | 1 |
| Ben Abdallah, M | 1 |
| Chandran, M | 1 |
| Candolfi, M | 1 |
| Shah, D | 1 |
| Mineharu, Y | 1 |
| Yadav, VN | 1 |
| Koschmann, C | 1 |
| Asad, AS | 1 |
| Feng, HB | 1 |
| Jiang, HR | 1 |
| Mei, X | 1 |
| Zhao, YY | 1 |
| Zhang, ZP | 1 |
| McTyre, E | 1 |
| Lucas, JT | 1 |
| Helis, C | 1 |
| Farris, M | 1 |
| Soike, M | 1 |
| Mott, R | 1 |
| Laxton, AW | 1 |
| Tatter, SB | 1 |
| Strowd, RE | 2 |
| Lo, HW | 1 |
| Chan, MD | 1 |
| Yaman, E | 3 |
| Buyukberber, S | 4 |
| Uner, A | 1 |
| Coskun, U | 4 |
| Akmansu, M | 2 |
| Benekli, M | 4 |
| Yamac, D | 1 |
| Ozturk, B | 3 |
| Kaya, AO | 3 |
| Yildiz, R | 3 |
| Ozkan, S | 1 |
| Gunel, N | 1 |
| Siangprasertkij, C | 1 |
| Navalitloha, Y | 1 |
| Sirachainan, N | 1 |
| Pakakasama, S | 1 |
| Visudithbhan, A | 1 |
| Chiamchanya, S | 1 |
| Tuntiyatorn, L | 1 |
| Dhanachai, M | 1 |
| Laothamatas, J | 1 |
| Hongeng, S | 1 |
| Huang, F | 2 |
| Kavan, P | 2 |
| Guiot, MC | 1 |
| Markovic, Y | 1 |
| Roberge, D | 1 |
| Kobayashi, I | 1 |
| Oka, H | 1 |
| Ujiie, H | 1 |
| Riffkin, CD | 1 |
| Lovric, MM | 1 |
| Mikeska, T | 1 |
| Dobrovic, A | 1 |
| Maxwell, JA | 2 |
| Drummond, KJ | 1 |
| Kaye, AH | 1 |
| Gan, HK | 1 |
| Johns, TG | 1 |
| Hawkins, CJ | 1 |
| Johnson, SP | 1 |
| McLendon, RE | 8 |
| Lister, DW | 1 |
| Horne, KS | 1 |
| Rasheed, A | 1 |
| Quinn, JA | 10 |
| Ali-Osman, F | 1 |
| Friedman, AH | 11 |
| Modrich, PL | 1 |
| Sauvageot, CM | 1 |
| Weatherbee, JL | 1 |
| Winters, SE | 1 |
| Barnes, J | 2 |
| Dellagatta, J | 1 |
| Ramakrishna, NR | 2 |
| Stiles, CD | 1 |
| Kung, AL | 3 |
| Kieran, MW | 3 |
| Dall'oglio, S | 1 |
| D'Amico, A | 1 |
| Pioli, F | 1 |
| Gabbani, M | 1 |
| Pasini, F | 1 |
| Passarin, MG | 1 |
| Talacchi, A | 1 |
| Turazzi, S | 1 |
| Maluta, S | 1 |
| Dario, A | 1 |
| Tomei, G | 1 |
| Perry, JR | 2 |
| Rizek, P | 1 |
| Cashman, R | 1 |
| Morrison, M | 1 |
| Morrison, T | 1 |
| Kang, GS | 1 |
| Mohler, ML | 1 |
| Kirichenko, OV | 1 |
| Patil, R | 1 |
| Orr, WE | 1 |
| Miller, DD | 1 |
| Geisert, EE | 1 |
| Dietrich, PY | 1 |
| Narayana, A | 1 |
| Golfinos, JG | 1 |
| Fischer, I | 1 |
| Raza, S | 1 |
| Kelly, P | 1 |
| Parker, E | 1 |
| Knopp, EA | 2 |
| Medabalmi, P | 1 |
| Zagzag, D | 1 |
| Eagan, P | 1 |
| Gruber, ML | 2 |
| Cordera, S | 1 |
| Joosens, E | 1 |
| Pouratian, N | 3 |
| Nader, P | 1 |
| Remington, M | 1 |
| Chtchetinin, J | 1 |
| Ancheta, K | 1 |
| Nghiemphu, PL | 1 |
| Cloughesy, T | 5 |
| Lai, A | 2 |
| Morris, EB | 1 |
| Kasow, K | 1 |
| Reiss, U | 1 |
| Ellison, D | 1 |
| Kayama, T | 2 |
| Nishikawa, R | 4 |
| Takahashi, H | 4 |
| Yoshimine, T | 2 |
| Hashimoto, N | 3 |
| Aoki, T | 3 |
| Kurisu, K | 1 |
| Ogura, M | 3 |
| Yoshida, J | 7 |
| Shervington, A | 2 |
| Patel, R | 2 |
| Speer, TW | 1 |
| Chua, C | 1 |
| Zaiden, N | 1 |
| Chong, KH | 1 |
| See, SJ | 2 |
| Wong, MC | 1 |
| Linnebank, M | 1 |
| Eisele, G | 1 |
| Hingtgen, S | 1 |
| Terwilliger, E | 1 |
| Classon, M | 1 |
| Weissleder, R | 3 |
| Shah, K | 1 |
| Hassouna, I | 1 |
| Sperling, S | 1 |
| Schulz-Schaeffer, W | 1 |
| Rave-Fränk, M | 1 |
| Hasselblatt, M | 1 |
| Jelkmann, W | 1 |
| Ehrenreich, H | 1 |
| Yang, TM | 1 |
| Chang, WN | 1 |
| Chang, HW | 1 |
| Papait, R | 1 |
| Rigamonti, D | 1 |
| Cattaneo, E | 1 |
| Rosso, L | 1 |
| Brock, CS | 5 |
| Saleem, A | 2 |
| Price, PM | 2 |
| Turkheimer, FE | 1 |
| Aboagye, EO | 2 |
| LaFrankie, D | 1 |
| Doherty, L | 1 |
| Macklin, EA | 1 |
| Muzikansky, A | 1 |
| Norden, AD | 2 |
| Ciampa, A | 1 |
| Bradshaw, J | 1 |
| Levy, B | 1 |
| Radakovic, G | 1 |
| Ramakrishna, N | 3 |
| Black, PM | 1 |
| Watkins, JM | 1 |
| Marshall, DT | 1 |
| Patel, S | 3 |
| Giglio, P | 1 |
| Herrin, AE | 1 |
| Garrett-Mayer, E | 1 |
| Jenrette, JM | 1 |
| Chaskis, C | 2 |
| De Ridder, M | 2 |
| McCann, CM | 1 |
| Waterman, P | 2 |
| Figueiredo, JL | 1 |
| Aikawa, E | 1 |
| Chen, JW | 1 |
| Scheurer, ME | 1 |
| Vera-Bolaños, E | 1 |
| Manning, R | 1 |
| Okcu, MF | 1 |
| Bondy, M | 1 |
| Zhou, R | 2 |
| Milano, V | 1 |
| Piao, Y | 3 |
| LaFortune, T | 1 |
| Lena, A | 1 |
| Rechichi, M | 1 |
| Salvetti, A | 1 |
| Bartoli, B | 1 |
| Vecchio, D | 1 |
| Scarcelli, V | 1 |
| Amoroso, R | 1 |
| Benvenuti, L | 1 |
| Gagliardi, R | 1 |
| Gremigni, V | 1 |
| Rossi, L | 1 |
| Coskun, O | 1 |
| Buyukberber, N | 1 |
| Jiang, SX | 3 |
| Gururangan, S | 9 |
| Sampson, JH | 11 |
| Walker, A | 2 |
| Tritschler, I | 1 |
| Adams, B | 1 |
| Banissi, C | 1 |
| Ghiringhelli, F | 1 |
| Carpentier, AF | 3 |
| Pascher, C | 2 |
| Jauch, T | 2 |
| Bogdahn, U | 4 |
| Ohno, M | 2 |
| Fujii, M | 3 |
| Bleau, AM | 1 |
| Ozawa, T | 2 |
| Fomchenko, EI | 1 |
| Brennan, CW | 1 |
| Holland, EC | 4 |
| Zwinkels, H | 1 |
| Roon, K | 1 |
| Jeurissen, FJ | 1 |
| Hop, WC | 1 |
| Vecht, CJ | 1 |
| Ulasov, IV | 2 |
| Sonabend, AM | 1 |
| Khramtsov, A | 1 |
| Jäger, E | 1 |
| Edelweiss, MI | 1 |
| Pohlmann, AR | 1 |
| Guterres, SS | 1 |
| Bell, D | 1 |
| Molnár, P | 1 |
| Méhes, G | 1 |
| Akbar, U | 1 |
| Jones, T | 3 |
| Winestone, J | 1 |
| Michael, M | 1 |
| Shukla, A | 1 |
| Duntsch, C | 1 |
| Kaliberova, LN | 1 |
| Krendelchtchikova, V | 1 |
| Harmon, DK | 1 |
| Stockard, CR | 1 |
| Petersen, AS | 1 |
| Grizzle, WE | 1 |
| Buchsbaum, DJ | 2 |
| Kaliberov, SA | 1 |
| Wyss, M | 1 |
| Bruehlmeier, M | 1 |
| Hefti, M | 1 |
| Uhlmann, C | 1 |
| Bärtschi, E | 1 |
| Buettner, UW | 1 |
| Virrey, JJ | 1 |
| Golden, EB | 1 |
| Sivakumar, W | 1 |
| Pen, L | 1 |
| Ruiz, J | 1 |
| Wiemels, JL | 2 |
| Wilson, D | 1 |
| Patil, C | 1 |
| Patoka, J | 1 |
| McCoy, L | 1 |
| Rice, T | 2 |
| Schwartzbaum, J | 1 |
| Heimberger, A | 1 |
| Chang, S | 4 |
| Wiencke, JK | 2 |
| Wrensch, M | 1 |
| Kawase, T | 3 |
| Tyler, MA | 1 |
| Osman, I | 1 |
| Orlow, SJ | 1 |
| Hervouet, E | 1 |
| Debien, E | 1 |
| Campion, L | 1 |
| Charbord, J | 1 |
| Menanteau, J | 1 |
| Tilleul, P | 2 |
| Brignone, M | 2 |
| Hassani, Y | 2 |
| Taillibert, S | 6 |
| Cartalat-Carel, S | 1 |
| Borget, I | 2 |
| Ogino, A | 3 |
| Yachi, K | 3 |
| Ohta, T | 3 |
| Fukushima, T | 3 |
| Watanabe, T | 3 |
| Okamoto, Y | 3 |
| Naruse, N | 2 |
| Sano, H | 2 |
| Seery, TE | 1 |
| Bressler, LR | 1 |
| Pirtoli, L | 1 |
| Cevenini, G | 1 |
| Tini, P | 1 |
| Vannini, M | 1 |
| Oliveri, G | 1 |
| Marsili, S | 1 |
| Mourmouras, V | 1 |
| Rubino, G | 1 |
| Miracco, C | 1 |
| Ji, YW | 1 |
| Pan, Q | 2 |
| Hashizume, R | 1 |
| Dinca, EB | 1 |
| Banerjee, A | 1 |
| Gupta, N | 1 |
| Zheng, CQ | 1 |
| Ji, SP | 1 |
| Li, AM | 1 |
| Tai, JL | 1 |
| Zhang, YP | 1 |
| Raut, N | 1 |
| Arora, B | 1 |
| Dutta, D | 1 |
| Munshi, A | 1 |
| Kurkure, P | 1 |
| Najim, N | 1 |
| Podmore, ID | 1 |
| McGown, A | 1 |
| Estlin, EJ | 1 |
| D'Elia, A | 1 |
| Formichella, AI | 1 |
| Frati, A | 1 |
| Berrocal, A | 1 |
| Perez Segura, P | 1 |
| Gil, M | 1 |
| Garcia Lopez, J | 1 |
| Yaya, R | 1 |
| Rodríguez, J | 2 |
| Reynes, G | 3 |
| Gallego, O | 2 |
| Iglesias, L | 1 |
| Ningaraj, NS | 1 |
| Sankpal, UT | 1 |
| Khaitan, D | 1 |
| Meister, EA | 1 |
| Vats, TS | 1 |
| Brandsma, D | 4 |
| Zustovich, F | 1 |
| Lombardi, G | 1 |
| Della Puppa, A | 1 |
| Rotilio, A | 2 |
| Scienza, R | 2 |
| Pastorelli, D | 1 |
| Bernier, V | 1 |
| Kim, TG | 3 |
| Kim, CH | 2 |
| Park, SD | 2 |
| Chung, DS | 1 |
| Engel, C | 1 |
| Stoffels, M | 1 |
| Stockhammer, F | 3 |
| Koeppen, S | 1 |
| Ketter, R | 2 |
| Meyermann, R | 2 |
| Wiestler, OD | 1 |
| Ernemann, U | 1 |
| Bamberg, M | 1 |
| Qian, ZZ | 1 |
| Wang, HQ | 1 |
| Liu, XM | 1 |
| Verhoeff, JJC | 1 |
| Lavini, C | 1 |
| Stalpers, LJA | 1 |
| Majoie, CBLM | 1 |
| van Furth, WR | 1 |
| Richel, DJ | 1 |
| Gousias, K | 1 |
| Konstantinos, G | 1 |
| Kyritsis, A | 1 |
| Athanasios, K | 1 |
| Recinos, VR | 2 |
| Tyler, BM | 2 |
| Bekelis, K | 1 |
| Sunshine, SB | 1 |
| Vellimana, A | 1 |
| Li, KW | 2 |
| Cruickshanks, N | 1 |
| Shervington, L | 1 |
| Munje, C | 1 |
| Thakkar, D | 1 |
| Chiang, KL | 1 |
| Chang, KP | 1 |
| Lee, YY | 1 |
| Huang, PI | 1 |
| Hsu, TR | 1 |
| Chen, YW | 1 |
| Chang, FC | 1 |
| Bélanger, K | 1 |
| Fulton, D | 1 |
| Easaw, J | 1 |
| Shields, C | 1 |
| Kirby, S | 1 |
| Eisenstat, DD | 1 |
| Pouliot, JF | 1 |
| Agha, CA | 1 |
| Ibrahim, S | 1 |
| Hassan, A | 1 |
| Elias, DA | 1 |
| Stevens, MF | 4 |
| Laughton, CA | 2 |
| Madhusudan, S | 2 |
| Chiba, Y | 1 |
| Tsuboi, A | 1 |
| Oka, Y | 1 |
| Murao, A | 1 |
| Kinoshita, M | 1 |
| Oji, Y | 1 |
| Hosen, N | 1 |
| Nishida, S | 1 |
| Sugiyama, H | 1 |
| Musat, E | 1 |
| Roelofs, E | 1 |
| Fenton, P | 1 |
| Gulyban, A | 2 |
| Collette, L | 1 |
| Bernard Davis, J | 1 |
| Aird, E | 1 |
| Müerköster, SS | 1 |
| Penfold, ME | 1 |
| Schall, TJ | 1 |
| Zhang, YH | 2 |
| Yue, ZJ | 2 |
| Oshige, H | 1 |
| Yamahara, T | 1 |
| Oishi, T | 1 |
| Zhen, Y | 1 |
| Numa, Y | 1 |
| Kawamoto, K | 1 |
| Tsumoto, K | 2 |
| Sure, D | 1 |
| Dunn, I | 1 |
| Norden, A | 1 |
| Anderson, WS | 1 |
| Kitange, GJ | 1 |
| Carlson, BL | 1 |
| Schroeder, MA | 1 |
| Decker, PA | 1 |
| Morlan, BW | 1 |
| Ballman, KV | 1 |
| Giannini, C | 1 |
| Sarkaria, JN | 2 |
| Parot-Schinkel, E | 1 |
| Loiseau, H | 1 |
| Jacquet, G | 1 |
| Sierra del Rio, M | 1 |
| Watt, HL | 1 |
| Rachid, Z | 1 |
| Jean-Claude, BJ | 1 |
| Germano, IM | 5 |
| Emdad, L | 1 |
| Qadeer, ZA | 1 |
| Binello, E | 1 |
| Uzzaman, M | 2 |
| Kim, WH | 2 |
| Yoon, SH | 1 |
| Kim, KJ | 1 |
| Kim, HJ | 1 |
| Tonn, JC | 3 |
| Pentheroudakis, G | 2 |
| Hwu, WJ | 1 |
| Voss, V | 1 |
| Senft, C | 1 |
| Lang, V | 1 |
| Seifert, V | 2 |
| Sobol, RW | 2 |
| Nikiforova, MN | 1 |
| Nikiforov, YE | 1 |
| Lyons-Weiler, MA | 1 |
| LaFramboise, WA | 1 |
| Gilles, FH | 1 |
| Yates, AJ | 1 |
| Beauchamp, DC | 1 |
| Westgate, MR | 1 |
| Kelly, JJ | 1 |
| Oner, Y | 1 |
| Uncu, D | 1 |
| Kang, HC | 1 |
| Han, JH | 1 |
| Choe, GY | 1 |
| Pan, T | 1 |
| Sharp, JR | 1 |
| Bouffet, E | 2 |
| Stempak, D | 1 |
| Gammon, J | 1 |
| Johnston, DL | 1 |
| Eisenstat, D | 1 |
| Hukin, J | 1 |
| Samson, Y | 1 |
| Bartels, U | 1 |
| Tabori, U | 1 |
| Huang, A | 1 |
| Baruchel, S | 1 |
| Zhou, M | 1 |
| Bracci, PM | 1 |
| Wrensch, MR | 1 |
| McCoy, LS | 1 |
| Sison, JD | 1 |
| Patoka, JS | 1 |
| Tsuboi, K | 1 |
| Barone, G | 1 |
| Tang, GS | 1 |
| Stenning, S | 1 |
| Levy, D | 1 |
| Rampling, R | 1 |
| Erridge, S | 1 |
| Gattamaneni, R | 1 |
| Hopkins, K | 1 |
| Beall, S | 1 |
| Lee, SM | 1 |
| Ochsenbein, AF | 1 |
| Schubert, AD | 1 |
| Vassella, E | 1 |
| Mariani, L | 1 |
| Hsieh, A | 1 |
| Ellsworth, R | 1 |
| Hsieh, D | 1 |
| Cho, WH | 1 |
| Moon, S | 1 |
| Park, SH | 2 |
| Kim, DG | 1 |
| Jung, HW | 1 |
| Cha, SH | 1 |
| Nozell, SE | 1 |
| Diers, A | 1 |
| McClugage, SG | 1 |
| Darley-Usmar, VM | 1 |
| Bailey, SM | 1 |
| Landar, A | 1 |
| Abacioglu, U | 1 |
| Caglar, HB | 1 |
| Yumuk, PF | 1 |
| Akgun, Z | 1 |
| Atasoy, BM | 1 |
| Sengoz, M | 1 |
| Stummer, W | 1 |
| Nestler, U | 1 |
| Krex, D | 1 |
| Kern, BC | 1 |
| Vince, GH | 1 |
| Pichlmeier, U | 1 |
| Apicella, G | 1 |
| Manfrida, S | 1 |
| Mangiola, A | 1 |
| Azario, L | 1 |
| D'Agostino, GR | 1 |
| Frascino, V | 1 |
| Dinapoli, N | 1 |
| Mantini, G | 1 |
| Albanese, A | 1 |
| de Bonis, P | 1 |
| Chiesa, S | 1 |
| Valentini, V | 1 |
| Anile, C | 1 |
| Cellini, N | 1 |
| Sylvester, RK | 1 |
| Steen, P | 1 |
| Tate, JM | 1 |
| Petrich, RJ | 1 |
| Berg, A | 1 |
| Kolesar, J | 1 |
| Laffaire, J | 1 |
| Paris, S | 2 |
| Boisselier, B | 1 |
| Ganswindt, U | 1 |
| Schwarz, SB | 1 |
| Kreth, FW | 2 |
| Geisler, J | 1 |
| Ertl, L | 1 |
| Linn, J | 1 |
| Siefert, A | 1 |
| Sitbon Sitruk, L | 1 |
| Prades, M | 1 |
| Lefebvre, G | 1 |
| Schubert, B | 1 |
| Fields, EC | 1 |
| Gaspar, LE | 1 |
| Liu, AK | 1 |
| Kavanagh, BD | 1 |
| Waziri, A | 1 |
| Lillehei, K | 1 |
| Fassan, M | 1 |
| Tassone, E | 1 |
| Onisto, M | 1 |
| D'Avella, D | 1 |
| Gardiman, MP | 1 |
| van Nifterik, KA | 2 |
| Van Den Berg, J | 3 |
| Van Rijn, J | 2 |
| Jha, P | 2 |
| Jain, A | 1 |
| Sharma, MC | 1 |
| Pathak, P | 1 |
| Srivastava, A | 1 |
| Suri, A | 1 |
| Gupta, D | 1 |
| Chattopadhyay, P | 1 |
| Sarkar, C | 1 |
| Fujita, M | 2 |
| Snyder, LA | 1 |
| Okada, H | 1 |
| Preusser, M | 1 |
| Elandt, K | 1 |
| Schwarzinger, I | 1 |
| Heinzl, H | 1 |
| Muscarella, LA | 1 |
| Barbano, R | 1 |
| D'Angelo, V | 1 |
| Copetti, M | 1 |
| Coco, M | 1 |
| Balsamo, T | 1 |
| la Torre, A | 1 |
| Notarangelo, A | 1 |
| Troiano, M | 1 |
| Icolaro, N | 1 |
| Catapano, D | 1 |
| Valori, VM | 1 |
| Pellegrini, F | 1 |
| Merla, G | 1 |
| Carella, M | 1 |
| Fazio, VM | 1 |
| Parrella, P | 1 |
| Lee, SY | 1 |
| Mitchell, RM | 1 |
| Slagle-Webb, B | 1 |
| Hong, YS | 1 |
| Sheehan, JM | 1 |
| Connor, JR | 1 |
| Mrugala, MM | 1 |
| Adair, J | 1 |
| Kiem, HP | 1 |
| Sherman, JH | 2 |
| Moldovan, K | 1 |
| Yeoh, HK | 1 |
| Starke, RM | 1 |
| Chaponis, D | 1 |
| Barnes, JW | 1 |
| Dellagatta, JL | 1 |
| Fast, E | 1 |
| Sauvageot, C | 1 |
| Panagrahy, D | 1 |
| Greene, ER | 1 |
| Stiles, C | 1 |
| Natsumeda, M | 1 |
| Aoki, H | 1 |
| Miyahara, H | 1 |
| Yajima, N | 1 |
| Uzuka, T | 2 |
| Toyoshima, Y | 1 |
| Kakita, A | 1 |
| Fujii, Y | 1 |
| Chansriwong, P | 1 |
| Sirisinha, T | 1 |
| Takahashi, J | 1 |
| Sugiyama, K | 1 |
| Zhuang, D | 1 |
| Luan, S | 1 |
| Wei, ZP | 1 |
| Pei, DS | 1 |
| Zheng, JN | 1 |
| Chang, YJ | 1 |
| Ku, MS | 1 |
| Chung, KT | 1 |
| Gong, X | 1 |
| Schwartz, PH | 1 |
| Linskey, ME | 1 |
| DiBiase, S | 1 |
| Meisenberg, B | 1 |
| Flannery, T | 1 |
| Patel, A | 1 |
| Dhople, A | 1 |
| Cheston, S | 1 |
| Amin, P | 1 |
| Short, SC | 2 |
| Giampieri, S | 1 |
| Worku, M | 1 |
| Alcaide-German, M | 1 |
| Sioftanos, G | 1 |
| Bourne, S | 1 |
| Lio, KI | 1 |
| Shaked-Rabi, M | 1 |
| Martindale, C | 1 |
| Kreth, S | 1 |
| Thon, N | 1 |
| Eigenbrod, S | 1 |
| Lutz, J | 1 |
| Ledderose, C | 1 |
| Egensperger, R | 1 |
| Kretzschmar, HA | 1 |
| Hinske, LC | 1 |
| Grauer, O | 1 |
| Zeman, F | 1 |
| Brawanski, A | 1 |
| Tang, JB | 1 |
| Svilar, D | 1 |
| Trivedi, RN | 1 |
| Wang, XH | 1 |
| Goellner, EM | 1 |
| Moore, B | 1 |
| Banze, LA | 1 |
| Brown, AR | 1 |
| Moroz, MA | 1 |
| Kochetkov, T | 1 |
| Thaler, H | 1 |
| de Stanchina, E | 1 |
| Gamez, I | 1 |
| Ryan, RP | 1 |
| Blasberg, RG | 1 |
| Bruyère, C | 1 |
| Mijatovic, T | 2 |
| Lonez, C | 1 |
| Spiegl-Kreinecker, S | 1 |
| Berger, W | 1 |
| Kast, RE | 1 |
| Ruysschaert, JM | 1 |
| Kiss, R | 3 |
| Lefranc, F | 3 |
| Zheng, YR | 1 |
| Wang, JJ | 1 |
| Wu, ZC | 1 |
| Sun, JH | 1 |
| Kogias, E | 1 |
| Osterberg, N | 1 |
| Baumer, B | 1 |
| Psarras, N | 1 |
| Koentges, C | 1 |
| Papazoglou, A | 1 |
| Saavedra, JE | 1 |
| Keefer, LK | 1 |
| Weyerbrock, A | 1 |
| Quillien, V | 1 |
| Saikali, S | 1 |
| Lesimple, T | 1 |
| Hamlat, A | 1 |
| Mosser, J | 1 |
| Lawrence, YR | 2 |
| Dicker, AP | 3 |
| Andrews, D | 1 |
| Curran, WJ | 1 |
| Michalski, JM | 1 |
| Souhami, L | 1 |
| Cuneo, KC | 1 |
| Willett, CG | 1 |
| Kirkpatrick, JP | 1 |
| Wachsberger, PR | 1 |
| Lawrence, RY | 1 |
| Andersen, B | 1 |
| Nannya, Y | 1 |
| Ichikawa, M | 1 |
| Nakamura, F | 1 |
| Kurokawa, M | 1 |
| Mu, YG | 2 |
| de Groot, JF | 1 |
| Lamborn, KR | 4 |
| Jackson, EF | 1 |
| Menuel, C | 1 |
| Costalat, R | 1 |
| Abud, L | 1 |
| Habas, C | 1 |
| De Marco, G | 1 |
| Chiras, J | 1 |
| Inaba, N | 2 |
| Kimura, M | 2 |
| Fujioka, K | 2 |
| Somura, H | 1 |
| Akiyoshi, K | 1 |
| Inoue, Y | 2 |
| Nomura, M | 1 |
| Saito, Y | 2 |
| Saito, H | 2 |
| Nandipati, S | 1 |
| Demopoulos, A | 1 |
| Holzmüller, R | 1 |
| Haczek, C | 1 |
| Rognoni, E | 1 |
| Kasajima, A | 1 |
| Weichert, W | 1 |
| Treue, D | 1 |
| Schuster, T | 1 |
| Gänsbacher, B | 1 |
| Hummersone, M | 1 |
| Ziegler, DS | 1 |
| Keating, J | 1 |
| Fast, EM | 1 |
| Zawel, L | 1 |
| Veldhuijzen van Zanten, SE | 1 |
| Jing, Z | 1 |
| Threatt, S | 1 |
| Coan, AD | 1 |
| Sloan, A | 1 |
| Carraway, H | 1 |
| Piantadosi, S | 1 |
| Lashkari, HP | 1 |
| Saso, S | 1 |
| Athanasiou, T | 1 |
| Berkhof, J | 1 |
| Hoekstra, OS | 1 |
| Noske, DP | 1 |
| Herbet, G | 1 |
| Maldonado, IL | 1 |
| Moritz-Gasser, S | 1 |
| Kerr, C | 1 |
| Tichy, J | 1 |
| Thanendrarajan, S | 1 |
| Stuplich, M | 1 |
| Mack, F | 1 |
| Simon, M | 1 |
| Scheffler, B | 1 |
| Boström, J | 1 |
| Glas, M | 1 |
| Tashiro, S | 1 |
| Aguilar, LK | 1 |
| Bell, SD | 1 |
| Hardcastle, J | 1 |
| Cavaliere, R | 1 |
| McGregor, J | 1 |
| Lo, S | 1 |
| Ray-Chaudhuri, A | 1 |
| Grecula, J | 1 |
| Newton, H | 1 |
| Harris, KS | 1 |
| Grossman, RG | 1 |
| Trask, TW | 1 |
| Baskin, DS | 1 |
| Monterroso, C | 1 |
| Manzanera, AG | 1 |
| Aguilar-Cordova, E | 1 |
| New, PZ | 1 |
| Brower, V | 1 |
| Wang, HM | 1 |
| Dong, XT | 1 |
| Li, JM | 1 |
| Moellering, DR | 1 |
| Faragó, N | 1 |
| Fehér, LZ | 1 |
| Kitajka, K | 1 |
| Das, UN | 1 |
| Puskás, LG | 1 |
| Ishizawa, S | 1 |
| Warren, KE | 1 |
| Wallace, D | 2 |
| Balis, FM | 1 |
| Berg, SL | 1 |
| Packer, RJ | 2 |
| Minturn, JE | 1 |
| Boyett, JM | 1 |
| Kun, LE | 2 |
| Gaviani, P | 1 |
| Silvani, A | 2 |
| Lamperti, E | 2 |
| Botturi, A | 1 |
| Simonetti, G | 1 |
| Ferrari, D | 1 |
| Salmaggi, A | 3 |
| Catalán-Uribarrena, G | 1 |
| Bilbao-Barandica, G | 1 |
| Pomposo-Gaztelu, I | 1 |
| Undabeitia-Huertas, J | 1 |
| Ruiz de Gopegui-Ruiz, E | 1 |
| Galbarriatu-Gutiérrez, L | 1 |
| Canales-Llantada, M | 1 |
| Aurrecoechea-Obieta, J | 1 |
| Igartua-Azkune, A | 1 |
| Carbayo-Lozano, G | 1 |
| Lafleur, MV | 1 |
| Stalpers, LJ | 1 |
| Pu, P | 3 |
| Lin, CJ | 2 |
| Shih, YL | 2 |
| Lin, TY | 1 |
| Wang, SH | 2 |
| Lin, YF | 1 |
| Smolczyk, DR | 1 |
| Janzen, E | 1 |
| Schmieder, K | 1 |
| Lohr, F | 1 |
| Wenz, F | 1 |
| Weiss, C | 1 |
| Dittmann, LM | 1 |
| Danner, A | 1 |
| Gronych, J | 1 |
| Wolter, M | 1 |
| Stühler, K | 1 |
| Grzendowski, M | 1 |
| Becker, N | 1 |
| Bageritz, J | 1 |
| Goidts, V | 1 |
| Toedt, G | 1 |
| Barbus, S | 1 |
| Lichter, P | 1 |
| Tews, B | 1 |
| Tu, Q | 1 |
| Yan, T | 1 |
| Skaftnesmo, KO | 1 |
| Leiss, L | 1 |
| Sleire, L | 1 |
| Enger, PØ | 1 |
| Tian, A | 1 |
| Fang, HH | 1 |
| Nie, Q | 1 |
| Kang, JB | 1 |
| Li, FM | 1 |
| Cai, CL | 1 |
| Gu, K | 1 |
| Håvik, AB | 1 |
| Brandal, P | 1 |
| Honne, H | 1 |
| Dahlback, HS | 1 |
| Scheie, D | 1 |
| Hektoen, M | 1 |
| Meling, TR | 1 |
| Helseth, E | 1 |
| Heim, S | 1 |
| Lothe, RA | 1 |
| Lind, GE | 1 |
| Ruban, A | 1 |
| Berkutzki, T | 1 |
| Cooper, I | 1 |
| Mohar, B | 1 |
| Teichberg, VI | 1 |
| Segers-van Rijn, JM | 1 |
| van Heuvel, I | 2 |
| van der Rijt, CC | 1 |
| Sillevis Smitt, PA | 3 |
| Labrande, C | 1 |
| Pedeboscq, S | 1 |
| Gensollen, S | 1 |
| Lahille, B | 1 |
| Exinger, D | 1 |
| Bertholle, V | 1 |
| Billard, M | 1 |
| Charlety, D | 1 |
| Prebay, D | 1 |
| Pinguet, F | 1 |
| Cartalat, S | 1 |
| Jensen, SA | 1 |
| Habermehl, D | 1 |
| Jaekel, O | 1 |
| Strik, HM | 1 |
| Schultz, CR | 1 |
| Golembieski, WA | 1 |
| King, DA | 1 |
| Brown, SL | 1 |
| Rempel, SA | 1 |
| Ling, Y | 1 |
| Wei, K | 1 |
| Zou, F | 1 |
| Sk, UH | 1 |
| Huber-Keener, KJ | 1 |
| Sun, YW | 1 |
| Amin, S | 1 |
| Hayashi, H | 1 |
| Kokuho, N | 1 |
| Morimoto, T | 1 |
| Kobayashi, K | 2 |
| Abe, S | 1 |
| Fujita, K | 1 |
| Azuma, A | 1 |
| Gemma, A | 1 |
| Fairchild, A | 1 |
| Fenton, PA | 1 |
| Kim, DS | 1 |
| Ra, YS | 1 |
| Baek, HJ | 1 |
| Choi, HS | 1 |
| Paccapelo, A | 1 |
| Lolli, I | 1 |
| Fabrini, MG | 1 |
| Silvano, G | 1 |
| Detti, B | 1 |
| Perrone, F | 1 |
| Savio, G | 1 |
| Santoni, M | 1 |
| Bonizzoni, E | 1 |
| Perrone, T | 1 |
| Terés, S | 1 |
| Lladó, V | 1 |
| Higuera, M | 1 |
| Barceló-Coblijn, G | 1 |
| Martin, ML | 1 |
| Noguera-Salvà, MA | 1 |
| Marcilla-Etxenike, A | 1 |
| García-Verdugo, JM | 1 |
| Soriano-Navarro, M | 1 |
| Saus, C | 1 |
| Gómez-Pinedo, U | 1 |
| Busquets, X | 1 |
| Escribá, PV | 1 |
| Gil, MJ | 1 |
| de Las Peñas, R | 1 |
| Peréz-Segura, P | 1 |
| García-Velasco, A | 1 |
| Mesia, C | 1 |
| Fernández-Chacón, C | 1 |
| Martínez-García, M | 1 |
| Herrero, A | 1 |
| Andrés, R | 1 |
| Benavides, M | 1 |
| Quintanar, T | 1 |
| Pérez-Martin, X | 1 |
| Oszvald, Á | 1 |
| Quick, J | 1 |
| Franz, K | 1 |
| Güresir, E | 1 |
| Szelényi, A | 1 |
| Vatter, H | 1 |
| Dagıstan, Y | 1 |
| Karaca, I | 1 |
| Bozkurt, ER | 1 |
| Ozar, E | 1 |
| Yagmurlu, K | 1 |
| Toklu, A | 1 |
| Kaley, TJ | 2 |
| Mondesire-Crump, I | 1 |
| Gavrilovic, IT | 2 |
| Den, RB | 1 |
| Kamrava, M | 1 |
| Dougherty, E | 1 |
| Marinucchi, M | 1 |
| Hegarty, S | 1 |
| Hyslop, T | 1 |
| Andrews, DW | 1 |
| Glass, J | 1 |
| Friedman, DP | 1 |
| Green, MR | 1 |
| Camphausen, K | 1 |
| Yoon, WS | 1 |
| Park, KY | 1 |
| Lim, JY | 1 |
| Ramis, G | 1 |
| Thomàs-Moyà, E | 1 |
| Fernández de Mattos, S | 1 |
| Villalonga, P | 1 |
| Chen, TH | 1 |
| Faraji, AH | 1 |
| Engh, JA | 1 |
| Horowitz, M | 1 |
| Lunsford, LD | 1 |
| Park, DM | 1 |
| Raghavan, D | 1 |
| Boxerman, J | 2 |
| Jeyapalan, S | 2 |
| Rogg, J | 1 |
| Zheng, X | 1 |
| Spinelli, GP | 1 |
| Miele, E | 1 |
| Lo Russo, G | 1 |
| Miscusi, M | 1 |
| Codacci-Pisanelli, G | 1 |
| Petrozza, V | 1 |
| Papa, A | 1 |
| Frati, L | 1 |
| Della Rocca, C | 1 |
| Gulino, A | 1 |
| Tomao, S | 1 |
| Villalva, C | 1 |
| Cortes, U | 1 |
| Wager, M | 1 |
| Tourani, JM | 1 |
| Rivet, P | 1 |
| Marquant, C | 1 |
| Martin, S | 1 |
| Turhan, AG | 1 |
| Karayan-Tapon, L | 1 |
| Dixit, S | 1 |
| Baker, L | 1 |
| Walmsley, V | 1 |
| Hingorani, M | 1 |
| Waters, JD | 1 |
| Sanchez, C | 1 |
| Sahin, A | 1 |
| Gonda, DD | 1 |
| Scheer, JK | 1 |
| Palanichamy, K | 2 |
| Morse, B | 1 |
| Marsh, N | 1 |
| Furfine, E | 1 |
| Carvajal, I | 1 |
| Chandler, JP | 1 |
| Newman, SB | 1 |
| Levy, RM | 1 |
| Jovanovic, B | 1 |
| Lee, WJ | 1 |
| Yi, KS | 1 |
| Sohn, CH | 1 |
| Lu, XY | 1 |
| Cao, K | 1 |
| Li, QY | 1 |
| Yuan, ZC | 1 |
| Lu, PS | 1 |
| Viaccoz, A | 1 |
| Lekoubou, A | 1 |
| Reid, JM | 1 |
| Kuhn, JG | 1 |
| McGovern, RM | 1 |
| Ames, MM | 1 |
| Espinoza-Delgado, I | 1 |
| De Vos, FY | 1 |
| Gijtenbeek, JM | 1 |
| Bleeker-Rovers, CP | 1 |
| van Herpen, CM | 1 |
| Tseng, J | 1 |
| Leong, MN | 1 |
| Goldkorn, A | 1 |
| Petasis, NA | 1 |
| Louie, SG | 1 |
| Demirci, U | 1 |
| Yaman, M | 1 |
| Baykara, M | 1 |
| Uslu, K | 1 |
| Ozet, A | 1 |
| Bagriacik, EU | 1 |
| Geng, J | 1 |
| Luo, H | 1 |
| Pu, Y | 1 |
| Xu, W | 1 |
| Safdie, F | 1 |
| Brandhorst, S | 1 |
| Lee, C | 1 |
| Hwang, S | 1 |
| Conti, PS | 1 |
| Longo, VD | 1 |
| Nagai, S | 1 |
| Alonso-Llamazares, A | 1 |
| Vega-Castro, A | 1 |
| Beitia-Mazuecos, JM | 1 |
| Mateo-Borrega, B | 1 |
| Cardenas-Contreras, R | 1 |
| Miyake, K | 1 |
| Shinomiya, A | 1 |
| Kawai, N | 1 |
| Tamiya, T | 1 |
| Chou, AP | 1 |
| Phillips, HS | 1 |
| Selfridge, J | 1 |
| Zurayk, M | 1 |
| Lou, JJ | 1 |
| Everson, RG | 1 |
| Wu, KC | 1 |
| Faull, KF | 1 |
| Liau, LM | 1 |
| Wang, HD | 1 |
| Zhu, L | 1 |
| Cong, ZX | 1 |
| Ji, XJ | 1 |
| Pan, H | 1 |
| Wang, JW | 1 |
| Li, WC | 1 |
| De Sanctis, V | 1 |
| Lanzetta, G | 1 |
| Falco, T | 1 |
| Di Stefano, D | 1 |
| Enrici, RM | 1 |
| Sengupta, S | 1 |
| Marrinan, J | 1 |
| Frishman, C | 1 |
| Sampath, P | 1 |
| Duntze, J | 1 |
| Litré, CF | 1 |
| Eap, C | 1 |
| Théret, E | 1 |
| Debreuve, A | 1 |
| Jovenin, N | 1 |
| Lechapt-Zalcman, E | 1 |
| Colin, P | 1 |
| Emery, E | 1 |
| Rousseaux, P | 1 |
| Vellimana, AK | 1 |
| Fowers, KD | 1 |
| Okonma, S | 1 |
| Eberhart, CG | 1 |
| Shi, ZD | 1 |
| Qian, XM | 1 |
| Liu, CY | 1 |
| Zhang, KL | 1 |
| Zhang, JX | 1 |
| Pu, PY | 1 |
| Yuan, XB | 1 |
| Lu, JQ | 1 |
| Wilson, BA | 1 |
| Pugh, J | 1 |
| Mehta, V | 2 |
| Nolan, CP | 1 |
| Salvant, C | 1 |
| Heguy, A | 1 |
| Kaufman, A | 1 |
| Mellinghoff, I | 1 |
| Aguilera, DG | 1 |
| Mazewski, C | 1 |
| Hayes, L | 1 |
| Jordan, C | 1 |
| Esiashivilli, N | 1 |
| Janns, A | 1 |
| Macdonald, TJ | 1 |
| Shao, CJ | 1 |
| Wu, MW | 1 |
| Xia, YF | 1 |
| Momiyama, M | 1 |
| Suetsugu, A | 1 |
| Chishima, T | 1 |
| Bouvet, M | 1 |
| Endo, I | 1 |
| Hoffman, RM | 1 |
| Tham, CK | 1 |
| Tan, SH | 1 |
| Lim, KH | 1 |
| Chong, DQ | 1 |
| Chua, ET | 1 |
| Karavasilis, V | 1 |
| Kotoula, V | 1 |
| Televantou, D | 1 |
| Lambaki, S | 1 |
| Chrisafi, S | 1 |
| Bobos, M | 1 |
| Fountzilas, G | 1 |
| Blackwood, R | 1 |
| Brown, M | 1 |
| Lovato, J | 1 |
| Yalcinkaya, T | 1 |
| Berhorn, T | 1 |
| Blau, T | 1 |
| Schroeter, M | 1 |
| Hirst, TC | 1 |
| Vesterinen, HM | 1 |
| Sena, ES | 1 |
| Egan, KJ | 1 |
| Macleod, MR | 1 |
| Whittle, IR | 1 |
| Yue, S | 1 |
| Albanese, C | 1 |
| Alzani, R | 1 |
| Amboldi, N | 1 |
| Degrassi, A | 1 |
| Festuccia, C | 1 |
| Fiorentini, F | 1 |
| Gravina, G | 1 |
| Mercurio, C | 1 |
| Pastori, W | 1 |
| Brasca, M | 1 |
| Pesenti, E | 1 |
| Galvani, A | 1 |
| Ciomei, M | 1 |
| Tsuchiya, K | 1 |
| Aguilar, HN | 1 |
| Hung, RW | 1 |
| Kotylak, T | 1 |
| Knizhnik, AV | 1 |
| Nikolova, T | 1 |
| Quiros, S | 1 |
| Tomaszowski, KH | 1 |
| Christmann, M | 1 |
| Donahue, J | 1 |
| Goldman, M | 1 |
| Kinsella, T | 1 |
| Dipetrillo, T | 1 |
| Evans, D | 1 |
| Elinzano, H | 1 |
| Constantinou, M | 1 |
| Stopa, E | 1 |
| Puthawala, Y | 1 |
| Cielo, D | 1 |
| Santaniello, A | 1 |
| Oyelese, A | 1 |
| Mantripragada, K | 1 |
| Rosati, K | 1 |
| Isdale, D | 1 |
| Safran, H | 1 |
| Danson, SJ | 1 |
| Middleton, MR | 1 |
| Trent, S | 1 |
| Kong, A | 1 |
| Traish, D | 2 |
| Ashley, S | 3 |
| Dowe, A | 2 |
| Hines, F | 2 |
| Bocangel, DB | 2 |
| Finkelstein, S | 1 |
| Schold, SC | 2 |
| Bhakat, KK | 1 |
| Mitra, S | 1 |
| Kokkinakis, DM | 2 |
| Branle, F | 1 |
| Camby, I | 1 |
| Jeuken, J | 1 |
| Geurts-Moespot, A | 1 |
| Sprenger, S | 1 |
| Sweep, F | 1 |
| Salmon, I | 1 |
| Tentori, L | 1 |
| Portarena, I | 1 |
| Torino, F | 1 |
| Scerrati, M | 1 |
| Navarra, P | 1 |
| Graziani, G | 1 |
| Gaya, A | 1 |
| Greenstein, A | 1 |
| Stebbing, J | 1 |
| Kuttesch, JF | 1 |
| Olson, JJ | 1 |
| Reaman, GH | 1 |
| Zaknoen, SL | 1 |
| Lashford, LS | 1 |
| Thiesse, P | 1 |
| Jouvet, A | 1 |
| Couanet, D | 2 |
| Griffiths, PD | 1 |
| Doz, F | 1 |
| Ironside, J | 1 |
| Robson, K | 1 |
| Hobson, R | 1 |
| Dugan, M | 2 |
| Günther, W | 1 |
| Pawlak, E | 1 |
| Damasceno, R | 1 |
| Arnold, H | 1 |
| Terzis, AJ | 1 |
| Provenzale, JM | 2 |
| Avgeropoulos, N | 1 |
| Finlay, J | 1 |
| Tourt-Uhlig, S | 2 |
| Evans, B | 2 |
| Stafford-Fox, V | 1 |
| Zaknoen, S | 2 |
| Reed, K | 2 |
| Guo, P | 3 |
| Barkhof, F | 1 |
| Baayen, HC | 1 |
| Boogerd, W | 1 |
| Castelijns, JA | 1 |
| Elkhuizen, PH | 1 |
| Kreklau, EL | 1 |
| Erickson, LC | 1 |
| Korones, DN | 2 |
| Benita-Weiss, M | 1 |
| Coyle, TE | 1 |
| Mechtler, L | 1 |
| Bushunow, P | 1 |
| Friedman, H | 1 |
| Figul, M | 1 |
| Söling, A | 1 |
| Dong, HJ | 1 |
| Chou, TC | 2 |
| Rainov, NG | 2 |
| Houghton, PJ | 2 |
| Glantz, M | 1 |
| Chamberlain, M | 1 |
| Litofsky, NS | 1 |
| Recht, LD | 1 |
| Brown, GD | 1 |
| Brady, F | 1 |
| Osman, S | 2 |
| Luthra, SK | 1 |
| Ranicar, AS | 1 |
| Newlands, E | 3 |
| Price, P | 3 |
| Kuo, DJ | 1 |
| Weiner, HL | 1 |
| Wisoff, J | 1 |
| Miller, DC | 1 |
| Jaeckle, KA | 2 |
| Hess, KR | 2 |
| Greenberg, H | 2 |
| Fine, H | 3 |
| Kuhn, J | 4 |
| Fink, K | 2 |
| Newlands, ES | 7 |
| Foster, T | 1 |
| Kanzawa, T | 3 |
| Kondo, Y | 4 |
| Ito, H | 2 |
| Kyo, S | 1 |
| Kondo, S | 4 |
| Trippoli, S | 1 |
| Pelagotti, F | 1 |
| Messori, A | 1 |
| Vacca, F | 1 |
| Vaiani, M | 1 |
| Maltoni, S | 1 |
| Brown, P | 1 |
| Buckner, J | 1 |
| Panetta, JC | 1 |
| Kirstein, MN | 1 |
| Gajjar, AJ | 1 |
| Nair, G | 1 |
| Stewart, CF | 2 |
| Nagasubramanian, R | 1 |
| Dolan, ME | 2 |
| Viviers, L | 2 |
| Abson, C | 2 |
| Britton, J | 1 |
| Sardell, S | 1 |
| Gonsalves, A | 2 |
| Wilkins, P | 2 |
| Westbury, C | 1 |
| Galiè, E | 1 |
| Telera, S | 1 |
| Cianciulli, AM | 1 |
| Canalini, P | 1 |
| Jandolo, B | 1 |
| Bedwell, J | 1 |
| Komata, T | 1 |
| Theodosopoulos, P | 1 |
| Lamborn, K | 2 |
| Malec, M | 3 |
| Rabbitt, J | 2 |
| Page, M | 1 |
| Buster, WP | 1 |
| Murphy, PS | 1 |
| Rowland, IJ | 1 |
| Dzik-Jurasz, AS | 1 |
| Eoli, M | 1 |
| Maccagnano, E | 1 |
| Broggi, G | 1 |
| Boiardi, A | 2 |
| Junck, L | 3 |
| Fink, KL | 2 |
| Hess, K | 1 |
| Schold, C | 1 |
| Ashley, DL | 3 |
| Cher, L | 5 |
| Ostermann, S | 2 |
| Csajka, C | 1 |
| Buclin, T | 2 |
| Leyvraz, S | 5 |
| Lejeune, F | 3 |
| Decosterd, LA | 2 |
| Verschuur, AC | 1 |
| Lelouch-Tubiana, A | 1 |
| Kalifa, C | 1 |
| Malkin, MG | 2 |
| Kleber, M | 1 |
| Paz, MF | 1 |
| Yaya-Tur, R | 1 |
| Rojas-Marcos, I | 1 |
| Pollan, M | 1 |
| Aguirre-Cruz, L | 1 |
| García-Lopez, JL | 1 |
| Piquer, J | 1 |
| Safont, MJ | 1 |
| Sanchez-Cespedes, M | 1 |
| García-Villanueva, M | 1 |
| Arribas, L | 1 |
| Balzarotti, M | 1 |
| Ciusani, E | 1 |
| Calatozzolo, C | 1 |
| Croci, D | 1 |
| de Wit, MC | 1 |
| de Bruin, HG | 2 |
| Eijkenboom, W | 1 |
| Mäenpää, HO | 1 |
| Aaltonen, K | 1 |
| Mäntylä, R | 1 |
| Minn, H | 1 |
| Iacono, L | 1 |
| Bowers, DC | 2 |
| Stewart, C | 1 |
| Krasin, MJ | 2 |
| Trog, D | 4 |
| Moenkemann, H | 3 |
| Haertel, N | 2 |
| Schüller, H | 1 |
| Golubnitschaja, O | 4 |
| Kocher, M | 1 |
| Kunze, S | 1 |
| Eich, HT | 1 |
| Semrau, R | 1 |
| Müller, RP | 1 |
| Xu, GW | 1 |
| Mymryk, JS | 1 |
| Wasserfallen, JB | 1 |
| Lonardi, S | 1 |
| Huchet, A | 1 |
| Wharram, B | 1 |
| Wilkins, M | 1 |
| Khong, HT | 1 |
| Wheeler, CJ | 1 |
| Das, A | 1 |
| Black, KL | 1 |
| Tihan, T | 1 |
| Eberhard, DA | 1 |
| Jelluma, N | 1 |
| Arvold, ND | 1 |
| Baumber, R | 1 |
| Kapadia, A | 2 |
| Stokoe, D | 1 |
| Tsien, CI | 1 |
| Shen, Z | 1 |
| Tatro, DS | 1 |
| Ten Haken, R | 1 |
| Kessler, ML | 1 |
| Chenevert, TL | 1 |
| Lawrence, TS | 1 |
| Mancuso, A | 1 |
| Zhu, A | 1 |
| Beardsley, NJ | 1 |
| Glickson, JD | 1 |
| Wehrli, S | 1 |
| Pickup, S | 1 |
| Cavallo, G | 2 |
| Scopece, L | 2 |
| Esposti, RD | 1 |
| Paioli, G | 1 |
| Paioli, A | 1 |
| Palmerini, E | 1 |
| Foschini, MP | 1 |
| Marliani, AF | 1 |
| Crinò, L | 1 |
| van der Rijt, CD | 1 |
| Smith, A | 1 |
| Foreman, N | 1 |
| Sathornsumetee, S | 2 |
| Badruddoja, M | 1 |
| McLendon, R | 2 |
| Provenzale, J | 1 |
| Dowell, JM | 1 |
| Burkart, JL | 1 |
| Newton, HB | 1 |
| Nerio, E | 1 |
| Ishii, D | 3 |
| Tsuno, T | 2 |
| Hatano, H | 2 |
| Mizuno, M | 2 |
| Tafuto, S | 1 |
| Tortoriello, A | 1 |
| Pisano, A | 1 |
| Comella, P | 1 |
| Formato, R | 1 |
| Quattrin, S | 1 |
| Iaffaioli, RV | 1 |
| Grosu, AL | 1 |
| Weber, WA | 1 |
| Franz, M | 1 |
| Stärk, S | 1 |
| Piert, M | 1 |
| Thamm, R | 1 |
| Gumprecht, H | 1 |
| Molls, M | 1 |
| Nieder, C | 2 |
| Weingart, J | 1 |
| Delaney, SM | 1 |
| Rich, J | 1 |
| Pegg, AE | 2 |
| Moschel, RC | 2 |
| Birch, R | 1 |
| Dancey, JE | 1 |
| Maxwell, J | 1 |
| Kocak, M | 1 |
| Iacono, LC | 1 |
| Merchant, TE | 1 |
| Ledet, D | 1 |
| Sawamura, Y | 2 |
| Tanaka, R | 1 |
| Wemmert, S | 1 |
| Rahnenführer, J | 1 |
| Beerenwinkel, N | 1 |
| Strowitzki, M | 1 |
| Feiden, W | 1 |
| Lengauer, T | 1 |
| Zang, KD | 1 |
| Meese, E | 1 |
| Steudel, WI | 1 |
| Urbschat, S | 1 |
| Sadones, J | 1 |
| Keyaerts, M | 1 |
| Veld, PI | 1 |
| Cefalo, G | 1 |
| Mazzarella, G | 1 |
| Di Rocco, C | 1 |
| Madon, E | 1 |
| Abate, ME | 1 |
| Clerico, A | 1 |
| Sandri, A | 1 |
| Son, MJ | 2 |
| Kim, MH | 2 |
| Song, HS | 2 |
| Kim, JT | 3 |
| Shin, T | 1 |
| Jeon, HJ | 1 |
| Park, SY | 1 |
| Park, K | 1 |
| Groves, MD | 3 |
| Chan, DT | 1 |
| Chan, YL | 1 |
| Wong, S | 1 |
| Dowling, A | 1 |
| Jennens, R | 1 |
| Woods, AM | 1 |
| Parlato, C | 1 |
| Barbarisi, M | 1 |
| Moraci, M | 1 |
| Moraci, A | 1 |
| Hermisson, M | 1 |
| Klumpp, A | 1 |
| Wischhusen, J | 1 |
| Nagel, G | 1 |
| Roos, W | 1 |
| Burton, E | 2 |
| Page, MS | 1 |
| Fedoroff, A | 1 |
| Kelley, SK | 1 |
| Kracht, LW | 1 |
| Burghaus, L | 1 |
| Jacobs, AH | 1 |
| Heiss, WD | 1 |
| Herholz, K | 1 |
| Benouaich-Amiel, A | 3 |
| Ermani, M | 3 |
| Ghimenton, C | 1 |
| Gardiman, M | 2 |
| Pasetto, L | 1 |
| Blatt, V | 2 |
| Itasaka, S | 1 |
| Fountoulakis, M | 2 |
| Friedlein, A | 2 |
| Hunter, C | 1 |
| Smith, R | 1 |
| Stephens, P | 1 |
| Stevens, C | 1 |
| Teague, J | 1 |
| Greenman, C | 1 |
| Edkins, S | 1 |
| Bignell, G | 1 |
| Davies, H | 1 |
| O'Meara, S | 1 |
| Parker, A | 1 |
| Avis, T | 1 |
| Barthorpe, S | 1 |
| Brackenbury, L | 1 |
| Buck, G | 1 |
| Butler, A | 1 |
| Clements, J | 1 |
| Cole, J | 1 |
| Dicks, E | 1 |
| Forbes, S | 1 |
| Gorton, M | 1 |
| Gray, K | 1 |
| Halliday, K | 1 |
| Harrison, R | 1 |
| Hills, K | 1 |
| Hinton, J | 1 |
| Jenkinson, A | 1 |
| Jones, D | 1 |
| Kosmidou, V | 1 |
| Laman, R | 1 |
| Lugg, R | 1 |
| Menzies, A | 1 |
| Petty, R | 1 |
| Raine, K | 1 |
| Richardson, D | 1 |
| Shepherd, R | 1 |
| Small, A | 1 |
| Solomon, H | 1 |
| Tofts, C | 1 |
| Varian, J | 1 |
| West, S | 1 |
| Widaa, S | 1 |
| Yates, A | 2 |
| Easton, DF | 1 |
| Riggins, G | 1 |
| Roy, JE | 1 |
| Levine, KK | 1 |
| Mueller, W | 1 |
| Louis, DN | 1 |
| Stratton, MR | 1 |
| Futreal, PA | 1 |
| Wooster, R | 1 |
| Jaeckle, K | 1 |
| Liu, V | 1 |
| Hahnen, E | 1 |
| Tränkle, C | 1 |
| Siebzehnrübl, FA | 1 |
| Buslei, R | 1 |
| Fahlbusch, R | 1 |
| Blümcke, I | 1 |
| Ko, KW | 1 |
| Kang, CM | 1 |
| Shin, HJ | 1 |
| Eoh, W | 1 |
| Hassler, M | 1 |
| Micksche, M | 1 |
| Stockhammer, G | 1 |
| Pichler, J | 1 |
| Payer, F | 1 |
| Abuja, B | 1 |
| Deinsberger, R | 1 |
| Yeghiazaryan, K | 1 |
| Schueller, H | 2 |
| Breipohl, W | 2 |
| Schild, H | 2 |
| Leppert, D | 1 |
| Batista, LF | 1 |
| Naumann, SC | 1 |
| Frank, B | 1 |
| Möhle, R | 1 |
| Charnley, N | 1 |
| West, CM | 1 |
| Barnett, CM | 1 |
| Brock, C | 2 |
| Bydder, GM | 1 |
| Glaser, M | 2 |
| Swindell, R | 1 |
| Matthews, J | 2 |
| Kim, MK | 1 |
| Lee, TK | 1 |
| Lee, KS | 1 |
| Kang, JK | 1 |
| Kim, MC | 1 |
| Mutter, N | 1 |
| Kawaguchi, T | 1 |
| Mabasa, VH | 1 |
| Taylor, SC | 1 |
| Auger, N | 1 |
| Thillet, J | 2 |
| Wanherdrick, K | 1 |
| Legrier, ME | 1 |
| Dutrillaux, B | 1 |
| Poupon, MF | 1 |
| Banna, GL | 1 |
| Bettio, D | 1 |
| Simonelli, M | 1 |
| Rodriguez Baena, R | 1 |
| Aimar, E | 1 |
| Gaetani, P | 1 |
| Colombo, P | 1 |
| Rognone, F | 1 |
| Contreras Martínez, J | 1 |
| Azcoaga Blasco, JM | 1 |
| Delgado Rico, R | 1 |
| Wals Zurita, A | 1 |
| Villanueva Alvarez, A | 1 |
| Rivas Sánchez, D | 1 |
| Herruzo Cabrera, I | 1 |
| Gasco, J | 1 |
| Park, JA | 1 |
| Joe, YA | 1 |
| Gerber, DE | 1 |
| Zeltzman, M | 1 |
| Parisi, MA | 1 |
| Kleinberg, L | 1 |
| Alonso, MM | 3 |
| Gomez-Manzano, C | 4 |
| Fueyo, J | 4 |
| Ishii, N | 1 |
| Murata, J | 1 |
| Iwasaki, Y | 1 |
| Zhang, JP | 1 |
| Shi, HL | 1 |
| Yue, WY | 1 |
| Everhard, S | 1 |
| Crinière, E | 1 |
| Lejeune, J | 3 |
| Marie, Y | 2 |
| Kujas, M | 2 |
| Taniguchi, T | 1 |
| D'Andrea, A | 1 |
| Pradilla, G | 1 |
| Legnani, F | 1 |
| Caplan, J | 1 |
| Nuthalapati, S | 1 |
| Jones, B | 1 |
| Sanghera, P | 1 |
| Koch, D | 1 |
| Marg, E | 1 |
| Bauer, B | 1 |
| Rudolph, R | 1 |
| Rauch, M | 1 |
| Brenner, A | 1 |
| Rieckmann, P | 1 |
| Schuth, J | 1 |
| Koch, H | 1 |
| Monje, ML | 1 |
| Young, G | 1 |
| Doherty, LM | 1 |
| Fehlauer, F | 1 |
| Muench, M | 1 |
| Richter, E | 1 |
| Rades, D | 1 |
| Allen, JC | 1 |
| Phillips, PC | 1 |
| Watral, MA | 1 |
| Krauser, JM | 1 |
| de la Fuente, BP | 1 |
| Dalmau, J | 1 |
| Aghi, M | 1 |
| Rabkin, S | 1 |
| Martuza, RL | 1 |
| Keller, G | 1 |
| Amiel-Benouaich, A | 1 |
| McConville, P | 1 |
| Moody, JB | 1 |
| Leopold, WR | 1 |
| Kreger, AR | 1 |
| Woolliscroft, MJ | 1 |
| Rehemtulla, A | 1 |
| Ross, BD | 1 |
| Diakite, F | 1 |
| Renard, MA | 1 |
| Iraqi, W | 1 |
| Simon, JM | 1 |
| Polivka, M | 1 |
| Jordan, JT | 1 |
| Hussain, SF | 1 |
| DeAngulo, G | 1 |
| Prabhu, SS | 1 |
| Heimberger, AB | 2 |
| Sasai, K | 1 |
| Akagi, T | 1 |
| Aoyanagi, E | 1 |
| Tabu, K | 1 |
| Kaneko, S | 1 |
| Bekele, NB | 1 |
| Alemany, R | 1 |
| Maruta, H | 1 |
| Shimato, S | 2 |
| Katsumata, S | 1 |
| Osawa, H | 1 |
| Nakahara, N | 1 |
| Satoh, Y | 1 |
| Inagaki, M | 1 |
| Khanduri, S | 1 |
| Gerrard, G | 1 |
| Yu, SK | 1 |
| Woo, SJ | 1 |
| Kim, HS | 1 |
| Park, MY | 1 |
| Blaschke, B | 1 |
| Dancey, J | 1 |
| Crott, R | 1 |
| Jeuken, JW | 1 |
| Cornelissen, SJ | 1 |
| Vriezen, M | 1 |
| Dekkers, MM | 1 |
| Errami, A | 1 |
| Sijben, A | 1 |
| Boots-Sprenger, SH | 1 |
| Yin, LT | 1 |
| Fu, YJ | 1 |
| Xu, QL | 1 |
| Liu, ZL | 1 |
| Liang, AH | 1 |
| Fan, XJ | 1 |
| Xu, CG | 1 |
| Asano, Y | 1 |
| Takeuchi, H | 1 |
| Iwado, E | 1 |
| Daido, S | 1 |
| Mizutani, T | 1 |
| Nojima, K | 1 |
| Adachi, J | 1 |
| Matsutani, M | 1 |
| Galanopoulos, N | 1 |
| Rawlani, V | 1 |
| Veerapong, J | 1 |
| Bickenbach, K | 1 |
| Garside, R | 1 |
| Pitt, M | 1 |
| Anderson, R | 1 |
| Rogers, G | 1 |
| Dyer, M | 1 |
| Mealing, S | 1 |
| Somerville, M | 1 |
| Price, A | 1 |
| Stein, K | 1 |
| Loghin, ME | 1 |
| Wen, P | 1 |
| Metha, M | 1 |
| Robins, IH | 1 |
| Sijens, PE | 1 |
| Heesters, MA | 1 |
| van der Graaf, WT | 1 |
| Potze, JH | 1 |
| Irwan, R | 1 |
| Meiners, LC | 1 |
| Oudkerk, M | 1 |
| Bekele, BN | 1 |
| Kunwar, S | 1 |
| Shaffrey, M | 1 |
| Croteau, D | 1 |
| Parker, K | 1 |
| Grahn, AY | 1 |
| Sherman, JW | 1 |
| Husain, SR | 1 |
| Puri, RK | 1 |
| Tachmazoglou, F | 1 |
| Rao, JS | 1 |
| Sandström, M | 1 |
| Johansson, M | 1 |
| Bergström, P | 1 |
| Bergenheim, AT | 1 |
| Mizoguchi, M | 1 |
| Shono, T | 1 |
| Balmaceda, C | 1 |
| Pannullo, S | 1 |
| Cheung, YK | 1 |
| Fisher, PG | 1 |
| Alavi, J | 1 |
| Sisti, M | 1 |
| Fine, RL | 1 |
| da Fonseca, CO | 1 |
| Schwartsmann, G | 1 |
| Fischer, J | 1 |
| Nagel, J | 1 |
| Futuro, D | 1 |
| Quirico-Santos, T | 1 |
| Gattass, CR | 1 |
| Le Mercier, M | 1 |
| Debeir, O | 1 |
| Haibe-Kains, B | 1 |
| Bontempi, G | 1 |
| Decaestecker, C | 1 |
| Mathieu, V | 1 |
| Kunz-Schughart, L | 1 |
| Baumgart, U | 1 |
| Hirschmann, B | 1 |
| Weimann, E | 1 |
| Muhleisen, H | 1 |
| Ruemmele, P | 1 |
| Steinbrecher, A | 1 |
| Reichle, A | 1 |
| Lagattuta, TF | 1 |
| Egorin, MJ | 1 |
| Salvado, AJ | 1 |
| Lin, SH | 1 |
| Kleinberg, LR | 1 |
| Choi, JD | 1 |
| Powers, CJ | 1 |
| Huang, XJ | 1 |
| Li, CT | 1 |
| Zhang, WP | 1 |
| Lu, YB | 1 |
| Fang, SH | 1 |
| Wei, EQ | 1 |
| Bertorelle, R | 1 |
| Bonaldi, L | 1 |
| Geiger, GA | 1 |
| Fu, W | 1 |
| Kao, GD | 1 |
| Miller, CR | 1 |
| Gujrati, M | 1 |
| Scheithauer, BW | 1 |
| Zambrano, SC | 1 |
| Jost, SC | 1 |
| Raghavan, R | 1 |
| Cochran, EJ | 1 |
| Stalpers, L | 1 |
| da Frota, ML | 1 |
| Canedo, AD | 1 |
| Klamt, F | 1 |
| Apel, MA | 1 |
| Mothes, B | 1 |
| Lerner, C | 1 |
| Henriques, AT | 1 |
| Moreira, JC | 1 |
| Bischof, M | 1 |
| Welzel, T | 1 |
| Hof, H | 1 |
| Oertel, S | 1 |
| Schulz-Ertner, D | 1 |
| Oliver, PG | 1 |
| Belenky, ML | 1 |
| Swaak-Kragten, AT | 1 |
| Smitt, PA | 1 |
| van Es, CA | 1 |
| Timmerman, R | 1 |
| Ingle, AM | 1 |
| Flom, L | 1 |
| Adamson, PC | 1 |
| McVie, JG | 1 |
| Devineni, D | 1 |
| Klein-Szanto, A | 2 |
| O'Reilly, SM | 2 |
| Glaser, MG | 1 |
| Bower, M | 3 |
| Evans, H | 3 |
| Brampton, MH | 4 |
| Colquhoun, I | 3 |
| Lewis, P | 2 |
| Rice-Edwards, JM | 1 |
| Illingworth, RD | 1 |
| Richards, PG | 1 |
| Bleehen, NM | 1 |
| Begent, RJ | 1 |
| Calvert, H | 2 |
| Meikle, SR | 1 |
| Matthews, JC | 1 |
| Wells, P | 1 |
| Harte, RJ | 1 |
| Cunningham, VJ | 1 |
| Wedge, SR | 1 |
| Roddie, M | 1 |
| Rustin, GJ | 2 |
| Marzolini, C | 2 |
| Gander, M | 3 |
| Bauer, J | 1 |
| Biollaz, J | 2 |
| Fei, ZL | 1 |
| Decosterd, L | 1 |
| Bonfanti, M | 1 |
| Liénard, D | 1 |
| Perey, L | 1 |
| Colella, G | 1 |
| Yarosh, D | 1 |
| Belanich, M | 1 |
| D'Incalci, M | 1 |
| Judson, I | 1 |
| Beale, P | 1 |
| Reidenberg, P | 1 |
| Statkevich, P | 1 |
| Batra, V | 1 |
| Cutler, D | 1 |
| Young, H | 1 |
| Batchelor, T | 1 |
| van der Valk, P | 1 |
| Janinis, J | 1 |
| Efstathiou, E | 1 |
| Panopoulos, C | 1 |
| Samantas, E | 1 |
| Aravantinos, G | 1 |
| Christodoulou, C | 1 |
| Skarlos, D | 1 |
| Kerby, T | 1 |
| Archer, GE | 1 |
| Hulette, C | 1 |
| Pasetto, LM | 1 |
| Vastola, F | 1 |
| Monfardini, S | 2 |
| Osoba, D | 1 |
| Basso, U | 1 |
| Amistà, P | 1 |
| Berti, F | 1 |
| Pinna, G | 1 |
| Dinnes, J | 1 |
| Cave, C | 1 |
| Major, K | 1 |
| Milne, R | 1 |
| Harris, MT | 1 |
| Lemoine, MG | 1 |
| Mitlianga, P | 1 |
| Liu, TJ | 1 |
| Fels, C | 1 |
| Droege, JW | 1 |
| Schäfer, C | 1 |
| Khan, RB | 1 |
| Bazylewicz, KA | 1 |
| Schulz, JB | 1 |
| Dichgans, J | 1 |
| Rodemann, HP | 1 |
| Murphy, M | 1 |
| O'Dwyer, PJ | 1 |
| Berman, E | 1 |
| Sipos, L | 1 |
| Vitanovics, D | 1 |
| Afra, D | 1 |
| Blackledge, GR | 1 |
| Slack, JA | 1 |
| Smith, DB | 1 |
| Stuart, NS | 1 |
| Quarterman, CP | 1 |
| Hoffman, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Non-Randomized, Open-Label, Multi-Center Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-414 in Japanese Subjects With Malignant Glioma[NCT02590263] | Phase 1/Phase 2 | 53 participants (Actual) | Interventional | 2015-08-24 | Completed | ||
| A Prospective Study of Concurrent Chemoradiotherapy With Temozolomide Versus Radiation Therapy Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas[NCT02766270] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2016-09-26 | Recruiting | ||
| Effects of Low Dose Naltrexone on Quality of Life in High Grade Glioma Patients: A Placebo-Controlled, Double-Blind Randomized Trial[NCT01303835] | Phase 2 | 110 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Effect of rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temzolomide[NCT03687957] | Phase 1/Phase 2 | 70 participants (Anticipated) | Interventional | 2019-01-04 | Recruiting | ||
| A Phase II Open-Label, Randomized, Multi-Centre Comparative Study Of Bevacizumab-Based Therapy In Paediatric Patients With Newly Diagnosed Supratentorial, Infratentorial Cerebellar, or Peduncular High-Grade Glioma[NCT01390948] | Phase 2 | 124 participants (Actual) | Interventional | 2011-10-18 | Completed | ||
| A Phase I/II Study of ABT-888, An Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG)[NCT01514201] | Phase 1/Phase 2 | 66 participants (Actual) | Interventional | 2012-02-01 | Completed | ||
| Phase 1b/2a Study Combining LY2157299 With Standard Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma[NCT01220271] | Phase 1/Phase 2 | 75 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma[NCT02414165] | Phase 2/Phase 3 | 403 participants (Actual) | Interventional | 2015-11-30 | Terminated (stopped due to Sponsor Decision) | ||
| A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects With Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment[NCT01480050] | Phase 1 | 28 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Use of TTFields in Germany in Routine Clinical Care Study PROgram - Daily Activity, Sleep and Neurocognitive Functioning in Newly Diagnosed Glioblastoma Patients Study[NCT04717739] | 500 participants (Anticipated) | Observational | 2021-12-30 | Recruiting | |||
| Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma[NCT00887146] | Phase 3 | 360 participants (Anticipated) | Interventional | 2009-09-30 | Recruiting | ||
| Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study[NCT00182819] | Phase 3 | 709 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas[NCT00114140] | Phase 2 | 136 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Randomized Trial Assessing the Significance of Bevacizumab in Recurrent Grade II and Grade III Gliomas - The TAVAREC Trial[NCT01164189] | Phase 2 | 155 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| Safety of Intensity-modulated Radiotherapy Treatment With Inhomogeneous Dose Distribution in Patients With Relapsed High-grade Gliomas.[NCT04610229] | 12 participants (Actual) | Interventional | 2016-02-01 | Completed | |||
| An Open Label, Prospective, Pilot Study to Evaluate the Efficacy and Safety of Best Physician's Choice of Standard of Care Combined With NaviFUS System in Patients With Recurrent Glioblastoma Multiforme[NCT04446416] | 6 participants (Actual) | Interventional | 2020-07-21 | Completed | |||
| A Study to Evaluate the Safety and Feasibility of Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound With Intravenous Ultrasound Contrast Agents in the Treatment of Brain Tumours With Doxorubicin[NCT02343991] | 10 participants (Anticipated) | Interventional | 2014-10-31 | Active, not recruiting | |||
| Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis[NCT05554302] | Phase 2 | 20 participants (Anticipated) | Interventional | 2023-01-10 | Recruiting | ||
| NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621] | Phase 2 | 135 participants (Actual) | Interventional | 2019-03-25 | Completed | ||
| A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas[NCT02209428] | Phase 2 | 54 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| Phase II Study of 7 Days On/7 Days Off Temozolomide in Patients With High-Grade Glioma[NCT00619112] | Phase 2 | 60 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma[NCT05425004] | Phase 2 | 24 participants (Anticipated) | Interventional | 2022-05-27 | Recruiting | ||
| A Pilot Study Using Carboplatin, Vincristine And Temozolomide For Children ≤ 10 Years With Progressive/Symptomatic Low-Grade Gliomas[NCT00077207] | 66 participants (Actual) | Interventional | 2004-07-31 | Completed | |||
| EPIBRAINRAD : Study of Neurological Complication After Radiotherapy for Glioblastoma High Grade[NCT02544178] | 200 participants (Anticipated) | Observational | 2015-04-30 | Recruiting | |||
| Evaluation of 18F-Fluciclovine PET-MRI to Differentiate Tumor Progression From Post-treatment Changes in Pediatric High-grade Glioma (HGG)[NCT05553041] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2023-08-07 | Recruiting | ||
| The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial[NCT01847235] | Phase 2 | 23 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Secondary Prophylaxis Use of Romiplostim for the Prevention of Thrombocytopenia Induced by Temozolomide in Newly Diagnosed Glioblastoma Patients[NCT02227576] | Phase 2 | 20 participants (Actual) | Interventional | 2014-07-10 | Terminated (stopped due to Study halted for efficacy following the results of the interim analysis provided for in the protocol on 20 patients.) | ||
| Neural Stem Cell Oncolytic Adenoviral Virotherapy of Newly Diagnosed Malignant Glioma[NCT03072134] | Phase 1 | 12 participants (Actual) | Interventional | 2017-04-24 | Completed | ||
| Evaluation of Topical Application of 5% Imiquimod, 0.05% Imiquimod and 0.05% Nanoencapsulated Imiquimod Gel in the Treatment of Actinic Cheilitis: a Randomized Controlled Trial[NCT04219358] | Phase 1 | 49 participants (Actual) | Interventional | 2019-03-23 | Terminated (stopped due to Study terminated because of COVID19 pandemics.) | ||
| Phase I Trial of Temodar Plus O6-Benzylguanine (O6-BG) (NSC 637037) in the Treatment of Patients With Newly Diagnosed (Part 1) or Recurrent/Progressive (Parts 1 and 2) Cerebral Anaplastic Gliomas[NCT00006474] | Phase 1 | 0 participants | Interventional | 2001-03-31 | Completed | ||
| The Temozolomide RESCUE Study: A Phase II Trial of Continuous (28/28) Dose-intense Temozolomide (CDIT) Chemotherapy After Progression on Conventional 5/28 Day Temozolomide in Patients With Recurrent Malignant Glioma[NCT00392171] | Phase 2 | 120 participants (Actual) | Interventional | 2006-06-09 | Completed | ||
| Genomic Landscape of Intramedullary Astrocytoma[NCT04211974] | 50 participants (Anticipated) | Observational | 2019-12-10 | Recruiting | |||
| Phase II Study of Patients With Recurrent Glioblastoma Multiforme Treated With Maximal Safe Neurosurgical Resection and Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent Electronic Brachytherapy System and Bevacizumab[NCT04681677] | Phase 2 | 100 participants (Anticipated) | Interventional | 2021-11-02 | Recruiting | ||
| A Pilot Study of Patients With Recurrent Glioblastoma Treated With Maximal Safe Neurosurgical Resection, Intra-Operative Radiation Therapy (IORT) Using the Xoft® Axxent® Electronic Brachytherapy System[NCT04763031] | 1 participants (Actual) | Interventional | 2021-03-05 | Terminated (stopped due to No potential patients enrolled since first enrollment on 06/27/2022.) | |||
| A Phase II Study of Concurrent Radiation and Temozolomide Followed By Temozolomide and CCNU in the Treatment of Children With High-Grade Glioma[NCT00100802] | Phase 2 | 118 participants (Actual) | Interventional | 2005-03-21 | Completed | ||
| A Phase II Study of Temozolomide in the Treatment of Children With High Grade Glioma[NCT00028795] | Phase 2 | 170 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV[NCT00052455] | Phase 3 | 500 participants (Anticipated) | Interventional | 2002-10-31 | Completed | ||
| Efficacy of a Protracted Temozolomide Schedule in Patients With Progression After Standard Dose Temozolomide for High-grade Gliomas[NCT00575887] | Phase 2 | 25 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| A Phase I Dose Escalation Study of Vandetanib (ZACTIMA, ZD6474) With Hypofractionated Stereotactic Radiotherapy in Patients With Recurrent Malignant Gliomas[NCT00822887] | Phase 1 | 13 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas[NCT00369590] | Phase 2 | 58 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| A Phase 1b Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Gliomas[NCT00751270] | Phase 1 | 15 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Valproic Acid for Children With Recurrent and Progressive Brain Tumors[NCT01861990] | Phase 1 | 0 participants (Actual) | Interventional | 2013-05-31 | Withdrawn (stopped due to Feasibility of the trial was proven to be absent.) | ||
| Glioblastoma Lines as the Disease Model[NCT04180046] | 10 participants (Anticipated) | Observational | 2019-06-26 | Recruiting | |||
| Role of Glutamate-mediate Excitotoxicity in Invasion and Progression Processes of Glioblastoma Multiforme[NCT05775458] | 50 participants (Anticipated) | Observational | 2020-06-01 | Recruiting | |||
| Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors[NCT04592354] | 40 participants (Anticipated) | Interventional | 2020-10-15 | Recruiting | |||
| A Phase 2, Randomized, Open-Label Study of Anhydrous Enol-Oxaloacetate in Subjects With Newly Diagnosed Glioblastoma Multiforme[NCT04450160] | Phase 2 | 80 participants (Anticipated) | Interventional | 2020-12-31 | Not yet recruiting | ||
| A Randomized Double Blind Placebo Controlled Trial to Determine the Effects of Oxaloacetate on Improving Fatigue in ME/CFS[NCT05273372] | 80 participants (Anticipated) | Interventional | 2022-03-15 | Enrolling by invitation | |||
| Metabolomic Profiling of Erector Spinae Plane Block for Breast Cancer Surgery[NCT04689945] | 91 participants (Actual) | Observational | 2021-02-01 | Completed | |||
| A Feasibility Pilot Trial Evaluating Caloric Restriction for Oncology Research in Early Stage Breast Cancer Patients[NCT01819233] | 38 participants (Actual) | Interventional | 2013-03-08 | Completed | |||
| Can Fasting Decrease the Side Effects of Chemotherapy?[NCT04027478] | 39 participants (Anticipated) | Interventional | 2019-09-01 | Enrolling by invitation | |||
| A Phase II Study of Hypofractionated Stereotactic Radiotherapy Combined With Anlotinib in Patients With Recurrent High-Grade Glioma[NCT04197492] | Phase 2 | 32 participants (Anticipated) | Interventional | 2019-12-16 | Recruiting | ||
| A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma[NCT00498927] | Phase 2 | 47 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study[NCT01402063] | Phase 2 | 63 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas[NCT00003176] | Phase 2 | 82 participants | Interventional | 1998-03-25 | Completed | ||
| Treatment of Newly Diagnosed High-Grade Gliomas in Patients Ages Greater Than or Equal to 3 and Less Than or Equal to 21 Years With a Phase II Irinotecan Window Followed by Radiation Therapy and Temozolomide[NCT00004068] | Phase 2 | 53 participants (Actual) | Interventional | 1999-03-31 | Completed | ||
| Amino-acid PET Versus MRI Guided Re-irradiation in Patients With Recurrent Glioblastoma Multiforme - a Randomised Phase II Trial[NCT01252459] | Phase 2 | 200 participants (Anticipated) | Interventional | 2011-07-31 | Not yet recruiting | ||
| Phase II, Single Arm, Open Label Clinical Trial With Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas[NCT01574092] | Phase 2 | 39 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies[NCT00770263] | Phase 1 | 46 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Phase I Trial of Combination of DNX-2401 (Formerly Named Delta-24-RGD) Oncolytic Adenovirus With a Short Course of Temozolomide for Treatment of Glioblastoma at First Recurrent[NCT01956734] | Phase 1 | 31 participants (Anticipated) | Interventional | 2013-09-30 | Completed | ||
| A Phase I Study Of ZD 1839 And Temozolomide For The Treatment Of Gliomas[NCT00027625] | Phase 1 | 0 participants | Interventional | 2002-01-28 | Completed | ||
| (Cost)Effectiveness of MR-guided LITT Therapy in Patients With Primary Irresectable Glioblastoma: a Prospective Multicenter Randomized Controlled Trial (EMITT)[NCT05318612] | Phase 3 | 238 participants (Anticipated) | Interventional | 2022-04-08 | Recruiting | ||
| Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma[NCT00006025] | Phase 1 | 0 participants | Interventional | 2001-01-05 | Completed | ||
| Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients.[NCT03178032] | Phase 1 | 12 participants (Actual) | Interventional | 2017-05-26 | Completed | ||
| A Phase I Study of Imatinib Mesylate in Combination With Temozolomide in Patients With Malignant Glioma[NCT00354068] | Phase 1 | 65 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| A Phase I Study of Temozolomide and CCNU in Pediatric Patients With Newly Diagnosed Incompletely Resected Non-Brainstem High-Grade Gliomas[NCT00006024] | Phase 1 | 32 participants (Actual) | Interventional | 2000-11-30 | Completed | ||
| A Phase II Study of Temozolomide (SCH 52365, Temodal(R)) for the Treatment of Recurrent Malignant Glioma[NCT00004113] | Phase 2 | 0 participants | Interventional | 1999-06-30 | Completed | ||
| Pre-operative Radiation Therapy (RT) and Temozolomide (TMZ) in Patients With Newly Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)[NCT03480867] | Phase 1 | 0 participants (Actual) | Interventional | 2017-03-31 | Withdrawn (stopped due to competing study was opened by the surgeon after this trial was opened) | ||
| Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases[NCT00582075] | Phase 2 | 25 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients completed the 6-minute walk test (6MWT) at each QoL measurement assessment. The 6 minute walk test is a measure of functional capacity in which the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes is measured. The mean difference in distance traveled (in meters) between the 3rd QoL measurement (approximately 16 weeks from initial assessment) and the initial baseline assessment are reported. A difference greater than 0 indicates an increase in distance traveled, while a difference less than 0 indicates a decrease. (NCT01303835)
Timeframe: Baseline and 16 weeks
| Intervention | Meters (Mean) |
|---|---|
| Low Dose Naltrexone (LDN) | 13.43 |
| Placebo | -6.42 |
Patients completed neurocognitive testing at each QoL measurement assessment. Neurocognitive function was measured via a computerized neurocognitive test battery called CNS Vital Signs. The battery consists of 7 tests that assess verbal and visual memory, finger tapping, symbol digit coding, the Stroop Test, a test of shifting attention, and continuous performance. The battery provides scores over 9 domains with higher scores indicating better performance. Scores were normalized to a standard score mean of 100 and standard deviation of 15 using a normative sample. The mean difference in score in each domain between the 3rd QoL measurement (approximately 16 weeks from initial assessment) and the initial baseline assessment are reported. A difference greater than 0 indicates an increase in mean score, while a difference less than 0 indicates a decrease in mean score. (NCT01303835)
Timeframe: Baseline and 16 weeks
| Intervention | Scores on a Scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Memory | Processing Speed | Reaction Time | Verbal Memory | Visual Memory | Cognitive Flexibility | Complex Attention | Psychomotor Speed | Executive Functioning | |
| Low Dose Naltrexone (LDN) | -5.38 | -0.71 | -7.24 | -0.1 | -8.38 | 3.62 | 7.33 | -0.76 | 3.9 |
| Placebo | -0.24 | 7.32 | -8.64 | 2 | -2.24 | 7.44 | 6.24 | 4.72 | 7.56 |
"The difference in QoL scores between the 3rd QoL measurement (approximately 16 weeks from initial assessment) and the initial baseline assessment are reported. QoL instruments included are listed below. Higher scores indicate more favorable outcomes unless otherwise indicated.~Functional Assessment of Cancer Therapy-Brain (FACT-Br) measures general QoL reflecting symptoms associated with brain malignancies (range 0-132)~Functional Assessment of Chronic Illness Therapy (FACIT-F) measures level of fatigue during patients' usual daily activities (range 0-52)~Epworth Sleepiness Scale measures level of daytime sleepiness. Note that higher scores indicate a greater level of sleepiness (range 0-24)~Medical Outcomes Survey (MOS) measures QoL including physical, mental and general health via 8 domains (range 0-100 for each domain)~Zung Self-Rating Depression Scale quantifies the depressed status of a patient. Lower scores indicate more favorable outcome (range 20-80) A difference" (NCT01303835)
Timeframe: Baseline and 16 weeks
| Intervention | Scores on a Scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FACT-Brain Trial Outcome Index (TOI) | FACIT-Fatigue | Epworth Sleepiness Scale | MOS - Physical Functioning | MOS - Role Limitations due to Physical Health | MOS - Role Limitations due to Emotional Issues | MOS - Energy/Fatigue | MOS - Emotional Well Being | MOS - Social Functioning | MOS - Pain | MOS - General Health | Zung Depression Scale | |
| Low Dose Naltrexone (LDN) | -3.73 | -4.22 | 3.47 | -5.54 | 0 | 2.69 | -6.22 | 3.5 | 1.34 | 10.41 | -13.38 | 0.86 |
| Placebo | -6.06 | -4.1 | 0.81 | -3.42 | 20.39 | 12.3 | -4.61 | -1.89 | 7.87 | 2.39 | -12.11 | 3.54 |
Concordance is presented as the percentage of participants with concordance between assessments. EFS concordance was defined as event Structural assessment and Diffusion Perfusion assessment occurs within 28 days or no event Structural and no Diffusion Perfusion. (NCT01390948)
Timeframe: Up to 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Chemoradiation + TMZ | 96.6 |
| Chemoradiation + Bevacizumab + TMZ | 87.1 |
EFS was defined as the time from randomisation to the earliest occurrence of any of the following: tumor progression, tumor recurrence, second primary non-HGG malignancy or death attributable to any cause. Tumor assessments were conducted using MRI and reviewed by the investigator using RANO criteria. Tumor progression was defined as clear clinical progression or >/= 25% increase in the sum of the products of perpendicular diameters of the contrast enhancing lesions compared with the smallest tumor measurement obtained either at baseline (if no decrease was observed) or best response and with the participant on stable or increasing doses of corticosteroids. Tumor recurrence was defined as recurrence after tumor was completely resected (no disease present at baseline). EFS was estimated using the Kaplan-Meier method. (NCT01390948)
Timeframe: From the time of randomization to the date of any defined event (up to 12 months)
| Intervention | months (Median) |
|---|---|
| Chemoradiation + TMZ | 11.79 |
| Chemoradiation + Bevacizumab + TMZ | 11.27 |
EFS was defined as the time from randomisation to the earliest occurrence of any of the following: tumor progression, tumor recurrence, second primary non- HGG malignancy or death attributable to any cause. Tumor assessments were conducted using magnetic resonance imaging (MRI) and reviewed by the site-independent CRRC using Response Assessment in Neuro-Oncology (RANO) criteria. Tumor progression was defined as clear clinical progression or >/= 25% increase in the sum of the products of perpendicular diameters of the contrast enhancing lesions compared with the smallest tumor measurement obtained either at baseline (if no decrease was observed) or best response and with the subject on stable or increasing doses of corticosteroids. Tumor recurrence was defined as recurrence after tumor was completely resected (no disease present at baseline). EFS was estimated using the Kaplan-Meier method. (NCT01390948)
Timeframe: From the time of randomization to the date of any defined event (up to 12 months)
| Intervention | months (Median) |
|---|---|
| Chemoradiation + TMZ | 11.79 |
| Chemoradiation + Bevacizumab + TMZ | 8.21 |
The Wechsler Intelligence Scale for Children version IV (WISC-IV) was used to generate a full scale intelligence quotient (IQ) which represents a child's general intellectual ability. The average IQ score is 100, with lower scores representing lower intellectual ability. (NCT01390948)
Timeframe: End of treatment (approximately 58 weeks post-baseline)
| Intervention | units on a scale (Mean) |
|---|---|
| Chemoradiation + TMZ | 92.0 |
| Chemoradiation + Bevacizumab + TMZ | 97.0 |
Number of doses were assessed for the concurrent phase, which is the treatment period after the initial treatment phase and including the subsequent treatment break of approximately 4 weeks. (NCT01390948)
Timeframe: Beginning of the concurrent phase to end of treatment break (10 weeks)
| Intervention | Grays (Median) |
|---|---|
| Chemoradiation + TMZ | 54.0 |
| Chemoradiation + Bevacizumab + TMZ | 54.0 |
ORR was defined as the percentage of participants with a complete response (CR) or partial response (PR) determined on two consecutive occasions >/= 4 weeks apart. Tumor assessments were conducted using MRI and reviewed by the site-independent CRRC using RANO criteria. The following were needed to qualify as CR: complete disappearance of all measurable enhancing lesions sustained for at least 4 weeks by MRI, no steroids above physiological levels, clinical status stable or improved compared to baseline. The following were needed to qualify as PR: ≥ 50% decrease from baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions sustained for at least 4 weeks by MRI, steroid dose not increased compared to baseline, clinical status stable or improved compared to baseline. (NCT01390948)
Timeframe: From the time of randomization to the date of any defined event (up to 12 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Chemoradiation + TMZ | 40 |
| Chemoradiation + Bevacizumab + TMZ | 41.7 |
Overall Survival was defined as the time of diagnosis to the date of death due to any cause. Overall Survival was estimated using the Kaplan-Meier method. (NCT01390948)
Timeframe: From the time of randomization to the date of death (up to approximately 60 months)
| Intervention | months (Median) |
|---|---|
| Chemoradiation + TMZ | 20.27 |
| Chemoradiation + Bevacizumab + TMZ | 18.30 |
1-year survival was estimated using the Kaplan-Meier method. (NCT01390948)
Timeframe: 1 year after end of treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Chemoradiation + TMZ | 67.69 |
| Chemoradiation + Bevacizumab + TMZ | 74.83 |
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. (NCT01390948)
Timeframe: From the time of randomization of the first participant to the date of clinical cutoff (approximately 60 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Chemoradiation + TMZ | 100 |
| Chemoradiation + Bevacizumab + TMZ | 98.3 |
EFS was defined as the time from randomisation to the earliest occurrence of any of the following: tumor progression, tumor recurrence, second primary non- HGG malignancy or death attributable to any cause. Tumor assessments were conducted using MRI and reviewed by the site-independent CRRC using RANO criteria. Tumor progression was defined as clear clinical progression or >/= 25% increase in the sum of the products of perpendicular diameters of the contrast enhancing lesions compared with the smallest tumor measurement obtained either at baseline (if no decrease was observed) or best response and with the subject on stable or increasing doses of corticosteroids. Tumor recurrence was defined as recurrence after tumor was completely resected (no disease present at baseline). EFS was estimated using the Kaplan-Meier method. (NCT01390948)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Chemoradiation + TMZ | 48.37 |
| Chemoradiation + Bevacizumab + TMZ | 38.28 |
EFS was defined as the time from randomisation to the earliest occurrence of any of the following: tumor progression, tumor recurrence, second primary non- HGG malignancy or death attributable to any cause. Tumor assessments were conducted using MRI and reviewed by the site-independent CRRC using RANO criteria. Tumor progression was defined as clear clinical progression or >/= 25% increase in the sum of the products of perpendicular diameters of the contrast enhancing lesions compared with the smallest tumor measurement obtained either at baseline (if no decrease was observed) or best response and with the subject on stable or increasing doses of corticosteroids. Tumor recurrence was defined as recurrence after tumor was completely resected (no disease present at baseline). EFS was estimated using the Kaplan-Meier method. (NCT01390948)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Chemoradiation + TMZ | 66.46 |
| Chemoradiation + Bevacizumab + TMZ | 68.43 |
HUI is a preference-based, multi-attitude, health-related instrument specifically developed for use with children. HUI consists of eight attributes of health status: vision, hearing, speech, ambulation, dexterity, emotion, cognition and pain. Each attribute had 5 or 6 levels varying from highly impaired to normal. Each of the eight health dimensions was tested separately and a composite score ranging between 1 (perfect health) and 0 (death) was obtained for participants aged 5 years or older. (NCT01390948)
Timeframe: Baseline, Cycle 6 of the adjuvant phase, end of treatment (approximately 58 weeks post-baseline), and yearly during the follow-up period (maximum 5 years in follow-up)
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Cycle 6, Day 1 | End of Treatment | Yearly Follow-Up 1 | Yearly Follow-up 2 | Additional Safety Follow-Up (Visit 2) | Additional Safety Follow-Up (Visit 4) | Additional Safety Follow-Up (Visit 6) | Additional Safety Follow-Up (Visit 8) | End of Study | |
| Chemoradiation + Bevacizumab + TMZ | 0.730 | 0.779 | 0.820 | 0.926 | 0.793 | 0.901 | 0.830 | 0.490 | 0.930 | 0.790 |
HUI is a preference-based, multi-attitude, health-related instrument specifically developed for use with children. HUI consists of eight attributes of health status: vision, hearing, speech, ambulation, dexterity, emotion, cognition and pain. Each attribute had 5 or 6 levels varying from highly impaired to normal. Each of the eight health dimensions was tested separately and a composite score ranging between 1 (perfect health) and 0 (death) was obtained for participants aged 5 years or older. (NCT01390948)
Timeframe: Baseline, Cycle 6 of the adjuvant phase, end of treatment (approximately 58 weeks post-baseline), and yearly during the follow-up period (maximum 5 years in follow-up)
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Cycle 6, Day 1 | End of Treatment | Yearly Follow-Up 1 | Yearly Follow-up 2 | Additional Safety Follow-Up (Visit 2) | Additional Safety Follow-Up (Visit 4) | Additional Safety Follow-Up (Visit 6) | End of Study | |
| Chemoradiation + TMZ | 0.713 | 0.785 | 0.832 | 0.906 | 0.737 | 0.784 | 0.814 | 1.000 | 0.647 |
Number of doses were assessed for the concurrent phase, which is the treatment period after the initial treatment phase and including the subsequent treatment break of approximately 4 weeks. (NCT01390948)
Timeframe: Beginning of the concurrent phase to end of treatment break (10 weeks)
| Intervention | number of dose administrations (Median) | |
|---|---|---|
| TMZ | Bevacizumab | |
| Chemoradiation + Bevacizumab + TMZ | 42.0 | 6.0 |
| Chemoradiation + TMZ | 42.0 | NA |
(NCT01390948)
Timeframe: From the time of randomization of the first participant to the date of clinical cutoff (approximately 60 months)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Radiotherapy | TMZ | |
| Chemoradiation + Bevacizumab + TMZ | 98.3 | 88.3 |
| Chemoradiation + TMZ | 94.6 | 85.7 |
(NCT01390948)
Timeframe: From the time of randomization of the first participant to the date of clinical cutoff (approximately 60 months)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| AE leading to dose modification/interruption | AE leading to withdrawal from treatment | |
| Chemoradiation + Bevacizumab + TMZ | 71.7 | 21.7 |
| Chemoradiation + TMZ | 60.7 | 5.4 |
During course 1, blood samples were collected pre-veliparib on day 1, at 0.5, 1, 2, and 6-8 hours after the first dose, pre-veliparib on day 4 (steady state), and 2 hours after the morning dose. Veliparib concentrations were measured using a liquid chromatography tandem mass spectrometry assay and pharmacokinetic parameters were evaluated using a non-compartmental analysis. (NCT01514201)
Timeframe: Up to day 4
| Intervention | L/m^2 (Mean) |
|---|---|
| Phase I, Dose Level 1 (50 mg) | 75.4 |
| Phase I, Dose Level 2 (65 mg) | 56.1 |
| Phase I, Dose Level 3 (85 mg) | 63.9 |
| Phase II (MTD) | 73.1 |
During course 1, blood samples were collected pre-veliparib on day 1, at 0.5, 1, 2, and 6-8 hours after the first dose, pre-veliparib on day 4 (steady state), and 2 hours after the morning dose. Veliparib concentrations were measured using a liquid chromatography tandem mass spectrometry assay and pharmacokinetic parameters were evaluated using a non-compartmental analysis. Cmax measures the highest concentration of drug. (NCT01514201)
Timeframe: Day 1
| Intervention | μM (Mean) |
|---|---|
| Phase I, Dose Level 1 (50 mg) | 2.12 |
| Phase I, Dose Level 2 (65 mg) | 3.45 |
| Phase I, Dose Level 3 (85 mg) | 4.40 |
| Phase II (MTD) | 3.45 |
The traditional 3+3 dose finding algorithm was used to estimate the maximum-tolerated dose of veliparib given concurrently with radiation therapy. The dose-limiting toxicity observation period was the first 10 weeks of therapy. Dose-limiting toxicities included any grade 4 non-hematologic toxicity, any grade 3 non-hematologic toxicity with a few exceptions (see section 5.2.1.2 of the protocol document), any grade 2 non-hematologic toxicity that persisted for >7 days and considered medically significant that required treatment interruption; grade 3 or higher thrombocytopenia or grade 4 neutropenia; and any Veliparib related adverse event that led to a dose reduction or the permanent cessation of therapy. (NCT01514201)
Timeframe: 10 weeks
| Intervention | mg/m2/dose BID (Number) |
|---|---|
| Phase I Patients | 65 |
During course 1, blood samples were collected pre-veliparib on day 1, at 0.5, 1, 2, and 6-8 hours after the first dose, pre-veliparib on day 4 (steady state), and 2 hours after the morning dose. Veliparib concentrations were measured using a liquid chromatography tandem mass spectrometry assay and pharmacokinetic parameters were evaluated using a non-compartmental analysis. (NCT01514201)
Timeframe: Up to day 4
| Intervention | L/m^2/h (Mean) |
|---|---|
| Phase I, Dose Level 1 (50 mg) | 16.1 |
| Phase I, Dose Level 2 (65 mg) | 13.2 |
| Phase I, Dose Level 3 (85 mg) | 15.8 |
| Phase II (MTD) | 11.7 |
DLTs were defined as any of the following adverse events that were at least possibly attributable to Veliparib observed during the dose finding phase (the first 10 weeks of therapy). Hematologic dose limiting toxicities included grade 3 and higher thrombocytopenia or grade 4 neutropenia. Non-hematologic dose limiting toxicities included any grade 4 non-hematologic toxicity, any grade 3 non-hematologic toxicity with some exceptions (e.g., nausea and vomiting of <5 days; fever or infection of <5 days; hypophosphatemia, hypokalemia, hypocalcemia or hypomagnesemia responsive to oral supplementation; elevation of transaminases that return to levels meeting eligibility criteria within 7 days), or any grade non-hematologic toxicity that persisted for >7 days and considered medically significant or sufficiently intolerable by patients that required treatment interruption. (NCT01514201)
Timeframe: 10 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase I, Dose Level 1 (50 mg) | 1 |
| Phase I, Dose Level 2 (65 mg) | 0 |
| Phase I, Dose Level 3 (85 mg) | 3 |
Overall survival was defined as the interval from date on treatment to date of death from any cause or to date of last follow-up. Patients who had not failed (died) at the time of analyses were censored at their last date of contact. The method of Kaplan and Meier was used to estimate overall survival. The 3-year estimate with a 95% confidence interval is reported. (NCT01514201)
Timeframe: Time from initiation of therapy to the date of death from any cause or to the date patient was known to be alive for surviving patients, assessed to up to 3 years
| Intervention | Percent probability (Number) |
|---|---|
| Phase II Patients + Phase I MTD Patients | 5.3 |
Unacceptable toxicities during maintenance included events at least possibly attributable to Veliparib and temozolomide (TMZ) such as any grade 4 non-hematologic toxicity, any grade 3 non-hematologic toxicity with some exceptions (e.g., grade 3 nausea/vomiting <5 days, grade 3 fever or infection <5 days), grade 3+ thrombocytopenia, grade 4 neutropenia, delay >14 days in starting subsequent cycle due to neutrophil <1,000/mm3 or platelet <100,000/mm3. Maintenance therapy was initiated with 25 mg/m2 Veliparib and 135 mg/m2 of TMZ, with the possibility to escalate TMZ to 175 mg/m2 and 200 mg/m2 in courses 2 and 3, respectively, if no unacceptable toxicities occurred following one course of treatment at each of the dose levels to be tested. Intra-patient dose escalation to a given dose (135, 175, or 200 mg/m2) was halted based on rules employed in 3+3 designs. This dose escalation was intended for all patients but was halted early, during the phase I portion, as it was not well tolerated. (NCT01514201)
Timeframe: 28 days per treatment cycle
| Intervention | % of participants (Number) |
|---|---|
| Dose Level 1 (135 mg/m2) | 9 |
| Dose Level 2 (175 mg/m2) | 40 |
| Dose Level 3 (200 mg/m2) | 67 |
Blood samples were collected from patients and assessed pre- and post-Veliparib to assess treatment-induced changes. A significant change in PBMC PARP level was arbitrarily defined as a >50% increase or decrease from the pre-treatment level, documented at week 6 and/or week 11 after starting protocol therapy. (NCT01514201)
Timeframe: Baseline and up to 11 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Phase I, Dose Level 1 (50 mg) | 100 |
| Phase I, Dose Level 2 (65 mg) | 100 |
| Phase I, Dose Level 3 (85 mg) | 75 |
| Phase II (MTD) | 36 |
For participants that showed possible tumor progression (pseudo progression) on magnetic resonance imaging (MRI) during the first 6 months of therapy, treating physicians had the option of allowing patients to remain on therapy and repeating the disease assessment in 4-6 weeks. If the repeat MRI at 4-6 weeks showed disease progression, the patient was noted to have true disease progression (and the progression date corresponded to that of the first MRI). If the repeat MRI at 4-6 weeks did not show disease progression, then the patient was noted to have pseudo progression. The percentage of patients observed to have experienced pseudo progression was provided with a 95% confidence interval. (NCT01514201)
Timeframe: Up to 6 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Phase I, Dose Level 1 (50 mg) | 33.3 |
| Phase I, Dose Level 2 (65 mg) | 16.7 |
| Phase I, Dose Level 3 (85 mg) | 0 |
| Phase II (MTD) | 12.8 |
PFS was defined as the interval from date of treatment initiation to date of first event (disease progression or relapse, second malignancy or death from any cause). Patients who had not failed at the time of analyses were censored at their last date of contact. The method of Kaplan and Meier was used to estimate PFS. A 3-year estimate with a 95% confidence interval is reported. (NCT01514201)
Timeframe: Time from initiation of treatment to the earliest date of failure (disease progression, death from any cause, or second malignancy), assessed up to 3 years
| Intervention | Percent probability (Number) |
|---|---|
| Phase II Patients + Phase I MTD Patients | 2.9 |
During course 1, blood samples were collected pre-veliparib on day 1, at 0.5, 1, 2, and 6-8 hours after the first dose, pre-veliparib on day 4 (steady state), and 2 hours after the morning dose. Veliparib concentrations were measured using a liquid chromatography tandem mass spectrometry assay and pharmacokinetic parameters were evaluated using a non-compartmental analysis. (NCT01514201)
Timeframe: Up to day 4
| Intervention | Hour (Mean) |
|---|---|
| Phase I, Dose Level 1 (50 mg) | 5.18 |
| Phase I, Dose Level 2 (65 mg) | 2.62 |
| Phase I, Dose Level 3 (85 mg) | 4.45 |
| Phase II (MTD) | 2.18 |
During course 1, blood samples were collected pre-veliparib on day 1, at 0.5, 1, 2, and 6-8 hours after the first dose, pre-veliparib on day 4 (steady state), and 2 hours after the morning dose. Veliparib concentrations were measured using a liquid chromatography tandem mass spectrometry assay and pharmacokinetic parameters were evaluated using a non-compartmental analysis. (NCT01514201)
Timeframe: Up to day 4
| Intervention | ng/mL (Mean) |
|---|---|
| Phase I, Dose Level 1 (50 mg) | 58 |
| Phase I, Dose Level 2 (65 mg) | 140 |
| Phase I, Dose Level 3 (85 mg) | 163 |
| Phase II (MTD) | 84 |
Urine samples were analyzed for a panel of biomarkers. Netrin-1 levels were determined by ELISA. Levels of matrix metalloproteinase 3 (MMP3) and basic fibroblast growth factor (bFGF) were analyzed using custom Luminex® screening assays. Tissue inhibitor of metalloproteinase 1 (TIMP1) levels were analyzed using a Luminex® performance assay. Protein concentrations are given in picograms per microgram (pg/μg), and were determined by dividing the concentration of the target protein in the sample (pg/mL) by the concentration of total protein in the sample (μg/mL) as a normalization measure. (NCT01514201)
Timeframe: Baseline to up to 3 years
| Intervention | pg/μg (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MMP3 at pre-study | MMP3 at week 10-11 | MMP3 at week 18 | MMP3 at week 26 | Netrin-1 at pre-study | Netrin-1 at week 10-11 | Netrin-1 at week 18 | Netrin-1 at week 26 | TIMP1 at pre-study | TIMP1 at week 10-11 | TIMP1 at week 18 | TIMP1 at week 26 | bFGF at pre-study | bFGF at week 10-11 | bFGF at week 18 | bFGF at week 26 | |
| Phase I, Dose Level 1 (50 mg) | 2.0 | 1.4 | 4.3 | 2.9 | 0.1 | 0.1 | 0.3 | 0.4 | 3.4 | 6.2 | 10.7 | 7.3 | 3.1 | 3.6 | 10.3 | 7.7 |
| Phase I, Dose Level 2 (65 mg) | 1.0 | 1.0 | 1.7 | 0.4 | 0.1 | 0.1 | 0.1 | 0.2 | 9.9 | 11.9 | 7.7 | 5.2 | 1.9 | 2.1 | 3.5 | 0.9 |
| Phase I, Dose Level 3 (85 mg) | 0.0 | 0.8 | 0.7 | 1.0 | 0.1 | 0.1 | 0.0 | 0.0 | 10.8 | 12.3 | 14.8 | 32.8 | 1.2 | 1.8 | 1.3 | 1.1 |
| Phase II (MTD) | 1.1 | 2.6 | 2.3 | 3.0 | 0.1 | 0.0 | 0.1 | 0.0 | 7.3 | 7.5 | 7.1 | 10.7 | 4.5 | 3.5 | 4.4 | 4.5 |
During course 1, blood samples were collected pre-veliparib on day 1, at 0.5, 1, 2, and 6-8 hours after the first dose, pre-veliparib on day 4 (steady state), and 2 hours after the morning dose. Veliparib concentrations were measured using a liquid chromatography tandem mass spectrometry assay and pharmacokinetic parameters were evaluated using a non-compartmental analysis. Cmax measures the highest concentration of drug. (NCT01514201)
Timeframe: Up to day 4
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Day 1, Cmax (ng/mL) | Day 4, Cmax (ng/mL) | |
| Phase I, Dose Level 1 (50 mg) | 519 | 409 |
| Phase I, Dose Level 2 (65 mg) | 843 | 788 |
| Phase I, Dose Level 3 (85 mg) | 1074 | 954 |
| Phase II (MTD) | 844 | 717 |
Survival time is defined as time from registration to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. This analysis was planned to occur when all patients had been potentially followed for at least 3 years. (NCT00114140)
Timeframe: Registration to 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Temozolomide + Radiation Therapy (RT) | 73.1 |
"Progressive Disease (PD) is defined as 25% or > increase in the cross-sectional area of enhancing or non-enhancing tumor on consecutive MRI scans, or any new area(s) of tumor. Under exceptional circumstances, disease progression may be declared in the absence of an increase in tumor size based on clinical deterioration including the need for increasing doses of steroid and/or a worsening Karnofsky Performance Status(KPS) / Neurologic Function Score(NFS). Progression-free survival time is defined as time from registration to date of progressive disease or death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Median survival time is reported." (NCT00114140)
Timeframe: From registration to last follow-up, up to 7.1 years. Analysis occurs after all patients have been on study for at least 3 years.
| Intervention | years (Median) |
|---|---|
| Temozolomide + Radiation Therapy (RT) | 4.5 |
"Hopkins Verbal Learning Test (HVLT) is a test measuring learning memory retrieval, and memory consolidation processes.; Controlled Oral Word Association Test (COWAT) is a test of phonemic verbal fluency. The patient produces as many words as possible in 1 min. (each) for a specific letter (C, F, L or P, R, W).; Trail Making Test (TMT) is a measure of visuospatial scanning, attention, sequencing, and speed in Part A (TMT A) and executive function in Part B (TMT B). Patients must connect the dots either in a numbered sequence or alternating letters and numbers. Difference between pre-treatment baseline and follow-up assessment scores determined by the reliable change (RC) index, using a 90% confidence interval to designate statistically significant change." (NCT00114140)
Timeframe: Baseline, 6 months, and 12 months.
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HVLT Recall Status: Deterioration | HVLT Recall Status: No change | HVLT Recall Status: Improvement | COWA Status: Deterioration | COWA Status: No change | COWA Status: Improvement | TMT A Status: Deterioration | TMT A Status: No change | TMT A Status: Improvement | TMT B Status: Deterioration | TMT B Status: No change | TMT B Status: Improvement | |
| Temozolomide + Radiation Therapy (RT) at 12 Months | 8 | 22 | 15 | 3 | 28 | 12 | 7 | 24 | 14 | 7 | 22 | 15 |
| Temozolomide + Radiation Therapy (RT) at 6 Months | 11 | 26 | 13 | 1 | 42 | 6 | 15 | 24 | 11 | 11 | 27 | 11 |
Functional Assessment of Cancer Therapy Scale with brain module (FACT-BR): a 50-question self-report questionnaire contains the following domains (scales): Physical well-being (7 questions totalling 0-28), social/family well-being (7 questions totalling 0-28), emotional well-being (6 questions totalling 0-24), functional well-being (7 questions totalling 0-28) and brain cancer subscale which contains concerns relevant to patients with brain tumors (19 questions totalling 0-76). Each question has a value 0-4. For some questions a higher indicates better outcome and others are the opposite. The former are summed as is, the latter are reversed in value before adding, such that each domain ranges from 0 to 4 multiplied by the number of questions in the domain, with 0 indicating worst and the highest possible value indicating best outcome. The FACT-Br total (0-184) is obtained by adding all domains together if the overall question response rate is greater than 80%. (NCT00114140)
Timeframe: Baseline, 6 months, and 12 months.
| Intervention | units on a scale (Median) | |||||
|---|---|---|---|---|---|---|
| Physical Well-Being | Social/Family Well-Being | Emotional Well-Being | Functional Well-Being | Brain Cancer Subscale | FACT-Br Total | |
| Temozolomide + Radiation Therapy (RT) at 12 Months | 23 | 24.3 | 23.0 | 19.5 | 59.0 | 140.0 |
| Temozolomide + Radiation Therapy (RT) at 6 Months | 22 | 24.0 | 20.0 | 18.0 | 52.0 | 129.9 |
| Temozolomide + Radiation Therapy (RT) at Baseline | 23 | 24.5 | 18.5 | 17.0 | 54.0 | 135.3 |
"Survival time is defined as time from registration to date of death from any cause. Progressive Disease (PD) is defined as 25% or > increase in the cross-sectional area of enhancing or non-enhancing tumor on consecutive MRI scans, or any new area(s) of tumor. Under exceptional circumstances, disease progression may be declared in the absence of an increase in tumor size based on clinical deterioration including the need for increasing doses of steroid and/or a worsening Karnofsky Performance Status(KPS) / Neurologic Function Score(NFS). Survival and progression-free survival are estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact." (NCT00114140)
Timeframe: Registration to 3 years
| Intervention | years (Median) | |
|---|---|---|
| Overall Survival | Progression-free Survival | |
| Temozolomide + Radiation Therapy (RT) - Methylated | NA | NA |
| Temozolomide + Radiation Therapy (RT) - Unmethylated | 3.0 | 2.0 |
Efficacy of dose-intense temozolomide treatment schedule, as measured by 6 months progression-free survival (NCT00619112)
Timeframe: First day of treatment until progression or until 6 months mark
| Intervention | percentage of patients (Number) |
|---|---|
| Glioblastoma | 10 |
| Grade III Glioma | 50 |
(NCT00619112)
Timeframe: up to 2 years after treatment
| Intervention | weeks (Median) |
|---|---|
| Glioblastoma | 21.6 |
| Grade III Glioma | 100.6 |
(NCT00619112)
Timeframe: From beginning of voluntarily temozolomide discontinued up to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Glioblastoma | 4 |
| Grade III Glioma | 4 |
(NCT00619112)
Timeframe: After two first-line adjuvant courses of temozolomide
| Intervention | Participants (Count of Participants) |
|---|---|
| Glioblastoma | 3 |
| Grade III Glioma | 0 |
(NCT00619112)
Timeframe: Within 6 months after 6th adjuvant course of temozolomide
| Intervention | Participants (Count of Participants) |
|---|---|
| Glioblastoma | 4 |
| Grade III Glioma | 1 |
PCR analysis of tumor tissue for microsatellite instability (MSI). Tissue was obtained during surgeries prior this study. (NCT00619112)
Timeframe: prior to start of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Glioblastoma | 0 |
| Grade III Glioma | 0 |
Progression-free survival data (obtained for Primary Outcome Measure) was correlated with tumor MGMT (O(6)-methylguanine-DNA methyltransferase) promoter methylation status, obtained from patients as part of the study. (NCT00619112)
Timeframe: First day of treatment until progression or until 6 months mark
| Intervention | weeks (Median) |
|---|---|
| Glioblastoma With Methylated MGMT | 8.14 |
| Glioblastoma With Unmethylated MGMT | 7.57 |
| Grade III Glioma With Methylated MGMT | 38.1 |
| Grade III Glioma With Unmethylated MGMT | 48.6 |
"Success is defined as the completion of induction plus four cycles of maintenance within 60 weeks of enrollment without more than a 25% reduction in either carboplatin or temozolomide dosage.~If the participant completes all therapy within 60 weeks the patient is a long-term feasibility success. As such, a patient who experiences short term feasibility failure can be classified as a long-term feasibility success." (NCT00077207)
Timeframe: 60 weeks
| Intervention | participants (Number) |
|---|---|
| Treatment (Carboplatin, Vincristine Sulfate, Temozolomide) | 41 |
Occurence of grade 3 or 4 thrombocytopenia or neutropenia while receiving protocol therapy. (NCT00077207)
Timeframe: Up to 18 months of protocol therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Carboplatin, Vincristine Sulfate, Temozolomide) | 43 |
Primary safety endpoints are (1) the occurrence of toxic death, which is death during treatment that is not primarily attributable to disease progression, and (2) the occurrence of grade 4 allergy to carboplatin. (NCT00077207)
Timeframe: Up to 6 years after the start of protocol therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Carboplatin, Vincristine Sulfate, Temozolomide) | 0 |
Percentage probability of being alive and without the occurrence of disease progression 3 years following enrollment. (NCT00077207)
Timeframe: 3 years
| Intervention | Percent probability PFS (Number) |
|---|---|
| Carboplatin, Vincristine Sulfate, Temozolomide) | 60.59 |
Percentage probability of being alive and without the occurrence of disease progression or second malignant neoplasm 6 years following enrollment. (NCT00077207)
Timeframe: Six years
| Intervention | percent probability EFS (Number) |
|---|---|
| Carboplatin, Vincristine Sulfate, Temozolomide) | 40.89 |
"Success is defined as the completion of induction plus one cycle of maintenance within 24 weeks of enrollment without more than a 25% reduction in either carboplatin or temozolomide dosage.~Failure to complete the induction and one cycle of maintenance within 24 weeks counts as a short-term-feasibility failure." (NCT00077207)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| Treatment (Carboplatin, Vincristine Sulfate, Temozolomide) | 25 |
Median overall survival (NCT03072134)
Timeframe: Two years
| Intervention | Months (Median) |
|---|---|
| Total Cohort | 18.4 |
Using a 3+3 dose escalation design, three to six patients were to be enrolled per dose in each of the 3 cohorts. If no patients in the cohort experienced a dose-limiting toxicity (DLT), then the next cohort enrolled a minimum of 3 patients. If one of three patients experienced a DLT, then 3 more patients were evaluated at that dose level. If none of these three additional patients experienced a DLT, then dose escalation occurs, unless this is the highest dose, in which case dose escalation is stopped and the highest dose is declared the MTD. If 1 or more of these additional 3 patients had a DLT, then three additional patients may be entered, after discussion with the sponsor, at the next lowest does level if only three patients were treated previously at that dose. If two or more patients experienced a DLT Dose escalation will be stopped; 3 more patients could be added with sponsor approval at the next lower dose level. (NCT03072134)
Timeframe: Two years
| Intervention | Percentage of dose-limiting toxicities (Number) |
|---|---|
| Arm B/Cohort 1 | 0 |
| Arm B/Cohort 2 | 0 |
| ArmB/Cohort 3 | 17 |
Median progression-free survival (NCT03072134)
Timeframe: two years
| Intervention | Months (Median) |
|---|---|
| Total Cohort | 9.1 |
Per Response Assessment in Neuro-Oncology Criteria (RANO, 2017) for target lesions as assessed by MRI: Complete Response (CR): The enhancing tumor is no longer seen by neuroimaging; Partial Response (PR): Decrease of ≥ 50% in the product of two diameters with the patient on a stable or decreasing dose of steroids; Minor Response (MR): Decrease in diameter products of < 50% with the patient on a stable or decreasing dose of steroids; Stable Disease (SD): The scan shows no change. Patients should be receiving stable or decreasing doses of steroids; Progression (P): Increase of > 25% in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period. A concomitant decrease in steroid dose will rule out a progression designation during the first two months after completion of radiation; Pseudoprogression (PP): Radiological changes without concomitant neurological changes. (NCT03072134)
Timeframe: Two years
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Percentage of participants with tumor response: Partial | Percentage of participants with tumor response: Pseudoprogression | Percentage of participants with tumor response: Stable disease | |
| Total Cohort | 8 | 8 | 84 |
Progression-free survival as determined by Kaplan-Meier method. (NCT00392171)
Timeframe: 6 months
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| Anaplastic Glioma (n=28) | Early Glioblastoma Multiforme (GBM) (n=33) | Extended Glioblastoma Multiforme (GBM) (n=27) | Rechallenge Glioblastoma Multiforme (GBM) (n=28) | |
| Temozolomide | 35.7 | 27.3 | 7.4 | 35.7 |
Number of deaths due to complications of protocol therapy. (NCT00100802)
Timeframe: While receiving protocol therapy (up to 301 days excluding delays) or within 30 days of Termination of Protocol Therapy
| Intervention | patients (Number) |
|---|---|
| Surgery, Chemoradiotherapy, Rest, Maintenance, FUP | 1 |
Estimated one year survival using the Kaplan-Meier methodology. (NCT00100802)
Timeframe: One year
| Intervention | Estimated probability (Number) |
|---|---|
| Surgery, Chemoradiotherapy, Rest, Maintenance, FUP | 0.7208 |
(NCT00575887)
Timeframe: Until progression
| Intervention | percentage of participants (Number) |
|---|---|
| Temozolomide | 17.3 |
all patients alive as of the last contact were censored for survival on the basis of that contact date (NCT00369590)
Timeframe: 3 years
| Intervention | weeks (Median) |
|---|---|
| Arm I - Anaplastic Glioma | 55 |
| Arm 2 - Glioblastoma | 39 |
"pts with confirmed radiographic response and their rate of progression (PFS).~Response determined by modified MacDonald Criteria Complete Response (CR): Complete disappearance of all measurable and evaluable disease, no new lesions. no steroids Partial Response (PR): Greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable lesions. no new lesions. steroid dose no > than maximum dose used in first 8 weeks of treatment.~Stable: Does not qualify for CR, PR, or progression steroid dose no > than maximum dose used in first 8 weeks of treatment.~Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no increase) Clear clinical worsening." (NCT00369590)
Timeframe: up to 3 years
| Intervention | weeks (Median) |
|---|---|
| Arm I - Anaplastic Glioma | 45 |
| Arm 2 - Glioblastoma | 23 |
"This design yields 85% power to detect a true 30% 6-month PFS rate, while maintaining .91 probability of rejecting for a true 15% 6-month PFS rate.~pts had MRIs at screening and at the 3rd and 5th cycles then every 8 weeks until progression.~Response determined by modified MacDonald Criteria Complete Response (CR): Complete disappearance of all measurable and evaluable disease, no new lesions. no steroids Partial Response (PR): Greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable lesions. no new lesions. steroid dose no > than maximum dose used in first 8 weeks of treatment.~Stable: Does not qualify for CR, PR, or progression steroid dose no > than maximum dose used in first 8 weeks of treatment.~Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no increase) Clear clinical worsening." (NCT00369590)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I - Anaplastic Glioma | 25 |
| Arm 2 - Glioblastoma | 7.7 |
number of patients who experienced toxicity that led to being taken off treatment (NCT00369590)
Timeframe: Approximately 1 year (start of treatment - end of treatment)
| Intervention | participants (Number) |
|---|---|
| Arm I - Anaplastic Glioma | 8 |
| Arm 2 - Glioblastoma | 6 |
number of cycles patient was able to have before developing a toxicity that required removing the patient from treatment. Treatment: Aflibercept 4mg/kg intravenously on day 1 of every 14-day cycle - 2 week cycle. (NCT00369590)
Timeframe: Start to End of treatment 39 cycles or 1yr 7.5months (78 weeks)
| Intervention | cycles (Median) |
|---|---|
| Arm I - Anaplastic Glioma | 5 |
| Arm 2 - Glioblastoma | 3.5 |
"pts had MRIs at screening and at the 3rd and 5th cycles then every 8 weeks until progression. All responders were centrally reviewed for confirmation~Response determined by modified MacDonald Criteria Complete Response (CR): Complete disappearance of all measurable and evaluable disease, no new lesions. no steroids Partial Response (PR): Greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable lesions. no new lesions. steroid dose no > than maximum dose used in first 8 weeks of treatment.~Stable: Does not qualify for CR, PR, or progression steroid dose no > than maximum dose used in first 8 weeks of treatment.~Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no increase) Clear clinical worsening." (NCT00369590)
Timeframe: Up to 2 years
| Intervention | participants (Number) | |
|---|---|---|
| Complete Response | Partial Response | |
| Arm 2 - Glioblastoma | 0 | 7 |
| Arm I - Anaplastic Glioma | 1 | 6 |
Analyzed via a paired t-test. Change in body fat measurement as determined by the Durnin-Womersley 4-fold technique (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study
| Intervention | percentage of change in body fat (Mean) |
|---|---|
| Behavioral Dietary Intervention | -3.1 |
Assessed via mixed-effects regression. Weight changes over time assessed by modeling BMI as a function of time (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study
| Intervention | percentage of change in BMI (Mean) |
|---|---|
| Behavioral Dietary Intervention | -1.2 |
Assessed via mixed-effects regression. (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study
| Intervention | beats per minute (Mean) |
|---|---|
| Behavioral Dietary Intervention | 67.3 |
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Behavioral Dietary Intervention | NA |
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Behavioral Dietary Intervention | NA |
Computed along with a 95% exact confidence interval. Exact binomial test (with a one-sided alpha of 0.05) will be used to test whether adherence is greater than 60%. (NCT01819233)
Timeframe: Up to week 12
| Intervention | participants (Number) |
|---|---|
| Behavioral Dietary Intervention | 28 |
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Behavioral Dietary Intervention | NA |
Assessed via mixed-effects regression. The FACT-B is a questionnaire using a 5-point Likert scale (0-Not at all to 4-Very much) (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study
| Intervention | score on a scale (Mean) |
|---|---|
| Behavioral Dietary Intervention | 0.8 |
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Behavioral Dietary Intervention | NA |
All patients will have their tumor measurements recorded at baseline and at the time of each MRI scan. Lesions must be measured in two dimensions. The dose of gadolinium must be held constant from scan to scan. Macdonald criteria will be used for assessment of tumor response. (NCT00498927)
Timeframe: 2 years
| Intervention | months (Median) |
|---|---|
| Temozolomide | 7 |
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00498927)
Timeframe: at 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Temozolomide | 19 |
"MRI response evaluated by RANO criteria~Complete Response (CR): Circumstance when the enhancing tumor is no longer seen by neuroimaging, with the patient off all steroids or on adrenal maintenance only; CR will be coded only if confirmed by a second CT/MR scan performed a minimum of 4 weeks after the initial scan coding a response.~Partial Response (PR): Decrease of > 50% in the product of two diameters. Patients should be receiving stable or decreasing doses of steroids. PR will be coded only if confirmed by a second CT/MR scan performed a minimum of 4 weeks after the initial scan.~Progression (P): A > 25% increase in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period. This will not need a confirmatory scan. A concomitant decrease in steroid dose will rule out a progression designation during the first 2 months after completion of XRT." (NCT01402063)
Timeframe: Q 3 months on study then Q3 months in f/u for yr 1, q 4 months yr 2, q 6 months for approximately 4 ys.
| Intervention | participants (Number) |
|---|---|
| Radiation Plus PPX(CT2103 | 31 |
| Radiation + Temozolomide | 15 |
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
(NCT00582075)
Timeframe: 2 years
| Intervention | weeks (Median) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 31 |
Patients developing distant brain failure (DBF) at one year. An approximation method was used to arrive at the reported percentage. (NCT00582075)
Timeframe: 1 years
| Intervention | percentage of participants (Number) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 37 |
142 reviews available for temozolomide and Glioma
| Article | Year |
|---|---|
MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2021 |
MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2021 |
MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2021 |
MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2021 |
Prognostic and Predictive Biomarkers in Gliomas.
Topics: Animals; Biomarkers, Tumor; Central Nervous System Neoplasms; DNA Methylation; DNA, Neoplasm; Glioma | 2021 |
Prognostic and Predictive Biomarkers in Gliomas.
Topics: Animals; Biomarkers, Tumor; Central Nervous System Neoplasms; DNA Methylation; DNA, Neoplasm; Glioma | 2021 |
Prognostic and Predictive Biomarkers in Gliomas.
Topics: Animals; Biomarkers, Tumor; Central Nervous System Neoplasms; DNA Methylation; DNA, Neoplasm; Glioma | 2021 |
Prognostic and Predictive Biomarkers in Gliomas.
Topics: Animals; Biomarkers, Tumor; Central Nervous System Neoplasms; DNA Methylation; DNA, Neoplasm; Glioma | 2021 |
Comprehensive pharmacogenomics characterization of temozolomide response in gliomas.
Topics: Brain Neoplasms; DNA Repair; Glioma; Humans; Pharmacogenetics; Polymorphism, Genetic; Temozolomide | 2021 |
Comprehensive pharmacogenomics characterization of temozolomide response in gliomas.
Topics: Brain Neoplasms; DNA Repair; Glioma; Humans; Pharmacogenetics; Polymorphism, Genetic; Temozolomide | 2021 |
Comprehensive pharmacogenomics characterization of temozolomide response in gliomas.
Topics: Brain Neoplasms; DNA Repair; Glioma; Humans; Pharmacogenetics; Polymorphism, Genetic; Temozolomide | 2021 |
Comprehensive pharmacogenomics characterization of temozolomide response in gliomas.
Topics: Brain Neoplasms; DNA Repair; Glioma; Humans; Pharmacogenetics; Polymorphism, Genetic; Temozolomide | 2021 |
Temozolomide sensitivity of malignant glioma cell lines - a systematic review assessing consistencies between in vitro studies.
Topics: Animals; Antineoplastic Agents, Alkylating; Bias; Brain Neoplasms; Cell Line, Tumor; Cell Survival; | 2021 |
Temozolomide sensitivity of malignant glioma cell lines - a systematic review assessing consistencies between in vitro studies.
Topics: Animals; Antineoplastic Agents, Alkylating; Bias; Brain Neoplasms; Cell Line, Tumor; Cell Survival; | 2021 |
Temozolomide sensitivity of malignant glioma cell lines - a systematic review assessing consistencies between in vitro studies.
Topics: Animals; Antineoplastic Agents, Alkylating; Bias; Brain Neoplasms; Cell Line, Tumor; Cell Survival; | 2021 |
Temozolomide sensitivity of malignant glioma cell lines - a systematic review assessing consistencies between in vitro studies.
Topics: Animals; Antineoplastic Agents, Alkylating; Bias; Brain Neoplasms; Cell Line, Tumor; Cell Survival; | 2021 |
Executive summary of American Radium Society's appropriate use criteria for the postoperative management of lower grade gliomas.
Topics: Astrocytoma; Brain Neoplasms; Glioma; Humans; Oligodendroglioma; Radium; Temozolomide | 2022 |
Executive summary of American Radium Society's appropriate use criteria for the postoperative management of lower grade gliomas.
Topics: Astrocytoma; Brain Neoplasms; Glioma; Humans; Oligodendroglioma; Radium; Temozolomide | 2022 |
Executive summary of American Radium Society's appropriate use criteria for the postoperative management of lower grade gliomas.
Topics: Astrocytoma; Brain Neoplasms; Glioma; Humans; Oligodendroglioma; Radium; Temozolomide | 2022 |
Executive summary of American Radium Society's appropriate use criteria for the postoperative management of lower grade gliomas.
Topics: Astrocytoma; Brain Neoplasms; Glioma; Humans; Oligodendroglioma; Radium; Temozolomide | 2022 |
NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review).
Topics: Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; RNA, Untranslated; Temozolomide | 2022 |
NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review).
Topics: Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; RNA, Untranslated; Temozolomide | 2022 |
NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review).
Topics: Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; RNA, Untranslated; Temozolomide | 2022 |
NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review).
Topics: Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; RNA, Untranslated; Temozolomide | 2022 |
Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Drug Combinations; Gl | 2022 |
Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Drug Combinations; Gl | 2022 |
Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Drug Combinations; Gl | 2022 |
Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Drug Combinations; Gl | 2022 |
Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; | 2022 |
Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; | 2022 |
Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; | 2022 |
Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; | 2022 |
Regulation of temozolomide resistance via lncRNAs: Clinical and biological properties of lncRNAs in gliomas (Review).
Topics: Cell Line, Tumor; Dacarbazine; Glioma; Humans; RNA, Long Noncoding; Temozolomide | 2022 |
Regulation of temozolomide resistance via lncRNAs: Clinical and biological properties of lncRNAs in gliomas (Review).
Topics: Cell Line, Tumor; Dacarbazine; Glioma; Humans; RNA, Long Noncoding; Temozolomide | 2022 |
Regulation of temozolomide resistance via lncRNAs: Clinical and biological properties of lncRNAs in gliomas (Review).
Topics: Cell Line, Tumor; Dacarbazine; Glioma; Humans; RNA, Long Noncoding; Temozolomide | 2022 |
Regulation of temozolomide resistance via lncRNAs: Clinical and biological properties of lncRNAs in gliomas (Review).
Topics: Cell Line, Tumor; Dacarbazine; Glioma; Humans; RNA, Long Noncoding; Temozolomide | 2022 |
MicroRNA delivery systems in glioma therapy and perspectives: A systematic review.
Topics: Arginine; Brain Neoplasms; Glioma; Humans; Liposomes; MicroRNAs; Nanoparticles; Peptides; Temozolomi | 2022 |
MicroRNA delivery systems in glioma therapy and perspectives: A systematic review.
Topics: Arginine; Brain Neoplasms; Glioma; Humans; Liposomes; MicroRNAs; Nanoparticles; Peptides; Temozolomi | 2022 |
MicroRNA delivery systems in glioma therapy and perspectives: A systematic review.
Topics: Arginine; Brain Neoplasms; Glioma; Humans; Liposomes; MicroRNAs; Nanoparticles; Peptides; Temozolomi | 2022 |
MicroRNA delivery systems in glioma therapy and perspectives: A systematic review.
Topics: Arginine; Brain Neoplasms; Glioma; Humans; Liposomes; MicroRNAs; Nanoparticles; Peptides; Temozolomi | 2022 |
Current Considerations in the Treatment of Grade 3 Gliomas.
Topics: Astrocytoma; Brain Neoplasms; Glioma; Humans; Isocitrate Dehydrogenase; Lymphoma, Follicular; Mutati | 2022 |
Current Considerations in the Treatment of Grade 3 Gliomas.
Topics: Astrocytoma; Brain Neoplasms; Glioma; Humans; Isocitrate Dehydrogenase; Lymphoma, Follicular; Mutati | 2022 |
Current Considerations in the Treatment of Grade 3 Gliomas.
Topics: Astrocytoma; Brain Neoplasms; Glioma; Humans; Isocitrate Dehydrogenase; Lymphoma, Follicular; Mutati | 2022 |
Current Considerations in the Treatment of Grade 3 Gliomas.
Topics: Astrocytoma; Brain Neoplasms; Glioma; Humans; Isocitrate Dehydrogenase; Lymphoma, Follicular; Mutati | 2022 |
Progress in research and development of temozolomide brain-targeted preparations: a review.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neopla | 2023 |
Progress in research and development of temozolomide brain-targeted preparations: a review.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neopla | 2023 |
Progress in research and development of temozolomide brain-targeted preparations: a review.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neopla | 2023 |
Progress in research and development of temozolomide brain-targeted preparations: a review.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neopla | 2023 |
Current and promising treatment strategies in glioma.
Topics: Brain Neoplasms; Glioma; Humans; Immunotherapy; Mutation; Precision Medicine; Temozolomide | 2023 |
Current and promising treatment strategies in glioma.
Topics: Brain Neoplasms; Glioma; Humans; Immunotherapy; Mutation; Precision Medicine; Temozolomide | 2023 |
Current and promising treatment strategies in glioma.
Topics: Brain Neoplasms; Glioma; Humans; Immunotherapy; Mutation; Precision Medicine; Temozolomide | 2023 |
Current and promising treatment strategies in glioma.
Topics: Brain Neoplasms; Glioma; Humans; Immunotherapy; Mutation; Precision Medicine; Temozolomide | 2023 |
MicroRNAs, Key Regulators in Glioma Progression as Potential Therapeutic Targets for Chinese Medicine.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioma; Humans; Medicine, Chinese | 2022 |
MicroRNAs, Key Regulators in Glioma Progression as Potential Therapeutic Targets for Chinese Medicine.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioma; Humans; Medicine, Chinese | 2022 |
MicroRNAs, Key Regulators in Glioma Progression as Potential Therapeutic Targets for Chinese Medicine.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioma; Humans; Medicine, Chinese | 2022 |
MicroRNAs, Key Regulators in Glioma Progression as Potential Therapeutic Targets for Chinese Medicine.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioma; Humans; Medicine, Chinese | 2022 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas-a radiation oncologist's perspective.
Topics: Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Radiation Oncologists; Radiation Toleranc | 2023 |
TFR2 regulates ferroptosis and enhances temozolomide chemo-sensitization in gliomas.
Topics: Apoptosis; Cell Line, Tumor; Ferroptosis; Glioma; Humans; Iron; Reactive Oxygen Species; Receptors, | 2023 |
TFR2 regulates ferroptosis and enhances temozolomide chemo-sensitization in gliomas.
Topics: Apoptosis; Cell Line, Tumor; Ferroptosis; Glioma; Humans; Iron; Reactive Oxygen Species; Receptors, | 2023 |
TFR2 regulates ferroptosis and enhances temozolomide chemo-sensitization in gliomas.
Topics: Apoptosis; Cell Line, Tumor; Ferroptosis; Glioma; Humans; Iron; Reactive Oxygen Species; Receptors, | 2023 |
TFR2 regulates ferroptosis and enhances temozolomide chemo-sensitization in gliomas.
Topics: Apoptosis; Cell Line, Tumor; Ferroptosis; Glioma; Humans; Iron; Reactive Oxygen Species; Receptors, | 2023 |
Glioblastoma and Other Primary Brain Malignancies in Adults: A Review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Glioblastoma; Glioma; | 2023 |
Glioblastoma and Other Primary Brain Malignancies in Adults: A Review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Glioblastoma; Glioma; | 2023 |
Glioblastoma and Other Primary Brain Malignancies in Adults: A Review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Glioblastoma; Glioma; | 2023 |
Glioblastoma and Other Primary Brain Malignancies in Adults: A Review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Glioblastoma; Glioma; | 2023 |
Temozolomide Chronotherapy in Glioma: A Systematic Review.
Topics: Brain Neoplasms; Chronotherapy; Glioma; Humans; Prospective Studies; Randomized Controlled Trials as | 2023 |
Temozolomide Chronotherapy in Glioma: A Systematic Review.
Topics: Brain Neoplasms; Chronotherapy; Glioma; Humans; Prospective Studies; Randomized Controlled Trials as | 2023 |
Temozolomide Chronotherapy in Glioma: A Systematic Review.
Topics: Brain Neoplasms; Chronotherapy; Glioma; Humans; Prospective Studies; Randomized Controlled Trials as | 2023 |
Temozolomide Chronotherapy in Glioma: A Systematic Review.
Topics: Brain Neoplasms; Chronotherapy; Glioma; Humans; Prospective Studies; Randomized Controlled Trials as | 2023 |
Expert opinion on translational research for advanced glioblastoma treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Expert Testimony; Glioblastoma; Glioma; Humans; | 2023 |
Expert opinion on translational research for advanced glioblastoma treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Expert Testimony; Glioblastoma; Glioma; Humans; | 2023 |
Expert opinion on translational research for advanced glioblastoma treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Expert Testimony; Glioblastoma; Glioma; Humans; | 2023 |
Expert opinion on translational research for advanced glioblastoma treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Expert Testimony; Glioblastoma; Glioma; Humans; | 2023 |
Nitric oxide synthase inhibitors as potential therapeutic agents for gliomas: A systematic review.
Topics: Animals; Brain Neoplasms; Enzyme Inhibitors; Glioblastoma; Glioma; Humans; NG-Nitroarginine Methyl E | 2023 |
Nitric oxide synthase inhibitors as potential therapeutic agents for gliomas: A systematic review.
Topics: Animals; Brain Neoplasms; Enzyme Inhibitors; Glioblastoma; Glioma; Humans; NG-Nitroarginine Methyl E | 2023 |
Nitric oxide synthase inhibitors as potential therapeutic agents for gliomas: A systematic review.
Topics: Animals; Brain Neoplasms; Enzyme Inhibitors; Glioblastoma; Glioma; Humans; NG-Nitroarginine Methyl E | 2023 |
Nitric oxide synthase inhibitors as potential therapeutic agents for gliomas: A systematic review.
Topics: Animals; Brain Neoplasms; Enzyme Inhibitors; Glioblastoma; Glioma; Humans; NG-Nitroarginine Methyl E | 2023 |
Strategies increasing the effectiveness of temozolomide at various levels of anti-GBL therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Strategies increasing the effectiveness of temozolomide at various levels of anti-GBL therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Strategies increasing the effectiveness of temozolomide at various levels of anti-GBL therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Strategies increasing the effectiveness of temozolomide at various levels of anti-GBL therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques.
Topics: Brain Neoplasms; Glioblastoma; Glioma; Humans; Oncolytic Virotherapy; Temozolomide | 2023 |
Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques.
Topics: Brain Neoplasms; Glioblastoma; Glioma; Humans; Oncolytic Virotherapy; Temozolomide | 2023 |
Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques.
Topics: Brain Neoplasms; Glioblastoma; Glioma; Humans; Oncolytic Virotherapy; Temozolomide | 2023 |
Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques.
Topics: Brain Neoplasms; Glioblastoma; Glioma; Humans; Oncolytic Virotherapy; Temozolomide | 2023 |
Challenging the indiscriminate use of temozolomide in pediatric high-grade gliomas: A review of past, current, and emerging therapies.
Topics: Antineoplastic Agents, Alkylating; Child; Glioma; Humans; Neoplasm Grading; Temozolomide | 2020 |
Challenging the indiscriminate use of temozolomide in pediatric high-grade gliomas: A review of past, current, and emerging therapies.
Topics: Antineoplastic Agents, Alkylating; Child; Glioma; Humans; Neoplasm Grading; Temozolomide | 2020 |
Challenging the indiscriminate use of temozolomide in pediatric high-grade gliomas: A review of past, current, and emerging therapies.
Topics: Antineoplastic Agents, Alkylating; Child; Glioma; Humans; Neoplasm Grading; Temozolomide | 2020 |
Challenging the indiscriminate use of temozolomide in pediatric high-grade gliomas: A review of past, current, and emerging therapies.
Topics: Antineoplastic Agents, Alkylating; Child; Glioma; Humans; Neoplasm Grading; Temozolomide | 2020 |
Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2020 |
Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2020 |
Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2020 |
Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2020 |
Focused Ultrasound Strategies for Brain Tumor Therapy.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Neoplasms; Glioma; Humans; Temozolomide | 2020 |
Focused Ultrasound Strategies for Brain Tumor Therapy.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Neoplasms; Glioma; Humans; Temozolomide | 2020 |
Focused Ultrasound Strategies for Brain Tumor Therapy.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Neoplasms; Glioma; Humans; Temozolomide | 2020 |
Focused Ultrasound Strategies for Brain Tumor Therapy.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Neoplasms; Glioma; Humans; Temozolomide | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Narrative review of palliative hypofractionated radiotherapy for high grade glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Male; Quality of Life; Tem | 2021 |
Narrative review of palliative hypofractionated radiotherapy for high grade glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Male; Quality of Life; Tem | 2021 |
Narrative review of palliative hypofractionated radiotherapy for high grade glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Male; Quality of Life; Tem | 2021 |
Narrative review of palliative hypofractionated radiotherapy for high grade glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Male; Quality of Life; Tem | 2021 |
Updated Insights on EGFR Signaling Pathways in Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Gene | 2021 |
Updated Insights on EGFR Signaling Pathways in Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Gene | 2021 |
Updated Insights on EGFR Signaling Pathways in Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Gene | 2021 |
Updated Insights on EGFR Signaling Pathways in Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Gene | 2021 |
The Prognostic Impact of Radiotherapy in Conjunction with Temozolomide in Diffuse Intrinsic Pontine Glioma: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Chemoradiotherapy; Diffuse Intrinsic Pontin | 2021 |
The Prognostic Impact of Radiotherapy in Conjunction with Temozolomide in Diffuse Intrinsic Pontine Glioma: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Chemoradiotherapy; Diffuse Intrinsic Pontin | 2021 |
The Prognostic Impact of Radiotherapy in Conjunction with Temozolomide in Diffuse Intrinsic Pontine Glioma: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Chemoradiotherapy; Diffuse Intrinsic Pontin | 2021 |
The Prognostic Impact of Radiotherapy in Conjunction with Temozolomide in Diffuse Intrinsic Pontine Glioma: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Chemoradiotherapy; Diffuse Intrinsic Pontin | 2021 |
The Multifaceted Role of CMA in Glioma: Enemy or Ally?
Topics: Antineoplastic Agents, Alkylating; Chaperone-Mediated Autophagy; Glioma; Humans; Nuclear Proteins; P | 2021 |
The Multifaceted Role of CMA in Glioma: Enemy or Ally?
Topics: Antineoplastic Agents, Alkylating; Chaperone-Mediated Autophagy; Glioma; Humans; Nuclear Proteins; P | 2021 |
The Multifaceted Role of CMA in Glioma: Enemy or Ally?
Topics: Antineoplastic Agents, Alkylating; Chaperone-Mediated Autophagy; Glioma; Humans; Nuclear Proteins; P | 2021 |
The Multifaceted Role of CMA in Glioma: Enemy or Ally?
Topics: Antineoplastic Agents, Alkylating; Chaperone-Mediated Autophagy; Glioma; Humans; Nuclear Proteins; P | 2021 |
Potential new targets and drugs related to histone modifications in glioma treatment.
Topics: Antineoplastic Agents; Brain Neoplasms; DNA Damage; Drug Resistance, Neoplasm; Glioma; Histones; Hum | 2021 |
Potential new targets and drugs related to histone modifications in glioma treatment.
Topics: Antineoplastic Agents; Brain Neoplasms; DNA Damage; Drug Resistance, Neoplasm; Glioma; Histones; Hum | 2021 |
Potential new targets and drugs related to histone modifications in glioma treatment.
Topics: Antineoplastic Agents; Brain Neoplasms; DNA Damage; Drug Resistance, Neoplasm; Glioma; Histones; Hum | 2021 |
Potential new targets and drugs related to histone modifications in glioma treatment.
Topics: Antineoplastic Agents; Brain Neoplasms; DNA Damage; Drug Resistance, Neoplasm; Glioma; Histones; Hum | 2021 |
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2021 |
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2021 |
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2021 |
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2021 |
Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.
Topics: Antineoplastic Agents, Alkylating; Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; Temozolo | 2021 |
Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.
Topics: Antineoplastic Agents, Alkylating; Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; Temozolo | 2021 |
Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.
Topics: Antineoplastic Agents, Alkylating; Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; Temozolo | 2021 |
Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.
Topics: Antineoplastic Agents, Alkylating; Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; Temozolo | 2021 |
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Basigin; beta-Transducin Repeat-Containing Protein | 2021 |
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Basigin; beta-Transducin Repeat-Containing Protein | 2021 |
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Basigin; beta-Transducin Repeat-Containing Protein | 2021 |
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Basigin; beta-Transducin Repeat-Containing Protein | 2021 |
Hypermutations in gliomas: a potential immunotherapy target.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Glioma; Humans; Immunotherapy; Mutation; Te | 2017 |
Hypermutations in gliomas: a potential immunotherapy target.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Glioma; Humans; Immunotherapy; Mutation; Te | 2017 |
Hypermutations in gliomas: a potential immunotherapy target.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Glioma; Humans; Immunotherapy; Mutation; Te | 2017 |
Hypermutations in gliomas: a potential immunotherapy target.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Glioma; Humans; Immunotherapy; Mutation; Te | 2017 |
MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Re | 2017 |
MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Re | 2017 |
MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Re | 2017 |
MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Re | 2017 |
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Dis | 2017 |
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Dis | 2017 |
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Dis | 2017 |
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Dis | 2017 |
Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2017 |
Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2017 |
Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2017 |
Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2017 |
Fractionated Radiotherapy of Intracranial Gliomas.
Topics: Adult; Brain Neoplasms; Dacarbazine; Dose Fractionation, Radiation; Glioblastoma; Glioma; Humans; Ma | 2018 |
Fractionated Radiotherapy of Intracranial Gliomas.
Topics: Adult; Brain Neoplasms; Dacarbazine; Dose Fractionation, Radiation; Glioblastoma; Glioma; Humans; Ma | 2018 |
Fractionated Radiotherapy of Intracranial Gliomas.
Topics: Adult; Brain Neoplasms; Dacarbazine; Dose Fractionation, Radiation; Glioblastoma; Glioma; Humans; Ma | 2018 |
Fractionated Radiotherapy of Intracranial Gliomas.
Topics: Adult; Brain Neoplasms; Dacarbazine; Dose Fractionation, Radiation; Glioblastoma; Glioma; Humans; Ma | 2018 |
Chemotherapy of High-Grade Astrocytomas in Adults.
Topics: Adult; Astrocytoma; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Neoplasm Grading; Te | 2018 |
Chemotherapy of High-Grade Astrocytomas in Adults.
Topics: Adult; Astrocytoma; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Neoplasm Grading; Te | 2018 |
Chemotherapy of High-Grade Astrocytomas in Adults.
Topics: Adult; Astrocytoma; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Neoplasm Grading; Te | 2018 |
Chemotherapy of High-Grade Astrocytomas in Adults.
Topics: Adult; Astrocytoma; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Neoplasm Grading; Te | 2018 |
Temozolomide-associated hypermutation in gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Progression; DNA Methylation; DNA Repair | 2018 |
Temozolomide-associated hypermutation in gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Progression; DNA Methylation; DNA Repair | 2018 |
Temozolomide-associated hypermutation in gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Progression; DNA Methylation; DNA Repair | 2018 |
Temozolomide-associated hypermutation in gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Progression; DNA Methylation; DNA Repair | 2018 |
Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas.
Topics: Animals; Brain Neoplasms; Dacarbazine; Down-Regulation; Glioma; Humans; PPAR gamma; Temozolomide; Wn | 2018 |
Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas.
Topics: Animals; Brain Neoplasms; Dacarbazine; Down-Regulation; Glioma; Humans; PPAR gamma; Temozolomide; Wn | 2018 |
Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas.
Topics: Animals; Brain Neoplasms; Dacarbazine; Down-Regulation; Glioma; Humans; PPAR gamma; Temozolomide; Wn | 2018 |
Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas.
Topics: Animals; Brain Neoplasms; Dacarbazine; Down-Regulation; Glioma; Humans; PPAR gamma; Temozolomide; Wn | 2018 |
Current state of immunotherapy for glioblastoma.
Topics: Biomarkers, Tumor; Blood-Brain Barrier; Combined Modality Therapy; Drug Resistance, Neoplasm; Gliobl | 2018 |
Current state of immunotherapy for glioblastoma.
Topics: Biomarkers, Tumor; Blood-Brain Barrier; Combined Modality Therapy; Drug Resistance, Neoplasm; Gliobl | 2018 |
Current state of immunotherapy for glioblastoma.
Topics: Biomarkers, Tumor; Blood-Brain Barrier; Combined Modality Therapy; Drug Resistance, Neoplasm; Gliobl | 2018 |
Current state of immunotherapy for glioblastoma.
Topics: Biomarkers, Tumor; Blood-Brain Barrier; Combined Modality Therapy; Drug Resistance, Neoplasm; Gliobl | 2018 |
Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Connexin 43; Drug Resistance, N | 2018 |
Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Connexin 43; Drug Resistance, N | 2018 |
Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Connexin 43; Drug Resistance, N | 2018 |
Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Connexin 43; Drug Resistance, N | 2018 |
Alternating Electric Fields Therapy for Malignant Gliomas: From Bench Observation to Clinical Reality.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Electric | 2018 |
Alternating Electric Fields Therapy for Malignant Gliomas: From Bench Observation to Clinical Reality.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Electric | 2018 |
Alternating Electric Fields Therapy for Malignant Gliomas: From Bench Observation to Clinical Reality.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Electric | 2018 |
Alternating Electric Fields Therapy for Malignant Gliomas: From Bench Observation to Clinical Reality.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Electric | 2018 |
Chemotherapy Treatment and Trials in Low-Grade Gliomas.
Topics: Brain Neoplasms; Chemoradiotherapy; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; G | 2019 |
Chemotherapy Treatment and Trials in Low-Grade Gliomas.
Topics: Brain Neoplasms; Chemoradiotherapy; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; G | 2019 |
Chemotherapy Treatment and Trials in Low-Grade Gliomas.
Topics: Brain Neoplasms; Chemoradiotherapy; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; G | 2019 |
Chemotherapy Treatment and Trials in Low-Grade Gliomas.
Topics: Brain Neoplasms; Chemoradiotherapy; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; G | 2019 |
The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topi | 2013 |
The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topi | 2013 |
The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topi | 2013 |
The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topi | 2013 |
Pseudoprogression after glioma therapy: a comprehensive review.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2013 |
Pseudoprogression after glioma therapy: a comprehensive review.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2013 |
Pseudoprogression after glioma therapy: a comprehensive review.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2013 |
Pseudoprogression after glioma therapy: a comprehensive review.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2013 |
Update in the treatment of high-grade Gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Glioma; Humans; Magn | 2013 |
Update in the treatment of high-grade Gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Glioma; Humans; Magn | 2013 |
Update in the treatment of high-grade Gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Glioma; Humans; Magn | 2013 |
Update in the treatment of high-grade Gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Glioma; Humans; Magn | 2013 |
O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas.
Topics: Animals; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Molecular Targeted | 2013 |
O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas.
Topics: Animals; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Molecular Targeted | 2013 |
O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas.
Topics: Animals; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Molecular Targeted | 2013 |
O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas.
Topics: Animals; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Molecular Targeted | 2013 |
High-grade glioma in elderly patients: can the oncogeriatrician help?
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Da | 2013 |
High-grade glioma in elderly patients: can the oncogeriatrician help?
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Da | 2013 |
High-grade glioma in elderly patients: can the oncogeriatrician help?
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Da | 2013 |
High-grade glioma in elderly patients: can the oncogeriatrician help?
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Da | 2013 |
Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Tensor Imaging; Glioblast | 2014 |
Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Tensor Imaging; Glioblast | 2014 |
Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Tensor Imaging; Glioblast | 2014 |
Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Tensor Imaging; Glioblast | 2014 |
MicroRNA as potential modulators in chemoresistant high-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Micr | 2014 |
MicroRNA as potential modulators in chemoresistant high-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Micr | 2014 |
MicroRNA as potential modulators in chemoresistant high-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Micr | 2014 |
MicroRNA as potential modulators in chemoresistant high-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; Micr | 2014 |
Current evidence of temozolomide and bevacizumab in treatment of gliomas.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineop | 2015 |
Current evidence of temozolomide and bevacizumab in treatment of gliomas.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineop | 2015 |
Current evidence of temozolomide and bevacizumab in treatment of gliomas.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineop | 2015 |
Current evidence of temozolomide and bevacizumab in treatment of gliomas.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineop | 2015 |
[Management of gliomas].
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2014 |
[Management of gliomas].
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2014 |
[Management of gliomas].
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2014 |
[Management of gliomas].
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2014 |
Management of high-grade gliomas in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2014 |
Management of high-grade gliomas in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2014 |
Management of high-grade gliomas in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2014 |
Management of high-grade gliomas in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2014 |
Comprehensive analysis of temozolomide treatment for patients with glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Prognosis; Temozolo | 2014 |
Comprehensive analysis of temozolomide treatment for patients with glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Prognosis; Temozolo | 2014 |
Comprehensive analysis of temozolomide treatment for patients with glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Prognosis; Temozolo | 2014 |
Comprehensive analysis of temozolomide treatment for patients with glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Prognosis; Temozolo | 2014 |
Economics of Malignant Gliomas: A Critical Review.
Topics: Brain Neoplasms; Canada; Cost of Illness; Costs and Cost Analysis; Dacarbazine; Drug Therapy; Europe | 2015 |
Economics of Malignant Gliomas: A Critical Review.
Topics: Brain Neoplasms; Canada; Cost of Illness; Costs and Cost Analysis; Dacarbazine; Drug Therapy; Europe | 2015 |
Economics of Malignant Gliomas: A Critical Review.
Topics: Brain Neoplasms; Canada; Cost of Illness; Costs and Cost Analysis; Dacarbazine; Drug Therapy; Europe | 2015 |
Economics of Malignant Gliomas: A Critical Review.
Topics: Brain Neoplasms; Canada; Cost of Illness; Costs and Cost Analysis; Dacarbazine; Drug Therapy; Europe | 2015 |
Low-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2015 |
Low-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2015 |
Low-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2015 |
Low-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2015 |
Chemoresistance and chemotherapy targeting stem-like cells in malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Mismatch Repair; DNA M | 2015 |
Chemoresistance and chemotherapy targeting stem-like cells in malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Mismatch Repair; DNA M | 2015 |
Chemoresistance and chemotherapy targeting stem-like cells in malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Mismatch Repair; DNA M | 2015 |
Chemoresistance and chemotherapy targeting stem-like cells in malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Mismatch Repair; DNA M | 2015 |
Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens?: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Glioma; Humans; Te | 2015 |
Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens?: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Glioma; Humans; Te | 2015 |
Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens?: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Glioma; Humans; Te | 2015 |
Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens?: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Glioma; Humans; Te | 2015 |
The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Neoplasm Recurrence | 2015 |
The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Neoplasm Recurrence | 2015 |
The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Neoplasm Recurrence | 2015 |
The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Neoplasm Recurrence | 2015 |
Nitrosoureas in the Management of Malignant Gliomas.
Topics: Dacarbazine; Glioma; Humans; Lomustine; Nitrosourea Compounds; Organophosphorus Compounds; Procarbaz | 2016 |
Nitrosoureas in the Management of Malignant Gliomas.
Topics: Dacarbazine; Glioma; Humans; Lomustine; Nitrosourea Compounds; Organophosphorus Compounds; Procarbaz | 2016 |
Nitrosoureas in the Management of Malignant Gliomas.
Topics: Dacarbazine; Glioma; Humans; Lomustine; Nitrosourea Compounds; Organophosphorus Compounds; Procarbaz | 2016 |
Nitrosoureas in the Management of Malignant Gliomas.
Topics: Dacarbazine; Glioma; Humans; Lomustine; Nitrosourea Compounds; Organophosphorus Compounds; Procarbaz | 2016 |
A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Bevacizumab; Brain Neoplasm | 2016 |
A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Bevacizumab; Brain Neoplasm | 2016 |
A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Bevacizumab; Brain Neoplasm | 2016 |
A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Bevacizumab; Brain Neoplasm | 2016 |
Current management of low-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease- | 2016 |
Current management of low-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease- | 2016 |
Current management of low-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease- | 2016 |
Current management of low-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease- | 2016 |
Single vs. combination immunotherapeutic strategies for glioma.
Topics: Animals; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Genetic Therapy; | 2017 |
Single vs. combination immunotherapeutic strategies for glioma.
Topics: Animals; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Genetic Therapy; | 2017 |
Single vs. combination immunotherapeutic strategies for glioma.
Topics: Animals; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Genetic Therapy; | 2017 |
Single vs. combination immunotherapeutic strategies for glioma.
Topics: Animals; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Genetic Therapy; | 2017 |
The safety of the temozolomide in patients with malignant glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Child; Clinical Trials as Topic; Dacarbazine; Drug Interac | 2006 |
The safety of the temozolomide in patients with malignant glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Child; Clinical Trials as Topic; Dacarbazine; Drug Interac | 2006 |
The safety of the temozolomide in patients with malignant glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Child; Clinical Trials as Topic; Dacarbazine; Drug Interac | 2006 |
The safety of the temozolomide in patients with malignant glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Child; Clinical Trials as Topic; Dacarbazine; Drug Interac | 2006 |
New (alternative) temozolomide regimens for the treatment of glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; O(6)-Methylguanine- | 2009 |
New (alternative) temozolomide regimens for the treatment of glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; O(6)-Methylguanine- | 2009 |
New (alternative) temozolomide regimens for the treatment of glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; O(6)-Methylguanine- | 2009 |
New (alternative) temozolomide regimens for the treatment of glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; O(6)-Methylguanine- | 2009 |
[Predictive molecular pathological testing in the diagnosis of high-grade tumors of glial origin].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human, Pair | 2009 |
[Predictive molecular pathological testing in the diagnosis of high-grade tumors of glial origin].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human, Pair | 2009 |
[Predictive molecular pathological testing in the diagnosis of high-grade tumors of glial origin].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human, Pair | 2009 |
[Predictive molecular pathological testing in the diagnosis of high-grade tumors of glial origin].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human, Pair | 2009 |
Low-grade gliomas.
Topics: Adult; Aged; Central Nervous System Neoplasms; Chromosome Mapping; Clinical Trials as Topic; Dacarba | 2009 |
Low-grade gliomas.
Topics: Adult; Aged; Central Nervous System Neoplasms; Chromosome Mapping; Clinical Trials as Topic; Dacarba | 2009 |
Low-grade gliomas.
Topics: Adult; Aged; Central Nervous System Neoplasms; Chromosome Mapping; Clinical Trials as Topic; Dacarba | 2009 |
Low-grade gliomas.
Topics: Adult; Aged; Central Nervous System Neoplasms; Chromosome Mapping; Clinical Trials as Topic; Dacarba | 2009 |
[Prescription guidebook for temozolomide usage in brain tumors].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Admi | 2009 |
[Prescription guidebook for temozolomide usage in brain tumors].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Admi | 2009 |
[Prescription guidebook for temozolomide usage in brain tumors].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Admi | 2009 |
[Prescription guidebook for temozolomide usage in brain tumors].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Admi | 2009 |
Temozolomide in malignant gliomas: current use and future targets.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; | 2009 |
Temozolomide in malignant gliomas: current use and future targets.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; | 2009 |
Temozolomide in malignant gliomas: current use and future targets.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; | 2009 |
Temozolomide in malignant gliomas: current use and future targets.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioma; | 2009 |
Insights into pharmacotherapy of malignant glioma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2009 |
Insights into pharmacotherapy of malignant glioma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2009 |
Insights into pharmacotherapy of malignant glioma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2009 |
Insights into pharmacotherapy of malignant glioma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2009 |
Pseudoprogression and pseudoresponse in the treatment of gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Diagnostic Imaging; Disease Progression; Glioma | 2009 |
Pseudoprogression and pseudoresponse in the treatment of gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Diagnostic Imaging; Disease Progression; Glioma | 2009 |
Pseudoprogression and pseudoresponse in the treatment of gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Diagnostic Imaging; Disease Progression; Glioma | 2009 |
Pseudoprogression and pseudoresponse in the treatment of gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Diagnostic Imaging; Disease Progression; Glioma | 2009 |
Temozolomide for malignant primary spinal cord glioma: an experience of six cases and a literature review.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Gliom | 2011 |
Temozolomide for malignant primary spinal cord glioma: an experience of six cases and a literature review.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Gliom | 2011 |
Temozolomide for malignant primary spinal cord glioma: an experience of six cases and a literature review.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Gliom | 2011 |
Temozolomide for malignant primary spinal cord glioma: an experience of six cases and a literature review.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Gliom | 2011 |
Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects.
Topics: Antineoplastic Agents, Alkylating; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Drug Adm | 2010 |
Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects.
Topics: Antineoplastic Agents, Alkylating; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Drug Adm | 2010 |
Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects.
Topics: Antineoplastic Agents, Alkylating; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Drug Adm | 2010 |
Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects.
Topics: Antineoplastic Agents, Alkylating; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Drug Adm | 2010 |
Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2010 |
Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2010 |
Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2010 |
Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2010 |
O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarbazine; | 2010 |
O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarbazine; | 2010 |
O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarbazine; | 2010 |
O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarbazine; | 2010 |
Temozolomide: Expanding its role in brain cancer.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; | 2010 |
Temozolomide: Expanding its role in brain cancer.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; | 2010 |
Temozolomide: Expanding its role in brain cancer.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; | 2010 |
Temozolomide: Expanding its role in brain cancer.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; | 2010 |
A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylase | 2011 |
A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylase | 2011 |
A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylase | 2011 |
A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylase | 2011 |
An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.
Topics: Algorithms; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chem | 2011 |
An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.
Topics: Algorithms; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chem | 2011 |
An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.
Topics: Algorithms; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chem | 2011 |
An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.
Topics: Algorithms; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chem | 2011 |
[MGMT analysis in gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Repair; Glioma; Humans; Neoplas | 2011 |
[MGMT analysis in gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Repair; Glioma; Humans; Neoplas | 2011 |
[MGMT analysis in gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Repair; Glioma; Humans; Neoplas | 2011 |
[MGMT analysis in gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Repair; Glioma; Humans; Neoplas | 2011 |
Temozolomide may induce therapy-related acute lymphoblastic leukaemia.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioma; Humans; Neoplasms, Second Primary; Precursor | 2011 |
Temozolomide may induce therapy-related acute lymphoblastic leukaemia.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioma; Humans; Neoplasms, Second Primary; Precursor | 2011 |
Temozolomide may induce therapy-related acute lymphoblastic leukaemia.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioma; Humans; Neoplasms, Second Primary; Precursor | 2011 |
Temozolomide may induce therapy-related acute lymphoblastic leukaemia.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioma; Humans; Neoplasms, Second Primary; Precursor | 2011 |
Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule | 2011 |
Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule | 2011 |
Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule | 2011 |
Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule | 2011 |
[Issues around diffuse glioma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2011 |
[Issues around diffuse glioma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2011 |
[Issues around diffuse glioma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2011 |
[Issues around diffuse glioma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2011 |
The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond.
Topics: Antineoplastic Agents; Brain Neoplasms; Caspases; Cell Nucleus; Combined Modality Therapy; Dacarbazi | 2012 |
The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond.
Topics: Antineoplastic Agents; Brain Neoplasms; Caspases; Cell Nucleus; Combined Modality Therapy; Dacarbazi | 2012 |
The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond.
Topics: Antineoplastic Agents; Brain Neoplasms; Caspases; Cell Nucleus; Combined Modality Therapy; Dacarbazi | 2012 |
The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond.
Topics: Antineoplastic Agents; Brain Neoplasms; Caspases; Cell Nucleus; Combined Modality Therapy; Dacarbazi | 2012 |
Temozolomide dosing regimens for glioma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; G | 2012 |
Temozolomide dosing regimens for glioma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; G | 2012 |
Temozolomide dosing regimens for glioma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; G | 2012 |
Temozolomide dosing regimens for glioma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; G | 2012 |
Chemotherapy and target therapy in the management of adult high- grade gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Central N | 2012 |
Chemotherapy and target therapy in the management of adult high- grade gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Central N | 2012 |
Chemotherapy and target therapy in the management of adult high- grade gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Central N | 2012 |
Chemotherapy and target therapy in the management of adult high- grade gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Central N | 2012 |
Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2012 |
Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2012 |
Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2012 |
Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2012 |
Chemotherapy in low-grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Clinical Trials | 2012 |
Chemotherapy in low-grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Clinical Trials | 2012 |
Chemotherapy in low-grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Clinical Trials | 2012 |
Chemotherapy in low-grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Clinical Trials | 2012 |
Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; Dacarbazine; Gliom | 2013 |
Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; Dacarbazine; Gliom | 2013 |
Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; Dacarbazine; Gliom | 2013 |
Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; Dacarbazine; Gliom | 2013 |
Impact of temozolomide on immune response during malignant glioma chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; | 2012 |
Impact of temozolomide on immune response during malignant glioma chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; | 2012 |
Impact of temozolomide on immune response during malignant glioma chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; | 2012 |
Impact of temozolomide on immune response during malignant glioma chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; | 2012 |
Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Gl | 2013 |
Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Gl | 2013 |
Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Gl | 2013 |
Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Gl | 2013 |
Imaging characteristics of an unusual, high-grade angiocentric glioma: a case report and review of the literature.
Topics: Adolescent; Brain Neoplasms; Combined Modality Therapy; Cranial Nerve Diseases; Dacarbazine; Diagnos | 2012 |
Imaging characteristics of an unusual, high-grade angiocentric glioma: a case report and review of the literature.
Topics: Adolescent; Brain Neoplasms; Combined Modality Therapy; Cranial Nerve Diseases; Dacarbazine; Diagnos | 2012 |
Imaging characteristics of an unusual, high-grade angiocentric glioma: a case report and review of the literature.
Topics: Adolescent; Brain Neoplasms; Combined Modality Therapy; Cranial Nerve Diseases; Dacarbazine; Diagnos | 2012 |
Imaging characteristics of an unusual, high-grade angiocentric glioma: a case report and review of the literature.
Topics: Adolescent; Brain Neoplasms; Combined Modality Therapy; Cranial Nerve Diseases; Dacarbazine; Diagnos | 2012 |
Temozolomide: a novel oral alkylating agent.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administ | 2001 |
Temozolomide: a novel oral alkylating agent.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administ | 2001 |
Temozolomide: a novel oral alkylating agent.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administ | 2001 |
Temozolomide: a novel oral alkylating agent.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administ | 2001 |
The use of temozolomide in recurrent malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; H | 2002 |
The use of temozolomide in recurrent malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; H | 2002 |
The use of temozolomide in recurrent malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; H | 2002 |
The use of temozolomide in recurrent malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; H | 2002 |
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic | 2003 |
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic | 2003 |
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic | 2003 |
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic | 2003 |
Temozolomide: realizing the promise and potential.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Dacarbazine; D | 2003 |
Temozolomide: realizing the promise and potential.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Dacarbazine; D | 2003 |
Temozolomide: realizing the promise and potential.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Dacarbazine; D | 2003 |
Temozolomide: realizing the promise and potential.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Dacarbazine; D | 2003 |
Benefits of adjuvant chemotherapy in high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Hum | 2003 |
Benefits of adjuvant chemotherapy in high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Hum | 2003 |
Benefits of adjuvant chemotherapy in high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Hum | 2003 |
Benefits of adjuvant chemotherapy in high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Hum | 2003 |
Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2003 |
Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2003 |
Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2003 |
Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2003 |
Should radiotherapy be standard therapy for brain tumors in the elderly? Cons.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; | 2003 |
Should radiotherapy be standard therapy for brain tumors in the elderly? Cons.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; | 2003 |
Should radiotherapy be standard therapy for brain tumors in the elderly? Cons.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; | 2003 |
Should radiotherapy be standard therapy for brain tumors in the elderly? Cons.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; | 2003 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
Neuro-oncology: the growing role of chemotherapy in glioma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; D | 2005 |
Neuro-oncology: the growing role of chemotherapy in glioma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; D | 2005 |
Neuro-oncology: the growing role of chemotherapy in glioma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; D | 2005 |
Neuro-oncology: the growing role of chemotherapy in glioma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; D | 2005 |
Adjuvant chemotherapy in the treatment of high grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2005 |
Adjuvant chemotherapy in the treatment of high grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2005 |
Adjuvant chemotherapy in the treatment of high grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2005 |
Adjuvant chemotherapy in the treatment of high grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2005 |
Optimal role of temozolomide in the treatment of malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Admi | 2005 |
Optimal role of temozolomide in the treatment of malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Admi | 2005 |
Optimal role of temozolomide in the treatment of malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Admi | 2005 |
Optimal role of temozolomide in the treatment of malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Admi | 2005 |
[Role of extracellular matrix degradation enzyme for glioma invasion].
Topics: ADAM Proteins; Brain Neoplasms; Dacarbazine; Drug Design; Enzyme Inhibitors; Extracellular Matrix; G | 2005 |
[Role of extracellular matrix degradation enzyme for glioma invasion].
Topics: ADAM Proteins; Brain Neoplasms; Dacarbazine; Drug Design; Enzyme Inhibitors; Extracellular Matrix; G | 2005 |
[Role of extracellular matrix degradation enzyme for glioma invasion].
Topics: ADAM Proteins; Brain Neoplasms; Dacarbazine; Drug Design; Enzyme Inhibitors; Extracellular Matrix; G | 2005 |
[Role of extracellular matrix degradation enzyme for glioma invasion].
Topics: ADAM Proteins; Brain Neoplasms; Dacarbazine; Drug Design; Enzyme Inhibitors; Extracellular Matrix; G | 2005 |
[Chemotherapy for gliomas in children].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brai | 2005 |
[Chemotherapy for gliomas in children].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brai | 2005 |
[Chemotherapy for gliomas in children].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brai | 2005 |
[Chemotherapy for gliomas in children].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brai | 2005 |
[Treatment of malignant gliomas in the elderly].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M | 2005 |
[Treatment of malignant gliomas in the elderly].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M | 2005 |
[Treatment of malignant gliomas in the elderly].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M | 2005 |
[Treatment of malignant gliomas in the elderly].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M | 2005 |
The role of chemotherapy in the treatment of low-grade glioma. A review of the literature.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Proca | 2005 |
The role of chemotherapy in the treatment of low-grade glioma. A review of the literature.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Proca | 2005 |
The role of chemotherapy in the treatment of low-grade glioma. A review of the literature.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Proca | 2005 |
The role of chemotherapy in the treatment of low-grade glioma. A review of the literature.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Proca | 2005 |
Recent developments in the use of chemotherapy in brain tumours.
Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Dacarbazine; Glioma; Humans; Irinotecan; Temoz | 2006 |
Recent developments in the use of chemotherapy in brain tumours.
Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Dacarbazine; Glioma; Humans; Irinotecan; Temoz | 2006 |
Recent developments in the use of chemotherapy in brain tumours.
Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Dacarbazine; Glioma; Humans; Irinotecan; Temoz | 2006 |
Recent developments in the use of chemotherapy in brain tumours.
Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Dacarbazine; Glioma; Humans; Irinotecan; Temoz | 2006 |
[Update on cerebral tumors].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy | 2006 |
[Update on cerebral tumors].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy | 2006 |
[Update on cerebral tumors].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy | 2006 |
[Update on cerebral tumors].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy | 2006 |
[Glioma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; | 2006 |
[Glioma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; | 2006 |
[Glioma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; | 2006 |
[Glioma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; | 2006 |
Temozolomide: a milestone in neuro-oncology and beyond?
Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplasms; Clinical Trials, Phase II as | 2006 |
Temozolomide: a milestone in neuro-oncology and beyond?
Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplasms; Clinical Trials, Phase II as | 2006 |
Temozolomide: a milestone in neuro-oncology and beyond?
Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplasms; Clinical Trials, Phase II as | 2006 |
Temozolomide: a milestone in neuro-oncology and beyond?
Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplasms; Clinical Trials, Phase II as | 2006 |
Glioma therapy in adults.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Neurosurgica | 2006 |
Glioma therapy in adults.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Neurosurgica | 2006 |
Glioma therapy in adults.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Neurosurgica | 2006 |
Glioma therapy in adults.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Neurosurgica | 2006 |
Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; DNA Repair; Drug Resist | 2006 |
Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; DNA Repair; Drug Resist | 2006 |
Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; DNA Repair; Drug Resist | 2006 |
Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; DNA Repair; Drug Resist | 2006 |
[Molecular pharmacology on DNA methylating agent temozolomide].
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Division; Dacarbazine; DNA Damag | 2007 |
[Molecular pharmacology on DNA methylating agent temozolomide].
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Division; Dacarbazine; DNA Damag | 2007 |
[Molecular pharmacology on DNA methylating agent temozolomide].
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Division; Dacarbazine; DNA Damag | 2007 |
[Molecular pharmacology on DNA methylating agent temozolomide].
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Division; Dacarbazine; DNA Damag | 2007 |
[Pattern of care of high-grade gliomas].
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Anticonvulsants; Antineoplastic Agents, Alkylatin | 2006 |
[Pattern of care of high-grade gliomas].
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Anticonvulsants; Antineoplastic Agents, Alkylatin | 2006 |
[Pattern of care of high-grade gliomas].
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Anticonvulsants; Antineoplastic Agents, Alkylatin | 2006 |
[Pattern of care of high-grade gliomas].
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Anticonvulsants; Antineoplastic Agents, Alkylatin | 2006 |
[Glioma therapy up-date].
Topics: Anticoagulants; Anticonvulsants; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothe | 2007 |
[Glioma therapy up-date].
Topics: Anticoagulants; Anticonvulsants; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothe | 2007 |
[Glioma therapy up-date].
Topics: Anticoagulants; Anticonvulsants; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothe | 2007 |
[Glioma therapy up-date].
Topics: Anticoagulants; Anticonvulsants; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothe | 2007 |
[Chemotherapy for malignant gliomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Combined Modal | 2007 |
[Chemotherapy for malignant gliomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Combined Modal | 2007 |
[Chemotherapy for malignant gliomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Combined Modal | 2007 |
[Chemotherapy for malignant gliomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Combined Modal | 2007 |
The economics of temozolomide in brain cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cost-Benefit Analysis | 2007 |
The economics of temozolomide in brain cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cost-Benefit Analysis | 2007 |
The economics of temozolomide in brain cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cost-Benefit Analysis | 2007 |
The economics of temozolomide in brain cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cost-Benefit Analysis | 2007 |
Potential biochemical therapy of glioma cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Indoles; Models, Bi | 2007 |
Potential biochemical therapy of glioma cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Indoles; Models, Bi | 2007 |
Potential biochemical therapy of glioma cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Indoles; Models, Bi | 2007 |
Potential biochemical therapy of glioma cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Indoles; Models, Bi | 2007 |
Molecular targeted therapies and chemotherapy in malignant gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Disease-Free Survival | 2007 |
Molecular targeted therapies and chemotherapy in malignant gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Disease-Free Survival | 2007 |
Molecular targeted therapies and chemotherapy in malignant gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Disease-Free Survival | 2007 |
Molecular targeted therapies and chemotherapy in malignant gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Disease-Free Survival | 2007 |
Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2007 |
Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2007 |
Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2007 |
Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2007 |
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2007 |
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2007 |
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2007 |
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2007 |
[Molecular genetic analysis for malignant gliomas: clinical implications and future directions].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Re | 2008 |
[Molecular genetic analysis for malignant gliomas: clinical implications and future directions].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Re | 2008 |
[Molecular genetic analysis for malignant gliomas: clinical implications and future directions].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Re | 2008 |
[Molecular genetic analysis for malignant gliomas: clinical implications and future directions].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Re | 2008 |
Overcoming therapeutic resistance in malignant gliomas: current practices and future directions.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy | 2008 |
Overcoming therapeutic resistance in malignant gliomas: current practices and future directions.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy | 2008 |
Overcoming therapeutic resistance in malignant gliomas: current practices and future directions.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy | 2008 |
Overcoming therapeutic resistance in malignant gliomas: current practices and future directions.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy | 2008 |
[Recent advances in chemotherapy for malignant gliomas].
Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Dacarbazine; DNA Repair; Glioma; Humans; Meta-A | 2008 |
[Recent advances in chemotherapy for malignant gliomas].
Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Dacarbazine; DNA Repair; Glioma; Humans; Meta-A | 2008 |
[Recent advances in chemotherapy for malignant gliomas].
Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Dacarbazine; DNA Repair; Glioma; Humans; Meta-A | 2008 |
[Recent advances in chemotherapy for malignant gliomas].
Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Dacarbazine; DNA Repair; Glioma; Humans; Meta-A | 2008 |
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dac | 2008 |
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dac | 2008 |
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dac | 2008 |
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dac | 2008 |
[Genetic diagnoses and individualized treatment of gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2008 |
[Genetic diagnoses and individualized treatment of gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2008 |
[Genetic diagnoses and individualized treatment of gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2008 |
[Genetic diagnoses and individualized treatment of gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, | 2008 |
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Apoptosis; Brain Edema; Brain Neoplasms; Chemother | 2008 |
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Apoptosis; Brain Edema; Brain Neoplasms; Chemother | 2008 |
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Apoptosis; Brain Edema; Brain Neoplasms; Chemother | 2008 |
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Apoptosis; Brain Edema; Brain Neoplasms; Chemother | 2008 |
The therapeutic challenge of gliomas.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Glioma; Humans; Temozolomi | 1993 |
The therapeutic challenge of gliomas.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Glioma; Humans; Temozolomi | 1993 |
The therapeutic challenge of gliomas.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Glioma; Humans; Temozolomi | 1993 |
The therapeutic challenge of gliomas.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Glioma; Humans; Temozolomi | 1993 |
New chemotherapy options for the treatment of malignant gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Dacarbazine; | 1999 |
New chemotherapy options for the treatment of malignant gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Dacarbazine; | 1999 |
New chemotherapy options for the treatment of malignant gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Dacarbazine; | 1999 |
New chemotherapy options for the treatment of malignant gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Dacarbazine; | 1999 |
Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; | 2000 |
Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; | 2000 |
Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; | 2000 |
Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; | 2000 |
Temozolomide and treatment of malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Gliobl | 2000 |
Temozolomide and treatment of malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Gliobl | 2000 |
Temozolomide and treatment of malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Gliobl | 2000 |
Temozolomide and treatment of malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Gliobl | 2000 |
'Chemotherapy is useful in treatment of gliomas'.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy; Glioma; Humans; | 2000 |
'Chemotherapy is useful in treatment of gliomas'.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy; Glioma; Humans; | 2000 |
'Chemotherapy is useful in treatment of gliomas'.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy; Glioma; Humans; | 2000 |
'Chemotherapy is useful in treatment of gliomas'.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy; Glioma; Humans; | 2000 |
Temozolomide in patients with high grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Clinical Trials, Phase I as Top | 2000 |
Temozolomide in patients with high grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Clinical Trials, Phase I as Top | 2000 |
Temozolomide in patients with high grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Clinical Trials, Phase I as Top | 2000 |
Temozolomide in patients with high grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Clinical Trials, Phase I as Top | 2000 |
The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; Evidence-Bas | 2001 |
The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; Evidence-Bas | 2001 |
The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; Evidence-Bas | 2001 |
The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; Evidence-Bas | 2001 |
Temozolomide for recurrent high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Central Nervous System Neoplasms; Clinical Trials as | 2001 |
Temozolomide for recurrent high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Central Nervous System Neoplasms; Clinical Trials as | 2001 |
Temozolomide for recurrent high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Central Nervous System Neoplasms; Clinical Trials as | 2001 |
Temozolomide for recurrent high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Central Nervous System Neoplasms; Clinical Trials as | 2001 |
New approaches for temozolomide therapy: use in newly diagnosed glioma.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Clinica | 2001 |
New approaches for temozolomide therapy: use in newly diagnosed glioma.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Clinica | 2001 |
New approaches for temozolomide therapy: use in newly diagnosed glioma.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Clinica | 2001 |
New approaches for temozolomide therapy: use in newly diagnosed glioma.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Clinica | 2001 |
Temozolomide in combination with other cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carmustine; Central Nervous System Neo | 2001 |
Temozolomide in combination with other cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carmustine; Central Nervous System Neo | 2001 |
Temozolomide in combination with other cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carmustine; Central Nervous System Neo | 2001 |
Temozolomide in combination with other cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carmustine; Central Nervous System Neo | 2001 |
Current and future developments in the use of temozolomide for the treatment of brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Res | 2001 |
Current and future developments in the use of temozolomide for the treatment of brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Res | 2001 |
Current and future developments in the use of temozolomide for the treatment of brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Res | 2001 |
Current and future developments in the use of temozolomide for the treatment of brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Res | 2001 |
163 trials available for temozolomide and Glioma
| Article | Year |
|---|---|
Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Chemoradiotherapy; Drug Therapy; Er | 2021 |
Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Chemoradiotherapy; Drug Therapy; Er | 2021 |
Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Chemoradiotherapy; Drug Therapy; Er | 2021 |
Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Chemoradiotherapy; Drug Therapy; Er | 2021 |
Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study.
Topics: Brain Neoplasms; Chemoradiotherapy; Female; Glioma; Humans; Isocitrate Dehydrogenase; Male; Mutation | 2022 |
Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study.
Topics: Brain Neoplasms; Chemoradiotherapy; Female; Glioma; Humans; Isocitrate Dehydrogenase; Male; Mutation | 2022 |
Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study.
Topics: Brain Neoplasms; Chemoradiotherapy; Female; Glioma; Humans; Isocitrate Dehydrogenase; Male; Mutation | 2022 |
Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study.
Topics: Brain Neoplasms; Chemoradiotherapy; Female; Glioma; Humans; Isocitrate Dehydrogenase; Male; Mutation | 2022 |
Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial.
Topics: Double-Blind Method; Glioma; Humans; Male; Middle Aged; Naltrexone; Quality of Life; Temozolomide | 2022 |
Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial.
Topics: Double-Blind Method; Glioma; Humans; Male; Middle Aged; Naltrexone; Quality of Life; Temozolomide | 2022 |
Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial.
Topics: Double-Blind Method; Glioma; Humans; Male; Middle Aged; Naltrexone; Quality of Life; Temozolomide | 2022 |
Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial.
Topics: Double-Blind Method; Glioma; Humans; Male; Middle Aged; Naltrexone; Quality of Life; Temozolomide | 2022 |
Efficacy and Safety of Temozolomide Combined with Radiotherapy in the Treatment of Malignant Glioma.
Topics: Antineoplastic Agents, Alkylating; Glioma; Humans; Postoperative Complications; Quality of Life; Tem | 2022 |
Efficacy and Safety of Temozolomide Combined with Radiotherapy in the Treatment of Malignant Glioma.
Topics: Antineoplastic Agents, Alkylating; Glioma; Humans; Postoperative Complications; Quality of Life; Tem | 2022 |
Efficacy and Safety of Temozolomide Combined with Radiotherapy in the Treatment of Malignant Glioma.
Topics: Antineoplastic Agents, Alkylating; Glioma; Humans; Postoperative Complications; Quality of Life; Tem | 2022 |
Efficacy and Safety of Temozolomide Combined with Radiotherapy in the Treatment of Malignant Glioma.
Topics: Antineoplastic Agents, Alkylating; Glioma; Humans; Postoperative Complications; Quality of Life; Tem | 2022 |
Comparison of Clinical Effects of Temozolomide Single Agent and Combined Doxorubicin in the Treatment of Glioma.
Topics: Doxorubicin; Glioma; Humans; Nausea; Temozolomide; Thrombocytopenia; Treatment Outcome; Vomiting | 2022 |
Comparison of Clinical Effects of Temozolomide Single Agent and Combined Doxorubicin in the Treatment of Glioma.
Topics: Doxorubicin; Glioma; Humans; Nausea; Temozolomide; Thrombocytopenia; Treatment Outcome; Vomiting | 2022 |
Comparison of Clinical Effects of Temozolomide Single Agent and Combined Doxorubicin in the Treatment of Glioma.
Topics: Doxorubicin; Glioma; Humans; Nausea; Temozolomide; Thrombocytopenia; Treatment Outcome; Vomiting | 2022 |
Comparison of Clinical Effects of Temozolomide Single Agent and Combined Doxorubicin in the Treatment of Glioma.
Topics: Doxorubicin; Glioma; Humans; Nausea; Temozolomide; Thrombocytopenia; Treatment Outcome; Vomiting | 2022 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2023 |
Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2023 |
Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2023 |
Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2023 |
Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up.
Topics: Brain Neoplasms; Chlorogenic Acid; Dacarbazine; Follow-Up Studies; Glioma; Humans; Temozolomide | 2023 |
Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up.
Topics: Brain Neoplasms; Chlorogenic Acid; Dacarbazine; Follow-Up Studies; Glioma; Humans; Temozolomide | 2023 |
Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up.
Topics: Brain Neoplasms; Chlorogenic Acid; Dacarbazine; Follow-Up Studies; Glioma; Humans; Temozolomide | 2023 |
Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up.
Topics: Brain Neoplasms; Chlorogenic Acid; Dacarbazine; Follow-Up Studies; Glioma; Humans; Temozolomide | 2023 |
Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatmen
Topics: Bevacizumab; Brain Neoplasms; Glioma; Humans; Quality of Life; Temozolomide; World Health Organizati | 2023 |
Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatmen
Topics: Bevacizumab; Brain Neoplasms; Glioma; Humans; Quality of Life; Temozolomide; World Health Organizati | 2023 |
Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatmen
Topics: Bevacizumab; Brain Neoplasms; Glioma; Humans; Quality of Life; Temozolomide; World Health Organizati | 2023 |
Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatmen
Topics: Bevacizumab; Brain Neoplasms; Glioma; Humans; Quality of Life; Temozolomide; World Health Organizati | 2023 |
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Brain Neoplasms; Female; Glioma; Humans | 2020 |
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Brain Neoplasms; Female; Glioma; Humans | 2020 |
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Brain Neoplasms; Female; Glioma; Humans | 2020 |
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Brain Neoplasms; Female; Glioma; Humans | 2020 |
Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Follow-Up Studies; Glioma; | 2019 |
Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Follow-Up Studies; Glioma; | 2019 |
Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Follow-Up Studies; Glioma; | 2019 |
Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Follow-Up Studies; Glioma; | 2019 |
Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study).
Topics: Adult; Antineoplastic Agents, Alkylating; Female; Glioma; Humans; Male; Neoplasm Grading; Temozolomi | 2020 |
Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study).
Topics: Adult; Antineoplastic Agents, Alkylating; Female; Glioma; Humans; Male; Neoplasm Grading; Temozolomi | 2020 |
Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study).
Topics: Adult; Antineoplastic Agents, Alkylating; Female; Glioma; Humans; Male; Neoplasm Grading; Temozolomi | 2020 |
Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study).
Topics: Adult; Antineoplastic Agents, Alkylating; Female; Glioma; Humans; Male; Neoplasm Grading; Temozolomi | 2020 |
Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adju | 2019 |
Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adju | 2019 |
Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adju | 2019 |
Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adju | 2019 |
A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Brain Stem Neoplasm | 2020 |
A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Brain Stem Neoplasm | 2020 |
A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Brain Stem Neoplasm | 2020 |
A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Brain Stem Neoplasm | 2020 |
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brai | 2020 |
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brai | 2020 |
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brai | 2020 |
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brai | 2020 |
Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Neop | 2020 |
Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Neop | 2020 |
Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Neop | 2020 |
Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Neop | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neop | 2020 |
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neop | 2020 |
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neop | 2020 |
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neop | 2020 |
Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study).
Topics: Brain Neoplasms; Chemoradiotherapy; Glioma; Humans; Lymphoma, Follicular; Quality of Life; Temozolom | 2022 |
Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study).
Topics: Brain Neoplasms; Chemoradiotherapy; Glioma; Humans; Lymphoma, Follicular; Quality of Life; Temozolom | 2022 |
Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study).
Topics: Brain Neoplasms; Chemoradiotherapy; Glioma; Humans; Lymphoma, Follicular; Quality of Life; Temozolom | 2022 |
Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study).
Topics: Brain Neoplasms; Chemoradiotherapy; Glioma; Humans; Lymphoma, Follicular; Quality of Life; Temozolom | 2022 |
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cal | 2017 |
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cal | 2017 |
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cal | 2017 |
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cal | 2017 |
A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Bra | 2017 |
A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Bra | 2017 |
A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Bra | 2017 |
A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Bra | 2017 |
Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neo | 2018 |
Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neo | 2018 |
Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neo | 2018 |
Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neo | 2018 |
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; CpG Islands; Discoidin Domain Receptors; | 2018 |
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; CpG Islands; Discoidin Domain Receptors; | 2018 |
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; CpG Islands; Discoidin Domain Receptors; | 2018 |
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; CpG Islands; Discoidin Domain Receptors; | 2018 |
Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Female; Glioma; | 2018 |
Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Female; Glioma; | 2018 |
Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Female; Glioma; | 2018 |
Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Female; Glioma; | 2018 |
Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosome Deletion; Chr | 2018 |
Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosome Deletion; Chr | 2018 |
Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosome Deletion; Chr | 2018 |
Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosome Deletion; Chr | 2018 |
Shadow study: randomized comparison of clinic with video follow-up in glioma undergoing adjuvant temozolomide therapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up | 2018 |
Shadow study: randomized comparison of clinic with video follow-up in glioma undergoing adjuvant temozolomide therapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up | 2018 |
Shadow study: randomized comparison of clinic with video follow-up in glioma undergoing adjuvant temozolomide therapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up | 2018 |
Shadow study: randomized comparison of clinic with video follow-up in glioma undergoing adjuvant temozolomide therapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up | 2018 |
Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial.
Topics: Adolescent; Bevacizumab; CD8-Positive T-Lymphocytes; Chemoradiotherapy; Child; Child, Preschool; DNA | 2018 |
Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial.
Topics: Adolescent; Bevacizumab; CD8-Positive T-Lymphocytes; Chemoradiotherapy; Child; Child, Preschool; DNA | 2018 |
Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial.
Topics: Adolescent; Bevacizumab; CD8-Positive T-Lymphocytes; Chemoradiotherapy; Child; Child, Preschool; DNA | 2018 |
Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial.
Topics: Adolescent; Bevacizumab; CD8-Positive T-Lymphocytes; Chemoradiotherapy; Child; Child, Preschool; DNA | 2018 |
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; DNA Methylation; | 2018 |
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; DNA Methylation; | 2018 |
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; DNA Methylation; | 2018 |
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; DNA Methylation; | 2018 |
Convection-Enhanced Delivery of Polymeric Nanoparticles Encapsulating Chemotherapy in Canines with Spontaneous Supratentorial Tumors.
Topics: Animals; Antineoplastic Agents; Brain; Convection; Dacarbazine; Dog Diseases; Dogs; Drug Delivery Sy | 2018 |
Convection-Enhanced Delivery of Polymeric Nanoparticles Encapsulating Chemotherapy in Canines with Spontaneous Supratentorial Tumors.
Topics: Animals; Antineoplastic Agents; Brain; Convection; Dacarbazine; Dog Diseases; Dogs; Drug Delivery Sy | 2018 |
Convection-Enhanced Delivery of Polymeric Nanoparticles Encapsulating Chemotherapy in Canines with Spontaneous Supratentorial Tumors.
Topics: Animals; Antineoplastic Agents; Brain; Convection; Dacarbazine; Dog Diseases; Dogs; Drug Delivery Sy | 2018 |
Convection-Enhanced Delivery of Polymeric Nanoparticles Encapsulating Chemotherapy in Canines with Spontaneous Supratentorial Tumors.
Topics: Animals; Antineoplastic Agents; Brain; Convection; Dacarbazine; Dog Diseases; Dogs; Drug Delivery Sy | 2018 |
Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combi | 2018 |
Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combi | 2018 |
Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combi | 2018 |
Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combi | 2018 |
Intratumoral temozolomide in spontaneous canine gliomas: feasibility of a novel therapy using implanted microcylinders.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dog Diseases; Dogs; Drug Implants; Fema | 2019 |
Intratumoral temozolomide in spontaneous canine gliomas: feasibility of a novel therapy using implanted microcylinders.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dog Diseases; Dogs; Drug Implants; Fema | 2019 |
Intratumoral temozolomide in spontaneous canine gliomas: feasibility of a novel therapy using implanted microcylinders.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dog Diseases; Dogs; Drug Implants; Fema | 2019 |
Intratumoral temozolomide in spontaneous canine gliomas: feasibility of a novel therapy using implanted microcylinders.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dog Diseases; Dogs; Drug Implants; Fema | 2019 |
Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation.
Topics: Adolescent; Adult; Aged; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Female; Glioma; Humans; Ma | 2019 |
Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation.
Topics: Adolescent; Adult; Aged; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Female; Glioma; Humans; Ma | 2019 |
Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation.
Topics: Adolescent; Adult; Aged; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Female; Glioma; Humans; Ma | 2019 |
Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation.
Topics: Adolescent; Adult; Aged; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Female; Glioma; Humans; Ma | 2019 |
A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Child; Ch | 2013 |
A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Child; Ch | 2013 |
A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Child; Ch | 2013 |
A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Child; Ch | 2013 |
Secondary hematological malignancies associated with temozolomide in patients with glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chil | 2013 |
Secondary hematological malignancies associated with temozolomide in patients with glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chil | 2013 |
Secondary hematological malignancies associated with temozolomide in patients with glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chil | 2013 |
Secondary hematological malignancies associated with temozolomide in patients with glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chil | 2013 |
[Multicenter randomized controlled study of temozolomide versus semustine in the treatment of recurrent malignant glioma].
Topics: Adult; Astrocytoma; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm R | 2013 |
[Multicenter randomized controlled study of temozolomide versus semustine in the treatment of recurrent malignant glioma].
Topics: Adult; Astrocytoma; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm R | 2013 |
[Multicenter randomized controlled study of temozolomide versus semustine in the treatment of recurrent malignant glioma].
Topics: Adult; Astrocytoma; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm R | 2013 |
[Multicenter randomized controlled study of temozolomide versus semustine in the treatment of recurrent malignant glioma].
Topics: Adult; Astrocytoma; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm R | 2013 |
Phase I study of temozolomide combined with oral etoposide in children with malignant glial tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; C | 2013 |
Phase I study of temozolomide combined with oral etoposide in children with malignant glial tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; C | 2013 |
Phase I study of temozolomide combined with oral etoposide in children with malignant glial tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; C | 2013 |
Phase I study of temozolomide combined with oral etoposide in children with malignant glial tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; C | 2013 |
Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy--results of a United Kingdom phase II trial (CNS 2007 04).
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Chemoradiotherapy; Chemotherapy | 2013 |
Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy--results of a United Kingdom phase II trial (CNS 2007 04).
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Chemoradiotherapy; Chemotherapy | 2013 |
Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy--results of a United Kingdom phase II trial (CNS 2007 04).
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Chemoradiotherapy; Chemotherapy | 2013 |
Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy--results of a United Kingdom phase II trial (CNS 2007 04).
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Chemoradiotherapy; Chemotherapy | 2013 |
Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brai | 2014 |
Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brai | 2014 |
Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brai | 2014 |
Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brai | 2014 |
Chemotherapy alleviates subacute recurrent glioma-associated refractory cerebral edema by downregulating vascular endothelial growth factor.
Topics: Adult; Aged; Brain Edema; Brain Neoplasms; Cisplatin; Dacarbazine; Down-Regulation; Female; Glioma; | 2014 |
Chemotherapy alleviates subacute recurrent glioma-associated refractory cerebral edema by downregulating vascular endothelial growth factor.
Topics: Adult; Aged; Brain Edema; Brain Neoplasms; Cisplatin; Dacarbazine; Down-Regulation; Female; Glioma; | 2014 |
Chemotherapy alleviates subacute recurrent glioma-associated refractory cerebral edema by downregulating vascular endothelial growth factor.
Topics: Adult; Aged; Brain Edema; Brain Neoplasms; Cisplatin; Dacarbazine; Down-Regulation; Female; Glioma; | 2014 |
Chemotherapy alleviates subacute recurrent glioma-associated refractory cerebral edema by downregulating vascular endothelial growth factor.
Topics: Adult; Aged; Brain Edema; Brain Neoplasms; Cisplatin; Dacarbazine; Down-Regulation; Female; Glioma; | 2014 |
Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial.
Topics: Antineoplastic Agents; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dac | 2014 |
Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial.
Topics: Antineoplastic Agents; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dac | 2014 |
Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial.
Topics: Antineoplastic Agents; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dac | 2014 |
Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial.
Topics: Antineoplastic Agents; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dac | 2014 |
Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dis | 2015 |
Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dis | 2015 |
Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dis | 2015 |
Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dis | 2015 |
Clinical observation of three dimensional conformal radiotherapy with tamoxifen in treatment of postoperative malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Combine | 2015 |
Clinical observation of three dimensional conformal radiotherapy with tamoxifen in treatment of postoperative malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Combine | 2015 |
Clinical observation of three dimensional conformal radiotherapy with tamoxifen in treatment of postoperative malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Combine | 2015 |
Clinical observation of three dimensional conformal radiotherapy with tamoxifen in treatment of postoperative malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Combine | 2015 |
Radiotherapy and temozolomide for anaplastic astrocytic gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Chemoradiotherapy; Cohort Studies; Daca | 2015 |
Radiotherapy and temozolomide for anaplastic astrocytic gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Chemoradiotherapy; Cohort Studies; Daca | 2015 |
Radiotherapy and temozolomide for anaplastic astrocytic gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Chemoradiotherapy; Cohort Studies; Daca | 2015 |
Radiotherapy and temozolomide for anaplastic astrocytic gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Chemoradiotherapy; Cohort Studies; Daca | 2015 |
BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2015 |
BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2015 |
BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2015 |
BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2015 |
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Dose-Respons | 2015 |
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Dose-Respons | 2015 |
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Dose-Respons | 2015 |
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Dose-Respons | 2015 |
Frequency of O⁶-methylguanine-DNA methyltransferase promoter methylation in cytological samples from small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Biopsy, Fine-Needle; Dacarbazine; DNA Methylation; Glioma; Guanine; | 2015 |
Frequency of O⁶-methylguanine-DNA methyltransferase promoter methylation in cytological samples from small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Biopsy, Fine-Needle; Dacarbazine; DNA Methylation; Glioma; Guanine; | 2015 |
Frequency of O⁶-methylguanine-DNA methyltransferase promoter methylation in cytological samples from small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Biopsy, Fine-Needle; Dacarbazine; DNA Methylation; Glioma; Guanine; | 2015 |
Frequency of O⁶-methylguanine-DNA methyltransferase promoter methylation in cytological samples from small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Biopsy, Fine-Needle; Dacarbazine; DNA Methylation; Glioma; Guanine; | 2015 |
Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benz | 2015 |
Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benz | 2015 |
Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benz | 2015 |
Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benz | 2015 |
Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2015 |
Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2015 |
Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2015 |
Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2015 |
[Randomized controlled study of limited margins IMRT and temozolomide chemotherapy in patients with malignant glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacar | 2015 |
[Randomized controlled study of limited margins IMRT and temozolomide chemotherapy in patients with malignant glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacar | 2015 |
[Randomized controlled study of limited margins IMRT and temozolomide chemotherapy in patients with malignant glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacar | 2015 |
[Randomized controlled study of limited margins IMRT and temozolomide chemotherapy in patients with malignant glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacar | 2015 |
Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chil | 2016 |
Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chil | 2016 |
Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chil | 2016 |
Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chil | 2016 |
Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).
Topics: Administration, Intravenous; Antineoplastic Agents; Chemoradiotherapy; Dacarbazine; Female; Glioma; | 2016 |
Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).
Topics: Administration, Intravenous; Antineoplastic Agents; Chemoradiotherapy; Dacarbazine; Female; Glioma; | 2016 |
Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).
Topics: Administration, Intravenous; Antineoplastic Agents; Chemoradiotherapy; Dacarbazine; Female; Glioma; | 2016 |
Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).
Topics: Administration, Intravenous; Antineoplastic Agents; Chemoradiotherapy; Dacarbazine; Female; Glioma; | 2016 |
Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2017 |
Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2017 |
Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2017 |
Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2017 |
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Topics: Brain Neoplasms; Dacarbazine; Glioma; Humans; Neoplasm Grading; Prospective Studies; Quality of Life | 2016 |
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Topics: Brain Neoplasms; Dacarbazine; Glioma; Humans; Neoplasm Grading; Prospective Studies; Quality of Life | 2016 |
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Topics: Brain Neoplasms; Dacarbazine; Glioma; Humans; Neoplasm Grading; Prospective Studies; Quality of Life | 2016 |
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Topics: Brain Neoplasms; Dacarbazine; Glioma; Humans; Neoplasm Grading; Prospective Studies; Quality of Life | 2016 |
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Isocitrate D | 2016 |
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Isocitrate D | 2016 |
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Isocitrate D | 2016 |
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Isocitrate D | 2016 |
Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dendritic Cells; Female; Glioblastoma; | 2016 |
Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dendritic Cells; Female; Glioblastoma; | 2016 |
Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dendritic Cells; Female; Glioblastoma; | 2016 |
Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dendritic Cells; Female; Glioblastoma; | 2016 |
Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bioma | 2016 |
Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bioma | 2016 |
Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bioma | 2016 |
Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bioma | 2016 |
Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2017 |
Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2017 |
Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2017 |
Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2017 |
Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Brain Neoplasms; Dacarba | 2017 |
Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Brain Neoplasms; Dacarba | 2017 |
Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Brain Neoplasms; Dacarba | 2017 |
Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Brain Neoplasms; Dacarba | 2017 |
Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma.
Topics: Age Factors; Age of Onset; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy P | 2008 |
Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma.
Topics: Age Factors; Age of Onset; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy P | 2008 |
Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma.
Topics: Age Factors; Age of Onset; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy P | 2008 |
Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma.
Topics: Age Factors; Age of Onset; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy P | 2008 |
When temozolomide alone fails: adding procarbazine in salvage therapy of glioma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Magnetic R | 2008 |
When temozolomide alone fails: adding procarbazine in salvage therapy of glioma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Magnetic R | 2008 |
When temozolomide alone fails: adding procarbazine in salvage therapy of glioma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Magnetic R | 2008 |
When temozolomide alone fails: adding procarbazine in salvage therapy of glioma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Magnetic R | 2008 |
Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2008 |
Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2008 |
Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2008 |
Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2008 |
A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Ther | 2008 |
A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Ther | 2008 |
A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Ther | 2008 |
A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Ther | 2008 |
Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2009 |
Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2009 |
Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2009 |
Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2009 |
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Resi | 2009 |
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Resi | 2009 |
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Resi | 2009 |
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Resi | 2009 |
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; G | 2009 |
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; G | 2009 |
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; G | 2009 |
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; G | 2009 |
Early metabolic responses in temozolomide treated low-grade glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Fluorine Radioisotop | 2009 |
Early metabolic responses in temozolomide treated low-grade glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Fluorine Radioisotop | 2009 |
Early metabolic responses in temozolomide treated low-grade glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Fluorine Radioisotop | 2009 |
Early metabolic responses in temozolomide treated low-grade glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Fluorine Radioisotop | 2009 |
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbaz | 2009 |
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbaz | 2009 |
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbaz | 2009 |
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbaz | 2009 |
Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Combined Mo | 2010 |
Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Combined Mo | 2010 |
Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Combined Mo | 2010 |
Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Combined Mo | 2010 |
Extended-schedule dose-dense temozolomide in refractory gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Sc | 2010 |
Extended-schedule dose-dense temozolomide in refractory gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Sc | 2010 |
Extended-schedule dose-dense temozolomide in refractory gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Sc | 2010 |
Extended-schedule dose-dense temozolomide in refractory gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Sc | 2010 |
A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; | 2009 |
A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; | 2009 |
A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; | 2009 |
A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; | 2009 |
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2009 |
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2009 |
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2009 |
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2009 |
[A multicenter randomized controlled study of temozolomide in 97 patients with malignant brain glioma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Daca | 2009 |
[A multicenter randomized controlled study of temozolomide in 97 patients with malignant brain glioma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Daca | 2009 |
[A multicenter randomized controlled study of temozolomide in 97 patients with malignant brain glioma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Daca | 2009 |
[A multicenter randomized controlled study of temozolomide in 97 patients with malignant brain glioma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Daca | 2009 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality | 2010 |
Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality | 2010 |
Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality | 2010 |
Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality | 2010 |
A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Canada; Child; Child, Preschool | 2010 |
A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Canada; Child; Child, Preschool | 2010 |
A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Canada; Child; Child, Preschool | 2010 |
A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Canada; Child; Child, Preschool | 2010 |
Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chi-Square | 2010 |
Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chi-Square | 2010 |
Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chi-Square | 2010 |
Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chi-Square | 2010 |
Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarb | 2011 |
Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarb | 2011 |
Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarb | 2011 |
Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarb | 2011 |
Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Antineoplastic Agents; Brain Neoplasms; Combined Modal | 2011 |
Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Antineoplastic Agents; Brain Neoplasms; Combined Modal | 2011 |
Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Antineoplastic Agents; Brain Neoplasms; Combined Modal | 2011 |
Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Antineoplastic Agents; Brain Neoplasms; Combined Modal | 2011 |
Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacar | 2010 |
Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacar | 2010 |
Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacar | 2010 |
Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacar | 2010 |
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2012 |
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2012 |
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2012 |
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2012 |
A multicenter phase I trial of combination therapy with interferon-β and temozolomide for high-grade gliomas (INTEGRA study): the final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2011 |
A multicenter phase I trial of combination therapy with interferon-β and temozolomide for high-grade gliomas (INTEGRA study): the final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2011 |
A multicenter phase I trial of combination therapy with interferon-β and temozolomide for high-grade gliomas (INTEGRA study): the final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2011 |
A multicenter phase I trial of combination therapy with interferon-β and temozolomide for high-grade gliomas (INTEGRA study): the final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2011 |
Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradio | 2012 |
Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradio | 2012 |
Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradio | 2012 |
Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradio | 2012 |
Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05).
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neopl | 2011 |
Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05).
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neopl | 2011 |
Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05).
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neopl | 2011 |
Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05).
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neopl | 2011 |
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dacarba | 2011 |
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dacarba | 2011 |
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dacarba | 2011 |
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dacarba | 2011 |
A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carotenoids; Dacarbazi | 2011 |
A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carotenoids; Dacarbazi | 2011 |
A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carotenoids; Dacarbazi | 2011 |
A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carotenoids; Dacarbazi | 2011 |
MRI and thallium-201 SPECT in the prediction of survival in glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2012 |
MRI and thallium-201 SPECT in the prediction of survival in glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2012 |
MRI and thallium-201 SPECT in the prediction of survival in glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2012 |
MRI and thallium-201 SPECT in the prediction of survival in glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2012 |
Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.
Topics: Acyclovir; Adenoviridae; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents, Alkylating; Ant | 2011 |
Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.
Topics: Acyclovir; Adenoviridae; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents, Alkylating; Ant | 2011 |
Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.
Topics: Acyclovir; Adenoviridae; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents, Alkylating; Ant | 2011 |
Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.
Topics: Acyclovir; Adenoviridae; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents, Alkylating; Ant | 2011 |
A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.
Topics: Adolescent; Antineoplastic Agents; Brain Stem Neoplasms; Child; Child, Preschool; Dacarbazine; DNA M | 2012 |
A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.
Topics: Adolescent; Antineoplastic Agents; Brain Stem Neoplasms; Child; Child, Preschool; Dacarbazine; DNA M | 2012 |
A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.
Topics: Adolescent; Antineoplastic Agents; Brain Stem Neoplasms; Child; Child, Preschool; Dacarbazine; DNA M | 2012 |
A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.
Topics: Adolescent; Antineoplastic Agents; Brain Stem Neoplasms; Child; Child, Preschool; Dacarbazine; DNA M | 2012 |
Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
[Safety and efficacy of three-dimensional conformal radiotherapy combined with temozolomide in treatment of diffuse brainstem gliomas].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Injuries; Brain Stem Neoplasms; Chemorad | 2011 |
[Safety and efficacy of three-dimensional conformal radiotherapy combined with temozolomide in treatment of diffuse brainstem gliomas].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Injuries; Brain Stem Neoplasms; Chemorad | 2011 |
[Safety and efficacy of three-dimensional conformal radiotherapy combined with temozolomide in treatment of diffuse brainstem gliomas].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Injuries; Brain Stem Neoplasms; Chemorad | 2011 |
[Safety and efficacy of three-dimensional conformal radiotherapy combined with temozolomide in treatment of diffuse brainstem gliomas].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Injuries; Brain Stem Neoplasms; Chemorad | 2011 |
[Comparison of two regimens of postoperative concurrent chemoradiotherapy in adult patients with grade III-IV cerebral gliomas].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherap | 2012 |
[Comparison of two regimens of postoperative concurrent chemoradiotherapy in adult patients with grade III-IV cerebral gliomas].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherap | 2012 |
[Comparison of two regimens of postoperative concurrent chemoradiotherapy in adult patients with grade III-IV cerebral gliomas].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherap | 2012 |
[Comparison of two regimens of postoperative concurrent chemoradiotherapy in adult patients with grade III-IV cerebral gliomas].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherap | 2012 |
Quality assurance in the EORTC 22033-26033/CE5 phase III randomized trial for low grade glioma: the digital individual case review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Electron | 2012 |
Quality assurance in the EORTC 22033-26033/CE5 phase III randomized trial for low grade glioma: the digital individual case review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Electron | 2012 |
Quality assurance in the EORTC 22033-26033/CE5 phase III randomized trial for low grade glioma: the digital individual case review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Electron | 2012 |
Quality assurance in the EORTC 22033-26033/CE5 phase III randomized trial for low grade glioma: the digital individual case review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Electron | 2012 |
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell | 2013 |
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell | 2013 |
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell | 2013 |
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell | 2013 |
Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Ar | 2012 |
Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Ar | 2012 |
Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Ar | 2012 |
Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Ar | 2012 |
Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Artifacts; Brain Neoplasms; Chemoradioth | 2012 |
Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Artifacts; Brain Neoplasms; Chemoradioth | 2012 |
Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Artifacts; Brain Neoplasms; Chemoradioth | 2012 |
Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Artifacts; Brain Neoplasms; Chemoradioth | 2012 |
Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2012 |
Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2012 |
Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2012 |
Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2012 |
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dos | 2013 |
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dos | 2013 |
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dos | 2013 |
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dos | 2013 |
A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2013 |
A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2013 |
A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2013 |
A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2013 |
"One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2013 |
"One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2013 |
"One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2013 |
"One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2013 |
Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Chemora | 2014 |
Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Chemora | 2014 |
Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Chemora | 2014 |
Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Chemora | 2014 |
A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Fe | 2002 |
A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Fe | 2002 |
A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Fe | 2002 |
A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Fe | 2002 |
Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Child; Child, Preschool | 2002 |
Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Child; Child, Preschool | 2002 |
Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Child; Child, Preschool | 2002 |
Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Child; Child, Preschool | 2002 |
Phase II trial of temozolomide in patients with progressive low-grade glioma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Combined Modality Therapy; Dacarbazine; | 2003 |
Phase II trial of temozolomide in patients with progressive low-grade glioma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Combined Modality Therapy; Dacarbazine; | 2003 |
Phase II trial of temozolomide in patients with progressive low-grade glioma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Combined Modality Therapy; Dacarbazine; | 2003 |
Phase II trial of temozolomide in patients with progressive low-grade glioma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Combined Modality Therapy; Dacarbazine; | 2003 |
Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2003 |
Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2003 |
Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2003 |
Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2003 |
Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazin | 2003 |
Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazin | 2003 |
Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazin | 2003 |
Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazin | 2003 |
Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astro | 2003 |
Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astro | 2003 |
Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astro | 2003 |
Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astro | 2003 |
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progressio | 2003 |
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progressio | 2003 |
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progressio | 2003 |
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progressio | 2003 |
Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Prog | 2003 |
Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Prog | 2003 |
Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Prog | 2003 |
Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Prog | 2003 |
Temozolomide in the treatment of recurrent malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Dacarba | 2004 |
Temozolomide in the treatment of recurrent malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Dacarba | 2004 |
Temozolomide in the treatment of recurrent malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Dacarba | 2004 |
Temozolomide in the treatment of recurrent malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Dacarba | 2004 |
Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasm | 2004 |
Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasm | 2004 |
Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasm | 2004 |
Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasm | 2004 |
Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Choline; Dacarbazin | 2004 |
Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Choline; Dacarbazin | 2004 |
Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Choline; Dacarbazin | 2004 |
Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Choline; Dacarbazin | 2004 |
Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherap | 2004 |
Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherap | 2004 |
Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherap | 2004 |
Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherap | 2004 |
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2004 |
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2004 |
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2004 |
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2004 |
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Pr | 2004 |
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Pr | 2004 |
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Pr | 2004 |
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Pr | 2004 |
Temozolomide in paediatric high-grade glioma: a key for combination therapy?
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2004 |
Temozolomide in paediatric high-grade glioma: a key for combination therapy?
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2004 |
Temozolomide in paediatric high-grade glioma: a key for combination therapy?
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2004 |
Temozolomide in paediatric high-grade glioma: a key for combination therapy?
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
Temozolomide treatment in glioma--experiences in two university hospitals in Finland.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; | 2004 |
Temozolomide treatment in glioma--experiences in two university hospitals in Finland.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; | 2004 |
Temozolomide treatment in glioma--experiences in two university hospitals in Finland.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; | 2004 |
Temozolomide treatment in glioma--experiences in two university hospitals in Finland.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; | 2004 |
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Camptothe | 2005 |
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Camptothe | 2005 |
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Camptothe | 2005 |
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Camptothe | 2005 |
Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost of Illness; Cost-Benefit Analy | 2005 |
Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost of Illness; Cost-Benefit Analy | 2005 |
Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost of Illness; Cost-Benefit Analy | 2005 |
Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost of Illness; Cost-Benefit Analy | 2005 |
Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cohort Studies; Dacarbazine; Female; Glioma; Humans; | 2005 |
Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cohort Studies; Dacarbazine; Female; Glioma; Humans; | 2005 |
Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cohort Studies; Dacarbazine; Female; Glioma; Humans; | 2005 |
Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cohort Studies; Dacarbazine; Female; Glioma; Humans; | 2005 |
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve | 2005 |
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve | 2005 |
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve | 2005 |
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve | 2005 |
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbaz | 2005 |
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbaz | 2005 |
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbaz | 2005 |
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbaz | 2005 |
Phase I study of temozolomide and lomustine in the treatment of high grade malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2006 |
Phase I study of temozolomide and lomustine in the treatment of high grade malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2006 |
Phase I study of temozolomide and lomustine in the treatment of high grade malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2006 |
Phase I study of temozolomide and lomustine in the treatment of high grade malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2006 |
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease P | 2005 |
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease P | 2005 |
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease P | 2005 |
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease P | 2005 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neopl | 2006 |
Phase II trial of temozolomide in children with recurrent high-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Child; Child, Preschool | 2006 |
Phase II trial of temozolomide in children with recurrent high-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Child; Child, Preschool | 2006 |
Phase II trial of temozolomide in children with recurrent high-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Child; Child, Preschool | 2006 |
Phase II trial of temozolomide in children with recurrent high-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Child; Child, Preschool | 2006 |
Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administrat | 2005 |
Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administrat | 2005 |
Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administrat | 2005 |
Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administrat | 2005 |
Phase II study of two-weekly temozolomide in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dose-Response Relationship, Drug; Drug | 2006 |
Phase II study of two-weekly temozolomide in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dose-Response Relationship, Drug; Drug | 2006 |
Phase II study of two-weekly temozolomide in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dose-Response Relationship, Drug; Drug | 2006 |
Phase II study of two-weekly temozolomide in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dose-Response Relationship, Drug; Drug | 2006 |
Surgery, radiotherapy and temozolomide in treating high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Co | 2006 |
Surgery, radiotherapy and temozolomide in treating high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Co | 2006 |
Surgery, radiotherapy and temozolomide in treating high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Co | 2006 |
Surgery, radiotherapy and temozolomide in treating high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Co | 2006 |
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacar | 2006 |
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacar | 2006 |
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacar | 2006 |
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacar | 2006 |
Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Male; Methionin | 2006 |
Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Male; Methionin | 2006 |
Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Male; Methionin | 2006 |
Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Male; Methionin | 2006 |
Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytochrome P-450 E | 2006 |
Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytochrome P-450 E | 2006 |
Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytochrome P-450 E | 2006 |
Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytochrome P-450 E | 2006 |
Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Austria; Brain Neoplasms; Dacarbazine; F | 2006 |
Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Austria; Brain Neoplasms; Dacarbazine; F | 2006 |
Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Austria; Brain Neoplasms; Dacarbazine; F | 2006 |
Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Austria; Brain Neoplasms; Dacarbazine; F | 2006 |
Temozolomide chemotherapy in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; | 2006 |
Temozolomide chemotherapy in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; | 2006 |
Temozolomide chemotherapy in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; | 2006 |
Temozolomide chemotherapy in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; | 2006 |
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Surv | 2007 |
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Surv | 2007 |
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Surv | 2007 |
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; Humans; Surv | 2007 |
[Temozolomide in the treatment of recurrent malignant glioma].
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; D | 2006 |
[Temozolomide in the treatment of recurrent malignant glioma].
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; D | 2006 |
[Temozolomide in the treatment of recurrent malignant glioma].
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; D | 2006 |
[Temozolomide in the treatment of recurrent malignant glioma].
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; D | 2006 |
MGMT methylation: a marker of response to temozolomide in low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Dis | 2006 |
MGMT methylation: a marker of response to temozolomide in low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Dis | 2006 |
MGMT methylation: a marker of response to temozolomide in low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Dis | 2006 |
MGMT methylation: a marker of response to temozolomide in low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Dis | 2006 |
Estimation of radiobiologic parameters and equivalent radiation dose of cytotoxic chemotherapy in malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Dacarbazine; Glioma; Humans; Mont | 2007 |
Estimation of radiobiologic parameters and equivalent radiation dose of cytotoxic chemotherapy in malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Dacarbazine; Glioma; Humans; Mont | 2007 |
Estimation of radiobiologic parameters and equivalent radiation dose of cytotoxic chemotherapy in malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Dacarbazine; Glioma; Humans; Mont | 2007 |
Estimation of radiobiologic parameters and equivalent radiation dose of cytotoxic chemotherapy in malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Dacarbazine; Glioma; Humans; Mont | 2007 |
Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Fr | 2007 |
Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Fr | 2007 |
Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Fr | 2007 |
Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Fr | 2007 |
Temozolomide in children with progressive low-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2007 |
Temozolomide in children with progressive low-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2007 |
Temozolomide in children with progressive low-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2007 |
Temozolomide in children with progressive low-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2007 |
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Met | 2007 |
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Met | 2007 |
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Met | 2007 |
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Met | 2007 |
Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Anti | 2008 |
Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Anti | 2008 |
Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Anti | 2008 |
Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Anti | 2008 |
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Campt | 2007 |
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Campt | 2007 |
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Campt | 2007 |
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Campt | 2007 |
Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2008 |
Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2008 |
Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2008 |
Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2008 |
Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas.
Topics: Administration, Intranasal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Blood-Brain Ba | 2008 |
Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas.
Topics: Administration, Intranasal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Blood-Brain Ba | 2008 |
Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas.
Topics: Administration, Intranasal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Blood-Brain Ba | 2008 |
Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas.
Topics: Administration, Intranasal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Blood-Brain Ba | 2008 |
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabin | 2007 |
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabin | 2007 |
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabin | 2007 |
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabin | 2007 |
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neop | 2008 |
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neop | 2008 |
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neop | 2008 |
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neop | 2008 |
Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarba | 2008 |
Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarba | 2008 |
Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarba | 2008 |
Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarba | 2008 |
Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Combined Modality Ther | 2008 |
Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Combined Modality Ther | 2008 |
Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Combined Modality Ther | 2008 |
Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Combined Modality Ther | 2008 |
A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2008 |
A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2008 |
A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2008 |
A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2008 |
The Charing Cross Hospital experience with temozolomide in patients with gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 1996 |
The Charing Cross Hospital experience with temozolomide in patients with gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 1996 |
The Charing Cross Hospital experience with temozolomide in patients with gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 1996 |
The Charing Cross Hospital experience with temozolomide in patients with gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 1996 |
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans | 1997 |
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans | 1997 |
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans | 1997 |
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans | 1997 |
Phase I trial of temozolomide using an extended continuous oral schedule.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calibration; | 1998 |
Phase I trial of temozolomide using an extended continuous oral schedule.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calibration; | 1998 |
Phase I trial of temozolomide using an extended continuous oral schedule.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calibration; | 1998 |
Phase I trial of temozolomide using an extended continuous oral schedule.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calibration; | 1998 |
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barri | 1998 |
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barri | 1998 |
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barri | 1998 |
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barri | 1998 |
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Resp | 1999 |
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Resp | 1999 |
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Resp | 1999 |
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Resp | 1999 |
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Biological Availability; Brain | 1999 |
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Biological Availability; Brain | 1999 |
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Biological Availability; Brain | 1999 |
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Biological Availability; Brain | 1999 |
Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Evaluation Studies as Topic; | 2000 |
Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Evaluation Studies as Topic; | 2000 |
Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Evaluation Studies as Topic; | 2000 |
Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Evaluation Studies as Topic; | 2000 |
Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Male; Middle Ag | 2000 |
Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Male; Middle Ag | 2000 |
Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Male; Middle Ag | 2000 |
Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Male; Middle Ag | 2000 |
Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; D | 2001 |
Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; D | 2001 |
Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; D | 2001 |
Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; D | 2001 |
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2002 |
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2002 |
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2002 |
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2002 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
1053 other studies available for temozolomide and Glioma
| Article | Year |
|---|---|
Selective cytotoxicity and apoptosis induction in glioma cell lines by 5-oxygenated-6,7-methylenedioxycoumarins from Pterocaulon species.
Topics: Animals; Antineoplastic Agents; Apoptosis; Asteraceae; Benzodioxoles; Cell Line, Tumor; Cell Surviva | 2012 |
Selective cytotoxicity and apoptosis induction in glioma cell lines by 5-oxygenated-6,7-methylenedioxycoumarins from Pterocaulon species.
Topics: Animals; Antineoplastic Agents; Apoptosis; Asteraceae; Benzodioxoles; Cell Line, Tumor; Cell Surviva | 2012 |
Selective cytotoxicity and apoptosis induction in glioma cell lines by 5-oxygenated-6,7-methylenedioxycoumarins from Pterocaulon species.
Topics: Animals; Antineoplastic Agents; Apoptosis; Asteraceae; Benzodioxoles; Cell Line, Tumor; Cell Surviva | 2012 |
Selective cytotoxicity and apoptosis induction in glioma cell lines by 5-oxygenated-6,7-methylenedioxycoumarins from Pterocaulon species.
Topics: Animals; Antineoplastic Agents; Apoptosis; Asteraceae; Benzodioxoles; Cell Line, Tumor; Cell Surviva | 2012 |
Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Crystallography, X-Ray; Drug S | 2014 |
Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Crystallography, X-Ray; Drug S | 2014 |
Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Crystallography, X-Ray; Drug S | 2014 |
Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Crystallography, X-Ray; Drug S | 2014 |
Bioactive triterpenoid saponins and phenolic compounds against glioma cells.
Topics: Animals; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, A | 2014 |
Bioactive triterpenoid saponins and phenolic compounds against glioma cells.
Topics: Animals; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, A | 2014 |
Bioactive triterpenoid saponins and phenolic compounds against glioma cells.
Topics: Animals; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, A | 2014 |
Bioactive triterpenoid saponins and phenolic compounds against glioma cells.
Topics: Animals; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, A | 2014 |
Thiazolidin-4-ones from 4-(methylthio)benzaldehyde and 4-(methylsulfonyl)benzaldehyde: Synthesis, antiglioma activity and cytotoxicity.
Topics: Astrocytes; Benzaldehydes; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Glioma | 2016 |
Thiazolidin-4-ones from 4-(methylthio)benzaldehyde and 4-(methylsulfonyl)benzaldehyde: Synthesis, antiglioma activity and cytotoxicity.
Topics: Astrocytes; Benzaldehydes; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Glioma | 2016 |
Thiazolidin-4-ones from 4-(methylthio)benzaldehyde and 4-(methylsulfonyl)benzaldehyde: Synthesis, antiglioma activity and cytotoxicity.
Topics: Astrocytes; Benzaldehydes; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Glioma | 2016 |
Thiazolidin-4-ones from 4-(methylthio)benzaldehyde and 4-(methylsulfonyl)benzaldehyde: Synthesis, antiglioma activity and cytotoxicity.
Topics: Astrocytes; Benzaldehydes; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Glioma | 2016 |
Targeting gliomas with triazene-based hybrids: Structure-activity relationship, mechanistic study and stability.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Movement; Cell Proliferation; Cell Survival; Dose-Respo | 2019 |
Targeting gliomas with triazene-based hybrids: Structure-activity relationship, mechanistic study and stability.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Movement; Cell Proliferation; Cell Survival; Dose-Respo | 2019 |
Targeting gliomas with triazene-based hybrids: Structure-activity relationship, mechanistic study and stability.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Movement; Cell Proliferation; Cell Survival; Dose-Respo | 2019 |
Targeting gliomas with triazene-based hybrids: Structure-activity relationship, mechanistic study and stability.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Movement; Cell Proliferation; Cell Survival; Dose-Respo | 2019 |
Efficient identification of novel anti-glioma lead compounds by machine learning models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Female; Glioma; Humans; Machine Learn | 2020 |
Efficient identification of novel anti-glioma lead compounds by machine learning models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Female; Glioma; Humans; Machine Learn | 2020 |
Efficient identification of novel anti-glioma lead compounds by machine learning models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Female; Glioma; Humans; Machine Learn | 2020 |
Efficient identification of novel anti-glioma lead compounds by machine learning models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Female; Glioma; Humans; Machine Learn | 2020 |
The 3-D conformational shape of N-naphthyl-cyclopenta[d]pyrimidines affects their potency as microtubule targeting agents and their antitumor activity.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cyclopentanes; Dose-Response Re | 2021 |
The 3-D conformational shape of N-naphthyl-cyclopenta[d]pyrimidines affects their potency as microtubule targeting agents and their antitumor activity.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cyclopentanes; Dose-Response Re | 2021 |
The 3-D conformational shape of N-naphthyl-cyclopenta[d]pyrimidines affects their potency as microtubule targeting agents and their antitumor activity.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cyclopentanes; Dose-Response Re | 2021 |
The 3-D conformational shape of N-naphthyl-cyclopenta[d]pyrimidines affects their potency as microtubule targeting agents and their antitumor activity.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cyclopentanes; Dose-Response Re | 2021 |
AEG-1 silencing attenuates M2-polarization of glioma-associated microglia/macrophages and sensitizes glioma cells to temozolomide.
Topics: Astrocytes; Brain Neoplasms; Cell Survival; Computational Biology; Cytokines; DNA Damage; Gene Expre | 2021 |
AEG-1 silencing attenuates M2-polarization of glioma-associated microglia/macrophages and sensitizes glioma cells to temozolomide.
Topics: Astrocytes; Brain Neoplasms; Cell Survival; Computational Biology; Cytokines; DNA Damage; Gene Expre | 2021 |
AEG-1 silencing attenuates M2-polarization of glioma-associated microglia/macrophages and sensitizes glioma cells to temozolomide.
Topics: Astrocytes; Brain Neoplasms; Cell Survival; Computational Biology; Cytokines; DNA Damage; Gene Expre | 2021 |
AEG-1 silencing attenuates M2-polarization of glioma-associated microglia/macrophages and sensitizes glioma cells to temozolomide.
Topics: Astrocytes; Brain Neoplasms; Cell Survival; Computational Biology; Cytokines; DNA Damage; Gene Expre | 2021 |
Imipramine impedes glioma progression by inhibiting YAP as a Hippo pathway independent manner and synergizes with temozolomide.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease M | 2021 |
Imipramine impedes glioma progression by inhibiting YAP as a Hippo pathway independent manner and synergizes with temozolomide.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease M | 2021 |
Imipramine impedes glioma progression by inhibiting YAP as a Hippo pathway independent manner and synergizes with temozolomide.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease M | 2021 |
Imipramine impedes glioma progression by inhibiting YAP as a Hippo pathway independent manner and synergizes with temozolomide.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease M | 2021 |
Temozolomide is additive with cytotoxic effect of irradiation in canine glioma cell lines.
Topics: Animals; Brain Neoplasms; Cell Line; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; D | 2021 |
Temozolomide is additive with cytotoxic effect of irradiation in canine glioma cell lines.
Topics: Animals; Brain Neoplasms; Cell Line; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; D | 2021 |
Temozolomide is additive with cytotoxic effect of irradiation in canine glioma cell lines.
Topics: Animals; Brain Neoplasms; Cell Line; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; D | 2021 |
Temozolomide is additive with cytotoxic effect of irradiation in canine glioma cell lines.
Topics: Animals; Brain Neoplasms; Cell Line; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; D | 2021 |
A positive feedback loop of lncRNA-RMRP/ZNRF3 axis and Wnt/β-catenin signaling regulates the progression and temozolomide resistance in glioma.
Topics: Adult; Animals; Apoptosis; beta Catenin; Brain; Cell Line, Tumor; Disease Progression; Down-Regulati | 2021 |
A positive feedback loop of lncRNA-RMRP/ZNRF3 axis and Wnt/β-catenin signaling regulates the progression and temozolomide resistance in glioma.
Topics: Adult; Animals; Apoptosis; beta Catenin; Brain; Cell Line, Tumor; Disease Progression; Down-Regulati | 2021 |
A positive feedback loop of lncRNA-RMRP/ZNRF3 axis and Wnt/β-catenin signaling regulates the progression and temozolomide resistance in glioma.
Topics: Adult; Animals; Apoptosis; beta Catenin; Brain; Cell Line, Tumor; Disease Progression; Down-Regulati | 2021 |
A positive feedback loop of lncRNA-RMRP/ZNRF3 axis and Wnt/β-catenin signaling regulates the progression and temozolomide resistance in glioma.
Topics: Adult; Animals; Apoptosis; beta Catenin; Brain; Cell Line, Tumor; Disease Progression; Down-Regulati | 2021 |
Accurately Controlled Delivery of Temozolomide by Biocompatible UiO-66-NH
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; | 2021 |
Accurately Controlled Delivery of Temozolomide by Biocompatible UiO-66-NH
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; | 2021 |
Accurately Controlled Delivery of Temozolomide by Biocompatible UiO-66-NH
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; | 2021 |
Accurately Controlled Delivery of Temozolomide by Biocompatible UiO-66-NH
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; | 2021 |
A natural protein based platform for the delivery of Temozolomide acid to glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Products; Cell Line, Tumor; Cell Survival; Dr | 2021 |
A natural protein based platform for the delivery of Temozolomide acid to glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Products; Cell Line, Tumor; Cell Survival; Dr | 2021 |
A natural protein based platform for the delivery of Temozolomide acid to glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Products; Cell Line, Tumor; Cell Survival; Dr | 2021 |
A natural protein based platform for the delivery of Temozolomide acid to glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Products; Cell Line, Tumor; Cell Survival; Dr | 2021 |
A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas.
Topics: Animals; Brain Neoplasms; Glioma; Humans; Immunotherapy; Mice, Nude; O(6)-Methylguanine-DNA Methyltr | 2021 |
A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas.
Topics: Animals; Brain Neoplasms; Glioma; Humans; Immunotherapy; Mice, Nude; O(6)-Methylguanine-DNA Methyltr | 2021 |
A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas.
Topics: Animals; Brain Neoplasms; Glioma; Humans; Immunotherapy; Mice, Nude; O(6)-Methylguanine-DNA Methyltr | 2021 |
A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas.
Topics: Animals; Brain Neoplasms; Glioma; Humans; Immunotherapy; Mice, Nude; O(6)-Methylguanine-DNA Methyltr | 2021 |
Curcumol inhibits malignant biological behaviors and TMZ-resistance in glioma cells by inhibiting long noncoding RNA FOXD2-As1-promoted EZH2 activation.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; | 2021 |
Curcumol inhibits malignant biological behaviors and TMZ-resistance in glioma cells by inhibiting long noncoding RNA FOXD2-As1-promoted EZH2 activation.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; | 2021 |
Curcumol inhibits malignant biological behaviors and TMZ-resistance in glioma cells by inhibiting long noncoding RNA FOXD2-As1-promoted EZH2 activation.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; | 2021 |
Curcumol inhibits malignant biological behaviors and TMZ-resistance in glioma cells by inhibiting long noncoding RNA FOXD2-As1-promoted EZH2 activation.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; | 2021 |
Human Glioma Cells Therapy Using ATRA-Induced Differentiation Method to Promote the Inhibitive Effect of TMZ and CCDP.
Topics: Cell Differentiation; Cell Line, Tumor; Glioma; Humans; Neoplastic Stem Cells; Temozolomide; Tretino | 2021 |
Human Glioma Cells Therapy Using ATRA-Induced Differentiation Method to Promote the Inhibitive Effect of TMZ and CCDP.
Topics: Cell Differentiation; Cell Line, Tumor; Glioma; Humans; Neoplastic Stem Cells; Temozolomide; Tretino | 2021 |
Human Glioma Cells Therapy Using ATRA-Induced Differentiation Method to Promote the Inhibitive Effect of TMZ and CCDP.
Topics: Cell Differentiation; Cell Line, Tumor; Glioma; Humans; Neoplastic Stem Cells; Temozolomide; Tretino | 2021 |
Human Glioma Cells Therapy Using ATRA-Induced Differentiation Method to Promote the Inhibitive Effect of TMZ and CCDP.
Topics: Cell Differentiation; Cell Line, Tumor; Glioma; Humans; Neoplastic Stem Cells; Temozolomide; Tretino | 2021 |
Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carbamates; Cell Line, Tumor; Cell Pr | 2021 |
Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carbamates; Cell Line, Tumor; Cell Pr | 2021 |
Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carbamates; Cell Line, Tumor; Cell Pr | 2021 |
Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carbamates; Cell Line, Tumor; Cell Pr | 2021 |
FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide.
Topics: Brain Neoplasms; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Prognosis; RNA, Messenger; Sodi | 2021 |
FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide.
Topics: Brain Neoplasms; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Prognosis; RNA, Messenger; Sodi | 2021 |
FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide.
Topics: Brain Neoplasms; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Prognosis; RNA, Messenger; Sodi | 2021 |
FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide.
Topics: Brain Neoplasms; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Prognosis; RNA, Messenger; Sodi | 2021 |
Exosome-Mediated Transfer of circ-
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Exosomes; Gene Expression | 2023 |
Exosome-Mediated Transfer of circ-
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Exosomes; Gene Expression | 2023 |
Exosome-Mediated Transfer of circ-
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Exosomes; Gene Expression | 2023 |
Exosome-Mediated Transfer of circ-
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Exosomes; Gene Expression | 2023 |
A petroclival glioma mimicking trigeminal schwannoma: A case report.
Topics: Antineoplastic Agents, Alkylating; Cranial Nerve Neoplasms; Female; Glioma; Humans; Magnetic Resonan | 2021 |
A petroclival glioma mimicking trigeminal schwannoma: A case report.
Topics: Antineoplastic Agents, Alkylating; Cranial Nerve Neoplasms; Female; Glioma; Humans; Magnetic Resonan | 2021 |
A petroclival glioma mimicking trigeminal schwannoma: A case report.
Topics: Antineoplastic Agents, Alkylating; Cranial Nerve Neoplasms; Female; Glioma; Humans; Magnetic Resonan | 2021 |
A petroclival glioma mimicking trigeminal schwannoma: A case report.
Topics: Antineoplastic Agents, Alkylating; Cranial Nerve Neoplasms; Female; Glioma; Humans; Magnetic Resonan | 2021 |
Combined intracranial Acriflavine, temozolomide and radiation extends survival in a rat glioma model.
Topics: Absorbable Implants; Acriflavine; Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Surviv | 2022 |
Combined intracranial Acriflavine, temozolomide and radiation extends survival in a rat glioma model.
Topics: Absorbable Implants; Acriflavine; Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Surviv | 2022 |
Combined intracranial Acriflavine, temozolomide and radiation extends survival in a rat glioma model.
Topics: Absorbable Implants; Acriflavine; Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Surviv | 2022 |
Combined intracranial Acriflavine, temozolomide and radiation extends survival in a rat glioma model.
Topics: Absorbable Implants; Acriflavine; Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Surviv | 2022 |
Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models.
Topics: Animals; Brain Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Clinical Trials, Phase I as | 2022 |
Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models.
Topics: Animals; Brain Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Clinical Trials, Phase I as | 2022 |
Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models.
Topics: Animals; Brain Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Clinical Trials, Phase I as | 2022 |
Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models.
Topics: Animals; Brain Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Clinical Trials, Phase I as | 2022 |
Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study.
Topics: Adult; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; Myeloid Cel | 2022 |
Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study.
Topics: Adult; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; Myeloid Cel | 2022 |
Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study.
Topics: Adult; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; Myeloid Cel | 2022 |
Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study.
Topics: Adult; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; Myeloid Cel | 2022 |
The Longevity-Associated Variant of BPIFB4 Reduces Senescence in Glioma Cells and in Patients' Lymphocytes Favoring Chemotherapy Efficacy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cellular Senescence; Cytokines; Glioma; Humans; Intercellul | 2022 |
The Longevity-Associated Variant of BPIFB4 Reduces Senescence in Glioma Cells and in Patients' Lymphocytes Favoring Chemotherapy Efficacy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cellular Senescence; Cytokines; Glioma; Humans; Intercellul | 2022 |
The Longevity-Associated Variant of BPIFB4 Reduces Senescence in Glioma Cells and in Patients' Lymphocytes Favoring Chemotherapy Efficacy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cellular Senescence; Cytokines; Glioma; Humans; Intercellul | 2022 |
The Longevity-Associated Variant of BPIFB4 Reduces Senescence in Glioma Cells and in Patients' Lymphocytes Favoring Chemotherapy Efficacy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cellular Senescence; Cytokines; Glioma; Humans; Intercellul | 2022 |
Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Cross-Sectional Studies; Female; Glioma; Humans; Male; Mi | 2022 |
Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Cross-Sectional Studies; Female; Glioma; Humans; Male; Mi | 2022 |
Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Cross-Sectional Studies; Female; Glioma; Humans; Male; Mi | 2022 |
Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Cross-Sectional Studies; Female; Glioma; Humans; Male; Mi | 2022 |
Overexpression of lncRNA IRAIN restrains the progression and Temozolomide resistance of glioma via repressing IGF-1R-PI3K-NF-κB signaling pathway.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glioma; Hum | 2022 |
Overexpression of lncRNA IRAIN restrains the progression and Temozolomide resistance of glioma via repressing IGF-1R-PI3K-NF-κB signaling pathway.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glioma; Hum | 2022 |
Overexpression of lncRNA IRAIN restrains the progression and Temozolomide resistance of glioma via repressing IGF-1R-PI3K-NF-κB signaling pathway.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glioma; Hum | 2022 |
Overexpression of lncRNA IRAIN restrains the progression and Temozolomide resistance of glioma via repressing IGF-1R-PI3K-NF-κB signaling pathway.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glioma; Hum | 2022 |
Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy.
Topics: Animals; Antineoplastic Agents; Benzamides; Brain Neoplasms; Cell Line, Tumor; DNA Repair; Glioblast | 2022 |
Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy.
Topics: Animals; Antineoplastic Agents; Benzamides; Brain Neoplasms; Cell Line, Tumor; DNA Repair; Glioblast | 2022 |
Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy.
Topics: Animals; Antineoplastic Agents; Benzamides; Brain Neoplasms; Cell Line, Tumor; DNA Repair; Glioblast | 2022 |
Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy.
Topics: Animals; Antineoplastic Agents; Benzamides; Brain Neoplasms; Cell Line, Tumor; DNA Repair; Glioblast | 2022 |
Acquired temozolomide resistance in MGMT
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; D | 2022 |
Acquired temozolomide resistance in MGMT
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; D | 2022 |
Acquired temozolomide resistance in MGMT
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; D | 2022 |
Acquired temozolomide resistance in MGMT
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; D | 2022 |
HSP90-CDC37 functions as a chaperone for the oncogenic FGFR3-TACC3 fusion.
Topics: Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Chaperonins; Glioblastoma; Glioma; HSP90 Heat | 2022 |
HSP90-CDC37 functions as a chaperone for the oncogenic FGFR3-TACC3 fusion.
Topics: Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Chaperonins; Glioblastoma; Glioma; HSP90 Heat | 2022 |
HSP90-CDC37 functions as a chaperone for the oncogenic FGFR3-TACC3 fusion.
Topics: Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Chaperonins; Glioblastoma; Glioma; HSP90 Heat | 2022 |
HSP90-CDC37 functions as a chaperone for the oncogenic FGFR3-TACC3 fusion.
Topics: Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Chaperonins; Glioblastoma; Glioma; HSP90 Heat | 2022 |
CCL2 activates AKT signaling to promote glycolysis and chemoresistance in glioma cells.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Chemokine CCL2; Drug Resistance, Neoplasm; Glioma; Gly | 2022 |
CCL2 activates AKT signaling to promote glycolysis and chemoresistance in glioma cells.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Chemokine CCL2; Drug Resistance, Neoplasm; Glioma; Gly | 2022 |
CCL2 activates AKT signaling to promote glycolysis and chemoresistance in glioma cells.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Chemokine CCL2; Drug Resistance, Neoplasm; Glioma; Gly | 2022 |
CCL2 activates AKT signaling to promote glycolysis and chemoresistance in glioma cells.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Chemokine CCL2; Drug Resistance, Neoplasm; Glioma; Gly | 2022 |
Tumor treating fields therapy is feasible and safe in a 3-year-old patient with diffuse midline glioma H3K27M - a case report.
Topics: Adult; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Electric Stimulation The | 2022 |
Tumor treating fields therapy is feasible and safe in a 3-year-old patient with diffuse midline glioma H3K27M - a case report.
Topics: Adult; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Electric Stimulation The | 2022 |
Tumor treating fields therapy is feasible and safe in a 3-year-old patient with diffuse midline glioma H3K27M - a case report.
Topics: Adult; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Electric Stimulation The | 2022 |
Tumor treating fields therapy is feasible and safe in a 3-year-old patient with diffuse midline glioma H3K27M - a case report.
Topics: Adult; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Electric Stimulation The | 2022 |
Hsa_circ_0072309 enhances autophagy and TMZ sensitivity in glioblastoma.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulat | 2022 |
Hsa_circ_0072309 enhances autophagy and TMZ sensitivity in glioblastoma.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulat | 2022 |
Hsa_circ_0072309 enhances autophagy and TMZ sensitivity in glioblastoma.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulat | 2022 |
Hsa_circ_0072309 enhances autophagy and TMZ sensitivity in glioblastoma.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulat | 2022 |
CRB2 enhances malignancy of glioblastoma via activation of the NF-κB pathway.
Topics: Brain Neoplasms; Carrier Proteins; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Gliobla | 2022 |
CRB2 enhances malignancy of glioblastoma via activation of the NF-κB pathway.
Topics: Brain Neoplasms; Carrier Proteins; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Gliobla | 2022 |
CRB2 enhances malignancy of glioblastoma via activation of the NF-κB pathway.
Topics: Brain Neoplasms; Carrier Proteins; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Gliobla | 2022 |
CRB2 enhances malignancy of glioblastoma via activation of the NF-κB pathway.
Topics: Brain Neoplasms; Carrier Proteins; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Gliobla | 2022 |
LncRNA UCA1/miR-182-5p/MGMT axis modulates glioma cell sensitivity to temozolomide through MGMT-related DNA damage pathways.
Topics: Animals; Carcinoma, Transitional Cell; Cell Line, Tumor; DNA; DNA Damage; DNA Modification Methylase | 2022 |
LncRNA UCA1/miR-182-5p/MGMT axis modulates glioma cell sensitivity to temozolomide through MGMT-related DNA damage pathways.
Topics: Animals; Carcinoma, Transitional Cell; Cell Line, Tumor; DNA; DNA Damage; DNA Modification Methylase | 2022 |
LncRNA UCA1/miR-182-5p/MGMT axis modulates glioma cell sensitivity to temozolomide through MGMT-related DNA damage pathways.
Topics: Animals; Carcinoma, Transitional Cell; Cell Line, Tumor; DNA; DNA Damage; DNA Modification Methylase | 2022 |
LncRNA UCA1/miR-182-5p/MGMT axis modulates glioma cell sensitivity to temozolomide through MGMT-related DNA damage pathways.
Topics: Animals; Carcinoma, Transitional Cell; Cell Line, Tumor; DNA; DNA Damage; DNA Modification Methylase | 2022 |
Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Glioma; Humans; Mice; Mitochondri | 2022 |
Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Glioma; Humans; Mice; Mitochondri | 2022 |
Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Glioma; Humans; Mice; Mitochondri | 2022 |
Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Glioma; Humans; Mice; Mitochondri | 2022 |
The RNA-binding protein fragile-X mental retardation autosomal 1 (FXR1) modulates glioma cells sensitivity to temozolomide by regulating ferroptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2022 |
The RNA-binding protein fragile-X mental retardation autosomal 1 (FXR1) modulates glioma cells sensitivity to temozolomide by regulating ferroptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2022 |
The RNA-binding protein fragile-X mental retardation autosomal 1 (FXR1) modulates glioma cells sensitivity to temozolomide by regulating ferroptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2022 |
The RNA-binding protein fragile-X mental retardation autosomal 1 (FXR1) modulates glioma cells sensitivity to temozolomide by regulating ferroptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2022 |
Poly-guanidine shows high cytotoxicity in glioma cell cultures and glioma stem cells.
Topics: Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; | 2022 |
Poly-guanidine shows high cytotoxicity in glioma cell cultures and glioma stem cells.
Topics: Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; | 2022 |
Poly-guanidine shows high cytotoxicity in glioma cell cultures and glioma stem cells.
Topics: Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; | 2022 |
Poly-guanidine shows high cytotoxicity in glioma cell cultures and glioma stem cells.
Topics: Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; | 2022 |
Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Glioma; Humans; Male; Retrospective Stud | 2022 |
Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Glioma; Humans; Male; Retrospective Stud | 2022 |
Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Glioma; Humans; Male; Retrospective Stud | 2022 |
Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Glioma; Humans; Male; Retrospective Stud | 2022 |
Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain.
Topics: Animals; Apoferritins; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Ferroptosis; Gl | 2022 |
Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain.
Topics: Animals; Apoferritins; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Ferroptosis; Gl | 2022 |
Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain.
Topics: Animals; Apoferritins; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Ferroptosis; Gl | 2022 |
Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain.
Topics: Animals; Apoferritins; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Ferroptosis; Gl | 2022 |
Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA-Binding Proteins; Drug Res | 2022 |
Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA-Binding Proteins; Drug Res | 2022 |
Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA-Binding Proteins; Drug Res | 2022 |
Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA-Binding Proteins; Drug Res | 2022 |
PSMG3-AS1 enhances glioma resistance to temozolomide via stabilizing c-Myc in the nucleus.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resis | 2022 |
PSMG3-AS1 enhances glioma resistance to temozolomide via stabilizing c-Myc in the nucleus.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resis | 2022 |
PSMG3-AS1 enhances glioma resistance to temozolomide via stabilizing c-Myc in the nucleus.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resis | 2022 |
PSMG3-AS1 enhances glioma resistance to temozolomide via stabilizing c-Myc in the nucleus.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resis | 2022 |
LINC01564 Promotes the TMZ Resistance of Glioma Cells by Upregulating NFE2L2 Expression to Inhibit Ferroptosis.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm | 2022 |
LINC01564 Promotes the TMZ Resistance of Glioma Cells by Upregulating NFE2L2 Expression to Inhibit Ferroptosis.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm | 2022 |
LINC01564 Promotes the TMZ Resistance of Glioma Cells by Upregulating NFE2L2 Expression to Inhibit Ferroptosis.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm | 2022 |
LINC01564 Promotes the TMZ Resistance of Glioma Cells by Upregulating NFE2L2 Expression to Inhibit Ferroptosis.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm | 2022 |
Cost Effectiveness of
Topics: Brain Neoplasms; Cost-Benefit Analysis; Glioma; Humans; Magnetic Resonance Imaging; Positron-Emissio | 2022 |
Cost Effectiveness of
Topics: Brain Neoplasms; Cost-Benefit Analysis; Glioma; Humans; Magnetic Resonance Imaging; Positron-Emissio | 2022 |
Cost Effectiveness of
Topics: Brain Neoplasms; Cost-Benefit Analysis; Glioma; Humans; Magnetic Resonance Imaging; Positron-Emissio | 2022 |
Cost Effectiveness of
Topics: Brain Neoplasms; Cost-Benefit Analysis; Glioma; Humans; Magnetic Resonance Imaging; Positron-Emissio | 2022 |
PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisotopes; Chemotherapy, Adjuvant; Di | 2022 |
PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisotopes; Chemotherapy, Adjuvant; Di | 2022 |
PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisotopes; Chemotherapy, Adjuvant; Di | 2022 |
PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisotopes; Chemotherapy, Adjuvant; Di | 2022 |
Long non-coding RNA ATXN8OS promotes ferroptosis and inhibits the temozolomide-resistance of gliomas through the ADAR/GLS2 pathway.
Topics: Adenosine Deaminase; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Ferroptosis; Glioma; | 2022 |
Long non-coding RNA ATXN8OS promotes ferroptosis and inhibits the temozolomide-resistance of gliomas through the ADAR/GLS2 pathway.
Topics: Adenosine Deaminase; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Ferroptosis; Glioma; | 2022 |
Long non-coding RNA ATXN8OS promotes ferroptosis and inhibits the temozolomide-resistance of gliomas through the ADAR/GLS2 pathway.
Topics: Adenosine Deaminase; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Ferroptosis; Glioma; | 2022 |
Long non-coding RNA ATXN8OS promotes ferroptosis and inhibits the temozolomide-resistance of gliomas through the ADAR/GLS2 pathway.
Topics: Adenosine Deaminase; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Ferroptosis; Glioma; | 2022 |
Tryptophan hydroxylase 1 drives glioma progression by modulating the serotonin/L1CAM/NF-κB signaling pathway.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glioma; Humans; Mice; Neural Cell Adhesion Molecule L1; | 2022 |
Tryptophan hydroxylase 1 drives glioma progression by modulating the serotonin/L1CAM/NF-κB signaling pathway.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glioma; Humans; Mice; Neural Cell Adhesion Molecule L1; | 2022 |
Tryptophan hydroxylase 1 drives glioma progression by modulating the serotonin/L1CAM/NF-κB signaling pathway.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glioma; Humans; Mice; Neural Cell Adhesion Molecule L1; | 2022 |
Tryptophan hydroxylase 1 drives glioma progression by modulating the serotonin/L1CAM/NF-κB signaling pathway.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glioma; Humans; Mice; Neural Cell Adhesion Molecule L1; | 2022 |
Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Female; Glioma; Humans; Male; | 2022 |
Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Female; Glioma; Humans; Male; | 2022 |
Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Female; Glioma; Humans; Male; | 2022 |
Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Female; Glioma; Humans; Male; | 2022 |
Tumor-derived exosomes reversing TMZ resistance by synergistic drug delivery for glioma-targeting treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Exo | 2022 |
Tumor-derived exosomes reversing TMZ resistance by synergistic drug delivery for glioma-targeting treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Exo | 2022 |
Tumor-derived exosomes reversing TMZ resistance by synergistic drug delivery for glioma-targeting treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Exo | 2022 |
Tumor-derived exosomes reversing TMZ resistance by synergistic drug delivery for glioma-targeting treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Exo | 2022 |
Mannose inhibits proliferation and promotes apoptosis to enhance sensitivity of glioma cells to temozolomide through Wnt/β-catenin signaling pathway.
Topics: Apoptosis; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neo | 2022 |
Mannose inhibits proliferation and promotes apoptosis to enhance sensitivity of glioma cells to temozolomide through Wnt/β-catenin signaling pathway.
Topics: Apoptosis; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neo | 2022 |
Mannose inhibits proliferation and promotes apoptosis to enhance sensitivity of glioma cells to temozolomide through Wnt/β-catenin signaling pathway.
Topics: Apoptosis; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neo | 2022 |
Mannose inhibits proliferation and promotes apoptosis to enhance sensitivity of glioma cells to temozolomide through Wnt/β-catenin signaling pathway.
Topics: Apoptosis; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neo | 2022 |
Salvianolic acid A (Sal A) suppresses malignant progression of glioma and enhances temozolomide (TMZ) sensitivity via repressing transgelin-2 (TAGLN2) mediated phosphatidylinositol-3-kinase (PI3K) / protein kinase B (Akt) pathway.
Topics: Brain Neoplasms; Caffeic Acids; Cell Line, Tumor; Glioma; Humans; Lactates; Microfilament Proteins; | 2022 |
Salvianolic acid A (Sal A) suppresses malignant progression of glioma and enhances temozolomide (TMZ) sensitivity via repressing transgelin-2 (TAGLN2) mediated phosphatidylinositol-3-kinase (PI3K) / protein kinase B (Akt) pathway.
Topics: Brain Neoplasms; Caffeic Acids; Cell Line, Tumor; Glioma; Humans; Lactates; Microfilament Proteins; | 2022 |
Salvianolic acid A (Sal A) suppresses malignant progression of glioma and enhances temozolomide (TMZ) sensitivity via repressing transgelin-2 (TAGLN2) mediated phosphatidylinositol-3-kinase (PI3K) / protein kinase B (Akt) pathway.
Topics: Brain Neoplasms; Caffeic Acids; Cell Line, Tumor; Glioma; Humans; Lactates; Microfilament Proteins; | 2022 |
Salvianolic acid A (Sal A) suppresses malignant progression of glioma and enhances temozolomide (TMZ) sensitivity via repressing transgelin-2 (TAGLN2) mediated phosphatidylinositol-3-kinase (PI3K) / protein kinase B (Akt) pathway.
Topics: Brain Neoplasms; Caffeic Acids; Cell Line, Tumor; Glioma; Humans; Lactates; Microfilament Proteins; | 2022 |
Integration of synthetic and natural derivatives revives the therapeutic potential of temozolomide against glioma- an in vitro and in vivo perspective.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioma; HE | 2022 |
Integration of synthetic and natural derivatives revives the therapeutic potential of temozolomide against glioma- an in vitro and in vivo perspective.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioma; HE | 2022 |
Integration of synthetic and natural derivatives revives the therapeutic potential of temozolomide against glioma- an in vitro and in vivo perspective.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioma; HE | 2022 |
Integration of synthetic and natural derivatives revives the therapeutic potential of temozolomide against glioma- an in vitro and in vivo perspective.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioma; HE | 2022 |
Cyanidin-3-O-glucoside inhibits the β-catenin/MGMT pathway by upregulating miR-214-5p to reverse chemotherapy resistance in glioma cells.
Topics: Anthocyanins; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Cell Line | 2022 |
Cyanidin-3-O-glucoside inhibits the β-catenin/MGMT pathway by upregulating miR-214-5p to reverse chemotherapy resistance in glioma cells.
Topics: Anthocyanins; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Cell Line | 2022 |
Cyanidin-3-O-glucoside inhibits the β-catenin/MGMT pathway by upregulating miR-214-5p to reverse chemotherapy resistance in glioma cells.
Topics: Anthocyanins; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Cell Line | 2022 |
Cyanidin-3-O-glucoside inhibits the β-catenin/MGMT pathway by upregulating miR-214-5p to reverse chemotherapy resistance in glioma cells.
Topics: Anthocyanins; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Cell Line | 2022 |
Transcriptional Patterns of Lower-Grade Glioma Patients with Distinct Ferroptosis Levels, Immunotherapy Response, and Temozolomide Sensitivity.
Topics: Ferroptosis; Glioma; Humans; Immunotherapy; Phosphatidylinositol 3-Kinases; Temozolomide; Tumor Micr | 2022 |
Transcriptional Patterns of Lower-Grade Glioma Patients with Distinct Ferroptosis Levels, Immunotherapy Response, and Temozolomide Sensitivity.
Topics: Ferroptosis; Glioma; Humans; Immunotherapy; Phosphatidylinositol 3-Kinases; Temozolomide; Tumor Micr | 2022 |
Transcriptional Patterns of Lower-Grade Glioma Patients with Distinct Ferroptosis Levels, Immunotherapy Response, and Temozolomide Sensitivity.
Topics: Ferroptosis; Glioma; Humans; Immunotherapy; Phosphatidylinositol 3-Kinases; Temozolomide; Tumor Micr | 2022 |
Transcriptional Patterns of Lower-Grade Glioma Patients with Distinct Ferroptosis Levels, Immunotherapy Response, and Temozolomide Sensitivity.
Topics: Ferroptosis; Glioma; Humans; Immunotherapy; Phosphatidylinositol 3-Kinases; Temozolomide; Tumor Micr | 2022 |
Preliminary Study on Relationship Between Temozolomide Chemotherapy-Resistant Cells and Stem Cells in Gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
Preliminary Study on Relationship Between Temozolomide Chemotherapy-Resistant Cells and Stem Cells in Gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
Preliminary Study on Relationship Between Temozolomide Chemotherapy-Resistant Cells and Stem Cells in Gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
Preliminary Study on Relationship Between Temozolomide Chemotherapy-Resistant Cells and Stem Cells in Gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression.
Topics: Animals; Brain Neoplasms; ErbB Receptors; Glioblastoma; Glioma; Humans; Mice; Sequence Analysis, RNA | 2022 |
Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression.
Topics: Animals; Brain Neoplasms; ErbB Receptors; Glioblastoma; Glioma; Humans; Mice; Sequence Analysis, RNA | 2022 |
Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression.
Topics: Animals; Brain Neoplasms; ErbB Receptors; Glioblastoma; Glioma; Humans; Mice; Sequence Analysis, RNA | 2022 |
Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression.
Topics: Animals; Brain Neoplasms; ErbB Receptors; Glioblastoma; Glioma; Humans; Mice; Sequence Analysis, RNA | 2022 |
lncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PIK3R2-mediated PI3K/AKT pathway in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Re | 2022 |
lncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PIK3R2-mediated PI3K/AKT pathway in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Re | 2022 |
lncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PIK3R2-mediated PI3K/AKT pathway in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Re | 2022 |
lncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PIK3R2-mediated PI3K/AKT pathway in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Re | 2022 |
FOXM1-mediated NUF2 expression confers temozolomide resistance to human glioma cells by regulating autophagy via the PI3K/AKT/mTOR signaling pathway.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Proteins; Cell | 2022 |
FOXM1-mediated NUF2 expression confers temozolomide resistance to human glioma cells by regulating autophagy via the PI3K/AKT/mTOR signaling pathway.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Proteins; Cell | 2022 |
FOXM1-mediated NUF2 expression confers temozolomide resistance to human glioma cells by regulating autophagy via the PI3K/AKT/mTOR signaling pathway.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Proteins; Cell | 2022 |
FOXM1-mediated NUF2 expression confers temozolomide resistance to human glioma cells by regulating autophagy via the PI3K/AKT/mTOR signaling pathway.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Proteins; Cell | 2022 |
Targeting CXCR4 to suppress glioma-initiating cells and chemoresistance in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glioma; Humans; Mu | 2022 |
Targeting CXCR4 to suppress glioma-initiating cells and chemoresistance in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glioma; Humans; Mu | 2022 |
Targeting CXCR4 to suppress glioma-initiating cells and chemoresistance in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glioma; Humans; Mu | 2022 |
Targeting CXCR4 to suppress glioma-initiating cells and chemoresistance in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glioma; Humans; Mu | 2022 |
Hispidulin Enhances Temozolomide (TMZ)-Induced Cytotoxicity against Malignant Glioma Cells
Topics: Antineoplastic Agents, Alkylating; Autophagy; Cell Line, Tumor; Dacarbazine; Flavones; Glioma; Human | 2022 |
Hispidulin Enhances Temozolomide (TMZ)-Induced Cytotoxicity against Malignant Glioma Cells
Topics: Antineoplastic Agents, Alkylating; Autophagy; Cell Line, Tumor; Dacarbazine; Flavones; Glioma; Human | 2022 |
Hispidulin Enhances Temozolomide (TMZ)-Induced Cytotoxicity against Malignant Glioma Cells
Topics: Antineoplastic Agents, Alkylating; Autophagy; Cell Line, Tumor; Dacarbazine; Flavones; Glioma; Human | 2022 |
Hispidulin Enhances Temozolomide (TMZ)-Induced Cytotoxicity against Malignant Glioma Cells
Topics: Antineoplastic Agents, Alkylating; Autophagy; Cell Line, Tumor; Dacarbazine; Flavones; Glioma; Human | 2022 |
High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1/MRP1 upregulation.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Ferroptosis; Glioblastoma; Glioma; Humans; Multidrug Re | 2022 |
High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1/MRP1 upregulation.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Ferroptosis; Glioblastoma; Glioma; Humans; Multidrug Re | 2022 |
High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1/MRP1 upregulation.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Ferroptosis; Glioblastoma; Glioma; Humans; Multidrug Re | 2022 |
High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1/MRP1 upregulation.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Ferroptosis; Glioblastoma; Glioma; Humans; Multidrug Re | 2022 |
Exosomal circWDR62 promotes temozolomide resistance and malignant progression through regulation of the miR-370-3p/MGMT axis in glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Modifi | 2022 |
Exosomal circWDR62 promotes temozolomide resistance and malignant progression through regulation of the miR-370-3p/MGMT axis in glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Modifi | 2022 |
Exosomal circWDR62 promotes temozolomide resistance and malignant progression through regulation of the miR-370-3p/MGMT axis in glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Modifi | 2022 |
Exosomal circWDR62 promotes temozolomide resistance and malignant progression through regulation of the miR-370-3p/MGMT axis in glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Modifi | 2022 |
Circadian Clock Genes Act as Diagnostic and Prognostic Biomarkers of Glioma: Clinic Implications for Chronotherapy.
Topics: ARNTL Transcription Factors; Biomarkers; Chronotherapy; Circadian Clocks; Circadian Rhythm; Glioma; | 2022 |
Circadian Clock Genes Act as Diagnostic and Prognostic Biomarkers of Glioma: Clinic Implications for Chronotherapy.
Topics: ARNTL Transcription Factors; Biomarkers; Chronotherapy; Circadian Clocks; Circadian Rhythm; Glioma; | 2022 |
Circadian Clock Genes Act as Diagnostic and Prognostic Biomarkers of Glioma: Clinic Implications for Chronotherapy.
Topics: ARNTL Transcription Factors; Biomarkers; Chronotherapy; Circadian Clocks; Circadian Rhythm; Glioma; | 2022 |
Circadian Clock Genes Act as Diagnostic and Prognostic Biomarkers of Glioma: Clinic Implications for Chronotherapy.
Topics: ARNTL Transcription Factors; Biomarkers; Chronotherapy; Circadian Clocks; Circadian Rhythm; Glioma; | 2022 |
Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence.
Topics: Brain Neoplasms; Carmustine; Cell Line, Tumor; Glioma; Humans; Hydrogels; Neoplasm Recurrence, Local | 2022 |
Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence.
Topics: Brain Neoplasms; Carmustine; Cell Line, Tumor; Glioma; Humans; Hydrogels; Neoplasm Recurrence, Local | 2022 |
Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence.
Topics: Brain Neoplasms; Carmustine; Cell Line, Tumor; Glioma; Humans; Hydrogels; Neoplasm Recurrence, Local | 2022 |
Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence.
Topics: Brain Neoplasms; Carmustine; Cell Line, Tumor; Glioma; Humans; Hydrogels; Neoplasm Recurrence, Local | 2022 |
Substrate viscosity impairs temozolomide-mediated inhibition of glioblastoma cells' growth.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Glioblastoma; Glioma; Humans; Hydrogels; | 2022 |
Substrate viscosity impairs temozolomide-mediated inhibition of glioblastoma cells' growth.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Glioblastoma; Glioma; Humans; Hydrogels; | 2022 |
Substrate viscosity impairs temozolomide-mediated inhibition of glioblastoma cells' growth.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Glioblastoma; Glioma; Humans; Hydrogels; | 2022 |
Substrate viscosity impairs temozolomide-mediated inhibition of glioblastoma cells' growth.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Glioblastoma; Glioma; Humans; Hydrogels; | 2022 |
ZNF300 enhances temozolomide resistance in gliomas by regulating lncRNA SNHG12.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Re | 2022 |
ZNF300 enhances temozolomide resistance in gliomas by regulating lncRNA SNHG12.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Re | 2022 |
ZNF300 enhances temozolomide resistance in gliomas by regulating lncRNA SNHG12.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Re | 2022 |
ZNF300 enhances temozolomide resistance in gliomas by regulating lncRNA SNHG12.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Re | 2022 |
Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration of Human U251 Glioma Cells.
Topics: Antimicrobial Cationic Peptides; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cath | 2022 |
Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration of Human U251 Glioma Cells.
Topics: Antimicrobial Cationic Peptides; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cath | 2022 |
Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration of Human U251 Glioma Cells.
Topics: Antimicrobial Cationic Peptides; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cath | 2022 |
Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration of Human U251 Glioma Cells.
Topics: Antimicrobial Cationic Peptides; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cath | 2022 |
MAGED4B Promotes Glioma Progression via Inactivation of the TNF-α-induced Apoptotic Pathway by Down-regulating TRIM27 Expression.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA-Binding Proteins; Glioma; Humans; Me | 2023 |
MAGED4B Promotes Glioma Progression via Inactivation of the TNF-α-induced Apoptotic Pathway by Down-regulating TRIM27 Expression.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA-Binding Proteins; Glioma; Humans; Me | 2023 |
MAGED4B Promotes Glioma Progression via Inactivation of the TNF-α-induced Apoptotic Pathway by Down-regulating TRIM27 Expression.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA-Binding Proteins; Glioma; Humans; Me | 2023 |
MAGED4B Promotes Glioma Progression via Inactivation of the TNF-α-induced Apoptotic Pathway by Down-regulating TRIM27 Expression.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA-Binding Proteins; Glioma; Humans; Me | 2023 |
Safety of temozolomide use in adult patients with renal dysfunction.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Kidney Disea | 2022 |
Safety of temozolomide use in adult patients with renal dysfunction.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Kidney Disea | 2022 |
Safety of temozolomide use in adult patients with renal dysfunction.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Kidney Disea | 2022 |
Safety of temozolomide use in adult patients with renal dysfunction.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Kidney Disea | 2022 |
Bio-polymeric transferrin-targeted temozolomide nanoparticles in gel for synergistic post-surgical GBM therapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Glioblastoma; Glioma; Hydro | 2022 |
Bio-polymeric transferrin-targeted temozolomide nanoparticles in gel for synergistic post-surgical GBM therapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Glioblastoma; Glioma; Hydro | 2022 |
Bio-polymeric transferrin-targeted temozolomide nanoparticles in gel for synergistic post-surgical GBM therapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Glioblastoma; Glioma; Hydro | 2022 |
Bio-polymeric transferrin-targeted temozolomide nanoparticles in gel for synergistic post-surgical GBM therapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Glioblastoma; Glioma; Hydro | 2022 |
CircKIF4A promotes glioma growth and temozolomide resistance by accelerating glycolysis.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Fru | 2022 |
CircKIF4A promotes glioma growth and temozolomide resistance by accelerating glycolysis.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Fru | 2022 |
CircKIF4A promotes glioma growth and temozolomide resistance by accelerating glycolysis.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Fru | 2022 |
CircKIF4A promotes glioma growth and temozolomide resistance by accelerating glycolysis.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Fru | 2022 |
Essential oil of Ligusticum chuanxiong Hort. Regulated P-gp protein and tight junction protein to change pharmacokinetic parameters of temozolomide in blood, brain and tumor.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Chromatography, Liquid; Claudin-5; Gas Chromatography | 2022 |
Essential oil of Ligusticum chuanxiong Hort. Regulated P-gp protein and tight junction protein to change pharmacokinetic parameters of temozolomide in blood, brain and tumor.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Chromatography, Liquid; Claudin-5; Gas Chromatography | 2022 |
Essential oil of Ligusticum chuanxiong Hort. Regulated P-gp protein and tight junction protein to change pharmacokinetic parameters of temozolomide in blood, brain and tumor.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Chromatography, Liquid; Claudin-5; Gas Chromatography | 2022 |
Essential oil of Ligusticum chuanxiong Hort. Regulated P-gp protein and tight junction protein to change pharmacokinetic parameters of temozolomide in blood, brain and tumor.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Chromatography, Liquid; Claudin-5; Gas Chromatography | 2022 |
Mechanisms for hypoxia
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glioma; Humans; Hypoxia; | 2022 |
Mechanisms for hypoxia
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glioma; Humans; Hypoxia; | 2022 |
Mechanisms for hypoxia
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glioma; Humans; Hypoxia; | 2022 |
Mechanisms for hypoxia
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glioma; Humans; Hypoxia; | 2022 |
The mechanism of formononetin/calycosin compound optimizing the effects of temozolomide on C6 malignant glioma based on metabolomics and network pharmacology.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Ne | 2022 |
The mechanism of formononetin/calycosin compound optimizing the effects of temozolomide on C6 malignant glioma based on metabolomics and network pharmacology.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Ne | 2022 |
The mechanism of formononetin/calycosin compound optimizing the effects of temozolomide on C6 malignant glioma based on metabolomics and network pharmacology.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Ne | 2022 |
The mechanism of formononetin/calycosin compound optimizing the effects of temozolomide on C6 malignant glioma based on metabolomics and network pharmacology.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Ne | 2022 |
Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas.
Topics: Brain Neoplasms; Glioma; Humans; Immune Evasion; Immunologic Factors; Immunotherapy; Temozolomide; T | 2022 |
Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas.
Topics: Brain Neoplasms; Glioma; Humans; Immune Evasion; Immunologic Factors; Immunotherapy; Temozolomide; T | 2022 |
Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas.
Topics: Brain Neoplasms; Glioma; Humans; Immune Evasion; Immunologic Factors; Immunotherapy; Temozolomide; T | 2022 |
Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas.
Topics: Brain Neoplasms; Glioma; Humans; Immune Evasion; Immunologic Factors; Immunotherapy; Temozolomide; T | 2022 |
Prognostic value of m6A regulators and the nomogram construction in glioma patients.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Gene Expression Regulation, Neoplastic; Glioma; Human | 2022 |
Prognostic value of m6A regulators and the nomogram construction in glioma patients.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Gene Expression Regulation, Neoplastic; Glioma; Human | 2022 |
Prognostic value of m6A regulators and the nomogram construction in glioma patients.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Gene Expression Regulation, Neoplastic; Glioma; Human | 2022 |
Prognostic value of m6A regulators and the nomogram construction in glioma patients.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Gene Expression Regulation, Neoplastic; Glioma; Human | 2022 |
Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
Topics: Biomarkers, Tumor; Brain; Brain Neoplasms; Carcinogens; Glioma; Glutathione Peroxidase; Glutathione | 2022 |
Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
Topics: Biomarkers, Tumor; Brain; Brain Neoplasms; Carcinogens; Glioma; Glutathione Peroxidase; Glutathione | 2022 |
Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
Topics: Biomarkers, Tumor; Brain; Brain Neoplasms; Carcinogens; Glioma; Glutathione Peroxidase; Glutathione | 2022 |
Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
Topics: Biomarkers, Tumor; Brain; Brain Neoplasms; Carcinogens; Glioma; Glutathione Peroxidase; Glutathione | 2022 |
miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM).
Topics: Adrenomedullin; Animals; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; B | 2022 |
miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM).
Topics: Adrenomedullin; Animals; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; B | 2022 |
miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM).
Topics: Adrenomedullin; Animals; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; B | 2022 |
miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM).
Topics: Adrenomedullin; Animals; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; B | 2022 |
Mechanism of RIP2 enhancing stemness of glioma cells induces temozolomide resistance.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioma; Humans; Neoplastic St | 2022 |
Mechanism of RIP2 enhancing stemness of glioma cells induces temozolomide resistance.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioma; Humans; Neoplastic St | 2022 |
Mechanism of RIP2 enhancing stemness of glioma cells induces temozolomide resistance.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioma; Humans; Neoplastic St | 2022 |
Mechanism of RIP2 enhancing stemness of glioma cells induces temozolomide resistance.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioma; Humans; Neoplastic St | 2022 |
Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Glioblastoma; Glioma; | 2022 |
Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Glioblastoma; Glioma; | 2022 |
Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Glioblastoma; Glioma; | 2022 |
Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Glioblastoma; Glioma; | 2022 |
Differential role of Pax6 and its interaction with Shh-Gli1-IDH2 axis in regulation of glioma growth and chemoresistance.
Topics: Brain Neoplasms; Drug Resistance, Neoplasm; Glioma; Hedgehog Proteins; Humans; PAX6 Transcription Fa | 2023 |
Differential role of Pax6 and its interaction with Shh-Gli1-IDH2 axis in regulation of glioma growth and chemoresistance.
Topics: Brain Neoplasms; Drug Resistance, Neoplasm; Glioma; Hedgehog Proteins; Humans; PAX6 Transcription Fa | 2023 |
Differential role of Pax6 and its interaction with Shh-Gli1-IDH2 axis in regulation of glioma growth and chemoresistance.
Topics: Brain Neoplasms; Drug Resistance, Neoplasm; Glioma; Hedgehog Proteins; Humans; PAX6 Transcription Fa | 2023 |
Differential role of Pax6 and its interaction with Shh-Gli1-IDH2 axis in regulation of glioma growth and chemoresistance.
Topics: Brain Neoplasms; Drug Resistance, Neoplasm; Glioma; Hedgehog Proteins; Humans; PAX6 Transcription Fa | 2023 |
Exosomes Derived from Hypoxic Glioma Cells Reduce the Sensitivity of Glioma Cells to Temozolomide Through Carrying miR-106a-5p.
Topics: Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neopla | 2022 |
Exosomes Derived from Hypoxic Glioma Cells Reduce the Sensitivity of Glioma Cells to Temozolomide Through Carrying miR-106a-5p.
Topics: Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neopla | 2022 |
Exosomes Derived from Hypoxic Glioma Cells Reduce the Sensitivity of Glioma Cells to Temozolomide Through Carrying miR-106a-5p.
Topics: Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neopla | 2022 |
Exosomes Derived from Hypoxic Glioma Cells Reduce the Sensitivity of Glioma Cells to Temozolomide Through Carrying miR-106a-5p.
Topics: Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neopla | 2022 |
Topics: Aged; Astrocytoma; Brain Neoplasms; Carbohydrate Metabolism; Dexamethasone; Glioblastoma; Glioma; Gl | 2022 |
Topics: Aged; Astrocytoma; Brain Neoplasms; Carbohydrate Metabolism; Dexamethasone; Glioblastoma; Glioma; Gl | 2022 |
Topics: Aged; Astrocytoma; Brain Neoplasms; Carbohydrate Metabolism; Dexamethasone; Glioblastoma; Glioma; Gl | 2022 |
Topics: Aged; Astrocytoma; Brain Neoplasms; Carbohydrate Metabolism; Dexamethasone; Glioblastoma; Glioma; Gl | 2022 |
Anti‑tumor effects of anti‑epileptic drugs in malignant glioma cells.
Topics: Anticonvulsants; Cadherins; Carbamazepine; Glioma; Humans; Levetiracetam; Matrix Metalloproteinase 2 | 2022 |
Anti‑tumor effects of anti‑epileptic drugs in malignant glioma cells.
Topics: Anticonvulsants; Cadherins; Carbamazepine; Glioma; Humans; Levetiracetam; Matrix Metalloproteinase 2 | 2022 |
Anti‑tumor effects of anti‑epileptic drugs in malignant glioma cells.
Topics: Anticonvulsants; Cadherins; Carbamazepine; Glioma; Humans; Levetiracetam; Matrix Metalloproteinase 2 | 2022 |
Anti‑tumor effects of anti‑epileptic drugs in malignant glioma cells.
Topics: Anticonvulsants; Cadherins; Carbamazepine; Glioma; Humans; Levetiracetam; Matrix Metalloproteinase 2 | 2022 |
Blood-brain Barrier Permeable and Multi-stimuli Responsive Nanoplatform for Orthotopic Glioma Inhibition by Synergistic Enhanced Chemo-/Chemodynamic/Photothermal/Starvation Therapy.
Topics: Blood-Brain Barrier; Cell Line, Tumor; Glioma; Humans; Hyaluronic Acid; Hydrogen Peroxide; Nanoparti | 2023 |
Blood-brain Barrier Permeable and Multi-stimuli Responsive Nanoplatform for Orthotopic Glioma Inhibition by Synergistic Enhanced Chemo-/Chemodynamic/Photothermal/Starvation Therapy.
Topics: Blood-Brain Barrier; Cell Line, Tumor; Glioma; Humans; Hyaluronic Acid; Hydrogen Peroxide; Nanoparti | 2023 |
Blood-brain Barrier Permeable and Multi-stimuli Responsive Nanoplatform for Orthotopic Glioma Inhibition by Synergistic Enhanced Chemo-/Chemodynamic/Photothermal/Starvation Therapy.
Topics: Blood-Brain Barrier; Cell Line, Tumor; Glioma; Humans; Hyaluronic Acid; Hydrogen Peroxide; Nanoparti | 2023 |
Blood-brain Barrier Permeable and Multi-stimuli Responsive Nanoplatform for Orthotopic Glioma Inhibition by Synergistic Enhanced Chemo-/Chemodynamic/Photothermal/Starvation Therapy.
Topics: Blood-Brain Barrier; Cell Line, Tumor; Glioma; Humans; Hyaluronic Acid; Hydrogen Peroxide; Nanoparti | 2023 |
Loss of IDH mutation or secondary tumour manifestation? Evolution of an IDH-mutant and 1p/19q-codeleted oligodendroglioma after 15 years of continuous temozolomide treatment and radiotherapy: A case report.
Topics: Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Glioma; Humans; Isocitrate | 2023 |
Loss of IDH mutation or secondary tumour manifestation? Evolution of an IDH-mutant and 1p/19q-codeleted oligodendroglioma after 15 years of continuous temozolomide treatment and radiotherapy: A case report.
Topics: Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Glioma; Humans; Isocitrate | 2023 |
Loss of IDH mutation or secondary tumour manifestation? Evolution of an IDH-mutant and 1p/19q-codeleted oligodendroglioma after 15 years of continuous temozolomide treatment and radiotherapy: A case report.
Topics: Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Glioma; Humans; Isocitrate | 2023 |
Loss of IDH mutation or secondary tumour manifestation? Evolution of an IDH-mutant and 1p/19q-codeleted oligodendroglioma after 15 years of continuous temozolomide treatment and radiotherapy: A case report.
Topics: Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Glioma; Humans; Isocitrate | 2023 |
Comprehensive analysis of HHV-6 and HHV-7-related gene signature in prognosis and response to temozolomide of glioma.
Topics: Brain Neoplasms; F-Box Proteins; Glioma; Herpesvirus 6, Human; Herpesvirus 7, Human; Humans; Prognos | 2023 |
Comprehensive analysis of HHV-6 and HHV-7-related gene signature in prognosis and response to temozolomide of glioma.
Topics: Brain Neoplasms; F-Box Proteins; Glioma; Herpesvirus 6, Human; Herpesvirus 7, Human; Humans; Prognos | 2023 |
Comprehensive analysis of HHV-6 and HHV-7-related gene signature in prognosis and response to temozolomide of glioma.
Topics: Brain Neoplasms; F-Box Proteins; Glioma; Herpesvirus 6, Human; Herpesvirus 7, Human; Humans; Prognos | 2023 |
Comprehensive analysis of HHV-6 and HHV-7-related gene signature in prognosis and response to temozolomide of glioma.
Topics: Brain Neoplasms; F-Box Proteins; Glioma; Herpesvirus 6, Human; Herpesvirus 7, Human; Humans; Prognos | 2023 |
Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Retro | 2022 |
Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Retro | 2022 |
Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Retro | 2022 |
Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Retro | 2022 |
The Significance of
Topics: Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Gli | 2022 |
The Significance of
Topics: Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Gli | 2022 |
The Significance of
Topics: Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Gli | 2022 |
The Significance of
Topics: Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Gli | 2022 |
Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated
Topics: CpG Islands; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Phenotyp | 2022 |
Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated
Topics: CpG Islands; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Phenotyp | 2022 |
Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated
Topics: CpG Islands; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Phenotyp | 2022 |
Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated
Topics: CpG Islands; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Phenotyp | 2022 |
Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated
Topics: CpG Islands; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Phenotyp | 2022 |
Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated
Topics: CpG Islands; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Phenotyp | 2022 |
Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated
Topics: CpG Islands; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Phenotyp | 2022 |
Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated
Topics: CpG Islands; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Phenotyp | 2022 |
Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated
Topics: CpG Islands; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Phenotyp | 2022 |
Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated
Topics: CpG Islands; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Phenotyp | 2022 |
Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated
Topics: CpG Islands; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Phenotyp | 2022 |
Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated
Topics: CpG Islands; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Phenotyp | 2022 |
Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated
Topics: CpG Islands; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Phenotyp | 2022 |
Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated
Topics: CpG Islands; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Phenotyp | 2022 |
Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated
Topics: CpG Islands; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Phenotyp | 2022 |
Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated
Topics: CpG Islands; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Phenotyp | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
CD147 Protein Expression and Temozolomide Resistance in Glioma Cells: An Ex vivo and In vivo Study.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Collagen Type VI; Glioma; Humans; RNA, Messenger; Temo | 2023 |
SLC11A1 as a stratification indicator for immunotherapy or chemotherapy in patients with glioma.
Topics: Brain Neoplasms; China; Glioma; Humans; Immunotherapy; Temozolomide | 2022 |
SLC11A1 as a stratification indicator for immunotherapy or chemotherapy in patients with glioma.
Topics: Brain Neoplasms; China; Glioma; Humans; Immunotherapy; Temozolomide | 2022 |
SLC11A1 as a stratification indicator for immunotherapy or chemotherapy in patients with glioma.
Topics: Brain Neoplasms; China; Glioma; Humans; Immunotherapy; Temozolomide | 2022 |
SLC11A1 as a stratification indicator for immunotherapy or chemotherapy in patients with glioma.
Topics: Brain Neoplasms; China; Glioma; Humans; Immunotherapy; Temozolomide | 2022 |
αCT1 peptide sensitizes glioma cells to temozolomide in a glioblastoma organoid platform.
Topics: Cell Line, Tumor; Connexin 43; Glioblastoma; Glioma; Humans; Peptides; Signal Transduction; Temozolo | 2023 |
αCT1 peptide sensitizes glioma cells to temozolomide in a glioblastoma organoid platform.
Topics: Cell Line, Tumor; Connexin 43; Glioblastoma; Glioma; Humans; Peptides; Signal Transduction; Temozolo | 2023 |
αCT1 peptide sensitizes glioma cells to temozolomide in a glioblastoma organoid platform.
Topics: Cell Line, Tumor; Connexin 43; Glioblastoma; Glioma; Humans; Peptides; Signal Transduction; Temozolo | 2023 |
αCT1 peptide sensitizes glioma cells to temozolomide in a glioblastoma organoid platform.
Topics: Cell Line, Tumor; Connexin 43; Glioblastoma; Glioma; Humans; Peptides; Signal Transduction; Temozolo | 2023 |
PGAM4 silencing inhibited glycolysis and chemoresistance to temozolomide in glioma cells.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glioma; | 2023 |
PGAM4 silencing inhibited glycolysis and chemoresistance to temozolomide in glioma cells.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glioma; | 2023 |
PGAM4 silencing inhibited glycolysis and chemoresistance to temozolomide in glioma cells.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glioma; | 2023 |
PGAM4 silencing inhibited glycolysis and chemoresistance to temozolomide in glioma cells.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glioma; | 2023 |
The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Res | 2023 |
The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Res | 2023 |
The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Res | 2023 |
The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Res | 2023 |
Wnt signaling regulates MFSD2A-dependent drug delivery through endothelial transcytosis in glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Endothelial Cells; Glioblasto | 2023 |
Wnt signaling regulates MFSD2A-dependent drug delivery through endothelial transcytosis in glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Endothelial Cells; Glioblasto | 2023 |
Wnt signaling regulates MFSD2A-dependent drug delivery through endothelial transcytosis in glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Endothelial Cells; Glioblasto | 2023 |
Wnt signaling regulates MFSD2A-dependent drug delivery through endothelial transcytosis in glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Endothelial Cells; Glioblasto | 2023 |
Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis via Nrf2.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Ferroptosis; Glioma; Humans; Isocitrate Dehydrogenase; M | 2023 |
Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis via Nrf2.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Ferroptosis; Glioma; Humans; Isocitrate Dehydrogenase; M | 2023 |
Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis via Nrf2.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Ferroptosis; Glioma; Humans; Isocitrate Dehydrogenase; M | 2023 |
Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis via Nrf2.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Ferroptosis; Glioma; Humans; Isocitrate Dehydrogenase; M | 2023 |
Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA; DNA Breaks, Doub | 2023 |
Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA; DNA Breaks, Doub | 2023 |
Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA; DNA Breaks, Doub | 2023 |
Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA; DNA Breaks, Doub | 2023 |
ProNGF Expression and Targeting in Glioblastoma Multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
ProNGF Expression and Targeting in Glioblastoma Multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
ProNGF Expression and Targeting in Glioblastoma Multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
ProNGF Expression and Targeting in Glioblastoma Multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Observation of the delineation of the target volume of radiotherapy in adult-type diffuse gliomas after temozolomide-based chemoradiotherapy: analysis of recurrence patterns and predictive factors.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; | 2023 |
Observation of the delineation of the target volume of radiotherapy in adult-type diffuse gliomas after temozolomide-based chemoradiotherapy: analysis of recurrence patterns and predictive factors.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; | 2023 |
Observation of the delineation of the target volume of radiotherapy in adult-type diffuse gliomas after temozolomide-based chemoradiotherapy: analysis of recurrence patterns and predictive factors.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; | 2023 |
Observation of the delineation of the target volume of radiotherapy in adult-type diffuse gliomas after temozolomide-based chemoradiotherapy: analysis of recurrence patterns and predictive factors.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; | 2023 |
Induction of apoptosis in glioma cells by lycorine via reactive oxygen species generation and regulation of NF-κB pathways.
Topics: Apoptosis; Cell Line, Tumor; Glioma; Humans; NF-kappa B; Reactive Oxygen Species; Signal Transductio | 2023 |
Induction of apoptosis in glioma cells by lycorine via reactive oxygen species generation and regulation of NF-κB pathways.
Topics: Apoptosis; Cell Line, Tumor; Glioma; Humans; NF-kappa B; Reactive Oxygen Species; Signal Transductio | 2023 |
Induction of apoptosis in glioma cells by lycorine via reactive oxygen species generation and regulation of NF-κB pathways.
Topics: Apoptosis; Cell Line, Tumor; Glioma; Humans; NF-kappa B; Reactive Oxygen Species; Signal Transductio | 2023 |
Induction of apoptosis in glioma cells by lycorine via reactive oxygen species generation and regulation of NF-κB pathways.
Topics: Apoptosis; Cell Line, Tumor; Glioma; Humans; NF-kappa B; Reactive Oxygen Species; Signal Transductio | 2023 |
How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study.
Topics: Adolescent; Bevacizumab; Brain Neoplasms; Child; Chronic Disease; Glioma; Humans; Proto-Oncogene Pro | 2023 |
How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study.
Topics: Adolescent; Bevacizumab; Brain Neoplasms; Child; Chronic Disease; Glioma; Humans; Proto-Oncogene Pro | 2023 |
How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study.
Topics: Adolescent; Bevacizumab; Brain Neoplasms; Child; Chronic Disease; Glioma; Humans; Proto-Oncogene Pro | 2023 |
How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study.
Topics: Adolescent; Bevacizumab; Brain Neoplasms; Child; Chronic Disease; Glioma; Humans; Proto-Oncogene Pro | 2023 |
Tumor microenvironment targeting system for glioma treatment via fusion cell membrane coating nanotechnology.
Topics: Animals; Cell Line, Tumor; Cell Membrane; Drug Delivery Systems; Glioma; Mice; Nanoparticles; Nanote | 2023 |
Tumor microenvironment targeting system for glioma treatment via fusion cell membrane coating nanotechnology.
Topics: Animals; Cell Line, Tumor; Cell Membrane; Drug Delivery Systems; Glioma; Mice; Nanoparticles; Nanote | 2023 |
Tumor microenvironment targeting system for glioma treatment via fusion cell membrane coating nanotechnology.
Topics: Animals; Cell Line, Tumor; Cell Membrane; Drug Delivery Systems; Glioma; Mice; Nanoparticles; Nanote | 2023 |
Tumor microenvironment targeting system for glioma treatment via fusion cell membrane coating nanotechnology.
Topics: Animals; Cell Line, Tumor; Cell Membrane; Drug Delivery Systems; Glioma; Mice; Nanoparticles; Nanote | 2023 |
Photodynamic therapy enhances the cytotoxicity of temozolomide against glioblastoma via reprogramming anaerobic glycolysis.
Topics: Anaerobiosis; Animals; Apoptosis; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Glioblastoma; Glioma | 2023 |
Photodynamic therapy enhances the cytotoxicity of temozolomide against glioblastoma via reprogramming anaerobic glycolysis.
Topics: Anaerobiosis; Animals; Apoptosis; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Glioblastoma; Glioma | 2023 |
Photodynamic therapy enhances the cytotoxicity of temozolomide against glioblastoma via reprogramming anaerobic glycolysis.
Topics: Anaerobiosis; Animals; Apoptosis; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Glioblastoma; Glioma | 2023 |
Photodynamic therapy enhances the cytotoxicity of temozolomide against glioblastoma via reprogramming anaerobic glycolysis.
Topics: Anaerobiosis; Animals; Apoptosis; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Glioblastoma; Glioma | 2023 |
The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Focal Adhesion Kinase 2; Glioblastoma; Glioma; Humans; M | 2023 |
The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Focal Adhesion Kinase 2; Glioblastoma; Glioma; Humans; M | 2023 |
The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Focal Adhesion Kinase 2; Glioblastoma; Glioma; Humans; M | 2023 |
The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Focal Adhesion Kinase 2; Glioblastoma; Glioma; Humans; M | 2023 |
The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors.
Topics: Animals; Brain Neoplasms; Carboplatin; Chick Embryo; Disease Models, Animal; Glioma; Heterografts; H | 2023 |
The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors.
Topics: Animals; Brain Neoplasms; Carboplatin; Chick Embryo; Disease Models, Animal; Glioma; Heterografts; H | 2023 |
The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors.
Topics: Animals; Brain Neoplasms; Carboplatin; Chick Embryo; Disease Models, Animal; Glioma; Heterografts; H | 2023 |
The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors.
Topics: Animals; Brain Neoplasms; Carboplatin; Chick Embryo; Disease Models, Animal; Glioma; Heterografts; H | 2023 |
Givinostat Inhibition of Sp1-dependent MGMT Expression Sensitizes Glioma Stem Cells to Temozolomide.
Topics: DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Neoplastic Stem Cells | 2023 |
Givinostat Inhibition of Sp1-dependent MGMT Expression Sensitizes Glioma Stem Cells to Temozolomide.
Topics: DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Neoplastic Stem Cells | 2023 |
Givinostat Inhibition of Sp1-dependent MGMT Expression Sensitizes Glioma Stem Cells to Temozolomide.
Topics: DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Neoplastic Stem Cells | 2023 |
Givinostat Inhibition of Sp1-dependent MGMT Expression Sensitizes Glioma Stem Cells to Temozolomide.
Topics: DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Neoplastic Stem Cells | 2023 |
Purinergic approach to effective glioma treatment with temozolomide reveals enhanced anti-cancer effects mediated by P2X7 receptor.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tu | 2023 |
Purinergic approach to effective glioma treatment with temozolomide reveals enhanced anti-cancer effects mediated by P2X7 receptor.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tu | 2023 |
Purinergic approach to effective glioma treatment with temozolomide reveals enhanced anti-cancer effects mediated by P2X7 receptor.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tu | 2023 |
Purinergic approach to effective glioma treatment with temozolomide reveals enhanced anti-cancer effects mediated by P2X7 receptor.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tu | 2023 |
E3 ligase MAEA-mediated ubiquitination and degradation of PHD3 promotes glioblastoma progression.
Topics: Brain Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; Cytoskeletal Proteins; Drug Resistance, | 2023 |
E3 ligase MAEA-mediated ubiquitination and degradation of PHD3 promotes glioblastoma progression.
Topics: Brain Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; Cytoskeletal Proteins; Drug Resistance, | 2023 |
E3 ligase MAEA-mediated ubiquitination and degradation of PHD3 promotes glioblastoma progression.
Topics: Brain Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; Cytoskeletal Proteins; Drug Resistance, | 2023 |
E3 ligase MAEA-mediated ubiquitination and degradation of PHD3 promotes glioblastoma progression.
Topics: Brain Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; Cytoskeletal Proteins; Drug Resistance, | 2023 |
CEBPB upregulates P4HA2 to promote the malignant biological behavior in IDH1 wildtype glioma.
Topics: Animals; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; Cell Proliferation; Glioma; Humans; | 2023 |
CEBPB upregulates P4HA2 to promote the malignant biological behavior in IDH1 wildtype glioma.
Topics: Animals; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; Cell Proliferation; Glioma; Humans; | 2023 |
CEBPB upregulates P4HA2 to promote the malignant biological behavior in IDH1 wildtype glioma.
Topics: Animals; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; Cell Proliferation; Glioma; Humans; | 2023 |
CEBPB upregulates P4HA2 to promote the malignant biological behavior in IDH1 wildtype glioma.
Topics: Animals; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; Cell Proliferation; Glioma; Humans; | 2023 |
Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma.
Topics: Brain Neoplasms; Drug Resistance, Neoplasm; Early Growth Response Transcription Factors; Glioblastom | 2023 |
Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma.
Topics: Brain Neoplasms; Drug Resistance, Neoplasm; Early Growth Response Transcription Factors; Glioblastom | 2023 |
Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma.
Topics: Brain Neoplasms; Drug Resistance, Neoplasm; Early Growth Response Transcription Factors; Glioblastom | 2023 |
Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma.
Topics: Brain Neoplasms; Drug Resistance, Neoplasm; Early Growth Response Transcription Factors; Glioblastom | 2023 |
Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-κB/MGMT Axis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; | 2023 |
Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-κB/MGMT Axis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; | 2023 |
Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-κB/MGMT Axis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; | 2023 |
Downregulation of BASP1 Promotes Temozolomide Resistance in Gliomas via Epigenetic Activation of the FBXO32/NF-κB/MGMT Axis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; | 2023 |
Sitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances temozolomide cytotoxicity.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; | 2023 |
Sitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances temozolomide cytotoxicity.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; | 2023 |
Sitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances temozolomide cytotoxicity.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; | 2023 |
Sitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances temozolomide cytotoxicity.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; | 2023 |
Preclinical Activity of 4-Demethyl-4-cholesteryloxycarbonylpenclomedine in Melanoma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Female; Glioma; Humans; Melanoma; Mice; Mice, Inb | 2023 |
Preclinical Activity of 4-Demethyl-4-cholesteryloxycarbonylpenclomedine in Melanoma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Female; Glioma; Humans; Melanoma; Mice; Mice, Inb | 2023 |
Preclinical Activity of 4-Demethyl-4-cholesteryloxycarbonylpenclomedine in Melanoma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Female; Glioma; Humans; Melanoma; Mice; Mice, Inb | 2023 |
Preclinical Activity of 4-Demethyl-4-cholesteryloxycarbonylpenclomedine in Melanoma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Female; Glioma; Humans; Melanoma; Mice; Mice, Inb | 2023 |
SRSF4 Confers Temozolomide Resistance of Glioma via Accelerating Double Strand Break Repair.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Repair; Drug Resistance, N | 2023 |
SRSF4 Confers Temozolomide Resistance of Glioma via Accelerating Double Strand Break Repair.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Repair; Drug Resistance, N | 2023 |
SRSF4 Confers Temozolomide Resistance of Glioma via Accelerating Double Strand Break Repair.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Repair; Drug Resistance, N | 2023 |
SRSF4 Confers Temozolomide Resistance of Glioma via Accelerating Double Strand Break Repair.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Repair; Drug Resistance, N | 2023 |
Exosomes released from U87 glioma cells treated with curcumin and/or temozolomide produce apoptosis in naive U87 cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Brain-Derived Neurotrophic F | 2023 |
Exosomes released from U87 glioma cells treated with curcumin and/or temozolomide produce apoptosis in naive U87 cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Brain-Derived Neurotrophic F | 2023 |
Exosomes released from U87 glioma cells treated with curcumin and/or temozolomide produce apoptosis in naive U87 cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Brain-Derived Neurotrophic F | 2023 |
Exosomes released from U87 glioma cells treated with curcumin and/or temozolomide produce apoptosis in naive U87 cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Brain-Derived Neurotrophic F | 2023 |
LncRNA GSCAR promotes glioma stem cell maintenance via stabilizing SOX2 expression.
Topics: Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glioma; Humans; MicroR | 2023 |
LncRNA GSCAR promotes glioma stem cell maintenance via stabilizing SOX2 expression.
Topics: Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glioma; Humans; MicroR | 2023 |
LncRNA GSCAR promotes glioma stem cell maintenance via stabilizing SOX2 expression.
Topics: Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glioma; Humans; MicroR | 2023 |
LncRNA GSCAR promotes glioma stem cell maintenance via stabilizing SOX2 expression.
Topics: Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glioma; Humans; MicroR | 2023 |
In Situ Nitric Oxide Gas Nanogenerator Reprograms Glioma Immunosuppressive Microenvironment.
Topics: Cell Line, Tumor; Glioblastoma; Glioma; Humans; Immunosuppressive Agents; Nitric Oxide; Temozolomide | 2023 |
In Situ Nitric Oxide Gas Nanogenerator Reprograms Glioma Immunosuppressive Microenvironment.
Topics: Cell Line, Tumor; Glioblastoma; Glioma; Humans; Immunosuppressive Agents; Nitric Oxide; Temozolomide | 2023 |
In Situ Nitric Oxide Gas Nanogenerator Reprograms Glioma Immunosuppressive Microenvironment.
Topics: Cell Line, Tumor; Glioblastoma; Glioma; Humans; Immunosuppressive Agents; Nitric Oxide; Temozolomide | 2023 |
In Situ Nitric Oxide Gas Nanogenerator Reprograms Glioma Immunosuppressive Microenvironment.
Topics: Cell Line, Tumor; Glioblastoma; Glioma; Humans; Immunosuppressive Agents; Nitric Oxide; Temozolomide | 2023 |
Moderately Hypofractionated Radio(chemo)therapy With Simultaneous Integrated Boost for Recurrent, Previously Irradiated, High-grade Glioma.
Topics: Combined Modality Therapy; Glioma; Humans; Neoplasm Recurrence, Local; Prognosis; Temozolomide | 2023 |
Moderately Hypofractionated Radio(chemo)therapy With Simultaneous Integrated Boost for Recurrent, Previously Irradiated, High-grade Glioma.
Topics: Combined Modality Therapy; Glioma; Humans; Neoplasm Recurrence, Local; Prognosis; Temozolomide | 2023 |
Moderately Hypofractionated Radio(chemo)therapy With Simultaneous Integrated Boost for Recurrent, Previously Irradiated, High-grade Glioma.
Topics: Combined Modality Therapy; Glioma; Humans; Neoplasm Recurrence, Local; Prognosis; Temozolomide | 2023 |
Moderately Hypofractionated Radio(chemo)therapy With Simultaneous Integrated Boost for Recurrent, Previously Irradiated, High-grade Glioma.
Topics: Combined Modality Therapy; Glioma; Humans; Neoplasm Recurrence, Local; Prognosis; Temozolomide | 2023 |
Analgesics can affect the sensitivity of temozolomide to glioma chemotherapy through gap junction.
Topics: Analgesics; Cell Line, Tumor; Connexins; Gap Junctions; Glioma; Humans; Temozolomide; Tramadol | 2023 |
Analgesics can affect the sensitivity of temozolomide to glioma chemotherapy through gap junction.
Topics: Analgesics; Cell Line, Tumor; Connexins; Gap Junctions; Glioma; Humans; Temozolomide; Tramadol | 2023 |
Analgesics can affect the sensitivity of temozolomide to glioma chemotherapy through gap junction.
Topics: Analgesics; Cell Line, Tumor; Connexins; Gap Junctions; Glioma; Humans; Temozolomide; Tramadol | 2023 |
Analgesics can affect the sensitivity of temozolomide to glioma chemotherapy through gap junction.
Topics: Analgesics; Cell Line, Tumor; Connexins; Gap Junctions; Glioma; Humans; Temozolomide; Tramadol | 2023 |
Repurposing FDA-Approved Drugs for Temozolomide-Resistant IDH1 Mutant Glioma Using High-Throughput Miniaturized Screening on Droplet Microarray Chip.
Topics: Brain Neoplasms; Drug Repositioning; Glioma; Humans; Isocitrate Dehydrogenase; Temozolomide | 2023 |
Repurposing FDA-Approved Drugs for Temozolomide-Resistant IDH1 Mutant Glioma Using High-Throughput Miniaturized Screening on Droplet Microarray Chip.
Topics: Brain Neoplasms; Drug Repositioning; Glioma; Humans; Isocitrate Dehydrogenase; Temozolomide | 2023 |
Repurposing FDA-Approved Drugs for Temozolomide-Resistant IDH1 Mutant Glioma Using High-Throughput Miniaturized Screening on Droplet Microarray Chip.
Topics: Brain Neoplasms; Drug Repositioning; Glioma; Humans; Isocitrate Dehydrogenase; Temozolomide | 2023 |
Repurposing FDA-Approved Drugs for Temozolomide-Resistant IDH1 Mutant Glioma Using High-Throughput Miniaturized Screening on Droplet Microarray Chip.
Topics: Brain Neoplasms; Drug Repositioning; Glioma; Humans; Isocitrate Dehydrogenase; Temozolomide | 2023 |
TRIM25 promotes temozolomide resistance in glioma by regulating oxidative stress and ferroptotic cell death via the ubiquitination of keap1.
Topics: Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Kelch | 2023 |
TRIM25 promotes temozolomide resistance in glioma by regulating oxidative stress and ferroptotic cell death via the ubiquitination of keap1.
Topics: Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Kelch | 2023 |
TRIM25 promotes temozolomide resistance in glioma by regulating oxidative stress and ferroptotic cell death via the ubiquitination of keap1.
Topics: Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Kelch | 2023 |
TRIM25 promotes temozolomide resistance in glioma by regulating oxidative stress and ferroptotic cell death via the ubiquitination of keap1.
Topics: Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Kelch | 2023 |
[Medical Treatments for Malignant Brain Tumor].
Topics: Antineoplastic Agents; Brain Neoplasms; Glioma; Humans; Nitrosourea Compounds; Temozolomide | 2023 |
[Medical Treatments for Malignant Brain Tumor].
Topics: Antineoplastic Agents; Brain Neoplasms; Glioma; Humans; Nitrosourea Compounds; Temozolomide | 2023 |
[Medical Treatments for Malignant Brain Tumor].
Topics: Antineoplastic Agents; Brain Neoplasms; Glioma; Humans; Nitrosourea Compounds; Temozolomide | 2023 |
[Medical Treatments for Malignant Brain Tumor].
Topics: Antineoplastic Agents; Brain Neoplasms; Glioma; Humans; Nitrosourea Compounds; Temozolomide | 2023 |
LncRNA-PVT1 was identified as a key regulator for TMZ resistance and STAT-related pathway in glioma.
Topics: Datasets as Topic; Disease Progression; Drug Resistance, Neoplasm; Genome, Human; Genomics; Glioma; | 2023 |
LncRNA-PVT1 was identified as a key regulator for TMZ resistance and STAT-related pathway in glioma.
Topics: Datasets as Topic; Disease Progression; Drug Resistance, Neoplasm; Genome, Human; Genomics; Glioma; | 2023 |
LncRNA-PVT1 was identified as a key regulator for TMZ resistance and STAT-related pathway in glioma.
Topics: Datasets as Topic; Disease Progression; Drug Resistance, Neoplasm; Genome, Human; Genomics; Glioma; | 2023 |
LncRNA-PVT1 was identified as a key regulator for TMZ resistance and STAT-related pathway in glioma.
Topics: Datasets as Topic; Disease Progression; Drug Resistance, Neoplasm; Genome, Human; Genomics; Glioma; | 2023 |
Grade scoring system reveals distinct molecular subtypes and identifies KIF20A as a novel biomarker for predicting temozolomide treatment efficiency in gliomas.
Topics: Biomarkers; Brain Neoplasms; Glioblastoma; Glioma; Humans; Kinesins; Multigene Family; Prognosis; Te | 2023 |
Grade scoring system reveals distinct molecular subtypes and identifies KIF20A as a novel biomarker for predicting temozolomide treatment efficiency in gliomas.
Topics: Biomarkers; Brain Neoplasms; Glioblastoma; Glioma; Humans; Kinesins; Multigene Family; Prognosis; Te | 2023 |
Grade scoring system reveals distinct molecular subtypes and identifies KIF20A as a novel biomarker for predicting temozolomide treatment efficiency in gliomas.
Topics: Biomarkers; Brain Neoplasms; Glioblastoma; Glioma; Humans; Kinesins; Multigene Family; Prognosis; Te | 2023 |
Grade scoring system reveals distinct molecular subtypes and identifies KIF20A as a novel biomarker for predicting temozolomide treatment efficiency in gliomas.
Topics: Biomarkers; Brain Neoplasms; Glioblastoma; Glioma; Humans; Kinesins; Multigene Family; Prognosis; Te | 2023 |
Reduced YAP1 and FOLR1 in gliomas predict better response to chemotherapeutics.
Topics: Brain Neoplasms; Folate Receptor 1; Glioma; Humans; Interleukin-6; Interleukin-8; Mutation; Temozolo | 2023 |
Reduced YAP1 and FOLR1 in gliomas predict better response to chemotherapeutics.
Topics: Brain Neoplasms; Folate Receptor 1; Glioma; Humans; Interleukin-6; Interleukin-8; Mutation; Temozolo | 2023 |
Reduced YAP1 and FOLR1 in gliomas predict better response to chemotherapeutics.
Topics: Brain Neoplasms; Folate Receptor 1; Glioma; Humans; Interleukin-6; Interleukin-8; Mutation; Temozolo | 2023 |
Reduced YAP1 and FOLR1 in gliomas predict better response to chemotherapeutics.
Topics: Brain Neoplasms; Folate Receptor 1; Glioma; Humans; Interleukin-6; Interleukin-8; Mutation; Temozolo | 2023 |
Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; E2F1 Transcription Factor; Glioblastoma; Glioma; | 2023 |
Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; E2F1 Transcription Factor; Glioblastoma; Glioma; | 2023 |
Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; E2F1 Transcription Factor; Glioblastoma; Glioma; | 2023 |
Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; E2F1 Transcription Factor; Glioblastoma; Glioma; | 2023 |
Magnolol and Temozolomide exhibit a synergistic anti-glioma activity through MGMT inhibition.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; DNA Modification Methylases; DNA Repair Enzymes | 2023 |
Magnolol and Temozolomide exhibit a synergistic anti-glioma activity through MGMT inhibition.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; DNA Modification Methylases; DNA Repair Enzymes | 2023 |
Magnolol and Temozolomide exhibit a synergistic anti-glioma activity through MGMT inhibition.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; DNA Modification Methylases; DNA Repair Enzymes | 2023 |
Magnolol and Temozolomide exhibit a synergistic anti-glioma activity through MGMT inhibition.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; DNA Modification Methylases; DNA Repair Enzymes | 2023 |
Reduced malignant glioblastoma recurrence post-resection through the anti-CD47 antibody and Temozolomide co-embedded in-situ hydrogel system.
Topics: CD8-Positive T-Lymphocytes; Glioblastoma; Glioma; Humans; Receptors, Immunologic; Temozolomide | 2023 |
Reduced malignant glioblastoma recurrence post-resection through the anti-CD47 antibody and Temozolomide co-embedded in-situ hydrogel system.
Topics: CD8-Positive T-Lymphocytes; Glioblastoma; Glioma; Humans; Receptors, Immunologic; Temozolomide | 2023 |
Reduced malignant glioblastoma recurrence post-resection through the anti-CD47 antibody and Temozolomide co-embedded in-situ hydrogel system.
Topics: CD8-Positive T-Lymphocytes; Glioblastoma; Glioma; Humans; Receptors, Immunologic; Temozolomide | 2023 |
Reduced malignant glioblastoma recurrence post-resection through the anti-CD47 antibody and Temozolomide co-embedded in-situ hydrogel system.
Topics: CD8-Positive T-Lymphocytes; Glioblastoma; Glioma; Humans; Receptors, Immunologic; Temozolomide | 2023 |
Exploring the Functional Roles of Telomere Maintenance 2 in the Tumorigenesis of Glioblastoma Multiforme and Drug Responsiveness to Temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Tr | 2023 |
Exploring the Functional Roles of Telomere Maintenance 2 in the Tumorigenesis of Glioblastoma Multiforme and Drug Responsiveness to Temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Tr | 2023 |
Exploring the Functional Roles of Telomere Maintenance 2 in the Tumorigenesis of Glioblastoma Multiforme and Drug Responsiveness to Temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Tr | 2023 |
Exploring the Functional Roles of Telomere Maintenance 2 in the Tumorigenesis of Glioblastoma Multiforme and Drug Responsiveness to Temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Tr | 2023 |
Toward a theranostic device for gliomas.
Topics: Cell Line, Tumor; Glioblastoma; Glioma; Humans; Microbubbles; Neoplasm Recurrence, Local; Oligopepti | 2023 |
Toward a theranostic device for gliomas.
Topics: Cell Line, Tumor; Glioblastoma; Glioma; Humans; Microbubbles; Neoplasm Recurrence, Local; Oligopepti | 2023 |
Toward a theranostic device for gliomas.
Topics: Cell Line, Tumor; Glioblastoma; Glioma; Humans; Microbubbles; Neoplasm Recurrence, Local; Oligopepti | 2023 |
Toward a theranostic device for gliomas.
Topics: Cell Line, Tumor; Glioblastoma; Glioma; Humans; Microbubbles; Neoplasm Recurrence, Local; Oligopepti | 2023 |
Mechanism of NURP1 in temozolomide resistance in hypoxia-treated glioma cells via the KDM3A/TFEB axis.
Topics: Animals; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Disease Models, Ani | 2023 |
Mechanism of NURP1 in temozolomide resistance in hypoxia-treated glioma cells via the KDM3A/TFEB axis.
Topics: Animals; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Disease Models, Ani | 2023 |
Mechanism of NURP1 in temozolomide resistance in hypoxia-treated glioma cells via the KDM3A/TFEB axis.
Topics: Animals; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Disease Models, Ani | 2023 |
Mechanism of NURP1 in temozolomide resistance in hypoxia-treated glioma cells via the KDM3A/TFEB axis.
Topics: Animals; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Disease Models, Ani | 2023 |
Utility of Comprehensive Genomic Profiling for Precise Diagnosis of Pediatric-Type Diffuse High-Grade Glioma.
Topics: Adolescent; Brain Neoplasms; Child; Genomics; Glioma; Humans; Male; Mutation; Temozolomide | 2023 |
Utility of Comprehensive Genomic Profiling for Precise Diagnosis of Pediatric-Type Diffuse High-Grade Glioma.
Topics: Adolescent; Brain Neoplasms; Child; Genomics; Glioma; Humans; Male; Mutation; Temozolomide | 2023 |
Utility of Comprehensive Genomic Profiling for Precise Diagnosis of Pediatric-Type Diffuse High-Grade Glioma.
Topics: Adolescent; Brain Neoplasms; Child; Genomics; Glioma; Humans; Male; Mutation; Temozolomide | 2023 |
Utility of Comprehensive Genomic Profiling for Precise Diagnosis of Pediatric-Type Diffuse High-Grade Glioma.
Topics: Adolescent; Brain Neoplasms; Child; Genomics; Glioma; Humans; Male; Mutation; Temozolomide | 2023 |
Triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro.
Topics: Animals; Cell Survival; Dacarbazine; Dog Diseases; Dogs; Glioma; Lomustine; Temozolomide | 2023 |
Triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro.
Topics: Animals; Cell Survival; Dacarbazine; Dog Diseases; Dogs; Glioma; Lomustine; Temozolomide | 2023 |
Triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro.
Topics: Animals; Cell Survival; Dacarbazine; Dog Diseases; Dogs; Glioma; Lomustine; Temozolomide | 2023 |
Triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro.
Topics: Animals; Cell Survival; Dacarbazine; Dog Diseases; Dogs; Glioma; Lomustine; Temozolomide | 2023 |
Interferon-γ inducible protein 30 promotes the epithelial-mesenchymal transition-like phenotype and chemoresistance by activating EGFR/AKT/GSK3β/β-catenin pathway in glioma.
Topics: beta Catenin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epithe | 2023 |
Interferon-γ inducible protein 30 promotes the epithelial-mesenchymal transition-like phenotype and chemoresistance by activating EGFR/AKT/GSK3β/β-catenin pathway in glioma.
Topics: beta Catenin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epithe | 2023 |
Interferon-γ inducible protein 30 promotes the epithelial-mesenchymal transition-like phenotype and chemoresistance by activating EGFR/AKT/GSK3β/β-catenin pathway in glioma.
Topics: beta Catenin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epithe | 2023 |
Interferon-γ inducible protein 30 promotes the epithelial-mesenchymal transition-like phenotype and chemoresistance by activating EGFR/AKT/GSK3β/β-catenin pathway in glioma.
Topics: beta Catenin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epithe | 2023 |
Quercetin induces MGMT
Topics: Apoptosis; Apoptosis Regulatory Proteins; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Drug Resi | 2023 |
Quercetin induces MGMT
Topics: Apoptosis; Apoptosis Regulatory Proteins; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Drug Resi | 2023 |
Quercetin induces MGMT
Topics: Apoptosis; Apoptosis Regulatory Proteins; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Drug Resi | 2023 |
Quercetin induces MGMT
Topics: Apoptosis; Apoptosis Regulatory Proteins; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Drug Resi | 2023 |
Inhibition of autophagy and induction of glioblastoma cell death by NEO214, a perillyl alcohol-rolipram conjugate.
Topics: Autophagy; Cell Death; Chloroquine; Glioblastoma; Glioma; Humans; Lysosomes; Monoterpenes; Rolipram; | 2023 |
Inhibition of autophagy and induction of glioblastoma cell death by NEO214, a perillyl alcohol-rolipram conjugate.
Topics: Autophagy; Cell Death; Chloroquine; Glioblastoma; Glioma; Humans; Lysosomes; Monoterpenes; Rolipram; | 2023 |
Inhibition of autophagy and induction of glioblastoma cell death by NEO214, a perillyl alcohol-rolipram conjugate.
Topics: Autophagy; Cell Death; Chloroquine; Glioblastoma; Glioma; Humans; Lysosomes; Monoterpenes; Rolipram; | 2023 |
Inhibition of autophagy and induction of glioblastoma cell death by NEO214, a perillyl alcohol-rolipram conjugate.
Topics: Autophagy; Cell Death; Chloroquine; Glioblastoma; Glioma; Humans; Lysosomes; Monoterpenes; Rolipram; | 2023 |
Targeting MAGI2-AS3-modulated Akt-dependent ATP-binding cassette transporters as a possible strategy to reverse temozolomide resistance in temozolomide-resistant glioblastoma cells.
Topics: Adaptor Proteins, Signal Transducing; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Prol | 2023 |
Targeting MAGI2-AS3-modulated Akt-dependent ATP-binding cassette transporters as a possible strategy to reverse temozolomide resistance in temozolomide-resistant glioblastoma cells.
Topics: Adaptor Proteins, Signal Transducing; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Prol | 2023 |
Targeting MAGI2-AS3-modulated Akt-dependent ATP-binding cassette transporters as a possible strategy to reverse temozolomide resistance in temozolomide-resistant glioblastoma cells.
Topics: Adaptor Proteins, Signal Transducing; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Prol | 2023 |
Targeting MAGI2-AS3-modulated Akt-dependent ATP-binding cassette transporters as a possible strategy to reverse temozolomide resistance in temozolomide-resistant glioblastoma cells.
Topics: Adaptor Proteins, Signal Transducing; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Prol | 2023 |
Propofol Inhibits Glioma Stem Cell Growth and Migration and Their Interaction with Microglia via BDNF-AS and Extracellular Vesicles.
Topics: Brain Neoplasms; Brain-Derived Neurotrophic Factor; Extracellular Vesicles; Glioblastoma; Glioma; Hu | 2023 |
Propofol Inhibits Glioma Stem Cell Growth and Migration and Their Interaction with Microglia via BDNF-AS and Extracellular Vesicles.
Topics: Brain Neoplasms; Brain-Derived Neurotrophic Factor; Extracellular Vesicles; Glioblastoma; Glioma; Hu | 2023 |
Propofol Inhibits Glioma Stem Cell Growth and Migration and Their Interaction with Microglia via BDNF-AS and Extracellular Vesicles.
Topics: Brain Neoplasms; Brain-Derived Neurotrophic Factor; Extracellular Vesicles; Glioblastoma; Glioma; Hu | 2023 |
Propofol Inhibits Glioma Stem Cell Growth and Migration and Their Interaction with Microglia via BDNF-AS and Extracellular Vesicles.
Topics: Brain Neoplasms; Brain-Derived Neurotrophic Factor; Extracellular Vesicles; Glioblastoma; Glioma; Hu | 2023 |
Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA; | 2023 |
Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA; | 2023 |
Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA; | 2023 |
Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA; | 2023 |
Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences.
Topics: Adult; Astrocytoma; Child; Glioma; Humans; Mutation; Neoplasm Recurrence, Local; Temozolomide | 2023 |
Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences.
Topics: Adult; Astrocytoma; Child; Glioma; Humans; Mutation; Neoplasm Recurrence, Local; Temozolomide | 2023 |
Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences.
Topics: Adult; Astrocytoma; Child; Glioma; Humans; Mutation; Neoplasm Recurrence, Local; Temozolomide | 2023 |
Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences.
Topics: Adult; Astrocytoma; Child; Glioma; Humans; Mutation; Neoplasm Recurrence, Local; Temozolomide | 2023 |
Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.
Topics: Drug Delivery Systems; Drug Liberation; Glioblastoma; Glioma; Humans; Temozolomide | 2023 |
Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.
Topics: Drug Delivery Systems; Drug Liberation; Glioblastoma; Glioma; Humans; Temozolomide | 2023 |
Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.
Topics: Drug Delivery Systems; Drug Liberation; Glioblastoma; Glioma; Humans; Temozolomide | 2023 |
Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.
Topics: Drug Delivery Systems; Drug Liberation; Glioblastoma; Glioma; Humans; Temozolomide | 2023 |
Temozolomide-based sonodynamic therapy induces immunogenic cell death in glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Immunogenic Cell Death; | 2023 |
Temozolomide-based sonodynamic therapy induces immunogenic cell death in glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Immunogenic Cell Death; | 2023 |
Temozolomide-based sonodynamic therapy induces immunogenic cell death in glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Immunogenic Cell Death; | 2023 |
Temozolomide-based sonodynamic therapy induces immunogenic cell death in glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Immunogenic Cell Death; | 2023 |
Drug metabolism-related gene ABCA1 augments temozolomide chemoresistance and immune infiltration abundance of M2 macrophages in glioma.
Topics: ATP Binding Cassette Transporter 1; Drug Resistance, Neoplasm; Glioma; Humans; Macrophages; Molecula | 2023 |
Drug metabolism-related gene ABCA1 augments temozolomide chemoresistance and immune infiltration abundance of M2 macrophages in glioma.
Topics: ATP Binding Cassette Transporter 1; Drug Resistance, Neoplasm; Glioma; Humans; Macrophages; Molecula | 2023 |
Drug metabolism-related gene ABCA1 augments temozolomide chemoresistance and immune infiltration abundance of M2 macrophages in glioma.
Topics: ATP Binding Cassette Transporter 1; Drug Resistance, Neoplasm; Glioma; Humans; Macrophages; Molecula | 2023 |
Drug metabolism-related gene ABCA1 augments temozolomide chemoresistance and immune infiltration abundance of M2 macrophages in glioma.
Topics: ATP Binding Cassette Transporter 1; Drug Resistance, Neoplasm; Glioma; Humans; Macrophages; Molecula | 2023 |
Identifying predictors of glioma evolution from longitudinal sequencing.
Topics: Adult; Brain Neoplasms; Glioma; Humans; Mutation; Neoplasm Recurrence, Local; Precision Medicine; Te | 2023 |
Identifying predictors of glioma evolution from longitudinal sequencing.
Topics: Adult; Brain Neoplasms; Glioma; Humans; Mutation; Neoplasm Recurrence, Local; Precision Medicine; Te | 2023 |
Identifying predictors of glioma evolution from longitudinal sequencing.
Topics: Adult; Brain Neoplasms; Glioma; Humans; Mutation; Neoplasm Recurrence, Local; Precision Medicine; Te | 2023 |
Identifying predictors of glioma evolution from longitudinal sequencing.
Topics: Adult; Brain Neoplasms; Glioma; Humans; Mutation; Neoplasm Recurrence, Local; Precision Medicine; Te | 2023 |
Effect of Temozolomide Combined with Intensity Modulated Radiation Therapy on Serum Factor, Immune Function and Clinical Efficacy in Postoperative Glioma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Immunity; Temozolomide; Treatmen | 2023 |
Effect of Temozolomide Combined with Intensity Modulated Radiation Therapy on Serum Factor, Immune Function and Clinical Efficacy in Postoperative Glioma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Immunity; Temozolomide; Treatmen | 2023 |
Effect of Temozolomide Combined with Intensity Modulated Radiation Therapy on Serum Factor, Immune Function and Clinical Efficacy in Postoperative Glioma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Immunity; Temozolomide; Treatmen | 2023 |
Effect of Temozolomide Combined with Intensity Modulated Radiation Therapy on Serum Factor, Immune Function and Clinical Efficacy in Postoperative Glioma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Immunity; Temozolomide; Treatmen | 2023 |
Ceramide Is Involved in Temozolomide Resistance in Human Glioblastoma U87MG Overexpressing EGFR.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Ceramides; Drug Resistance, Ne | 2023 |
Ceramide Is Involved in Temozolomide Resistance in Human Glioblastoma U87MG Overexpressing EGFR.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Ceramides; Drug Resistance, Ne | 2023 |
Ceramide Is Involved in Temozolomide Resistance in Human Glioblastoma U87MG Overexpressing EGFR.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Ceramides; Drug Resistance, Ne | 2023 |
Ceramide Is Involved in Temozolomide Resistance in Human Glioblastoma U87MG Overexpressing EGFR.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Ceramides; Drug Resistance, Ne | 2023 |
Decreased eukaryotic initiation factors expression upon temozolomide treatment-potential novel implications for eIFs in glioma therapy.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Glioma; Humans; Phosphatidylinositol 3 | 2023 |
Decreased eukaryotic initiation factors expression upon temozolomide treatment-potential novel implications for eIFs in glioma therapy.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Glioma; Humans; Phosphatidylinositol 3 | 2023 |
Decreased eukaryotic initiation factors expression upon temozolomide treatment-potential novel implications for eIFs in glioma therapy.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Glioma; Humans; Phosphatidylinositol 3 | 2023 |
Decreased eukaryotic initiation factors expression upon temozolomide treatment-potential novel implications for eIFs in glioma therapy.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Glioma; Humans; Phosphatidylinositol 3 | 2023 |
Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
Topics: Astrocytoma; Brain Neoplasms; Genomics; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Retrospe | 2023 |
Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
Topics: Astrocytoma; Brain Neoplasms; Genomics; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Retrospe | 2023 |
Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
Topics: Astrocytoma; Brain Neoplasms; Genomics; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Retrospe | 2023 |
Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
Topics: Astrocytoma; Brain Neoplasms; Genomics; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Retrospe | 2023 |
[Curcumol reverses temozolomide resistance in glioma cells by regulating the UTX/MGMT axis].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Meth | 2023 |
[Curcumol reverses temozolomide resistance in glioma cells by regulating the UTX/MGMT axis].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Meth | 2023 |
[Curcumol reverses temozolomide resistance in glioma cells by regulating the UTX/MGMT axis].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Meth | 2023 |
[Curcumol reverses temozolomide resistance in glioma cells by regulating the UTX/MGMT axis].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Meth | 2023 |
Overcoming chemotherapy resistance in low-grade gliomas: A computational approach.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Temozolomide | 2023 |
Overcoming chemotherapy resistance in low-grade gliomas: A computational approach.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Temozolomide | 2023 |
Overcoming chemotherapy resistance in low-grade gliomas: A computational approach.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Temozolomide | 2023 |
Overcoming chemotherapy resistance in low-grade gliomas: A computational approach.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioma; Humans; Temozolomide | 2023 |
Identification of potential glioma drug resistance target proteins based on ultra-performance liquid chromatography-mass spectrometry differential proteomics.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chromatography, Liquid; Dacarb | 2023 |
Identification of potential glioma drug resistance target proteins based on ultra-performance liquid chromatography-mass spectrometry differential proteomics.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chromatography, Liquid; Dacarb | 2023 |
Identification of potential glioma drug resistance target proteins based on ultra-performance liquid chromatography-mass spectrometry differential proteomics.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chromatography, Liquid; Dacarb | 2023 |
Identification of potential glioma drug resistance target proteins based on ultra-performance liquid chromatography-mass spectrometry differential proteomics.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chromatography, Liquid; Dacarb | 2023 |
MicroRNA-302c enhances the chemosensitivity of human glioma cells to temozolomide by suppressing P-gp expression.
Topics: Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Ne | 2019 |
MicroRNA-302c enhances the chemosensitivity of human glioma cells to temozolomide by suppressing P-gp expression.
Topics: Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Ne | 2019 |
MicroRNA-302c enhances the chemosensitivity of human glioma cells to temozolomide by suppressing P-gp expression.
Topics: Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Ne | 2019 |
MicroRNA-302c enhances the chemosensitivity of human glioma cells to temozolomide by suppressing P-gp expression.
Topics: Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Ne | 2019 |
11PS04 is a new chemical entity identified by microRNA-based biosensing with promising therapeutic potential against cancer stem cells.
Topics: Animals; Antineoplastic Agents; Biosensing Techniques; Carcinogenesis; Cell Line, Tumor; Cell Prolif | 2019 |
11PS04 is a new chemical entity identified by microRNA-based biosensing with promising therapeutic potential against cancer stem cells.
Topics: Animals; Antineoplastic Agents; Biosensing Techniques; Carcinogenesis; Cell Line, Tumor; Cell Prolif | 2019 |
11PS04 is a new chemical entity identified by microRNA-based biosensing with promising therapeutic potential against cancer stem cells.
Topics: Animals; Antineoplastic Agents; Biosensing Techniques; Carcinogenesis; Cell Line, Tumor; Cell Prolif | 2019 |
11PS04 is a new chemical entity identified by microRNA-based biosensing with promising therapeutic potential against cancer stem cells.
Topics: Animals; Antineoplastic Agents; Biosensing Techniques; Carcinogenesis; Cell Line, Tumor; Cell Prolif | 2019 |
WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial.
Topics: Adolescent; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Child; Child, Pr | 2020 |
WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial.
Topics: Adolescent; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Child; Child, Pr | 2020 |
WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial.
Topics: Adolescent; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Child; Child, Pr | 2020 |
WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial.
Topics: Adolescent; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Child; Child, Pr | 2020 |
Tim-3 expression in glioma cells is associated with drug resistance.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Resistance, | 2019 |
Tim-3 expression in glioma cells is associated with drug resistance.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Resistance, | 2019 |
Tim-3 expression in glioma cells is associated with drug resistance.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Resistance, | 2019 |
Tim-3 expression in glioma cells is associated with drug resistance.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Resistance, | 2019 |
LINC01198 promotes proliferation and temozolomide resistance in a NEDD4-1-dependent manner, repressing PTEN expression in glioma.
Topics: Brain Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, | 2019 |
LINC01198 promotes proliferation and temozolomide resistance in a NEDD4-1-dependent manner, repressing PTEN expression in glioma.
Topics: Brain Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, | 2019 |
LINC01198 promotes proliferation and temozolomide resistance in a NEDD4-1-dependent manner, repressing PTEN expression in glioma.
Topics: Brain Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, | 2019 |
LINC01198 promotes proliferation and temozolomide resistance in a NEDD4-1-dependent manner, repressing PTEN expression in glioma.
Topics: Brain Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, | 2019 |
MTBP regulates cell survival and therapeutic sensitivity in TP53 wildtype glioblastomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Carrier Proteins; Cell Lin | 2019 |
MTBP regulates cell survival and therapeutic sensitivity in TP53 wildtype glioblastomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Carrier Proteins; Cell Lin | 2019 |
MTBP regulates cell survival and therapeutic sensitivity in TP53 wildtype glioblastomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Carrier Proteins; Cell Lin | 2019 |
MTBP regulates cell survival and therapeutic sensitivity in TP53 wildtype glioblastomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Carrier Proteins; Cell Lin | 2019 |
DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide.
Topics: AMP-Activated Protein Kinases; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell | 2019 |
DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide.
Topics: AMP-Activated Protein Kinases; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell | 2019 |
DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide.
Topics: AMP-Activated Protein Kinases; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell | 2019 |
DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide.
Topics: AMP-Activated Protein Kinases; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell | 2019 |
Acquisition of temozolomide resistance by the rat C6 glioma cell line increases cell migration and side population phenotype.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Movement; Cell Prolifer | 2019 |
Acquisition of temozolomide resistance by the rat C6 glioma cell line increases cell migration and side population phenotype.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Movement; Cell Prolifer | 2019 |
Acquisition of temozolomide resistance by the rat C6 glioma cell line increases cell migration and side population phenotype.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Movement; Cell Prolifer | 2019 |
Acquisition of temozolomide resistance by the rat C6 glioma cell line increases cell migration and side population phenotype.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Movement; Cell Prolifer | 2019 |
The polymorphisms (rs3213801 and rs5744533) of DNA polymerase kappa gene are not related with glioma risk and prognosis: A case-control study.
Topics: Adult; Age Factors; Antineoplastic Agents, Alkylating; Asian People; Brain; Brain Neoplasms; Case-Co | 2019 |
The polymorphisms (rs3213801 and rs5744533) of DNA polymerase kappa gene are not related with glioma risk and prognosis: A case-control study.
Topics: Adult; Age Factors; Antineoplastic Agents, Alkylating; Asian People; Brain; Brain Neoplasms; Case-Co | 2019 |
The polymorphisms (rs3213801 and rs5744533) of DNA polymerase kappa gene are not related with glioma risk and prognosis: A case-control study.
Topics: Adult; Age Factors; Antineoplastic Agents, Alkylating; Asian People; Brain; Brain Neoplasms; Case-Co | 2019 |
The polymorphisms (rs3213801 and rs5744533) of DNA polymerase kappa gene are not related with glioma risk and prognosis: A case-control study.
Topics: Adult; Age Factors; Antineoplastic Agents, Alkylating; Asian People; Brain; Brain Neoplasms; Case-Co | 2019 |
Knockdown of circular RNA CEP128 suppresses proliferation and improves cytotoxic efficacy of temozolomide in glioma cells by regulating miR-145-5p.
Topics: Antineoplastic Agents; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expre | 2019 |
Knockdown of circular RNA CEP128 suppresses proliferation and improves cytotoxic efficacy of temozolomide in glioma cells by regulating miR-145-5p.
Topics: Antineoplastic Agents; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expre | 2019 |
Knockdown of circular RNA CEP128 suppresses proliferation and improves cytotoxic efficacy of temozolomide in glioma cells by regulating miR-145-5p.
Topics: Antineoplastic Agents; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expre | 2019 |
Knockdown of circular RNA CEP128 suppresses proliferation and improves cytotoxic efficacy of temozolomide in glioma cells by regulating miR-145-5p.
Topics: Antineoplastic Agents; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expre | 2019 |
BMP signaling mediates glioma stem cell quiescence and confers treatment resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Brain Neo | 2019 |
BMP signaling mediates glioma stem cell quiescence and confers treatment resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Brain Neo | 2019 |
BMP signaling mediates glioma stem cell quiescence and confers treatment resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Brain Neo | 2019 |
BMP signaling mediates glioma stem cell quiescence and confers treatment resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Brain Neo | 2019 |
Blood-Brain Barrier- and Blood-Brain Tumor Barrier-Penetrating Peptide-Derived Targeted Therapeutics for Glioma and Malignant Tumor Brain Metastases.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Drug Deliver | 2019 |
Blood-Brain Barrier- and Blood-Brain Tumor Barrier-Penetrating Peptide-Derived Targeted Therapeutics for Glioma and Malignant Tumor Brain Metastases.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Drug Deliver | 2019 |
Blood-Brain Barrier- and Blood-Brain Tumor Barrier-Penetrating Peptide-Derived Targeted Therapeutics for Glioma and Malignant Tumor Brain Metastases.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Drug Deliver | 2019 |
Blood-Brain Barrier- and Blood-Brain Tumor Barrier-Penetrating Peptide-Derived Targeted Therapeutics for Glioma and Malignant Tumor Brain Metastases.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Drug Deliver | 2019 |
Iguratimod encapsulated PLGA-NPs improves therapeutic outcome in glioma, glioma stem-like cells and temozolomide resistant glioma cells.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Ce | 2019 |
Iguratimod encapsulated PLGA-NPs improves therapeutic outcome in glioma, glioma stem-like cells and temozolomide resistant glioma cells.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Ce | 2019 |
Iguratimod encapsulated PLGA-NPs improves therapeutic outcome in glioma, glioma stem-like cells and temozolomide resistant glioma cells.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Ce | 2019 |
Iguratimod encapsulated PLGA-NPs improves therapeutic outcome in glioma, glioma stem-like cells and temozolomide resistant glioma cells.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Ce | 2019 |
Integrated proteomic and metabolomic profiling the global response of rat glioma model by temozolomide treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; G2 Phase C | 2020 |
Integrated proteomic and metabolomic profiling the global response of rat glioma model by temozolomide treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; G2 Phase C | 2020 |
Integrated proteomic and metabolomic profiling the global response of rat glioma model by temozolomide treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; G2 Phase C | 2020 |
Integrated proteomic and metabolomic profiling the global response of rat glioma model by temozolomide treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; G2 Phase C | 2020 |
LINC00174 down-regulation decreases chemoresistance to temozolomide in human glioma cells by regulating miR-138-5p/SOX9 axis.
Topics: Brain Neoplasms; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; SOX9 Transcription Factor; Te | 2020 |
LINC00174 down-regulation decreases chemoresistance to temozolomide in human glioma cells by regulating miR-138-5p/SOX9 axis.
Topics: Brain Neoplasms; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; SOX9 Transcription Factor; Te | 2020 |
LINC00174 down-regulation decreases chemoresistance to temozolomide in human glioma cells by regulating miR-138-5p/SOX9 axis.
Topics: Brain Neoplasms; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; SOX9 Transcription Factor; Te | 2020 |
LINC00174 down-regulation decreases chemoresistance to temozolomide in human glioma cells by regulating miR-138-5p/SOX9 axis.
Topics: Brain Neoplasms; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; SOX9 Transcription Factor; Te | 2020 |
Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neo | 2020 |
Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neo | 2020 |
Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neo | 2020 |
Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neo | 2020 |
Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy.
Topics: beta Catenin; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulati | 2020 |
Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy.
Topics: beta Catenin; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulati | 2020 |
Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy.
Topics: beta Catenin; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulati | 2020 |
Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy.
Topics: beta Catenin; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulati | 2020 |
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; Bortezomib; Brain Neoplasms; Cel | 2019 |
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; Bortezomib; Brain Neoplasms; Cel | 2019 |
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; Bortezomib; Brain Neoplasms; Cel | 2019 |
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; Bortezomib; Brain Neoplasms; Cel | 2019 |
IGF-1-enhanced miR-513a-5p signaling desensitizes glioma cells to temozolomide by targeting the NEDD4L-inhibited Wnt/β-catenin pathway.
Topics: 3' Untranslated Regions; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Ne | 2019 |
IGF-1-enhanced miR-513a-5p signaling desensitizes glioma cells to temozolomide by targeting the NEDD4L-inhibited Wnt/β-catenin pathway.
Topics: 3' Untranslated Regions; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Ne | 2019 |
IGF-1-enhanced miR-513a-5p signaling desensitizes glioma cells to temozolomide by targeting the NEDD4L-inhibited Wnt/β-catenin pathway.
Topics: 3' Untranslated Regions; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Ne | 2019 |
IGF-1-enhanced miR-513a-5p signaling desensitizes glioma cells to temozolomide by targeting the NEDD4L-inhibited Wnt/β-catenin pathway.
Topics: 3' Untranslated Regions; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Ne | 2019 |
Polyphyllin VII Promotes Apoptosis and Autophagic Cell Death via ROS-Inhibited AKT Activity, and Sensitizes Glioma Cells to Temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagic Cell Death; Brain Neoplasms; C | 2019 |
Polyphyllin VII Promotes Apoptosis and Autophagic Cell Death via ROS-Inhibited AKT Activity, and Sensitizes Glioma Cells to Temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagic Cell Death; Brain Neoplasms; C | 2019 |
Polyphyllin VII Promotes Apoptosis and Autophagic Cell Death via ROS-Inhibited AKT Activity, and Sensitizes Glioma Cells to Temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagic Cell Death; Brain Neoplasms; C | 2019 |
Polyphyllin VII Promotes Apoptosis and Autophagic Cell Death via ROS-Inhibited AKT Activity, and Sensitizes Glioma Cells to Temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagic Cell Death; Brain Neoplasms; C | 2019 |
Quantitative Proteomics Analysis Reveals Nuclear Perturbation in Human Glioma U87 Cells treated with Temozolomide.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Computational Biology; DNA Damage; DNA Repair; Glio | 2020 |
Quantitative Proteomics Analysis Reveals Nuclear Perturbation in Human Glioma U87 Cells treated with Temozolomide.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Computational Biology; DNA Damage; DNA Repair; Glio | 2020 |
Quantitative Proteomics Analysis Reveals Nuclear Perturbation in Human Glioma U87 Cells treated with Temozolomide.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Computational Biology; DNA Damage; DNA Repair; Glio | 2020 |
Quantitative Proteomics Analysis Reveals Nuclear Perturbation in Human Glioma U87 Cells treated with Temozolomide.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Computational Biology; DNA Damage; DNA Repair; Glio | 2020 |
Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma.
Topics: Antineoplastic Agents, Alkylating; Benzimidazoles; Blood-Brain Barrier; Brain Neoplasms; Cell Prolif | 2020 |
Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma.
Topics: Antineoplastic Agents, Alkylating; Benzimidazoles; Blood-Brain Barrier; Brain Neoplasms; Cell Prolif | 2020 |
Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma.
Topics: Antineoplastic Agents, Alkylating; Benzimidazoles; Blood-Brain Barrier; Brain Neoplasms; Cell Prolif | 2020 |
Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma.
Topics: Antineoplastic Agents, Alkylating; Benzimidazoles; Blood-Brain Barrier; Brain Neoplasms; Cell Prolif | 2020 |
Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Cancer Vaccines; Cell Line, Tumor; Combined Modality The | 2020 |
Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Cancer Vaccines; Cell Line, Tumor; Combined Modality The | 2020 |
Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Cancer Vaccines; Cell Line, Tumor; Combined Modality The | 2020 |
Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Cancer Vaccines; Cell Line, Tumor; Combined Modality The | 2020 |
Short-term outcomes and predictors of post-surgical seizures in patients with supratentorial low-grade gliomas.
Topics: Adult; Brain Neoplasms; Cohort Studies; Electroencephalography; Female; Glioma; Humans; Magnetic Res | 2020 |
Short-term outcomes and predictors of post-surgical seizures in patients with supratentorial low-grade gliomas.
Topics: Adult; Brain Neoplasms; Cohort Studies; Electroencephalography; Female; Glioma; Humans; Magnetic Res | 2020 |
Short-term outcomes and predictors of post-surgical seizures in patients with supratentorial low-grade gliomas.
Topics: Adult; Brain Neoplasms; Cohort Studies; Electroencephalography; Female; Glioma; Humans; Magnetic Res | 2020 |
Short-term outcomes and predictors of post-surgical seizures in patients with supratentorial low-grade gliomas.
Topics: Adult; Brain Neoplasms; Cohort Studies; Electroencephalography; Female; Glioma; Humans; Magnetic Res | 2020 |
A
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Calcium-Binding Proteins; Carrier Proteins; Cell L | 2020 |
A
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Calcium-Binding Proteins; Carrier Proteins; Cell L | 2020 |
A
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Calcium-Binding Proteins; Carrier Proteins; Cell L | 2020 |
A
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Calcium-Binding Proteins; Carrier Proteins; Cell L | 2020 |
Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cell
Topics: Animals; Antibodies; Antigens, CD; Antigens, Differentiation, Myelomonocytic; B7-H1 Antigen; Brain N | 2020 |
Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cell
Topics: Animals; Antibodies; Antigens, CD; Antigens, Differentiation, Myelomonocytic; B7-H1 Antigen; Brain N | 2020 |
Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cell
Topics: Animals; Antibodies; Antigens, CD; Antigens, Differentiation, Myelomonocytic; B7-H1 Antigen; Brain N | 2020 |
Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cell
Topics: Animals; Antibodies; Antigens, CD; Antigens, Differentiation, Myelomonocytic; B7-H1 Antigen; Brain N | 2020 |
Evaluation of the Prognosis of Neuroglioma Based on Dynamic Magnetic Resonance Enhancement.
Topics: Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemotherapy, Adjuvant; Contrast Me | 2020 |
Evaluation of the Prognosis of Neuroglioma Based on Dynamic Magnetic Resonance Enhancement.
Topics: Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemotherapy, Adjuvant; Contrast Me | 2020 |
Evaluation of the Prognosis of Neuroglioma Based on Dynamic Magnetic Resonance Enhancement.
Topics: Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemotherapy, Adjuvant; Contrast Me | 2020 |
Evaluation of the Prognosis of Neuroglioma Based on Dynamic Magnetic Resonance Enhancement.
Topics: Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemotherapy, Adjuvant; Contrast Me | 2020 |
Dual functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma via attenuating EGFR and MET signaling pathways.
Topics: Animals; Binding Sites; Brain; Cell Line, Tumor; Cell Membrane Permeability; DNA Damage; DNA Repair; | 2020 |
Dual functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma via attenuating EGFR and MET signaling pathways.
Topics: Animals; Binding Sites; Brain; Cell Line, Tumor; Cell Membrane Permeability; DNA Damage; DNA Repair; | 2020 |
Dual functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma via attenuating EGFR and MET signaling pathways.
Topics: Animals; Binding Sites; Brain; Cell Line, Tumor; Cell Membrane Permeability; DNA Damage; DNA Repair; | 2020 |
Dual functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma via attenuating EGFR and MET signaling pathways.
Topics: Animals; Binding Sites; Brain; Cell Line, Tumor; Cell Membrane Permeability; DNA Damage; DNA Repair; | 2020 |
The Interleukin-33/ST2 axis promotes glioma mesenchymal transition, stemness and TMZ resistance via JNK activation.
Topics: Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Epithelial-Mesenchymal Tr | 2020 |
The Interleukin-33/ST2 axis promotes glioma mesenchymal transition, stemness and TMZ resistance via JNK activation.
Topics: Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Epithelial-Mesenchymal Tr | 2020 |
The Interleukin-33/ST2 axis promotes glioma mesenchymal transition, stemness and TMZ resistance via JNK activation.
Topics: Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Epithelial-Mesenchymal Tr | 2020 |
The Interleukin-33/ST2 axis promotes glioma mesenchymal transition, stemness and TMZ resistance via JNK activation.
Topics: Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Epithelial-Mesenchymal Tr | 2020 |
Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions.
Topics: 5-Methylcytosine; Brain Neoplasms; Cell Line, Tumor; DNA Methylation; DNA Modification Methylases; D | 2020 |
Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions.
Topics: 5-Methylcytosine; Brain Neoplasms; Cell Line, Tumor; DNA Methylation; DNA Modification Methylases; D | 2020 |
Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions.
Topics: 5-Methylcytosine; Brain Neoplasms; Cell Line, Tumor; DNA Methylation; DNA Modification Methylases; D | 2020 |
Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions.
Topics: 5-Methylcytosine; Brain Neoplasms; Cell Line, Tumor; DNA Methylation; DNA Modification Methylases; D | 2020 |
MicroRNA-29b promotes cell sensitivity to Temozolomide by targeting STAT3 in glioma.
Topics: Apoptosis; Cell Survival; Down-Regulation; Glioma; Humans; MicroRNAs; STAT3 Transcription Factor; Te | 2020 |
MicroRNA-29b promotes cell sensitivity to Temozolomide by targeting STAT3 in glioma.
Topics: Apoptosis; Cell Survival; Down-Regulation; Glioma; Humans; MicroRNAs; STAT3 Transcription Factor; Te | 2020 |
MicroRNA-29b promotes cell sensitivity to Temozolomide by targeting STAT3 in glioma.
Topics: Apoptosis; Cell Survival; Down-Regulation; Glioma; Humans; MicroRNAs; STAT3 Transcription Factor; Te | 2020 |
MicroRNA-29b promotes cell sensitivity to Temozolomide by targeting STAT3 in glioma.
Topics: Apoptosis; Cell Survival; Down-Regulation; Glioma; Humans; MicroRNAs; STAT3 Transcription Factor; Te | 2020 |
miR-152-5p suppresses glioma progression and tumorigenesis and potentiates temozolomide sensitivity by targeting FBXL7.
Topics: Animals; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug | 2020 |
miR-152-5p suppresses glioma progression and tumorigenesis and potentiates temozolomide sensitivity by targeting FBXL7.
Topics: Animals; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug | 2020 |
miR-152-5p suppresses glioma progression and tumorigenesis and potentiates temozolomide sensitivity by targeting FBXL7.
Topics: Animals; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug | 2020 |
miR-152-5p suppresses glioma progression and tumorigenesis and potentiates temozolomide sensitivity by targeting FBXL7.
Topics: Animals; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug | 2020 |
MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2020 |
MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2020 |
MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2020 |
MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2020 |
Particle radiation therapy in the management of malignant glioma: Early experience at the Shanghai Proton and Heavy Ion Center.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; DNA Modification Methylases; DNA Repair Enzymes; Dos | 2020 |
Particle radiation therapy in the management of malignant glioma: Early experience at the Shanghai Proton and Heavy Ion Center.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; DNA Modification Methylases; DNA Repair Enzymes; Dos | 2020 |
Particle radiation therapy in the management of malignant glioma: Early experience at the Shanghai Proton and Heavy Ion Center.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; DNA Modification Methylases; DNA Repair Enzymes; Dos | 2020 |
Particle radiation therapy in the management of malignant glioma: Early experience at the Shanghai Proton and Heavy Ion Center.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; DNA Modification Methylases; DNA Repair Enzymes; Dos | 2020 |
MiR-3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway.
Topics: Animals; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistan | 2020 |
MiR-3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway.
Topics: Animals; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistan | 2020 |
MiR-3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway.
Topics: Animals; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistan | 2020 |
MiR-3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway.
Topics: Animals; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistan | 2020 |
Intranasal Delivery of Immunotherapeutic Nanoformulations for Treatment of Glioma Through in situ Activation of Immune Response.
Topics: Administration, Intranasal; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Del | 2020 |
Intranasal Delivery of Immunotherapeutic Nanoformulations for Treatment of Glioma Through in situ Activation of Immune Response.
Topics: Administration, Intranasal; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Del | 2020 |
Intranasal Delivery of Immunotherapeutic Nanoformulations for Treatment of Glioma Through in situ Activation of Immune Response.
Topics: Administration, Intranasal; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Del | 2020 |
Intranasal Delivery of Immunotherapeutic Nanoformulations for Treatment of Glioma Through in situ Activation of Immune Response.
Topics: Administration, Intranasal; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Del | 2020 |
Exosome-mediated transfer of circRNA CircNFIX enhances temozolomide resistance in glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug R | 2020 |
Exosome-mediated transfer of circRNA CircNFIX enhances temozolomide resistance in glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug R | 2020 |
Exosome-mediated transfer of circRNA CircNFIX enhances temozolomide resistance in glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug R | 2020 |
Exosome-mediated transfer of circRNA CircNFIX enhances temozolomide resistance in glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug R | 2020 |
Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity.
Topics: Adaptive Immunity; Animals; Antigen Presentation; Apoptosis; CD47 Antigen; Cell Line, Tumor; Cell Pr | 2020 |
Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity.
Topics: Adaptive Immunity; Animals; Antigen Presentation; Apoptosis; CD47 Antigen; Cell Line, Tumor; Cell Pr | 2020 |
Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity.
Topics: Adaptive Immunity; Animals; Antigen Presentation; Apoptosis; CD47 Antigen; Cell Line, Tumor; Cell Pr | 2020 |
Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity.
Topics: Adaptive Immunity; Animals; Antigen Presentation; Apoptosis; CD47 Antigen; Cell Line, Tumor; Cell Pr | 2020 |
MicroRNA-155-3p promotes glioma progression and temozolomide resistance by targeting Six1.
Topics: Animals; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; | 2020 |
MicroRNA-155-3p promotes glioma progression and temozolomide resistance by targeting Six1.
Topics: Animals; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; | 2020 |
MicroRNA-155-3p promotes glioma progression and temozolomide resistance by targeting Six1.
Topics: Animals; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; | 2020 |
MicroRNA-155-3p promotes glioma progression and temozolomide resistance by targeting Six1.
Topics: Animals; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; | 2020 |
All-stage precisional glioma targeted therapy enabled by a well-designed D-peptide.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Carriers; Endoplasmic Reticu | 2020 |
All-stage precisional glioma targeted therapy enabled by a well-designed D-peptide.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Carriers; Endoplasmic Reticu | 2020 |
All-stage precisional glioma targeted therapy enabled by a well-designed D-peptide.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Carriers; Endoplasmic Reticu | 2020 |
All-stage precisional glioma targeted therapy enabled by a well-designed D-peptide.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Carriers; Endoplasmic Reticu | 2020 |
miR-149 rs2292832 C allele enhances the cytotoxic effect of temozolomide against glioma cells.
Topics: Alleles; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Ce | 2020 |
miR-149 rs2292832 C allele enhances the cytotoxic effect of temozolomide against glioma cells.
Topics: Alleles; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Ce | 2020 |
miR-149 rs2292832 C allele enhances the cytotoxic effect of temozolomide against glioma cells.
Topics: Alleles; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Ce | 2020 |
miR-149 rs2292832 C allele enhances the cytotoxic effect of temozolomide against glioma cells.
Topics: Alleles; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Ce | 2020 |
CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells.
Topics: Aminopyridines; Animals; Apoptosis; Benzimidazoles; Brain Neoplasms; Cell Line, Tumor; Cell Prolifer | 2020 |
CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells.
Topics: Aminopyridines; Animals; Apoptosis; Benzimidazoles; Brain Neoplasms; Cell Line, Tumor; Cell Prolifer | 2020 |
CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells.
Topics: Aminopyridines; Animals; Apoptosis; Benzimidazoles; Brain Neoplasms; Cell Line, Tumor; Cell Prolifer | 2020 |
CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells.
Topics: Aminopyridines; Animals; Apoptosis; Benzimidazoles; Brain Neoplasms; Cell Line, Tumor; Cell Prolifer | 2020 |
Mechanisms and therapeutic implications of hypermutation in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Mismatch Repair; Gene Frequency; Ge | 2020 |
Mechanisms and therapeutic implications of hypermutation in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Mismatch Repair; Gene Frequency; Ge | 2020 |
Mechanisms and therapeutic implications of hypermutation in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Mismatch Repair; Gene Frequency; Ge | 2020 |
Mechanisms and therapeutic implications of hypermutation in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Mismatch Repair; Gene Frequency; Ge | 2020 |
Inhibition of Nrf2 might enhance the anti-tumor effect of temozolomide in glioma cells via inhibition of Ras/Raf/MEK signaling pathway.
Topics: Antineoplastic Agents, Alkylating; Glioma; Humans; MAP Kinase Kinase Kinases; NF-E2-Related Factor 2 | 2021 |
Inhibition of Nrf2 might enhance the anti-tumor effect of temozolomide in glioma cells via inhibition of Ras/Raf/MEK signaling pathway.
Topics: Antineoplastic Agents, Alkylating; Glioma; Humans; MAP Kinase Kinase Kinases; NF-E2-Related Factor 2 | 2021 |
Inhibition of Nrf2 might enhance the anti-tumor effect of temozolomide in glioma cells via inhibition of Ras/Raf/MEK signaling pathway.
Topics: Antineoplastic Agents, Alkylating; Glioma; Humans; MAP Kinase Kinase Kinases; NF-E2-Related Factor 2 | 2021 |
Inhibition of Nrf2 might enhance the anti-tumor effect of temozolomide in glioma cells via inhibition of Ras/Raf/MEK signaling pathway.
Topics: Antineoplastic Agents, Alkylating; Glioma; Humans; MAP Kinase Kinase Kinases; NF-E2-Related Factor 2 | 2021 |
Blockade of Cell Volume Regulatory Protein NKCC1 Increases TMZ-Induced Glioma Apoptosis and Reduces Astrogliosis.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Prolif | 2020 |
Blockade of Cell Volume Regulatory Protein NKCC1 Increases TMZ-Induced Glioma Apoptosis and Reduces Astrogliosis.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Prolif | 2020 |
Blockade of Cell Volume Regulatory Protein NKCC1 Increases TMZ-Induced Glioma Apoptosis and Reduces Astrogliosis.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Prolif | 2020 |
Blockade of Cell Volume Regulatory Protein NKCC1 Increases TMZ-Induced Glioma Apoptosis and Reduces Astrogliosis.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Prolif | 2020 |
Hypermutated Gliomas Respond Poorly to Immunotherapy.
Topics: Glioma; Humans; Immunotherapy; Temozolomide | 2020 |
Hypermutated Gliomas Respond Poorly to Immunotherapy.
Topics: Glioma; Humans; Immunotherapy; Temozolomide | 2020 |
Hypermutated Gliomas Respond Poorly to Immunotherapy.
Topics: Glioma; Humans; Immunotherapy; Temozolomide | 2020 |
Hypermutated Gliomas Respond Poorly to Immunotherapy.
Topics: Glioma; Humans; Immunotherapy; Temozolomide | 2020 |
Synthetic High-density Lipoprotein Nanodiscs for Personalized Immunotherapy Against Gliomas.
Topics: Animals; Antigens, Neoplasm; B7-H1 Antigen; Cancer Vaccines; Cell Line, Tumor; Glioma; Humans; Immun | 2020 |
Synthetic High-density Lipoprotein Nanodiscs for Personalized Immunotherapy Against Gliomas.
Topics: Animals; Antigens, Neoplasm; B7-H1 Antigen; Cancer Vaccines; Cell Line, Tumor; Glioma; Humans; Immun | 2020 |
Synthetic High-density Lipoprotein Nanodiscs for Personalized Immunotherapy Against Gliomas.
Topics: Animals; Antigens, Neoplasm; B7-H1 Antigen; Cancer Vaccines; Cell Line, Tumor; Glioma; Humans; Immun | 2020 |
Synthetic High-density Lipoprotein Nanodiscs for Personalized Immunotherapy Against Gliomas.
Topics: Animals; Antigens, Neoplasm; B7-H1 Antigen; Cancer Vaccines; Cell Line, Tumor; Glioma; Humans; Immun | 2020 |
Coumarins modulate the anti-glioma properties of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Beclin-1; Brain Neoplasms; Cas | 2020 |
Coumarins modulate the anti-glioma properties of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Beclin-1; Brain Neoplasms; Cas | 2020 |
Coumarins modulate the anti-glioma properties of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Beclin-1; Brain Neoplasms; Cas | 2020 |
Coumarins modulate the anti-glioma properties of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Beclin-1; Brain Neoplasms; Cas | 2020 |
New advances on the inhibition of Siwei Xiaoliuyin combined with Temozolomide in glioma based on the regulatory mechanism of miRNA21/221.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Models, Animal; Drug Therapy, C | 2020 |
New advances on the inhibition of Siwei Xiaoliuyin combined with Temozolomide in glioma based on the regulatory mechanism of miRNA21/221.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Models, Animal; Drug Therapy, C | 2020 |
New advances on the inhibition of Siwei Xiaoliuyin combined with Temozolomide in glioma based on the regulatory mechanism of miRNA21/221.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Models, Animal; Drug Therapy, C | 2020 |
New advances on the inhibition of Siwei Xiaoliuyin combined with Temozolomide in glioma based on the regulatory mechanism of miRNA21/221.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Models, Animal; Drug Therapy, C | 2020 |
Long term follow-up and outcomes in adult patients with thalamic gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Female; Follow | 2020 |
Long term follow-up and outcomes in adult patients with thalamic gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Female; Follow | 2020 |
Long term follow-up and outcomes in adult patients with thalamic gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Female; Follow | 2020 |
Long term follow-up and outcomes in adult patients with thalamic gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Female; Follow | 2020 |
Letter referencing "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting in glioma patients receiving adjuvant temozolomide".
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Letter referencing "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting in glioma patients receiving adjuvant temozolomide".
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Letter referencing "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting in glioma patients receiving adjuvant temozolomide".
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Letter referencing "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting in glioma patients receiving adjuvant temozolomide".
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Dru | 2020 |
Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Dru | 2020 |
Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Dru | 2020 |
Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Dru | 2020 |
Noninvasive diffusion magnetic resonance imaging of brain tumour cell size for the early detection of therapeutic response.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Diffusio | 2020 |
Noninvasive diffusion magnetic resonance imaging of brain tumour cell size for the early detection of therapeutic response.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Diffusio | 2020 |
Noninvasive diffusion magnetic resonance imaging of brain tumour cell size for the early detection of therapeutic response.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Diffusio | 2020 |
Noninvasive diffusion magnetic resonance imaging of brain tumour cell size for the early detection of therapeutic response.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Diffusio | 2020 |
Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Female; Follow-Up S | 2021 |
Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Female; Follow-Up S | 2021 |
Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Female; Follow-Up S | 2021 |
Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Female; Follow-Up S | 2021 |
LncRNA MIR155HG Promotes Temozolomide Resistance by Activating the Wnt/β-Catenin Pathway Via Binding to PTBP1 in Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2021 |
LncRNA MIR155HG Promotes Temozolomide Resistance by Activating the Wnt/β-Catenin Pathway Via Binding to PTBP1 in Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2021 |
LncRNA MIR155HG Promotes Temozolomide Resistance by Activating the Wnt/β-Catenin Pathway Via Binding to PTBP1 in Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2021 |
LncRNA MIR155HG Promotes Temozolomide Resistance by Activating the Wnt/β-Catenin Pathway Via Binding to PTBP1 in Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2021 |
Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Child | 2020 |
Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Child | 2020 |
Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Child | 2020 |
Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Child | 2020 |
A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults.
Topics: Adult; Brain Neoplasms; Glioblastoma; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Neoplasm R | 2020 |
A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults.
Topics: Adult; Brain Neoplasms; Glioblastoma; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Neoplasm R | 2020 |
A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults.
Topics: Adult; Brain Neoplasms; Glioblastoma; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Neoplasm R | 2020 |
A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults.
Topics: Adult; Brain Neoplasms; Glioblastoma; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Neoplasm R | 2020 |
Injectable postoperative enzyme-responsive hydrogels for reversing temozolomide resistance and reducing local recurrence after glioma operation.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioma; | 2020 |
Injectable postoperative enzyme-responsive hydrogels for reversing temozolomide resistance and reducing local recurrence after glioma operation.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioma; | 2020 |
Injectable postoperative enzyme-responsive hydrogels for reversing temozolomide resistance and reducing local recurrence after glioma operation.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioma; | 2020 |
Injectable postoperative enzyme-responsive hydrogels for reversing temozolomide resistance and reducing local recurrence after glioma operation.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioma; | 2020 |
Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Dendrime | 2020 |
Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Dendrime | 2020 |
Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Dendrime | 2020 |
Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Dendrime | 2020 |
A composite of graphene oxide and iron oxide nanoparticles for targeted drug delivery of temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2020 |
A composite of graphene oxide and iron oxide nanoparticles for targeted drug delivery of temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2020 |
A composite of graphene oxide and iron oxide nanoparticles for targeted drug delivery of temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2020 |
A composite of graphene oxide and iron oxide nanoparticles for targeted drug delivery of temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2020 |
Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide: A nationwide population-based cohort study in Taiwan.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Enzyme Inhibitors; Fema | 2020 |
Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide: A nationwide population-based cohort study in Taiwan.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Enzyme Inhibitors; Fema | 2020 |
Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide: A nationwide population-based cohort study in Taiwan.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Enzyme Inhibitors; Fema | 2020 |
Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide: A nationwide population-based cohort study in Taiwan.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Enzyme Inhibitors; Fema | 2020 |
Hypoxia induced ferritin light chain (FTL) promoted epithelia mesenchymal transition and chemoresistance of glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoferritins; Apoptosis; Biomarkers, Tumor; Cell Movemen | 2020 |
Hypoxia induced ferritin light chain (FTL) promoted epithelia mesenchymal transition and chemoresistance of glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoferritins; Apoptosis; Biomarkers, Tumor; Cell Movemen | 2020 |
Hypoxia induced ferritin light chain (FTL) promoted epithelia mesenchymal transition and chemoresistance of glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoferritins; Apoptosis; Biomarkers, Tumor; Cell Movemen | 2020 |
Hypoxia induced ferritin light chain (FTL) promoted epithelia mesenchymal transition and chemoresistance of glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoferritins; Apoptosis; Biomarkers, Tumor; Cell Movemen | 2020 |
FTO Inhibition Enhances the Antitumor Effect of Temozolomide by Targeting MYC-miR-155/23a Cluster-MXI1 Feedback Circuit in Glioma.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Animals; Antineoplastic Agents, Alkylating; Basic Hel | 2020 |
FTO Inhibition Enhances the Antitumor Effect of Temozolomide by Targeting MYC-miR-155/23a Cluster-MXI1 Feedback Circuit in Glioma.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Animals; Antineoplastic Agents, Alkylating; Basic Hel | 2020 |
FTO Inhibition Enhances the Antitumor Effect of Temozolomide by Targeting MYC-miR-155/23a Cluster-MXI1 Feedback Circuit in Glioma.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Animals; Antineoplastic Agents, Alkylating; Basic Hel | 2020 |
FTO Inhibition Enhances the Antitumor Effect of Temozolomide by Targeting MYC-miR-155/23a Cluster-MXI1 Feedback Circuit in Glioma.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Animals; Antineoplastic Agents, Alkylating; Basic Hel | 2020 |
Piperine synergistically enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines.
Topics: Alkaloids; Apoptosis; Benzodioxoles; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergis | 2020 |
Piperine synergistically enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines.
Topics: Alkaloids; Apoptosis; Benzodioxoles; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergis | 2020 |
Piperine synergistically enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines.
Topics: Alkaloids; Apoptosis; Benzodioxoles; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergis | 2020 |
Piperine synergistically enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines.
Topics: Alkaloids; Apoptosis; Benzodioxoles; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergis | 2020 |
ABCC8 mRNA expression is an independent prognostic factor for glioma and can predict chemosensitivity.
Topics: Adult; Biomarkers, Tumor; Brain Neoplasms; Chromosome Deletion; Female; Gene Expression Regulation, | 2020 |
ABCC8 mRNA expression is an independent prognostic factor for glioma and can predict chemosensitivity.
Topics: Adult; Biomarkers, Tumor; Brain Neoplasms; Chromosome Deletion; Female; Gene Expression Regulation, | 2020 |
ABCC8 mRNA expression is an independent prognostic factor for glioma and can predict chemosensitivity.
Topics: Adult; Biomarkers, Tumor; Brain Neoplasms; Chromosome Deletion; Female; Gene Expression Regulation, | 2020 |
ABCC8 mRNA expression is an independent prognostic factor for glioma and can predict chemosensitivity.
Topics: Adult; Biomarkers, Tumor; Brain Neoplasms; Chromosome Deletion; Female; Gene Expression Regulation, | 2020 |
MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas.
Topics: Adolescent; Adult; Aged; Animals; Brain Neoplasms; Cell Line, Tumor; DNA Adducts; DNA Methylation; D | 2020 |
MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas.
Topics: Adolescent; Adult; Aged; Animals; Brain Neoplasms; Cell Line, Tumor; DNA Adducts; DNA Methylation; D | 2020 |
MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas.
Topics: Adolescent; Adult; Aged; Animals; Brain Neoplasms; Cell Line, Tumor; DNA Adducts; DNA Methylation; D | 2020 |
MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas.
Topics: Adolescent; Adult; Aged; Animals; Brain Neoplasms; Cell Line, Tumor; DNA Adducts; DNA Methylation; D | 2020 |
Temozolomide desensitization followed by metronomic dosing in patients with hypersensitivity.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoth | 2020 |
Temozolomide desensitization followed by metronomic dosing in patients with hypersensitivity.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoth | 2020 |
Temozolomide desensitization followed by metronomic dosing in patients with hypersensitivity.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoth | 2020 |
Temozolomide desensitization followed by metronomic dosing in patients with hypersensitivity.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoth | 2020 |
Brachyury Is Associated with Glioma Differentiation and Response to Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Mov | 2020 |
Brachyury Is Associated with Glioma Differentiation and Response to Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Mov | 2020 |
Brachyury Is Associated with Glioma Differentiation and Response to Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Mov | 2020 |
Brachyury Is Associated with Glioma Differentiation and Response to Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Mov | 2020 |
β-arrestin 1 transfection induced cell death in high grade glioma
Topics: Antineoplastic Agents, Alkylating; beta-Arrestin 1; Cell Death; Cell Proliferation; Cell Survival; D | 2020 |
β-arrestin 1 transfection induced cell death in high grade glioma
Topics: Antineoplastic Agents, Alkylating; beta-Arrestin 1; Cell Death; Cell Proliferation; Cell Survival; D | 2020 |
β-arrestin 1 transfection induced cell death in high grade glioma
Topics: Antineoplastic Agents, Alkylating; beta-Arrestin 1; Cell Death; Cell Proliferation; Cell Survival; D | 2020 |
β-arrestin 1 transfection induced cell death in high grade glioma
Topics: Antineoplastic Agents, Alkylating; beta-Arrestin 1; Cell Death; Cell Proliferation; Cell Survival; D | 2020 |
Effect of Phosphoribosyltransferase Down-regulation on Malignant Glioma Cell Characteristics.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Cytokines; Down-Regulation; | 2020 |
Effect of Phosphoribosyltransferase Down-regulation on Malignant Glioma Cell Characteristics.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Cytokines; Down-Regulation; | 2020 |
Effect of Phosphoribosyltransferase Down-regulation on Malignant Glioma Cell Characteristics.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Cytokines; Down-Regulation; | 2020 |
Effect of Phosphoribosyltransferase Down-regulation on Malignant Glioma Cell Characteristics.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Cytokines; Down-Regulation; | 2020 |
Temozolomide and AZD7762 Induce Synergistic Cytotoxicity Effects on Human Glioma Cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Syner | 2020 |
Temozolomide and AZD7762 Induce Synergistic Cytotoxicity Effects on Human Glioma Cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Syner | 2020 |
Temozolomide and AZD7762 Induce Synergistic Cytotoxicity Effects on Human Glioma Cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Syner | 2020 |
Temozolomide and AZD7762 Induce Synergistic Cytotoxicity Effects on Human Glioma Cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Syner | 2020 |
Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; | 2020 |
Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; | 2020 |
Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; | 2020 |
Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
Topics: Animals; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; | 2020 |
Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patien
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patien
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patien
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patien
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Long Noncoding RNA KCNQ1OT1 Confers Gliomas Resistance to Temozolomide and Enhances Cell Growth by Retrieving PIM1 From miR-761.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Re | 2022 |
Long Noncoding RNA KCNQ1OT1 Confers Gliomas Resistance to Temozolomide and Enhances Cell Growth by Retrieving PIM1 From miR-761.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Re | 2022 |
Long Noncoding RNA KCNQ1OT1 Confers Gliomas Resistance to Temozolomide and Enhances Cell Growth by Retrieving PIM1 From miR-761.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Re | 2022 |
Long Noncoding RNA KCNQ1OT1 Confers Gliomas Resistance to Temozolomide and Enhances Cell Growth by Retrieving PIM1 From miR-761.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Re | 2022 |
LINC00470 promotes tumour proliferation and invasion, and attenuates chemosensitivity through the LINC00470/miR-134/Myc/ABCC1 axis in glioma.
Topics: Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Ne | 2020 |
LINC00470 promotes tumour proliferation and invasion, and attenuates chemosensitivity through the LINC00470/miR-134/Myc/ABCC1 axis in glioma.
Topics: Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Ne | 2020 |
LINC00470 promotes tumour proliferation and invasion, and attenuates chemosensitivity through the LINC00470/miR-134/Myc/ABCC1 axis in glioma.
Topics: Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Ne | 2020 |
LINC00470 promotes tumour proliferation and invasion, and attenuates chemosensitivity through the LINC00470/miR-134/Myc/ABCC1 axis in glioma.
Topics: Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Ne | 2020 |
Oroxylin A reversed Fibronectin-induced glioma insensitivity to Temozolomide by suppressing IP
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Biomarkers, Tumor; Cell Prolife | 2020 |
Oroxylin A reversed Fibronectin-induced glioma insensitivity to Temozolomide by suppressing IP
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Biomarkers, Tumor; Cell Prolife | 2020 |
Oroxylin A reversed Fibronectin-induced glioma insensitivity to Temozolomide by suppressing IP
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Biomarkers, Tumor; Cell Prolife | 2020 |
Oroxylin A reversed Fibronectin-induced glioma insensitivity to Temozolomide by suppressing IP
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Biomarkers, Tumor; Cell Prolife | 2020 |
Downregulation of hsa_circ_0000936 sensitizes resistant glioma cells to temozolomide by sponging miR-1294.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Base Pairing; Base Sequence; Brain Neoplasms; Cell Lin | 2020 |
Downregulation of hsa_circ_0000936 sensitizes resistant glioma cells to temozolomide by sponging miR-1294.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Base Pairing; Base Sequence; Brain Neoplasms; Cell Lin | 2020 |
Downregulation of hsa_circ_0000936 sensitizes resistant glioma cells to temozolomide by sponging miR-1294.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Base Pairing; Base Sequence; Brain Neoplasms; Cell Lin | 2020 |
Downregulation of hsa_circ_0000936 sensitizes resistant glioma cells to temozolomide by sponging miR-1294.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Base Pairing; Base Sequence; Brain Neoplasms; Cell Lin | 2020 |
Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology.
Topics: Animals; Brain Neoplasms; Glioblastoma; Glioma; Heterografts; Humans; Mice; Neoplasm Recurrence, Loc | 2020 |
Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology.
Topics: Animals; Brain Neoplasms; Glioblastoma; Glioma; Heterografts; Humans; Mice; Neoplasm Recurrence, Loc | 2020 |
Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology.
Topics: Animals; Brain Neoplasms; Glioblastoma; Glioma; Heterografts; Humans; Mice; Neoplasm Recurrence, Loc | 2020 |
Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology.
Topics: Animals; Brain Neoplasms; Glioblastoma; Glioma; Heterografts; Humans; Mice; Neoplasm Recurrence, Loc | 2020 |
Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.
Topics: Adult; Aged; Brain Neoplasms; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplas | 2021 |
Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.
Topics: Adult; Aged; Brain Neoplasms; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplas | 2021 |
Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.
Topics: Adult; Aged; Brain Neoplasms; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplas | 2021 |
Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.
Topics: Adult; Aged; Brain Neoplasms; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplas | 2021 |
Thermosensitive magnetic nanoparticles exposed to alternating magnetic field and heat-mediated chemotherapy for an effective dual therapy in rat glioma model.
Topics: Animals; Folic Acid; Glioma; Magnetic Fields; Magnetite Nanoparticles; Rats; Temozolomide | 2021 |
Thermosensitive magnetic nanoparticles exposed to alternating magnetic field and heat-mediated chemotherapy for an effective dual therapy in rat glioma model.
Topics: Animals; Folic Acid; Glioma; Magnetic Fields; Magnetite Nanoparticles; Rats; Temozolomide | 2021 |
Thermosensitive magnetic nanoparticles exposed to alternating magnetic field and heat-mediated chemotherapy for an effective dual therapy in rat glioma model.
Topics: Animals; Folic Acid; Glioma; Magnetic Fields; Magnetite Nanoparticles; Rats; Temozolomide | 2021 |
Thermosensitive magnetic nanoparticles exposed to alternating magnetic field and heat-mediated chemotherapy for an effective dual therapy in rat glioma model.
Topics: Animals; Folic Acid; Glioma; Magnetic Fields; Magnetite Nanoparticles; Rats; Temozolomide | 2021 |
In Regard to Fisher et al.
Topics: Chemoradiotherapy; Glioma; Humans; Temozolomide | 2020 |
In Regard to Fisher et al.
Topics: Chemoradiotherapy; Glioma; Humans; Temozolomide | 2020 |
In Regard to Fisher et al.
Topics: Chemoradiotherapy; Glioma; Humans; Temozolomide | 2020 |
In Regard to Fisher et al.
Topics: Chemoradiotherapy; Glioma; Humans; Temozolomide | 2020 |
In Reply to Saini and Jalali.
Topics: Glioma; Humans; Temozolomide | 2020 |
In Reply to Saini and Jalali.
Topics: Glioma; Humans; Temozolomide | 2020 |
In Reply to Saini and Jalali.
Topics: Glioma; Humans; Temozolomide | 2020 |
In Reply to Saini and Jalali.
Topics: Glioma; Humans; Temozolomide | 2020 |
Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Female; Glioma; Human | 2021 |
Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Female; Glioma; Human | 2021 |
Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Female; Glioma; Human | 2021 |
Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Female; Glioma; Human | 2021 |
Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; DNA Modi | 2020 |
Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; DNA Modi | 2020 |
Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; DNA Modi | 2020 |
Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; DNA Modi | 2020 |
RPN2 is targeted by miR-181c and mediates glioma progression and temozolomide sensitivity via the wnt/β-catenin signaling pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Carcinogenesis; Cell Line, Tumo | 2020 |
RPN2 is targeted by miR-181c and mediates glioma progression and temozolomide sensitivity via the wnt/β-catenin signaling pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Carcinogenesis; Cell Line, Tumo | 2020 |
RPN2 is targeted by miR-181c and mediates glioma progression and temozolomide sensitivity via the wnt/β-catenin signaling pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Carcinogenesis; Cell Line, Tumo | 2020 |
RPN2 is targeted by miR-181c and mediates glioma progression and temozolomide sensitivity via the wnt/β-catenin signaling pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Carcinogenesis; Cell Line, Tumo | 2020 |
MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Prolife | 2021 |
MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Prolife | 2021 |
MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Prolife | 2021 |
MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Prolife | 2021 |
Synthetic Betulin Derivatives Inhibit Growth of Glioma Cells
Topics: Acetylene; Animals; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Ce | 2020 |
Synthetic Betulin Derivatives Inhibit Growth of Glioma Cells
Topics: Acetylene; Animals; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Ce | 2020 |
Synthetic Betulin Derivatives Inhibit Growth of Glioma Cells
Topics: Acetylene; Animals; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Ce | 2020 |
Synthetic Betulin Derivatives Inhibit Growth of Glioma Cells
Topics: Acetylene; Animals; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Ce | 2020 |
Hepatitis B virus reactivation during temozolomide administration for malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA, Viral; Glioma; Hepatitis B; Hepatitis B Ant | 2021 |
Hepatitis B virus reactivation during temozolomide administration for malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA, Viral; Glioma; Hepatitis B; Hepatitis B Ant | 2021 |
Hepatitis B virus reactivation during temozolomide administration for malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA, Viral; Glioma; Hepatitis B; Hepatitis B Ant | 2021 |
Hepatitis B virus reactivation during temozolomide administration for malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA, Viral; Glioma; Hepatitis B; Hepatitis B Ant | 2021 |
Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Progression-Free Survival; Temoz | 2021 |
Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Progression-Free Survival; Temoz | 2021 |
Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Progression-Free Survival; Temoz | 2021 |
Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Progression-Free Survival; Temoz | 2021 |
Methylation associated miR-1246 contributes to poor prognosis in gliomas treated with temozolomide.
Topics: Brain Neoplasms; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; H | 2021 |
Methylation associated miR-1246 contributes to poor prognosis in gliomas treated with temozolomide.
Topics: Brain Neoplasms; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; H | 2021 |
Methylation associated miR-1246 contributes to poor prognosis in gliomas treated with temozolomide.
Topics: Brain Neoplasms; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; H | 2021 |
Methylation associated miR-1246 contributes to poor prognosis in gliomas treated with temozolomide.
Topics: Brain Neoplasms; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; H | 2021 |
Early Treatment Response Assessment Using
Topics: Adult; Aged; Brain Neoplasms; Glioma; Humans; Middle Aged; Temozolomide; Young Adult | 2021 |
Early Treatment Response Assessment Using
Topics: Adult; Aged; Brain Neoplasms; Glioma; Humans; Middle Aged; Temozolomide; Young Adult | 2021 |
Early Treatment Response Assessment Using
Topics: Adult; Aged; Brain Neoplasms; Glioma; Humans; Middle Aged; Temozolomide; Young Adult | 2021 |
Early Treatment Response Assessment Using
Topics: Adult; Aged; Brain Neoplasms; Glioma; Humans; Middle Aged; Temozolomide; Young Adult | 2021 |
Circ-VPS18 Knockdown Enhances TMZ Sensitivity and Inhibits Glioma Progression by MiR-370/RUNX1 Axis.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B | 2021 |
Circ-VPS18 Knockdown Enhances TMZ Sensitivity and Inhibits Glioma Progression by MiR-370/RUNX1 Axis.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B | 2021 |
Circ-VPS18 Knockdown Enhances TMZ Sensitivity and Inhibits Glioma Progression by MiR-370/RUNX1 Axis.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B | 2021 |
Circ-VPS18 Knockdown Enhances TMZ Sensitivity and Inhibits Glioma Progression by MiR-370/RUNX1 Axis.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B | 2021 |
Glioma and temozolomide induced alterations in gut microbiome.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dysbiosis; Female; G | 2020 |
Glioma and temozolomide induced alterations in gut microbiome.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dysbiosis; Female; G | 2020 |
Glioma and temozolomide induced alterations in gut microbiome.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dysbiosis; Female; G | 2020 |
Glioma and temozolomide induced alterations in gut microbiome.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dysbiosis; Female; G | 2020 |
Radiotherapy, Temozolomide, and Antiprogrammed Cell Death Protein 1 Treatments Modulate the Immune Microenvironment in Experimental High-Grade Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Brain Neoplasms; C | 2021 |
Radiotherapy, Temozolomide, and Antiprogrammed Cell Death Protein 1 Treatments Modulate the Immune Microenvironment in Experimental High-Grade Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Brain Neoplasms; C | 2021 |
Radiotherapy, Temozolomide, and Antiprogrammed Cell Death Protein 1 Treatments Modulate the Immune Microenvironment in Experimental High-Grade Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Brain Neoplasms; C | 2021 |
Radiotherapy, Temozolomide, and Antiprogrammed Cell Death Protein 1 Treatments Modulate the Immune Microenvironment in Experimental High-Grade Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Brain Neoplasms; C | 2021 |
Post-treatment hypermutation in a recurrent diffuse glioma with H3.3 p.G34 Mutation.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Drug Re | 2021 |
Post-treatment hypermutation in a recurrent diffuse glioma with H3.3 p.G34 Mutation.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Drug Re | 2021 |
Post-treatment hypermutation in a recurrent diffuse glioma with H3.3 p.G34 Mutation.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Drug Re | 2021 |
Post-treatment hypermutation in a recurrent diffuse glioma with H3.3 p.G34 Mutation.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Drug Re | 2021 |
Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2020 |
Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2020 |
Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2020 |
Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2020 |
Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.
Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cellular Reprogramming; Chemoradiotherapy; Ga | 2021 |
Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.
Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cellular Reprogramming; Chemoradiotherapy; Ga | 2021 |
Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.
Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cellular Reprogramming; Chemoradiotherapy; Ga | 2021 |
Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.
Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cellular Reprogramming; Chemoradiotherapy; Ga | 2021 |
Involvement of N-methylpurine DNA glycosylase in resistance to temozolomide in patient-derived glioma cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Line, Tum | 2020 |
Involvement of N-methylpurine DNA glycosylase in resistance to temozolomide in patient-derived glioma cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Line, Tum | 2020 |
Involvement of N-methylpurine DNA glycosylase in resistance to temozolomide in patient-derived glioma cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Line, Tum | 2020 |
Involvement of N-methylpurine DNA glycosylase in resistance to temozolomide in patient-derived glioma cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Line, Tum | 2020 |
Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Topics: Administration, Intranasal; Animals; Apoptosis; Brain Neoplasms; Cell Line; Cell Line, Tumor; Drug R | 2021 |
Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Topics: Administration, Intranasal; Animals; Apoptosis; Brain Neoplasms; Cell Line; Cell Line, Tumor; Drug R | 2021 |
Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Topics: Administration, Intranasal; Animals; Apoptosis; Brain Neoplasms; Cell Line; Cell Line, Tumor; Drug R | 2021 |
Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Topics: Administration, Intranasal; Animals; Apoptosis; Brain Neoplasms; Cell Line; Cell Line, Tumor; Drug R | 2021 |
Anti-tumour activity of deer growing antlers and its potential applications in the treatment of malignant gliomas.
Topics: Animals; Antineoplastic Agents; Antlers; Apoptosis; Cell Cycle; Cell Line, Tumor; Deer; Glioma; Huma | 2021 |
Anti-tumour activity of deer growing antlers and its potential applications in the treatment of malignant gliomas.
Topics: Animals; Antineoplastic Agents; Antlers; Apoptosis; Cell Cycle; Cell Line, Tumor; Deer; Glioma; Huma | 2021 |
Anti-tumour activity of deer growing antlers and its potential applications in the treatment of malignant gliomas.
Topics: Animals; Antineoplastic Agents; Antlers; Apoptosis; Cell Cycle; Cell Line, Tumor; Deer; Glioma; Huma | 2021 |
Anti-tumour activity of deer growing antlers and its potential applications in the treatment of malignant gliomas.
Topics: Animals; Antineoplastic Agents; Antlers; Apoptosis; Cell Cycle; Cell Line, Tumor; Deer; Glioma; Huma | 2021 |
Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; DNA Modifi | 2021 |
Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; DNA Modifi | 2021 |
Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; DNA Modifi | 2021 |
Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; DNA Modifi | 2021 |
Relationship between CYP17A1-Mediated DNA Demethylation and Proliferation, Invasion and Metastasis of Glioma Cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dehydroepiandrosterone; DNA Demethyl | 2020 |
Relationship between CYP17A1-Mediated DNA Demethylation and Proliferation, Invasion and Metastasis of Glioma Cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dehydroepiandrosterone; DNA Demethyl | 2020 |
Relationship between CYP17A1-Mediated DNA Demethylation and Proliferation, Invasion and Metastasis of Glioma Cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dehydroepiandrosterone; DNA Demethyl | 2020 |
Relationship between CYP17A1-Mediated DNA Demethylation and Proliferation, Invasion and Metastasis of Glioma Cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dehydroepiandrosterone; DNA Demethyl | 2020 |
Molecular biological investigation of temozolomide and KC7F2 combination in U87MG glioma cell line.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tum | 2021 |
Molecular biological investigation of temozolomide and KC7F2 combination in U87MG glioma cell line.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tum | 2021 |
Molecular biological investigation of temozolomide and KC7F2 combination in U87MG glioma cell line.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tum | 2021 |
Molecular biological investigation of temozolomide and KC7F2 combination in U87MG glioma cell line.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tum | 2021 |
High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cell-Free Nucleic Acids; Chemoradiotherapy; Clonal | 2021 |
High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cell-Free Nucleic Acids; Chemoradiotherapy; Clonal | 2021 |
High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cell-Free Nucleic Acids; Chemoradiotherapy; Clonal | 2021 |
High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cell-Free Nucleic Acids; Chemoradiotherapy; Clonal | 2021 |
The NRG3/ERBB4 signaling cascade as a novel therapeutic target for canine glioma.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dog Diseases; Do | 2021 |
The NRG3/ERBB4 signaling cascade as a novel therapeutic target for canine glioma.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dog Diseases; Do | 2021 |
The NRG3/ERBB4 signaling cascade as a novel therapeutic target for canine glioma.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dog Diseases; Do | 2021 |
The NRG3/ERBB4 signaling cascade as a novel therapeutic target for canine glioma.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dog Diseases; Do | 2021 |
Inhibition of mitochondrial carrier homolog 2 (MTCH2) suppresses tumor invasion and enhances sensitivity to temozolomide in malignant glioma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Gen | 2021 |
Inhibition of mitochondrial carrier homolog 2 (MTCH2) suppresses tumor invasion and enhances sensitivity to temozolomide in malignant glioma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Gen | 2021 |
Inhibition of mitochondrial carrier homolog 2 (MTCH2) suppresses tumor invasion and enhances sensitivity to temozolomide in malignant glioma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Gen | 2021 |
Inhibition of mitochondrial carrier homolog 2 (MTCH2) suppresses tumor invasion and enhances sensitivity to temozolomide in malignant glioma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Gen | 2021 |
[Establishment of a mouse model bearing orthotopic temozolomide-resistant glioma].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Disease Models, Anima | 2021 |
[Establishment of a mouse model bearing orthotopic temozolomide-resistant glioma].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Disease Models, Anima | 2021 |
[Establishment of a mouse model bearing orthotopic temozolomide-resistant glioma].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Disease Models, Anima | 2021 |
[Establishment of a mouse model bearing orthotopic temozolomide-resistant glioma].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Disease Models, Anima | 2021 |
A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Female; Germany; Glioma; Humans; Isocitrate Dehydro | 2021 |
A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Female; Germany; Glioma; Humans; Isocitrate Dehydro | 2021 |
A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Female; Germany; Glioma; Humans; Isocitrate Dehydro | 2021 |
A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Female; Germany; Glioma; Humans; Isocitrate Dehydro | 2021 |
Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; ATP Binding Cassette Transporter, Subf | 2021 |
Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; ATP Binding Cassette Transporter, Subf | 2021 |
Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; ATP Binding Cassette Transporter, Subf | 2021 |
Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; ATP Binding Cassette Transporter, Subf | 2021 |
AS602801 sensitizes glioma cells to temozolomide and vincristine by blocking gap junction communication between glioma cells and astrocytes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Astrocytes; Benzothiazoles; Brai | 2021 |
AS602801 sensitizes glioma cells to temozolomide and vincristine by blocking gap junction communication between glioma cells and astrocytes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Astrocytes; Benzothiazoles; Brai | 2021 |
AS602801 sensitizes glioma cells to temozolomide and vincristine by blocking gap junction communication between glioma cells and astrocytes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Astrocytes; Benzothiazoles; Brai | 2021 |
AS602801 sensitizes glioma cells to temozolomide and vincristine by blocking gap junction communication between glioma cells and astrocytes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Astrocytes; Benzothiazoles; Brai | 2021 |
Nicardipine sensitizes temozolomide by inhibiting autophagy and promoting cell apoptosis in glioma stem cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Calcium Channel Blockers; | 2021 |
Nicardipine sensitizes temozolomide by inhibiting autophagy and promoting cell apoptosis in glioma stem cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Calcium Channel Blockers; | 2021 |
Nicardipine sensitizes temozolomide by inhibiting autophagy and promoting cell apoptosis in glioma stem cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Calcium Channel Blockers; | 2021 |
Nicardipine sensitizes temozolomide by inhibiting autophagy and promoting cell apoptosis in glioma stem cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Calcium Channel Blockers; | 2021 |
Exosomal connexin 43 regulates the resistance of glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Connexin 43; Dr | 2021 |
Exosomal connexin 43 regulates the resistance of glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Connexin 43; Dr | 2021 |
Exosomal connexin 43 regulates the resistance of glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Connexin 43; Dr | 2021 |
Exosomal connexin 43 regulates the resistance of glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Connexin 43; Dr | 2021 |
The Paired Siglecs in Brain Tumours Therapy: The Immunomodulatory Effect of Dexamethasone and Temozolomide in Human Glioma In Vitro Model.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protoc | 2021 |
The Paired Siglecs in Brain Tumours Therapy: The Immunomodulatory Effect of Dexamethasone and Temozolomide in Human Glioma In Vitro Model.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protoc | 2021 |
The Paired Siglecs in Brain Tumours Therapy: The Immunomodulatory Effect of Dexamethasone and Temozolomide in Human Glioma In Vitro Model.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protoc | 2021 |
The Paired Siglecs in Brain Tumours Therapy: The Immunomodulatory Effect of Dexamethasone and Temozolomide in Human Glioma In Vitro Model.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protoc | 2021 |
Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2021 |
Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2021 |
Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2021 |
Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2021 |
Knockdown of TRIM32 inhibits tumor growth and increases the therapeutic sensitivity to temozolomide in glioma in a p53-dependent and -independent manner.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resist | 2021 |
Knockdown of TRIM32 inhibits tumor growth and increases the therapeutic sensitivity to temozolomide in glioma in a p53-dependent and -independent manner.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resist | 2021 |
Knockdown of TRIM32 inhibits tumor growth and increases the therapeutic sensitivity to temozolomide in glioma in a p53-dependent and -independent manner.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resist | 2021 |
Knockdown of TRIM32 inhibits tumor growth and increases the therapeutic sensitivity to temozolomide in glioma in a p53-dependent and -independent manner.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resist | 2021 |
Cognitive outcomes in patients with low-grade glioma.
Topics: Brain Neoplasms; Cognition; Glioma; Humans; Memory; Temozolomide | 2021 |
Cognitive outcomes in patients with low-grade glioma.
Topics: Brain Neoplasms; Cognition; Glioma; Humans; Memory; Temozolomide | 2021 |
Cognitive outcomes in patients with low-grade glioma.
Topics: Brain Neoplasms; Cognition; Glioma; Humans; Memory; Temozolomide | 2021 |
Cognitive outcomes in patients with low-grade glioma.
Topics: Brain Neoplasms; Cognition; Glioma; Humans; Memory; Temozolomide | 2021 |
Nidogen-1 expression is associated with overall survival and temozolomide sensitivity in low-grade glioma patients.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Gliom | 2021 |
Nidogen-1 expression is associated with overall survival and temozolomide sensitivity in low-grade glioma patients.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Gliom | 2021 |
Nidogen-1 expression is associated with overall survival and temozolomide sensitivity in low-grade glioma patients.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Gliom | 2021 |
Nidogen-1 expression is associated with overall survival and temozolomide sensitivity in low-grade glioma patients.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Gliom | 2021 |
Corilagin induces apoptosis and autophagy in NRF2‑addicted U251 glioma cell line.
Topics: Adult; Aged; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Reg | 2021 |
Corilagin induces apoptosis and autophagy in NRF2‑addicted U251 glioma cell line.
Topics: Adult; Aged; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Reg | 2021 |
Corilagin induces apoptosis and autophagy in NRF2‑addicted U251 glioma cell line.
Topics: Adult; Aged; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Reg | 2021 |
Corilagin induces apoptosis and autophagy in NRF2‑addicted U251 glioma cell line.
Topics: Adult; Aged; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Reg | 2021 |
Could upfront temozolomide chemotherapy postpone the need for radiotherapy in young patients with high-risk low-grade gliomas?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Temozolomide | 2021 |
Could upfront temozolomide chemotherapy postpone the need for radiotherapy in young patients with high-risk low-grade gliomas?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Temozolomide | 2021 |
Could upfront temozolomide chemotherapy postpone the need for radiotherapy in young patients with high-risk low-grade gliomas?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Temozolomide | 2021 |
Could upfront temozolomide chemotherapy postpone the need for radiotherapy in young patients with high-risk low-grade gliomas?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioma; Humans; Temozolomide | 2021 |
Effects of the Anti-Tumorigenic Agent AT101 on Human Glioblastoma Cells in the Microenvironmental Glioma Stem Cell Niche.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Carcinogenesis; Cell Line, T | 2021 |
Effects of the Anti-Tumorigenic Agent AT101 on Human Glioblastoma Cells in the Microenvironmental Glioma Stem Cell Niche.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Carcinogenesis; Cell Line, T | 2021 |
Effects of the Anti-Tumorigenic Agent AT101 on Human Glioblastoma Cells in the Microenvironmental Glioma Stem Cell Niche.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Carcinogenesis; Cell Line, T | 2021 |
Effects of the Anti-Tumorigenic Agent AT101 on Human Glioblastoma Cells in the Microenvironmental Glioma Stem Cell Niche.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Carcinogenesis; Cell Line, T | 2021 |
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
Topics: Brain; Brain Neoplasms; Glioma; Humans; Mutation; Neoplasm Recurrence, Local; Temozolomide | 2021 |
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
Topics: Brain; Brain Neoplasms; Glioma; Humans; Mutation; Neoplasm Recurrence, Local; Temozolomide | 2021 |
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
Topics: Brain; Brain Neoplasms; Glioma; Humans; Mutation; Neoplasm Recurrence, Local; Temozolomide | 2021 |
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
Topics: Brain; Brain Neoplasms; Glioma; Humans; Mutation; Neoplasm Recurrence, Local; Temozolomide | 2021 |
Kinomic profile in patient-derived glioma cells during hypoxia reveals c-MET-PI3K dependency for adaptation.
Topics: Animals; Antioxidants; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; H | 2021 |
Kinomic profile in patient-derived glioma cells during hypoxia reveals c-MET-PI3K dependency for adaptation.
Topics: Animals; Antioxidants; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; H | 2021 |
Kinomic profile in patient-derived glioma cells during hypoxia reveals c-MET-PI3K dependency for adaptation.
Topics: Animals; Antioxidants; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; H | 2021 |
Kinomic profile in patient-derived glioma cells during hypoxia reveals c-MET-PI3K dependency for adaptation.
Topics: Animals; Antioxidants; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; H | 2021 |
FOXO3a protects glioma cells against temozolomide-induced DNA double strand breaks via promotion of BNIP3-mediated mitophagy.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; DNA Breaks, Double-Stranded; Forkhead B | 2021 |
FOXO3a protects glioma cells against temozolomide-induced DNA double strand breaks via promotion of BNIP3-mediated mitophagy.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; DNA Breaks, Double-Stranded; Forkhead B | 2021 |
FOXO3a protects glioma cells against temozolomide-induced DNA double strand breaks via promotion of BNIP3-mediated mitophagy.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; DNA Breaks, Double-Stranded; Forkhead B | 2021 |
FOXO3a protects glioma cells against temozolomide-induced DNA double strand breaks via promotion of BNIP3-mediated mitophagy.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; DNA Breaks, Double-Stranded; Forkhead B | 2021 |
Rab18 interacted with V-set and immunoglobulin domain-containing 4 (VSIG4) to involve in the apoptosis of glioma and the sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2021 |
Rab18 interacted with V-set and immunoglobulin domain-containing 4 (VSIG4) to involve in the apoptosis of glioma and the sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2021 |
Rab18 interacted with V-set and immunoglobulin domain-containing 4 (VSIG4) to involve in the apoptosis of glioma and the sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2021 |
Rab18 interacted with V-set and immunoglobulin domain-containing 4 (VSIG4) to involve in the apoptosis of glioma and the sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2021 |
Temozolomide-Induced Changes in Gut Microbial Composition in a Mouse Model of Brain Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Disease Models, Anima | 2021 |
Temozolomide-Induced Changes in Gut Microbial Composition in a Mouse Model of Brain Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Disease Models, Anima | 2021 |
Temozolomide-Induced Changes in Gut Microbial Composition in a Mouse Model of Brain Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Disease Models, Anima | 2021 |
Temozolomide-Induced Changes in Gut Microbial Composition in a Mouse Model of Brain Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Disease Models, Anima | 2021 |
Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cadherins; Cell Line, Tumor; Disease Mo | 2021 |
Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cadherins; Cell Line, Tumor; Disease Mo | 2021 |
Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cadherins; Cell Line, Tumor; Disease Mo | 2021 |
Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cadherins; Cell Line, Tumor; Disease Mo | 2021 |
Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas.
Topics: Adult; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Diagnosis, Differential; Female; Glioma; | 2021 |
Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas.
Topics: Adult; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Diagnosis, Differential; Female; Glioma; | 2021 |
Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas.
Topics: Adult; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Diagnosis, Differential; Female; Glioma; | 2021 |
Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas.
Topics: Adult; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Diagnosis, Differential; Female; Glioma; | 2021 |
Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma.
Topics: AlkB Homolog 5, RNA Demethylase; Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Resistance | 2021 |
Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma.
Topics: AlkB Homolog 5, RNA Demethylase; Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Resistance | 2021 |
Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma.
Topics: AlkB Homolog 5, RNA Demethylase; Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Resistance | 2021 |
Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma.
Topics: AlkB Homolog 5, RNA Demethylase; Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Resistance | 2021 |
Benefit of adjuvant, but not concurrent, temozolomide for IDH-mutant anaplastic astrocytoma.
Topics: Astrocytoma; Glioma; Humans; Temozolomide | 2021 |
Benefit of adjuvant, but not concurrent, temozolomide for IDH-mutant anaplastic astrocytoma.
Topics: Astrocytoma; Glioma; Humans; Temozolomide | 2021 |
Benefit of adjuvant, but not concurrent, temozolomide for IDH-mutant anaplastic astrocytoma.
Topics: Astrocytoma; Glioma; Humans; Temozolomide | 2021 |
Benefit of adjuvant, but not concurrent, temozolomide for IDH-mutant anaplastic astrocytoma.
Topics: Astrocytoma; Glioma; Humans; Temozolomide | 2021 |
Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Brain Neoplasms; Cell Line, Tum | 2021 |
Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Brain Neoplasms; Cell Line, Tum | 2021 |
Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Brain Neoplasms; Cell Line, Tum | 2021 |
Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Brain Neoplasms; Cell Line, Tum | 2021 |
Anaplastic glioma: benefit of temozolomide clarified.
Topics: Brain Neoplasms; Glioma; Humans; Temozolomide | 2021 |
Anaplastic glioma: benefit of temozolomide clarified.
Topics: Brain Neoplasms; Glioma; Humans; Temozolomide | 2021 |
Anaplastic glioma: benefit of temozolomide clarified.
Topics: Brain Neoplasms; Glioma; Humans; Temozolomide | 2021 |
Anaplastic glioma: benefit of temozolomide clarified.
Topics: Brain Neoplasms; Glioma; Humans; Temozolomide | 2021 |
lncRNA TUG1 inhibits the cancer stem cell‑like properties of temozolomide‑resistant glioma cells by interacting with EZH2.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; | 2021 |
lncRNA TUG1 inhibits the cancer stem cell‑like properties of temozolomide‑resistant glioma cells by interacting with EZH2.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; | 2021 |
lncRNA TUG1 inhibits the cancer stem cell‑like properties of temozolomide‑resistant glioma cells by interacting with EZH2.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; | 2021 |
lncRNA TUG1 inhibits the cancer stem cell‑like properties of temozolomide‑resistant glioma cells by interacting with EZH2.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; | 2021 |
Heparanase confers temozolomide resistance by regulation of exosome secretion and circular RNA composition in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2021 |
Heparanase confers temozolomide resistance by regulation of exosome secretion and circular RNA composition in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2021 |
Heparanase confers temozolomide resistance by regulation of exosome secretion and circular RNA composition in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2021 |
Heparanase confers temozolomide resistance by regulation of exosome secretion and circular RNA composition in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2021 |
miR-29a sensitizes the response of glioma cells to temozolomide by modulating the P53/MDM2 feedback loop.
Topics: 3' Untranslated Regions; Antagomirs; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Ce | 2021 |
miR-29a sensitizes the response of glioma cells to temozolomide by modulating the P53/MDM2 feedback loop.
Topics: 3' Untranslated Regions; Antagomirs; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Ce | 2021 |
miR-29a sensitizes the response of glioma cells to temozolomide by modulating the P53/MDM2 feedback loop.
Topics: 3' Untranslated Regions; Antagomirs; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Ce | 2021 |
miR-29a sensitizes the response of glioma cells to temozolomide by modulating the P53/MDM2 feedback loop.
Topics: 3' Untranslated Regions; Antagomirs; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Ce | 2021 |
Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Convection; DNA; Glioma; Humans; Intercalating Agents; M | 2021 |
Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Convection; DNA; Glioma; Humans; Intercalating Agents; M | 2021 |
Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Convection; DNA; Glioma; Humans; Intercalating Agents; M | 2021 |
Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Convection; DNA; Glioma; Humans; Intercalating Agents; M | 2021 |
Elevated GIGYF2 expression suppresses tumor migration and enhances sensitivity to temozolomide in malignant glioma.
Topics: Brain Neoplasms; Carrier Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Glioma; Huma | 2022 |
Elevated GIGYF2 expression suppresses tumor migration and enhances sensitivity to temozolomide in malignant glioma.
Topics: Brain Neoplasms; Carrier Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Glioma; Huma | 2022 |
Elevated GIGYF2 expression suppresses tumor migration and enhances sensitivity to temozolomide in malignant glioma.
Topics: Brain Neoplasms; Carrier Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Glioma; Huma | 2022 |
Elevated GIGYF2 expression suppresses tumor migration and enhances sensitivity to temozolomide in malignant glioma.
Topics: Brain Neoplasms; Carrier Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Glioma; Huma | 2022 |
Caffeine Inhibits Growth of Temozolomide-Treated Glioma via Increasing Autophagy and Apoptosis but Not via Modulating Hypoxia, Angiogenesis, or Endoplasmic Reticulum Stress in Rats.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Caffeine; Cell Line, Tumor; Endoplasmic Reticulum St | 2022 |
Caffeine Inhibits Growth of Temozolomide-Treated Glioma via Increasing Autophagy and Apoptosis but Not via Modulating Hypoxia, Angiogenesis, or Endoplasmic Reticulum Stress in Rats.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Caffeine; Cell Line, Tumor; Endoplasmic Reticulum St | 2022 |
Caffeine Inhibits Growth of Temozolomide-Treated Glioma via Increasing Autophagy and Apoptosis but Not via Modulating Hypoxia, Angiogenesis, or Endoplasmic Reticulum Stress in Rats.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Caffeine; Cell Line, Tumor; Endoplasmic Reticulum St | 2022 |
Caffeine Inhibits Growth of Temozolomide-Treated Glioma via Increasing Autophagy and Apoptosis but Not via Modulating Hypoxia, Angiogenesis, or Endoplasmic Reticulum Stress in Rats.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Caffeine; Cell Line, Tumor; Endoplasmic Reticulum St | 2022 |
Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM.
Topics: AC133 Antigen; Adenosine; Adult; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle Check | 2021 |
Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM.
Topics: AC133 Antigen; Adenosine; Adult; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle Check | 2021 |
Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM.
Topics: AC133 Antigen; Adenosine; Adult; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle Check | 2021 |
Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM.
Topics: AC133 Antigen; Adenosine; Adult; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle Check | 2021 |
Receptor-Interacting Protein 140 Enhanced Temozolomide-Induced Cellular Apoptosis Through Regulation of E2F1 in Human Glioma Cell Lines.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; E2F1 Transcription Factor; | 2022 |
Receptor-Interacting Protein 140 Enhanced Temozolomide-Induced Cellular Apoptosis Through Regulation of E2F1 in Human Glioma Cell Lines.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; E2F1 Transcription Factor; | 2022 |
Receptor-Interacting Protein 140 Enhanced Temozolomide-Induced Cellular Apoptosis Through Regulation of E2F1 in Human Glioma Cell Lines.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; E2F1 Transcription Factor; | 2022 |
Receptor-Interacting Protein 140 Enhanced Temozolomide-Induced Cellular Apoptosis Through Regulation of E2F1 in Human Glioma Cell Lines.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; E2F1 Transcription Factor; | 2022 |
miR-23b-5p promotes the chemosensitivity of temozolomide via negatively regulating TLR4 in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; Neoplasm Pr | 2021 |
miR-23b-5p promotes the chemosensitivity of temozolomide via negatively regulating TLR4 in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; Neoplasm Pr | 2021 |
miR-23b-5p promotes the chemosensitivity of temozolomide via negatively regulating TLR4 in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; Neoplasm Pr | 2021 |
miR-23b-5p promotes the chemosensitivity of temozolomide via negatively regulating TLR4 in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; Neoplasm Pr | 2021 |
Synthesis and Characterization of a Series of Temozolomide Esters and Its Anti-glioma Study.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Esters; Glioblastoma; Glioma; | 2021 |
Synthesis and Characterization of a Series of Temozolomide Esters and Its Anti-glioma Study.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Esters; Glioblastoma; Glioma; | 2021 |
Synthesis and Characterization of a Series of Temozolomide Esters and Its Anti-glioma Study.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Esters; Glioblastoma; Glioma; | 2021 |
Synthesis and Characterization of a Series of Temozolomide Esters and Its Anti-glioma Study.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Esters; Glioblastoma; Glioma; | 2021 |
Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Chemoradi | 2021 |
Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Chemoradi | 2021 |
Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Chemoradi | 2021 |
Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Chemoradi | 2021 |
The function and mechanism of the JARID2/CCND1 axis in modulating glioma cell growth and sensitivity to temozolomide (TMZ).
Topics: Brain Neoplasms; Cell Line, Tumor; Cyclin D1; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; | 2021 |
The function and mechanism of the JARID2/CCND1 axis in modulating glioma cell growth and sensitivity to temozolomide (TMZ).
Topics: Brain Neoplasms; Cell Line, Tumor; Cyclin D1; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; | 2021 |
The function and mechanism of the JARID2/CCND1 axis in modulating glioma cell growth and sensitivity to temozolomide (TMZ).
Topics: Brain Neoplasms; Cell Line, Tumor; Cyclin D1; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; | 2021 |
The function and mechanism of the JARID2/CCND1 axis in modulating glioma cell growth and sensitivity to temozolomide (TMZ).
Topics: Brain Neoplasms; Cell Line, Tumor; Cyclin D1; Drug Resistance, Neoplasm; Glioma; Humans; MicroRNAs; | 2021 |
CD90
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm | 2021 |
CD90
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm | 2021 |
CD90
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm | 2021 |
CD90
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm | 2021 |
A Noninvasive Gut-to-Brain Oral Drug Delivery System for Treating Brain Tumors.
Topics: Administration, Oral; Animals; Antineoplastic Agents; beta-Glucans; Blood-Brain Barrier; Brain Neopl | 2021 |
A Noninvasive Gut-to-Brain Oral Drug Delivery System for Treating Brain Tumors.
Topics: Administration, Oral; Animals; Antineoplastic Agents; beta-Glucans; Blood-Brain Barrier; Brain Neopl | 2021 |
A Noninvasive Gut-to-Brain Oral Drug Delivery System for Treating Brain Tumors.
Topics: Administration, Oral; Animals; Antineoplastic Agents; beta-Glucans; Blood-Brain Barrier; Brain Neopl | 2021 |
A Noninvasive Gut-to-Brain Oral Drug Delivery System for Treating Brain Tumors.
Topics: Administration, Oral; Animals; Antineoplastic Agents; beta-Glucans; Blood-Brain Barrier; Brain Neopl | 2021 |
Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2021 |
Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2021 |
Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2021 |
Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2021 |
Synergistic Effect of Gefitinib and Temozolomide on U87MG Glioblastoma Angiogenesis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Dru | 2022 |
Synergistic Effect of Gefitinib and Temozolomide on U87MG Glioblastoma Angiogenesis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Dru | 2022 |
Synergistic Effect of Gefitinib and Temozolomide on U87MG Glioblastoma Angiogenesis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Dru | 2022 |
Synergistic Effect of Gefitinib and Temozolomide on U87MG Glioblastoma Angiogenesis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Dru | 2022 |
Chemosensitization of Temozolomide-Resistant Pediatric Diffuse Midline Glioma Using Potent Nanoencapsulated Forms of a N(3)-Propargyl Analogue.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoferritins; beta-Cyclodextrins; Cell Line, Tumor; Drug | 2021 |
Chemosensitization of Temozolomide-Resistant Pediatric Diffuse Midline Glioma Using Potent Nanoencapsulated Forms of a N(3)-Propargyl Analogue.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoferritins; beta-Cyclodextrins; Cell Line, Tumor; Drug | 2021 |
Chemosensitization of Temozolomide-Resistant Pediatric Diffuse Midline Glioma Using Potent Nanoencapsulated Forms of a N(3)-Propargyl Analogue.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoferritins; beta-Cyclodextrins; Cell Line, Tumor; Drug | 2021 |
Chemosensitization of Temozolomide-Resistant Pediatric Diffuse Midline Glioma Using Potent Nanoencapsulated Forms of a N(3)-Propargyl Analogue.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoferritins; beta-Cyclodextrins; Cell Line, Tumor; Drug | 2021 |
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma.
Topics: Glioma; Humans; Isocitrate Dehydrogenase; Temozolomide | 2021 |
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma.
Topics: Glioma; Humans; Isocitrate Dehydrogenase; Temozolomide | 2021 |
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma.
Topics: Glioma; Humans; Isocitrate Dehydrogenase; Temozolomide | 2021 |
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma.
Topics: Glioma; Humans; Isocitrate Dehydrogenase; Temozolomide | 2021 |
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma - Authors' reply.
Topics: Glioma; Humans; Isocitrate Dehydrogenase; Temozolomide | 2021 |
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma - Authors' reply.
Topics: Glioma; Humans; Isocitrate Dehydrogenase; Temozolomide | 2021 |
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma - Authors' reply.
Topics: Glioma; Humans; Isocitrate Dehydrogenase; Temozolomide | 2021 |
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma - Authors' reply.
Topics: Glioma; Humans; Isocitrate Dehydrogenase; Temozolomide | 2021 |
Leukemia associated RUNX1T1 gene reduced proliferation and invasiveness of glioblastoma cells.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Gene | 2021 |
Leukemia associated RUNX1T1 gene reduced proliferation and invasiveness of glioblastoma cells.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Gene | 2021 |
Leukemia associated RUNX1T1 gene reduced proliferation and invasiveness of glioblastoma cells.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Gene | 2021 |
Leukemia associated RUNX1T1 gene reduced proliferation and invasiveness of glioblastoma cells.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Gene | 2021 |
Molecular Characterization of AEBP1 at Transcriptional Level in Glioma.
Topics: Brain Neoplasms; Carboxypeptidases; Cell Line, Tumor; Databases, Genetic; DNA Methylation; DNA Modif | 2021 |
Molecular Characterization of AEBP1 at Transcriptional Level in Glioma.
Topics: Brain Neoplasms; Carboxypeptidases; Cell Line, Tumor; Databases, Genetic; DNA Methylation; DNA Modif | 2021 |
Molecular Characterization of AEBP1 at Transcriptional Level in Glioma.
Topics: Brain Neoplasms; Carboxypeptidases; Cell Line, Tumor; Databases, Genetic; DNA Methylation; DNA Modif | 2021 |
Molecular Characterization of AEBP1 at Transcriptional Level in Glioma.
Topics: Brain Neoplasms; Carboxypeptidases; Cell Line, Tumor; Databases, Genetic; DNA Methylation; DNA Modif | 2021 |
Molecular characteristics of single patient-derived glioma stem-like cells from primary and recurrent glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation; | 2022 |
Molecular characteristics of single patient-derived glioma stem-like cells from primary and recurrent glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation; | 2022 |
Molecular characteristics of single patient-derived glioma stem-like cells from primary and recurrent glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation; | 2022 |
Molecular characteristics of single patient-derived glioma stem-like cells from primary and recurrent glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation; | 2022 |
Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Carmustine; Cell Line, Tumor; Cell | 2017 |
Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Carmustine; Cell Line, Tumor; Cell | 2017 |
Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Carmustine; Cell Line, Tumor; Cell | 2017 |
Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Carmustine; Cell Line, Tumor; Cell | 2017 |
Management and Survival Patterns of Patients with Gliomatosis Cerebri: A SEER-Based Analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain N | 2017 |
Management and Survival Patterns of Patients with Gliomatosis Cerebri: A SEER-Based Analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain N | 2017 |
Management and Survival Patterns of Patients with Gliomatosis Cerebri: A SEER-Based Analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain N | 2017 |
Management and Survival Patterns of Patients with Gliomatosis Cerebri: A SEER-Based Analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain N | 2017 |
Mustard-inspired delivery shuttle for enhanced blood-brain barrier penetration and effective drug delivery in glioma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Blood-Brain Barrier; Brain Neoplas | 2017 |
Mustard-inspired delivery shuttle for enhanced blood-brain barrier penetration and effective drug delivery in glioma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Blood-Brain Barrier; Brain Neoplas | 2017 |
Mustard-inspired delivery shuttle for enhanced blood-brain barrier penetration and effective drug delivery in glioma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Blood-Brain Barrier; Brain Neoplas | 2017 |
Mustard-inspired delivery shuttle for enhanced blood-brain barrier penetration and effective drug delivery in glioma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Blood-Brain Barrier; Brain Neoplas | 2017 |
β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Antineoplastic Agents, Alkylating; ATP Binding Cassette | 2017 |
β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Antineoplastic Agents, Alkylating; ATP Binding Cassette | 2017 |
β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Antineoplastic Agents, Alkylating; ATP Binding Cassette | 2017 |
β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Antineoplastic Agents, Alkylating; ATP Binding Cassette | 2017 |
Temozolomide increases MHC-I expression via NF-κB signaling in glioma stem cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Genes, MHC | 2017 |
Temozolomide increases MHC-I expression via NF-κB signaling in glioma stem cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Genes, MHC | 2017 |
Temozolomide increases MHC-I expression via NF-κB signaling in glioma stem cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Genes, MHC | 2017 |
Temozolomide increases MHC-I expression via NF-κB signaling in glioma stem cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Genes, MHC | 2017 |
Differential pro-apoptotic effects of synthetic 4-thiazolidinone derivative Les-3288, doxorubicin and temozolomide in human glioma U251 cells.
Topics: Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Caspase 3; Cell Line, Tumor; | 2017 |
Differential pro-apoptotic effects of synthetic 4-thiazolidinone derivative Les-3288, doxorubicin and temozolomide in human glioma U251 cells.
Topics: Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Caspase 3; Cell Line, Tumor; | 2017 |
Differential pro-apoptotic effects of synthetic 4-thiazolidinone derivative Les-3288, doxorubicin and temozolomide in human glioma U251 cells.
Topics: Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Caspase 3; Cell Line, Tumor; | 2017 |
Differential pro-apoptotic effects of synthetic 4-thiazolidinone derivative Les-3288, doxorubicin and temozolomide in human glioma U251 cells.
Topics: Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Caspase 3; Cell Line, Tumor; | 2017 |
Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; Brain Neoplasms; China; Dacarbazine; D | 2017 |
Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; Brain Neoplasms; China; Dacarbazine; D | 2017 |
Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; Brain Neoplasms; China; Dacarbazine; D | 2017 |
Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; Brain Neoplasms; China; Dacarbazine; D | 2017 |
Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Differentiation; Cell | 2017 |
Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Differentiation; Cell | 2017 |
Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Differentiation; Cell | 2017 |
Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Differentiation; Cell | 2017 |
Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2017 |
Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2017 |
Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2017 |
Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2017 |
The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells.
Topics: Aldehyde Oxidoreductases; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2017 |
The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells.
Topics: Aldehyde Oxidoreductases; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2017 |
The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells.
Topics: Aldehyde Oxidoreductases; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2017 |
The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells.
Topics: Aldehyde Oxidoreductases; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2017 |
Biological activity of tumor-treating fields in preclinical glioma models.
Topics: Apoptosis; Brain Neoplasms; Caspases; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; Da | 2017 |
Biological activity of tumor-treating fields in preclinical glioma models.
Topics: Apoptosis; Brain Neoplasms; Caspases; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; Da | 2017 |
Biological activity of tumor-treating fields in preclinical glioma models.
Topics: Apoptosis; Brain Neoplasms; Caspases; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; Da | 2017 |
Biological activity of tumor-treating fields in preclinical glioma models.
Topics: Apoptosis; Brain Neoplasms; Caspases; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; Da | 2017 |
IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2017 |
IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2017 |
IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2017 |
IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2017 |
Aspirin inhibits the SHH/GLI1 signaling pathway and sensitizes malignant glioma cells to temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Aspirin; Brain Neoplasms; Cell Line, Tumor; Dacarbazin | 2017 |
Aspirin inhibits the SHH/GLI1 signaling pathway and sensitizes malignant glioma cells to temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Aspirin; Brain Neoplasms; Cell Line, Tumor; Dacarbazin | 2017 |
Aspirin inhibits the SHH/GLI1 signaling pathway and sensitizes malignant glioma cells to temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Aspirin; Brain Neoplasms; Cell Line, Tumor; Dacarbazin | 2017 |
Aspirin inhibits the SHH/GLI1 signaling pathway and sensitizes malignant glioma cells to temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Aspirin; Brain Neoplasms; Cell Line, Tumor; Dacarbazin | 2017 |
Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit.
Topics: Animals; Antineoplastic Agents, Alkylating; Antipsychotic Agents; Brain Neoplasms; Cattle; Cell Line | 2017 |
Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit.
Topics: Animals; Antineoplastic Agents, Alkylating; Antipsychotic Agents; Brain Neoplasms; Cattle; Cell Line | 2017 |
Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit.
Topics: Animals; Antineoplastic Agents, Alkylating; Antipsychotic Agents; Brain Neoplasms; Cattle; Cell Line | 2017 |
Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit.
Topics: Animals; Antineoplastic Agents, Alkylating; Antipsychotic Agents; Brain Neoplasms; Cattle; Cell Line | 2017 |
MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.
Topics: Acetylation; Brain Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gene Exp | 2018 |
MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.
Topics: Acetylation; Brain Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gene Exp | 2018 |
MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.
Topics: Acetylation; Brain Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gene Exp | 2018 |
MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.
Topics: Acetylation; Brain Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gene Exp | 2018 |
Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme.
Topics: Antidepressive Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Su | 2017 |
Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme.
Topics: Antidepressive Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Su | 2017 |
Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme.
Topics: Antidepressive Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Su | 2017 |
Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme.
Topics: Antidepressive Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Su | 2017 |
The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Comet Assay; Cycl | 2018 |
The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Comet Assay; Cycl | 2018 |
The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Comet Assay; Cycl | 2018 |
The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Comet Assay; Cycl | 2018 |
Guanosine promotes cytotoxicity via adenosine receptors and induces apoptosis in temozolomide-treated A172 glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Sur | 2017 |
Guanosine promotes cytotoxicity via adenosine receptors and induces apoptosis in temozolomide-treated A172 glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Sur | 2017 |
Guanosine promotes cytotoxicity via adenosine receptors and induces apoptosis in temozolomide-treated A172 glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Sur | 2017 |
Guanosine promotes cytotoxicity via adenosine receptors and induces apoptosis in temozolomide-treated A172 glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Sur | 2017 |
Down-Regulation of AQP4 Expression via p38 MAPK Signaling in Temozolomide-Induced Glioma Cells Growth Inhibition and Invasion Impairment.
Topics: Aquaporin 4; Cell Line, Tumor; Dacarbazine; Down-Regulation; Gene Expression Regulation, Neoplastic; | 2017 |
Down-Regulation of AQP4 Expression via p38 MAPK Signaling in Temozolomide-Induced Glioma Cells Growth Inhibition and Invasion Impairment.
Topics: Aquaporin 4; Cell Line, Tumor; Dacarbazine; Down-Regulation; Gene Expression Regulation, Neoplastic; | 2017 |
Down-Regulation of AQP4 Expression via p38 MAPK Signaling in Temozolomide-Induced Glioma Cells Growth Inhibition and Invasion Impairment.
Topics: Aquaporin 4; Cell Line, Tumor; Dacarbazine; Down-Regulation; Gene Expression Regulation, Neoplastic; | 2017 |
Down-Regulation of AQP4 Expression via p38 MAPK Signaling in Temozolomide-Induced Glioma Cells Growth Inhibition and Invasion Impairment.
Topics: Aquaporin 4; Cell Line, Tumor; Dacarbazine; Down-Regulation; Gene Expression Regulation, Neoplastic; | 2017 |
The rs16906252:C>T SNP is not associated with increased overall survival or temozolomide response in a Han-Chinese glioma cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; China; Cohort Studies; Dacar | 2017 |
The rs16906252:C>T SNP is not associated with increased overall survival or temozolomide response in a Han-Chinese glioma cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; China; Cohort Studies; Dacar | 2017 |
The rs16906252:C>T SNP is not associated with increased overall survival or temozolomide response in a Han-Chinese glioma cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; China; Cohort Studies; Dacar | 2017 |
The rs16906252:C>T SNP is not associated with increased overall survival or temozolomide response in a Han-Chinese glioma cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; China; Cohort Studies; Dacar | 2017 |
Haematological malignancies following temozolomide treatment for paediatric high-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Austria; Child; Child, Preschool; Dacarbazine; Female | 2017 |
Haematological malignancies following temozolomide treatment for paediatric high-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Austria; Child; Child, Preschool; Dacarbazine; Female | 2017 |
Haematological malignancies following temozolomide treatment for paediatric high-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Austria; Child; Child, Preschool; Dacarbazine; Female | 2017 |
Haematological malignancies following temozolomide treatment for paediatric high-grade glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Austria; Child; Child, Preschool; Dacarbazine; Female | 2017 |
Thermoresponsive nanocomposite gel for local drug delivery to suppress the growth of glioma by inducing autophagy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; Cell Prolifera | 2017 |
Thermoresponsive nanocomposite gel for local drug delivery to suppress the growth of glioma by inducing autophagy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; Cell Prolifera | 2017 |
Thermoresponsive nanocomposite gel for local drug delivery to suppress the growth of glioma by inducing autophagy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; Cell Prolifera | 2017 |
Thermoresponsive nanocomposite gel for local drug delivery to suppress the growth of glioma by inducing autophagy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; Cell Prolifera | 2017 |
Effects of Connexin43 Overexpression on U251 Cell Growth, Migration, and Apoptosis.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Conn | 2017 |
Effects of Connexin43 Overexpression on U251 Cell Growth, Migration, and Apoptosis.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Conn | 2017 |
Effects of Connexin43 Overexpression on U251 Cell Growth, Migration, and Apoptosis.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Conn | 2017 |
Effects of Connexin43 Overexpression on U251 Cell Growth, Migration, and Apoptosis.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Conn | 2017 |
The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in
Topics: Acrylamides; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Enzyme Inhib | 2017 |
The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in
Topics: Acrylamides; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Enzyme Inhib | 2017 |
The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in
Topics: Acrylamides; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Enzyme Inhib | 2017 |
The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in
Topics: Acrylamides; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Enzyme Inhib | 2017 |
Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; | 2018 |
Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; | 2018 |
Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; | 2018 |
Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; | 2018 |
Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated αβ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Brain Neoplasms; Cell Line, Tumor; Child; Daca | 2017 |
Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated αβ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Brain Neoplasms; Cell Line, Tumor; Child; Daca | 2017 |
Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated αβ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Brain Neoplasms; Cell Line, Tumor; Child; Daca | 2017 |
Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated αβ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Brain Neoplasms; Cell Line, Tumor; Child; Daca | 2017 |
Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.
Topics: Animals; Antineoplastic Agents; Benzamides; Blood-Brain Barrier; Cell Line, Tumor; Cell Movement; Ce | 2017 |
Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.
Topics: Animals; Antineoplastic Agents; Benzamides; Blood-Brain Barrier; Cell Line, Tumor; Cell Movement; Ce | 2017 |
Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.
Topics: Animals; Antineoplastic Agents; Benzamides; Blood-Brain Barrier; Cell Line, Tumor; Cell Movement; Ce | 2017 |
Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.
Topics: Animals; Antineoplastic Agents; Benzamides; Blood-Brain Barrier; Cell Line, Tumor; Cell Movement; Ce | 2017 |
Glioma sensitive or chemoresistant to temozolomide differentially modulate macrophage protumor activities.
Topics: Animals; Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Cell Line, Tumor; Cell Polarity | 2017 |
Glioma sensitive or chemoresistant to temozolomide differentially modulate macrophage protumor activities.
Topics: Animals; Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Cell Line, Tumor; Cell Polarity | 2017 |
Glioma sensitive or chemoresistant to temozolomide differentially modulate macrophage protumor activities.
Topics: Animals; Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Cell Line, Tumor; Cell Polarity | 2017 |
Glioma sensitive or chemoresistant to temozolomide differentially modulate macrophage protumor activities.
Topics: Animals; Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Cell Line, Tumor; Cell Polarity | 2017 |
Combination of sonodynamic with temozolomide inhibits C6 glioma migration and promotes mitochondrial pathway apoptosis via suppressing NHE-1 expression.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Combined Modality Therapy; Dacarbazine; Gene Expression | 2017 |
Combination of sonodynamic with temozolomide inhibits C6 glioma migration and promotes mitochondrial pathway apoptosis via suppressing NHE-1 expression.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Combined Modality Therapy; Dacarbazine; Gene Expression | 2017 |
Combination of sonodynamic with temozolomide inhibits C6 glioma migration and promotes mitochondrial pathway apoptosis via suppressing NHE-1 expression.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Combined Modality Therapy; Dacarbazine; Gene Expression | 2017 |
Combination of sonodynamic with temozolomide inhibits C6 glioma migration and promotes mitochondrial pathway apoptosis via suppressing NHE-1 expression.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Combined Modality Therapy; Dacarbazine; Gene Expression | 2017 |
Early initiation of chemoradiation following index craniotomy is associated with decreased survival in high-grade glioma.
Topics: Age Factors; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Craniotomy; Dacarbazine; Female; | 2017 |
Early initiation of chemoradiation following index craniotomy is associated with decreased survival in high-grade glioma.
Topics: Age Factors; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Craniotomy; Dacarbazine; Female; | 2017 |
Early initiation of chemoradiation following index craniotomy is associated with decreased survival in high-grade glioma.
Topics: Age Factors; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Craniotomy; Dacarbazine; Female; | 2017 |
Early initiation of chemoradiation following index craniotomy is associated with decreased survival in high-grade glioma.
Topics: Age Factors; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Craniotomy; Dacarbazine; Female; | 2017 |
Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433).
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Cell Line, Tumor; Drug Carriers; Gl | 2017 |
Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433).
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Cell Line, Tumor; Drug Carriers; Gl | 2017 |
Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433).
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Cell Line, Tumor; Drug Carriers; Gl | 2017 |
Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433).
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Cell Line, Tumor; Drug Carriers; Gl | 2017 |
β-asarone inhibited cell growth and promoted autophagy via P53/Bcl-2/Bclin-1 and P53/AMPK/mTOR pathways in Human Glioma U251 cells.
Topics: Allylbenzene Derivatives; AMP-Activated Protein Kinases; Anisoles; Antineoplastic Agents; Antineopla | 2018 |
β-asarone inhibited cell growth and promoted autophagy via P53/Bcl-2/Bclin-1 and P53/AMPK/mTOR pathways in Human Glioma U251 cells.
Topics: Allylbenzene Derivatives; AMP-Activated Protein Kinases; Anisoles; Antineoplastic Agents; Antineopla | 2018 |
β-asarone inhibited cell growth and promoted autophagy via P53/Bcl-2/Bclin-1 and P53/AMPK/mTOR pathways in Human Glioma U251 cells.
Topics: Allylbenzene Derivatives; AMP-Activated Protein Kinases; Anisoles; Antineoplastic Agents; Antineopla | 2018 |
β-asarone inhibited cell growth and promoted autophagy via P53/Bcl-2/Bclin-1 and P53/AMPK/mTOR pathways in Human Glioma U251 cells.
Topics: Allylbenzene Derivatives; AMP-Activated Protein Kinases; Anisoles; Antineoplastic Agents; Antineopla | 2018 |
Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Dacarbazine; Glioma; Humans; Male; Temozolomi | 2017 |
Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Dacarbazine; Glioma; Humans; Male; Temozolomi | 2017 |
Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Dacarbazine; Glioma; Humans; Male; Temozolomi | 2017 |
Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Dacarbazine; Glioma; Humans; Male; Temozolomi | 2017 |
[RNA interference targeting DNA-PKcs inhibits glioma cells malignancies and enhances temozolomide sensitivity].
Topics: Cell Line, Tumor; Cell Proliferation; DNA; DNA-Activated Protein Kinase; Glioma; Humans; Neoplasm In | 2017 |
[RNA interference targeting DNA-PKcs inhibits glioma cells malignancies and enhances temozolomide sensitivity].
Topics: Cell Line, Tumor; Cell Proliferation; DNA; DNA-Activated Protein Kinase; Glioma; Humans; Neoplasm In | 2017 |
[RNA interference targeting DNA-PKcs inhibits glioma cells malignancies and enhances temozolomide sensitivity].
Topics: Cell Line, Tumor; Cell Proliferation; DNA; DNA-Activated Protein Kinase; Glioma; Humans; Neoplasm In | 2017 |
[RNA interference targeting DNA-PKcs inhibits glioma cells malignancies and enhances temozolomide sensitivity].
Topics: Cell Line, Tumor; Cell Proliferation; DNA; DNA-Activated Protein Kinase; Glioma; Humans; Neoplasm In | 2017 |
Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cerebral Vent | 2017 |
Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cerebral Vent | 2017 |
Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cerebral Vent | 2017 |
Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cerebral Vent | 2017 |
Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas.
Topics: Anthelmintics; Cell Cycle Checkpoints; Cell Line, Tumor; Cellular Senescence; Drug Resistance, Neopl | 2018 |
Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas.
Topics: Anthelmintics; Cell Cycle Checkpoints; Cell Line, Tumor; Cellular Senescence; Drug Resistance, Neopl | 2018 |
Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas.
Topics: Anthelmintics; Cell Cycle Checkpoints; Cell Line, Tumor; Cellular Senescence; Drug Resistance, Neopl | 2018 |
Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas.
Topics: Anthelmintics; Cell Cycle Checkpoints; Cell Line, Tumor; Cellular Senescence; Drug Resistance, Neopl | 2018 |
The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Anim | 2017 |
The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Anim | 2017 |
The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Anim | 2017 |
The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Anim | 2017 |
Phase I/II Trial of Combination of Temozolomide Chemotherapy and Immunotherapy With Fusions of Dendritic and Glioma Cells in Patients With Glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Immunotherapy; Temozolomide | 2017 |
Phase I/II Trial of Combination of Temozolomide Chemotherapy and Immunotherapy With Fusions of Dendritic and Glioma Cells in Patients With Glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Immunotherapy; Temozolomide | 2017 |
Phase I/II Trial of Combination of Temozolomide Chemotherapy and Immunotherapy With Fusions of Dendritic and Glioma Cells in Patients With Glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Immunotherapy; Temozolomide | 2017 |
Phase I/II Trial of Combination of Temozolomide Chemotherapy and Immunotherapy With Fusions of Dendritic and Glioma Cells in Patients With Glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Immunotherapy; Temozolomide | 2017 |
Significance of perivascular tumour cells defined by CD109 expression in progression of glioma.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacar | 2017 |
Significance of perivascular tumour cells defined by CD109 expression in progression of glioma.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacar | 2017 |
Significance of perivascular tumour cells defined by CD109 expression in progression of glioma.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacar | 2017 |
Significance of perivascular tumour cells defined by CD109 expression in progression of glioma.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacar | 2017 |
MiR-26b reverses temozolomide resistance via targeting Wee1 in glioma cells.
Topics: Base Sequence; Biomarkers, Tumor; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Dacarbazine; | 2017 |
MiR-26b reverses temozolomide resistance via targeting Wee1 in glioma cells.
Topics: Base Sequence; Biomarkers, Tumor; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Dacarbazine; | 2017 |
MiR-26b reverses temozolomide resistance via targeting Wee1 in glioma cells.
Topics: Base Sequence; Biomarkers, Tumor; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Dacarbazine; | 2017 |
MiR-26b reverses temozolomide resistance via targeting Wee1 in glioma cells.
Topics: Base Sequence; Biomarkers, Tumor; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Dacarbazine; | 2017 |
Controlled release of liposome-encapsulated temozolomide for brain tumour treatment by convection-enhanced delivery.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplas | 2018 |
Controlled release of liposome-encapsulated temozolomide for brain tumour treatment by convection-enhanced delivery.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplas | 2018 |
Controlled release of liposome-encapsulated temozolomide for brain tumour treatment by convection-enhanced delivery.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplas | 2018 |
Controlled release of liposome-encapsulated temozolomide for brain tumour treatment by convection-enhanced delivery.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplas | 2018 |
Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chil | 2018 |
Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chil | 2018 |
Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chil | 2018 |
Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chil | 2018 |
Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Blood Vessels; Brain Neoplasms; | 2017 |
Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Blood Vessels; Brain Neoplasms; | 2017 |
Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Blood Vessels; Brain Neoplasms; | 2017 |
Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Blood Vessels; Brain Neoplasms; | 2017 |
Hyperthermia with different temperatures inhibits proliferation and promotes apoptosis through the EGFR/STAT3 pathway in C6 rat glioma cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dacarbazi | 2017 |
Hyperthermia with different temperatures inhibits proliferation and promotes apoptosis through the EGFR/STAT3 pathway in C6 rat glioma cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dacarbazi | 2017 |
Hyperthermia with different temperatures inhibits proliferation and promotes apoptosis through the EGFR/STAT3 pathway in C6 rat glioma cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dacarbazi | 2017 |
Hyperthermia with different temperatures inhibits proliferation and promotes apoptosis through the EGFR/STAT3 pathway in C6 rat glioma cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dacarbazi | 2017 |
Sequential proton boost after standard chemoradiation for high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarb | 2017 |
Sequential proton boost after standard chemoradiation for high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarb | 2017 |
Sequential proton boost after standard chemoradiation for high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarb | 2017 |
Sequential proton boost after standard chemoradiation for high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarb | 2017 |
Propyl Gallate Exerts an Antimigration Effect on Temozolomide-Treated Malignant Glioma Cells through Inhibition of ROS and the NF-
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Synergism; Drug Therapy, Combination; | 2017 |
Propyl Gallate Exerts an Antimigration Effect on Temozolomide-Treated Malignant Glioma Cells through Inhibition of ROS and the NF-
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Synergism; Drug Therapy, Combination; | 2017 |
Propyl Gallate Exerts an Antimigration Effect on Temozolomide-Treated Malignant Glioma Cells through Inhibition of ROS and the NF-
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Synergism; Drug Therapy, Combination; | 2017 |
Propyl Gallate Exerts an Antimigration Effect on Temozolomide-Treated Malignant Glioma Cells through Inhibition of ROS and the NF-
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Synergism; Drug Therapy, Combination; | 2017 |
Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair | 2017 |
Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair | 2017 |
Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair | 2017 |
Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair | 2017 |
Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition.
Topics: Antineoplastic Agents, Alkylating; Bcl-2-Like Protein 11; Cadherins; Cdc20 Proteins; Cell Line, Tumo | 2017 |
Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition.
Topics: Antineoplastic Agents, Alkylating; Bcl-2-Like Protein 11; Cadherins; Cdc20 Proteins; Cell Line, Tumo | 2017 |
Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition.
Topics: Antineoplastic Agents, Alkylating; Bcl-2-Like Protein 11; Cadherins; Cdc20 Proteins; Cell Line, Tumo | 2017 |
Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition.
Topics: Antineoplastic Agents, Alkylating; Bcl-2-Like Protein 11; Cadherins; Cdc20 Proteins; Cell Line, Tumo | 2017 |
Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Sur | 2018 |
Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Sur | 2018 |
Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Sur | 2018 |
Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Sur | 2018 |
Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chromosome Deletion; Chromos | 2018 |
Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chromosome Deletion; Chromos | 2018 |
Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chromosome Deletion; Chromos | 2018 |
Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chromosome Deletion; Chromos | 2018 |
Development of temozolomide coated nano zinc oxide for reversing the resistance of malignant glioma stem cells.
Topics: Cell Line, Tumor; Dacarbazine; Glioma; Green Chemistry Technology; Humans; Metal Nanoparticles; Plan | 2018 |
Development of temozolomide coated nano zinc oxide for reversing the resistance of malignant glioma stem cells.
Topics: Cell Line, Tumor; Dacarbazine; Glioma; Green Chemistry Technology; Humans; Metal Nanoparticles; Plan | 2018 |
Development of temozolomide coated nano zinc oxide for reversing the resistance of malignant glioma stem cells.
Topics: Cell Line, Tumor; Dacarbazine; Glioma; Green Chemistry Technology; Humans; Metal Nanoparticles; Plan | 2018 |
Development of temozolomide coated nano zinc oxide for reversing the resistance of malignant glioma stem cells.
Topics: Cell Line, Tumor; Dacarbazine; Glioma; Green Chemistry Technology; Humans; Metal Nanoparticles; Plan | 2018 |
Farewell to monomodality treatment in patients with WHO lower grade glioma?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as | 2018 |
Farewell to monomodality treatment in patients with WHO lower grade glioma?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as | 2018 |
Farewell to monomodality treatment in patients with WHO lower grade glioma?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as | 2018 |
Farewell to monomodality treatment in patients with WHO lower grade glioma?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as | 2018 |
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dihydroxyphenylalanine; Female; Gli | 2018 |
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dihydroxyphenylalanine; Female; Gli | 2018 |
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dihydroxyphenylalanine; Female; Gli | 2018 |
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dihydroxyphenylalanine; Female; Gli | 2018 |
Chitosan Engineered PAMAM Dendrimers as Nanoconstructs for the Enhanced Anti-Cancer Potential and Improved In vivo Brain Pharmacokinetics of Temozolomide.
Topics: Animals; Antineoplastic Agents; Biological Transport; Blood-Brain Barrier; Brain; Cell Line, Tumor; | 2018 |
Chitosan Engineered PAMAM Dendrimers as Nanoconstructs for the Enhanced Anti-Cancer Potential and Improved In vivo Brain Pharmacokinetics of Temozolomide.
Topics: Animals; Antineoplastic Agents; Biological Transport; Blood-Brain Barrier; Brain; Cell Line, Tumor; | 2018 |
Chitosan Engineered PAMAM Dendrimers as Nanoconstructs for the Enhanced Anti-Cancer Potential and Improved In vivo Brain Pharmacokinetics of Temozolomide.
Topics: Animals; Antineoplastic Agents; Biological Transport; Blood-Brain Barrier; Brain; Cell Line, Tumor; | 2018 |
Chitosan Engineered PAMAM Dendrimers as Nanoconstructs for the Enhanced Anti-Cancer Potential and Improved In vivo Brain Pharmacokinetics of Temozolomide.
Topics: Animals; Antineoplastic Agents; Biological Transport; Blood-Brain Barrier; Brain; Cell Line, Tumor; | 2018 |
Differential Characterization of Temozolomide-Resistant Human Glioma Cells.
Topics: Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Connexin 43; Dacarbazine; DNA Modif | 2018 |
Differential Characterization of Temozolomide-Resistant Human Glioma Cells.
Topics: Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Connexin 43; Dacarbazine; DNA Modif | 2018 |
Differential Characterization of Temozolomide-Resistant Human Glioma Cells.
Topics: Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Connexin 43; Dacarbazine; DNA Modif | 2018 |
Differential Characterization of Temozolomide-Resistant Human Glioma Cells.
Topics: Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Connexin 43; Dacarbazine; DNA Modif | 2018 |
NKG2D ligands in glioma stem-like cells: expression in situ and in vitro.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Dacarbazine; | 2018 |
NKG2D ligands in glioma stem-like cells: expression in situ and in vitro.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Dacarbazine; | 2018 |
NKG2D ligands in glioma stem-like cells: expression in situ and in vitro.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Dacarbazine; | 2018 |
NKG2D ligands in glioma stem-like cells: expression in situ and in vitro.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Dacarbazine; | 2018 |
Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance temozolomide sensitivity in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; | 2018 |
Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance temozolomide sensitivity in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; | 2018 |
Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance temozolomide sensitivity in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; | 2018 |
Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance temozolomide sensitivity in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; | 2018 |
Role of Radiosensitizers in Radiation Treatment of Gliomas.
Topics: Dacarbazine; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; | 2018 |
Role of Radiosensitizers in Radiation Treatment of Gliomas.
Topics: Dacarbazine; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; | 2018 |
Role of Radiosensitizers in Radiation Treatment of Gliomas.
Topics: Dacarbazine; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; | 2018 |
Role of Radiosensitizers in Radiation Treatment of Gliomas.
Topics: Dacarbazine; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; | 2018 |
Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults.
Topics: Adult; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Humans; Procarbazi | 2018 |
Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults.
Topics: Adult; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Humans; Procarbazi | 2018 |
Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults.
Topics: Adult; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Humans; Procarbazi | 2018 |
Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults.
Topics: Adult; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Humans; Procarbazi | 2018 |
Chemotherapy of Oligodendrogliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2018 |
Chemotherapy of Oligodendrogliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2018 |
Chemotherapy of Oligodendrogliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2018 |
Chemotherapy of Oligodendrogliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2018 |
Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antineoplastic Combined Chemotherapy Protoco | 2018 |
Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antineoplastic Combined Chemotherapy Protoco | 2018 |
Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antineoplastic Combined Chemotherapy Protoco | 2018 |
Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antineoplastic Combined Chemotherapy Protoco | 2018 |
FBW7 is associated with prognosis, inhibits malignancies and enhances temozolomide sensitivity in glioblastoma cells.
Topics: Apoptosis; Aurora Kinase B; Cell Count; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cel | 2018 |
FBW7 is associated with prognosis, inhibits malignancies and enhances temozolomide sensitivity in glioblastoma cells.
Topics: Apoptosis; Aurora Kinase B; Cell Count; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cel | 2018 |
FBW7 is associated with prognosis, inhibits malignancies and enhances temozolomide sensitivity in glioblastoma cells.
Topics: Apoptosis; Aurora Kinase B; Cell Count; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cel | 2018 |
FBW7 is associated with prognosis, inhibits malignancies and enhances temozolomide sensitivity in glioblastoma cells.
Topics: Apoptosis; Aurora Kinase B; Cell Count; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cel | 2018 |
MiR-634 sensitizes glioma cells to temozolomide by targeting CYR61 through Raf-ERK signaling pathway.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cysteine-Rich Pro | 2018 |
MiR-634 sensitizes glioma cells to temozolomide by targeting CYR61 through Raf-ERK signaling pathway.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cysteine-Rich Pro | 2018 |
MiR-634 sensitizes glioma cells to temozolomide by targeting CYR61 through Raf-ERK signaling pathway.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cysteine-Rich Pro | 2018 |
MiR-634 sensitizes glioma cells to temozolomide by targeting CYR61 through Raf-ERK signaling pathway.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cysteine-Rich Pro | 2018 |
Hyperbaric oxygen as an adjuvant to temozolomide nanoparticle inhibits glioma growth by inducing G2/M phase arrest.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; G2 | 2018 |
Hyperbaric oxygen as an adjuvant to temozolomide nanoparticle inhibits glioma growth by inducing G2/M phase arrest.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; G2 | 2018 |
Hyperbaric oxygen as an adjuvant to temozolomide nanoparticle inhibits glioma growth by inducing G2/M phase arrest.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; G2 | 2018 |
Hyperbaric oxygen as an adjuvant to temozolomide nanoparticle inhibits glioma growth by inducing G2/M phase arrest.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; G2 | 2018 |
Risk Factors for Malignant Transformation of Low-Grade Glioma.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents | 2018 |
Risk Factors for Malignant Transformation of Low-Grade Glioma.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents | 2018 |
Risk Factors for Malignant Transformation of Low-Grade Glioma.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents | 2018 |
Risk Factors for Malignant Transformation of Low-Grade Glioma.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents | 2018 |
Tumor Volume Changes During and After Temozolomide Treatment for Newly Diagnosed Higher-Grade Glioma (III and IV).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Com | 2018 |
Tumor Volume Changes During and After Temozolomide Treatment for Newly Diagnosed Higher-Grade Glioma (III and IV).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Com | 2018 |
Tumor Volume Changes During and After Temozolomide Treatment for Newly Diagnosed Higher-Grade Glioma (III and IV).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Com | 2018 |
Tumor Volume Changes During and After Temozolomide Treatment for Newly Diagnosed Higher-Grade Glioma (III and IV).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Com | 2018 |
DMC is not better than TMZ on intracranial anti-glioma effects.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Curcumin | 2018 |
DMC is not better than TMZ on intracranial anti-glioma effects.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Curcumin | 2018 |
DMC is not better than TMZ on intracranial anti-glioma effects.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Curcumin | 2018 |
DMC is not better than TMZ on intracranial anti-glioma effects.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Curcumin | 2018 |
Improved effects of honokiol on temozolomide-induced autophagy and apoptosis of drug-sensitive and -tolerant glioma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Biphenyl Compounds; Caspase 3; Cell Cycle C | 2018 |
Improved effects of honokiol on temozolomide-induced autophagy and apoptosis of drug-sensitive and -tolerant glioma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Biphenyl Compounds; Caspase 3; Cell Cycle C | 2018 |
Improved effects of honokiol on temozolomide-induced autophagy and apoptosis of drug-sensitive and -tolerant glioma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Biphenyl Compounds; Caspase 3; Cell Cycle C | 2018 |
Improved effects of honokiol on temozolomide-induced autophagy and apoptosis of drug-sensitive and -tolerant glioma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Biphenyl Compounds; Caspase 3; Cell Cycle C | 2018 |
Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma.
Topics: Binding Sites; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Down-Regulation; Gene Expression R | 2018 |
Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma.
Topics: Binding Sites; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Down-Regulation; Gene Expression R | 2018 |
Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma.
Topics: Binding Sites; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Down-Regulation; Gene Expression R | 2018 |
Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma.
Topics: Binding Sites; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Down-Regulation; Gene Expression R | 2018 |
Quantitative dynamic susceptibility contrast perfusion-weighted imaging-guided customized gamma knife re-irradiation of recurrent high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Contrast Media; | 2018 |
Quantitative dynamic susceptibility contrast perfusion-weighted imaging-guided customized gamma knife re-irradiation of recurrent high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Contrast Media; | 2018 |
Quantitative dynamic susceptibility contrast perfusion-weighted imaging-guided customized gamma knife re-irradiation of recurrent high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Contrast Media; | 2018 |
Quantitative dynamic susceptibility contrast perfusion-weighted imaging-guided customized gamma knife re-irradiation of recurrent high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Contrast Media; | 2018 |
Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2018 |
Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2018 |
Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2018 |
Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2018 |
Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide).
Topics: Adult; Biomarkers, Tumor; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; | 2018 |
Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide).
Topics: Adult; Biomarkers, Tumor; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; | 2018 |
Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide).
Topics: Adult; Biomarkers, Tumor; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; | 2018 |
Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide).
Topics: Adult; Biomarkers, Tumor; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; | 2018 |
Overexpression of Fn14 in gliomas: tumor progression and poor prognosis.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Line, Tumor; Chem | 2018 |
Overexpression of Fn14 in gliomas: tumor progression and poor prognosis.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Line, Tumor; Chem | 2018 |
Overexpression of Fn14 in gliomas: tumor progression and poor prognosis.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Line, Tumor; Chem | 2018 |
Overexpression of Fn14 in gliomas: tumor progression and poor prognosis.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Line, Tumor; Chem | 2018 |
Mitochondria Transcription Factor A: A Putative Target for the Effect of Melatonin on U87MG Malignant Glioma Cell Line.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Replica | 2018 |
Mitochondria Transcription Factor A: A Putative Target for the Effect of Melatonin on U87MG Malignant Glioma Cell Line.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Replica | 2018 |
Mitochondria Transcription Factor A: A Putative Target for the Effect of Melatonin on U87MG Malignant Glioma Cell Line.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Replica | 2018 |
Mitochondria Transcription Factor A: A Putative Target for the Effect of Melatonin on U87MG Malignant Glioma Cell Line.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Replica | 2018 |
Association between SOX9 and CA9 in glioma, and its effects on chemosensitivity to TMZ.
Topics: Antigens, Neoplasm; Apoptosis; Carbonic Anhydrase IX; Cell Line, Tumor; Cell Proliferation; Dacarbaz | 2018 |
Association between SOX9 and CA9 in glioma, and its effects on chemosensitivity to TMZ.
Topics: Antigens, Neoplasm; Apoptosis; Carbonic Anhydrase IX; Cell Line, Tumor; Cell Proliferation; Dacarbaz | 2018 |
Association between SOX9 and CA9 in glioma, and its effects on chemosensitivity to TMZ.
Topics: Antigens, Neoplasm; Apoptosis; Carbonic Anhydrase IX; Cell Line, Tumor; Cell Proliferation; Dacarbaz | 2018 |
Association between SOX9 and CA9 in glioma, and its effects on chemosensitivity to TMZ.
Topics: Antigens, Neoplasm; Apoptosis; Carbonic Anhydrase IX; Cell Line, Tumor; Cell Proliferation; Dacarbaz | 2018 |
GSK3β‑mediated Ser156 phosphorylation modulates a BH3‑like domain in BCL2L12 during TMZ‑induced apoptosis and autophagy in glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Cell Line, Tumor; Dacarbazine; Glioma; Glyc | 2018 |
GSK3β‑mediated Ser156 phosphorylation modulates a BH3‑like domain in BCL2L12 during TMZ‑induced apoptosis and autophagy in glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Cell Line, Tumor; Dacarbazine; Glioma; Glyc | 2018 |
GSK3β‑mediated Ser156 phosphorylation modulates a BH3‑like domain in BCL2L12 during TMZ‑induced apoptosis and autophagy in glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Cell Line, Tumor; Dacarbazine; Glioma; Glyc | 2018 |
GSK3β‑mediated Ser156 phosphorylation modulates a BH3‑like domain in BCL2L12 during TMZ‑induced apoptosis and autophagy in glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Cell Line, Tumor; Dacarbazine; Glioma; Glyc | 2018 |
Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
Topics: Animals; Antibodies, Neoplasm; Brain; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Ly | 2018 |
Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
Topics: Animals; Antibodies, Neoplasm; Brain; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Ly | 2018 |
Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
Topics: Animals; Antibodies, Neoplasm; Brain; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Ly | 2018 |
Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
Topics: Animals; Antibodies, Neoplasm; Brain; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Ly | 2018 |
[Clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent brain glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Da | 2018 |
[Clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent brain glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Da | 2018 |
[Clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent brain glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Da | 2018 |
[Clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent brain glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Da | 2018 |
Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Azepines; Blood-Brain | 2018 |
Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Azepines; Blood-Brain | 2018 |
Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Azepines; Blood-Brain | 2018 |
Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Azepines; Blood-Brain | 2018 |
Cytomegalovirus Hemorrhagic Cystitis in a Malignant Glioma Patient Treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antiviral Agents; Cystitis; Cytomegalovirus Infectio | 2018 |
Cytomegalovirus Hemorrhagic Cystitis in a Malignant Glioma Patient Treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antiviral Agents; Cystitis; Cytomegalovirus Infectio | 2018 |
Cytomegalovirus Hemorrhagic Cystitis in a Malignant Glioma Patient Treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antiviral Agents; Cystitis; Cytomegalovirus Infectio | 2018 |
Cytomegalovirus Hemorrhagic Cystitis in a Malignant Glioma Patient Treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antiviral Agents; Cystitis; Cytomegalovirus Infectio | 2018 |
Memory and attention recovery in patients with High Grade Glioma who completed the Stupp protocol: A before-after study.
Topics: Adult; Aged; Attention; Brain Neoplasms; Cognition; Combined Modality Therapy; Dacarbazine; Female; | 2018 |
Memory and attention recovery in patients with High Grade Glioma who completed the Stupp protocol: A before-after study.
Topics: Adult; Aged; Attention; Brain Neoplasms; Cognition; Combined Modality Therapy; Dacarbazine; Female; | 2018 |
Memory and attention recovery in patients with High Grade Glioma who completed the Stupp protocol: A before-after study.
Topics: Adult; Aged; Attention; Brain Neoplasms; Cognition; Combined Modality Therapy; Dacarbazine; Female; | 2018 |
Memory and attention recovery in patients with High Grade Glioma who completed the Stupp protocol: A before-after study.
Topics: Adult; Aged; Attention; Brain Neoplasms; Cognition; Combined Modality Therapy; Dacarbazine; Female; | 2018 |
Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance.
Topics: Adenine; Animals; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Cytokine Receptor | 2018 |
Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance.
Topics: Adenine; Animals; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Cytokine Receptor | 2018 |
Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance.
Topics: Adenine; Animals; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Cytokine Receptor | 2018 |
Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance.
Topics: Adenine; Animals; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Cytokine Receptor | 2018 |
Synergistic Anticancer Effects of Formononetin and Temozolomide on Glioma C6 Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dr | 2018 |
Synergistic Anticancer Effects of Formononetin and Temozolomide on Glioma C6 Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dr | 2018 |
Synergistic Anticancer Effects of Formononetin and Temozolomide on Glioma C6 Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dr | 2018 |
Synergistic Anticancer Effects of Formononetin and Temozolomide on Glioma C6 Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dr | 2018 |
TRIM14 promotes chemoresistance in gliomas by activating Wnt/β-catenin signaling via stabilizing Dvl2.
Topics: Carrier Proteins; Dishevelled Proteins; Drug Resistance, Neoplasm; Gene Silencing; Glioma; Humans; I | 2018 |
TRIM14 promotes chemoresistance in gliomas by activating Wnt/β-catenin signaling via stabilizing Dvl2.
Topics: Carrier Proteins; Dishevelled Proteins; Drug Resistance, Neoplasm; Gene Silencing; Glioma; Humans; I | 2018 |
TRIM14 promotes chemoresistance in gliomas by activating Wnt/β-catenin signaling via stabilizing Dvl2.
Topics: Carrier Proteins; Dishevelled Proteins; Drug Resistance, Neoplasm; Gene Silencing; Glioma; Humans; I | 2018 |
TRIM14 promotes chemoresistance in gliomas by activating Wnt/β-catenin signaling via stabilizing Dvl2.
Topics: Carrier Proteins; Dishevelled Proteins; Drug Resistance, Neoplasm; Gene Silencing; Glioma; Humans; I | 2018 |
[Establishment of a glioma orthotopic xenograft model based on imaging technology].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease | 2016 |
[Establishment of a glioma orthotopic xenograft model based on imaging technology].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease | 2016 |
[Establishment of a glioma orthotopic xenograft model based on imaging technology].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease | 2016 |
[Establishment of a glioma orthotopic xenograft model based on imaging technology].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease | 2016 |
Autophagy inhibition synergizes with calcium mobilization to achieve efficient therapy of malignant gliomas.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Protein 5; Calcium; Cell Line, Tumor; Chloroquine; | 2018 |
Autophagy inhibition synergizes with calcium mobilization to achieve efficient therapy of malignant gliomas.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Protein 5; Calcium; Cell Line, Tumor; Chloroquine; | 2018 |
Autophagy inhibition synergizes with calcium mobilization to achieve efficient therapy of malignant gliomas.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Protein 5; Calcium; Cell Line, Tumor; Chloroquine; | 2018 |
Autophagy inhibition synergizes with calcium mobilization to achieve efficient therapy of malignant gliomas.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Protein 5; Calcium; Cell Line, Tumor; Chloroquine; | 2018 |
USE OF PERFUSION MRI FOR DETERMINATION OF IRRADIATION VOLUMES IN RADIOTHERAPY OF PATIENTS WITH BRAIN GLIOMA.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Contrast Media; Diffusion Magnetic Resona | 2018 |
USE OF PERFUSION MRI FOR DETERMINATION OF IRRADIATION VOLUMES IN RADIOTHERAPY OF PATIENTS WITH BRAIN GLIOMA.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Contrast Media; Diffusion Magnetic Resona | 2018 |
USE OF PERFUSION MRI FOR DETERMINATION OF IRRADIATION VOLUMES IN RADIOTHERAPY OF PATIENTS WITH BRAIN GLIOMA.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Contrast Media; Diffusion Magnetic Resona | 2018 |
USE OF PERFUSION MRI FOR DETERMINATION OF IRRADIATION VOLUMES IN RADIOTHERAPY OF PATIENTS WITH BRAIN GLIOMA.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Contrast Media; Diffusion Magnetic Resona | 2018 |
Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated With IMRT.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; DNA Methylation; DNA | 2019 |
Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated With IMRT.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; DNA Methylation; DNA | 2019 |
Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated With IMRT.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; DNA Methylation; DNA | 2019 |
Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated With IMRT.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; DNA Methylation; DNA | 2019 |
Codelivery of temozolomide and siRNA with polymeric nanocarrier for effective glioma treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; Dacarbazine; Drug Carriers; | 2018 |
Codelivery of temozolomide and siRNA with polymeric nanocarrier for effective glioma treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; Dacarbazine; Drug Carriers; | 2018 |
Codelivery of temozolomide and siRNA with polymeric nanocarrier for effective glioma treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; Dacarbazine; Drug Carriers; | 2018 |
Codelivery of temozolomide and siRNA with polymeric nanocarrier for effective glioma treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; Dacarbazine; Drug Carriers; | 2018 |
Genetic variants related to angiogenesis and apoptosis in patients with glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neop | 2018 |
Genetic variants related to angiogenesis and apoptosis in patients with glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neop | 2018 |
Genetic variants related to angiogenesis and apoptosis in patients with glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neop | 2018 |
Genetic variants related to angiogenesis and apoptosis in patients with glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neop | 2018 |
Topics: Antineoplastic Agents, Alkylating; B-Cell Lymphoma 3 Protein; Brain Neoplasms; Carbonic Anhydrase II | 2018 |
Topics: Antineoplastic Agents, Alkylating; B-Cell Lymphoma 3 Protein; Brain Neoplasms; Carbonic Anhydrase II | 2018 |
Topics: Antineoplastic Agents, Alkylating; B-Cell Lymphoma 3 Protein; Brain Neoplasms; Carbonic Anhydrase II | 2018 |
Topics: Antineoplastic Agents, Alkylating; B-Cell Lymphoma 3 Protein; Brain Neoplasms; Carbonic Anhydrase II | 2018 |
Data-Driven Predictive Models of Diffuse Low-Grade Gliomas Under Chemotherapy.
Topics: Algorithms; Antineoplastic Agents; Brain; Brain Neoplasms; Computational Biology; Glioma; Humans; Ma | 2019 |
Data-Driven Predictive Models of Diffuse Low-Grade Gliomas Under Chemotherapy.
Topics: Algorithms; Antineoplastic Agents; Brain; Brain Neoplasms; Computational Biology; Glioma; Humans; Ma | 2019 |
Data-Driven Predictive Models of Diffuse Low-Grade Gliomas Under Chemotherapy.
Topics: Algorithms; Antineoplastic Agents; Brain; Brain Neoplasms; Computational Biology; Glioma; Humans; Ma | 2019 |
Data-Driven Predictive Models of Diffuse Low-Grade Gliomas Under Chemotherapy.
Topics: Algorithms; Antineoplastic Agents; Brain; Brain Neoplasms; Computational Biology; Glioma; Humans; Ma | 2019 |
Delivery of MGMT mRNA to glioma cells by reactive astrocyte-derived exosomes confers a temozolomide resistance phenotype.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Astrocytes; Brain Neoplasms; Cell Line, Tumor; DNA Mod | 2018 |
Delivery of MGMT mRNA to glioma cells by reactive astrocyte-derived exosomes confers a temozolomide resistance phenotype.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Astrocytes; Brain Neoplasms; Cell Line, Tumor; DNA Mod | 2018 |
Delivery of MGMT mRNA to glioma cells by reactive astrocyte-derived exosomes confers a temozolomide resistance phenotype.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Astrocytes; Brain Neoplasms; Cell Line, Tumor; DNA Mod | 2018 |
Delivery of MGMT mRNA to glioma cells by reactive astrocyte-derived exosomes confers a temozolomide resistance phenotype.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Astrocytes; Brain Neoplasms; Cell Line, Tumor; DNA Mod | 2018 |
[IV. How Do We Think about Generics of Anti-Cancer Agent - Focusing on Temozolomide Oral Preparation].
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Dacarbazine; Dosage Forms; Drugs, Generic; | 2018 |
[IV. How Do We Think about Generics of Anti-Cancer Agent - Focusing on Temozolomide Oral Preparation].
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Dacarbazine; Dosage Forms; Drugs, Generic; | 2018 |
[IV. How Do We Think about Generics of Anti-Cancer Agent - Focusing on Temozolomide Oral Preparation].
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Dacarbazine; Dosage Forms; Drugs, Generic; | 2018 |
[IV. How Do We Think about Generics of Anti-Cancer Agent - Focusing on Temozolomide Oral Preparation].
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Dacarbazine; Dosage Forms; Drugs, Generic; | 2018 |
Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasm | 2018 |
Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasm | 2018 |
Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasm | 2018 |
Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasm | 2018 |
A Novel Tumor-Suppressor, CDH18, Inhibits Glioma Cell Invasiveness Via UQCRC2 and Correlates with the Prognosis of Glioma Patients.
Topics: Aged; Animals; Biomarkers, Tumor; Brain Neoplasms; Cadherins; Cell Line, Tumor; Cell Movement; Cell | 2018 |
A Novel Tumor-Suppressor, CDH18, Inhibits Glioma Cell Invasiveness Via UQCRC2 and Correlates with the Prognosis of Glioma Patients.
Topics: Aged; Animals; Biomarkers, Tumor; Brain Neoplasms; Cadherins; Cell Line, Tumor; Cell Movement; Cell | 2018 |
A Novel Tumor-Suppressor, CDH18, Inhibits Glioma Cell Invasiveness Via UQCRC2 and Correlates with the Prognosis of Glioma Patients.
Topics: Aged; Animals; Biomarkers, Tumor; Brain Neoplasms; Cadherins; Cell Line, Tumor; Cell Movement; Cell | 2018 |
A Novel Tumor-Suppressor, CDH18, Inhibits Glioma Cell Invasiveness Via UQCRC2 and Correlates with the Prognosis of Glioma Patients.
Topics: Aged; Animals; Biomarkers, Tumor; Brain Neoplasms; Cadherins; Cell Line, Tumor; Cell Movement; Cell | 2018 |
β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; beta Cat | 2018 |
β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; beta Cat | 2018 |
β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; beta Cat | 2018 |
β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; beta Cat | 2018 |
Bevacizumab therapy for recurrent gliomas: another disappointment?
Topics: Bevacizumab; Brain Neoplasms; Glioma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2018 |
Bevacizumab therapy for recurrent gliomas: another disappointment?
Topics: Bevacizumab; Brain Neoplasms; Glioma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2018 |
Bevacizumab therapy for recurrent gliomas: another disappointment?
Topics: Bevacizumab; Brain Neoplasms; Glioma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2018 |
Bevacizumab therapy for recurrent gliomas: another disappointment?
Topics: Bevacizumab; Brain Neoplasms; Glioma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2018 |
Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cohort Studies; | 2019 |
Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cohort Studies; | 2019 |
Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cohort Studies; | 2019 |
Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cohort Studies; | 2019 |
Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cann | 2018 |
Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cann | 2018 |
Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cann | 2018 |
Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cann | 2018 |
Oxaliplatin disrupts pathological features of glioma cells and associated macrophages independent of apoptosis induction.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum | 2018 |
Oxaliplatin disrupts pathological features of glioma cells and associated macrophages independent of apoptosis induction.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum | 2018 |
Oxaliplatin disrupts pathological features of glioma cells and associated macrophages independent of apoptosis induction.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum | 2018 |
Oxaliplatin disrupts pathological features of glioma cells and associated macrophages independent of apoptosis induction.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum | 2018 |
PLK1 inhibitor facilitates the suppressing effect of temozolomide on human brain glioma stem cells.
Topics: AC133 Antigen; Apoptosis; Cell Cycle Proteins; Cell Proliferation; Dose-Response Relationship, Drug; | 2018 |
PLK1 inhibitor facilitates the suppressing effect of temozolomide on human brain glioma stem cells.
Topics: AC133 Antigen; Apoptosis; Cell Cycle Proteins; Cell Proliferation; Dose-Response Relationship, Drug; | 2018 |
PLK1 inhibitor facilitates the suppressing effect of temozolomide on human brain glioma stem cells.
Topics: AC133 Antigen; Apoptosis; Cell Cycle Proteins; Cell Proliferation; Dose-Response Relationship, Drug; | 2018 |
PLK1 inhibitor facilitates the suppressing effect of temozolomide on human brain glioma stem cells.
Topics: AC133 Antigen; Apoptosis; Cell Cycle Proteins; Cell Proliferation; Dose-Response Relationship, Drug; | 2018 |
Adeno-associated virus 2 mediated gene transfer of vascular endothelial growth factor Trap: a new treatment option for glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cell Line, Tu | 2019 |
Adeno-associated virus 2 mediated gene transfer of vascular endothelial growth factor Trap: a new treatment option for glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cell Line, Tu | 2019 |
Adeno-associated virus 2 mediated gene transfer of vascular endothelial growth factor Trap: a new treatment option for glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cell Line, Tu | 2019 |
Adeno-associated virus 2 mediated gene transfer of vascular endothelial growth factor Trap: a new treatment option for glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cell Line, Tu | 2019 |
ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts.
Topics: Animals; Benzimidazoles; Cell Line, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; | 2018 |
ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts.
Topics: Animals; Benzimidazoles; Cell Line, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; | 2018 |
ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts.
Topics: Animals; Benzimidazoles; Cell Line, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; | 2018 |
ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts.
Topics: Animals; Benzimidazoles; Cell Line, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; | 2018 |
Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dose-Response Relationship, Drug; Female; | 2018 |
Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dose-Response Relationship, Drug; Female; | 2018 |
Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dose-Response Relationship, Drug; Female; | 2018 |
Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dose-Response Relationship, Drug; Female; | 2018 |
Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Proliferation; | 2019 |
Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Proliferation; | 2019 |
Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Proliferation; | 2019 |
Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Proliferation; | 2019 |
Cell Subpopulations Overexpressing p75NTR Have Tumor-initiating Properties in the C6 Glioma Cell Line.
Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Da | 2018 |
Cell Subpopulations Overexpressing p75NTR Have Tumor-initiating Properties in the C6 Glioma Cell Line.
Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Da | 2018 |
Cell Subpopulations Overexpressing p75NTR Have Tumor-initiating Properties in the C6 Glioma Cell Line.
Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Da | 2018 |
Cell Subpopulations Overexpressing p75NTR Have Tumor-initiating Properties in the C6 Glioma Cell Line.
Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Da | 2018 |
Honokiol enhances temozolomide-induced apoptotic insults to malignant glioma cells via an intrinsic mitochondrion-dependent pathway.
Topics: Animals; Apoptosis; Biphenyl Compounds; Caspases; Cell Line, Tumor; Cell Survival; Cytochromes c; Da | 2018 |
Honokiol enhances temozolomide-induced apoptotic insults to malignant glioma cells via an intrinsic mitochondrion-dependent pathway.
Topics: Animals; Apoptosis; Biphenyl Compounds; Caspases; Cell Line, Tumor; Cell Survival; Cytochromes c; Da | 2018 |
Honokiol enhances temozolomide-induced apoptotic insults to malignant glioma cells via an intrinsic mitochondrion-dependent pathway.
Topics: Animals; Apoptosis; Biphenyl Compounds; Caspases; Cell Line, Tumor; Cell Survival; Cytochromes c; Da | 2018 |
Honokiol enhances temozolomide-induced apoptotic insults to malignant glioma cells via an intrinsic mitochondrion-dependent pathway.
Topics: Animals; Apoptosis; Biphenyl Compounds; Caspases; Cell Line, Tumor; Cell Survival; Cytochromes c; Da | 2018 |
APOBEC3B is expressed in human glioma, and influences cell proliferation and temozolomide resistance.
Topics: Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Cytidine Deaminase; Drug Re | 2018 |
APOBEC3B is expressed in human glioma, and influences cell proliferation and temozolomide resistance.
Topics: Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Cytidine Deaminase; Drug Re | 2018 |
APOBEC3B is expressed in human glioma, and influences cell proliferation and temozolomide resistance.
Topics: Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Cytidine Deaminase; Drug Re | 2018 |
APOBEC3B is expressed in human glioma, and influences cell proliferation and temozolomide resistance.
Topics: Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Cytidine Deaminase; Drug Re | 2018 |
PAXX Participates in Base Excision Repair via Interacting with Pol β and Contributes to TMZ Resistance in Glioma Cells.
Topics: Cell Line, Tumor; DNA Polymerase beta; DNA-Binding Proteins; Drug Resistance, Neoplasm; Glioma; Huma | 2018 |
PAXX Participates in Base Excision Repair via Interacting with Pol β and Contributes to TMZ Resistance in Glioma Cells.
Topics: Cell Line, Tumor; DNA Polymerase beta; DNA-Binding Proteins; Drug Resistance, Neoplasm; Glioma; Huma | 2018 |
PAXX Participates in Base Excision Repair via Interacting with Pol β and Contributes to TMZ Resistance in Glioma Cells.
Topics: Cell Line, Tumor; DNA Polymerase beta; DNA-Binding Proteins; Drug Resistance, Neoplasm; Glioma; Huma | 2018 |
PAXX Participates in Base Excision Repair via Interacting with Pol β and Contributes to TMZ Resistance in Glioma Cells.
Topics: Cell Line, Tumor; DNA Polymerase beta; DNA-Binding Proteins; Drug Resistance, Neoplasm; Glioma; Huma | 2018 |
Thioredoxin Confers Intrinsic Resistance to Cytostatic Drugs in Human Glioma Cells.
Topics: Apoptosis; Blotting, Western; Carrier Proteins; Cell Line, Tumor; Cytostatic Agents; Disulfides; Gli | 2018 |
Thioredoxin Confers Intrinsic Resistance to Cytostatic Drugs in Human Glioma Cells.
Topics: Apoptosis; Blotting, Western; Carrier Proteins; Cell Line, Tumor; Cytostatic Agents; Disulfides; Gli | 2018 |
Thioredoxin Confers Intrinsic Resistance to Cytostatic Drugs in Human Glioma Cells.
Topics: Apoptosis; Blotting, Western; Carrier Proteins; Cell Line, Tumor; Cytostatic Agents; Disulfides; Gli | 2018 |
Thioredoxin Confers Intrinsic Resistance to Cytostatic Drugs in Human Glioma Cells.
Topics: Apoptosis; Blotting, Western; Carrier Proteins; Cell Line, Tumor; Cytostatic Agents; Disulfides; Gli | 2018 |
Blockade of Na/H exchanger stimulates glioma tumor immunogenicity and enhances combinatorial TMZ and anti-PD-1 therapy.
Topics: Animals; Antibodies; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Female; Glioma; I | 2018 |
Blockade of Na/H exchanger stimulates glioma tumor immunogenicity and enhances combinatorial TMZ and anti-PD-1 therapy.
Topics: Animals; Antibodies; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Female; Glioma; I | 2018 |
Blockade of Na/H exchanger stimulates glioma tumor immunogenicity and enhances combinatorial TMZ and anti-PD-1 therapy.
Topics: Animals; Antibodies; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Female; Glioma; I | 2018 |
Blockade of Na/H exchanger stimulates glioma tumor immunogenicity and enhances combinatorial TMZ and anti-PD-1 therapy.
Topics: Animals; Antibodies; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Female; Glioma; I | 2018 |
Crocus sativus L. Causes a Non Apoptotic Calpain Dependent Death in C6 Rat Glioma Cells, Exhibiting a Synergistic Effect with Temozolomide.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Calpain; Cell Death; Cell Line, Tu | 2019 |
Crocus sativus L. Causes a Non Apoptotic Calpain Dependent Death in C6 Rat Glioma Cells, Exhibiting a Synergistic Effect with Temozolomide.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Calpain; Cell Death; Cell Line, Tu | 2019 |
Crocus sativus L. Causes a Non Apoptotic Calpain Dependent Death in C6 Rat Glioma Cells, Exhibiting a Synergistic Effect with Temozolomide.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Calpain; Cell Death; Cell Line, Tu | 2019 |
Crocus sativus L. Causes a Non Apoptotic Calpain Dependent Death in C6 Rat Glioma Cells, Exhibiting a Synergistic Effect with Temozolomide.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Calpain; Cell Death; Cell Line, Tu | 2019 |
Feasibility and robustness of dynamic
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carbon; Female; Glioma; Heavy Ion Radiotherapy; Humans | 2018 |
Feasibility and robustness of dynamic
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carbon; Female; Glioma; Heavy Ion Radiotherapy; Humans | 2018 |
Feasibility and robustness of dynamic
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carbon; Female; Glioma; Heavy Ion Radiotherapy; Humans | 2018 |
Feasibility and robustness of dynamic
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carbon; Female; Glioma; Heavy Ion Radiotherapy; Humans | 2018 |
Resveratrol restores sensitivity of glioma cells to temozolamide through inhibiting the activation of Wnt signaling pathway.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; | 2019 |
Resveratrol restores sensitivity of glioma cells to temozolamide through inhibiting the activation of Wnt signaling pathway.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; | 2019 |
Resveratrol restores sensitivity of glioma cells to temozolamide through inhibiting the activation of Wnt signaling pathway.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; | 2019 |
Resveratrol restores sensitivity of glioma cells to temozolamide through inhibiting the activation of Wnt signaling pathway.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; | 2019 |
Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Drug Inte | 2019 |
Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Drug Inte | 2019 |
Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Drug Inte | 2019 |
Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Drug Inte | 2019 |
Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylat | 2019 |
Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylat | 2019 |
Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylat | 2019 |
Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylat | 2019 |
Down-regulation of ABCE1 inhibits temozolomide resistance in glioma through the PI3K/Akt/NF-κB signaling pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP-Binding Cassette Transporters; Brain Neoplasms; Cell | 2018 |
Down-regulation of ABCE1 inhibits temozolomide resistance in glioma through the PI3K/Akt/NF-κB signaling pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP-Binding Cassette Transporters; Brain Neoplasms; Cell | 2018 |
Down-regulation of ABCE1 inhibits temozolomide resistance in glioma through the PI3K/Akt/NF-κB signaling pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP-Binding Cassette Transporters; Brain Neoplasms; Cell | 2018 |
Down-regulation of ABCE1 inhibits temozolomide resistance in glioma through the PI3K/Akt/NF-κB signaling pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP-Binding Cassette Transporters; Brain Neoplasms; Cell | 2018 |
Carnosic acid potentiates the anticancer effect of temozolomide by inducing apoptosis and autophagy in glioma.
Topics: Abietanes; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Chec | 2019 |
Carnosic acid potentiates the anticancer effect of temozolomide by inducing apoptosis and autophagy in glioma.
Topics: Abietanes; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Chec | 2019 |
Carnosic acid potentiates the anticancer effect of temozolomide by inducing apoptosis and autophagy in glioma.
Topics: Abietanes; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Chec | 2019 |
Carnosic acid potentiates the anticancer effect of temozolomide by inducing apoptosis and autophagy in glioma.
Topics: Abietanes; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Chec | 2019 |
Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2019 |
Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2019 |
Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2019 |
Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2019 |
Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2019 |
Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2019 |
Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2019 |
Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2019 |
A prospective longitudinal evaluation of cognition and depression in postoperative patients with high-grade glioma following radiotherapy and chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cogni | 2018 |
A prospective longitudinal evaluation of cognition and depression in postoperative patients with high-grade glioma following radiotherapy and chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cogni | 2018 |
A prospective longitudinal evaluation of cognition and depression in postoperative patients with high-grade glioma following radiotherapy and chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cogni | 2018 |
A prospective longitudinal evaluation of cognition and depression in postoperative patients with high-grade glioma following radiotherapy and chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cogni | 2018 |
MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dose-R | 2019 |
MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dose-R | 2019 |
MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dose-R | 2019 |
MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dose-R | 2019 |
Local delivery of temozolomide via a biologically inert carrier (Temodex) prolongs survival in glioma patients, irrespectively of the methylation status of MGMT.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2019 |
Local delivery of temozolomide via a biologically inert carrier (Temodex) prolongs survival in glioma patients, irrespectively of the methylation status of MGMT.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2019 |
Local delivery of temozolomide via a biologically inert carrier (Temodex) prolongs survival in glioma patients, irrespectively of the methylation status of MGMT.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2019 |
Local delivery of temozolomide via a biologically inert carrier (Temodex) prolongs survival in glioma patients, irrespectively of the methylation status of MGMT.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2019 |
Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell P | 2019 |
Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell P | 2019 |
Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell P | 2019 |
Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell P | 2019 |
Combination of 3-methyladenine therapy and Asn-Gly-Arg (NGR)-modified mesoporous silica nanoparticles loaded with temozolomide for glioma therapy in vitro.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Drug Carriers; Drug Delivery Systems; | 2019 |
Combination of 3-methyladenine therapy and Asn-Gly-Arg (NGR)-modified mesoporous silica nanoparticles loaded with temozolomide for glioma therapy in vitro.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Drug Carriers; Drug Delivery Systems; | 2019 |
Combination of 3-methyladenine therapy and Asn-Gly-Arg (NGR)-modified mesoporous silica nanoparticles loaded with temozolomide for glioma therapy in vitro.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Drug Carriers; Drug Delivery Systems; | 2019 |
Combination of 3-methyladenine therapy and Asn-Gly-Arg (NGR)-modified mesoporous silica nanoparticles loaded with temozolomide for glioma therapy in vitro.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Drug Carriers; Drug Delivery Systems; | 2019 |
Downregulation of miR-196b Promotes Glioma Cell Sensitivity to Temozolomide Chemotherapy and Radiotherapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumo | 2018 |
Downregulation of miR-196b Promotes Glioma Cell Sensitivity to Temozolomide Chemotherapy and Radiotherapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumo | 2018 |
Downregulation of miR-196b Promotes Glioma Cell Sensitivity to Temozolomide Chemotherapy and Radiotherapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumo | 2018 |
Downregulation of miR-196b Promotes Glioma Cell Sensitivity to Temozolomide Chemotherapy and Radiotherapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumo | 2018 |
Medroxyprogesterone effects on colony growth, autophagy and mitochondria of C6 glioma cells are augmented with tibolone and temozolomide: Cell kinetic and electron microscopical studies with a broad review of the literature.
Topics: Autophagy; Brain Neoplasms; Glioblastoma; Glioma; Humans; Medroxyprogesterone; Medroxyprogesterone A | 2019 |
Medroxyprogesterone effects on colony growth, autophagy and mitochondria of C6 glioma cells are augmented with tibolone and temozolomide: Cell kinetic and electron microscopical studies with a broad review of the literature.
Topics: Autophagy; Brain Neoplasms; Glioblastoma; Glioma; Humans; Medroxyprogesterone; Medroxyprogesterone A | 2019 |
Medroxyprogesterone effects on colony growth, autophagy and mitochondria of C6 glioma cells are augmented with tibolone and temozolomide: Cell kinetic and electron microscopical studies with a broad review of the literature.
Topics: Autophagy; Brain Neoplasms; Glioblastoma; Glioma; Humans; Medroxyprogesterone; Medroxyprogesterone A | 2019 |
Medroxyprogesterone effects on colony growth, autophagy and mitochondria of C6 glioma cells are augmented with tibolone and temozolomide: Cell kinetic and electron microscopical studies with a broad review of the literature.
Topics: Autophagy; Brain Neoplasms; Glioblastoma; Glioma; Humans; Medroxyprogesterone; Medroxyprogesterone A | 2019 |
MIR93 (microRNA -93) regulates tumorigenicity and therapy response of glioblastoma by targeting autophagy.
Topics: Animals; Autophagy; Autophagy-Related Proteins; Glioma; HEK293 Cells; Humans; Mice, Nude; MicroRNAs; | 2019 |
MIR93 (microRNA -93) regulates tumorigenicity and therapy response of glioblastoma by targeting autophagy.
Topics: Animals; Autophagy; Autophagy-Related Proteins; Glioma; HEK293 Cells; Humans; Mice, Nude; MicroRNAs; | 2019 |
MIR93 (microRNA -93) regulates tumorigenicity and therapy response of glioblastoma by targeting autophagy.
Topics: Animals; Autophagy; Autophagy-Related Proteins; Glioma; HEK293 Cells; Humans; Mice, Nude; MicroRNAs; | 2019 |
MIR93 (microRNA -93) regulates tumorigenicity and therapy response of glioblastoma by targeting autophagy.
Topics: Animals; Autophagy; Autophagy-Related Proteins; Glioma; HEK293 Cells; Humans; Mice, Nude; MicroRNAs; | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Doxorubicin; Drug | 2019 |
Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Contrast | 2019 |
Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Contrast | 2019 |
Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Contrast | 2019 |
Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Contrast | 2019 |
YB-1 modulates the drug resistance of glioma cells by activation of MDM2/p53 pathway.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug | 2019 |
YB-1 modulates the drug resistance of glioma cells by activation of MDM2/p53 pathway.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug | 2019 |
YB-1 modulates the drug resistance of glioma cells by activation of MDM2/p53 pathway.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug | 2019 |
YB-1 modulates the drug resistance of glioma cells by activation of MDM2/p53 pathway.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug | 2019 |
Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2019 |
Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2019 |
Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2019 |
Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2019 |
Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Combined Modality Therapy; Drug Delive | 2019 |
Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Combined Modality Therapy; Drug Delive | 2019 |
Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Combined Modality Therapy; Drug Delive | 2019 |
Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Combined Modality Therapy; Drug Delive | 2019 |
Oroxylin A increases the sensitivity of temozolomide on glioma cells by hypoxia-inducible factor 1α/hedgehog pathway under hypoxia.
Topics: Animals; Brain Neoplasms; Cell Movement; Cell Proliferation; Flavonoids; Gene Expression Regulation, | 2019 |
Oroxylin A increases the sensitivity of temozolomide on glioma cells by hypoxia-inducible factor 1α/hedgehog pathway under hypoxia.
Topics: Animals; Brain Neoplasms; Cell Movement; Cell Proliferation; Flavonoids; Gene Expression Regulation, | 2019 |
Oroxylin A increases the sensitivity of temozolomide on glioma cells by hypoxia-inducible factor 1α/hedgehog pathway under hypoxia.
Topics: Animals; Brain Neoplasms; Cell Movement; Cell Proliferation; Flavonoids; Gene Expression Regulation, | 2019 |
Oroxylin A increases the sensitivity of temozolomide on glioma cells by hypoxia-inducible factor 1α/hedgehog pathway under hypoxia.
Topics: Animals; Brain Neoplasms; Cell Movement; Cell Proliferation; Flavonoids; Gene Expression Regulation, | 2019 |
Knockdown of the TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Sensitizes Glioma Cells to Hypoxia, Irradiation and Temozolomide.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Cell Hypoxia; Cell Line, Tumor; Drug Resistanc | 2019 |
Knockdown of the TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Sensitizes Glioma Cells to Hypoxia, Irradiation and Temozolomide.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Cell Hypoxia; Cell Line, Tumor; Drug Resistanc | 2019 |
Knockdown of the TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Sensitizes Glioma Cells to Hypoxia, Irradiation and Temozolomide.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Cell Hypoxia; Cell Line, Tumor; Drug Resistanc | 2019 |
Knockdown of the TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Sensitizes Glioma Cells to Hypoxia, Irradiation and Temozolomide.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Cell Hypoxia; Cell Line, Tumor; Drug Resistanc | 2019 |
MicroRNA-34a-5p suppresses tumorigenesis and progression of glioma and potentiates Temozolomide-induced cytotoxicity for glioma cells by targeting HMGA2.
Topics: Animals; Base Sequence; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease | 2019 |
MicroRNA-34a-5p suppresses tumorigenesis and progression of glioma and potentiates Temozolomide-induced cytotoxicity for glioma cells by targeting HMGA2.
Topics: Animals; Base Sequence; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease | 2019 |
MicroRNA-34a-5p suppresses tumorigenesis and progression of glioma and potentiates Temozolomide-induced cytotoxicity for glioma cells by targeting HMGA2.
Topics: Animals; Base Sequence; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease | 2019 |
MicroRNA-34a-5p suppresses tumorigenesis and progression of glioma and potentiates Temozolomide-induced cytotoxicity for glioma cells by targeting HMGA2.
Topics: Animals; Base Sequence; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease | 2019 |
Diffuse intrinsic pontine glioma cells are vulnerable to low intensity electric fields delivered by intratumoral modulation therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Cell Survival; Child; Child, Preschool; Com | 2019 |
Diffuse intrinsic pontine glioma cells are vulnerable to low intensity electric fields delivered by intratumoral modulation therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Cell Survival; Child; Child, Preschool; Com | 2019 |
Diffuse intrinsic pontine glioma cells are vulnerable to low intensity electric fields delivered by intratumoral modulation therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Cell Survival; Child; Child, Preschool; Com | 2019 |
Diffuse intrinsic pontine glioma cells are vulnerable to low intensity electric fields delivered by intratumoral modulation therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Cell Survival; Child; Child, Preschool; Com | 2019 |
Development of transferrin-modified poly(lactic-co-glycolic acid) nanoparticles for glioma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Car | 2019 |
Development of transferrin-modified poly(lactic-co-glycolic acid) nanoparticles for glioma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Car | 2019 |
Development of transferrin-modified poly(lactic-co-glycolic acid) nanoparticles for glioma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Car | 2019 |
Development of transferrin-modified poly(lactic-co-glycolic acid) nanoparticles for glioma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Car | 2019 |
Elevated signature of a gene module coexpressed with CDC20 marks genomic instability in glioma.
Topics: Animals; Biomarkers, Tumor; Cdc20 Proteins; Chemotherapy, Adjuvant; Female; Gene Expression Profilin | 2019 |
Elevated signature of a gene module coexpressed with CDC20 marks genomic instability in glioma.
Topics: Animals; Biomarkers, Tumor; Cdc20 Proteins; Chemotherapy, Adjuvant; Female; Gene Expression Profilin | 2019 |
Elevated signature of a gene module coexpressed with CDC20 marks genomic instability in glioma.
Topics: Animals; Biomarkers, Tumor; Cdc20 Proteins; Chemotherapy, Adjuvant; Female; Gene Expression Profilin | 2019 |
Elevated signature of a gene module coexpressed with CDC20 marks genomic instability in glioma.
Topics: Animals; Biomarkers, Tumor; Cdc20 Proteins; Chemotherapy, Adjuvant; Female; Gene Expression Profilin | 2019 |
Roscovitine effectively enhances antitumor activity of temozolomide in vitro and in vivo mediated by increased autophagy and Caspase-3 dependent apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Caspase 3; Cell Line, Tumor; Cel | 2019 |
Roscovitine effectively enhances antitumor activity of temozolomide in vitro and in vivo mediated by increased autophagy and Caspase-3 dependent apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Caspase 3; Cell Line, Tumor; Cel | 2019 |
Roscovitine effectively enhances antitumor activity of temozolomide in vitro and in vivo mediated by increased autophagy and Caspase-3 dependent apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Caspase 3; Cell Line, Tumor; Cel | 2019 |
Roscovitine effectively enhances antitumor activity of temozolomide in vitro and in vivo mediated by increased autophagy and Caspase-3 dependent apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Caspase 3; Cell Line, Tumor; Cel | 2019 |
CtIP contributes to non-homologous end joining formation through interacting with ligase IV and promotion of TMZ resistance in glioma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; DNA End-Joining Repair; DNA Ligase ATP; Drug Resis | 2019 |
CtIP contributes to non-homologous end joining formation through interacting with ligase IV and promotion of TMZ resistance in glioma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; DNA End-Joining Repair; DNA Ligase ATP; Drug Resis | 2019 |
CtIP contributes to non-homologous end joining formation through interacting with ligase IV and promotion of TMZ resistance in glioma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; DNA End-Joining Repair; DNA Ligase ATP; Drug Resis | 2019 |
CtIP contributes to non-homologous end joining formation through interacting with ligase IV and promotion of TMZ resistance in glioma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; DNA End-Joining Repair; DNA Ligase ATP; Drug Resis | 2019 |
Mild thermotherapy and hyperbaric oxygen enhance sensitivity of TMZ/PSi nanoparticles via decreasing the stemness in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2019 |
Mild thermotherapy and hyperbaric oxygen enhance sensitivity of TMZ/PSi nanoparticles via decreasing the stemness in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2019 |
Mild thermotherapy and hyperbaric oxygen enhance sensitivity of TMZ/PSi nanoparticles via decreasing the stemness in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2019 |
Mild thermotherapy and hyperbaric oxygen enhance sensitivity of TMZ/PSi nanoparticles via decreasing the stemness in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2019 |
TRPC5‑induced autophagy promotes the TMZ‑resistance of glioma cells via the CAMMKβ/AMPKα/mTOR pathway.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Calcium-Calmodulin-Dependent Protein Kinase Kinas | 2019 |
TRPC5‑induced autophagy promotes the TMZ‑resistance of glioma cells via the CAMMKβ/AMPKα/mTOR pathway.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Calcium-Calmodulin-Dependent Protein Kinase Kinas | 2019 |
TRPC5‑induced autophagy promotes the TMZ‑resistance of glioma cells via the CAMMKβ/AMPKα/mTOR pathway.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Calcium-Calmodulin-Dependent Protein Kinase Kinas | 2019 |
TRPC5‑induced autophagy promotes the TMZ‑resistance of glioma cells via the CAMMKβ/AMPKα/mTOR pathway.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Calcium-Calmodulin-Dependent Protein Kinase Kinas | 2019 |
Assessment of Early Therapeutic Response to Nitroxoline in Temozolomide-Resistant Glioblastoma by Amide Proton Transfer Imaging: A Preliminary Comparative Study with Diffusion-weighted Imaging.
Topics: Algorithms; Amides; Animals; Brain Neoplasms; Diffusion Magnetic Resonance Imaging; Glioblastoma; Gl | 2019 |
Assessment of Early Therapeutic Response to Nitroxoline in Temozolomide-Resistant Glioblastoma by Amide Proton Transfer Imaging: A Preliminary Comparative Study with Diffusion-weighted Imaging.
Topics: Algorithms; Amides; Animals; Brain Neoplasms; Diffusion Magnetic Resonance Imaging; Glioblastoma; Gl | 2019 |
Assessment of Early Therapeutic Response to Nitroxoline in Temozolomide-Resistant Glioblastoma by Amide Proton Transfer Imaging: A Preliminary Comparative Study with Diffusion-weighted Imaging.
Topics: Algorithms; Amides; Animals; Brain Neoplasms; Diffusion Magnetic Resonance Imaging; Glioblastoma; Gl | 2019 |
Assessment of Early Therapeutic Response to Nitroxoline in Temozolomide-Resistant Glioblastoma by Amide Proton Transfer Imaging: A Preliminary Comparative Study with Diffusion-weighted Imaging.
Topics: Algorithms; Amides; Animals; Brain Neoplasms; Diffusion Magnetic Resonance Imaging; Glioblastoma; Gl | 2019 |
In vitro and in vivo Study on Glioma Treatment Enhancement by Combining Temozolomide with Calycosin and Formononetin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2019 |
In vitro and in vivo Study on Glioma Treatment Enhancement by Combining Temozolomide with Calycosin and Formononetin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2019 |
In vitro and in vivo Study on Glioma Treatment Enhancement by Combining Temozolomide with Calycosin and Formononetin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2019 |
In vitro and in vivo Study on Glioma Treatment Enhancement by Combining Temozolomide with Calycosin and Formononetin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2019 |
Photodynamic therapy combined with temozolomide inhibits C6 glioma migration and invasion and promotes mitochondrial-associated apoptosis by inhibiting sodium-hydrogen exchanger isoform 1.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Movement; Cytoskeletal Proteins; Dos | 2019 |
Photodynamic therapy combined with temozolomide inhibits C6 glioma migration and invasion and promotes mitochondrial-associated apoptosis by inhibiting sodium-hydrogen exchanger isoform 1.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Movement; Cytoskeletal Proteins; Dos | 2019 |
Photodynamic therapy combined with temozolomide inhibits C6 glioma migration and invasion and promotes mitochondrial-associated apoptosis by inhibiting sodium-hydrogen exchanger isoform 1.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Movement; Cytoskeletal Proteins; Dos | 2019 |
Photodynamic therapy combined with temozolomide inhibits C6 glioma migration and invasion and promotes mitochondrial-associated apoptosis by inhibiting sodium-hydrogen exchanger isoform 1.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Movement; Cytoskeletal Proteins; Dos | 2019 |
RETRACTED: IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Brain Neoplasms; Cell Hypoxia; Dru | 2019 |
RETRACTED: IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Brain Neoplasms; Cell Hypoxia; Dru | 2019 |
RETRACTED: IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Brain Neoplasms; Cell Hypoxia; Dru | 2019 |
RETRACTED: IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Brain Neoplasms; Cell Hypoxia; Dru | 2019 |
Targeting miR‑155‑5p and miR‑221‑3p by peptide nucleic acids induces caspase‑3 activation and apoptosis in temozolomide‑resistant T98G glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Drug | 2019 |
Targeting miR‑155‑5p and miR‑221‑3p by peptide nucleic acids induces caspase‑3 activation and apoptosis in temozolomide‑resistant T98G glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Drug | 2019 |
Targeting miR‑155‑5p and miR‑221‑3p by peptide nucleic acids induces caspase‑3 activation and apoptosis in temozolomide‑resistant T98G glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Drug | 2019 |
Targeting miR‑155‑5p and miR‑221‑3p by peptide nucleic acids induces caspase‑3 activation and apoptosis in temozolomide‑resistant T98G glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Drug | 2019 |
Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; En | 2020 |
Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; En | 2020 |
Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; En | 2020 |
Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; En | 2020 |
Angiopep-2 Modified Cationic Lipid-Poly-Lactic-Co-Glycolic Acid Delivery Temozolomide and DNA Repair Inhibitor Dbait to Achieve Synergetic Chemo-Radiotherapy Against Glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; DNA Repair; Glioblastoma; Glioma; Glycolates; | 2019 |
Angiopep-2 Modified Cationic Lipid-Poly-Lactic-Co-Glycolic Acid Delivery Temozolomide and DNA Repair Inhibitor Dbait to Achieve Synergetic Chemo-Radiotherapy Against Glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; DNA Repair; Glioblastoma; Glioma; Glycolates; | 2019 |
Angiopep-2 Modified Cationic Lipid-Poly-Lactic-Co-Glycolic Acid Delivery Temozolomide and DNA Repair Inhibitor Dbait to Achieve Synergetic Chemo-Radiotherapy Against Glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; DNA Repair; Glioblastoma; Glioma; Glycolates; | 2019 |
Angiopep-2 Modified Cationic Lipid-Poly-Lactic-Co-Glycolic Acid Delivery Temozolomide and DNA Repair Inhibitor Dbait to Achieve Synergetic Chemo-Radiotherapy Against Glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; DNA Repair; Glioblastoma; Glioma; Glycolates; | 2019 |
Ultrasmall theranostic gadolinium-based nanoparticles improve high-grade rat glioma survival.
Topics: Animals; Brain Neoplasms; Chemoradiotherapy; Contrast Media; Gadolinium; Glioma; Magnetic Resonance | 2019 |
Ultrasmall theranostic gadolinium-based nanoparticles improve high-grade rat glioma survival.
Topics: Animals; Brain Neoplasms; Chemoradiotherapy; Contrast Media; Gadolinium; Glioma; Magnetic Resonance | 2019 |
Ultrasmall theranostic gadolinium-based nanoparticles improve high-grade rat glioma survival.
Topics: Animals; Brain Neoplasms; Chemoradiotherapy; Contrast Media; Gadolinium; Glioma; Magnetic Resonance | 2019 |
Ultrasmall theranostic gadolinium-based nanoparticles improve high-grade rat glioma survival.
Topics: Animals; Brain Neoplasms; Chemoradiotherapy; Contrast Media; Gadolinium; Glioma; Magnetic Resonance | 2019 |
Exosomes derived from microRNA-199a-overexpressing mesenchymal stem cells inhibit glioma progression by down-regulating AGAP2.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell | 2019 |
Exosomes derived from microRNA-199a-overexpressing mesenchymal stem cells inhibit glioma progression by down-regulating AGAP2.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell | 2019 |
Exosomes derived from microRNA-199a-overexpressing mesenchymal stem cells inhibit glioma progression by down-regulating AGAP2.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell | 2019 |
Exosomes derived from microRNA-199a-overexpressing mesenchymal stem cells inhibit glioma progression by down-regulating AGAP2.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell | 2019 |
Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Prol | 2013 |
Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Prol | 2013 |
Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Prol | 2013 |
Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Prol | 2013 |
Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Comb | 2013 |
Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Comb | 2013 |
Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Comb | 2013 |
Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Comb | 2013 |
Combined temozolomide and sunitinib treatment leads to better tumour control but increased vascular resistance in O6-methylguanine methyltransferase-methylated gliomas.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; C | 2013 |
Combined temozolomide and sunitinib treatment leads to better tumour control but increased vascular resistance in O6-methylguanine methyltransferase-methylated gliomas.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; C | 2013 |
Combined temozolomide and sunitinib treatment leads to better tumour control but increased vascular resistance in O6-methylguanine methyltransferase-methylated gliomas.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; C | 2013 |
Combined temozolomide and sunitinib treatment leads to better tumour control but increased vascular resistance in O6-methylguanine methyltransferase-methylated gliomas.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; C | 2013 |
[Regulation of MGMT and application for the therapy to attenuate the chemoresistance].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Re | 2012 |
[Regulation of MGMT and application for the therapy to attenuate the chemoresistance].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Re | 2012 |
[Regulation of MGMT and application for the therapy to attenuate the chemoresistance].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Re | 2012 |
[Regulation of MGMT and application for the therapy to attenuate the chemoresistance].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Re | 2012 |
The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neopla | 2013 |
The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neopla | 2013 |
The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neopla | 2013 |
The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neopla | 2013 |
MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; B | 2013 |
MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; B | 2013 |
MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; B | 2013 |
MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; B | 2013 |
Temozolomide-modulated glioma proteome: role of interleukin-1 receptor-associated kinase-4 (IRAK4) in chemosensitivity.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Line, Tumor; Cell Survival; Cluster Analy | 2013 |
Temozolomide-modulated glioma proteome: role of interleukin-1 receptor-associated kinase-4 (IRAK4) in chemosensitivity.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Line, Tumor; Cell Survival; Cluster Analy | 2013 |
Temozolomide-modulated glioma proteome: role of interleukin-1 receptor-associated kinase-4 (IRAK4) in chemosensitivity.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Line, Tumor; Cell Survival; Cluster Analy | 2013 |
Temozolomide-modulated glioma proteome: role of interleukin-1 receptor-associated kinase-4 (IRAK4) in chemosensitivity.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Line, Tumor; Cell Survival; Cluster Analy | 2013 |
miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine | 2013 |
miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine | 2013 |
miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine | 2013 |
miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine | 2013 |
Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineop | 2013 |
Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineop | 2013 |
Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineop | 2013 |
Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineop | 2013 |
Effect of temozolomide on male gametes: an epigenetic risk to the offspring?
Topics: Adult; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Epigenesis, Ge | 2013 |
Effect of temozolomide on male gametes: an epigenetic risk to the offspring?
Topics: Adult; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Epigenesis, Ge | 2013 |
Effect of temozolomide on male gametes: an epigenetic risk to the offspring?
Topics: Adult; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Epigenesis, Ge | 2013 |
Effect of temozolomide on male gametes: an epigenetic risk to the offspring?
Topics: Adult; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Epigenesis, Ge | 2013 |
Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation | 2013 |
Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation | 2013 |
Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation | 2013 |
Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation | 2013 |
Connexin43 confers Temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway.
Topics: Analysis of Variance; Annexin A5; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2013 |
Connexin43 confers Temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway.
Topics: Analysis of Variance; Annexin A5; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2013 |
Connexin43 confers Temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway.
Topics: Analysis of Variance; Annexin A5; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2013 |
Connexin43 confers Temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway.
Topics: Analysis of Variance; Annexin A5; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2013 |
Tumor derived mutations of protein tyrosine phosphatase receptor type k affect its function and alter sensitivity to chemotherapeutics in glioma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Enzyme Inhi | 2013 |
Tumor derived mutations of protein tyrosine phosphatase receptor type k affect its function and alter sensitivity to chemotherapeutics in glioma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Enzyme Inhi | 2013 |
Tumor derived mutations of protein tyrosine phosphatase receptor type k affect its function and alter sensitivity to chemotherapeutics in glioma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Enzyme Inhi | 2013 |
Tumor derived mutations of protein tyrosine phosphatase receptor type k affect its function and alter sensitivity to chemotherapeutics in glioma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Enzyme Inhi | 2013 |
Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carboxylic Acids; Cell Line, Tumor; Cell Proliferatio | 2013 |
Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carboxylic Acids; Cell Line, Tumor; Cell Proliferatio | 2013 |
Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carboxylic Acids; Cell Line, Tumor; Cell Proliferatio | 2013 |
Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carboxylic Acids; Cell Line, Tumor; Cell Proliferatio | 2013 |
Glioma initiating cells form a differentiation niche via the induction of extracellular matrices and integrin αV.
Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Adhesion; Cell Differentiation; Cell Movement; Cell S | 2013 |
Glioma initiating cells form a differentiation niche via the induction of extracellular matrices and integrin αV.
Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Adhesion; Cell Differentiation; Cell Movement; Cell S | 2013 |
Glioma initiating cells form a differentiation niche via the induction of extracellular matrices and integrin αV.
Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Adhesion; Cell Differentiation; Cell Movement; Cell S | 2013 |
Glioma initiating cells form a differentiation niche via the induction of extracellular matrices and integrin αV.
Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Adhesion; Cell Differentiation; Cell Movement; Cell S | 2013 |
Restoration of sensitivity in chemo-resistant glioma cells by cold atmospheric plasma.
Topics: Adult; Atmosphere; Brain Neoplasms; Cell Death; Cell Division; Cell Line, Tumor; Cell Proliferation; | 2013 |
Restoration of sensitivity in chemo-resistant glioma cells by cold atmospheric plasma.
Topics: Adult; Atmosphere; Brain Neoplasms; Cell Death; Cell Division; Cell Line, Tumor; Cell Proliferation; | 2013 |
Restoration of sensitivity in chemo-resistant glioma cells by cold atmospheric plasma.
Topics: Adult; Atmosphere; Brain Neoplasms; Cell Death; Cell Division; Cell Line, Tumor; Cell Proliferation; | 2013 |
Restoration of sensitivity in chemo-resistant glioma cells by cold atmospheric plasma.
Topics: Adult; Atmosphere; Brain Neoplasms; Cell Death; Cell Division; Cell Line, Tumor; Cell Proliferation; | 2013 |
Craniospinal irradiation with concurrent temozolomide and nimotuzumab in a child with primary metastatic diffuse intrinsic pontine glioma. A compassionate use treatment.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neopla | 2013 |
Craniospinal irradiation with concurrent temozolomide and nimotuzumab in a child with primary metastatic diffuse intrinsic pontine glioma. A compassionate use treatment.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neopla | 2013 |
Craniospinal irradiation with concurrent temozolomide and nimotuzumab in a child with primary metastatic diffuse intrinsic pontine glioma. A compassionate use treatment.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neopla | 2013 |
Craniospinal irradiation with concurrent temozolomide and nimotuzumab in a child with primary metastatic diffuse intrinsic pontine glioma. A compassionate use treatment.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neopla | 2013 |
Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Community-Acquired | 2013 |
Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Community-Acquired | 2013 |
Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Community-Acquired | 2013 |
Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Community-Acquired | 2013 |
Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine | 2013 |
Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine | 2013 |
Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine | 2013 |
Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine | 2013 |
Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study).
Topics: Aminolevulinic Acid; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free S | 2014 |
Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study).
Topics: Aminolevulinic Acid; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free S | 2014 |
Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study).
Topics: Aminolevulinic Acid; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free S | 2014 |
Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study).
Topics: Aminolevulinic Acid; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free S | 2014 |
Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Convection; Dacarbazine; Drug Delivery Systems; Ferric C | 2014 |
Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Convection; Dacarbazine; Drug Delivery Systems; Ferric C | 2014 |
Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Convection; Dacarbazine; Drug Delivery Systems; Ferric C | 2014 |
Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Convection; Dacarbazine; Drug Delivery Systems; Ferric C | 2014 |
Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Child; Child, Preschool; Daca | 2013 |
Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Child; Child, Preschool; Daca | 2013 |
Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Child; Child, Preschool; Daca | 2013 |
Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Child; Child, Preschool; Daca | 2013 |
The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle; Colony-Forming Units Assay; | 2013 |
The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle; Colony-Forming Units Assay; | 2013 |
The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle; Colony-Forming Units Assay; | 2013 |
The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle; Colony-Forming Units Assay; | 2013 |
Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Sy | 2014 |
Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Sy | 2014 |
Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Sy | 2014 |
Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Sy | 2014 |
Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.
Topics: Amidohydrolases; Animals; Antifungal Agents; Aspartic Acid; Astrocytes; Brain; Brain Neoplasms; Cell | 2014 |
Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.
Topics: Amidohydrolases; Animals; Antifungal Agents; Aspartic Acid; Astrocytes; Brain; Brain Neoplasms; Cell | 2014 |
Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.
Topics: Amidohydrolases; Animals; Antifungal Agents; Aspartic Acid; Astrocytes; Brain; Brain Neoplasms; Cell | 2014 |
Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.
Topics: Amidohydrolases; Animals; Antifungal Agents; Aspartic Acid; Astrocytes; Brain; Brain Neoplasms; Cell | 2014 |
Biodegradable implants efficiently deliver combination of paclitaxel and temozolomide to glioma C6 cancer cells in vitro.
Topics: Absorbable Implants; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; | 2014 |
Biodegradable implants efficiently deliver combination of paclitaxel and temozolomide to glioma C6 cancer cells in vitro.
Topics: Absorbable Implants; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; | 2014 |
Biodegradable implants efficiently deliver combination of paclitaxel and temozolomide to glioma C6 cancer cells in vitro.
Topics: Absorbable Implants; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; | 2014 |
Biodegradable implants efficiently deliver combination of paclitaxel and temozolomide to glioma C6 cancer cells in vitro.
Topics: Absorbable Implants; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; | 2014 |
Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; D | 2013 |
Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; D | 2013 |
Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; D | 2013 |
Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; D | 2013 |
YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells.
Topics: Adenoviridae; Animals; Astrocytes; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferati | 2013 |
YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells.
Topics: Adenoviridae; Animals; Astrocytes; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferati | 2013 |
YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells.
Topics: Adenoviridae; Animals; Astrocytes; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferati | 2013 |
YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells.
Topics: Adenoviridae; Animals; Astrocytes; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferati | 2013 |
miR-125b inhibits Connexin43 and promotes glioma growth.
Topics: 3' Untranslated Regions; Animals; Apoptosis; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell | 2013 |
miR-125b inhibits Connexin43 and promotes glioma growth.
Topics: 3' Untranslated Regions; Animals; Apoptosis; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell | 2013 |
miR-125b inhibits Connexin43 and promotes glioma growth.
Topics: 3' Untranslated Regions; Animals; Apoptosis; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell | 2013 |
miR-125b inhibits Connexin43 and promotes glioma growth.
Topics: 3' Untranslated Regions; Animals; Apoptosis; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell | 2013 |
Treatment of children with diffuse intrinsic pontine gliomas with chemoradiotherapy followed by a combination of temozolomide, irinotecan, and bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2013 |
Treatment of children with diffuse intrinsic pontine gliomas with chemoradiotherapy followed by a combination of temozolomide, irinotecan, and bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2013 |
Treatment of children with diffuse intrinsic pontine gliomas with chemoradiotherapy followed by a combination of temozolomide, irinotecan, and bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2013 |
Treatment of children with diffuse intrinsic pontine gliomas with chemoradiotherapy followed by a combination of temozolomide, irinotecan, and bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2013 |
Long-term treatment with temozolomide in malignant glioma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combin | 2014 |
Long-term treatment with temozolomide in malignant glioma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combin | 2014 |
Long-term treatment with temozolomide in malignant glioma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combin | 2014 |
Long-term treatment with temozolomide in malignant glioma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combin | 2014 |
The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2014 |
The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2014 |
The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2014 |
The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2014 |
Improved therapeutic effect on malignant glioma with adenoviral suicide gene therapy combined with temozolomide.
Topics: Adenoviruses, Human; Animals; Antineoplastic Agents, Alkylating; Antiviral Agents; Combined Modality | 2013 |
Improved therapeutic effect on malignant glioma with adenoviral suicide gene therapy combined with temozolomide.
Topics: Adenoviruses, Human; Animals; Antineoplastic Agents, Alkylating; Antiviral Agents; Combined Modality | 2013 |
Improved therapeutic effect on malignant glioma with adenoviral suicide gene therapy combined with temozolomide.
Topics: Adenoviruses, Human; Animals; Antineoplastic Agents, Alkylating; Antiviral Agents; Combined Modality | 2013 |
Improved therapeutic effect on malignant glioma with adenoviral suicide gene therapy combined with temozolomide.
Topics: Adenoviruses, Human; Animals; Antineoplastic Agents, Alkylating; Antiviral Agents; Combined Modality | 2013 |
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosi | 2013 |
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosi | 2013 |
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosi | 2013 |
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosi | 2013 |
MiR-221/222 target the DNA methyltransferase MGMT in glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Modific | 2013 |
MiR-221/222 target the DNA methyltransferase MGMT in glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Modific | 2013 |
MiR-221/222 target the DNA methyltransferase MGMT in glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Modific | 2013 |
MiR-221/222 target the DNA methyltransferase MGMT in glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Modific | 2013 |
Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell P | 2013 |
Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell P | 2013 |
Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell P | 2013 |
Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell P | 2013 |
Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
Topics: Animals; Antibodies; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
Topics: Animals; Antibodies; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
Topics: Animals; Antibodies; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
Topics: Animals; Antibodies; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Atrophy; Brain Neoplasms; Cerebral Corte | 2014 |
Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Atrophy; Brain Neoplasms; Cerebral Corte | 2014 |
Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Atrophy; Brain Neoplasms; Cerebral Corte | 2014 |
Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Atrophy; Brain Neoplasms; Cerebral Corte | 2014 |
Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movem | 2013 |
Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movem | 2013 |
Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movem | 2013 |
Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movem | 2013 |
Mechanism of temozolomide-induced antitumour effects on glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Dacarbazine; Flow Cytometry; Glioma; | 2014 |
Mechanism of temozolomide-induced antitumour effects on glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Dacarbazine; Flow Cytometry; Glioma; | 2014 |
Mechanism of temozolomide-induced antitumour effects on glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Dacarbazine; Flow Cytometry; Glioma; | 2014 |
Mechanism of temozolomide-induced antitumour effects on glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Dacarbazine; Flow Cytometry; Glioma; | 2014 |
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; DNA Helicases; DNA Mutationa | 2014 |
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; DNA Helicases; DNA Mutationa | 2014 |
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; DNA Helicases; DNA Mutationa | 2014 |
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; DNA Helicases; DNA Mutationa | 2014 |
Concomitant treatment with pertussis toxin plus temozolomide increases the survival of rats bearing intracerebral RG2 glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2014 |
Concomitant treatment with pertussis toxin plus temozolomide increases the survival of rats bearing intracerebral RG2 glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2014 |
Concomitant treatment with pertussis toxin plus temozolomide increases the survival of rats bearing intracerebral RG2 glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2014 |
Concomitant treatment with pertussis toxin plus temozolomide increases the survival of rats bearing intracerebral RG2 glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2014 |
A patient-specific therapeutic approach for tumour cell population extinction and drug toxicity reduction using control systems-based dose-profile design.
Topics: Antineoplastic Agents; Combined Modality Therapy; Computer Simulation; Dacarbazine; Dose-Response Re | 2013 |
A patient-specific therapeutic approach for tumour cell population extinction and drug toxicity reduction using control systems-based dose-profile design.
Topics: Antineoplastic Agents; Combined Modality Therapy; Computer Simulation; Dacarbazine; Dose-Response Re | 2013 |
A patient-specific therapeutic approach for tumour cell population extinction and drug toxicity reduction using control systems-based dose-profile design.
Topics: Antineoplastic Agents; Combined Modality Therapy; Computer Simulation; Dacarbazine; Dose-Response Re | 2013 |
A patient-specific therapeutic approach for tumour cell population extinction and drug toxicity reduction using control systems-based dose-profile design.
Topics: Antineoplastic Agents; Combined Modality Therapy; Computer Simulation; Dacarbazine; Dose-Response Re | 2013 |
Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Mov | 2014 |
Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Mov | 2014 |
Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Mov | 2014 |
Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Mov | 2014 |
Diffuse intrinsic pontine glioma in children and adolescents: a single-center experience.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Child; Dacarbazine; Female; Gli | 2014 |
Diffuse intrinsic pontine glioma in children and adolescents: a single-center experience.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Child; Dacarbazine; Female; Gli | 2014 |
Diffuse intrinsic pontine glioma in children and adolescents: a single-center experience.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Child; Dacarbazine; Female; Gli | 2014 |
Diffuse intrinsic pontine glioma in children and adolescents: a single-center experience.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Child; Dacarbazine; Female; Gli | 2014 |
Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin.
Topics: Aminoglycosides; Angiogenesis Inhibitors; Animals; Anti-Bacterial Agents; Apoptosis; Brain; Brain Ne | 2014 |
Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin.
Topics: Aminoglycosides; Angiogenesis Inhibitors; Animals; Anti-Bacterial Agents; Apoptosis; Brain; Brain Ne | 2014 |
Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin.
Topics: Aminoglycosides; Angiogenesis Inhibitors; Animals; Anti-Bacterial Agents; Apoptosis; Brain; Brain Ne | 2014 |
Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin.
Topics: Aminoglycosides; Angiogenesis Inhibitors; Animals; Anti-Bacterial Agents; Apoptosis; Brain; Brain Ne | 2014 |
Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dac | 2014 |
Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dac | 2014 |
Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dac | 2014 |
Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dac | 2014 |
MGMT promoter methylation in plasma of glioma patients receiving temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Fr | 2014 |
MGMT promoter methylation in plasma of glioma patients receiving temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Fr | 2014 |
MGMT promoter methylation in plasma of glioma patients receiving temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Fr | 2014 |
MGMT promoter methylation in plasma of glioma patients receiving temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Fr | 2014 |
IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Prolife | 2014 |
IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Prolife | 2014 |
IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Prolife | 2014 |
IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Prolife | 2014 |
Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioma; Glutaminase; Glutamine; Glutarates; HEK293 C | 2014 |
Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioma; Glutaminase; Glutamine; Glutarates; HEK293 C | 2014 |
Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioma; Glutaminase; Glutamine; Glutarates; HEK293 C | 2014 |
Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioma; Glutaminase; Glutamine; Glutarates; HEK293 C | 2014 |
Analysis of salivary fluid and chemosensory functions in patients treated for primary malignant brain tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Combined Moda | 2015 |
Analysis of salivary fluid and chemosensory functions in patients treated for primary malignant brain tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Combined Moda | 2015 |
Analysis of salivary fluid and chemosensory functions in patients treated for primary malignant brain tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Combined Moda | 2015 |
Analysis of salivary fluid and chemosensory functions in patients treated for primary malignant brain tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Combined Moda | 2015 |
Craniospinal irradiation with concurrent temozolomide for primary metastatic pediatric high-grade or diffuse intrinsic pontine gliomas. A first report from the GPOH-HIT-HGG Study Group.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Chemoradiotherapy; Child; Child | 2014 |
Craniospinal irradiation with concurrent temozolomide for primary metastatic pediatric high-grade or diffuse intrinsic pontine gliomas. A first report from the GPOH-HIT-HGG Study Group.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Chemoradiotherapy; Child; Child | 2014 |
Craniospinal irradiation with concurrent temozolomide for primary metastatic pediatric high-grade or diffuse intrinsic pontine gliomas. A first report from the GPOH-HIT-HGG Study Group.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Chemoradiotherapy; Child; Child | 2014 |
Craniospinal irradiation with concurrent temozolomide for primary metastatic pediatric high-grade or diffuse intrinsic pontine gliomas. A first report from the GPOH-HIT-HGG Study Group.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Chemoradiotherapy; Child; Child | 2014 |
Antitumor effect of fibrin glue containing temozolomide against malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; | 2014 |
Antitumor effect of fibrin glue containing temozolomide against malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; | 2014 |
Antitumor effect of fibrin glue containing temozolomide against malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; | 2014 |
Antitumor effect of fibrin glue containing temozolomide against malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; | 2014 |
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Brain Neoplasms; Cell Line, T | 2014 |
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Brain Neoplasms; Cell Line, T | 2014 |
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Brain Neoplasms; Cell Line, T | 2014 |
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Brain Neoplasms; Cell Line, T | 2014 |
Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-κB signaling in glioma initiating cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Transformation, Neopla | 2014 |
Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-κB signaling in glioma initiating cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Transformation, Neopla | 2014 |
Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-κB signaling in glioma initiating cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Transformation, Neopla | 2014 |
Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-κB signaling in glioma initiating cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Transformation, Neopla | 2014 |
Inadvertent high-dose therapy with temozolomide in a child with recurrent pontine glioma followed by a rapid clinical response but deteriorated after substitution with low-dose therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Child; Dacarbazine; Dose-Response Relations | 2014 |
Inadvertent high-dose therapy with temozolomide in a child with recurrent pontine glioma followed by a rapid clinical response but deteriorated after substitution with low-dose therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Child; Dacarbazine; Dose-Response Relations | 2014 |
Inadvertent high-dose therapy with temozolomide in a child with recurrent pontine glioma followed by a rapid clinical response but deteriorated after substitution with low-dose therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Child; Dacarbazine; Dose-Response Relations | 2014 |
Inadvertent high-dose therapy with temozolomide in a child with recurrent pontine glioma followed by a rapid clinical response but deteriorated after substitution with low-dose therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Child; Dacarbazine; Dose-Response Relations | 2014 |
Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Stem; Brain Stem Neoplasms; | 2014 |
Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Stem; Brain Stem Neoplasms; | 2014 |
Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Stem; Brain Stem Neoplasms; | 2014 |
Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Stem; Brain Stem Neoplasms; | 2014 |
Temozolomide induces autophagy via ATM‑AMPK‑ULK1 pathways in glioma.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Prot | 2014 |
Temozolomide induces autophagy via ATM‑AMPK‑ULK1 pathways in glioma.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Prot | 2014 |
Temozolomide induces autophagy via ATM‑AMPK‑ULK1 pathways in glioma.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Prot | 2014 |
Temozolomide induces autophagy via ATM‑AMPK‑ULK1 pathways in glioma.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Prot | 2014 |
Hypoxia enhances the antiglioma cytotoxicity of B10, a glycosylated derivative of betulinic acid.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Betulinic Acid; Cathepsin B; C | 2014 |
Hypoxia enhances the antiglioma cytotoxicity of B10, a glycosylated derivative of betulinic acid.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Betulinic Acid; Cathepsin B; C | 2014 |
Hypoxia enhances the antiglioma cytotoxicity of B10, a glycosylated derivative of betulinic acid.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Betulinic Acid; Cathepsin B; C | 2014 |
Hypoxia enhances the antiglioma cytotoxicity of B10, a glycosylated derivative of betulinic acid.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Betulinic Acid; Cathepsin B; C | 2014 |
[Bevacizumab associated with radiotherapy and temozolomide as a first line treatment for high-grade gliomas: one answer but too many questions].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevac | 2014 |
[Bevacizumab associated with radiotherapy and temozolomide as a first line treatment for high-grade gliomas: one answer but too many questions].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevac | 2014 |
[Bevacizumab associated with radiotherapy and temozolomide as a first line treatment for high-grade gliomas: one answer but too many questions].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevac | 2014 |
[Bevacizumab associated with radiotherapy and temozolomide as a first line treatment for high-grade gliomas: one answer but too many questions].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevac | 2014 |
Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Blotting, | 2014 |
Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Blotting, | 2014 |
Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Blotting, | 2014 |
Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Blotting, | 2014 |
Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.
Topics: Aminoglycosides; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; | 2014 |
Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.
Topics: Aminoglycosides; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; | 2014 |
Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.
Topics: Aminoglycosides; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; | 2014 |
Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.
Topics: Aminoglycosides; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; | 2014 |
[Intranasal administration of temozolomide for brain-targeting delivery: therapeutic effect on glioma in rats].
Topics: Administration, Intranasal; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; | 2014 |
[Intranasal administration of temozolomide for brain-targeting delivery: therapeutic effect on glioma in rats].
Topics: Administration, Intranasal; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; | 2014 |
[Intranasal administration of temozolomide for brain-targeting delivery: therapeutic effect on glioma in rats].
Topics: Administration, Intranasal; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; | 2014 |
[Intranasal administration of temozolomide for brain-targeting delivery: therapeutic effect on glioma in rats].
Topics: Administration, Intranasal; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; | 2014 |
MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras.
Topics: Animals; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Genes | 2014 |
MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras.
Topics: Animals; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Genes | 2014 |
MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras.
Topics: Animals; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Genes | 2014 |
MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras.
Topics: Animals; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Genes | 2014 |
TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Follow-U | 2014 |
TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Follow-U | 2014 |
TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Follow-U | 2014 |
TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Follow-U | 2014 |
MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2014 |
MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2014 |
MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2014 |
MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2014 |
A complex mechanism for HDGF-mediated cell growth, migration, invasion, and TMZ chemosensitivity in glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cadherins; C | 2014 |
A complex mechanism for HDGF-mediated cell growth, migration, invasion, and TMZ chemosensitivity in glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cadherins; C | 2014 |
A complex mechanism for HDGF-mediated cell growth, migration, invasion, and TMZ chemosensitivity in glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cadherins; C | 2014 |
A complex mechanism for HDGF-mediated cell growth, migration, invasion, and TMZ chemosensitivity in glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cadherins; C | 2014 |
Surface-coated PLA nanoparticles loaded with temozolomide for improved brain deposition and potential treatment of gliomas: development, characterization and in vivo studies.
Topics: Animals; Brain; Cell Line; Cell Line, Tumor; Dacarbazine; Dogs; Drug Carriers; Drug Delivery Systems | 2016 |
Surface-coated PLA nanoparticles loaded with temozolomide for improved brain deposition and potential treatment of gliomas: development, characterization and in vivo studies.
Topics: Animals; Brain; Cell Line; Cell Line, Tumor; Dacarbazine; Dogs; Drug Carriers; Drug Delivery Systems | 2016 |
Surface-coated PLA nanoparticles loaded with temozolomide for improved brain deposition and potential treatment of gliomas: development, characterization and in vivo studies.
Topics: Animals; Brain; Cell Line; Cell Line, Tumor; Dacarbazine; Dogs; Drug Carriers; Drug Delivery Systems | 2016 |
Surface-coated PLA nanoparticles loaded with temozolomide for improved brain deposition and potential treatment of gliomas: development, characterization and in vivo studies.
Topics: Animals; Brain; Cell Line; Cell Line, Tumor; Dacarbazine; Dogs; Drug Carriers; Drug Delivery Systems | 2016 |
Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance.
Topics: Cell Line, Tumor; Cell Transformation, Neoplastic; Dacarbazine; DNA Damage; DNA Repair; Drug Resista | 2014 |
Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance.
Topics: Cell Line, Tumor; Cell Transformation, Neoplastic; Dacarbazine; DNA Damage; DNA Repair; Drug Resista | 2014 |
Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance.
Topics: Cell Line, Tumor; Cell Transformation, Neoplastic; Dacarbazine; DNA Damage; DNA Repair; Drug Resista | 2014 |
Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance.
Topics: Cell Line, Tumor; Cell Transformation, Neoplastic; Dacarbazine; DNA Damage; DNA Repair; Drug Resista | 2014 |
Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2014 |
Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2014 |
Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2014 |
Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2014 |
Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents, Alkylating; Brain Neopl | 2014 |
Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents, Alkylating; Brain Neopl | 2014 |
Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents, Alkylating; Brain Neopl | 2014 |
Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents, Alkylating; Brain Neopl | 2014 |
Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2014 |
Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2014 |
Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2014 |
Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2014 |
Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease- | 2015 |
Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease- | 2015 |
Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease- | 2015 |
Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease- | 2015 |
FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2014 |
FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2014 |
FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2014 |
FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2014 |
Hypoxia-induced miR-497 decreases glioma cell sensitivity to TMZ by inhibiting apoptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Base Sequence; Binding | 2014 |
Hypoxia-induced miR-497 decreases glioma cell sensitivity to TMZ by inhibiting apoptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Base Sequence; Binding | 2014 |
Hypoxia-induced miR-497 decreases glioma cell sensitivity to TMZ by inhibiting apoptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Base Sequence; Binding | 2014 |
Hypoxia-induced miR-497 decreases glioma cell sensitivity to TMZ by inhibiting apoptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Base Sequence; Binding | 2014 |
Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazin | 2014 |
Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazin | 2014 |
Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazin | 2014 |
Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazin | 2014 |
Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Diphosphonates; Drug Synergis | 2014 |
Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Diphosphonates; Drug Synergis | 2014 |
Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Diphosphonates; Drug Synergis | 2014 |
Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Diphosphonates; Drug Synergis | 2014 |
Specific inhibition of DNMT1/CFP1 reduces cancer phenotypes and enhances chemotherapy effectiveness.
Topics: Animals; Cell Proliferation; Dacarbazine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-M | 2014 |
Specific inhibition of DNMT1/CFP1 reduces cancer phenotypes and enhances chemotherapy effectiveness.
Topics: Animals; Cell Proliferation; Dacarbazine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-M | 2014 |
Specific inhibition of DNMT1/CFP1 reduces cancer phenotypes and enhances chemotherapy effectiveness.
Topics: Animals; Cell Proliferation; Dacarbazine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-M | 2014 |
Specific inhibition of DNMT1/CFP1 reduces cancer phenotypes and enhances chemotherapy effectiveness.
Topics: Animals; Cell Proliferation; Dacarbazine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-M | 2014 |
RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell | 2014 |
RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell | 2014 |
RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell | 2014 |
RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell | 2014 |
Temozolomide after radiotherapy in recurrent "low grade" diffuse brainstem glioma in adults.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Stem; Brain Stem Neoplasms; Combined Modality | 2014 |
Temozolomide after radiotherapy in recurrent "low grade" diffuse brainstem glioma in adults.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Stem; Brain Stem Neoplasms; Combined Modality | 2014 |
Temozolomide after radiotherapy in recurrent "low grade" diffuse brainstem glioma in adults.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Stem; Brain Stem Neoplasms; Combined Modality | 2014 |
Temozolomide after radiotherapy in recurrent "low grade" diffuse brainstem glioma in adults.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Stem; Brain Stem Neoplasms; Combined Modality | 2014 |
Clinicopathological and molecular features of malignant optic pathway glioma in an adult.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2015 |
Clinicopathological and molecular features of malignant optic pathway glioma in an adult.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2015 |
Clinicopathological and molecular features of malignant optic pathway glioma in an adult.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2015 |
Clinicopathological and molecular features of malignant optic pathway glioma in an adult.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2015 |
Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor | 2015 |
Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor | 2015 |
Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor | 2015 |
Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor | 2015 |
EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition.
Topics: Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Tra | 2015 |
EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition.
Topics: Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Tra | 2015 |
EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition.
Topics: Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Tra | 2015 |
EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition.
Topics: Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Tra | 2015 |
Temozolomide in low-grade gliomas: living longer and better.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Male; Seizu | 2015 |
Temozolomide in low-grade gliomas: living longer and better.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Male; Seizu | 2015 |
Temozolomide in low-grade gliomas: living longer and better.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Male; Seizu | 2015 |
Temozolomide in low-grade gliomas: living longer and better.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Male; Seizu | 2015 |
VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Biomarkers, Tumor; Brain Neoplasms; Cell Cycle; Cell P | 2015 |
VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Biomarkers, Tumor; Brain Neoplasms; Cell Cycle; Cell P | 2015 |
VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Biomarkers, Tumor; Brain Neoplasms; Cell Cycle; Cell P | 2015 |
VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Biomarkers, Tumor; Brain Neoplasms; Cell Cycle; Cell P | 2015 |
Concomitant treatment with temozolomide enhances apoptotic cell death in glioma cells induced by photodynamic therapy with talaporfin sodium.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug T | 2014 |
Concomitant treatment with temozolomide enhances apoptotic cell death in glioma cells induced by photodynamic therapy with talaporfin sodium.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug T | 2014 |
Concomitant treatment with temozolomide enhances apoptotic cell death in glioma cells induced by photodynamic therapy with talaporfin sodium.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug T | 2014 |
Concomitant treatment with temozolomide enhances apoptotic cell death in glioma cells induced by photodynamic therapy with talaporfin sodium.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug T | 2014 |
MiR-136 modulates glioma cell sensitivity to temozolomide by targeting astrocyte elevated gene-1.
Topics: Antineoplastic Agents, Alkylating; Astrocytes; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proli | 2014 |
MiR-136 modulates glioma cell sensitivity to temozolomide by targeting astrocyte elevated gene-1.
Topics: Antineoplastic Agents, Alkylating; Astrocytes; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proli | 2014 |
MiR-136 modulates glioma cell sensitivity to temozolomide by targeting astrocyte elevated gene-1.
Topics: Antineoplastic Agents, Alkylating; Astrocytes; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proli | 2014 |
MiR-136 modulates glioma cell sensitivity to temozolomide by targeting astrocyte elevated gene-1.
Topics: Antineoplastic Agents, Alkylating; Astrocytes; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proli | 2014 |
ADC texture--an imaging biomarker for high-grade glioma?
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiothera | 2014 |
ADC texture--an imaging biomarker for high-grade glioma?
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiothera | 2014 |
ADC texture--an imaging biomarker for high-grade glioma?
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiothera | 2014 |
ADC texture--an imaging biomarker for high-grade glioma?
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiothera | 2014 |
Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.
Topics: Cell Proliferation; Cisplatin; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioma; Humans; | 2015 |
Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.
Topics: Cell Proliferation; Cisplatin; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioma; Humans; | 2015 |
Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.
Topics: Cell Proliferation; Cisplatin; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioma; Humans; | 2015 |
Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.
Topics: Cell Proliferation; Cisplatin; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioma; Humans; | 2015 |
Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2014 |
Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2014 |
Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2014 |
Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2014 |
Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Prol | 2014 |
Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Prol | 2014 |
Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Prol | 2014 |
Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Prol | 2014 |
Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Es | 2015 |
Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Es | 2015 |
Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Es | 2015 |
Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Es | 2015 |
Lower expression of Nrdp1 in human glioma contributes tumor progression by reducing apoptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain; Case-Control Studies; Caspas | 2014 |
Lower expression of Nrdp1 in human glioma contributes tumor progression by reducing apoptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain; Case-Control Studies; Caspas | 2014 |
Lower expression of Nrdp1 in human glioma contributes tumor progression by reducing apoptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain; Case-Control Studies; Caspas | 2014 |
Lower expression of Nrdp1 in human glioma contributes tumor progression by reducing apoptosis.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain; Case-Control Studies; Caspas | 2014 |
Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo.
Topics: Animals; Apoptosis; Brain Neoplasms; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Cispla | 2014 |
Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo.
Topics: Animals; Apoptosis; Brain Neoplasms; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Cispla | 2014 |
Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo.
Topics: Animals; Apoptosis; Brain Neoplasms; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Cispla | 2014 |
Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo.
Topics: Animals; Apoptosis; Brain Neoplasms; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Cispla | 2014 |
Suppressor of fused (Sufu) represses Gli1 transcription and nuclear accumulation, inhibits glioma cell proliferation, invasion and vasculogenic mimicry, improving glioma chemo-sensitivity and prognosis.
Topics: Adult; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dacarbazine; Di | 2014 |
Suppressor of fused (Sufu) represses Gli1 transcription and nuclear accumulation, inhibits glioma cell proliferation, invasion and vasculogenic mimicry, improving glioma chemo-sensitivity and prognosis.
Topics: Adult; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dacarbazine; Di | 2014 |
Suppressor of fused (Sufu) represses Gli1 transcription and nuclear accumulation, inhibits glioma cell proliferation, invasion and vasculogenic mimicry, improving glioma chemo-sensitivity and prognosis.
Topics: Adult; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dacarbazine; Di | 2014 |
Suppressor of fused (Sufu) represses Gli1 transcription and nuclear accumulation, inhibits glioma cell proliferation, invasion and vasculogenic mimicry, improving glioma chemo-sensitivity and prognosis.
Topics: Adult; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dacarbazine; Di | 2014 |
Downregulation of osteopontin enhances the sensitivity of glioma U251 cells to temozolomide and cisplatin by targeting the NF-κB/Bcl‑2 pathway.
Topics: Apoptosis; Cell Line, Tumor; Cisplatin; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Enz | 2015 |
Downregulation of osteopontin enhances the sensitivity of glioma U251 cells to temozolomide and cisplatin by targeting the NF-κB/Bcl‑2 pathway.
Topics: Apoptosis; Cell Line, Tumor; Cisplatin; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Enz | 2015 |
Downregulation of osteopontin enhances the sensitivity of glioma U251 cells to temozolomide and cisplatin by targeting the NF-κB/Bcl‑2 pathway.
Topics: Apoptosis; Cell Line, Tumor; Cisplatin; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Enz | 2015 |
Downregulation of osteopontin enhances the sensitivity of glioma U251 cells to temozolomide and cisplatin by targeting the NF-κB/Bcl‑2 pathway.
Topics: Apoptosis; Cell Line, Tumor; Cisplatin; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Enz | 2015 |
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Transformation, Neoplastic; Dacarbazine; Glioma; Humans | 2014 |
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Transformation, Neoplastic; Dacarbazine; Glioma; Humans | 2014 |
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Transformation, Neoplastic; Dacarbazine; Glioma; Humans | 2014 |
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Transformation, Neoplastic; Dacarbazine; Glioma; Humans | 2014 |
Combination of photodynamic therapy and temozolomide on glioma in a rat C6 glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug The | 2014 |
Combination of photodynamic therapy and temozolomide on glioma in a rat C6 glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug The | 2014 |
Combination of photodynamic therapy and temozolomide on glioma in a rat C6 glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug The | 2014 |
Combination of photodynamic therapy and temozolomide on glioma in a rat C6 glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug The | 2014 |
Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise?
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem; Brain Stem Neoplasms; Chemotherapy, Adjuv | 2015 |
Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise?
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem; Brain Stem Neoplasms; Chemotherapy, Adjuv | 2015 |
Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise?
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem; Brain Stem Neoplasms; Chemotherapy, Adjuv | 2015 |
Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise?
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem; Brain Stem Neoplasms; Chemotherapy, Adjuv | 2015 |
Pharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Capillaries; Capillary Permeability; Cell Line, | 2014 |
Pharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Capillaries; Capillary Permeability; Cell Line, | 2014 |
Pharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Capillaries; Capillary Permeability; Cell Line, | 2014 |
Pharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Capillaries; Capillary Permeability; Cell Line, | 2014 |
An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment.
Topics: Adenoviridae; Antineoplastic Agents; Bystander Effect; Cell Line, Tumor; Cell Survival; Cytopathogen | 2015 |
An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment.
Topics: Adenoviridae; Antineoplastic Agents; Bystander Effect; Cell Line, Tumor; Cell Survival; Cytopathogen | 2015 |
An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment.
Topics: Adenoviridae; Antineoplastic Agents; Bystander Effect; Cell Line, Tumor; Cell Survival; Cytopathogen | 2015 |
An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment.
Topics: Adenoviridae; Antineoplastic Agents; Bystander Effect; Cell Line, Tumor; Cell Survival; Cytopathogen | 2015 |
MiR-203 sensitizes glioma cells to temozolomide and inhibits glioma cell invasion by targeting E2F3.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Binding Sites; Cell Line, Tumor; Cell Movement; Da | 2015 |
MiR-203 sensitizes glioma cells to temozolomide and inhibits glioma cell invasion by targeting E2F3.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Binding Sites; Cell Line, Tumor; Cell Movement; Da | 2015 |
MiR-203 sensitizes glioma cells to temozolomide and inhibits glioma cell invasion by targeting E2F3.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Binding Sites; Cell Line, Tumor; Cell Movement; Da | 2015 |
MiR-203 sensitizes glioma cells to temozolomide and inhibits glioma cell invasion by targeting E2F3.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Binding Sites; Cell Line, Tumor; Cell Movement; Da | 2015 |
Chloroquine potentiates temozolomide cytotoxicity by inhibiting mitochondrial autophagy in glioma cells.
Topics: Animals; Antimalarials; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Chloroquine; Dacarb | 2015 |
Chloroquine potentiates temozolomide cytotoxicity by inhibiting mitochondrial autophagy in glioma cells.
Topics: Animals; Antimalarials; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Chloroquine; Dacarb | 2015 |
Chloroquine potentiates temozolomide cytotoxicity by inhibiting mitochondrial autophagy in glioma cells.
Topics: Animals; Antimalarials; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Chloroquine; Dacarb | 2015 |
Chloroquine potentiates temozolomide cytotoxicity by inhibiting mitochondrial autophagy in glioma cells.
Topics: Animals; Antimalarials; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Chloroquine; Dacarb | 2015 |
Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas.
Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; | 2015 |
Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas.
Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; | 2015 |
Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas.
Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; | 2015 |
Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas.
Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; | 2015 |
Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Cycle Checkpoin | 2015 |
Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Cycle Checkpoin | 2015 |
Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Cycle Checkpoin | 2015 |
Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Cycle Checkpoin | 2015 |
Bcl2L12 with a BH3-like domain in regulating apoptosis and TMZ-induced autophagy: a prospective combination of ABT-737 and TMZ for treating glioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; bcl-X Protein; Biphenyl Compou | 2015 |
Bcl2L12 with a BH3-like domain in regulating apoptosis and TMZ-induced autophagy: a prospective combination of ABT-737 and TMZ for treating glioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; bcl-X Protein; Biphenyl Compou | 2015 |
Bcl2L12 with a BH3-like domain in regulating apoptosis and TMZ-induced autophagy: a prospective combination of ABT-737 and TMZ for treating glioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; bcl-X Protein; Biphenyl Compou | 2015 |
Bcl2L12 with a BH3-like domain in regulating apoptosis and TMZ-induced autophagy: a prospective combination of ABT-737 and TMZ for treating glioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; bcl-X Protein; Biphenyl Compou | 2015 |
Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence.
Topics: Aged; Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Dacarbazine; Disease Progression; Fema | 2015 |
Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence.
Topics: Aged; Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Dacarbazine; Disease Progression; Fema | 2015 |
Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence.
Topics: Aged; Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Dacarbazine; Disease Progression; Fema | 2015 |
Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence.
Topics: Aged; Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Dacarbazine; Disease Progression; Fema | 2015 |
Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes.
Topics: Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Calcium; Cell Communication; Cocultur | 2015 |
Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes.
Topics: Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Calcium; Cell Communication; Cocultur | 2015 |
Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes.
Topics: Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Calcium; Cell Communication; Cocultur | 2015 |
Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes.
Topics: Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Calcium; Cell Communication; Cocultur | 2015 |
Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2015 |
Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2015 |
Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2015 |
Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2015 |
MutL homolog 1 contributes to temozolomide-induced autophagy via ataxia-telangiectasia mutated in glioma.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Antineoplastic Agents, Alkylati | 2015 |
MutL homolog 1 contributes to temozolomide-induced autophagy via ataxia-telangiectasia mutated in glioma.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Antineoplastic Agents, Alkylati | 2015 |
MutL homolog 1 contributes to temozolomide-induced autophagy via ataxia-telangiectasia mutated in glioma.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Antineoplastic Agents, Alkylati | 2015 |
MutL homolog 1 contributes to temozolomide-induced autophagy via ataxia-telangiectasia mutated in glioma.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Antineoplastic Agents, Alkylati | 2015 |
Cerebral peduncle tumor ablated by novel 3-mm laser tip.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Camptothecin; Cerebral Ped | 2015 |
Cerebral peduncle tumor ablated by novel 3-mm laser tip.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Camptothecin; Cerebral Ped | 2015 |
Cerebral peduncle tumor ablated by novel 3-mm laser tip.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Camptothecin; Cerebral Ped | 2015 |
Cerebral peduncle tumor ablated by novel 3-mm laser tip.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Camptothecin; Cerebral Ped | 2015 |
Over-expression of tetraspanin 8 in malignant glioma regulates tumor cell progression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; | 2015 |
Over-expression of tetraspanin 8 in malignant glioma regulates tumor cell progression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; | 2015 |
Over-expression of tetraspanin 8 in malignant glioma regulates tumor cell progression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; | 2015 |
Over-expression of tetraspanin 8 in malignant glioma regulates tumor cell progression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; | 2015 |
Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cel | 2015 |
Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cel | 2015 |
Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cel | 2015 |
Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cel | 2015 |
p38 MAPK-dependent Nrf2 induction enhances the resistance of glioma cells against TMZ.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Enzyme | 2015 |
p38 MAPK-dependent Nrf2 induction enhances the resistance of glioma cells against TMZ.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Enzyme | 2015 |
p38 MAPK-dependent Nrf2 induction enhances the resistance of glioma cells against TMZ.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Enzyme | 2015 |
p38 MAPK-dependent Nrf2 induction enhances the resistance of glioma cells against TMZ.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Enzyme | 2015 |
Single-cell analysis challenges the connection between autophagy and senescence induced by DNA damage.
Topics: AMP-Activated Protein Kinases; Apoptosis; Autophagy; Autophagy-Related Protein-1 Homolog; Cell Cycle | 2015 |
Single-cell analysis challenges the connection between autophagy and senescence induced by DNA damage.
Topics: AMP-Activated Protein Kinases; Apoptosis; Autophagy; Autophagy-Related Protein-1 Homolog; Cell Cycle | 2015 |
Single-cell analysis challenges the connection between autophagy and senescence induced by DNA damage.
Topics: AMP-Activated Protein Kinases; Apoptosis; Autophagy; Autophagy-Related Protein-1 Homolog; Cell Cycle | 2015 |
Single-cell analysis challenges the connection between autophagy and senescence induced by DNA damage.
Topics: AMP-Activated Protein Kinases; Apoptosis; Autophagy; Autophagy-Related Protein-1 Homolog; Cell Cycle | 2015 |
Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Disease Progression | 2015 |
Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Disease Progression | 2015 |
Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Disease Progression | 2015 |
Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Disease Progression | 2015 |
[Caspase-independent programmed cell death induced by temozolomide in rat glioma C6 cell line].
Topics: Animals; Apoptosis; Caspases; Cell Line, Tumor; Dacarbazine; Down-Regulation; Glioma; Rats; Temozolo | 2015 |
[Caspase-independent programmed cell death induced by temozolomide in rat glioma C6 cell line].
Topics: Animals; Apoptosis; Caspases; Cell Line, Tumor; Dacarbazine; Down-Regulation; Glioma; Rats; Temozolo | 2015 |
[Caspase-independent programmed cell death induced by temozolomide in rat glioma C6 cell line].
Topics: Animals; Apoptosis; Caspases; Cell Line, Tumor; Dacarbazine; Down-Regulation; Glioma; Rats; Temozolo | 2015 |
[Caspase-independent programmed cell death induced by temozolomide in rat glioma C6 cell line].
Topics: Animals; Apoptosis; Caspases; Cell Line, Tumor; Dacarbazine; Down-Regulation; Glioma; Rats; Temozolo | 2015 |
Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Progression; DNA Damage; DNA Repair | 2015 |
Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Progression; DNA Damage; DNA Repair | 2015 |
Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Progression; DNA Damage; DNA Repair | 2015 |
Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Progression; DNA Damage; DNA Repair | 2015 |
The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Dr | 2015 |
The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Dr | 2015 |
The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Dr | 2015 |
The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Dr | 2015 |
The evolving genomic landscape of recurrent gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Helicases; Genomics; Glioma; Hu | 2015 |
The evolving genomic landscape of recurrent gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Helicases; Genomics; Glioma; Hu | 2015 |
The evolving genomic landscape of recurrent gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Helicases; Genomics; Glioma; Hu | 2015 |
The evolving genomic landscape of recurrent gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Helicases; Genomics; Glioma; Hu | 2015 |
Downregulation of Id2 increases chemosensitivity of glioma.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Gene Expres | 2015 |
Downregulation of Id2 increases chemosensitivity of glioma.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Gene Expres | 2015 |
Downregulation of Id2 increases chemosensitivity of glioma.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Gene Expres | 2015 |
Downregulation of Id2 increases chemosensitivity of glioma.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Gene Expres | 2015 |
Decoy Receptor DcR1 Is Induced in a p50/Bcl3-Dependent Manner and Attenuates the Efficacy of Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; B-Cell Lymphoma 3 Protein; Base Sequence; Binding Sites; | 2015 |
Decoy Receptor DcR1 Is Induced in a p50/Bcl3-Dependent Manner and Attenuates the Efficacy of Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; B-Cell Lymphoma 3 Protein; Base Sequence; Binding Sites; | 2015 |
Decoy Receptor DcR1 Is Induced in a p50/Bcl3-Dependent Manner and Attenuates the Efficacy of Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; B-Cell Lymphoma 3 Protein; Base Sequence; Binding Sites; | 2015 |
Decoy Receptor DcR1 Is Induced in a p50/Bcl3-Dependent Manner and Attenuates the Efficacy of Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; B-Cell Lymphoma 3 Protein; Base Sequence; Binding Sites; | 2015 |
Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Carbonic Anhydrases; Cell Line, | 2015 |
Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Carbonic Anhydrases; Cell Line, | 2015 |
Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Carbonic Anhydrases; Cell Line, | 2015 |
Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Carbonic Anhydrases; Cell Line, | 2015 |
Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: a very long term comparative study and literature review.
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Male; | 2015 |
Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: a very long term comparative study and literature review.
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Male; | 2015 |
Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: a very long term comparative study and literature review.
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Male; | 2015 |
Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: a very long term comparative study and literature review.
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; Male; | 2015 |
Dopamine induces growth inhibition and vascular normalization through reprogramming M2-polarized macrophages in rat C6 glioma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Cell Movement; Dacarbazine; Dop | 2015 |
Dopamine induces growth inhibition and vascular normalization through reprogramming M2-polarized macrophages in rat C6 glioma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Cell Movement; Dacarbazine; Dop | 2015 |
Dopamine induces growth inhibition and vascular normalization through reprogramming M2-polarized macrophages in rat C6 glioma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Cell Movement; Dacarbazine; Dop | 2015 |
Dopamine induces growth inhibition and vascular normalization through reprogramming M2-polarized macrophages in rat C6 glioma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Cell Movement; Dacarbazine; Dop | 2015 |
Volumetric modulated arc therapy for hippocampal-sparing radiotherapy in transformed low-grade glioma: A treatment planning case report.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Damage, Chronic; Cell Dedifferentiation; Combi | 2015 |
Volumetric modulated arc therapy for hippocampal-sparing radiotherapy in transformed low-grade glioma: A treatment planning case report.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Damage, Chronic; Cell Dedifferentiation; Combi | 2015 |
Volumetric modulated arc therapy for hippocampal-sparing radiotherapy in transformed low-grade glioma: A treatment planning case report.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Damage, Chronic; Cell Dedifferentiation; Combi | 2015 |
Volumetric modulated arc therapy for hippocampal-sparing radiotherapy in transformed low-grade glioma: A treatment planning case report.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Damage, Chronic; Cell Dedifferentiation; Combi | 2015 |
A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: a Children's Oncology Group study†.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carbopl | 2015 |
A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: a Children's Oncology Group study†.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carbopl | 2015 |
A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: a Children's Oncology Group study†.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carbopl | 2015 |
A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: a Children's Oncology Group study†.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carbopl | 2015 |
Silencing of R-Spondin1 increases radiosensitivity of glioma cells.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; A | 2015 |
Silencing of R-Spondin1 increases radiosensitivity of glioma cells.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; A | 2015 |
Silencing of R-Spondin1 increases radiosensitivity of glioma cells.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; A | 2015 |
Silencing of R-Spondin1 increases radiosensitivity of glioma cells.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; A | 2015 |
ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
Topics: Apoptosis; Autophagy; Benzimidazoles; Brain Neoplasms; Culture Media, Serum-Free; Dacarbazine; DNA B | 2015 |
ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
Topics: Apoptosis; Autophagy; Benzimidazoles; Brain Neoplasms; Culture Media, Serum-Free; Dacarbazine; DNA B | 2015 |
ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
Topics: Apoptosis; Autophagy; Benzimidazoles; Brain Neoplasms; Culture Media, Serum-Free; Dacarbazine; DNA B | 2015 |
ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
Topics: Apoptosis; Autophagy; Benzimidazoles; Brain Neoplasms; Culture Media, Serum-Free; Dacarbazine; DNA B | 2015 |
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2015 |
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2015 |
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2015 |
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2015 |
Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapies.
Topics: Animals; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Neoplasms; Temozolomide; Therapies, Investig | 2015 |
Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapies.
Topics: Animals; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Neoplasms; Temozolomide; Therapies, Investig | 2015 |
Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapies.
Topics: Animals; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Neoplasms; Temozolomide; Therapies, Investig | 2015 |
Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapies.
Topics: Animals; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Neoplasms; Temozolomide; Therapies, Investig | 2015 |
Upfront chemotherapy and subsequent resection for molecularly defined gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Daca | 2015 |
Upfront chemotherapy and subsequent resection for molecularly defined gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Daca | 2015 |
Upfront chemotherapy and subsequent resection for molecularly defined gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Daca | 2015 |
Upfront chemotherapy and subsequent resection for molecularly defined gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Daca | 2015 |
Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain | 2015 |
Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain | 2015 |
Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain | 2015 |
Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain | 2015 |
Development of resistance to antiglioma agents in rat C6 cells caused collateral sensitivity to doxorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regula | 2015 |
Development of resistance to antiglioma agents in rat C6 cells caused collateral sensitivity to doxorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regula | 2015 |
Development of resistance to antiglioma agents in rat C6 cells caused collateral sensitivity to doxorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regula | 2015 |
Development of resistance to antiglioma agents in rat C6 cells caused collateral sensitivity to doxorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regula | 2015 |
Secreted frizzled-related protein 4 inhibits glioma stem-like cells by reversing epithelial to mesenchymal transition, inducing apoptosis and decreasing cancer stem cell properties.
Topics: Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Tr | 2015 |
Secreted frizzled-related protein 4 inhibits glioma stem-like cells by reversing epithelial to mesenchymal transition, inducing apoptosis and decreasing cancer stem cell properties.
Topics: Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Tr | 2015 |
Secreted frizzled-related protein 4 inhibits glioma stem-like cells by reversing epithelial to mesenchymal transition, inducing apoptosis and decreasing cancer stem cell properties.
Topics: Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Tr | 2015 |
Secreted frizzled-related protein 4 inhibits glioma stem-like cells by reversing epithelial to mesenchymal transition, inducing apoptosis and decreasing cancer stem cell properties.
Topics: Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Tr | 2015 |
Ca2+-Activated IK K+ Channel Blockade Radiosensitizes Glioblastoma Cells.
Topics: Animals; Calcium; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; F | 2015 |
Ca2+-Activated IK K+ Channel Blockade Radiosensitizes Glioblastoma Cells.
Topics: Animals; Calcium; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; F | 2015 |
Ca2+-Activated IK K+ Channel Blockade Radiosensitizes Glioblastoma Cells.
Topics: Animals; Calcium; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; F | 2015 |
Ca2+-Activated IK K+ Channel Blockade Radiosensitizes Glioblastoma Cells.
Topics: Animals; Calcium; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; F | 2015 |
The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Glioma; Humans; | 2016 |
The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Glioma; Humans; | 2016 |
The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Glioma; Humans; | 2016 |
The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Glioma; Humans; | 2016 |
Photochemical internalization of bleomycin and temozolomide--in vitro studies on the glioma cell line F98.
Topics: Animals; Antineoplastic Agents; Bleomycin; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioma; Lig | 2015 |
Photochemical internalization of bleomycin and temozolomide--in vitro studies on the glioma cell line F98.
Topics: Animals; Antineoplastic Agents; Bleomycin; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioma; Lig | 2015 |
Photochemical internalization of bleomycin and temozolomide--in vitro studies on the glioma cell line F98.
Topics: Animals; Antineoplastic Agents; Bleomycin; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioma; Lig | 2015 |
Photochemical internalization of bleomycin and temozolomide--in vitro studies on the glioma cell line F98.
Topics: Animals; Antineoplastic Agents; Bleomycin; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioma; Lig | 2015 |
Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice.
Topics: Animals; Cell Division; Cell Line; Cell Line, Tumor; Dacarbazine; Down-Regulation; Endothelial Cells | 2015 |
Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice.
Topics: Animals; Cell Division; Cell Line; Cell Line, Tumor; Dacarbazine; Down-Regulation; Endothelial Cells | 2015 |
Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice.
Topics: Animals; Cell Division; Cell Line; Cell Line, Tumor; Dacarbazine; Down-Regulation; Endothelial Cells | 2015 |
Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice.
Topics: Animals; Cell Division; Cell Line; Cell Line, Tumor; Dacarbazine; Down-Regulation; Endothelial Cells | 2015 |
Prognostic impact of molecular phenotype in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases | 2015 |
Prognostic impact of molecular phenotype in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases | 2015 |
Prognostic impact of molecular phenotype in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases | 2015 |
Prognostic impact of molecular phenotype in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases | 2015 |
Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein.
Topics: Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Dacarbazine; Gene Expression | 2015 |
Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein.
Topics: Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Dacarbazine; Gene Expression | 2015 |
Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein.
Topics: Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Dacarbazine; Gene Expression | 2015 |
Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein.
Topics: Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Dacarbazine; Gene Expression | 2015 |
IL-24 Induces Apoptosis via Upregulation of RNA-Activated Protein Kinase and Enhances Temozolomide-Induced Apoptosis in Glioma Cells.
Topics: Apoptosis; Cell Line, Tumor; Dacarbazine; eIF-2 Kinase; Glioma; Humans; Interleukins; Phosphorylatio | 2014 |
IL-24 Induces Apoptosis via Upregulation of RNA-Activated Protein Kinase and Enhances Temozolomide-Induced Apoptosis in Glioma Cells.
Topics: Apoptosis; Cell Line, Tumor; Dacarbazine; eIF-2 Kinase; Glioma; Humans; Interleukins; Phosphorylatio | 2014 |
IL-24 Induces Apoptosis via Upregulation of RNA-Activated Protein Kinase and Enhances Temozolomide-Induced Apoptosis in Glioma Cells.
Topics: Apoptosis; Cell Line, Tumor; Dacarbazine; eIF-2 Kinase; Glioma; Humans; Interleukins; Phosphorylatio | 2014 |
IL-24 Induces Apoptosis via Upregulation of RNA-Activated Protein Kinase and Enhances Temozolomide-Induced Apoptosis in Glioma Cells.
Topics: Apoptosis; Cell Line, Tumor; Dacarbazine; eIF-2 Kinase; Glioma; Humans; Interleukins; Phosphorylatio | 2014 |
A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, An | 2015 |
A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, An | 2015 |
A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, An | 2015 |
A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, An | 2015 |
NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2015 |
NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2015 |
NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2015 |
NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2015 |
MEK2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neop | 2016 |
MEK2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neop | 2016 |
MEK2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neop | 2016 |
MEK2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neop | 2016 |
Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Liposomes; | 2015 |
Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Liposomes; | 2015 |
Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Liposomes; | 2015 |
Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Liposomes; | 2015 |
Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Carriers; Drug Liberation; Glioblastom | 2016 |
Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Carriers; Drug Liberation; Glioblastom | 2016 |
Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Carriers; Drug Liberation; Glioblastom | 2016 |
Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Carriers; Drug Liberation; Glioblastom | 2016 |
Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Dacarbazine; Drug Carri | 2016 |
Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Dacarbazine; Drug Carri | 2016 |
Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Dacarbazine; Drug Carri | 2016 |
Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Dacarbazine; Drug Carri | 2016 |
Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Che | 2015 |
Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Che | 2015 |
Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Che | 2015 |
Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Che | 2015 |
Discovery of Power-Law Growth in the Self-Renewal of Heterogeneous Glioma Stem Cell Populations.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Self Renewal; Cell Size; Clone Cells; Dacarbazine; Glioma | 2015 |
Discovery of Power-Law Growth in the Self-Renewal of Heterogeneous Glioma Stem Cell Populations.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Self Renewal; Cell Size; Clone Cells; Dacarbazine; Glioma | 2015 |
Discovery of Power-Law Growth in the Self-Renewal of Heterogeneous Glioma Stem Cell Populations.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Self Renewal; Cell Size; Clone Cells; Dacarbazine; Glioma | 2015 |
Discovery of Power-Law Growth in the Self-Renewal of Heterogeneous Glioma Stem Cell Populations.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Self Renewal; Cell Size; Clone Cells; Dacarbazine; Glioma | 2015 |
A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells.
Topics: 5-Methylcytosine; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dac | 2015 |
A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells.
Topics: 5-Methylcytosine; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dac | 2015 |
A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells.
Topics: 5-Methylcytosine; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dac | 2015 |
A New Epigenetic Mechanism of Temozolomide Action in Glioma Cells.
Topics: 5-Methylcytosine; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dac | 2015 |
Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cel | 2015 |
Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cel | 2015 |
Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cel | 2015 |
Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cel | 2015 |
Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Prol | 2015 |
Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Prol | 2015 |
Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Prol | 2015 |
Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Prol | 2015 |
DNMT1 mediates chemosensitivity by reducing methylation of miRNA-20a promoter in glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Dacarbazine; DNA (Cyt | 2015 |
DNMT1 mediates chemosensitivity by reducing methylation of miRNA-20a promoter in glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Dacarbazine; DNA (Cyt | 2015 |
DNMT1 mediates chemosensitivity by reducing methylation of miRNA-20a promoter in glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Dacarbazine; DNA (Cyt | 2015 |
DNMT1 mediates chemosensitivity by reducing methylation of miRNA-20a promoter in glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Dacarbazine; DNA (Cyt | 2015 |
Profile Analysis of Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Female; | 2015 |
Profile Analysis of Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Female; | 2015 |
Profile Analysis of Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Female; | 2015 |
Profile Analysis of Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Female; | 2015 |
Spatiotemporal Evolution of the Primary Glioblastoma Genome.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Isoci | 2015 |
Spatiotemporal Evolution of the Primary Glioblastoma Genome.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Isoci | 2015 |
Spatiotemporal Evolution of the Primary Glioblastoma Genome.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Isoci | 2015 |
Spatiotemporal Evolution of the Primary Glioblastoma Genome.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Isoci | 2015 |
Combined Delivery of Temozolomide and Anti-miR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2015 |
Combined Delivery of Temozolomide and Anti-miR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2015 |
Combined Delivery of Temozolomide and Anti-miR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2015 |
Combined Delivery of Temozolomide and Anti-miR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2015 |
Combination of temozolomide and Taxol exerts a synergistic inhibitory effect on Taxol‑resistant glioma cells via inhibition of glucose metabolism.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neopl | 2015 |
Combination of temozolomide and Taxol exerts a synergistic inhibitory effect on Taxol‑resistant glioma cells via inhibition of glucose metabolism.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neopl | 2015 |
Combination of temozolomide and Taxol exerts a synergistic inhibitory effect on Taxol‑resistant glioma cells via inhibition of glucose metabolism.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neopl | 2015 |
Combination of temozolomide and Taxol exerts a synergistic inhibitory effect on Taxol‑resistant glioma cells via inhibition of glucose metabolism.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neopl | 2015 |
miRNA-182 and the regulation of the glioblastoma phenotype - toward miRNA-based precision therapeutics.
Topics: Animals; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Dacarbazine; Gen | 2015 |
miRNA-182 and the regulation of the glioblastoma phenotype - toward miRNA-based precision therapeutics.
Topics: Animals; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Dacarbazine; Gen | 2015 |
miRNA-182 and the regulation of the glioblastoma phenotype - toward miRNA-based precision therapeutics.
Topics: Animals; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Dacarbazine; Gen | 2015 |
miRNA-182 and the regulation of the glioblastoma phenotype - toward miRNA-based precision therapeutics.
Topics: Animals; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Dacarbazine; Gen | 2015 |
Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfami | 2016 |
Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfami | 2016 |
Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfami | 2016 |
Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfami | 2016 |
Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Femal | 2016 |
Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Femal | 2016 |
Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Femal | 2016 |
Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Femal | 2016 |
Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Antisense Elements (Genetics); Brain Neoplasms; Caspase 3; Cell L | 2015 |
Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Antisense Elements (Genetics); Brain Neoplasms; Caspase 3; Cell L | 2015 |
Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Antisense Elements (Genetics); Brain Neoplasms; Caspase 3; Cell L | 2015 |
Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Antisense Elements (Genetics); Brain Neoplasms; Caspase 3; Cell L | 2015 |
Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas.
Topics: Adult; Amino Acids; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Dacarbazine; Disease-F | 2016 |
Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas.
Topics: Adult; Amino Acids; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Dacarbazine; Disease-F | 2016 |
Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas.
Topics: Adult; Amino Acids; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Dacarbazine; Disease-F | 2016 |
Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas.
Topics: Adult; Amino Acids; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Dacarbazine; Disease-F | 2016 |
Topological robustness analysis of protein interaction networks reveals key targets for overcoming chemotherapy resistance in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Gene Knock | 2015 |
Topological robustness analysis of protein interaction networks reveals key targets for overcoming chemotherapy resistance in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Gene Knock | 2015 |
Topological robustness analysis of protein interaction networks reveals key targets for overcoming chemotherapy resistance in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Gene Knock | 2015 |
Topological robustness analysis of protein interaction networks reveals key targets for overcoming chemotherapy resistance in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Gene Knock | 2015 |
Evolving management of low grade glioma: No consensus amongst treating clinicians.
Topics: Adult; Australia; Brain Neoplasms; Cohort Studies; Consensus; Dacarbazine; Disease Management; Femal | 2016 |
Evolving management of low grade glioma: No consensus amongst treating clinicians.
Topics: Adult; Australia; Brain Neoplasms; Cohort Studies; Consensus; Dacarbazine; Disease Management; Femal | 2016 |
Evolving management of low grade glioma: No consensus amongst treating clinicians.
Topics: Adult; Australia; Brain Neoplasms; Cohort Studies; Consensus; Dacarbazine; Disease Management; Femal | 2016 |
Evolving management of low grade glioma: No consensus amongst treating clinicians.
Topics: Adult; Australia; Brain Neoplasms; Cohort Studies; Consensus; Dacarbazine; Disease Management; Femal | 2016 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Cele | 2015 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Cele | 2015 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Cele | 2015 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Cele | 2015 |
A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms | 2016 |
A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms | 2016 |
A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms | 2016 |
A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms | 2016 |
Overexpression of iASPP-SV in glioma is associated with poor prognosis by promoting cell viability and antagonizing apoptosis.
Topics: Adult; Aged; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Disease-Fr | 2016 |
Overexpression of iASPP-SV in glioma is associated with poor prognosis by promoting cell viability and antagonizing apoptosis.
Topics: Adult; Aged; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Disease-Fr | 2016 |
Overexpression of iASPP-SV in glioma is associated with poor prognosis by promoting cell viability and antagonizing apoptosis.
Topics: Adult; Aged; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Disease-Fr | 2016 |
Overexpression of iASPP-SV in glioma is associated with poor prognosis by promoting cell viability and antagonizing apoptosis.
Topics: Adult; Aged; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Disease-Fr | 2016 |
Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Synergism; Enzyme In | 2016 |
Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Synergism; Enzyme In | 2016 |
Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Synergism; Enzyme In | 2016 |
Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Synergism; Enzyme In | 2016 |
Overexpression of hSNF2H in glioma promotes cell proliferation, invasion, and chemoresistance through its interaction with Rsf-1.
Topics: Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Blotting | 2016 |
Overexpression of hSNF2H in glioma promotes cell proliferation, invasion, and chemoresistance through its interaction with Rsf-1.
Topics: Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Blotting | 2016 |
Overexpression of hSNF2H in glioma promotes cell proliferation, invasion, and chemoresistance through its interaction with Rsf-1.
Topics: Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Blotting | 2016 |
Overexpression of hSNF2H in glioma promotes cell proliferation, invasion, and chemoresistance through its interaction with Rsf-1.
Topics: Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Blotting | 2016 |
A versatile ex vivo technique for assaying tumor angiogenesis and microglia in the brain.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2016 |
A versatile ex vivo technique for assaying tumor angiogenesis and microglia in the brain.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2016 |
A versatile ex vivo technique for assaying tumor angiogenesis and microglia in the brain.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2016 |
A versatile ex vivo technique for assaying tumor angiogenesis and microglia in the brain.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2016 |
A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Dacarbazi | 2016 |
A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Dacarbazi | 2016 |
A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Dacarbazi | 2016 |
A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Dacarbazi | 2016 |
EpiBrainRad: an epidemiologic study of the neurotoxicity induced by radiotherapy in high grade glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition Disorde | 2015 |
EpiBrainRad: an epidemiologic study of the neurotoxicity induced by radiotherapy in high grade glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition Disorde | 2015 |
EpiBrainRad: an epidemiologic study of the neurotoxicity induced by radiotherapy in high grade glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition Disorde | 2015 |
EpiBrainRad: an epidemiologic study of the neurotoxicity induced by radiotherapy in high grade glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition Disorde | 2015 |
High levels of apoptosis are induced in human glioma cell lines by co-administration of peptide nucleic acids targeting miR-221 and miR-222.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; | 2016 |
High levels of apoptosis are induced in human glioma cell lines by co-administration of peptide nucleic acids targeting miR-221 and miR-222.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; | 2016 |
High levels of apoptosis are induced in human glioma cell lines by co-administration of peptide nucleic acids targeting miR-221 and miR-222.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; | 2016 |
High levels of apoptosis are induced in human glioma cell lines by co-administration of peptide nucleic acids targeting miR-221 and miR-222.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; | 2016 |
Double Blockade of Glioma Cell Proliferation and Migration by Temozolomide Conjugated with NPPB, a Chloride Channel Blocker.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferati | 2016 |
Double Blockade of Glioma Cell Proliferation and Migration by Temozolomide Conjugated with NPPB, a Chloride Channel Blocker.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferati | 2016 |
Double Blockade of Glioma Cell Proliferation and Migration by Temozolomide Conjugated with NPPB, a Chloride Channel Blocker.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferati | 2016 |
Double Blockade of Glioma Cell Proliferation and Migration by Temozolomide Conjugated with NPPB, a Chloride Channel Blocker.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferati | 2016 |
Plasmid pORF-hTRAIL targeting to glioma using transferrin-modified polyamidoamine dendrimer.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Dendrimers; Gene Expression Regu | 2016 |
Plasmid pORF-hTRAIL targeting to glioma using transferrin-modified polyamidoamine dendrimer.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Dendrimers; Gene Expression Regu | 2016 |
Plasmid pORF-hTRAIL targeting to glioma using transferrin-modified polyamidoamine dendrimer.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Dendrimers; Gene Expression Regu | 2016 |
Plasmid pORF-hTRAIL targeting to glioma using transferrin-modified polyamidoamine dendrimer.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Dendrimers; Gene Expression Regu | 2016 |
MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; | 2015 |
MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; | 2015 |
MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; | 2015 |
MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; | 2015 |
Cognitive Dysfunction After Cranial Radiation for a Brain Tumor.
Topics: Acyclovir; Antineoplastic Agents, Alkylating; Antiviral Agents; Brain Stem Neoplasms; Cognitive Dysf | 2016 |
Cognitive Dysfunction After Cranial Radiation for a Brain Tumor.
Topics: Acyclovir; Antineoplastic Agents, Alkylating; Antiviral Agents; Brain Stem Neoplasms; Cognitive Dysf | 2016 |
Cognitive Dysfunction After Cranial Radiation for a Brain Tumor.
Topics: Acyclovir; Antineoplastic Agents, Alkylating; Antiviral Agents; Brain Stem Neoplasms; Cognitive Dysf | 2016 |
Cognitive Dysfunction After Cranial Radiation for a Brain Tumor.
Topics: Acyclovir; Antineoplastic Agents, Alkylating; Antiviral Agents; Brain Stem Neoplasms; Cognitive Dysf | 2016 |
Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor | 2016 |
Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor | 2016 |
Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor | 2016 |
Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor | 2016 |
Pharmacokinetics and antitumor efficacy of DSPE-PEG2000 polymeric liposomes loaded with quercetin and temozolomide: Analysis of their effectiveness in enhancing the chemosensitization of drug-resistant glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Delive | 2016 |
Pharmacokinetics and antitumor efficacy of DSPE-PEG2000 polymeric liposomes loaded with quercetin and temozolomide: Analysis of their effectiveness in enhancing the chemosensitization of drug-resistant glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Delive | 2016 |
Pharmacokinetics and antitumor efficacy of DSPE-PEG2000 polymeric liposomes loaded with quercetin and temozolomide: Analysis of their effectiveness in enhancing the chemosensitization of drug-resistant glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Delive | 2016 |
Pharmacokinetics and antitumor efficacy of DSPE-PEG2000 polymeric liposomes loaded with quercetin and temozolomide: Analysis of their effectiveness in enhancing the chemosensitization of drug-resistant glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Delive | 2016 |
Prognostic factors and survival study in high-grade glioma in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2016 |
Prognostic factors and survival study in high-grade glioma in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2016 |
Prognostic factors and survival study in high-grade glioma in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2016 |
Prognostic factors and survival study in high-grade glioma in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2016 |
Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Death; Cell Line, Tumor; Dacarbazine; Disease | 2016 |
Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Death; Cell Line, Tumor; Dacarbazine; Disease | 2016 |
Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Death; Cell Line, Tumor; Dacarbazine; Disease | 2016 |
Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Death; Cell Line, Tumor; Dacarbazine; Disease | 2016 |
Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbaz | 2016 |
Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbaz | 2016 |
Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbaz | 2016 |
Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbaz | 2016 |
mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; D | 2016 |
mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; D | 2016 |
mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; D | 2016 |
mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; D | 2016 |
Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cel | 2016 |
Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cel | 2016 |
Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cel | 2016 |
Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cel | 2016 |
Non-thermal atmospheric plasma induces ROS-independent cell death in U373MG glioma cells and augments the cytotoxicity of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug S | 2016 |
Non-thermal atmospheric plasma induces ROS-independent cell death in U373MG glioma cells and augments the cytotoxicity of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug S | 2016 |
Non-thermal atmospheric plasma induces ROS-independent cell death in U373MG glioma cells and augments the cytotoxicity of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug S | 2016 |
Non-thermal atmospheric plasma induces ROS-independent cell death in U373MG glioma cells and augments the cytotoxicity of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug S | 2016 |
Downregulation of miR-137 and miR-6500-3p promotes cell proliferation in pediatric high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Prol | 2016 |
Downregulation of miR-137 and miR-6500-3p promotes cell proliferation in pediatric high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Prol | 2016 |
Downregulation of miR-137 and miR-6500-3p promotes cell proliferation in pediatric high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Prol | 2016 |
Downregulation of miR-137 and miR-6500-3p promotes cell proliferation in pediatric high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Prol | 2016 |
Systematic analysis of overall survival and interactions between tumor mutations and drug treatment.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioma; Humans; Isocitrate Dehydrogenase; Kaplan-Mei | 2016 |
Systematic analysis of overall survival and interactions between tumor mutations and drug treatment.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioma; Humans; Isocitrate Dehydrogenase; Kaplan-Mei | 2016 |
Systematic analysis of overall survival and interactions between tumor mutations and drug treatment.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioma; Humans; Isocitrate Dehydrogenase; Kaplan-Mei | 2016 |
Systematic analysis of overall survival and interactions between tumor mutations and drug treatment.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioma; Humans; Isocitrate Dehydrogenase; Kaplan-Mei | 2016 |
Breakable mesoporous silica nanoparticles for targeted drug delivery.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Disulfides; Drug Carriers; Drug Delivery Syste | 2016 |
Breakable mesoporous silica nanoparticles for targeted drug delivery.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Disulfides; Drug Carriers; Drug Delivery Syste | 2016 |
Breakable mesoporous silica nanoparticles for targeted drug delivery.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Disulfides; Drug Carriers; Drug Delivery Syste | 2016 |
Breakable mesoporous silica nanoparticles for targeted drug delivery.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Disulfides; Drug Carriers; Drug Delivery Syste | 2016 |
Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema.
Topics: Amino Acid Transport System X-AG; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal | 2016 |
Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema.
Topics: Amino Acid Transport System X-AG; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal | 2016 |
Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema.
Topics: Amino Acid Transport System X-AG; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal | 2016 |
Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema.
Topics: Amino Acid Transport System X-AG; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal | 2016 |
KLF8 Promotes Temozolomide Resistance in Glioma Cells via β-Catenin Activation.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Blotting, Western; Brain Neopla | 2016 |
KLF8 Promotes Temozolomide Resistance in Glioma Cells via β-Catenin Activation.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Blotting, Western; Brain Neopla | 2016 |
KLF8 Promotes Temozolomide Resistance in Glioma Cells via β-Catenin Activation.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Blotting, Western; Brain Neopla | 2016 |
KLF8 Promotes Temozolomide Resistance in Glioma Cells via β-Catenin Activation.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Blotting, Western; Brain Neopla | 2016 |
Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment.
Topics: Apoptosis; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2016 |
Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment.
Topics: Apoptosis; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2016 |
Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment.
Topics: Apoptosis; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2016 |
Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment.
Topics: Apoptosis; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2016 |
KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; CDC2 Protein Kinase; Cell Li | 2016 |
KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; CDC2 Protein Kinase; Cell Li | 2016 |
KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; CDC2 Protein Kinase; Cell Li | 2016 |
KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; CDC2 Protein Kinase; Cell Li | 2016 |
Evidence for the Inhibition by Temozolomide, an Imidazotetrazine Family Alkylator, of Intermediate-Conductance Ca2+-Activated K+ Channels in Glioma Cells.
Topics: Alkylating Agents; Benzimidazoles; Cell Line, Tumor; Dacarbazine; DNA Damage; Glioma; Humans; Interm | 2016 |
Evidence for the Inhibition by Temozolomide, an Imidazotetrazine Family Alkylator, of Intermediate-Conductance Ca2+-Activated K+ Channels in Glioma Cells.
Topics: Alkylating Agents; Benzimidazoles; Cell Line, Tumor; Dacarbazine; DNA Damage; Glioma; Humans; Interm | 2016 |
Evidence for the Inhibition by Temozolomide, an Imidazotetrazine Family Alkylator, of Intermediate-Conductance Ca2+-Activated K+ Channels in Glioma Cells.
Topics: Alkylating Agents; Benzimidazoles; Cell Line, Tumor; Dacarbazine; DNA Damage; Glioma; Humans; Interm | 2016 |
Evidence for the Inhibition by Temozolomide, an Imidazotetrazine Family Alkylator, of Intermediate-Conductance Ca2+-Activated K+ Channels in Glioma Cells.
Topics: Alkylating Agents; Benzimidazoles; Cell Line, Tumor; Dacarbazine; DNA Damage; Glioma; Humans; Interm | 2016 |
Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Brain Stem Neoplasms; Child; | 2016 |
Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Brain Stem Neoplasms; Child; | 2016 |
Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Brain Stem Neoplasms; Child; | 2016 |
Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Brain Stem Neoplasms; Child; | 2016 |
Radiologic response to radiation therapy concurrent with temozolomide for progressive simple dysembryoplastic neuroepithelial tumor.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Neop | 2016 |
Radiologic response to radiation therapy concurrent with temozolomide for progressive simple dysembryoplastic neuroepithelial tumor.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Neop | 2016 |
Radiologic response to radiation therapy concurrent with temozolomide for progressive simple dysembryoplastic neuroepithelial tumor.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Neop | 2016 |
Radiologic response to radiation therapy concurrent with temozolomide for progressive simple dysembryoplastic neuroepithelial tumor.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Neop | 2016 |
Silence of bFGF enhances chemosensitivity of glioma cells to temozolomide through the MAPK signal pathway.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Cell Cycle Checkpoints; Ce | 2016 |
Silence of bFGF enhances chemosensitivity of glioma cells to temozolomide through the MAPK signal pathway.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Cell Cycle Checkpoints; Ce | 2016 |
Silence of bFGF enhances chemosensitivity of glioma cells to temozolomide through the MAPK signal pathway.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Cell Cycle Checkpoints; Ce | 2016 |
Silence of bFGF enhances chemosensitivity of glioma cells to temozolomide through the MAPK signal pathway.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Cell Cycle Checkpoints; Ce | 2016 |
Frequent Nek1 overexpression in human gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dac | 2016 |
Frequent Nek1 overexpression in human gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dac | 2016 |
Frequent Nek1 overexpression in human gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dac | 2016 |
Frequent Nek1 overexpression in human gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dac | 2016 |
Malignant transformation of low-grade gliomas in patients undergoing adjuvant therapy.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Cell Transformation, Neoplastic; Chemoradiotherapy, A | 2017 |
Malignant transformation of low-grade gliomas in patients undergoing adjuvant therapy.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Cell Transformation, Neoplastic; Chemoradiotherapy, A | 2017 |
Malignant transformation of low-grade gliomas in patients undergoing adjuvant therapy.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Cell Transformation, Neoplastic; Chemoradiotherapy, A | 2017 |
Malignant transformation of low-grade gliomas in patients undergoing adjuvant therapy.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Cell Transformation, Neoplastic; Chemoradiotherapy, A | 2017 |
Fluoxetine synergizes with temozolomide to induce the CHOP-dependent endoplasmic reticulum stress-related apoptosis pathway in glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Prolif | 2016 |
Fluoxetine synergizes with temozolomide to induce the CHOP-dependent endoplasmic reticulum stress-related apoptosis pathway in glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Prolif | 2016 |
Fluoxetine synergizes with temozolomide to induce the CHOP-dependent endoplasmic reticulum stress-related apoptosis pathway in glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Prolif | 2016 |
Fluoxetine synergizes with temozolomide to induce the CHOP-dependent endoplasmic reticulum stress-related apoptosis pathway in glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Prolif | 2016 |
Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy.
Topics: Aniline Compounds; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Eukaryotic | 2016 |
Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy.
Topics: Aniline Compounds; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Eukaryotic | 2016 |
Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy.
Topics: Aniline Compounds; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Eukaryotic | 2016 |
Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy.
Topics: Aniline Compounds; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Eukaryotic | 2016 |
Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; C | 2016 |
Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; C | 2016 |
Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; C | 2016 |
Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; C | 2016 |
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2016 |
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2016 |
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2016 |
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2016 |
Temozolomide induces the expression of the glioma Big Potassium (gBK) ion channel, while inhibiting fascin-1 expression: possible targets for glioma therapy.
Topics: Antineoplastic Agents, Alkylating; Carrier Proteins; Cell Line, Tumor; Cell Movement; Dacarbazine; G | 2016 |
Temozolomide induces the expression of the glioma Big Potassium (gBK) ion channel, while inhibiting fascin-1 expression: possible targets for glioma therapy.
Topics: Antineoplastic Agents, Alkylating; Carrier Proteins; Cell Line, Tumor; Cell Movement; Dacarbazine; G | 2016 |
Temozolomide induces the expression of the glioma Big Potassium (gBK) ion channel, while inhibiting fascin-1 expression: possible targets for glioma therapy.
Topics: Antineoplastic Agents, Alkylating; Carrier Proteins; Cell Line, Tumor; Cell Movement; Dacarbazine; G | 2016 |
Temozolomide induces the expression of the glioma Big Potassium (gBK) ion channel, while inhibiting fascin-1 expression: possible targets for glioma therapy.
Topics: Antineoplastic Agents, Alkylating; Carrier Proteins; Cell Line, Tumor; Cell Movement; Dacarbazine; G | 2016 |
miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectely.
Topics: Alkylating Agents; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Repai | 2016 |
miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectely.
Topics: Alkylating Agents; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Repai | 2016 |
miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectely.
Topics: Alkylating Agents; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Repai | 2016 |
miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectely.
Topics: Alkylating Agents; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Repai | 2016 |
The effects of sequential treatments on hippocampal volumes in malignant glioma patients.
Topics: Adult; Aged; Antineoplastic Agents; Atrophy; Bevacizumab; Brain Neoplasms; Dacarbazine; Female; Glio | 2016 |
The effects of sequential treatments on hippocampal volumes in malignant glioma patients.
Topics: Adult; Aged; Antineoplastic Agents; Atrophy; Bevacizumab; Brain Neoplasms; Dacarbazine; Female; Glio | 2016 |
The effects of sequential treatments on hippocampal volumes in malignant glioma patients.
Topics: Adult; Aged; Antineoplastic Agents; Atrophy; Bevacizumab; Brain Neoplasms; Dacarbazine; Female; Glio | 2016 |
The effects of sequential treatments on hippocampal volumes in malignant glioma patients.
Topics: Adult; Aged; Antineoplastic Agents; Atrophy; Bevacizumab; Brain Neoplasms; Dacarbazine; Female; Glio | 2016 |
Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2016 |
Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2016 |
Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2016 |
Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2016 |
Akt and β-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; beta Catenin; Cell Line, Tu | 2016 |
Akt and β-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; beta Catenin; Cell Line, Tu | 2016 |
Akt and β-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; beta Catenin; Cell Line, Tu | 2016 |
Akt and β-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; beta Catenin; Cell Line, Tu | 2016 |
RLIP76 Depletion Enhances Autophagic Flux in U251 Cells.
Topics: Apoptosis; ATP-Binding Cassette Transporters; Autophagosomes; Autophagy; Brain Neoplasms; Cell Line, | 2017 |
RLIP76 Depletion Enhances Autophagic Flux in U251 Cells.
Topics: Apoptosis; ATP-Binding Cassette Transporters; Autophagosomes; Autophagy; Brain Neoplasms; Cell Line, | 2017 |
RLIP76 Depletion Enhances Autophagic Flux in U251 Cells.
Topics: Apoptosis; ATP-Binding Cassette Transporters; Autophagosomes; Autophagy; Brain Neoplasms; Cell Line, | 2017 |
RLIP76 Depletion Enhances Autophagic Flux in U251 Cells.
Topics: Apoptosis; ATP-Binding Cassette Transporters; Autophagosomes; Autophagy; Brain Neoplasms; Cell Line, | 2017 |
Targeting hyperactivated DNA-PKcs by KU0060648 inhibits glioma progression and enhances temozolomide therapy via suppression of AKT signaling.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazin | 2016 |
Targeting hyperactivated DNA-PKcs by KU0060648 inhibits glioma progression and enhances temozolomide therapy via suppression of AKT signaling.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazin | 2016 |
Targeting hyperactivated DNA-PKcs by KU0060648 inhibits glioma progression and enhances temozolomide therapy via suppression of AKT signaling.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazin | 2016 |
Targeting hyperactivated DNA-PKcs by KU0060648 inhibits glioma progression and enhances temozolomide therapy via suppression of AKT signaling.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazin | 2016 |
Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biphenyl Compounds; Brain Neoplasms; Cell Line, Tumor; | 2016 |
Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biphenyl Compounds; Brain Neoplasms; Cell Line, Tumor; | 2016 |
Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biphenyl Compounds; Brain Neoplasms; Cell Line, Tumor; | 2016 |
Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biphenyl Compounds; Brain Neoplasms; Cell Line, Tumor; | 2016 |
GSK621 Targets Glioma Cells via Activating AMP-Activated Protein Kinase Signalings.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; | 2016 |
GSK621 Targets Glioma Cells via Activating AMP-Activated Protein Kinase Signalings.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; | 2016 |
GSK621 Targets Glioma Cells via Activating AMP-Activated Protein Kinase Signalings.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; | 2016 |
GSK621 Targets Glioma Cells via Activating AMP-Activated Protein Kinase Signalings.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; | 2016 |
Molecular dissection of the valproic acid effects on glioma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatin; Dacarbazine; Decision Support Syst | 2016 |
Molecular dissection of the valproic acid effects on glioma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatin; Dacarbazine; Decision Support Syst | 2016 |
Molecular dissection of the valproic acid effects on glioma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatin; Dacarbazine; Decision Support Syst | 2016 |
Molecular dissection of the valproic acid effects on glioma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatin; Dacarbazine; Decision Support Syst | 2016 |
Reversibility of glioma stem cells' phenotypes explains their complex in vitro and in vivo behavior: Discovery of a novel neurosphere-specific enzyme, cGMP-dependent protein kinase 1, using the genomic landscape of human glioma stem cells as a discovery t
Topics: Animals; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prolif | 2016 |
Reversibility of glioma stem cells' phenotypes explains their complex in vitro and in vivo behavior: Discovery of a novel neurosphere-specific enzyme, cGMP-dependent protein kinase 1, using the genomic landscape of human glioma stem cells as a discovery t
Topics: Animals; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prolif | 2016 |
Reversibility of glioma stem cells' phenotypes explains their complex in vitro and in vivo behavior: Discovery of a novel neurosphere-specific enzyme, cGMP-dependent protein kinase 1, using the genomic landscape of human glioma stem cells as a discovery t
Topics: Animals; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prolif | 2016 |
Reversibility of glioma stem cells' phenotypes explains their complex in vitro and in vivo behavior: Discovery of a novel neurosphere-specific enzyme, cGMP-dependent protein kinase 1, using the genomic landscape of human glioma stem cells as a discovery t
Topics: Animals; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prolif | 2016 |
Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chin | 2016 |
Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chin | 2016 |
Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chin | 2016 |
Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chin | 2016 |
Stem cell markers in glioma progression and recurrence.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Differentiation; Dacarbazine; Disease Pro | 2016 |
Stem cell markers in glioma progression and recurrence.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Differentiation; Dacarbazine; Disease Pro | 2016 |
Stem cell markers in glioma progression and recurrence.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Differentiation; Dacarbazine; Disease Pro | 2016 |
Stem cell markers in glioma progression and recurrence.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Differentiation; Dacarbazine; Disease Pro | 2016 |
Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis.
Topics: Amino Acid Transport System y+; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Astrocytes; A | 2016 |
Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis.
Topics: Amino Acid Transport System y+; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Astrocytes; A | 2016 |
Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis.
Topics: Amino Acid Transport System y+; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Astrocytes; A | 2016 |
Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis.
Topics: Amino Acid Transport System y+; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Astrocytes; A | 2016 |
Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Brain Neoplasms; | 2016 |
Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Brain Neoplasms; | 2016 |
Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Brain Neoplasms; | 2016 |
Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Brain Neoplasms; | 2016 |
Combination of lentivirus-mediated silencing of PPM1D and temozolomide chemotherapy eradicates malignant glioma through cell apoptosis and cell cycle arrest.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Class Ia Phosphatidylinositol 3-Kinase; Combine | 2016 |
Combination of lentivirus-mediated silencing of PPM1D and temozolomide chemotherapy eradicates malignant glioma through cell apoptosis and cell cycle arrest.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Class Ia Phosphatidylinositol 3-Kinase; Combine | 2016 |
Combination of lentivirus-mediated silencing of PPM1D and temozolomide chemotherapy eradicates malignant glioma through cell apoptosis and cell cycle arrest.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Class Ia Phosphatidylinositol 3-Kinase; Combine | 2016 |
Combination of lentivirus-mediated silencing of PPM1D and temozolomide chemotherapy eradicates malignant glioma through cell apoptosis and cell cycle arrest.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Class Ia Phosphatidylinositol 3-Kinase; Combine | 2016 |
Highlights in Central Nervous System Tumors.
Topics: Aged; Aged, 80 and over; Central Nervous System Neoplasms; Clinical Trials as Topic; Combined Modali | 2016 |
Highlights in Central Nervous System Tumors.
Topics: Aged; Aged, 80 and over; Central Nervous System Neoplasms; Clinical Trials as Topic; Combined Modali | 2016 |
Highlights in Central Nervous System Tumors.
Topics: Aged; Aged, 80 and over; Central Nervous System Neoplasms; Clinical Trials as Topic; Combined Modali | 2016 |
Highlights in Central Nervous System Tumors.
Topics: Aged; Aged, 80 and over; Central Nervous System Neoplasms; Clinical Trials as Topic; Combined Modali | 2016 |
Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference?
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member | 2017 |
Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference?
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member | 2017 |
Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference?
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member | 2017 |
Targeting Gliomas: Can a New Alkylating Hybrid Compound Make a Difference?
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member | 2017 |
Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Brain Neoplasms; Dacarbazin | 2016 |
Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Brain Neoplasms; Dacarbazin | 2016 |
Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Brain Neoplasms; Dacarbazin | 2016 |
Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Brain Neoplasms; Dacarbazin | 2016 |
FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Depsipeptide | 2016 |
FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Depsipeptide | 2016 |
FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Depsipeptide | 2016 |
FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Depsipeptide | 2016 |
Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; F | 2016 |
Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; F | 2016 |
Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; F | 2016 |
Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; F | 2016 |
Temozolomide low-dose chemotherapy in newly diagnosed low-grade gliomas: activity, safety, and long-term follow-up.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Dacarbazine; Disease-Free Survival; DNA | 2017 |
Temozolomide low-dose chemotherapy in newly diagnosed low-grade gliomas: activity, safety, and long-term follow-up.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Dacarbazine; Disease-Free Survival; DNA | 2017 |
Temozolomide low-dose chemotherapy in newly diagnosed low-grade gliomas: activity, safety, and long-term follow-up.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Dacarbazine; Disease-Free Survival; DNA | 2017 |
Temozolomide low-dose chemotherapy in newly diagnosed low-grade gliomas: activity, safety, and long-term follow-up.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Dacarbazine; Disease-Free Survival; DNA | 2017 |
3D bioprinted glioma stem cells for brain tumor model and applications of drug susceptibility.
Topics: Alginates; Antineoplastic Agents, Alkylating; Bioprinting; Brain Neoplasms; Cell Line, Tumor; Cell P | 2016 |
3D bioprinted glioma stem cells for brain tumor model and applications of drug susceptibility.
Topics: Alginates; Antineoplastic Agents, Alkylating; Bioprinting; Brain Neoplasms; Cell Line, Tumor; Cell P | 2016 |
3D bioprinted glioma stem cells for brain tumor model and applications of drug susceptibility.
Topics: Alginates; Antineoplastic Agents, Alkylating; Bioprinting; Brain Neoplasms; Cell Line, Tumor; Cell P | 2016 |
3D bioprinted glioma stem cells for brain tumor model and applications of drug susceptibility.
Topics: Alginates; Antineoplastic Agents, Alkylating; Bioprinting; Brain Neoplasms; Cell Line, Tumor; Cell P | 2016 |
A Novel Computer-Assisted Approach to evaluate Multicellular Tumor Spheroid Invasion Assay.
Topics: Algorithms; Animals; Computer Simulation; Dacarbazine; Enzyme Inhibitors; Glioblastoma; Glioma; High | 2016 |
A Novel Computer-Assisted Approach to evaluate Multicellular Tumor Spheroid Invasion Assay.
Topics: Algorithms; Animals; Computer Simulation; Dacarbazine; Enzyme Inhibitors; Glioblastoma; Glioma; High | 2016 |
A Novel Computer-Assisted Approach to evaluate Multicellular Tumor Spheroid Invasion Assay.
Topics: Algorithms; Animals; Computer Simulation; Dacarbazine; Enzyme Inhibitors; Glioblastoma; Glioma; High | 2016 |
A Novel Computer-Assisted Approach to evaluate Multicellular Tumor Spheroid Invasion Assay.
Topics: Algorithms; Animals; Computer Simulation; Dacarbazine; Enzyme Inhibitors; Glioblastoma; Glioma; High | 2016 |
Deferiprone Enhances Temozolomide Cytotoxicity in Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Surv | 2016 |
Deferiprone Enhances Temozolomide Cytotoxicity in Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Surv | 2016 |
Deferiprone Enhances Temozolomide Cytotoxicity in Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Surv | 2016 |
Deferiprone Enhances Temozolomide Cytotoxicity in Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Surv | 2016 |
PPIC, EMP3 and CHI3L1 Are Novel Prognostic Markers for High Grade Glioma.
Topics: Adult; Age Factors; Aged; Biomarkers, Tumor; Chitinase-3-Like Protein 1; Cyclophilin C; Dacarbazine; | 2016 |
PPIC, EMP3 and CHI3L1 Are Novel Prognostic Markers for High Grade Glioma.
Topics: Adult; Age Factors; Aged; Biomarkers, Tumor; Chitinase-3-Like Protein 1; Cyclophilin C; Dacarbazine; | 2016 |
PPIC, EMP3 and CHI3L1 Are Novel Prognostic Markers for High Grade Glioma.
Topics: Adult; Age Factors; Aged; Biomarkers, Tumor; Chitinase-3-Like Protein 1; Cyclophilin C; Dacarbazine; | 2016 |
PPIC, EMP3 and CHI3L1 Are Novel Prognostic Markers for High Grade Glioma.
Topics: Adult; Age Factors; Aged; Biomarkers, Tumor; Chitinase-3-Like Protein 1; Cyclophilin C; Dacarbazine; | 2016 |
Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement.
Topics: Aged; Antineoplastic Agents; Brain; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; | 2016 |
Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement.
Topics: Aged; Antineoplastic Agents; Brain; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; | 2016 |
Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement.
Topics: Aged; Antineoplastic Agents; Brain; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; | 2016 |
Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement.
Topics: Aged; Antineoplastic Agents; Brain; Combined Modality Therapy; Dacarbazine; Female; Glioma; Humans; | 2016 |
Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2017 |
Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2017 |
Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2017 |
Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2017 |
Dec1 expression predicts prognosis and the response to temozolomide chemotherapy in patients with glioma.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Basic Helix-Loop-Helix Transcription Factor | 2016 |
Dec1 expression predicts prognosis and the response to temozolomide chemotherapy in patients with glioma.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Basic Helix-Loop-Helix Transcription Factor | 2016 |
Dec1 expression predicts prognosis and the response to temozolomide chemotherapy in patients with glioma.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Basic Helix-Loop-Helix Transcription Factor | 2016 |
Dec1 expression predicts prognosis and the response to temozolomide chemotherapy in patients with glioma.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Basic Helix-Loop-Helix Transcription Factor | 2016 |
Temozolomide inhibits cellular growth and motility via targeting ERK signaling in glioma C6 cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Transformed; Cell Line, Tumo | 2016 |
Temozolomide inhibits cellular growth and motility via targeting ERK signaling in glioma C6 cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Transformed; Cell Line, Tumo | 2016 |
Temozolomide inhibits cellular growth and motility via targeting ERK signaling in glioma C6 cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Transformed; Cell Line, Tumo | 2016 |
Temozolomide inhibits cellular growth and motility via targeting ERK signaling in glioma C6 cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Transformed; Cell Line, Tumo | 2016 |
Prognostic relevance of miRNA-155 methylation in anaplastic glioma.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2016 |
Prognostic relevance of miRNA-155 methylation in anaplastic glioma.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2016 |
Prognostic relevance of miRNA-155 methylation in anaplastic glioma.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2016 |
Prognostic relevance of miRNA-155 methylation in anaplastic glioma.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2016 |
Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemor | 2017 |
Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemor | 2017 |
Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemor | 2017 |
Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemor | 2017 |
Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain | 2017 |
Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain | 2017 |
Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain | 2017 |
Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain | 2017 |
The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; Glioma; Humans; Insulin- | 2016 |
The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; Glioma; Humans; Insulin- | 2016 |
The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; Glioma; Humans; Insulin- | 2016 |
The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; Glioma; Humans; Insulin- | 2016 |
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Ce | 2016 |
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Ce | 2016 |
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Ce | 2016 |
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Ce | 2016 |
MiR-433-3p suppresses cell growth and enhances chemosensitivity by targeting CREB in human glioma.
Topics: 3' Untranslated Regions; Adult; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation | 2017 |
MiR-433-3p suppresses cell growth and enhances chemosensitivity by targeting CREB in human glioma.
Topics: 3' Untranslated Regions; Adult; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation | 2017 |
MiR-433-3p suppresses cell growth and enhances chemosensitivity by targeting CREB in human glioma.
Topics: 3' Untranslated Regions; Adult; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation | 2017 |
MiR-433-3p suppresses cell growth and enhances chemosensitivity by targeting CREB in human glioma.
Topics: 3' Untranslated Regions; Adult; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation | 2017 |
Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dise | 2017 |
Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dise | 2017 |
Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dise | 2017 |
Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dise | 2017 |
Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment.
Topics: Animals; Antibodies; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lewis Lung; Dacarbazine; Dr | 2016 |
Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment.
Topics: Animals; Antibodies; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lewis Lung; Dacarbazine; Dr | 2016 |
Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment.
Topics: Animals; Antibodies; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lewis Lung; Dacarbazine; Dr | 2016 |
Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment.
Topics: Animals; Antibodies; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lewis Lung; Dacarbazine; Dr | 2016 |
The CHAC1-inhibited Notch3 pathway is involved in temozolomide-induced glioma cytotoxicity.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Calcium; Caspase 3; Caspase 9; Cell Line, Tumor; Cell | 2017 |
The CHAC1-inhibited Notch3 pathway is involved in temozolomide-induced glioma cytotoxicity.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Calcium; Caspase 3; Caspase 9; Cell Line, Tumor; Cell | 2017 |
The CHAC1-inhibited Notch3 pathway is involved in temozolomide-induced glioma cytotoxicity.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Calcium; Caspase 3; Caspase 9; Cell Line, Tumor; Cell | 2017 |
The CHAC1-inhibited Notch3 pathway is involved in temozolomide-induced glioma cytotoxicity.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Calcium; Caspase 3; Caspase 9; Cell Line, Tumor; Cell | 2017 |
Characteristics of sulfasalazine-induced cytotoxicity in C6 rat glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioma; Glu | 2017 |
Characteristics of sulfasalazine-induced cytotoxicity in C6 rat glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioma; Glu | 2017 |
Characteristics of sulfasalazine-induced cytotoxicity in C6 rat glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioma; Glu | 2017 |
Characteristics of sulfasalazine-induced cytotoxicity in C6 rat glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioma; Glu | 2017 |
Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2017 |
Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2017 |
Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2017 |
Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2017 |
LncRNA CASC2 Interacts With miR-181a to Modulate Glioma Growth and Resistance to TMZ Through PTEN Pathway.
Topics: Adult; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Female; Glioma; Humans; | 2017 |
LncRNA CASC2 Interacts With miR-181a to Modulate Glioma Growth and Resistance to TMZ Through PTEN Pathway.
Topics: Adult; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Female; Glioma; Humans; | 2017 |
LncRNA CASC2 Interacts With miR-181a to Modulate Glioma Growth and Resistance to TMZ Through PTEN Pathway.
Topics: Adult; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Female; Glioma; Humans; | 2017 |
LncRNA CASC2 Interacts With miR-181a to Modulate Glioma Growth and Resistance to TMZ Through PTEN Pathway.
Topics: Adult; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Female; Glioma; Humans; | 2017 |
Overexpression of ILK promotes temozolomide resistance in glioma cells.
Topics: Antineoplastic Agents, Alkylating; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3; Cell Line | 2017 |
Overexpression of ILK promotes temozolomide resistance in glioma cells.
Topics: Antineoplastic Agents, Alkylating; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3; Cell Line | 2017 |
Overexpression of ILK promotes temozolomide resistance in glioma cells.
Topics: Antineoplastic Agents, Alkylating; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3; Cell Line | 2017 |
Overexpression of ILK promotes temozolomide resistance in glioma cells.
Topics: Antineoplastic Agents, Alkylating; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3; Cell Line | 2017 |
DNA-Targeted Inhibition of MGMT.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; DNA; DNA Modification Me | 2017 |
DNA-Targeted Inhibition of MGMT.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; DNA; DNA Modification Me | 2017 |
DNA-Targeted Inhibition of MGMT.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; DNA; DNA Modification Me | 2017 |
DNA-Targeted Inhibition of MGMT.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; DNA; DNA Modification Me | 2017 |
PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas.
Topics: Cell Cycle Proteins; Dacarbazine; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Polo-Like Kina | 2017 |
PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas.
Topics: Cell Cycle Proteins; Dacarbazine; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Polo-Like Kina | 2017 |
PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas.
Topics: Cell Cycle Proteins; Dacarbazine; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Polo-Like Kina | 2017 |
PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas.
Topics: Cell Cycle Proteins; Dacarbazine; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Polo-Like Kina | 2017 |
Atorvastatin Promotes Cytotoxicity and Reduces Migration and Proliferation of Human A172 Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Atorvastatin; Autophagy; Brain Neoplasms; Cell Line, T | 2018 |
Atorvastatin Promotes Cytotoxicity and Reduces Migration and Proliferation of Human A172 Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Atorvastatin; Autophagy; Brain Neoplasms; Cell Line, T | 2018 |
Atorvastatin Promotes Cytotoxicity and Reduces Migration and Proliferation of Human A172 Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Atorvastatin; Autophagy; Brain Neoplasms; Cell Line, T | 2018 |
Atorvastatin Promotes Cytotoxicity and Reduces Migration and Proliferation of Human A172 Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Atorvastatin; Autophagy; Brain Neoplasms; Cell Line, T | 2018 |
FoxM1-mediated RFC5 expression promotes temozolomide resistance.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Forkhead Box | 2017 |
FoxM1-mediated RFC5 expression promotes temozolomide resistance.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Forkhead Box | 2017 |
FoxM1-mediated RFC5 expression promotes temozolomide resistance.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Forkhead Box | 2017 |
FoxM1-mediated RFC5 expression promotes temozolomide resistance.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Forkhead Box | 2017 |
Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Glioma; Humans; Isocitrate Dehydrogenase | 2017 |
Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Glioma; Humans; Isocitrate Dehydrogenase | 2017 |
Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Glioma; Humans; Isocitrate Dehydrogenase | 2017 |
Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Glioma; Humans; Isocitrate Dehydrogenase | 2017 |
A mathematical model of low grade gliomas treated with temozolomide and its therapeutical implications.
Topics: Brain Neoplasms; Cell Proliferation; Dacarbazine; Disease Progression; Female; Glioma; Humans; Male; | 2017 |
A mathematical model of low grade gliomas treated with temozolomide and its therapeutical implications.
Topics: Brain Neoplasms; Cell Proliferation; Dacarbazine; Disease Progression; Female; Glioma; Humans; Male; | 2017 |
A mathematical model of low grade gliomas treated with temozolomide and its therapeutical implications.
Topics: Brain Neoplasms; Cell Proliferation; Dacarbazine; Disease Progression; Female; Glioma; Humans; Male; | 2017 |
A mathematical model of low grade gliomas treated with temozolomide and its therapeutical implications.
Topics: Brain Neoplasms; Cell Proliferation; Dacarbazine; Disease Progression; Female; Glioma; Humans; Male; | 2017 |
Radicol, a Novel Trinorguaiane-Type Sesquiterpene, Induces Temozolomide-Resistant Glioma Cell Apoptosis via ER Stress and Akt/mTOR Pathway Blockade.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; Dictamnus; Drug Resistance | 2017 |
Radicol, a Novel Trinorguaiane-Type Sesquiterpene, Induces Temozolomide-Resistant Glioma Cell Apoptosis via ER Stress and Akt/mTOR Pathway Blockade.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; Dictamnus; Drug Resistance | 2017 |
Radicol, a Novel Trinorguaiane-Type Sesquiterpene, Induces Temozolomide-Resistant Glioma Cell Apoptosis via ER Stress and Akt/mTOR Pathway Blockade.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; Dictamnus; Drug Resistance | 2017 |
Radicol, a Novel Trinorguaiane-Type Sesquiterpene, Induces Temozolomide-Resistant Glioma Cell Apoptosis via ER Stress and Akt/mTOR Pathway Blockade.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; Dictamnus; Drug Resistance | 2017 |
Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line; Dacarbazine; Delayed-Action Preparations | 2017 |
Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line; Dacarbazine; Delayed-Action Preparations | 2017 |
Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line; Dacarbazine; Delayed-Action Preparations | 2017 |
Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line; Dacarbazine; Delayed-Action Preparations | 2017 |
Predictive models for diffuse low-grade glioma patients under chemotherapy.
Topics: Brain Neoplasms; Dacarbazine; Databases, Factual; Glioma; Humans; Linear Models; Magnetic Resonance | 2016 |
Predictive models for diffuse low-grade glioma patients under chemotherapy.
Topics: Brain Neoplasms; Dacarbazine; Databases, Factual; Glioma; Humans; Linear Models; Magnetic Resonance | 2016 |
Predictive models for diffuse low-grade glioma patients under chemotherapy.
Topics: Brain Neoplasms; Dacarbazine; Databases, Factual; Glioma; Humans; Linear Models; Magnetic Resonance | 2016 |
Predictive models for diffuse low-grade glioma patients under chemotherapy.
Topics: Brain Neoplasms; Dacarbazine; Databases, Factual; Glioma; Humans; Linear Models; Magnetic Resonance | 2016 |
β-Elemene Selectively Inhibits the Proliferation of Glioma Stem-Like Cells Through the Downregulation of Notch1.
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Down-Regulati | 2017 |
β-Elemene Selectively Inhibits the Proliferation of Glioma Stem-Like Cells Through the Downregulation of Notch1.
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Down-Regulati | 2017 |
β-Elemene Selectively Inhibits the Proliferation of Glioma Stem-Like Cells Through the Downregulation of Notch1.
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Down-Regulati | 2017 |
β-Elemene Selectively Inhibits the Proliferation of Glioma Stem-Like Cells Through the Downregulation of Notch1.
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Down-Regulati | 2017 |
Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Chemorad | 2018 |
Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Chemorad | 2018 |
Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Chemorad | 2018 |
Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Chemorad | 2018 |
Management of malignant glioma--quo vadis?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Hum | 2008 |
Management of malignant glioma--quo vadis?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Hum | 2008 |
Management of malignant glioma--quo vadis?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Hum | 2008 |
Management of malignant glioma--quo vadis?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Hum | 2008 |
Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2008 |
Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2008 |
Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2008 |
Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2008 |
A multivariate analysis of patients with glioma: a treatment outcome and prognostic factor for survival.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Child; Child, Prescho | 2008 |
A multivariate analysis of patients with glioma: a treatment outcome and prognostic factor for survival.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Child; Child, Prescho | 2008 |
A multivariate analysis of patients with glioma: a treatment outcome and prognostic factor for survival.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Child; Child, Prescho | 2008 |
A multivariate analysis of patients with glioma: a treatment outcome and prognostic factor for survival.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Child; Child, Prescho | 2008 |
Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-time reverse-transcription polymerase chain-reaction.
Topics: Adult; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Evidence-Based Medicine; Female; Gli | 2008 |
Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-time reverse-transcription polymerase chain-reaction.
Topics: Adult; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Evidence-Based Medicine; Female; Gli | 2008 |
Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-time reverse-transcription polymerase chain-reaction.
Topics: Adult; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Evidence-Based Medicine; Female; Gli | 2008 |
Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-time reverse-transcription polymerase chain-reaction.
Topics: Adult; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Evidence-Based Medicine; Female; Gli | 2008 |
In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytes; Carb | 2008 |
In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytes; Carb | 2008 |
In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytes; Carb | 2008 |
In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytes; Carb | 2008 |
Temozolomide for recurrent low-grade spinal cord gliomas in adults.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Drug Administration Sc | 2008 |
Temozolomide for recurrent low-grade spinal cord gliomas in adults.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Drug Administration Sc | 2008 |
Temozolomide for recurrent low-grade spinal cord gliomas in adults.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Drug Administration Sc | 2008 |
Temozolomide for recurrent low-grade spinal cord gliomas in adults.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Drug Administration Sc | 2008 |
[Current topics of treatment for glioma and mechanism of drug resistance].
Topics: Animals; Antineoplastic Agents, Alkylating; Chromosome Deletion; Dacarbazine; Drug Resistance, Neopl | 2008 |
[Current topics of treatment for glioma and mechanism of drug resistance].
Topics: Animals; Antineoplastic Agents, Alkylating; Chromosome Deletion; Dacarbazine; Drug Resistance, Neopl | 2008 |
[Current topics of treatment for glioma and mechanism of drug resistance].
Topics: Animals; Antineoplastic Agents, Alkylating; Chromosome Deletion; Dacarbazine; Drug Resistance, Neopl | 2008 |
[Current topics of treatment for glioma and mechanism of drug resistance].
Topics: Animals; Antineoplastic Agents, Alkylating; Chromosome Deletion; Dacarbazine; Drug Resistance, Neopl | 2008 |
Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplas | 2008 |
Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplas | 2008 |
Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplas | 2008 |
Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplas | 2008 |
Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Benzoquinones; Blotting, Western; Brain Neoplasms; Cell | 2009 |
Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Benzoquinones; Blotting, Western; Brain Neoplasms; Cell | 2009 |
Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Benzoquinones; Blotting, Western; Brain Neoplasms; Cell | 2009 |
Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Benzoquinones; Blotting, Western; Brain Neoplasms; Cell | 2009 |
Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2008 |
Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2008 |
Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2008 |
Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2008 |
Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Carmustine; Cell Line, Tumor; Dacarbazi | 2008 |
Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Carmustine; Cell Line, Tumor; Dacarbazi | 2008 |
Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Carmustine; Cell Line, Tumor; Dacarbazi | 2008 |
Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Carmustine; Cell Line, Tumor; Dacarbazi | 2008 |
Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2008 |
Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2008 |
Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2008 |
Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2008 |
Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2008 |
Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2008 |
Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2008 |
Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2008 |
Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2008 |
Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2008 |
Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2008 |
Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2008 |
Non-Hodgkin's lymphoma in patients with glioma treated with temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbaz | 2008 |
Non-Hodgkin's lymphoma in patients with glioma treated with temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbaz | 2008 |
Non-Hodgkin's lymphoma in patients with glioma treated with temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbaz | 2008 |
Non-Hodgkin's lymphoma in patients with glioma treated with temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbaz | 2008 |
The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Nucleus; Cell Proliferation; Cell Surviva | 2009 |
The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Nucleus; Cell Proliferation; Cell Surviva | 2009 |
The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Nucleus; Cell Proliferation; Cell Surviva | 2009 |
The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Nucleus; Cell Proliferation; Cell Surviva | 2009 |
Bone marrow transplantation for severe aplastic anemia secondary to temozolomide.
Topics: Adolescent; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Dacarb | 2009 |
Bone marrow transplantation for severe aplastic anemia secondary to temozolomide.
Topics: Adolescent; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Dacarb | 2009 |
Bone marrow transplantation for severe aplastic anemia secondary to temozolomide.
Topics: Adolescent; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Dacarb | 2009 |
Bone marrow transplantation for severe aplastic anemia secondary to temozolomide.
Topics: Adolescent; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Dacarb | 2009 |
Silencing DNA methyltransferase (DNMT) enhances glioma chemosensitivity.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Surviva | 2008 |
Silencing DNA methyltransferase (DNMT) enhances glioma chemosensitivity.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Surviva | 2008 |
Silencing DNA methyltransferase (DNMT) enhances glioma chemosensitivity.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Surviva | 2008 |
Silencing DNA methyltransferase (DNMT) enhances glioma chemosensitivity.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Surviva | 2008 |
Proapoptotic receptor agonists, targeted radionuclide therapy, and the treatment of central nervous system malignancies: in regard to Fiveash et Al. (Int J Radiat Oncol Biol Phys 2008;71:507-516).
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell | 2008 |
Proapoptotic receptor agonists, targeted radionuclide therapy, and the treatment of central nervous system malignancies: in regard to Fiveash et Al. (Int J Radiat Oncol Biol Phys 2008;71:507-516).
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell | 2008 |
Proapoptotic receptor agonists, targeted radionuclide therapy, and the treatment of central nervous system malignancies: in regard to Fiveash et Al. (Int J Radiat Oncol Biol Phys 2008;71:507-516).
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell | 2008 |
Proapoptotic receptor agonists, targeted radionuclide therapy, and the treatment of central nervous system malignancies: in regard to Fiveash et Al. (Int J Radiat Oncol Biol Phys 2008;71:507-516).
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell | 2008 |
Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Interact | 2009 |
Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Interact | 2009 |
Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Interact | 2009 |
Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Interact | 2009 |
Characterization of a side population of astrocytoma cells in response to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; ATP Binding Cassette Transporter, Subfamily | 2008 |
Characterization of a side population of astrocytoma cells in response to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; ATP Binding Cassette Transporter, Subfamily | 2008 |
Characterization of a side population of astrocytoma cells in response to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; ATP Binding Cassette Transporter, Subfamily | 2008 |
Characterization of a side population of astrocytoma cells in response to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; ATP Binding Cassette Transporter, Subfamily | 2008 |
ACNU-based chemotherapy for recurrent glioma in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2009 |
ACNU-based chemotherapy for recurrent glioma in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2009 |
ACNU-based chemotherapy for recurrent glioma in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2009 |
ACNU-based chemotherapy for recurrent glioma in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2009 |
Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Dependovirus; Genetic Therapy; Gen | 2008 |
Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Dependovirus; Genetic Therapy; Gen | 2008 |
Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Dependovirus; Genetic Therapy; Gen | 2008 |
Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Dependovirus; Genetic Therapy; Gen | 2008 |
Erythropoietin augments survival of glioma cells after radiation and temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell M | 2008 |
Erythropoietin augments survival of glioma cells after radiation and temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell M | 2008 |
Erythropoietin augments survival of glioma cells after radiation and temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell M | 2008 |
Erythropoietin augments survival of glioma cells after radiation and temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell M | 2008 |
Radiotherapy followed by adjuvant temozolomide treatment of malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; | 2008 |
Radiotherapy followed by adjuvant temozolomide treatment of malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; | 2008 |
Radiotherapy followed by adjuvant temozolomide treatment of malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; | 2008 |
Radiotherapy followed by adjuvant temozolomide treatment of malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Dacarbazine; Female; Follow-Up Studies; | 2008 |
Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Stud | 2009 |
Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Stud | 2009 |
Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Stud | 2009 |
Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Stud | 2009 |
Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells.
Topics: Acetylation; Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Line, Tumor; Cellular Se | 2009 |
Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells.
Topics: Acetylation; Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Line, Tumor; Cellular Se | 2009 |
Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells.
Topics: Acetylation; Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Line, Tumor; Cellular Se | 2009 |
Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells.
Topics: Acetylation; Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Line, Tumor; Cellular Se | 2009 |
A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carbon Radioisotope | 2009 |
A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carbon Radioisotope | 2009 |
A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carbon Radioisotope | 2009 |
A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carbon Radioisotope | 2009 |
High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2009 |
High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2009 |
High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2009 |
High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2009 |
Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2009 |
Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2009 |
Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2009 |
Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2009 |
Combined magnetic resonance and fluorescence imaging of the living mouse brain reveals glioma response to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioma; | 2009 |
Combined magnetic resonance and fluorescence imaging of the living mouse brain reveals glioma response to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioma; | 2009 |
Combined magnetic resonance and fluorescence imaging of the living mouse brain reveals glioma response to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioma; | 2009 |
Combined magnetic resonance and fluorescence imaging of the living mouse brain reveals glioma response to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioma; | 2009 |
Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Br | 2009 |
Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Br | 2009 |
Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Br | 2009 |
Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Br | 2009 |
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dasatinib; D | 2009 |
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dasatinib; D | 2009 |
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dasatinib; D | 2009 |
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dasatinib; D | 2009 |
Drugs targeting the mitochondrial pore act as cytotoxic and cytostatic agents in temozolomide-resistant glioma cells.
Topics: Acridine Orange; Betulinic Acid; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Cell Death; Cell Line, T | 2009 |
Drugs targeting the mitochondrial pore act as cytotoxic and cytostatic agents in temozolomide-resistant glioma cells.
Topics: Acridine Orange; Betulinic Acid; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Cell Death; Cell Line, T | 2009 |
Drugs targeting the mitochondrial pore act as cytotoxic and cytostatic agents in temozolomide-resistant glioma cells.
Topics: Acridine Orange; Betulinic Acid; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Cell Death; Cell Line, T | 2009 |
Drugs targeting the mitochondrial pore act as cytotoxic and cytostatic agents in temozolomide-resistant glioma cells.
Topics: Acridine Orange; Betulinic Acid; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Cell Death; Cell Line, T | 2009 |
Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; DN | 2009 |
Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; DN | 2009 |
Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; DN | 2009 |
Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; DN | 2009 |
Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.
Topics: Animals; Antineoplastic Agents, Alkylating; bcl-X Protein; Brain Neoplasms; Cell Adhesion; Cell Move | 2009 |
Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.
Topics: Animals; Antineoplastic Agents, Alkylating; bcl-X Protein; Brain Neoplasms; Cell Adhesion; Cell Move | 2009 |
Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.
Topics: Animals; Antineoplastic Agents, Alkylating; bcl-X Protein; Brain Neoplasms; Cell Adhesion; Cell Move | 2009 |
Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.
Topics: Animals; Antineoplastic Agents, Alkylating; bcl-X Protein; Brain Neoplasms; Cell Adhesion; Cell Move | 2009 |
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship | 2009 |
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship | 2009 |
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship | 2009 |
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relationship | 2009 |
Rechallenge with temozolomide in patients with recurrent gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cohort Studies; Dacarbazine; | 2009 |
Rechallenge with temozolomide in patients with recurrent gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cohort Studies; Dacarbazine; | 2009 |
Rechallenge with temozolomide in patients with recurrent gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cohort Studies; Dacarbazine; | 2009 |
Rechallenge with temozolomide in patients with recurrent gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cohort Studies; Dacarbazine; | 2009 |
Interferon-beta, MCNU, and conventional radiotherapy for pediatric patients with brainstem glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Carboplatin; Child | 2009 |
Interferon-beta, MCNU, and conventional radiotherapy for pediatric patients with brainstem glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Carboplatin; Child | 2009 |
Interferon-beta, MCNU, and conventional radiotherapy for pediatric patients with brainstem glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Carboplatin; Child | 2009 |
Interferon-beta, MCNU, and conventional radiotherapy for pediatric patients with brainstem glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Carboplatin; Child | 2009 |
The side story of stem-like glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily G, Member 2; | 2009 |
The side story of stem-like glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily G, Member 2; | 2009 |
The side story of stem-like glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily G, Member 2; | 2009 |
The side story of stem-like glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily G, Member 2; | 2009 |
PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, | 2009 |
PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, | 2009 |
PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, | 2009 |
PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, | 2009 |
Management of temozolomide toxicity by nurse practitioners in neuro-oncology.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; D | 2009 |
Management of temozolomide toxicity by nurse practitioners in neuro-oncology.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; D | 2009 |
Management of temozolomide toxicity by nurse practitioners in neuro-oncology.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; D | 2009 |
Management of temozolomide toxicity by nurse practitioners in neuro-oncology.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; D | 2009 |
Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cas | 2009 |
Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cas | 2009 |
Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cas | 2009 |
Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cas | 2009 |
Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Body Weight; Cell Division; Cell | 2009 |
Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Body Weight; Cell Division; Cell | 2009 |
Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Body Weight; Cell Division; Cell | 2009 |
Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Body Weight; Cell Division; Cell | 2009 |
Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain; Brain Neoplasms; Dacarbazi | 2009 |
Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain; Brain Neoplasms; Dacarbazi | 2009 |
Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain; Brain Neoplasms; Dacarbazi | 2009 |
Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain; Brain Neoplasms; Dacarbazi | 2009 |
Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection.
Topics: Animals; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain; Brain Neoplasms; Combine | 2009 |
Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection.
Topics: Animals; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain; Brain Neoplasms; Combine | 2009 |
Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection.
Topics: Animals; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain; Brain Neoplasms; Combine | 2009 |
Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection.
Topics: Animals; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain; Brain Neoplasms; Combine | 2009 |
CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Growth Pr | 2009 |
CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Growth Pr | 2009 |
CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Growth Pr | 2009 |
CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Growth Pr | 2009 |
[Research and therapeutic trials on gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Ther | 2009 |
[Research and therapeutic trials on gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Ther | 2009 |
[Research and therapeutic trials on gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Ther | 2009 |
[Research and therapeutic trials on gliomas].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Ther | 2009 |
Glioma-associated endothelial cells are chemoresistant to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Movement; Cell Prolife | 2009 |
Glioma-associated endothelial cells are chemoresistant to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Movement; Cell Prolife | 2009 |
Glioma-associated endothelial cells are chemoresistant to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Movement; Cell Prolife | 2009 |
Glioma-associated endothelial cells are chemoresistant to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Movement; Cell Prolife | 2009 |
IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Confounding F | 2009 |
IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Confounding F | 2009 |
IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Confounding F | 2009 |
IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Confounding F | 2009 |
Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Benzoquinones; Carmustine; Cell Cycle; Cell L | 2010 |
Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Benzoquinones; Carmustine; Cell Cycle; Cell L | 2010 |
Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Benzoquinones; Carmustine; Cell Cycle; Cell L | 2010 |
Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Benzoquinones; Carmustine; Cell Cycle; Cell L | 2010 |
Cancer cell death by design: apoptosis, autophagy and glioma virotherapy.
Topics: Adenoviridae; Apoptosis; Autophagy; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Oncolytic Virothe | 2009 |
Cancer cell death by design: apoptosis, autophagy and glioma virotherapy.
Topics: Adenoviridae; Apoptosis; Autophagy; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Oncolytic Virothe | 2009 |
Cancer cell death by design: apoptosis, autophagy and glioma virotherapy.
Topics: Adenoviridae; Apoptosis; Autophagy; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Oncolytic Virothe | 2009 |
Cancer cell death by design: apoptosis, autophagy and glioma virotherapy.
Topics: Adenoviridae; Apoptosis; Autophagy; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Oncolytic Virothe | 2009 |
Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell P | 2009 |
Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell P | 2009 |
Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell P | 2009 |
Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell P | 2009 |
Folate supplementation limits the aggressiveness of glioma via the remethylation of DNA repeats element and genes governing apoptosis and proliferation.
Topics: Aged; Apoptosis; Apoptosis Regulatory Proteins; Becaplermin; Cell Line, Tumor; Cell Proliferation; D | 2009 |
Folate supplementation limits the aggressiveness of glioma via the remethylation of DNA repeats element and genes governing apoptosis and proliferation.
Topics: Aged; Apoptosis; Apoptosis Regulatory Proteins; Becaplermin; Cell Line, Tumor; Cell Proliferation; D | 2009 |
Folate supplementation limits the aggressiveness of glioma via the remethylation of DNA repeats element and genes governing apoptosis and proliferation.
Topics: Aged; Apoptosis; Apoptosis Regulatory Proteins; Becaplermin; Cell Line, Tumor; Cell Proliferation; D | 2009 |
Folate supplementation limits the aggressiveness of glioma via the remethylation of DNA repeats element and genes governing apoptosis and proliferation.
Topics: Aged; Apoptosis; Apoptosis Regulatory Proteins; Becaplermin; Cell Line, Tumor; Cell Proliferation; D | 2009 |
Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.
Topics: Activating Transcription Factor 2; Anthracenes; Antineoplastic Agents, Alkylating; beta-Galactosidas | 2009 |
Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.
Topics: Activating Transcription Factor 2; Anthracenes; Antineoplastic Agents, Alkylating; beta-Galactosidas | 2009 |
Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.
Topics: Activating Transcription Factor 2; Anthracenes; Antineoplastic Agents, Alkylating; beta-Galactosidas | 2009 |
Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.
Topics: Activating Transcription Factor 2; Anthracenes; Antineoplastic Agents, Alkylating; beta-Galactosidas | 2009 |
The prognostic role of Beclin 1 protein expression in high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Biomarkers, T | 2009 |
The prognostic role of Beclin 1 protein expression in high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Biomarkers, T | 2009 |
The prognostic role of Beclin 1 protein expression in high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Biomarkers, T | 2009 |
The prognostic role of Beclin 1 protein expression in high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Biomarkers, T | 2009 |
Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Gli | 2009 |
Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Gli | 2009 |
Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Gli | 2009 |
Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Gli | 2009 |
[Central nervous system glioma. Multi-drug chemotherapy including temozolomide].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2009 |
[Central nervous system glioma. Multi-drug chemotherapy including temozolomide].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2009 |
[Central nervous system glioma. Multi-drug chemotherapy including temozolomide].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2009 |
[Central nervous system glioma. Multi-drug chemotherapy including temozolomide].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2009 |
A human brainstem glioma xenograft model enabled for bioluminescence imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Cell Line, Tumor; Dacarbazine; Dia | 2010 |
A human brainstem glioma xenograft model enabled for bioluminescence imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Cell Line, Tumor; Dacarbazine; Dia | 2010 |
A human brainstem glioma xenograft model enabled for bioluminescence imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Cell Line, Tumor; Dacarbazine; Dia | 2010 |
A human brainstem glioma xenograft model enabled for bioluminescence imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Cell Line, Tumor; Dacarbazine; Dia | 2010 |
[Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Azaciti | 2009 |
[Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Azaciti | 2009 |
[Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Azaciti | 2009 |
[Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Azaciti | 2009 |
Methionine restriction reduces the chemosensitivity of central nervous system tumour cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; Cerebellar Neop | 2009 |
Methionine restriction reduces the chemosensitivity of central nervous system tumour cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; Cerebellar Neop | 2009 |
Methionine restriction reduces the chemosensitivity of central nervous system tumour cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; Cerebellar Neop | 2009 |
Methionine restriction reduces the chemosensitivity of central nervous system tumour cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; Cerebellar Neop | 2009 |
Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopl | 2009 |
Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopl | 2009 |
Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopl | 2009 |
Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopl | 2009 |
Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Dacarbazi | 2010 |
Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Dacarbazi | 2010 |
Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Dacarbazi | 2010 |
Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Dacarbazi | 2010 |
Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocy | 2010 |
Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocy | 2010 |
Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocy | 2010 |
Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocy | 2010 |
Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2010 |
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2010 |
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2010 |
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2010 |
Comment on "Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma".
Topics: Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; Glioma; Humans; Opportun | 2010 |
Comment on "Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma".
Topics: Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; Glioma; Humans; Opportun | 2010 |
Comment on "Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma".
Topics: Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; Glioma; Humans; Opportun | 2010 |
Comment on "Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma".
Topics: Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; Glioma; Humans; Opportun | 2010 |
Temozolomide and MGMT forever?
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Modifica | 2010 |
Temozolomide and MGMT forever?
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Modifica | 2010 |
Temozolomide and MGMT forever?
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Modifica | 2010 |
Temozolomide and MGMT forever?
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Modifica | 2010 |
Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Models | 2010 |
Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Models | 2010 |
Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Models | 2010 |
Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Models | 2010 |
Can hsp90alpha-targeted siRNA combined with TMZ be a future therapy for glioma?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemotherapy, A | 2010 |
Can hsp90alpha-targeted siRNA combined with TMZ be a future therapy for glioma?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemotherapy, A | 2010 |
Can hsp90alpha-targeted siRNA combined with TMZ be a future therapy for glioma?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemotherapy, A | 2010 |
Can hsp90alpha-targeted siRNA combined with TMZ be a future therapy for glioma?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemotherapy, A | 2010 |
Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: experience at a single institution.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain | 2010 |
Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: experience at a single institution.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain | 2010 |
Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: experience at a single institution.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain | 2010 |
Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: experience at a single institution.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain | 2010 |
Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Pro | 2010 |
Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Pro | 2010 |
Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Pro | 2010 |
Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Pro | 2010 |
Bevacizumab is active as a single agent against recurrent malignant gliomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Bevacizumab is active as a single agent against recurrent malignant gliomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Bevacizumab is active as a single agent against recurrent malignant gliomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Bevacizumab is active as a single agent against recurrent malignant gliomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Repair; DNA, Neopl | 2010 |
Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Repair; DNA, Neopl | 2010 |
Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Repair; DNA, Neopl | 2010 |
Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Repair; DNA, Neopl | 2010 |
Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: First evaluation of quality of radiotherapy planning.
Topics: Adult; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Female; Gli | 2010 |
Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: First evaluation of quality of radiotherapy planning.
Topics: Adult; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Female; Gli | 2010 |
Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: First evaluation of quality of radiotherapy planning.
Topics: Adult; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Female; Gli | 2010 |
Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: First evaluation of quality of radiotherapy planning.
Topics: Adult; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Female; Gli | 2010 |
The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Camptothecin; Cell Movement; Cell Prolife | 2010 |
The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Camptothecin; Cell Movement; Cell Prolife | 2010 |
The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Camptothecin; Cell Movement; Cell Prolife | 2010 |
The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Camptothecin; Cell Movement; Cell Prolife | 2010 |
Temozolomide/PLGA microparticles: a new protocol for treatment of glioma in rats.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Dacarbazine; Glioma; In Situ Nick-End La | 2011 |
Temozolomide/PLGA microparticles: a new protocol for treatment of glioma in rats.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Dacarbazine; Glioma; In Situ Nick-End La | 2011 |
Temozolomide/PLGA microparticles: a new protocol for treatment of glioma in rats.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Dacarbazine; Glioma; In Situ Nick-End La | 2011 |
Temozolomide/PLGA microparticles: a new protocol for treatment of glioma in rats.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Dacarbazine; Glioma; In Situ Nick-End La | 2011 |
Flow cytometric analysis for the mechanism of the new antineoplastic agent temozolomide in glioma cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Dru | 2010 |
Flow cytometric analysis for the mechanism of the new antineoplastic agent temozolomide in glioma cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Dru | 2010 |
Flow cytometric analysis for the mechanism of the new antineoplastic agent temozolomide in glioma cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Dru | 2010 |
Flow cytometric analysis for the mechanism of the new antineoplastic agent temozolomide in glioma cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Dru | 2010 |
Gene expression profiling predicts response to temozolomide in malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2010 |
Gene expression profiling predicts response to temozolomide in malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2010 |
Gene expression profiling predicts response to temozolomide in malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2010 |
Gene expression profiling predicts response to temozolomide in malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2010 |
Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhage; Dacarbazine; Dose-Re | 2010 |
Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhage; Dacarbazine; Dose-Re | 2010 |
Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhage; Dacarbazine; Dose-Re | 2010 |
Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhage; Dacarbazine; Dose-Re | 2010 |
Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance.
Topics: Animals; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Agents; Blotting, Western; Brain Ne | 2010 |
Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance.
Topics: Animals; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Agents; Blotting, Western; Brain Ne | 2010 |
Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance.
Topics: Animals; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Agents; Blotting, Western; Brain Ne | 2010 |
Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance.
Topics: Animals; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Agents; Blotting, Western; Brain Ne | 2010 |
Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biocompa | 2010 |
Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biocompa | 2010 |
Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biocompa | 2010 |
Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biocompa | 2010 |
Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dis | 2010 |
Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dis | 2010 |
Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dis | 2010 |
Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dis | 2010 |
Receptor activation and inhibition in cellular response to chemotherapeutic combinational mimicries: the concept of divergent targeting.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Cy | 2010 |
Receptor activation and inhibition in cellular response to chemotherapeutic combinational mimicries: the concept of divergent targeting.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Cy | 2010 |
Receptor activation and inhibition in cellular response to chemotherapeutic combinational mimicries: the concept of divergent targeting.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Cy | 2010 |
Receptor activation and inhibition in cellular response to chemotherapeutic combinational mimicries: the concept of divergent targeting.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Cy | 2010 |
Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Prol | 2010 |
Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Prol | 2010 |
Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Prol | 2010 |
Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Prol | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Europe; Fo | 2010 |
The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma.
Topics: Animals; Apoptosis; Autophagy; Caspases; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; | 2010 |
The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma.
Topics: Animals; Apoptosis; Autophagy; Caspases; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; | 2010 |
The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma.
Topics: Animals; Apoptosis; Autophagy; Caspases; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; | 2010 |
The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma.
Topics: Animals; Apoptosis; Autophagy; Caspases; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; | 2010 |
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplas | 2010 |
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplas | 2010 |
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplas | 2010 |
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplas | 2010 |
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplas | 2010 |
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplas | 2010 |
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplas | 2010 |
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplas | 2010 |
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplas | 2010 |
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplas | 2010 |
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplas | 2010 |
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplas | 2010 |
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplas | 2010 |
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplas | 2010 |
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplas | 2010 |
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplas | 2010 |
Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Dacarbazine; DNA Methylation; | 2011 |
Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Dacarbazine; DNA Methylation; | 2011 |
Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Dacarbazine; DNA Methylation; | 2011 |
Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Dacarbazine; DNA Methylation; | 2011 |
Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2010 |
Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2010 |
Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2010 |
Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2010 |
Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2011 |
Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2011 |
Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2011 |
Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2011 |
MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3 | 2010 |
MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3 | 2010 |
MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3 | 2010 |
MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3 | 2010 |
Circulating levels of the innate and humoral immune regulators CD14 and CD23 are associated with adult glioma.
Topics: Adult; Case-Control Studies; Dacarbazine; Dexamethasone; Female; Glioma; Humans; Hypersensitivity; I | 2010 |
Circulating levels of the innate and humoral immune regulators CD14 and CD23 are associated with adult glioma.
Topics: Adult; Case-Control Studies; Dacarbazine; Dexamethasone; Female; Glioma; Humans; Hypersensitivity; I | 2010 |
Circulating levels of the innate and humoral immune regulators CD14 and CD23 are associated with adult glioma.
Topics: Adult; Case-Control Studies; Dacarbazine; Dexamethasone; Female; Glioma; Humans; Hypersensitivity; I | 2010 |
Circulating levels of the innate and humoral immune regulators CD14 and CD23 are associated with adult glioma.
Topics: Adult; Case-Control Studies; Dacarbazine; Dexamethasone; Female; Glioma; Humans; Hypersensitivity; I | 2010 |
Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2010 |
Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2010 |
Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2010 |
Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2010 |
Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2011 |
Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2011 |
Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2011 |
Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2011 |
Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2010 |
Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2010 |
Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2010 |
Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2010 |
Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methyla | 2011 |
Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methyla | 2011 |
Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methyla | 2011 |
Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methyla | 2011 |
Hedgehog/GLI1 regulates IGF dependent malignant behaviors in glioma stem cells.
Topics: Cell Proliferation; Cell Survival; Dacarbazine; Gene Expression Regulation, Neoplastic; Gene Knockdo | 2011 |
Hedgehog/GLI1 regulates IGF dependent malignant behaviors in glioma stem cells.
Topics: Cell Proliferation; Cell Survival; Dacarbazine; Gene Expression Regulation, Neoplastic; Gene Knockdo | 2011 |
Hedgehog/GLI1 regulates IGF dependent malignant behaviors in glioma stem cells.
Topics: Cell Proliferation; Cell Survival; Dacarbazine; Gene Expression Regulation, Neoplastic; Gene Knockdo | 2011 |
Hedgehog/GLI1 regulates IGF dependent malignant behaviors in glioma stem cells.
Topics: Cell Proliferation; Cell Survival; Dacarbazine; Gene Expression Regulation, Neoplastic; Gene Knockdo | 2011 |
Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Da | 2011 |
Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Da | 2011 |
Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Da | 2011 |
Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Da | 2011 |
Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Damage; DN | 2010 |
Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Damage; DN | 2010 |
Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Damage; DN | 2010 |
Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Damage; DN | 2010 |
Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patients.
Topics: Adult; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Binding | 2011 |
Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patients.
Topics: Adult; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Binding | 2011 |
Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patients.
Topics: Adult; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Binding | 2011 |
Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patients.
Topics: Adult; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Binding | 2011 |
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution | 2010 |
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution | 2010 |
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution | 2010 |
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution | 2010 |
Irradiation and bevacizumab in high-grade glioma retreatment settings.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Angiogenesis Inhibitors; Antibodies, Monoclonal, Huma | 2012 |
Irradiation and bevacizumab in high-grade glioma retreatment settings.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Angiogenesis Inhibitors; Antibodies, Monoclonal, Huma | 2012 |
Irradiation and bevacizumab in high-grade glioma retreatment settings.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Angiogenesis Inhibitors; Antibodies, Monoclonal, Huma | 2012 |
Irradiation and bevacizumab in high-grade glioma retreatment settings.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Angiogenesis Inhibitors; Antibodies, Monoclonal, Huma | 2012 |
[Unknown gonadotoxicity chemotherapy and preservation of fertility: example of Temozolomide].
Topics: Adult; Antineoplastic Agents, Alkylating; Cryopreservation; Dacarbazine; Embryo, Mammalian; Female; | 2010 |
[Unknown gonadotoxicity chemotherapy and preservation of fertility: example of Temozolomide].
Topics: Adult; Antineoplastic Agents, Alkylating; Cryopreservation; Dacarbazine; Embryo, Mammalian; Female; | 2010 |
[Unknown gonadotoxicity chemotherapy and preservation of fertility: example of Temozolomide].
Topics: Adult; Antineoplastic Agents, Alkylating; Cryopreservation; Dacarbazine; Embryo, Mammalian; Female; | 2010 |
[Unknown gonadotoxicity chemotherapy and preservation of fertility: example of Temozolomide].
Topics: Adult; Antineoplastic Agents, Alkylating; Cryopreservation; Dacarbazine; Embryo, Mammalian; Female; | 2010 |
MGMT promoter methylation in pediatric high-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Child; Combined Modality Therapy; Dacarbazine; DNA Methylati | 2011 |
MGMT promoter methylation in pediatric high-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Child; Combined Modality Therapy; Dacarbazine; DNA Methylati | 2011 |
MGMT promoter methylation in pediatric high-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Child; Combined Modality Therapy; Dacarbazine; DNA Methylati | 2011 |
MGMT promoter methylation in pediatric high-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Child; Combined Modality Therapy; Dacarbazine; DNA Methylati | 2011 |
Anti-tumour effects by a trimodal combination of temozolomide, meloxicam and X-rays in cultures of human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Combined Modality Therapy; Cyclooxygenase Inhibitors; | 2011 |
Anti-tumour effects by a trimodal combination of temozolomide, meloxicam and X-rays in cultures of human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Combined Modality Therapy; Cyclooxygenase Inhibitors; | 2011 |
Anti-tumour effects by a trimodal combination of temozolomide, meloxicam and X-rays in cultures of human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Combined Modality Therapy; Cyclooxygenase Inhibitors; | 2011 |
Anti-tumour effects by a trimodal combination of temozolomide, meloxicam and X-rays in cultures of human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Combined Modality Therapy; Cyclooxygenase Inhibitors; | 2011 |
Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.
Topics: Animals; Antibodies, Neutralizing; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chemokine CC | 2011 |
Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.
Topics: Animals; Antibodies, Neutralizing; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chemokine CC | 2011 |
Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.
Topics: Animals; Antibodies, Neutralizing; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chemokine CC | 2011 |
Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.
Topics: Animals; Antibodies, Neutralizing; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chemokine CC | 2011 |
Biodegradable microfibers deliver the antitumor drug temozolomide to glioma C6 cells in vitro.
Topics: Antineoplastic Agents, Alkylating; Calorimetry, Differential Scanning; Cell Line, Tumor; Cell Surviv | 2010 |
Biodegradable microfibers deliver the antitumor drug temozolomide to glioma C6 cells in vitro.
Topics: Antineoplastic Agents, Alkylating; Calorimetry, Differential Scanning; Cell Line, Tumor; Cell Surviv | 2010 |
Biodegradable microfibers deliver the antitumor drug temozolomide to glioma C6 cells in vitro.
Topics: Antineoplastic Agents, Alkylating; Calorimetry, Differential Scanning; Cell Line, Tumor; Cell Surviv | 2010 |
Biodegradable microfibers deliver the antitumor drug temozolomide to glioma C6 cells in vitro.
Topics: Antineoplastic Agents, Alkylating; Calorimetry, Differential Scanning; Cell Line, Tumor; Cell Surviv | 2010 |
Immature and absolute platelet count changes and thrombocytopenia in malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Austria; Blood Platelets; Dacarbazine; Female; Gliom | 2011 |
Immature and absolute platelet count changes and thrombocytopenia in malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Austria; Blood Platelets; Dacarbazine; Female; Gliom | 2011 |
Immature and absolute platelet count changes and thrombocytopenia in malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Austria; Blood Platelets; Dacarbazine; Female; Gliom | 2011 |
Immature and absolute platelet count changes and thrombocytopenia in malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Austria; Blood Platelets; Dacarbazine; Female; Gliom | 2011 |
Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient's outcome.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Methylation; Gene Expression Regulation, Neoplas | 2011 |
Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient's outcome.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Methylation; Gene Expression Regulation, Neoplas | 2011 |
Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient's outcome.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Methylation; Gene Expression Regulation, Neoplas | 2011 |
Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient's outcome.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Methylation; Gene Expression Regulation, Neoplas | 2011 |
HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Lin | 2011 |
HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Lin | 2011 |
HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Lin | 2011 |
HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Lin | 2011 |
Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; Dacarbazin | 2011 |
Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; Dacarbazin | 2011 |
Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; Dacarbazin | 2011 |
Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; Dacarbazin | 2011 |
Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2011 |
Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2011 |
Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2011 |
Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2011 |
Induction of autophagy in temozolomide treated malignant gliomas.
Topics: Adolescent; Adult; Aged; Autophagy; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Female; G | 2011 |
Induction of autophagy in temozolomide treated malignant gliomas.
Topics: Adolescent; Adult; Aged; Autophagy; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Female; G | 2011 |
Induction of autophagy in temozolomide treated malignant gliomas.
Topics: Adolescent; Adult; Aged; Autophagy; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Female; G | 2011 |
Induction of autophagy in temozolomide treated malignant gliomas.
Topics: Adolescent; Adult; Aged; Autophagy; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Female; G | 2011 |
Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Mo | 2010 |
Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Mo | 2010 |
Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Mo | 2010 |
Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Mo | 2010 |
TMZ-induced PrPc/par-4 interaction promotes the survival of human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor | 2012 |
TMZ-induced PrPc/par-4 interaction promotes the survival of human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor | 2012 |
TMZ-induced PrPc/par-4 interaction promotes the survival of human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor | 2012 |
TMZ-induced PrPc/par-4 interaction promotes the survival of human glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor | 2012 |
GRP78/BiP modulation of GRP78/BiP in altering sensitivity to chemotherapy.
Topics: Activating Transcription Factor 6; Animals; Antineoplastic Agents; Brain Neoplasms; Catechin; Cell L | 2011 |
GRP78/BiP modulation of GRP78/BiP in altering sensitivity to chemotherapy.
Topics: Activating Transcription Factor 6; Animals; Antineoplastic Agents; Brain Neoplasms; Catechin; Cell L | 2011 |
GRP78/BiP modulation of GRP78/BiP in altering sensitivity to chemotherapy.
Topics: Activating Transcription Factor 6; Animals; Antineoplastic Agents; Brain Neoplasms; Catechin; Cell L | 2011 |
GRP78/BiP modulation of GRP78/BiP in altering sensitivity to chemotherapy.
Topics: Activating Transcription Factor 6; Animals; Antineoplastic Agents; Brain Neoplasms; Catechin; Cell L | 2011 |
Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Synergism; Glioma; | 2011 |
Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Synergism; Glioma; | 2011 |
Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Synergism; Glioma; | 2011 |
Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Synergism; Glioma; | 2011 |
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Ce | 2011 |
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Ce | 2011 |
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Ce | 2011 |
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Ce | 2011 |
Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain | 2011 |
Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain | 2011 |
Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain | 2011 |
Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain | 2011 |
O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2011 |
O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2011 |
O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2011 |
O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2011 |
N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain; Brain Neoplasms; Cell Line, | 2011 |
N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain; Brain Neoplasms; Cell Line, | 2011 |
N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain; Brain Neoplasms; Cell Line, | 2011 |
N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain; Brain Neoplasms; Cell Line, | 2011 |
Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Corticotropin-Releasin | 2011 |
Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Corticotropin-Releasin | 2011 |
Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Corticotropin-Releasin | 2011 |
Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Corticotropin-Releasin | 2011 |
Temozolomide-induced modification of the CXC chemokine network in experimental gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemokines, CXC; Daca | 2011 |
Temozolomide-induced modification of the CXC chemokine network in experimental gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemokines, CXC; Daca | 2011 |
Temozolomide-induced modification of the CXC chemokine network in experimental gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemokines, CXC; Daca | 2011 |
Temozolomide-induced modification of the CXC chemokine network in experimental gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemokines, CXC; Daca | 2011 |
[Comparison of MGMT and ERCC₂ expression in temozolomide for the treatment of malignant glioma drug resistance and their genetic relationship].
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression; Genes | 2011 |
[Comparison of MGMT and ERCC₂ expression in temozolomide for the treatment of malignant glioma drug resistance and their genetic relationship].
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression; Genes | 2011 |
[Comparison of MGMT and ERCC₂ expression in temozolomide for the treatment of malignant glioma drug resistance and their genetic relationship].
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression; Genes | 2011 |
[Comparison of MGMT and ERCC₂ expression in temozolomide for the treatment of malignant glioma drug resistance and their genetic relationship].
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Gene Expression; Genes | 2011 |
Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-π-activated nitric oxide donor PABA/NO in malignant gliomas.
Topics: 4-Aminobenzoic Acid; Animals; Antineoplastic Combined Chemotherapy Protocols; Azo Compounds; Brain N | 2012 |
Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-π-activated nitric oxide donor PABA/NO in malignant gliomas.
Topics: 4-Aminobenzoic Acid; Animals; Antineoplastic Combined Chemotherapy Protocols; Azo Compounds; Brain N | 2012 |
Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-π-activated nitric oxide donor PABA/NO in malignant gliomas.
Topics: 4-Aminobenzoic Acid; Animals; Antineoplastic Combined Chemotherapy Protocols; Azo Compounds; Brain N | 2012 |
Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-π-activated nitric oxide donor PABA/NO in malignant gliomas.
Topics: 4-Aminobenzoic Acid; Animals; Antineoplastic Combined Chemotherapy Protocols; Azo Compounds; Brain N | 2012 |
Early toxicity predicts long-term survival in high-grade glioma.
Topics: Acute Disease; Adult; Aged; Analysis of Variance; Antineoplastic Agents; Chemotherapy, Adjuvant; Dac | 2011 |
Early toxicity predicts long-term survival in high-grade glioma.
Topics: Acute Disease; Adult; Aged; Analysis of Variance; Antineoplastic Agents; Chemotherapy, Adjuvant; Dac | 2011 |
Early toxicity predicts long-term survival in high-grade glioma.
Topics: Acute Disease; Adult; Aged; Analysis of Variance; Antineoplastic Agents; Chemotherapy, Adjuvant; Dac | 2011 |
Early toxicity predicts long-term survival in high-grade glioma.
Topics: Acute Disease; Adult; Aged; Analysis of Variance; Antineoplastic Agents; Chemotherapy, Adjuvant; Dac | 2011 |
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2012 |
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2012 |
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2012 |
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2012 |
Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2011 |
Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2011 |
Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2011 |
Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2011 |
[Nimotuzumab in combination with chemotherapy for patients with malignant gliomas].
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplas | 2011 |
[Nimotuzumab in combination with chemotherapy for patients with malignant gliomas].
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplas | 2011 |
[Nimotuzumab in combination with chemotherapy for patients with malignant gliomas].
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplas | 2011 |
[Nimotuzumab in combination with chemotherapy for patients with malignant gliomas].
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplas | 2011 |
Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Aspartic Acid; Brain Neoplasms; Choline; Creatine; D | 2011 |
Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Aspartic Acid; Brain Neoplasms; Choline; Creatine; D | 2011 |
Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Aspartic Acid; Brain Neoplasms; Choline; Creatine; D | 2011 |
Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Aspartic Acid; Brain Neoplasms; Choline; Creatine; D | 2011 |
The effect of PTEN on proliferation and drug-, and radiosensitivity in malignant glioma cells.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell | 2011 |
The effect of PTEN on proliferation and drug-, and radiosensitivity in malignant glioma cells.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell | 2011 |
The effect of PTEN on proliferation and drug-, and radiosensitivity in malignant glioma cells.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell | 2011 |
The effect of PTEN on proliferation and drug-, and radiosensitivity in malignant glioma cells.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell | 2011 |
Leptomeningeal dissemination of anaplastic glioma: prolonged survival in two patients treated with temozolomide.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Glioma; Humans; Male; Meningeal Carcinoma | 2011 |
Leptomeningeal dissemination of anaplastic glioma: prolonged survival in two patients treated with temozolomide.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Glioma; Humans; Male; Meningeal Carcinoma | 2011 |
Leptomeningeal dissemination of anaplastic glioma: prolonged survival in two patients treated with temozolomide.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Glioma; Humans; Male; Meningeal Carcinoma | 2011 |
Leptomeningeal dissemination of anaplastic glioma: prolonged survival in two patients treated with temozolomide.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Glioma; Humans; Male; Meningeal Carcinoma | 2011 |
YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma.
Topics: Adenoviridae; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Southern; Blotting, | 2011 |
YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma.
Topics: Adenoviridae; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Southern; Blotting, | 2011 |
YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma.
Topics: Adenoviridae; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Southern; Blotting, | 2011 |
YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma.
Topics: Adenoviridae; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Southern; Blotting, | 2011 |
Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Dacarbazine; | 2011 |
Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Dacarbazine; | 2011 |
Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Dacarbazine; | 2011 |
Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Dacarbazine; | 2011 |
A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cel | 2011 |
A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cel | 2011 |
A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cel | 2011 |
A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cel | 2011 |
Temozolomide decreases invasion of glioma stem cells by down-regulating TGF-β2.
Topics: Cell Line, Tumor; Dacarbazine; Down-Regulation; Female; Glioma; Humans; Male; Neoplastic Stem Cells; | 2011 |
Temozolomide decreases invasion of glioma stem cells by down-regulating TGF-β2.
Topics: Cell Line, Tumor; Dacarbazine; Down-Regulation; Female; Glioma; Humans; Male; Neoplastic Stem Cells; | 2011 |
Temozolomide decreases invasion of glioma stem cells by down-regulating TGF-β2.
Topics: Cell Line, Tumor; Dacarbazine; Down-Regulation; Female; Glioma; Humans; Male; Neoplastic Stem Cells; | 2011 |
Temozolomide decreases invasion of glioma stem cells by down-regulating TGF-β2.
Topics: Cell Line, Tumor; Dacarbazine; Down-Regulation; Female; Glioma; Humans; Male; Neoplastic Stem Cells; | 2011 |
Intravenous administration of temozolomide as a useful alternative over oral treatment with temozolomide capsules in patients with gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Capsules; Child; Child, Preschool; Dacarb | 2012 |
Intravenous administration of temozolomide as a useful alternative over oral treatment with temozolomide capsules in patients with gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Capsules; Child; Child, Preschool; Dacarb | 2012 |
Intravenous administration of temozolomide as a useful alternative over oral treatment with temozolomide capsules in patients with gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Capsules; Child; Child, Preschool; Dacarb | 2012 |
Intravenous administration of temozolomide as a useful alternative over oral treatment with temozolomide capsules in patients with gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Capsules; Child; Child, Preschool; Dacarb | 2012 |
Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; CD4 Lymphocyte C | 2011 |
Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; CD4 Lymphocyte C | 2011 |
Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; CD4 Lymphocyte C | 2011 |
Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; CD4 Lymphocyte C | 2011 |
[Problems of chemotherapy for glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA; DNA Mismatch Repair; Drug Resi | 2011 |
[Problems of chemotherapy for glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA; DNA Mismatch Repair; Drug Resi | 2011 |
[Problems of chemotherapy for glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA; DNA Mismatch Repair; Drug Resi | 2011 |
[Problems of chemotherapy for glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA; DNA Mismatch Repair; Drug Resi | 2011 |
Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition; Dacarbazine; Femal | 2012 |
Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition; Dacarbazine; Femal | 2012 |
Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition; Dacarbazine; Femal | 2012 |
Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition; Dacarbazine; Femal | 2012 |
Ifosfamide, carboplatin and etoposide in recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2011 |
Ifosfamide, carboplatin and etoposide in recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2011 |
Ifosfamide, carboplatin and etoposide in recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2011 |
Ifosfamide, carboplatin and etoposide in recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2011 |
Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas.
Topics: 2',5'-Oligoadenylate Synthetase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Ce | 2011 |
Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas.
Topics: 2',5'-Oligoadenylate Synthetase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Ce | 2011 |
Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas.
Topics: 2',5'-Oligoadenylate Synthetase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Ce | 2011 |
Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas.
Topics: 2',5'-Oligoadenylate Synthetase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Ce | 2011 |
Early-stage progress on glioma vaccines.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Clinical Trials as | 2011 |
Early-stage progress on glioma vaccines.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Clinical Trials as | 2011 |
Early-stage progress on glioma vaccines.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Clinical Trials as | 2011 |
Early-stage progress on glioma vaccines.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Clinical Trials as | 2011 |
Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioma; | 2012 |
Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioma; | 2012 |
Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioma; | 2012 |
Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioma; | 2012 |
Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA, Mitochondrial; Dru | 2011 |
Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA, Mitochondrial; Dru | 2011 |
Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA, Mitochondrial; Dru | 2011 |
Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA, Mitochondrial; Dru | 2011 |
MicroRNA profile of polyunsaturated fatty acid treated glioma cells reveal apoptosis-specific expression changes.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Arachidonic Acid; Cell | 2011 |
MicroRNA profile of polyunsaturated fatty acid treated glioma cells reveal apoptosis-specific expression changes.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Arachidonic Acid; Cell | 2011 |
MicroRNA profile of polyunsaturated fatty acid treated glioma cells reveal apoptosis-specific expression changes.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Arachidonic Acid; Cell | 2011 |
MicroRNA profile of polyunsaturated fatty acid treated glioma cells reveal apoptosis-specific expression changes.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Arachidonic Acid; Cell | 2011 |
Down-regulation of EGFR prolonged cell growth of glioma but did not increase the sensitivity to temozolomide.
Topics: Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Down-Regulation; Drug Scr | 2011 |
Down-regulation of EGFR prolonged cell growth of glioma but did not increase the sensitivity to temozolomide.
Topics: Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Down-Regulation; Drug Scr | 2011 |
Down-regulation of EGFR prolonged cell growth of glioma but did not increase the sensitivity to temozolomide.
Topics: Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Down-Regulation; Drug Scr | 2011 |
Down-regulation of EGFR prolonged cell growth of glioma but did not increase the sensitivity to temozolomide.
Topics: Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Down-Regulation; Drug Scr | 2011 |
Rechallenge with temozolomide in recurrent glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Gliom | 2011 |
Rechallenge with temozolomide in recurrent glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Gliom | 2011 |
Rechallenge with temozolomide in recurrent glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Gliom | 2011 |
Rechallenge with temozolomide in recurrent glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Gliom | 2011 |
Avastin: more questions than answers. . .
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2012 |
Avastin: more questions than answers. . .
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2012 |
Avastin: more questions than answers. . .
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2012 |
Avastin: more questions than answers. . .
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2012 |
Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine | 2012 |
Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine | 2012 |
Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine | 2012 |
Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine | 2012 |
Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Apoptotic Protease-Activating Factor 1; bcl-2-Associated X | 2012 |
Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Apoptotic Protease-Activating Factor 1; bcl-2-Associated X | 2012 |
Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Apoptotic Protease-Activating Factor 1; bcl-2-Associated X | 2012 |
Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Apoptotic Protease-Activating Factor 1; bcl-2-Associated X | 2012 |
LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway.
Topics: Antineoplastic Agents, Alkylating; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Chromone | 2012 |
LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway.
Topics: Antineoplastic Agents, Alkylating; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Chromone | 2012 |
LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway.
Topics: Antineoplastic Agents, Alkylating; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Chromone | 2012 |
LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway.
Topics: Antineoplastic Agents, Alkylating; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Chromone | 2012 |
Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2012 |
Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2012 |
Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2012 |
Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2012 |
Prolonged administration of temozolomide in adult patients with anaplastic glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma; Dacarbazine; Disease Pro | 2011 |
Prolonged administration of temozolomide in adult patients with anaplastic glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma; Dacarbazine; Disease Pro | 2011 |
Prolonged administration of temozolomide in adult patients with anaplastic glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma; Dacarbazine; Disease Pro | 2011 |
Prolonged administration of temozolomide in adult patients with anaplastic glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma; Dacarbazine; Disease Pro | 2011 |
Downregulation of PRDX1 by promoter hypermethylation is frequent in 1p/19q-deleted oligodendroglial tumours and increases radio- and chemosensitivity of Hs683 glioma cells in vitro.
Topics: Adult; Aged; Apoptosis; Cell Line, Tumor; Chromosome Deletion; Chromosomes, Human, Pair 1; CpG Islan | 2012 |
Downregulation of PRDX1 by promoter hypermethylation is frequent in 1p/19q-deleted oligodendroglial tumours and increases radio- and chemosensitivity of Hs683 glioma cells in vitro.
Topics: Adult; Aged; Apoptosis; Cell Line, Tumor; Chromosome Deletion; Chromosomes, Human, Pair 1; CpG Islan | 2012 |
Downregulation of PRDX1 by promoter hypermethylation is frequent in 1p/19q-deleted oligodendroglial tumours and increases radio- and chemosensitivity of Hs683 glioma cells in vitro.
Topics: Adult; Aged; Apoptosis; Cell Line, Tumor; Chromosome Deletion; Chromosomes, Human, Pair 1; CpG Islan | 2012 |
Downregulation of PRDX1 by promoter hypermethylation is frequent in 1p/19q-deleted oligodendroglial tumours and increases radio- and chemosensitivity of Hs683 glioma cells in vitro.
Topics: Adult; Aged; Apoptosis; Cell Line, Tumor; Chromosome Deletion; Chromosomes, Human, Pair 1; CpG Islan | 2012 |
[Efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide for glioma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
[Efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide for glioma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
[Efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide for glioma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
[Efficacy and safety of 3-dimensional conformal radiotherapy combined with temozolomide for glioma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy; Blotting, Western; Brain | 2011 |
Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy; Blotting, Western; Brain | 2011 |
Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy; Blotting, Western; Brain | 2011 |
Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy; Blotting, Western; Brain | 2011 |
Temozolomide for pediatric high-grade gliomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2012 |
Temozolomide for pediatric high-grade gliomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2012 |
Temozolomide for pediatric high-grade gliomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2012 |
Temozolomide for pediatric high-grade gliomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2012 |
The effect of temozolomide/poly(lactide-co-glycolide) (PLGA)/nano-hydroxyapatite microspheres on glioma U87 cells behavior.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Carriers; Durapati | 2012 |
The effect of temozolomide/poly(lactide-co-glycolide) (PLGA)/nano-hydroxyapatite microspheres on glioma U87 cells behavior.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Carriers; Durapati | 2012 |
The effect of temozolomide/poly(lactide-co-glycolide) (PLGA)/nano-hydroxyapatite microspheres on glioma U87 cells behavior.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Carriers; Durapati | 2012 |
The effect of temozolomide/poly(lactide-co-glycolide) (PLGA)/nano-hydroxyapatite microspheres on glioma U87 cells behavior.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Carriers; Durapati | 2012 |
CXCL12 mediates apoptosis resistance in rat C6 glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Proliferation; Chemokine CXCL12; Dacarba | 2012 |
CXCL12 mediates apoptosis resistance in rat C6 glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Proliferation; Chemokine CXCL12; Dacarba | 2012 |
CXCL12 mediates apoptosis resistance in rat C6 glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Proliferation; Chemokine CXCL12; Dacarba | 2012 |
CXCL12 mediates apoptosis resistance in rat C6 glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Proliferation; Chemokine CXCL12; Dacarba | 2012 |
MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR.
Topics: Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Gene Expression Regul | 2012 |
MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR.
Topics: Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Gene Expression Regul | 2012 |
MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR.
Topics: Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Gene Expression Regul | 2012 |
MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR.
Topics: Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Gene Expression Regul | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Brain; Brain Neoplasms; Cel | 2012 |
Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2012 |
Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2012 |
Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2012 |
Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2012 |
A multicenter prospective observational study of the conformity of temozolomide prescriptions in France.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2012 |
A multicenter prospective observational study of the conformity of temozolomide prescriptions in France.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2012 |
A multicenter prospective observational study of the conformity of temozolomide prescriptions in France.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2012 |
A multicenter prospective observational study of the conformity of temozolomide prescriptions in France.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2012 |
Proton and carbon ion radiotherapy for primary brain tumors delivered with active raster scanning at the Heidelberg Ion Therapy Center (HIT): early treatment results and study concepts.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carbon; Child; Combined Modality Th | 2012 |
Proton and carbon ion radiotherapy for primary brain tumors delivered with active raster scanning at the Heidelberg Ion Therapy Center (HIT): early treatment results and study concepts.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carbon; Child; Combined Modality Th | 2012 |
Proton and carbon ion radiotherapy for primary brain tumors delivered with active raster scanning at the Heidelberg Ion Therapy Center (HIT): early treatment results and study concepts.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carbon; Child; Combined Modality Th | 2012 |
Proton and carbon ion radiotherapy for primary brain tumors delivered with active raster scanning at the Heidelberg Ion Therapy Center (HIT): early treatment results and study concepts.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carbon; Child; Combined Modality Th | 2012 |
Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Dacarbazine; Glioma; HSP27 Heat-Shock Proteins; Huma | 2012 |
Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Dacarbazine; Glioma; HSP27 Heat-Shock Proteins; Huma | 2012 |
Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Dacarbazine; Glioma; HSP27 Heat-Shock Proteins; Huma | 2012 |
Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Dacarbazine; Glioma; HSP27 Heat-Shock Proteins; Huma | 2012 |
Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Brain Neoplasms; Cell Line, Tumor; | 2012 |
Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Brain Neoplasms; Cell Line, Tumor; | 2012 |
Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Brain Neoplasms; Cell Line, Tumor; | 2012 |
Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Brain Neoplasms; Cell Line, Tumor; | 2012 |
Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Bec | 2012 |
Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Bec | 2012 |
Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Bec | 2012 |
Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Bec | 2012 |
Fatal pneumonia associated with temozolomide therapy in patients with malignant glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Labeling; Fatal Outcome; Female; Glioma; | 2012 |
Fatal pneumonia associated with temozolomide therapy in patients with malignant glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Labeling; Fatal Outcome; Female; Glioma; | 2012 |
Fatal pneumonia associated with temozolomide therapy in patients with malignant glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Labeling; Fatal Outcome; Female; Glioma; | 2012 |
Fatal pneumonia associated with temozolomide therapy in patients with malignant glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Labeling; Fatal Outcome; Female; Glioma; | 2012 |
Prognosis of pediatric high-grade gliomas with temozolomide treatment: a retrospective, multicenter study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2012 |
Prognosis of pediatric high-grade gliomas with temozolomide treatment: a retrospective, multicenter study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2012 |
Prognosis of pediatric high-grade gliomas with temozolomide treatment: a retrospective, multicenter study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2012 |
Prognosis of pediatric high-grade gliomas with temozolomide treatment: a retrospective, multicenter study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2012 |
A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Logistic Models; Male; Middle Age | 2012 |
A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Logistic Models; Male; Middle Age | 2012 |
A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Logistic Models; Male; Middle Age | 2012 |
A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Logistic Models; Male; Middle Age | 2012 |
2-Hydroxyoleate, a nontoxic membrane binding anticancer drug, induces glioma cell differentiation and autophagy.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Ce | 2012 |
2-Hydroxyoleate, a nontoxic membrane binding anticancer drug, induces glioma cell differentiation and autophagy.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Ce | 2012 |
2-Hydroxyoleate, a nontoxic membrane binding anticancer drug, induces glioma cell differentiation and autophagy.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Ce | 2012 |
2-Hydroxyoleate, a nontoxic membrane binding anticancer drug, induces glioma cell differentiation and autophagy.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Ce | 2012 |
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Und | 2012 |
The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Und | 2012 |
The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Und | 2012 |
The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Und | 2012 |
Resection of gliomas in the cingulate gyrus: functional outcome and survival.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Gyrus | 2012 |
Resection of gliomas in the cingulate gyrus: functional outcome and survival.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Gyrus | 2012 |
Resection of gliomas in the cingulate gyrus: functional outcome and survival.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Gyrus | 2012 |
Resection of gliomas in the cingulate gyrus: functional outcome and survival.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Gyrus | 2012 |
Combination hyperbaric oxygen and temozolomide therapy in C6 rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Combined M | 2012 |
Combination hyperbaric oxygen and temozolomide therapy in C6 rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Combined M | 2012 |
Combination hyperbaric oxygen and temozolomide therapy in C6 rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Combined M | 2012 |
Combination hyperbaric oxygen and temozolomide therapy in C6 rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Combined M | 2012 |
Temozolomide or bevacizumab for spinal cord high-grade gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating | 2012 |
Temozolomide or bevacizumab for spinal cord high-grade gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating | 2012 |
Temozolomide or bevacizumab for spinal cord high-grade gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating | 2012 |
Temozolomide or bevacizumab for spinal cord high-grade gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating | 2012 |
Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enz | 2012 |
Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enz | 2012 |
Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enz | 2012 |
Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enz | 2012 |
EGFR inhibition in glioma cells modulates Rho signaling to inhibit cell motility and invasion and cooperates with temozolomide to reduce cell growth.
Topics: Cell Movement; Cell Proliferation; Colony-Forming Units Assay; Dacarbazine; Electrophoresis, Polyacr | 2012 |
EGFR inhibition in glioma cells modulates Rho signaling to inhibit cell motility and invasion and cooperates with temozolomide to reduce cell growth.
Topics: Cell Movement; Cell Proliferation; Colony-Forming Units Assay; Dacarbazine; Electrophoresis, Polyacr | 2012 |
EGFR inhibition in glioma cells modulates Rho signaling to inhibit cell motility and invasion and cooperates with temozolomide to reduce cell growth.
Topics: Cell Movement; Cell Proliferation; Colony-Forming Units Assay; Dacarbazine; Electrophoresis, Polyacr | 2012 |
EGFR inhibition in glioma cells modulates Rho signaling to inhibit cell motility and invasion and cooperates with temozolomide to reduce cell growth.
Topics: Cell Movement; Cell Proliferation; Colony-Forming Units Assay; Dacarbazine; Electrophoresis, Polyacr | 2012 |
Inhibition of mitochondria- and endoplasmic reticulum stress-mediated autophagy augments temozolomide-induced apoptosis in glioma cells.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Survival; Dacarbazine; Endoplasmic Reticulum Chaperone | 2012 |
Inhibition of mitochondria- and endoplasmic reticulum stress-mediated autophagy augments temozolomide-induced apoptosis in glioma cells.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Survival; Dacarbazine; Endoplasmic Reticulum Chaperone | 2012 |
Inhibition of mitochondria- and endoplasmic reticulum stress-mediated autophagy augments temozolomide-induced apoptosis in glioma cells.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Survival; Dacarbazine; Endoplasmic Reticulum Chaperone | 2012 |
Inhibition of mitochondria- and endoplasmic reticulum stress-mediated autophagy augments temozolomide-induced apoptosis in glioma cells.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Survival; Dacarbazine; Endoplasmic Reticulum Chaperone | 2012 |
Multiple discrete aneurysmal subarachnoid hemorrhages during multimodality management of a hypothalamic glioma--case report.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Ag | 2013 |
Multiple discrete aneurysmal subarachnoid hemorrhages during multimodality management of a hypothalamic glioma--case report.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Ag | 2013 |
Multiple discrete aneurysmal subarachnoid hemorrhages during multimodality management of a hypothalamic glioma--case report.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Ag | 2013 |
Multiple discrete aneurysmal subarachnoid hemorrhages during multimodality management of a hypothalamic glioma--case report.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Ag | 2013 |
Radiation necrosis of a high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Dacarbazine; | 2012 |
Radiation necrosis of a high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Dacarbazine; | 2012 |
Radiation necrosis of a high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Dacarbazine; | 2012 |
Radiation necrosis of a high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Dacarbazine; | 2012 |
CXCR4-positive subset of glioma is enriched for cancer stem cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Ne | 2011 |
CXCR4-positive subset of glioma is enriched for cancer stem cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Ne | 2011 |
CXCR4-positive subset of glioma is enriched for cancer stem cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Ne | 2011 |
CXCR4-positive subset of glioma is enriched for cancer stem cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Ne | 2011 |
Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor | 2012 |
Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor | 2012 |
Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor | 2012 |
Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor | 2012 |
O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions.
Topics: Aged; Algorithms; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; DNA Methylat | 2012 |
O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions.
Topics: Aged; Algorithms; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; DNA Methylat | 2012 |
O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions.
Topics: Aged; Algorithms; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; DNA Methylat | 2012 |
O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions.
Topics: Aged; Algorithms; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; DNA Methylat | 2012 |
Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR-21 inhibitor gene therapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modalit | 2012 |
Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR-21 inhibitor gene therapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modalit | 2012 |
Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR-21 inhibitor gene therapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modalit | 2012 |
Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR-21 inhibitor gene therapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modalit | 2012 |
CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Chemorad | 2012 |
CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Chemorad | 2012 |
CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Chemorad | 2012 |
CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Chemorad | 2012 |
[Temodal--an alkylating cytostatic agent. Effectiveness in patients with malignant gliomas].
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoc | 2012 |
[Temodal--an alkylating cytostatic agent. Effectiveness in patients with malignant gliomas].
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoc | 2012 |
[Temodal--an alkylating cytostatic agent. Effectiveness in patients with malignant gliomas].
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoc | 2012 |
[Temodal--an alkylating cytostatic agent. Effectiveness in patients with malignant gliomas].
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoc | 2012 |
The synergistic therapeutic effect of temozolomide and hyperbaric oxygen on glioma U251 cell lines is accompanied by alterations in vascular endothelial growth factor and multidrug resistance-associated protein-1 levels.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member | 2012 |
The synergistic therapeutic effect of temozolomide and hyperbaric oxygen on glioma U251 cell lines is accompanied by alterations in vascular endothelial growth factor and multidrug resistance-associated protein-1 levels.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member | 2012 |
The synergistic therapeutic effect of temozolomide and hyperbaric oxygen on glioma U251 cell lines is accompanied by alterations in vascular endothelial growth factor and multidrug resistance-associated protein-1 levels.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member | 2012 |
The synergistic therapeutic effect of temozolomide and hyperbaric oxygen on glioma U251 cell lines is accompanied by alterations in vascular endothelial growth factor and multidrug resistance-associated protein-1 levels.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member | 2012 |
Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
Topics: Administration, Intranasal; Animals; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferati | 2012 |
Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
Topics: Administration, Intranasal; Animals; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferati | 2012 |
Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
Topics: Administration, Intranasal; Animals; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferati | 2012 |
Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
Topics: Administration, Intranasal; Animals; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferati | 2012 |
Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Dac | 2012 |
Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Dac | 2012 |
Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Dac | 2012 |
Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Dac | 2012 |
Methylation mediated silencing of miR-23b expression and its role in glioma stem cells.
Topics: Antineoplastic Agents; Azacitidine; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell | 2012 |
Methylation mediated silencing of miR-23b expression and its role in glioma stem cells.
Topics: Antineoplastic Agents; Azacitidine; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell | 2012 |
Methylation mediated silencing of miR-23b expression and its role in glioma stem cells.
Topics: Antineoplastic Agents; Azacitidine; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell | 2012 |
Methylation mediated silencing of miR-23b expression and its role in glioma stem cells.
Topics: Antineoplastic Agents; Azacitidine; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Management of cytomegalovirus infection in a patient with malignant glioma treated with temozolomide and steroids.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cytomegalovirus; | 2012 |
Management of cytomegalovirus infection in a patient with malignant glioma treated with temozolomide and steroids.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cytomegalovirus; | 2012 |
Management of cytomegalovirus infection in a patient with malignant glioma treated with temozolomide and steroids.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cytomegalovirus; | 2012 |
Management of cytomegalovirus infection in a patient with malignant glioma treated with temozolomide and steroids.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cytomegalovirus; | 2012 |
Rapid desensitization with temozolomide in patients with delayed maculopapular rash.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Desensitization, Immun | 2012 |
Rapid desensitization with temozolomide in patients with delayed maculopapular rash.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Desensitization, Immun | 2012 |
Rapid desensitization with temozolomide in patients with delayed maculopapular rash.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Desensitization, Immun | 2012 |
Rapid desensitization with temozolomide in patients with delayed maculopapular rash.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Desensitization, Immun | 2012 |
Relapse of herpes encephalitis induced by temozolomide-based chemoradiation in a patient with malignant glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Encephali | 2013 |
Relapse of herpes encephalitis induced by temozolomide-based chemoradiation in a patient with malignant glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Encephali | 2013 |
Relapse of herpes encephalitis induced by temozolomide-based chemoradiation in a patient with malignant glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Encephali | 2013 |
Relapse of herpes encephalitis induced by temozolomide-based chemoradiation in a patient with malignant glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Encephali | 2013 |
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Adhesion; Cel | 2013 |
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Adhesion; Cel | 2013 |
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Adhesion; Cel | 2013 |
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Adhesion; Cel | 2013 |
Knockdown of Nrf2 enhances autophagy induced by temozolomide in U251 human glioma cell line.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Blotting, Western; Brain Neoplasms; Dacarba | 2013 |
Knockdown of Nrf2 enhances autophagy induced by temozolomide in U251 human glioma cell line.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Blotting, Western; Brain Neoplasms; Dacarba | 2013 |
Knockdown of Nrf2 enhances autophagy induced by temozolomide in U251 human glioma cell line.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Blotting, Western; Brain Neoplasms; Dacarba | 2013 |
Knockdown of Nrf2 enhances autophagy induced by temozolomide in U251 human glioma cell line.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Blotting, Western; Brain Neoplasms; Dacarba | 2013 |
Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dihydroxyphenylalanine | 2013 |
Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dihydroxyphenylalanine | 2013 |
Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dihydroxyphenylalanine | 2013 |
Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dihydroxyphenylalanine | 2013 |
Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemoradiotherapy, Adjuvant; Dacarbazine | 2013 |
Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemoradiotherapy, Adjuvant; Dacarbazine | 2013 |
Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemoradiotherapy, Adjuvant; Dacarbazine | 2013 |
Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemoradiotherapy, Adjuvant; Dacarbazine | 2013 |
Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Dacarbazine; Dise | 2013 |
Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Dacarbazine; Dise | 2013 |
Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Dacarbazine; Dise | 2013 |
Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Dacarbazine; Dise | 2013 |
Aspirin-/TMZ-coloaded microspheres exert synergistic antiglioma efficacy via inhibition of β-catenin transactivation.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspirin; beta Catenin; Cell Line, Tumor; Dacarbazine; Dr | 2013 |
Aspirin-/TMZ-coloaded microspheres exert synergistic antiglioma efficacy via inhibition of β-catenin transactivation.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspirin; beta Catenin; Cell Line, Tumor; Dacarbazine; Dr | 2013 |
Aspirin-/TMZ-coloaded microspheres exert synergistic antiglioma efficacy via inhibition of β-catenin transactivation.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspirin; beta Catenin; Cell Line, Tumor; Dacarbazine; Dr | 2013 |
Aspirin-/TMZ-coloaded microspheres exert synergistic antiglioma efficacy via inhibition of β-catenin transactivation.
Topics: Animals; Antineoplastic Agents, Alkylating; Aspirin; beta Catenin; Cell Line, Tumor; Dacarbazine; Dr | 2013 |
Malignant glioma with angiocentric features.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazi | 2013 |
Malignant glioma with angiocentric features.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazi | 2013 |
Malignant glioma with angiocentric features.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazi | 2013 |
Malignant glioma with angiocentric features.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazi | 2013 |
Prolonged survival after treatment of diffuse intrinsic pontine glioma with radiation, temozolamide, and bevacizumab: report of 2 cases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2013 |
Prolonged survival after treatment of diffuse intrinsic pontine glioma with radiation, temozolamide, and bevacizumab: report of 2 cases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2013 |
Prolonged survival after treatment of diffuse intrinsic pontine glioma with radiation, temozolamide, and bevacizumab: report of 2 cases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2013 |
Prolonged survival after treatment of diffuse intrinsic pontine glioma with radiation, temozolamide, and bevacizumab: report of 2 cases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2013 |
Histone deacetylase inhibitor, 2-propylpentanoic acid, increases the chemosensitivity and radiosensitivity of human glioma cell lines in vitro.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Dacarbazine; Flow Cytometry; Glioma; | 2012 |
Histone deacetylase inhibitor, 2-propylpentanoic acid, increases the chemosensitivity and radiosensitivity of human glioma cell lines in vitro.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Dacarbazine; Flow Cytometry; Glioma; | 2012 |
Histone deacetylase inhibitor, 2-propylpentanoic acid, increases the chemosensitivity and radiosensitivity of human glioma cell lines in vitro.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Dacarbazine; Flow Cytometry; Glioma; | 2012 |
Histone deacetylase inhibitor, 2-propylpentanoic acid, increases the chemosensitivity and radiosensitivity of human glioma cell lines in vitro.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Dacarbazine; Flow Cytometry; Glioma; | 2012 |
Subcellular real-time imaging of the efficacy of temozolomide on cancer cells in the brain of live mice.
Topics: Animals; Apoptosis; Brain Neoplasms; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Nucleus; Cranioto | 2013 |
Subcellular real-time imaging of the efficacy of temozolomide on cancer cells in the brain of live mice.
Topics: Animals; Apoptosis; Brain Neoplasms; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Nucleus; Cranioto | 2013 |
Subcellular real-time imaging of the efficacy of temozolomide on cancer cells in the brain of live mice.
Topics: Animals; Apoptosis; Brain Neoplasms; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Nucleus; Cranioto | 2013 |
Subcellular real-time imaging of the efficacy of temozolomide on cancer cells in the brain of live mice.
Topics: Animals; Apoptosis; Brain Neoplasms; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Nucleus; Cranioto | 2013 |
Combined temozolomide and radiation as an initial treatment for anaplastic glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease Progression; Diseas | 2013 |
Combined temozolomide and radiation as an initial treatment for anaplastic glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease Progression; Diseas | 2013 |
Combined temozolomide and radiation as an initial treatment for anaplastic glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease Progression; Diseas | 2013 |
Combined temozolomide and radiation as an initial treatment for anaplastic glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease Progression; Diseas | 2013 |
Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells.
Topics: Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Casset | 2013 |
Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells.
Topics: Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Casset | 2013 |
Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells.
Topics: Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Casset | 2013 |
Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells.
Topics: Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Casset | 2013 |
Impact of temozolomide on gonadal function in patients with primary malignant brain tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; F | 2013 |
Impact of temozolomide on gonadal function in patients with primary malignant brain tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; F | 2013 |
Impact of temozolomide on gonadal function in patients with primary malignant brain tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; F | 2013 |
Impact of temozolomide on gonadal function in patients with primary malignant brain tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; F | 2013 |
Downregulation of Src enhances the cytotoxic effect of temozolomide through AKT in glioma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Regulation; Gene Expression | 2013 |
Downregulation of Src enhances the cytotoxic effect of temozolomide through AKT in glioma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Regulation; Gene Expression | 2013 |
Downregulation of Src enhances the cytotoxic effect of temozolomide through AKT in glioma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Regulation; Gene Expression | 2013 |
Downregulation of Src enhances the cytotoxic effect of temozolomide through AKT in glioma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Regulation; Gene Expression | 2013 |
Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Prolife | 2013 |
Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Prolife | 2013 |
Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Prolife | 2013 |
Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Prolife | 2013 |
Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-F | 2014 |
Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-F | 2014 |
Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-F | 2014 |
Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-F | 2014 |
Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Autophagy; Cel | 2013 |
Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Autophagy; Cel | 2013 |
Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Autophagy; Cel | 2013 |
Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Autophagy; Cel | 2013 |
Temozolomide as second-line chemotherapy for relapsed gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans | 2002 |
Temozolomide as second-line chemotherapy for relapsed gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans | 2002 |
Temozolomide as second-line chemotherapy for relapsed gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans | 2002 |
Temozolomide as second-line chemotherapy for relapsed gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans | 2002 |
Multifaceted resistance of gliomas to temozolomide.
Topics: Alleles; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Base Pair Mismatch; Blotting, Wester | 2002 |
Multifaceted resistance of gliomas to temozolomide.
Topics: Alleles; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Base Pair Mismatch; Blotting, Wester | 2002 |
Multifaceted resistance of gliomas to temozolomide.
Topics: Alleles; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Base Pair Mismatch; Blotting, Wester | 2002 |
Multifaceted resistance of gliomas to temozolomide.
Topics: Alleles; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Base Pair Mismatch; Blotting, Wester | 2002 |
Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromosome Deletion; Chromosome | 2002 |
Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromosome Deletion; Chromosome | 2002 |
Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromosome Deletion; Chromosome | 2002 |
Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromosome Deletion; Chromosome | 2002 |
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain | 2002 |
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain | 2002 |
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain | 2002 |
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain | 2002 |
Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Division; Cell Movement; Cellular Senescence; Dac | 2003 |
Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Division; Cell Movement; Cellular Senescence; Dac | 2003 |
Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Division; Cell Movement; Cellular Senescence; Dac | 2003 |
Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Division; Cell Movement; Cellular Senescence; Dac | 2003 |
Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Models, An | 2003 |
Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Models, An | 2003 |
Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Models, An | 2003 |
Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Models, An | 2003 |
Interobserver variability in the radiological assessment of response to chemotherapy in glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2003 |
Interobserver variability in the radiological assessment of response to chemotherapy in glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2003 |
Interobserver variability in the radiological assessment of response to chemotherapy in glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2003 |
Interobserver variability in the radiological assessment of response to chemotherapy in glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2003 |
Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Cycle Proteins; Cell Survival; Colony | 2003 |
Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Cycle Proteins; Cell Survival; Colony | 2003 |
Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Cycle Proteins; Cell Survival; Colony | 2003 |
Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Cycle Proteins; Cell Survival; Colony | 2003 |
Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells.
Topics: Antineoplastic Agents, Alkylating; Benzamidines; Brain Neoplasms; Dacarbazine; Drug Synergism; Enzym | 2003 |
Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells.
Topics: Antineoplastic Agents, Alkylating; Benzamidines; Brain Neoplasms; Dacarbazine; Drug Synergism; Enzym | 2003 |
Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells.
Topics: Antineoplastic Agents, Alkylating; Benzamidines; Brain Neoplasms; Dacarbazine; Drug Synergism; Enzym | 2003 |
Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells.
Topics: Antineoplastic Agents, Alkylating; Benzamidines; Brain Neoplasms; Dacarbazine; Drug Synergism; Enzym | 2003 |
Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; C | 2003 |
Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; C | 2003 |
Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; C | 2003 |
Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; C | 2003 |
Metabolic activation of temozolomide measured in vivo using positron emission tomography.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biotransformation; Brain Neoplasms; Carbon Dioxide; | 2003 |
Metabolic activation of temozolomide measured in vivo using positron emission tomography.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biotransformation; Brain Neoplasms; Carbon Dioxide; | 2003 |
Metabolic activation of temozolomide measured in vivo using positron emission tomography.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biotransformation; Brain Neoplasms; Carbon Dioxide; | 2003 |
Metabolic activation of temozolomide measured in vivo using positron emission tomography.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biotransformation; Brain Neoplasms; Carbon Dioxide; | 2003 |
Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Disease-Free Su | 2003 |
Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Disease-Free Su | 2003 |
Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Disease-Free Su | 2003 |
Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Disease-Free Su | 2003 |
Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Death; Cell Division; Dacarbazine; DNA-Binding Proteins; Dos | 2003 |
Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Death; Cell Division; Dacarbazine; DNA-Binding Proteins; Dos | 2003 |
Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Death; Cell Division; Dacarbazine; DNA-Binding Proteins; Dos | 2003 |
Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Death; Cell Division; Dacarbazine; DNA-Binding Proteins; Dos | 2003 |
Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Central Nervous Syst | 2003 |
Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Central Nervous Syst | 2003 |
Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Central Nervous Syst | 2003 |
Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Central Nervous Syst | 2003 |
Temozolomide: too early for definitive conclusions.
Topics: Adult; Age Factors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Clinical Trials as To | 2003 |
Temozolomide: too early for definitive conclusions.
Topics: Adult; Age Factors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Clinical Trials as To | 2003 |
Temozolomide: too early for definitive conclusions.
Topics: Adult; Age Factors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Clinical Trials as To | 2003 |
Temozolomide: too early for definitive conclusions.
Topics: Adult; Age Factors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Clinical Trials as To | 2003 |
A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Marrow Cells; Dacarbazine; Glioma; Hemato | 2003 |
A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Marrow Cells; Dacarbazine; Glioma; Hemato | 2003 |
A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Marrow Cells; Dacarbazine; Glioma; Hemato | 2003 |
A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Marrow Cells; Dacarbazine; Glioma; Hemato | 2003 |
Promises and controversies in the management of low-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Combined Mod | 2003 |
Promises and controversies in the management of low-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Combined Mod | 2003 |
Promises and controversies in the management of low-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Combined Mod | 2003 |
Promises and controversies in the management of low-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Combined Mod | 2003 |
Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Repa | 2003 |
Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Repa | 2003 |
Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Repa | 2003 |
Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Repa | 2003 |
Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells.
Topics: Adenine; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Cell Cycle; Cell Line, Tumor; Cell | 2004 |
Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells.
Topics: Adenine; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Cell Cycle; Cell Line, Tumor; Cell | 2004 |
Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells.
Topics: Adenine; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Cell Cycle; Cell Line, Tumor; Cell | 2004 |
Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells.
Topics: Adenine; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Cell Cycle; Cell Line, Tumor; Cell | 2004 |
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; Chromatography, H | 2004 |
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; Chromatography, H | 2004 |
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; Chromatography, H | 2004 |
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; Chromatography, H | 2004 |
Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Checkpoint Kinase 1; Dacarbazine; Drug Resistanc | 2004 |
Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Checkpoint Kinase 1; Dacarbazine; Drug Resistanc | 2004 |
Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Checkpoint Kinase 1; Dacarbazine; Drug Resistanc | 2004 |
Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Checkpoint Kinase 1; Dacarbazine; Drug Resistanc | 2004 |
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
Topics: Adult; Aged; Alkylating Agents; Brain Neoplasms; Carmustine; CpG Islands; Dacarbazine; DNA; DNA Meth | 2004 |
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
Topics: Adult; Aged; Alkylating Agents; Brain Neoplasms; Carmustine; CpG Islands; Dacarbazine; DNA; DNA Meth | 2004 |
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
Topics: Adult; Aged; Alkylating Agents; Brain Neoplasms; Carmustine; CpG Islands; Dacarbazine; DNA; DNA Meth | 2004 |
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
Topics: Adult; Aged; Alkylating Agents; Brain Neoplasms; Carmustine; CpG Islands; Dacarbazine; DNA; DNA Meth | 2004 |
Effect of association of temozolomide with other chemotherapic agents on cell growth inhibition in glioma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 2004 |
Effect of association of temozolomide with other chemotherapic agents on cell growth inhibition in glioma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 2004 |
Effect of association of temozolomide with other chemotherapic agents on cell growth inhibition in glioma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 2004 |
Effect of association of temozolomide with other chemotherapic agents on cell growth inhibition in glioma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 2004 |
Expression of ABC-1 transporter is elevated in human glioma cells under irradiation and temozolomide treatment.
Topics: Antineoplastic Agents, Alkylating; ATP-Binding Cassette Transporters; Cell Line, Tumor; Dacarbazine; | 2005 |
Expression of ABC-1 transporter is elevated in human glioma cells under irradiation and temozolomide treatment.
Topics: Antineoplastic Agents, Alkylating; ATP-Binding Cassette Transporters; Cell Line, Tumor; Dacarbazine; | 2005 |
Expression of ABC-1 transporter is elevated in human glioma cells under irradiation and temozolomide treatment.
Topics: Antineoplastic Agents, Alkylating; ATP-Binding Cassette Transporters; Cell Line, Tumor; Dacarbazine; | 2005 |
Expression of ABC-1 transporter is elevated in human glioma cells under irradiation and temozolomide treatment.
Topics: Antineoplastic Agents, Alkylating; ATP-Binding Cassette Transporters; Cell Line, Tumor; Dacarbazine; | 2005 |
Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2005 |
Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2005 |
Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2005 |
Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2005 |
Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Benzothiazoles; Brain Neoplasms; Carmustine; Dacarbazine; DNA Dam | 2005 |
Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Benzothiazoles; Brain Neoplasms; Carmustine; Dacarbazine; DNA Dam | 2005 |
Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Benzothiazoles; Brain Neoplasms; Carmustine; Dacarbazine; DNA Dam | 2005 |
Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Benzothiazoles; Brain Neoplasms; Carmustine; Dacarbazine; DNA Dam | 2005 |
Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Carboplatin; Combined Modality Therapy; | 2005 |
Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Carboplatin; Combined Modality Therapy; | 2005 |
Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Carboplatin; Combined Modality Therapy; | 2005 |
Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Carboplatin; Combined Modality Therapy; | 2005 |
Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Carboxymethylc | 2005 |
Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Carboxymethylc | 2005 |
Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Carboxymethylc | 2005 |
Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Carboxymethylc | 2005 |
Artificial tumor model suitable for monitoring 31P and 13C NMR spectroscopic changes during chemotherapy-induced apoptosis in human glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carbon Isotopes; Cell Line, Tumor; Dac | 2005 |
Artificial tumor model suitable for monitoring 31P and 13C NMR spectroscopic changes during chemotherapy-induced apoptosis in human glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carbon Isotopes; Cell Line, Tumor; Dac | 2005 |
Artificial tumor model suitable for monitoring 31P and 13C NMR spectroscopic changes during chemotherapy-induced apoptosis in human glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carbon Isotopes; Cell Line, Tumor; Dac | 2005 |
Artificial tumor model suitable for monitoring 31P and 13C NMR spectroscopic changes during chemotherapy-induced apoptosis in human glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carbon Isotopes; Cell Line, Tumor; Dac | 2005 |
Temozolomide-induced partial response in a patient with primary diffuse leptomeningeal gliomatosis.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Im | 2005 |
Temozolomide-induced partial response in a patient with primary diffuse leptomeningeal gliomatosis.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Im | 2005 |
Temozolomide-induced partial response in a patient with primary diffuse leptomeningeal gliomatosis.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Im | 2005 |
Temozolomide-induced partial response in a patient with primary diffuse leptomeningeal gliomatosis.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Magnetic Resonance Im | 2005 |
[Favourable result for temozolomide in recurrent high-grade glioma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; F | 2005 |
[Favourable result for temozolomide in recurrent high-grade glioma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; F | 2005 |
[Favourable result for temozolomide in recurrent high-grade glioma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; F | 2005 |
[Favourable result for temozolomide in recurrent high-grade glioma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; F | 2005 |
Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, P | 2006 |
Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, P | 2006 |
Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, P | 2006 |
Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, P | 2006 |
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CDC2-CDC28 Kinases; Cell G | 2005 |
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CDC2-CDC28 Kinases; Cell G | 2005 |
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CDC2-CDC28 Kinases; Cell G | 2005 |
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CDC2-CDC28 Kinases; Cell G | 2005 |
IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; | 2005 |
IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; | 2005 |
IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; | 2005 |
IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; | 2005 |
Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Topics: Adult; Aged; alpha-Methyltyrosine; Analysis of Variance; Antineoplastic Agents, Alkylating; Astrocyt | 2005 |
Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Topics: Adult; Aged; alpha-Methyltyrosine; Analysis of Variance; Antineoplastic Agents, Alkylating; Astrocyt | 2005 |
Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Topics: Adult; Aged; alpha-Methyltyrosine; Analysis of Variance; Antineoplastic Agents, Alkylating; Astrocyt | 2005 |
Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Topics: Adult; Aged; alpha-Methyltyrosine; Analysis of Variance; Antineoplastic Agents, Alkylating; Astrocyt | 2005 |
Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; C | 2005 |
Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; C | 2005 |
Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; C | 2005 |
Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; C | 2005 |
Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2006 |
Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2006 |
Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2006 |
Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2006 |
Combination celecoxib and temozolomide in C6 rat glioma orthotopic model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Cyclooxygenase | 2006 |
Combination celecoxib and temozolomide in C6 rat glioma orthotopic model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Cyclooxygenase | 2006 |
Combination celecoxib and temozolomide in C6 rat glioma orthotopic model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Cyclooxygenase | 2006 |
Combination celecoxib and temozolomide in C6 rat glioma orthotopic model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Cyclooxygenase | 2006 |
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; bcl-X Protein; Carmustine; Cell Death; Cell Line, Tumor; Cell Sur | 2006 |
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; bcl-X Protein; Carmustine; Cell Death; Cell Line, Tumor; Cell Sur | 2006 |
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; bcl-X Protein; Carmustine; Cell Death; Cell Line, Tumor; Cell Sur | 2006 |
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; bcl-X Protein; Carmustine; Cell Death; Cell Line, Tumor; Cell Sur | 2006 |
Is protracted low-dose temozolomide feasible in glioma patients?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Dose- | 2006 |
Is protracted low-dose temozolomide feasible in glioma patients?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Dose- | 2006 |
Is protracted low-dose temozolomide feasible in glioma patients?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Dose- | 2006 |
Is protracted low-dose temozolomide feasible in glioma patients?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Dose- | 2006 |
Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Brain Neoplasms; Cell Proliferation; Combined Modality | 2006 |
Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Brain Neoplasms; Cell Proliferation; Combined Modality | 2006 |
Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Brain Neoplasms; Cell Proliferation; Combined Modality | 2006 |
Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Brain Neoplasms; Cell Proliferation; Combined Modality | 2006 |
Is current therapy of malignant gliomas beneficial for patients? Proteomics evidence of shifts in glioma cells expression patterns under clinically relevant treatment conditions.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cells, Cultured; Combined Modality Therapy; Dac | 2006 |
Is current therapy of malignant gliomas beneficial for patients? Proteomics evidence of shifts in glioma cells expression patterns under clinically relevant treatment conditions.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cells, Cultured; Combined Modality Therapy; Dac | 2006 |
Is current therapy of malignant gliomas beneficial for patients? Proteomics evidence of shifts in glioma cells expression patterns under clinically relevant treatment conditions.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cells, Cultured; Combined Modality Therapy; Dac | 2006 |
Is current therapy of malignant gliomas beneficial for patients? Proteomics evidence of shifts in glioma cells expression patterns under clinically relevant treatment conditions.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cells, Cultured; Combined Modality Therapy; Dac | 2006 |
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA-Binding Proteins; Female; | 2006 |
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA-Binding Proteins; Female; | 2006 |
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA-Binding Proteins; Female; | 2006 |
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA-Binding Proteins; Female; | 2006 |
Radical surgery after chemotherapy: a new therapeutic strategy to envision in grade II glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Corpus Callosu | 2006 |
Radical surgery after chemotherapy: a new therapeutic strategy to envision in grade II glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Corpus Callosu | 2006 |
Radical surgery after chemotherapy: a new therapeutic strategy to envision in grade II glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Corpus Callosu | 2006 |
Radical surgery after chemotherapy: a new therapeutic strategy to envision in grade II glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Corpus Callosu | 2006 |
Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275.
Topics: Animals; Antineoplastic Agents; Benzamides; Blood-Brain Barrier; Brain; Cell Adhesion Molecules, Neu | 2006 |
Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275.
Topics: Animals; Antineoplastic Agents; Benzamides; Blood-Brain Barrier; Brain; Cell Adhesion Molecules, Neu | 2006 |
Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275.
Topics: Animals; Antineoplastic Agents; Benzamides; Blood-Brain Barrier; Brain; Cell Adhesion Molecules, Neu | 2006 |
Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275.
Topics: Animals; Antineoplastic Agents; Benzamides; Blood-Brain Barrier; Brain; Cell Adhesion Molecules, Neu | 2006 |
Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Disease Models | 2006 |
Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Disease Models | 2006 |
Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Disease Models | 2006 |
Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Disease Models | 2006 |
Pro-invasive gene regulating effect of irradiation and combined temozolomide-radiation treatment on surviving human malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Sur | 2006 |
Pro-invasive gene regulating effect of irradiation and combined temozolomide-radiation treatment on surviving human malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Sur | 2006 |
Pro-invasive gene regulating effect of irradiation and combined temozolomide-radiation treatment on surviving human malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Sur | 2006 |
Pro-invasive gene regulating effect of irradiation and combined temozolomide-radiation treatment on surviving human malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Sur | 2006 |
Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Caspases; Cell Cyc | 2007 |
Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Caspases; Cell Cyc | 2007 |
Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Caspases; Cell Cyc | 2007 |
Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Caspases; Cell Cyc | 2007 |
Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; | 2006 |
Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; | 2006 |
Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; | 2006 |
Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; | 2006 |
Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Combined Modalit | 2006 |
Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Combined Modalit | 2006 |
Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Combined Modalit | 2006 |
Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Combined Modalit | 2006 |
Is protracted low-dose temozolomide feasible in glioma patients?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Combined Modal | 2006 |
Is protracted low-dose temozolomide feasible in glioma patients?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Combined Modal | 2006 |
Is protracted low-dose temozolomide feasible in glioma patients?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Combined Modal | 2006 |
Is protracted low-dose temozolomide feasible in glioma patients?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Combined Modal | 2006 |
DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Autophagy; | 2007 |
DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Autophagy; | 2007 |
DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Autophagy; | 2007 |
DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Autophagy; | 2007 |
Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; British Columbia | 2006 |
Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; British Columbia | 2006 |
Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; British Columbia | 2006 |
Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; British Columbia | 2006 |
Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Ex | 2006 |
Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Ex | 2006 |
Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Ex | 2006 |
Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Ex | 2006 |
Temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Delivery Systems; Gl | 2007 |
Temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Delivery Systems; Gl | 2007 |
Temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Delivery Systems; Gl | 2007 |
Temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Delivery Systems; Gl | 2007 |
Spanish co-operative group of Medical Neuro-oncology (GENOM).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; | 2006 |
Spanish co-operative group of Medical Neuro-oncology (GENOM).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; | 2006 |
Spanish co-operative group of Medical Neuro-oncology (GENOM).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; | 2006 |
Spanish co-operative group of Medical Neuro-oncology (GENOM).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioma; | 2006 |
Non-sufficient cell cycle control as possible clue for the resistance of human malignant glioma cells to clinically relevant treatment conditions.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Combined | 2007 |
Non-sufficient cell cycle control as possible clue for the resistance of human malignant glioma cells to clinically relevant treatment conditions.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Combined | 2007 |
Non-sufficient cell cycle control as possible clue for the resistance of human malignant glioma cells to clinically relevant treatment conditions.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Combined | 2007 |
Non-sufficient cell cycle control as possible clue for the resistance of human malignant glioma cells to clinically relevant treatment conditions.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Combined | 2007 |
Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2007 |
Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2007 |
Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2007 |
Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2007 |
Potentiation of antiglioma effect with combined temozolomide and interferon-beta.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2006 |
Potentiation of antiglioma effect with combined temozolomide and interferon-beta.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2006 |
Potentiation of antiglioma effect with combined temozolomide and interferon-beta.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2006 |
Potentiation of antiglioma effect with combined temozolomide and interferon-beta.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2006 |
The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; | 2007 |
The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; | 2007 |
The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; | 2007 |
The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; | 2007 |
[Individualized chemotherapy based on drug sensitivity and resistance assay and MGMT protein expression for patients with malignant glioma--analysis of 42 cases].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chi | 2006 |
[Individualized chemotherapy based on drug sensitivity and resistance assay and MGMT protein expression for patients with malignant glioma--analysis of 42 cases].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chi | 2006 |
[Individualized chemotherapy based on drug sensitivity and resistance assay and MGMT protein expression for patients with malignant glioma--analysis of 42 cases].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chi | 2006 |
[Individualized chemotherapy based on drug sensitivity and resistance assay and MGMT protein expression for patients with malignant glioma--analysis of 42 cases].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chi | 2006 |
[Recent advances in the medical treatment of glioma-temozolomide].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2006 |
[Recent advances in the medical treatment of glioma-temozolomide].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2006 |
[Recent advances in the medical treatment of glioma-temozolomide].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2006 |
[Recent advances in the medical treatment of glioma-temozolomide].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2006 |
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2007 |
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2007 |
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2007 |
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2007 |
Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biocompatible Materials; Brain Neoplasms; Comb | 2007 |
Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biocompatible Materials; Brain Neoplasms; Comb | 2007 |
Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biocompatible Materials; Brain Neoplasms; Comb | 2007 |
Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biocompatible Materials; Brain Neoplasms; Comb | 2007 |
Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neopla | 2007 |
Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neopla | 2007 |
Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neopla | 2007 |
Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neopla | 2007 |
[Cerebral tumours in the adult. A real increase].
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase | 2006 |
[Cerebral tumours in the adult. A real increase].
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase | 2006 |
[Cerebral tumours in the adult. A real increase].
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase | 2006 |
[Cerebral tumours in the adult. A real increase].
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase | 2006 |
Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Carcinoma, Squamous Cell; Cerebellar Neoplasms; Dacarbazine | 2007 |
Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Carcinoma, Squamous Cell; Cerebellar Neoplasms; Dacarbazine | 2007 |
Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Carcinoma, Squamous Cell; Cerebellar Neoplasms; Dacarbazine | 2007 |
Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Carcinoma, Squamous Cell; Cerebellar Neoplasms; Dacarbazine | 2007 |
The inhibition of proliferation and migration of glioma spheroids exposed to temozolomide is less than additive if combined with irradiation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Movement; Cell Proliferation; Combined Moda | 2007 |
The inhibition of proliferation and migration of glioma spheroids exposed to temozolomide is less than additive if combined with irradiation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Movement; Cell Proliferation; Combined Moda | 2007 |
The inhibition of proliferation and migration of glioma spheroids exposed to temozolomide is less than additive if combined with irradiation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Movement; Cell Proliferation; Combined Moda | 2007 |
The inhibition of proliferation and migration of glioma spheroids exposed to temozolomide is less than additive if combined with irradiation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Movement; Cell Proliferation; Combined Moda | 2007 |
Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Cell Line, Tum | 2006 |
Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Cell Line, Tum | 2006 |
Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Cell Line, Tum | 2006 |
Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Cell Line, Tum | 2006 |
Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Culture Techniques; Cell Line, Tumor; Cell Surviv | 2007 |
Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Culture Techniques; Cell Line, Tumor; Cell Surviv | 2007 |
Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Culture Techniques; Cell Line, Tumor; Cell Surviv | 2007 |
Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Culture Techniques; Cell Line, Tumor; Cell Surviv | 2007 |
Dynamic history of low-grade gliomas before and after temozolomide treatment.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes; Dacarbazin | 2007 |
Dynamic history of low-grade gliomas before and after temozolomide treatment.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes; Dacarbazin | 2007 |
Dynamic history of low-grade gliomas before and after temozolomide treatment.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes; Dacarbazin | 2007 |
Dynamic history of low-grade gliomas before and after temozolomide treatment.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes; Dacarbazin | 2007 |
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma.
Topics: Animals; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Genetic Engineering; Glioma; Magnetic | 2007 |
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma.
Topics: Animals; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Genetic Engineering; Glioma; Magnetic | 2007 |
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma.
Topics: Animals; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Genetic Engineering; Glioma; Magnetic | 2007 |
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma.
Topics: Animals; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Genetic Engineering; Glioma; Magnetic | 2007 |
Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, H | 2007 |
Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, H | 2007 |
Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, H | 2007 |
Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, H | 2007 |
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Chemokine CCL2; Chemokine CCL2 | 2008 |
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Chemokine CCL2; Chemokine CCL2 | 2008 |
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Chemokine CCL2; Chemokine CCL2 | 2008 |
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Chemokine CCL2; Chemokine CCL2 | 2008 |
O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Astrocytes; Cell Division; Dacarbazine; DNA Modification | 2007 |
O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Astrocytes; Cell Division; Dacarbazine; DNA Modification | 2007 |
O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Astrocytes; Cell Division; Dacarbazine; DNA Modification | 2007 |
O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Astrocytes; Cell Division; Dacarbazine; DNA Modification | 2007 |
Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Everolimus; | 2007 |
Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Everolimus; | 2007 |
Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Everolimus; | 2007 |
Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Everolimus; | 2007 |
A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2008 |
A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2008 |
A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2008 |
A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2008 |
Inhibition of Aurora-B function increases formation of multinucleated cells in p53 gene deficient cells and enhances anti-tumor effect of temozolomide in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Aurora Kinase B; Aurora Kinases; Blotting, Western; Brain Neoplas | 2007 |
Inhibition of Aurora-B function increases formation of multinucleated cells in p53 gene deficient cells and enhances anti-tumor effect of temozolomide in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Aurora Kinase B; Aurora Kinases; Blotting, Western; Brain Neoplas | 2007 |
Inhibition of Aurora-B function increases formation of multinucleated cells in p53 gene deficient cells and enhances anti-tumor effect of temozolomide in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Aurora Kinase B; Aurora Kinases; Blotting, Western; Brain Neoplas | 2007 |
Inhibition of Aurora-B function increases formation of multinucleated cells in p53 gene deficient cells and enhances anti-tumor effect of temozolomide in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Aurora Kinase B; Aurora Kinases; Blotting, Western; Brain Neoplas | 2007 |
Defining the standard of care for high-grade glioma--a NICE deal for UK patients?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Delivery of | 2007 |
Defining the standard of care for high-grade glioma--a NICE deal for UK patients?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Delivery of | 2007 |
Defining the standard of care for high-grade glioma--a NICE deal for UK patients?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Delivery of | 2007 |
Defining the standard of care for high-grade glioma--a NICE deal for UK patients?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Delivery of | 2007 |
Patients receiving standard-dose temozolomide therapy are at risk of Pneumocystis carinii pneumonia.
Topics: Adrenal Cortex Hormones; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; CD4 Lymphocyte C | 2007 |
Patients receiving standard-dose temozolomide therapy are at risk of Pneumocystis carinii pneumonia.
Topics: Adrenal Cortex Hormones; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; CD4 Lymphocyte C | 2007 |
Patients receiving standard-dose temozolomide therapy are at risk of Pneumocystis carinii pneumonia.
Topics: Adrenal Cortex Hormones; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; CD4 Lymphocyte C | 2007 |
Patients receiving standard-dose temozolomide therapy are at risk of Pneumocystis carinii pneumonia.
Topics: Adrenal Cortex Hormones; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; CD4 Lymphocyte C | 2007 |
Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Cancer Vaccines; CD8-Posi | 2007 |
Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Cancer Vaccines; CD8-Posi | 2007 |
Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Cancer Vaccines; CD8-Posi | 2007 |
Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Cancer Vaccines; CD8-Posi | 2007 |
MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Biopsy; Brain Neoplasms; Cell Line, Tumor; Dacarba | 2007 |
MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Biopsy; Brain Neoplasms; Cell Line, Tumor; Dacarba | 2007 |
MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Biopsy; Brain Neoplasms; Cell Line, Tumor; Dacarba | 2007 |
MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Biopsy; Brain Neoplasms; Cell Line, Tumor; Dacarba | 2007 |
Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chro | 2007 |
Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chro | 2007 |
Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chro | 2007 |
Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chro | 2007 |
What approach will lead to cure of glioblastoma multiforme? In regard to Barani et al. (Int J Radiat Oncol Biol Phys 2007;68:324-333) and Jones and Sanghera (Int J Radiat Oncol Biol Phys 2007;68:441-448).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Dacarbazine; G | 2007 |
What approach will lead to cure of glioblastoma multiforme? In regard to Barani et al. (Int J Radiat Oncol Biol Phys 2007;68:324-333) and Jones and Sanghera (Int J Radiat Oncol Biol Phys 2007;68:441-448).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Dacarbazine; G | 2007 |
What approach will lead to cure of glioblastoma multiforme? In regard to Barani et al. (Int J Radiat Oncol Biol Phys 2007;68:324-333) and Jones and Sanghera (Int J Radiat Oncol Biol Phys 2007;68:441-448).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Dacarbazine; G | 2007 |
What approach will lead to cure of glioblastoma multiforme? In regard to Barani et al. (Int J Radiat Oncol Biol Phys 2007;68:324-333) and Jones and Sanghera (Int J Radiat Oncol Biol Phys 2007;68:441-448).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Dacarbazine; G | 2007 |
Combined effect of 2-5A-linked antisense against telomerase RNA and conventional therapies on human malignant glioma cells in vitro and in vivo.
Topics: Adenine Nucleotides; Animals; Apoptosis; Astrocytes; Autophagy; Cell Line, Tumor; Combined Modality | 2007 |
Combined effect of 2-5A-linked antisense against telomerase RNA and conventional therapies on human malignant glioma cells in vitro and in vivo.
Topics: Adenine Nucleotides; Animals; Apoptosis; Astrocytes; Autophagy; Cell Line, Tumor; Combined Modality | 2007 |
Combined effect of 2-5A-linked antisense against telomerase RNA and conventional therapies on human malignant glioma cells in vitro and in vivo.
Topics: Adenine Nucleotides; Animals; Apoptosis; Astrocytes; Autophagy; Cell Line, Tumor; Combined Modality | 2007 |
Combined effect of 2-5A-linked antisense against telomerase RNA and conventional therapies on human malignant glioma cells in vitro and in vivo.
Topics: Adenine Nucleotides; Animals; Apoptosis; Astrocytes; Autophagy; Cell Line, Tumor; Combined Modality | 2007 |
Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Asian People; Brai | 2007 |
Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Asian People; Brai | 2007 |
Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Asian People; Brai | 2007 |
Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Asian People; Brai | 2007 |
Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combine | 2007 |
Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combine | 2007 |
Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combine | 2007 |
Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combine | 2007 |
Diffusion tensor imaging and chemical shift imaging assessment of heterogeneity in low grade glioma under temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Choline; Dacarbazine; Diffusion Magnetic Resonan | 2007 |
Diffusion tensor imaging and chemical shift imaging assessment of heterogeneity in low grade glioma under temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Choline; Dacarbazine; Diffusion Magnetic Resonan | 2007 |
Diffusion tensor imaging and chemical shift imaging assessment of heterogeneity in low grade glioma under temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Choline; Dacarbazine; Diffusion Magnetic Resonan | 2007 |
Diffusion tensor imaging and chemical shift imaging assessment of heterogeneity in low grade glioma under temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Choline; Dacarbazine; Diffusion Magnetic Resonan | 2007 |
Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain; Cell Line, Tumor; Dacarbazine; DNA | 2007 |
Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain; Cell Line, Tumor; Dacarbazine; DNA | 2007 |
Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain; Cell Line, Tumor; Dacarbazine; DNA | 2007 |
Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain; Cell Line, Tumor; Dacarbazine; DNA | 2007 |
Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain; Cell Line, Tumor; Dacarbazine; DNA | 2007 |
Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain; Cell Line, Tumor; Dacarbazine; DNA | 2007 |
Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain; Cell Line, Tumor; Dacarbazine; DNA | 2007 |
Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain; Cell Line, Tumor; Dacarbazine; DNA | 2007 |
Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain; Cell Line, Tumor; Dacarbazine; DNA | 2007 |
Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain; Cell Line, Tumor; Dacarbazine; DNA | 2007 |
Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain; Cell Line, Tumor; Dacarbazine; DNA | 2007 |
Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain; Cell Line, Tumor; Dacarbazine; DNA | 2007 |
Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain; Cell Line, Tumor; Dacarbazine; DNA | 2007 |
Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain; Cell Line, Tumor; Dacarbazine; DNA | 2007 |
Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain; Cell Line, Tumor; Dacarbazine; DNA | 2007 |
Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain; Cell Line, Tumor; Dacarbazine; DNA | 2007 |
Temozolomide and resistant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Recepto | 2008 |
Temozolomide and resistant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Recepto | 2008 |
Temozolomide and resistant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Recepto | 2008 |
Temozolomide and resistant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Glioma; Humans; Recepto | 2008 |
Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain; B | 2008 |
Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain; B | 2008 |
Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain; B | 2008 |
Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain; B | 2008 |
[Chemotherapy for brain tumors in adult patients].
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 1; C | 2008 |
[Chemotherapy for brain tumors in adult patients].
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 1; C | 2008 |
[Chemotherapy for brain tumors in adult patients].
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 1; C | 2008 |
[Chemotherapy for brain tumors in adult patients].
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 1; C | 2008 |
Evidence of galectin-1 involvement in glioma chemoresistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2008 |
Evidence of galectin-1 involvement in glioma chemoresistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2008 |
Evidence of galectin-1 involvement in glioma chemoresistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2008 |
Evidence of galectin-1 involvement in glioma chemoresistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2008 |
Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Collagen; Co | 2008 |
Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Collagen; Co | 2008 |
Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Collagen; Co | 2008 |
Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Collagen; Co | 2008 |
Cryptococcal meningitis in patients with glioma: a report of two cases.
Topics: Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Antineoplastic Agents, Alk | 2008 |
Cryptococcal meningitis in patients with glioma: a report of two cases.
Topics: Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Antineoplastic Agents, Alk | 2008 |
Cryptococcal meningitis in patients with glioma: a report of two cases.
Topics: Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Antineoplastic Agents, Alk | 2008 |
Cryptococcal meningitis in patients with glioma: a report of two cases.
Topics: Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Antineoplastic Agents, Alk | 2008 |
Dihydroartemisinin potentiates the cytotoxic effect of temozolomide in rat C6 glioma cells.
Topics: Animals; Antineoplastic Agents; Antipyrine; Apoptosis; Artemisinins; Cell Survival; Cisplatin; Dacar | 2008 |
Dihydroartemisinin potentiates the cytotoxic effect of temozolomide in rat C6 glioma cells.
Topics: Animals; Antineoplastic Agents; Antipyrine; Apoptosis; Artemisinins; Cell Survival; Cisplatin; Dacar | 2008 |
Dihydroartemisinin potentiates the cytotoxic effect of temozolomide in rat C6 glioma cells.
Topics: Animals; Antineoplastic Agents; Antipyrine; Apoptosis; Artemisinins; Cell Survival; Cisplatin; Dacar | 2008 |
Dihydroartemisinin potentiates the cytotoxic effect of temozolomide in rat C6 glioma cells.
Topics: Animals; Antineoplastic Agents; Antipyrine; Apoptosis; Artemisinins; Cell Survival; Cisplatin; Dacar | 2008 |
Temozolomide-mediated radiosensitization of human glioma cells in a zebrafish embryonic system.
Topics: Animals; Animals, Genetically Modified; Blood Vessels; Cell Proliferation; Cell Survival; Dacarbazin | 2008 |
Temozolomide-mediated radiosensitization of human glioma cells in a zebrafish embryonic system.
Topics: Animals; Animals, Genetically Modified; Blood Vessels; Cell Proliferation; Cell Survival; Dacarbazin | 2008 |
Temozolomide-mediated radiosensitization of human glioma cells in a zebrafish embryonic system.
Topics: Animals; Animals, Genetically Modified; Blood Vessels; Cell Proliferation; Cell Survival; Dacarbazin | 2008 |
Temozolomide-mediated radiosensitization of human glioma cells in a zebrafish embryonic system.
Topics: Animals; Animals, Genetically Modified; Blood Vessels; Cell Proliferation; Cell Survival; Dacarbazin | 2008 |
Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2009 |
Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2009 |
Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2009 |
Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2009 |
Brazilian marine sponge Polymastia janeirensis induces apoptotic cell death in human U138MG glioma cell line, but not in a normal cell culture.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Brazil; Cell | 2009 |
Brazilian marine sponge Polymastia janeirensis induces apoptotic cell death in human U138MG glioma cell line, but not in a normal cell culture.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Brazil; Cell | 2009 |
Brazilian marine sponge Polymastia janeirensis induces apoptotic cell death in human U138MG glioma cell line, but not in a normal cell culture.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Brazil; Cell | 2009 |
Brazilian marine sponge Polymastia janeirensis induces apoptotic cell death in human U138MG glioma cell line, but not in a normal cell culture.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Brazil; Cell | 2009 |
Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell | 2008 |
Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell | 2008 |
Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell | 2008 |
Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell | 2008 |
Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.
Topics: Adolescent; Adult; Aged; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease Progression | 2008 |
Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.
Topics: Adolescent; Adult; Aged; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease Progression | 2008 |
Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.
Topics: Adolescent; Adult; Aged; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease Progression | 2008 |
Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.
Topics: Adolescent; Adult; Aged; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease Progression | 2008 |
Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cyclohexan | 1996 |
Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cyclohexan | 1996 |
Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cyclohexan | 1996 |
Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cyclohexan | 1996 |
Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study.
Topics: Acridines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; | 1998 |
Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study.
Topics: Acridines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; | 1998 |
Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study.
Topics: Acridines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; | 1998 |
Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study.
Topics: Acridines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; | 1998 |
Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor.
Topics: Animals; Antineoplastic Agents, Alkylating; Capillaries; Carmustine; Cell Hypoxia; Dacarbazine; DNA, | 1998 |
Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor.
Topics: Animals; Antineoplastic Agents, Alkylating; Capillaries; Carmustine; Cell Hypoxia; Dacarbazine; DNA, | 1998 |
Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor.
Topics: Animals; Antineoplastic Agents, Alkylating; Capillaries; Carmustine; Cell Hypoxia; Dacarbazine; DNA, | 1998 |
Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor.
Topics: Animals; Antineoplastic Agents, Alkylating; Capillaries; Carmustine; Cell Hypoxia; Dacarbazine; DNA, | 1998 |
Understanding low-grade glioma: a decade of progress.
Topics: Antineoplastic Agents, Alkylating; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbaz | 2000 |
Understanding low-grade glioma: a decade of progress.
Topics: Antineoplastic Agents, Alkylating; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbaz | 2000 |
Understanding low-grade glioma: a decade of progress.
Topics: Antineoplastic Agents, Alkylating; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbaz | 2000 |
Understanding low-grade glioma: a decade of progress.
Topics: Antineoplastic Agents, Alkylating; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbaz | 2000 |
Temozolomide for malignant brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblast | 2000 |
Temozolomide for malignant brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblast | 2000 |
Temozolomide for malignant brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblast | 2000 |
Temozolomide for malignant brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblast | 2000 |
Survival of human glioma cells treated with various combination of temozolomide and X-rays.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Combined Modality Therapy; Dacarb | 2000 |
Survival of human glioma cells treated with various combination of temozolomide and X-rays.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Combined Modality Therapy; Dacarb | 2000 |
Survival of human glioma cells treated with various combination of temozolomide and X-rays.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Combined Modality Therapy; Dacarb | 2000 |
Survival of human glioma cells treated with various combination of temozolomide and X-rays.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Combined Modality Therapy; Dacarb | 2000 |
Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Catheterization; Catheters, Indw | 2000 |
Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Catheterization; Catheters, Indw | 2000 |
Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Catheterization; Catheters, Indw | 2000 |
Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Catheterization; Catheters, Indw | 2000 |
Effects of temozolomide in malignant brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Tri | 2000 |
Effects of temozolomide in malignant brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Tri | 2000 |
Effects of temozolomide in malignant brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Tri | 2000 |
Effects of temozolomide in malignant brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Clinical Tri | 2000 |
Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2001 |
Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2001 |
Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2001 |
Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2001 |
An Australian experience with temozolomide for the treatment of recurrent high grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Australia; Brain Neoplasms; Dacarbazine; Disease-Fre | 2001 |
An Australian experience with temozolomide for the treatment of recurrent high grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Australia; Brain Neoplasms; Dacarbazine; Disease-Fre | 2001 |
An Australian experience with temozolomide for the treatment of recurrent high grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Australia; Brain Neoplasms; Dacarbazine; Disease-Fre | 2001 |
An Australian experience with temozolomide for the treatment of recurrent high grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Australia; Brain Neoplasms; Dacarbazine; Disease-Fre | 2001 |
Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle Proteins; Cell Survival; Cyc | 2001 |
Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle Proteins; Cell Survival; Cyc | 2001 |
Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle Proteins; Cell Survival; Cyc | 2001 |
Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle Proteins; Cell Survival; Cyc | 2001 |
Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Dacarbazine; Drug Intera | 2001 |
Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Dacarbazine; Drug Intera | 2001 |
Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Dacarbazine; Drug Intera | 2001 |
Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Dacarbazine; Drug Intera | 2001 |
Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase.
Topics: 3T3 Cells; Animals; Antineoplastic Agents, Alkylating; Caspase 3; Caspases; Combined Modality Therap | 2002 |
Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase.
Topics: 3T3 Cells; Animals; Antineoplastic Agents, Alkylating; Caspase 3; Caspases; Combined Modality Therap | 2002 |
Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase.
Topics: 3T3 Cells; Animals; Antineoplastic Agents, Alkylating; Caspase 3; Caspases; Combined Modality Therap | 2002 |
Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase.
Topics: 3T3 Cells; Animals; Antineoplastic Agents, Alkylating; Caspase 3; Caspases; Combined Modality Therap | 2002 |
Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; | 2002 |
Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; | 2002 |
Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; | 2002 |
Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; | 2002 |
[Treatment of recidive malignant gliomas with temozolomide].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Male; Middle Ag | 2002 |
[Treatment of recidive malignant gliomas with temozolomide].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Male; Middle Ag | 2002 |
[Treatment of recidive malignant gliomas with temozolomide].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Male; Middle Ag | 2002 |
[Treatment of recidive malignant gliomas with temozolomide].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Male; Middle Ag | 2002 |
Temozolomide-induced flare in high-grade gliomas: a new clinical entity.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; G | 2002 |
Temozolomide-induced flare in high-grade gliomas: a new clinical entity.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; G | 2002 |
Temozolomide-induced flare in high-grade gliomas: a new clinical entity.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; G | 2002 |
Temozolomide-induced flare in high-grade gliomas: a new clinical entity.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; G | 2002 |